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Eugênia Abrantes de Figueiredo, Naiane Ferraz Bandeira Alves,
Matheus Morais de Oliveira Monteiro, Clenia de Oliveira Cavalcanti,
Tania Maria Sarmento da Silva, Telma Maria Guedes da Silva, Valdir de Andrade Braga and
Eduardo de Jesus Oliveira
Antioxidant and Antihypertensive Effects of a Chemically Defined Fraction of Syrah Red Wine
on Spontaneously Hypertensive Rats
Reprinted from: Nutrients 2017, 9, 574, doi: 10.3390/nu9060574 . . . . . . . . . . . . . . . . . . . . 237
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Preface to ”Effects of Polyphenol-Rich Foods on
Human Health”
The global burden of non-communicable diseases (NCDs) has been rising over the last century, 
and among the main NCDs are cardiovascular diseases (CVDs), cancers and diabetes. Besides genetic, 
environmental, and social factors, exploring dietary factors influencing such conditions is of primary 
importance to better define effective strategies for reducing the burden of disease. In fact, higher 
adherence to healthy and equilibrated dietary patterns has been shown to be implicated in prevention 
of NCDs.
In recent years, polyphenols have received a great deal of attention due to their potential 
beneficial effects on human health. Contained in foods commonly consumed in all populations 
worldwide, polyphenols offer a range of beneficial effects and are contained not only in fruits and 
vegetables, characteristic components of healthy dietary patterns, but also in other plant-derived 
foods, such as tea, coffee, and cocoa, which only recently have been scientifically exploited as 
being beneficial for humans. In addition to the numerous biological properties, polyphenols 
have been indicated as being responsible for a decreased risk of several health outcomes. 
Numerous epidemiological studies have demonstrated the association between both polyphenols and 
polyphenol-rich foods intake and human health. For example, recent meta-analyses show that high 
consumption of polyphenols and polyphenol-rich foods decrease the risk of overall and CVD-related 
mortality, cancer, CVD, diabetes and neurodegenerative diseases. However, some studies reported 
null results, which could be at least partially explained by significant differences in dietary intake 
of polyphenols in different populations, differences in food processing (loss of phenolic content), 
absorption, bioavailability, and metabolism of polyphenols.
Several molecular mechanisms have been taken into account for the beneficial effects of 
polyphenols. The antioxidant effects of dietary polyphenols can be attributed to the regulation of 
redox enzymes through reducing reactive oxygen species (ROS) production and modulation of the 
II-phase enzymes responsible for the cellular oxidative response. Moreover, several studies have 
suggested that polyphenols may exert protective effects on cardio-metabolic health by reducing 
inflammatory response, lowering LDL oxidation and blood pressure, and by improving endothelial 
function. Finally, polyphenols may exert chemo-preventive effects through a variety of mechanisms, 
including elimination of carcinogenic agents, modulation of pathways responsible for cancer cell 
signaling and cell cycle progression, and by promotion of apoptosis.
Even though research is ongoing, further evidence is needed in order to better characterize 
dietary factors that may exert beneficial effects toward prevention of chronic diseases associated with 
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Abstract: The market of plant-based nutraceuticals and food supplements is continuously growing
due to the increased consumer demand. The introduction of new products with relevant nutritional
characteristics represents a new way of providing bioactive compounds and (poly)phenols to
consumers, becoming a strategy to ideally guarantee the health benefits attributed to plant foodstuffs
and allowing the increase of daily bioactive compound intake. A paramount step in the study
of nutraceuticals is the evaluation of the bioavailability and metabolism of their putatively active
components. Therefore, the aim of the present study was to investigate the absorption profile of
the (poly)phenolic compounds contained in three different plant-based food supplements, made of
36 different plant matrices, which were consumed by 20 subjects in an open one-arm study design.
Blood samples were collected at baseline and 1, 2, 5, and 10 h after capsule intake. Twenty quantifiable
metabolites deriving from different (poly)phenolic compounds were identified. Results showed that
the consumption of the three capsules allowed the effective absorption of several (poly)phenolic
compounds and metabolites appearing at different times in plasma, thereby indicating different
absorption profiles. The capsules thus ensured potential health-promoting molecules to be potentially
available to target tissues and organs.
Keywords: fruit and vegetables; capsules; (poly)phenolic compounds; absorption
1. Introduction
Daily consumption of five portions or at least 400 g of fruits and vegetables is promoted in many
national and international dietary guidelines and by public policies [1,2]. An adequate consumption
Nutrients 2017, 9, 194; doi:10.3390/nu9030194 www.mdpi.com/journal/nutrients1
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of fruit and vegetables has been associated with human health promotion thanks to their role in
chronic disease prevention [3]. Conversely, it has been estimated that up to 2635 million deaths
per year can be attributable to low fruit and vegetable consumption [4]. In detail, several scientific
studies report the correlation between fruit and vegetable consumption with a reduction in all-cause
mortality [5], a decrease in overall cancer risk [6], and prevention of metabolic diseases like type
II diabetes [7,8]. Many national nutrition surveys have shown that the minimum population goal
of 400 g of fruit and vegetables per day established by FAO/WHO is not easily met, especially in
selected groups of population such as teenagers [9,10]. However, nowadays, consumers are more
aware of the health benefits associated with a healthy lifestyle, including high consumption of fruit
and vegetables, increasing their will to buy products rich in bioactive compounds [11]. In this
context, consumer health demands have boosted the market of plant-based nutraceuticals and food
supplements, encouraging the introduction of new products with relevant nutritional characteristics.
These products represent new ways of providing bioactive compounds to consumers, becoming a
relevant strategy to ideally guarantee the health benefits attributed to plant foodstuffs [12] and allowing
the increase of daily bioactive compound intake.
The nutritional relevance of fruit and vegetables on human health could be attributed to their
dietary fiber content, mainly soluble, as well as to a large range of micronutrients, including carotenoids,
vitamins (mainly vitamin C, and folate), and minerals (as potassium, calcium, and magnesium).
In addition, fruit and vegetables are well-recognized sources of non-nutrient bioactive compounds,
also called “phytochemicals”, among which (poly)phenolic compounds are the predominant and the
most investigated [13–17]. The term (poly)phenol includes a number of different chemical structures,
including flavonoids and related compounds, but also refers to hydroxycinnamates and phenolic acids,
which have only one phenolic ring [18].
A growing amount of experimental research is trying hard to demonstrate the beneficial
role of (poly)phenols in humans, trying to unravel the biological mechanisms behind the many
proposed effects. Daily consumption of (poly)phenols has been related to reduction of inflammation,
hypertension, risk of cardiovascular, metabolic, neurodegenerative diseases, and cancer [18–22].
An essential part of the scientific research in vivo is represented by the investigation of the absorption,
metabolism and bioavailability of (poly)phenolic compounds after human intake. In fact, the large
structure variety of this class of phytochemicals, together with the food matrices, complex human
metabolic pathways and the role of human intestinal microbiota, can deeply influence the metabolism
of (poly)phenol compounds, and as a consequence, the availability of their potentially beneficial
metabolites to the human body’s internal compartments.
The aim of the present study was to investigate the absorption profile of the (poly)phenolic
compounds contained in three different plant-based food supplements, made of 36 different vegetal
matrices, recently characterized for their (poly)phenol content [23], designed to integrate and increase
the daily intake of dietary phenolics. The supplements have been previously shown to exert wide
biological effects in diverse health conditions [24–28].
2. Materials and Methods
2.1. Subjects
The sample size of our study was based on the number of volunteers usually recruited for
bioavailability studies involving (poly)phenolic compounds. However, seven subjects would have
provided sufficient power (α error of 0.05, 80% power) to detect a minimum increase of 40 nmol/L in
2 h in the absorption kinetics of flavan-3-ols, based on available published data [29].
Twenty participants were recruited from the Graz region (comprising a radius of 50 km around
the center of Graz, Austria) to take part in the study. Selected participants were 9 males (m) and
11 females (f) with the following characteristics: age 34.3 ± 9.9 (m) and 32.9 ± 9.1 (f),
weight 71.9 ± 11.7 (m) and 63.6 ± 9.4 (f) kg, height 174 ± 9 (m) and 167 ± 9 (f) cm and BMI
2
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23.2 ± 3.0 (m) and 22.8 ± 3.05 (f) (kg/m2) (data expressed as mean ± SD). The volunteers had
to meet all the inclusion and exclusion criteria. Subjects had to be non-smokers, with a BMI between
20 and 30 kg/m2, not on medication, not premenopausal, following normal dietary habits (no specific
diets, meals and food components.) and adhering to a wash-out period. Exclusion criteria included:
not consuming more than four servings of fruits and vegetables per day, not having any type of food
allergy or histamine intolerance, not displaying a high level of physical activity (defined as more than
five training units/week), not having menstrual dysfunctions and not abusing alcohol.
All participants were informed about the purpose of the study via telephone calls or personal
meetings. Subjects who wanted to join the study signed the informed consent form before their
inclusion in the trial. Moreover, the selected subjects received a (poly)phenol-poor diet plan which
they had to adhere to for 48 h before the first blood sampling. The list of permitted and forbidden
foods is provided in Table S1. Relevant principles of Good Clinical Practice were followed throughout
the study. The study was conducted according to the guidelines laid down in the Declaration of
Helsinki, and all procedures involving human subjects were approved by the Ethics Committee of
the Medical University of Graz, Austria, (EC-number: 27-507ex14/15). The trial was registered at
www.clinicaltrials.gov (identifier No. NCT02587468).
2.2. Test Capsules
Capsules used for the study were provided by the Juice Plus Company/NSA LLC, Collierville, TN,
USA and manufactured for Europe by Natural Alternatives International (NAI), Manno, Switzerland.
The capsules contained powdered juice concentrate derived from 36 different fruits, vegetables, and
berries including juice and pulp from different vegetal matrices, namely Juice PLUS+® Vineyard
(a berry blend), Juice PLUS+® Fruit Blend and Juice PLUS+® Vegetable Blend, which were kindly
supplied by the Juice PLUS+® company. In detail, the powder samples differed for their composition:
Juice PLUS+® Vineyard (hereafter called “berry blend”) contained 750 mg of dried powder blend
of juice and pulp from grapes and berries (45.7%) including Concord grape, blueberry, cranberry,
blackberry, bilberry, raspberry, redcurrant, blackcurrant, elderberry, in varying proportions, besides
green tea, ginger root, grape seed, artichoke leaf powder, cocoa powder, and pomegranate powder.
Juice PLUS+® Fruit Blend (“fruit blend”) instead contained 750 mg of dried powder blend of juice
and pulp (52%) of apple, orange, pineapple, cranberry, peach, acerola cherry, papaya, in varying
proportions, beet root, date, and prune. Lastly, Juice PLUS+® Vegetable Blend (“vegetable blend”)
contained 750 mg of dried powder blend of juice and pulp (60%) of carrot, parsley, beet, kale, broccoli,
cabbage, tomato, and spinach, in varying proportions, as well as sugar beet, garlic powder, oat, and
rice bran. Moreover, the fruit and the vegetable powders were enriched with vitamins C, and folic
acid) and with a natural carotenoid and tocopherol blend. The berry blend powder was enriched with
vitamins C and folic acid as well as with a natural tocopherol blend.
2.3. Study Design
In an open one-arm study design, three capsules (one berry, fruit, and one vegetable blend), were
consumed by each participant on one single occasion. Before the test meal, participants were asked to
follow a two-week wash-out period avoiding all food supplements and dietetic products and all kinds
of drugs/medications. Additionally, participants were asked to consume a (poly)phenol-poor diet 48
h before the test day. To facilitate participant adherence to the dietary restrictions, a list of permitted
and forbidden foods was supplied. The day of the test, subjects visited the lab after an overnight
fast, and after the baseline blood drawing (T0), they received the three capsules (one of each blend),
to be consumed with 250 mL of still water. Four additional blood samples were collected, at 1, 2, 5,
and 10 h after capsule intake. After the 2 h blood sampling, the subjects consumed a standardized
(poly)phenol-poor snack, including white bread, cheese, ham, milk, and water ad libitum, in accordance
to Pereira-Caro [30]. For each blood drawing, 5 mL of venous EDTA-blood from the elbow were
3
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collected via vein catheter, in supine position. Blood was immediately centrifuged at 2500 g for ten
minutes to separate the plasma, which was frozen at −70 ◦C until uHPLC/MSn analyses.
2.4. Chemicals
All chemicals and solvents were of analytical grade. 3-Hydroxybenzoic acid, protocatechuic acid,
3-hydroxyphenylpropionic acid, hippuric acid, dihydrocaffeic acid, ferulic acid, dihydroferulic acid,
(+)-catechin, 3-caffeoylquinic acid, 5-caffeoylquinic acid, quercetin 3-glucuronide, (hydroxyphenyl)-
γ-valeric acid, and pyrogallol were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dihydrocaffeic
acid 3-O-sulfate, ferulic acid 4′-O-sulfate, dihydroferulic acid 4′-O-sulfate, caffeic acid 4′-O-glucuronide,
dihydrocaffeic acid 3-O-glucuronide, isoferulic acid 3-O-glucuronide were purchased from





4′-di-O-sulfate, and (5′-hydroxyphenyl)-γ-valerolactone-3′-O-glucuronide were synthesized in
house using the synthetic strategy previously outlined by Curti and colleagues [31] and following
known procedures reported in the literature [32,33]. Feruloylglycine, 4-hydroxyhippuric acid,
quercetin 3′-O-sulfate, hesperetin 3′-O-glucuronide, and hesperetin 7-O-glucuronide were kindly
supplied by Professor Alan Crozier. Vanillic acid and (3-methoxy, 4-hydroxyphenyl)acetic acid were
purchased from Alfa Aesar (Thermo Fisher (Kandel) GmbH, Postfach, Karlsruhe, Germany) and from
Extrasynthese (Genay Cedex, France), respectively. Naringenin 4′-O-glucuronide and naringenin
7-O-glucuronide were purchased from Bertin Pharma (Montigny le Bretonneux, France). Ultrapure
water from MilliQsystem (Millipore, Bedford, MA, USA) was used throughout the experiment.
2.5. Plasma Extraction
Plasma samples of all volunteers were extracted using a solid phase extraction (SPE) method
as reported by Urpi-Sarda and colleagues, with some modifications [34]. Oasis® HLB Vac cartridges
(1 cc, 30 mg sorbent, 30 μm particle size) (Waters, Milford, Massachusetts, MA, USA) were conditioned
with 1 mL of methanol and equilibrated with 1 mL of water. An aliquot of 800 μL of plasma was
added with 16 μL of o-phosphoric acid (2.5%) and then loaded into cartridges. The cartridges were
washed with 1 mL of acidified water (0.1% formic acid) and finally eluted with 1 mL of methanol
containing formic acid (1.5 mol/L). The eluates were evaporated overnight to dryness by means of a
rotary speed-vacuum at room temperature and reconstituted with 80 μL of methanol/acidified water
(0.1% formic acid) (50:50 v/v) prior uHPLC/MSn analysis.
2.6. UHPLC/MSn Analysis
Plasma extracts were analyzed by a UHPLC DIONEX Ultimate 3000 equipped with a triple
quadrupole TSQ Vantage (Thermo Fisher Scientific Inc., San Josè, CA, USA) fitted with a heated-ESI
(H-ESI) (Thermo Fisher Scientific Inc., San Josè, CA, USA) probe. Separations were carried out by
means of a Kinetex EVO C18 (100 × 2.1 mm) column, 1.7 μm particle size (Phenomenex, Torrance,
CA, USA).
For UHPLC, mobile phase A was acetonitrile containing 0.2% formic acid and mobile phase B
was 0.2% formic acid in water. The gradient started with 5% A, isocratic conditions were maintained
for 0.5 min, and reached 95% A after 6.5 min, followed by 1 min at 95%. The starting gradient was
then immediately reestablished and maintained for 4 min to re-equilibrate the column. The flow rate
was 0.4 mL/min, the injection volume was 5 μL, and the column temperature was set at 40 ◦C.
The applied mass spectrometry (MS) method consisted in the selective determination of each
target precursor ion by the acquisition of characteristic product ions in selective reaction monitoring
(SRM) mode (Table 1), applying a negative ionization.
4
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To optimize the method, all the available standard compounds were infused into the MS to set
the best mass parameters and to check the actual fragmentation patterns. Finally, for all the analyses,
the spray voltage was set at 3 kV, the vaporizer temperature at 300 ◦C, and the capillary temperature
operated at 270 ◦C. The sheath gas flow was 60 units, and auxiliary gas pressure was set to 10 units.
Ultrahigh purity argon gas was used for collision-induced dissociation (CID). The S-lens values
were defined for each compound based on infusion parameter optimization (Table 1). Conversely,
for compounds that were not available for infusion, the S-lens values were set using the values obtained
for the chemically closest available standards. Quantification was performed with calibration curves
of standards, when available (Table 1). Data processing was performed using Xcalibur software
(Thermo Scientific Inc., Waltham, MA, USA). All data were expressed as mean values ± SEM.
3. Results
(Poly)Phenolic Compound Absorption
The capsules consumed in the present study were previously characterized for (poly)phenolic
profile and quantified for their total phenolic content [23]. Capsules were made of 36 different plant
matrices, and contained a wide array of different phenolic compounds, principally ellagitannins,
flavan-3-ols, flavonols, and anthocyanins in berry blend capsules, flavones, flavonols, flavanones,
and anthocyanins in fruit blend capsules, and flavones and flavonols in vegetable blend capsules.
Out of the 92 monitored molecules, 20 quantifiable metabolites were identified, or tentatively
identified in plasma samples. All the quantified metabolites were found as conjugated compounds
with sulfate, glucuronide or glycine moieties. Three glycine-conjugated metabolites, hippuric acid,
4-hydroxyhippuric acid, and feruloylglycine, were detected. A total of five metabolites were flavonol
derivatives, including conjugates of quercetin, kaempferol, myricetin, and patuletin. Three metabolites
were directly linked to flavanone metabolism, namely naringenin, and hesperetin derivatives, whereas
only one flavone metabolite, namely diosmetin sulfate, was detected. Among flavan-3-ol derivatives,
three conjugated phenyl-γ-valerolactones were detected. Finally, five metabolites were small phenolic
derivatives, including hydroxyphenylpropionic acid sulfate, ferulic acid glucuronide, pyrogallol
sulfate, dihydroxybenzoic acid sulfate, and methyl-trihydroxybenzoic acid sulfate. Generally, with the
exception of hippuric acid, plasma levels of the quantified metabolites did not exceed the nanomolar
range. Considering those metabolites for which the origin is strictly attributable to (poly)phenolic
compounds contained in the capsules, the most abundant metabolites resulted in the low molecular
weight phenolics which are usually produced in the colon by microbial transformation of flavonoids.
The glycine-conjugated metabolites are ubiquitous and could originate both by endogenous
precursors [18,35] and by microbial metabolism of phenolic compounds [36–38]. Their potential
endogenous origin justifies the high concentration at baseline (Figure S1).
Actually, the absorption curves of hippuric acid and 4-hydroxyhippuric acid did not show a
notable concentration peak and their levels were basically constant during the study period. On the
contrary, feruloylglycine exhibited a peak plasma concentration 2 h after consumption, indicating
a stronger connection with the phenolic compounds introduced through the capsules, as only the
capsules were consumed within the 2 h.
Looking to the other circulating metabolites appearing after capsule consumption, two metabolic
phases could be easily distinguished. Conjugated metabolites appearing in the circulatory system
within 1 or 2 h after capsule ingestion suggest an absorption in the first part of the gastro-intestinal
tract. Native compounds are rapidly hydrolysed to release the aglycones, which are then conjugated
by sulfotransferases (SULTs) and uridine-5′-diphosphate glucuronosyltransferases (UGTs) at both
enterocyte and hepatic level before entering the systemic circulatory system [18]. Kaempferol
glucuronide, quercetin glucuronide, quercetin sulfate, myricetin glucuronide, and diosmetin sulfate
absorption curves are the expression of (poly)phenol metabolism in the first gastro-intestinal tract
(Figure 1).
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Figure 1. Absorption curves of kaempferol glucuronide, quercetin glucuronide, quercetin sulfate in
graph (A); and myricetin glucuronide and diosmetin sulfate in graph (B). Data are expressed as mean
values and bars represent standard error of means (SEM).
A concentration peak recorded between 5 and 10 h after test meal indicates, instead, a clear
interaction between the indigested (poly)phenolic fraction and the colonic microbiota. The absorption
profile outlined by patuletin sulfate and hesperetin sulfate likely represents a colonocyte level
absorption and a subsequent conjugation at hepatic level (Figure 2). Actually, their plasmatic
concentration reached a maximum level 5 h post capsule consumption.
Two quantified metabolites, namely naringenin glucuronide and hesperetin glucuronide, showed
a double phase metabolism (Figure 3).
Probably, naringenin and hesperetin were partially cleaved in the first gastro-intestinal tract and
rapidly absorbed and metabolized at intestinal/hepatic level, resulting in a first peak approximately
1 h after capsule ingestion. However, the peak between 5 and 10 h indicates a more important role of
the colonic microbiota in flavanone metabolism [30]. Similarly, ferulic acid glucuronide absorption
profile showed a double phase curve (Figure 3). Nevertheless, no ferulic acid was detected in the
capsules [23], suggesting that this compound probably originated by catechol-O-methyltransferase
(COMT) activity on other hydroxycinnamic acids present in the capsules [39].
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Figure 2. Absorption curves of patuletin sulfate in graph (A) and hesperetin sulfate in graph (B). Data
are expressed as mean values and bars represent standard error of means (SEM).
Figure 3. Absorption curves of naringenin glucuronide, hesperetin glucuronide, and ferulic acid
glucuronide. Data are expressed as mean values and bars represent standard error of means (SEM).
Finally, most (poly)phenolic compounds passing unmodified and unabsorbed through the
first gastro-intestinal tract become a suitable substrate for the locally hosted microbiota. Several
modifications on native compounds have been reported to be catalyzed by microbial enzymes,
resulting in the formation of low molecular weight compounds [40], which are efficiently absorbed by
colonocytes before hepatic conjugation.
9
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The three phenyl-γ-valerolactone derivatives, hydroxyphenylpropionic acid, pyrogallol,
dihydroxybenzoic acid, and methyl-trihydroxybenzoic acid, having a peak concentration registered
within 5 or 10 h, are typical metabolites generated by the host microbiota activity [41–43] (Figure 4).
Figure 4. Absorption curves of phenyl-γ-valerolactone-3′-O-sulfate, (4′-hydroxyphenyl)-γ-
valerolactone-3′-O-sulfate, and (4′-hydroxyphenyl)-γ-valerolactone-3′-O-glucuronide in graph (A);
hydroxyphenylpropionic acid sulfate and (dihydroxybenzoic acid sulfate in graph (B); and pyrogallol
sulfate and methyl-trihydroxybenzoic acid sulfate in graph (C). Data are expressed as mean values and
bars represent standard error of means (SEM).
4. Discussion
In the present study, the absorption profile of (poly)phenolic compounds derived from
the ingestion of Juice PLUS+® berry, fruit and vegetable blend capsules has been investigated.
A total of 20 circulating metabolites have been identified, or tentatively identified, and quantified.
As expected, detected metabolites derived from different (poly)phenols and appeared at different
10
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times in plasma. Flavonol metabolites principally originated in the first part of the gastro-intestinal
tract, as previously reported by other authors. Feliciano and colleagues [41] reported a time to
reach the maximum plasma concentration (Tmax) for kaempferol 3-O-glucuronide and quercetin
3-O-glucuronide of about 2 h. An absorption curve similar to those reported in the present study
for quercetin 3-glucuronide and quercetin 3-sulfate was reported by Mullen and colleagues, who
highlighted a concentration peak between 1 and 2 h after onion ingestion [44]. To the best of
our knowledge, this is the first study in which plasma concentrations of patuletin and myricetin
metabolites have been reported, suggesting that other flavonols could be effectively absorbed and
hence investigated for their potential bioactivity. Moreover, a new flavone metabolite at plasmatic
level has been detected, namely diosmetin sulfate. Its early peak plasma level registered at 1 h
is in contrast with scientific data previously reported for other flavones, like apigenin. The Tmax
of apigenin (measured as aglycone after enzymatic hydrolysis) has been reported to be around
7 h after consumption of parsley [45]. The few human feeding studies involving flavones available
so far reported a low bioavailability for this phytochemical [18,46], which could be ascribable to
the low absorption of flavones, as demonstrated in the present investigation. Conversely, several
scientific data are available for naringenin and hesperetin absorption, and all studies agree about
the importance of colonic microbiota activity on this class of (poly)phenols [47–49]. The absorption
curves observed in the present work confirm that flavanone metabolism principally occurs in the large
intestine. Brett and colleagues reported a plasma concentration peak of flavanone conjugates 6 h after
orange consumption [50], whereas the highest naringenin and hesperetin derivative urinary excretion
has been reported within 2 and 10 h after orange juice consumption [30]. Flavan-3-ols were the most
representative compounds in berry blend capsules [23]. However, no catechin monomer conjugates
nor dimers or oligomeric proanthocyanidins were detected in plasma. However, in vivo studies have
shown that both monomers and high molecular weight flavan-3-ols are effectively degraded by the gut
microbiota into hydroxyphenyl-γ-valerolactones [51–53]. Many phenyl-γ-valerolactone derivatives
have been detected after green tea [51,54], cocoa [34,55,56], wine [57] and almond [58] consumption.
Partially compensating for the absence of flavan-3-ol monomers in plasma in the present study,
three phenyl-γ-valerolactones were detected and quantified.
It was then demonstrated that phenyl-γ-valerolactones represent an intermediate step in the
microbial metabolism of flavan-3-ols and that other low molecular weight compounds, such as
phenylacetic, phenylpropionic, benzoic acids derivatives [59] and hippuric acid, which derive from
benzoic acids [60], could be formed. Likewise, flavonols, flavones, and flavanones, could be degraded
into smaller phenolics, namely phenylacetic, phenylpropionic, and benzoic acid derivatives [61].
Similarly, anthocyanins undergo an important colonic set of transformations, giving rise to low
molecular weight metabolites. After glucosidic cleavage of the sugar moiety, cyanidin could
be the precursor of caffeic acid, from which ferulic and isoferulic acids could be formed after
COMT activity [62–64]. Ferulic acid may undergo further phase II metabolism, namely sulfation
and glucuronidation, generating conjugated ferulic derivatives [39,65]. Feliciano and colleagues
recently hypothesized that peonidin could also lead to the formation of ferulic acids [41]. Moreover,
anthocyanins could be converted into small phenolics such as phenylpropionic, phenylacetic, benzoic
acids, and pyrogallol [62,64,66].
Concerning pyrogallol, the high plasmatic concentration of pyrogallol sulfate between 5 and 10 h
recorded in the present study is in agreement with a Tmax reported after cranberry consumption [41].
Gallic acid, which was present in the capsules, could have contributed to the formation of small
metabolites [67], but also to other compounds like methylgallic acid [68], and, after phase II metabolism,
to its 3-O-sulfate derivative [69].
It now appears clear that the extensive bioconversion of (poly)phenol compounds strictly depends
on the characteristics of individual colonic microbiota, and differences in microbiota composition
now allow to discriminate phenotypes associated with producers and non-producers of specific
metabolites [67,70,71]. As a matter of fact, inter-individual differences in the intestinal ecology may
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lead to differences in bioavailability, linked to specific metabolite production and, ideally, to differences
in health benefits [72]. In the present study, the absorption of phenolics and the production of
their metabolites is accompanied by a considerable inter-individual variability, plausibly due to the
interaction between these compounds and the gut microbiota of the host. A clear example of this
large variability among participants concerns the circulating concentration of phenyl-γ-valerolactones
resulting from the catabolic transformations of catechins and procyanidins, operated mainly by
Clostridium coccoides and Bifidobacterium spp. [73]. By analyzing the absorption curves of each
participants, five subjects resulted as abundant producers of phenyl-γ-valerolactones, whereas
the remaining subjects produced only extremely small amounts of these compounds (data not
shown), suggesting marked variations in the colonic microflora of the individual volunteers. The
inter-individual variability can affect not only the quantity of metabolites but also the timing of
their appearance. For instance, the wide bars observed in the curves of kaempferol glucuronide are
ascribable to the fact that these metabolites disappeared after 5 and 10 h in almost all the participants
with the only exception of two subjects, who showed a second, later peak, probably due to colonic
absorption. Considering this large variability, there is an increased interest in stratifying future
study participants based on their polyphenol-metabolizing phenotypes (i.e., metabotypes) [72], and
the present study supports the hypothesis that this variability should be carefully considered as a
confounder of in vivo studies evaluating health effects of these phytochemicals. Finally, considering
all the circulating detected metabolites, excluding those compounds whose origin could be attributed
to endogenous precursors, such as hippuric acid, 4-hydroxyhippuric acid, and feruloylglycine [18,35],
a “global” curve could be depicted to summarize the totality of quantified phenolic metabolites
at every specific time point (Figure 5). Observing this graph, some considerations can be drawn:
(i) the absorption and metabolism of (poly)phenols in the first gastro-intestinal tract (1–2 h after capsule
ingestion) is low when compared to what occurs in the colon (5–10 h after capsule consumption);
(ii) the plasma curves of the phenolic metabolites clearly highlighted the deep interaction between these
compounds and the gut microbiota; (iii) the beneficial effects attributed to the regular consumption
of these capsules does not depend on very high concentration of phenolic metabolites circulating
after their consumption. In fact, plasmatic metabolites rarely exceeded nanomolar concentrations, as
previously reported [18,19]. However, the effect of the regular and long time intake of these products
may modify the way our organism interacts with the contained phenolics, perhaps improving its ability
to absorb some of them at small intestinal level. Moreover, a modulation of the colonic microbiota
in the long run seems plausible, perhaps in the direction of improved transformations, leading to
increased absorption of microbial metabolites. Finally, the large variability observed in this short acute
absorption study should be taken into consideration in future interventions, as not all the recruited
volunteers might deal with Juice PLUS+® phenolics in the same way.
Figure 5. Total concentration of all circulating (poly)phenol metabolites, excluding hippuric acid,
4-hydroxyhippuric acid, and feruloylglycine. Data are expressed as mean values.
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5. Conclusions
In conclusion, the consumption of Juice PLUS+® Vineyard, Fruit, Vegetable blend, containing
36 different fruits, vegetables, and berries, allowed the effective absorption of several (poly)phenolic
compounds. The capsules therefore ensure potential health-promoting molecules to be potentially
available to target tissues and organs, presumably becoming responsible for the previously observed
health effects.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/9/3/194/s1,
Table S1: List of forbidden and permitted foods during the (poly)phenol-poor diet. Figure S1: Absorption curves
of (a) hippuric acid, (b) 4-hydroxyhippuric acid, (c) feruloylglycine. Data are expressed as mean values and bars
represent standard error of means (SEM).
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Abstract: Epidemiological studies have examined the effect of coffee intake on cardiovascular disease,
but the benefits and risks for the cardiovascular system remain controversial. Our objective was
to evaluate the association between coffee consumption and its polyphenols on cardiovascular risk
factors. Data came from the “Health Survey of São Paulo (ISA-Capital)” among 557 individuals,
in São Paulo, Brazil. Diet was assessed by two 24-h dietary recalls. Coffee consumption was
categorized into <1, 1–3, and ≥3 cups/day. Polyphenol intake was calculated by matching
food consumption data with the Phenol-Explorer database. Multiple logistic regression models
were used to assess the associations between cardiovascular risk factors (blood pressure, total
cholesterol, low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c),
triglycerides, fasting glucose, and homocysteine) and usual coffee intake. The odds were lower
among individuals who drank 1–3 cups of coffee/day to elevated systolic blood pressure (SBP)
(Odds Ratio (OR) = 0.45; 95% Confidence Interval (95% CI): 0.26, 0.78), elevated diastolic blood
pressure (DBP) (OR = 0.44; 95% CI: 0.20, 0.98), and hyperhomocysteinemia (OR = 0.32; 95% CI: 0.11,
0.93). Furthermore, significant inverse associations were also observed between moderate intake
of coffee polyphenols and elevated SBP (OR = 0.46; 95% CI: 0.24, 0.87), elevated DBP (OR = 0.51;
95% CI: 0.26, 0.98), and hyperhomocysteinemia (OR = 0.29; 95% CI: 0.11, 0.78). In conclusion, coffee
intake of 1–3 cups/day and its polyphenols were associated with lower odds of elevated SBP, DBP,
and hyperhomocysteinemia. Thus, the moderate consumption of coffee, a polyphenol-rich beverage,
could exert a protective effect against some cardiovascular risk factors.
Keywords: coffee consumption; coffee polyphenol intake; cardiovascular risk factors;
representative sample
1. Introduction
Cardiovascular diseases (CVD) are considered to be the leading global cause of death, accounting
for 17.3 million deaths per year, which is predicted to rise to more than 23.6 million by 2030 [1].
The main causes of CVD involve non-modifiable risk factors, in addition to the metabolic risk factors,
that are targeted together with the behavioral risk factors, such as unhealthy diets (rich in salt, saturated
fat, and calories) [2]. However, there are still food items whose role is controversial, such as coffee.
Coffee has been considered an important dietary factor, because it is one of the most popular and
widely consumed nonalcoholic beverages in the world. Finland is the largest coffee consumer market,
followed by Brazil. In Brazil, the average coffee consumption is 5.9 kg per capita [3], with an estimated
prevalence of intake of 79%, i.e., the second-most consumed food in the country [4].
Coffee beverage, a mixture of several pharmacologically-bioactive compounds, including caffeine,
phenolic acids, and the diterpene alcohols, cafestol and kahweol, can also have long term effects on
Nutrients 2017, 9, 276; doi:10.3390/nu9030276 www.mdpi.com/journal/nutrients18
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risk factors for CVD, such as blood pressure, plasma concentrations of cholesterol and homocysteine,
and the incidence of type 2 diabetes mellitus [5–7].
Caffeine, a central nervous system stimulant and psychoactive substance, has been positively
associated with blood pressure [8,9], systemic vascular resistance and unfavorable effects on
endothelial function [9], serum lipids concentration [10], and insulin resistance [11]. Other prospective
studies, however, have generally not supported adverse risk effects on CVD associated with coffee
consumption [12–14]. The major beneficial properties of coffee seem to depend on its content
of phenolic acids, which demonstrates protective roles in the cardiovascular system [15]. This
cardiovascular protection has been demonstrated in vivo, and can be explained by various mechanisms,
including their anti-inflammatory properties [16], the strong antioxidant capacity [17] related to nitric
oxide (NO) bioavailability, as well as low-density lipoprotein (LDL) oxidation, and antithrombotic
properties through endothelial protection [18].
Contrary to earlier studies focused on caffeine, existing evidence is suggesting that coffee may
exert a beneficial effect toward cardiovascular-related outcomes, together with all-cause and cancer
mortality [19]. However, the public debate about reducing or increasing the risk of CVD by drinking
coffee is still relevant due to the previous contrasting findings on cardiovascular effects. Additionally,
its effects on CVD might have considerable public health and clinical implications [12].
Therefore, the current study aimed to assess the association between usual coffee consumption and
coffee polyphenol intake on cardiovascular risk factors, e.g., systolic and diastolic blood pressure, total
cholesterol, low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c),
triglyceride, fasting plasma glucose, and homocysteine, in a representative sample of individuals aged
20 years or older in São Paulo City.
2. Materials and Methods
2.1. Study Population
Data were retrieved from the “Health Survey of São Paulo (ISA-Capital)”, a cross-sectional
population-based study designed to assess the health and nutritional status of non-institutionalized
individuals residing in São Paulo City in Southeastern Brazil, between 2008 and 2009.
A complex probabilistic sampling, by conglomerates, based on census tracts and households
that had already been drawn in the National Household Sample Survey 2005 (PNAD 2005) was used.
The drawing was systematic, and eight study domains were defined: less than one year old; one to
11 years old, and three more age groups by sex: 12 to 19 years (adolescents), 20 to 59 years (adults),
and 60 years or over (older adults). A minimum sample size of 300 in each of the six domains was
estimated to be needed based on a prevalence of 0.5 with a standard error of 0.07 at a 5% significance
level and a design effect of 1.5.
A total of 2691 individuals, aged 12 years or over, were selected to answer questions about
diet, life conditions, and sociodemographic information. Thereby, only 1662 individuals of the initial
sample agreed to participate. Of those, 750 subjects provided a blood sample for biochemical analysis,
completed two 24-h dietary recalls (24 HR), anthropometric data, as well as arterial blood pressure
measurements. For the present study, only adults and older adults were included, totaling a final
sample of 557 individuals.
The study protocol was reviewed and approved by the Ethics Committee at the School of Public
Health, University of São Paulo (Approval Number: 003.0.162.000-08). A written informed consent
form was obtained from all participants.
2.2. Dietary Assessment
The dietary intake was measured by two 24 HR. The first 24 HR was administered at households
by trained interviewers using the multiple pass method [20]; the second 24 HR was performed by
telephone using the automated multiple pass method [21]. The multiple pass method, automated
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or not, is structured in five steps: (1) a quick list, where participants list all of the foods and
beverages consumed uninterruptedly; (2) a forgotten list, where participants are asked about commonly
consumed forgotten foods, such as candies, coffees, and sodas; (3) time and location of food and
beverage intake; (4) detailing cycle, that is, a description of the way of preparation and amounts
consumed; and (5) a final review, which verifies whether a certain food consumed during the day was
not previously recorded. The sampling days covered all the days of the week and seasons. Dietary
data were entered into the Nutrition Data System for Research software (version 2007, University of
Minnesota, Minneapolis, MN, USA), which is mainly based on data from the food composition table
published by the United States Department for Agriculture (USDA).
The multiple source method (MSM), a statistical modeling technique, was used to estimate the
usual dietary intake of polyphenols and nutrients and to remove within-person variation. In the
first step, the probability of eating the food on a random day for each individual was estimated by
a logistic regression model. Secondly, the usual amount of food or nutrient intake is estimated by a
linear regression model. Finally, the resulting numbers from step one and two are multiplied by each
other to estimate the usual daily intake for each individual [22].
2.2.1. Assessment of Coffee Consumption
In the 24 HR, the participants reported if they consumed coffee on the day before the interview
and, thereafter, a question about the method of coffee preparation (filtered, instant, espresso, or other),
and whether additional items were typically added to the coffee (none, milk, sugar, artificial sweetener,
etc.) were probed. Daily coffee intake (in mL) was categorized, according to the standard cup size used
in the study (50 mL), into three categories: <1 cup/day, 1–3 cups/day, and ≥3 cups/day. The category
of <1 cup/day of coffee was used as the reference group.
2.2.2. Estimation of Polyphenol Intake from Coffee
Data on the polyphenol content in foods were obtained from the Phenol-Explorer database [23]
that presents data on the content of 502 polyphenols in 452 foods [24].
The polyphenol intake was calculated by matching usual food intake data from the 24HR with
the polyphenol content in foods from the Phenol-Explorer database. The individual polyphenol intake
from each food was calculated by multiplying the content of each polyphenol by the daily consumption
of each food, including coffee. The total polyphenol intake was the sum of all individual polyphenol
intakes from all food sources reported in the 24 HR. Other details on the estimation of polyphenol
intakes are available elsewhere in previous publications [25].
For the present study, the classes of polyphenols ingested from coffee included the phenolic
acids, especially hydroxycinnamic acids (4-caffeoylquinic acid, 5-caffeoylquinic acid, 3-caffeoylquinic
acid, 5-feruloylquinic acid, caffeic acid), alkylmethoxyphenols (4-ethylguaiacol, 4-vinylguaiacol), and
others (catechol, pyrogallol, phenol). The coffee polyphenols were categorized into three categories:
<101 mg/day (corresponding to <1 cup coffee/day), 101–337 mg/day (corresponding to 1–3 cups/day),
and ≥337 mg/day (corresponding to ≥3 cups/day).
2.3. Demographic and Lifestyle Characteristics
Sociodemographic and lifestyle characteristics included age, sex, household per capita income,
smoking status, alcohol drinking, and the use of medicines.
The physical activity included energy expenditure in leisure time by reporting type and duration
of activity according to the predetermined questionnaire items of the long version of the International
Physical Activity Questionnaire (IPAQ) [26], validated in Brazil. The physical activity level was
categorized as daily low, moderate and high. In the current study, physical activity was grouped in
two categories: low and moderate/high. More details for levels of physical activity proposed by IPAQ
are available online [27].
The smoking status was categorized as nonsmoker and current smoker or former smoker.
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2.4. Anthropometric Measurements
Anthropometric measurements were obtained in participant homes by a trained nursing assistant
following the procedures recommended by the WHO [28]. Body weight (kg) was measured using
a calibrated digital scale (Tanita®, model HD-313, Tanita Corporation of America, Inc., Arlington
Heights, IL, USA). Height (cm) was measured with a portable wall-mounted stadiometer (Seca®,
model 208, Seca Brazil, São Paulo, Brazil). Body mass index (BMI) was calculated by dividing weight
(kilograms) by the square of the height (meters).
2.5. Outcome Measurements
2.5.1. Blood Pressure (BP)
During the home visit, BP was measured using an automatic blood pressure monitor (Omron
HEM-712C, Omron Health Care, Inc., Vernon Hills, IL, USA) handled by a nursing technician,
according to the recommendations of the V Brazilian Guidelines on Hypertension [29]. Participants
were considered to have high BP if they had systolic (SBP) and/or diastolic (DBP) higher or
equal to 140 mmHg and 90 mmHg, respectively, according to the national and international
recommendations [29,30].
2.5.2. Blood Samples
The blood samples were collected by venipuncture after 12-h of overnight fasting by a nursing
assistant, using a standardized protocol.
Serum total cholesterol (TC) and fractions, LDL-c and HDL-c, as well as triglyceride (TG), were
determined by enzymatic-colorimetric method (Roche Diagnostics GmbH, Mannheim, Germany).
We considered the cut-off point value for elevated TC level ≥200 mg/dL, for elevated LDL-c
>100 mg/dL, reduced HDL-c <40 mg/dL in males or <50 mg/dL in females, and elevated TG
≥150 mg/dL [31].
Fasting plasma glucose (FPG) was measured by enzymatic-colorimetric glucose oxidase procedure
using the kit gluco-quant Glucose/HK (GLU Roche/Hitachi 1,447,513; Roche Diagnostics GmbH,
Mannheim, Germany). The cut-off value for elevated fasting glucose level was ≥100 mg/dL [31].
The immunoassay method of chemiluminescence microparticles using the ARCHITECT
Homocysteine Reagent Kit (Abbott Diagnostics Division, Abbott Park, Lake Forest, IL, USA) was used
to analyze the plasma concentrations of homocysteine. We selected the value of plasma homocysteine
>16 μmol/L for older adults and a value >12 μmol/L for adults, as cut-off point for categorization in
hyperhomocysteinemia [32].
2.6. Statistical Analysis
The characteristics of the study participants were described by coffee consumption
categories, and presented as medians and interquartile range (IQR) for continuous variables, and
frequencies and percentages for categorical variables. The variables were examined for normality
(Kolmogorov-Smirnov test). Differences between coffee consumption categories were tested by
Kruskall-Wallis test for continuous variables, and by the Chi-square test for categorical variables.
The associations between the independent variables (categories of usual coffee consumption and
coffee polyphenol intake) and the following dependent variables (i.e., SBP, DBP, FPG, serum TC, LDL-c,
HDL-c, TG, and homocysteine) were tested by multiple logistic regression analysis.
Two models were fitted for each independent variable. The first model was the crude model
(unadjusted). The second model (adjusted), corresponding to models 1, 2, 3, and 4, was adjusted for
classic potential confounders (i.e., age, sex, race, BMI, smoking status, alcohol consumption, physical
activity level, household per capita income, intake of caffeine, added sugars, total energy intake,
and saturated fat), and additionally adjusted for particular variables hypothesized to be associated
with each cardiovascular risk factor, according to the literature. Thus, model 1 corresponded to both
21
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SBP and DBP was additionally adjusted for sodium intake, and antihypertensive drugs; model 2
corresponded to fasting plasma glucose was additionally adjusted for hypoglycemic drugs; model
3 corresponded to TC, LDL-c, HDL-c, and TG was additionally adjusted for monounsaturated fat,
polyunsaturated fat, and hypolipidemic medicines; and lastly model 4 corresponded to homocysteine
was additionally adjusted for folate, B6, and B12 vitamins.
All analyses were conducted using the appropriate sample weights to account for the complex
survey design. For all analyses, Stata® statistical software package version 12 (StataCorp LLC, College
Station, TX, USA) was used and a p-value < 0.05 was considered statistically significant.
3. Results
The final study population had a mean age of 45.1 years, mostly women (54.2%), self-declared
white (61.1%), non-smokers (58.4%), insufficiently active (77.7%), and non-obese (74.5%).
The mean of coffee consumption for the whole population was 143.4 mL/day. A minority of
participants consumed espresso coffee (n = 7), and there were no decaffeinated coffee consumers in the
current study population. Furthermore, the median total intake of polyphenols was 363.9 mg/day.
Coffee provided 247.0 mg/day of polyphenols, which represented approximately 68% of the
total intake.
The sociodemographic, biochemical, and dietary characteristics of the studied population
according to coffee consumption categories are shown in Table 1. Coffee drinking was higher in
older adults than in adults, and among current smokers than in non-smokers. Differences were also
observed between the usual coffee consumption and polyphenols intake from coffee, and caffeine
intake. A further significant difference by coffee consumption was found with prevalence of DBP.
The associations between coffee consumption categories and cardiovascular risk factors are
presented in Table 2. The adjusted models demonstrated lower odds for SBP, DBP, and homocysteine
in individuals that were consuming 1–3 cups of coffee per day, than in individuals who drank less than
1 cup of coffee per day to elevated SBP (Odds Ratio (OR) 0.45, 95% Confidence Interval (95% CI): 0.26,
0.78); elevated DBP (OR 0.44, 95% CI: 0.20, 0.98), and hyperhomocysteinemia (OR 0.32, 95% CI: 0.11,
0.93). For those subjects with higher consumption (≥3 cups/day), the association was not significant
for any cardiovascular risk factors.
Table 3 shows the association between the same cardiovascular risk factors and categories of coffee
polyphenols in this population. After adjustment for potential confounding factors, OR showed that a
moderate intake of coffee polyphenols (101 to 337 mg/day) was inversely associated with elevated SBP
(OR 0.46, 95% CI: 0.24, 0.87), elevated DBP (OR 0.51, 95% CI: 0.26, 0.98), and hyperhomocysteinemia
(OR 0.29, 95% CI: 0.11, 0.78).
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4. Discussion
The current study found that a moderate coffee consumption (1 to 3 cups per day), which
corresponds to a coffee polyphenol intake of 101–337 mg/day, had a beneficial effect on cardiovascular
risk factors, such as, elevated SBP, elevated DBP, and hyperhomocysteinemia.
Previous epidemiological studies on the benefits of coffee consumption on the cardiovascular
system have provided inconsistent and conflicting results [33]. In this way, some studies suggested a
positive association between coffee consumption and risk of CVD [34,35], whereas others reported
no association [36,37], or even an inverse association [12–14]. Therefore, these controversial findings
may be due to the different types of studies, with different designs performed in distinct populations.
Additionally, inconsistent and conflicting results may be related to the various confounding dietary
factors, different forms of brewing coffee and the daily amount consumed.
Numerous risk factors for CVD have been described in the literature, and elevated BP is a
recognized and well-established risk factor for coronary heart disease and stroke. A large number of
epidemiological studies on the effect of coffee or caffeine on BP has been published, but they have
provided conflicting results, and the effect of chronic coffee consumption on BP is still unclear [9,38].
A meta-analysis of randomized controlled clinical trials has concluded that regular coffee consumption
slightly increases systolic and diastolic BP [8]. Interestingly, Noordzij et al. [8] showed that the
BP elevations were larger in the studies using caffeine than in the studies on coffee consumption.
In agreement with these findings, another recent systematic review and meta-analysis reports
that BP elevations appeared to be significant only for caffeine but not for coffee consumption [9].
The prevailing explanation for such effect is that caffeine antagonizes endogenous adenosine, resulting
in vasoconstriction and elevated total peripheral vascular resistance [39]. Moreover, although these
results suggesting that caffeine acutely increasing BP, its effects may be somehow attenuated if ingested
as coffee, so, it seems that other compounds in the coffee could potentially counterbalance the pressor
effect of caffeine [8]. Coffee is a drink with a very complex chemical composition, rich in BP-lowering
minerals (that is, potassium and magnesium) and antioxidant compounds (phenolic acids) that may
outweigh the hypertensive effects of caffeine [40]. The beneficial effects of these other components
in the cardiovascular system, may help explain the lack of association between long-term coffee
consumption and increase BP or CVD risk in large cohort studies [9].
It was observed in our study that moderate coffee drinking was associated with lower odds of
elevated SBP and DBP, especially due to the presence of polyphenols. The high content of phenolic
compounds in coffee, especially due to the group of hydroxycinnamic acids (caffeic, chlorogenic, feluric,
and p-coumaric acids), exhibits a strong antioxidant activity, and protects against atherothrombosis
or atherosclerotic lesion development through endothelial protection (attenuates oxidative stress,
improved NO bioavailability, and decreased E-selectin, intercellular adhesion molecule-1 (ICAM-1),
and vascular cell adhesion protein-1 (VCAM-1) expression, among others) [18,41]. In this context,
investigations during the last decade have implied that chlorogenic acid consumption can have
a significant lowering effect on BP [42,43]. This hypotensive effect might involve nitric oxide
(NO)-mediated vasodilation, and improvement of endothelial function. In this way, the dietary
intake of chlorogenic acids may hold promise for providing a non-pharmacological approach for the
prevention and treatment of high BP [42].
Increased concentrations of total plasma homocysteine have been associated with an increased
risk of cardiovascular disease [6,41]. Therefore, modifiable factors can influence homocysteine levels.
Besides folate intake i.e., the most important dietary determinant of plasma total homocysteine
concentration, coffee consumption has an effect on total homocysteine levels in the general
population [44].
A positive association, in a dose-dependent manner between homocysteine concentrations and
coffee consumption, was reported in a cross-sectional study [44] and has confirmed in randomized
controlled trials [45,46]. Grubben et al. [45] have suggested that 10% higher concentration of
homocysteine is associated with very high intake of unfiltered coffee (1 L/day), but it is not clear
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whether the serum lipid fraction, i.e., cholesterol-raising diterpenes present exclusively in unfiltered
coffee, is the only factor responsible for the increase in homocysteine concentration. Although the
authors were not able to conclude whether this association depends on the brewing method, it seems
that unfiltered coffee is more likely to increase total homocysteine than filtered coffee. They speculated
that the effect of coffee, mediated by caffeine, on increased plasma homocysteine concentrations
could be due to a decrease in blood vitamin B6 concentration, a vitamin related to homocysteine
metabolism, whose deficit results in higher production of homocysteine. Additionally, chlorogenic
acid, a polyphenol that is present in coffee, may also be partly responsible for the increase of the
homocysteine production through increased methylation reactions [47].
On the other hand, moderate coffee consumption among healthy subjects did not significantly
increase the homocysteine concentration [48], and a population based-study described that coffee was
no longer associated with plasma homocysteine after adjustment for plasma folate concentration [49].
In addition, Mursu et al. [50] found similar results and showed that the consumption of filtered coffee
has neither short- nor long-term detectable effects on lipid peroxidation nor on plasma homocysteine
concentrations in healthy non-smoking men. More recently, according to Corrêa et al. [51] in Brazilian
population, no changes were observed for plasma total homocysteine, after the consumption of three
or four cups of paper-filtered coffee per day. The inconsistencies between the above-mentioned
epidemiological studies suggest that not all types of coffee brew have the same effect on plasma
homocysteine concentrations or that the effect is spurious.
In the current study, we reported that individuals who were consuming more than three cups of
filtered coffee per day had lower odds (even not significant) for hyperhomocysteinemia, and moderate
consumption of filtered coffee and the polyphenols intake from coffee were inversely associated
with hyperhomocysteinemia. A possible hypothesis for this finding is that caffeic acid inhibited
hyperhomocysteinemia, elicited leukocyte rolling and adhesion, decreased reactive oxygen species
production and activation of cyclooxygenase-2 (COX-2) in endothelial cells. Additionally, caffeic
acid was seen to reduce the expression of adhesion molecules such as E-selectin and ICAM-1 on
endothelium and integrin CD11b/CD18 (Mac-1 (macrophage-1 antigen)) on leukocytes caused by
hyperhomocysteinemia [52,53]. However, the biological mechanisms involved on the effect of coffee
consumption on homocysteine concentrations are still unclear and need further investigation.
In addition, coffee consumption has also been associated with alterations in circulating lipids,
particularly higher serum TC and LDL-c concentrations, in some observational studies, but not in
all [5,6,41]. There are two distinct reasons for these findings. The reason in favor of coffee consumption
is that the antioxidants included in coffee might reduce lipid oxidation. The topic has been insufficiently
investigated, with two small studies reporting protective (unfiltered coffee for one week) and neutral
(filtered coffee for three weeks) effects [6]. The unfavorable reason is that unfiltered coffee is rich in
the cholesterol-raising oils (diterpenes, kahweol and cafestol), which contribute significantly to the
increase in TC, LDL-c and TG [54]. In contrast to unfiltered coffee, consumption of filtered coffee
had no substantial effects on blood lipids [41,55], because the brewing releases oil droplets containing
diterpenes from ground coffee beans, and the oil is retained by a paper filter [6,41]. In the present
study, we found no association between coffee consumption and serum lipids (cholesterol profiles,
and triglyceride levels), perhaps due to the fact that the traditional brewing method of coffee in Brazil
is filtering. Thus, our study corroborated and supported this information.
To our knowledge, this is the first study in Brazil to investigate the association between usual
coffee consumption and its polyphenols and the main cardiovascular risk factors, and the most
important merit of our study is the emphasis of the role of moderate coffee consumption through its
relation with BP and homocysteine in decreasing risk of CVD.
However, some limitations of this study should be considered when interpreting results. Firstly,
our study is of a cross-sectional nature, which does not allow definitive establishment of causal
inference. Furthermore, several confounders in multivariate models were controlled, but other
unknown or unmeasured confounders (such as genetic information) may exist. This should be
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the focus of future studies. Further research, especially coming from randomized clinical trials, is
warranted to confirm our findings and establish the biological basis of coffee’s potential preventive
effects on CVD.
5. Conclusions
Our study shows that moderate coffee consumption and its polyphenols were associated with
lower odds of elevated SBP and DBP, and hyperhomocysteinemia in this population. Therefore,
moderate coffee consumption, a polyphenol-rich beverage, could provide beneficial effects against
clinical cardiovascular risk factors.
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Abstract: The incidence of obesity is rising at an alarming rate throughout the world and is becoming a
major public health concern with incalculable social and economic costs. Gelidium elegans (GENS), also
previously known as Gelidium amansii, has been shown to exhibit anti-obesity effects. Nevertheless, the
mechanism by which GENS is able to do this remains unclear. In the present study, our results showed
that GENS prevents high-fat diet (HFD)-induced weight gain through modulation of the adenosine
monophosphate-activated protein kinase (AMPK)-PR domain-containing16 (PRDM16)-uncoupling
protein-1 (UCP-1) pathway in a mice model. We also found that GENS decreased hyperglycemia in
mice that had been fed a HFD compared to corresponding controls. We also assessed the beneficial
effect of the combined treatment with GENS and orlistat (a Food and Drug Administration-approved
obesity drug) on obesity characteristics in HFD-fed mice. We found that in HFD-fed mice, the
combination of GENS and orlistat is associated with more significant weight loss than orlistat
treatment alone. Moreover, our results demonstrated a positive synergistic effect of GENS and
orlistat on hyperglycemia and plasma triglyceride level in these animals. Thus, we suggest that a
combination therapy of GENS and orlistat may positively influence obesity-related health outcomes
in a diet-induced obese population.
Keywords: Gelidium elegans; Gelidium amansii; high-fat diet-induced obese mice; hyperglycemia; obesity
1. Introduction
Obesity is a global health concern that has reached epidemic proportions [1]. Obesity is caused by
body fat accumulation in adipose tissue due to abnormalities in energy metabolism. It is associated
with a number of metabolic diseases such as diabetes, cardiovascular disease, and low chronic
inflammation [2,3]. Although pharmaceutical treatment of obesity costs approximately $ 2 trillion per
year [4], the population of obese individuals is rapidly growing worldwide, indicating that prevention
or intervention of obesity may be difficult due to the complex multisystem pathophysiology [5].
Clinical guidelines from several countries recommend pharmacological agents such as orlistat for
obese patients [6,7]. Orlistat is a Food and Drug Administration (FDA)-approved medicine for the
treatment of obesity in the United States. It is an inhibitor of intestinal lipase that decreases dietary fat
absorption [8].
Although orlistat treatment helps to reduce weight [9,10], it is now generally believed that physical
activity and a healthy diet may prevent weight gain and obesity by maintaining energy balance and
efficiently burning excessive energy [11]. Increasing consumption of fruits, vegetables, and edible
plants and decreasing consumption of high-calorie foods leads to a decrease in weight gain and
Nutrients 2017, 9, 342; doi:10.3390/nu9040342 www.mdpi.com/journal/nutrients33
Nutrients 2017, 9, 342
stabilization of weight in participants [12]. The bioactive compounds present in these food categories
that are implicated in obesity prevention include resveratrol, curcumin, conjugated linoleic acid, and
omega-3 fatty acids [13–16].
Recent studies have indicated that seaweeds and their derivatives may also have potential
therapeutic implications for obesity [17,18]. In particular, Gelidium elegans (GENS), previously known
as Gelidium amansii, has been shown to have nutraceutical activities such as anti-adipogenesis and
anti-obesity effects [19–21]. However, the mechanism by which GENS is able to achieve its anti-obesity
effects remains to be clearly defined. We have previously demonstrated that GENS has the potential to
alter adipocyte phenotypes to beige-like adipocytes in vitro [22]. This suggests that GENS may act as
an energy expenditure enhancer by stimulating the PR domain-containing16 (PRDM16)/peroxisome
proliferator-activated receptor gamma coactivator 1 alpha (PGC1α)/uncoupling protein-1 (UCP-1)
pathway in vivo. We therefore aimed to determine the molecular mechanism of GENS and the
efficacy of the combination therapy of GENS and orlistat on weight gain, blood biochemistry and gene
expression changes in high-fat diet (HFD)-induced obese mice.
2. Materials and Methods
2.1. Materials
GENS extract was obtained from NEWTREE Inc. (Seongnam, Kyeonggi, Korea). The composition
of GENS extract is described in Table 1. The following antibodies were purchased from Santa Cruz
Biotechnology (Dallas, TX, USA): CCAAT/enhancer binding protein alpha (C/EBPα, SC-61),
diacylglycerol O-acyltransferase-1 (DGAT-1, SC-32861), fatty acid synthase (FAS, SC-20140), peroxisome
proliferator activated receptor gamma (PPARγ, SC-7273), glyceraldehyde 3-phosphate dehydrogenase
(GAPDH, SC-25778), sterol regulatory element binding protein-1 (SREBP-1, SC-366), and uncoupling
proteins-1 (UCP-1, SC-6529). PR domain-containing16 (PRDM16, ab106410) were obtained from
Abcam (Cambridge, MA, USA). Phospho-adenosine monophosphate-activated protein kinase (p-AMPK,
CS-2603s), AMPK (CS-2603s), phospho-acetyl-CoA carboxylase (p-ACC, CS-3661s), and ACC (CS-3662s)
were purchased from Cell Signaling Technology (Bedford, MA, USA). Orlistat and metformin were
purchased from Cayman Chemical Company (Ann Arbor, MI, USA). Glucose and methylcellulose were
purchased from Sigma (Sigma, St. Louis, MO, USA). All chemicals and reagents used were of analytical
and obtained from commercial sources.






Total polyphenols 8.79 mg per 1 g
2.2. Animal Husbandry and Maintenance
Male ICR mice (5 weeks old) were purchased form Orient Bio Co. (Gapyeong, Kyeonggi, Korea)
and maintained in the animal facility at CHA University, Seongnam, Kyeonggi, Korea. The project was
approved by the Institutional Animal Care and Use committee of CHA University (IACUC Approval
Number 150071). Male mice were individually housed for 1 week under a 12-h light/dark cycle in
temperature (20–24 ◦C) and humidity (44.5%–51.8%). After a 1-week adaptation period, mice were
randomly divided into six groups (n = 6 per group). Mice were fed for 7 weeks with either 60% HFD
(Central Lab Animal Inc., Seoul, Korea) or NIH-07 rodent chow diet (Zeigler Brothers, Gardners, PA,
USA). GENS (50, 200 mg/kg/day) and/or orlistat (20 mg/kg/day) or an equal volume of vehicle
(1.0% methylcellulose, HFD and chow diet group) were orally administered to the mice by gavage
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every day for 7 weeks. During the experiment period, and survival rates were investigated daily.
The body weight, food intake, and water consumption were recorded weekly.
2.3. Concentration of Blood Glucose
The blood glucose concentration was measured from mice tail vein after 12 h (dark-period) of
fasting every week, using a glucose analyzer (GlucoDr, Allmedicus, Kyeonggi, Korea).
2.4. Intraperitoneal Glucose Tolerance Test (IPGTT)
Mice were fasted for 12 h (dark-period) before IPGTT experiments, and glucose (1.0 g/kg body
weight) was administered by intraperitoneal injection), as previously described [24]. Blood samples
were collected from tail vein at 30, 60, and 90 min to assess in vivo glucose clearance. Blood glucose
levels were determined immediately using a glucometer (G-Doctor, Allmedicus, Anyang, Korea).
2.5. Biochemical Analysis
Mice were sacrificed by CO2 asphyxiation and cervical dislocation. Blood collected by direct
cardiac puncture in an ethylenediaminetetraacetic acid (EDTA)-coated tube aseptically. Blood was
allowed to clot for 1 h at room temperature and then plasma was isolated by centrifuging the blood at
13,000× g for 15 min at 4 ◦C to collect plasma. The plasma samples were collected and stored at −80 ◦C.
Plasma triglycerides (TG) and high-density lipoprotein (HDL)-cholesterol levels were measured by
enzymatically commercial kits (Roche, Mannheim, Germany), Plasma insulin levels were measured
by enzymatically commercial kit (Wako Pure Chemical. Ltd., Osaka, Japan). The hepatic TG content
was determined using a commercially available TG quantification kit (Cayman Chemical Company,
Ann Arbor, MI, USA).
2.6. Organ Weight
Mice were euthanized using CO2 and cervical dislocation. Heart, lung, kidney, spleen, liver,
abdominal fat, and subcutaneous fat were removed and weighed carefully.
2.7. Tissue Samples Preparation for Oil Red O
Hepatic tissues were fixed in 4% paraformaldehyde, embedded in using tissue freezing medium,
optimum cutting temperature (OCT) (Cell Path Ltd., Newtown, UK). To detect fat deposition in the
liver, frozen sections of 6 μm for liver were rinsed with distilled water, stained with 0.18% Oil red O
(Sigma, St. Louis, MO, USA) with 60% 2-propanol (Sigma, St. Louis, MO, USA) for 20 min at 37 ◦C,
and then rinsed with distilled water and examined under light microscopy with Nikon Eclipse E600
(Nikon, Tokyo, Japan).
2.8. Western Blot Analysis
For protein extraction, frozen tissues were homogenized in specific lysis buffer (PRO-PREP;
iNtRON Biotechnology Inc., Seoul, Korea) containing protease with phosphatase inhibitor cocktail 2
and 3 (Sigma, St. Louis, MO, USA). The lysates were clarified by centrifugation at 12,000× g for 20
min at 4 ◦C. The protein concentration of clarified supernatants was determined by the Bradford assay
(Bio Legend, San Diego, CA, USA). Protein samples (30 μg) were separated by sodium dodecyl sulfate
polyacrylamide gel electrophores (SDS-PAGE), and transferred onto polyvinylidene fluoride (PVDF)
membranes (Bio-Rad, Hercules, CA, USA), as previously described [25]. The membranes were probed
with each antibodies and visualized using an enhanced chemiluminescence substrate. The signals
were detected with LAS image software (Fuji, New York, NY, USA).
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2.9. Quantitative Reverse Transcription Polymerase Chain Reaction (Quantitative RT-PCR) Analysis
Mouse liver RNA was extracted by using TRIzol reagent (Invitrogen, Carlsbad, CA, USA).
Total RNA was reverse transcribed with the Maxime PCR premix Kit (iNtRON Biotechnology,
Seongnam, Korea). Quantitative RT-PCR using SYBR Green 2× master mix kit (m.biotech., Inc.,
Seoul, Korea) was run in hexaplicate on a CFX96 Touch real-Time PCR Detection System (Bio-Rad,
Hercrules, CA, USA). The 18s was used for the relative quantization of the target genes based on
the comparative ΔΔ threshold cycle (Ct) method, as previously described [26]. Primer sequences are
shown in Table 2.
Table 2. Sequence identification and primers used for quantitative reverse transcription (RT)-PCR
analysis of specific messenger RNA.










HMG-CoA: hydoxymethylglutaryl-CoA; LDLR: low-density lipoprotein receptor.
2.10. Statistical Analysis
All statistical analyses were performed using the Statistical Package for Social Sciences version
12.0 (SPSS, Chicago, IL, USA). One-way analysis of variance (ANOVA) was used for comparisons
among group. Significant differences between the mean values were assessed using Duncan’s test.
All values are presented as the mean ± standard deviation (SD) values. The p-value in the multiple
comparison results (e.g., a, b, c, and d) indicate significant differences among the groups, p < 0.05.
3. Results
3.1. Effect of GENS on Changes in Body Weight, Blood Glucose, Insulin, TG, and Gene Expression in
Abdominal White Adipose Tissue in HFD-Fed Mice
Changes in the body weight of mice fed with chow diet or HFD with the absence or presence of
GENS were measured once a week during the experimental period. The introduction of GENS at 50 and
200 mg/kg/day strongly prevented this weight gain and resulted in low amounts of subcutaneous fat
and abdominal fat in the mice, as shown in Figure 1A–C. Although the total food intake and average
water consumption were not significantly different among the group (Figure 1D and Table 3), the group
with HFD alone showed a continuous increase in body weight compared to the chow diet group.
Table 3. Effect of supplementation with GENS on water consumption in chow diet and HFD-induced
obese mice for 7 weeks.
Group
Water Consumption (mL)
1 Week 2 Weeks 3 Weeks 4 Weeks 5 Weeks 6 Weeks 7 Weeks
Chow diet 129.5 ± 0.7 a 125.0 ± 0.0 a 117.0 ± 4.2 a 124.5 ± 0.7 a 117.0 ± 9.9 130.5 ± 2.1 a 119.0 ± 11.3
HFD 130.0 ± 1.4 a 103.5 ± 6.4 ab 93.5 ± 2.1 b 90.5 ± 2.1 b 77.5 ± 0.7 114.5 ± 5.0 a 118.5 ± 7.9
HFD+GENS 50 * 99.0 ± 7.1 b 106.5 ± 3.5 b 89.0 ± 11.3 b 91.0 ± 0.0 b 97.0 ± 1.4 96.0 ± 7.1 b 104.5 ± 20.5
HFD+GENS 200 * 110.5 ± 0.7 b 95.5 ± 3.5 b 90.0 ± 0.0 b 106.0 ± 4.2 a,b 82.5 ± 15.0 91.0 ± 2.8 b 99.5 ± 0.7
* (mg/kg/day), Data are mean ± SD (n = 6).
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Figure 1. Effect of GENS on body weight change (A); subcutaneous fat (B); abdominal fat (C); total
food intake (D); serum levels of insulin (E); levels of serum triglycerides (TG) (F); and high-density
lipoprotein (HDL)-cholesterol concentration (G) in high-fat diet (HFD)-fed mice. Five-week-old mice
were maintained with or without GENS (50 and 200 mg/kg/day) under HFD for 7 weeks. Data are
mean ± SD (n = 6).
In addition, we observed that the HFD increased the average weight of the liver, subcutaneous fat
and abdominal fat compared to the chow diet in mice (Table 4). However, the average weight of the
heart, lungs, spleen, and kidney were not affected. Obesity is initially characterized by excess adipose
tissue mass and hyperglycemia [27,28].
Table 4. Effect of GENS on organ weight in chow diet and HFD-induced obese mice for 7 weeks.
Variables
Group Organ Weight (g)
Chow Diet HFD
GENS 0 * GENS 0 * GENS 50 * GENS 200 *
Liver 1.6 ± 0.1 c 1.9 ± 0.3 a 1.5 ± 0.2 b 1.5 ± 0.1 b,c
Subcutaneous fat 0.7 ± 0.4 b 2.8 ± 0.6 a 1.6 ± 0.5 b 1.3 ± 0.6 b
Abdominal fat 0.5 ± 0.2 b 1.6 ± 0.6 a 0.8 ± 0.2 b 0.6 ± 0.3 b
Heart 0.3 ± 0.1 0.3 ± 0.1 0.2 ± 0.0 0.2 ± 0.0
Lung 0.3 ± 0.0 0.3 ± 0.1 0.3 ± 0.0 0.3 ± 0.0
Kidney 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.0 0.7 ± 0.0
Spleen 0.1 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
* (mg/kg/day), Data are mean ± SD (n = 6).
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Finding an effective treatment for hyperglycemia is one of the top priorities in obesity-associated
disease research [29]. Moreover, it has been suggested that hyperglycemia in certain types of health
conditions is associated with an increased risk of obesity development [30,31].
We therefore investigated whether HFD causes hyperglycemia in our experimental system and
whether GENS is able to prevent HFD-mediated hyperglycemia in vivo. As shown in Table 5, the
fasting blood glucose level in all group of mice before the treatment was within the normal range
(126.0 ± 3.2 mg/dL). We observed that the blood glucose level was significantly increased after
2 weeks of HFD compared to mice fed a chow diet and remained constant for 7 weeks.
In contrast, administration of GENS dramatically prevented this increase in HFD-fed mice.
Moreover, hyperglycemia is characterized by an increase in insulin and TG levels in blood serum.
Therefore, the level of serum insulin and TG were also measured as shown in Figure 1E,F. The levels
of serum insulin and TG in HFD-fed mice were significantly increased as compared to chow diet.
However, GENS group dramatically decreased insulin and TG level in blood serum, indicating that
GENS may efficiently ameliorate HFD-induced hyperglycemia in these animals. Moreover, it is well
known that obesity is frequently associated with low levels of serum HDL-cholesterol [32]. As shown
Figure 1G, the HDL-cholesterol in the HFD group were decreased as compared to chow diet. In contrast,
administration of GENS significantly increased HDL-cholesterol level in blood serum. Our results thus
provide preliminary evidence that GENS has potential as a preventive agent for diet-induced obesity
and hyperglycemia.
Table 5. Effect of supplementation with GENS on fasting glucose level in chow diet and HFD-induced
obese mice for 7 weeks.
Group
Blood Glucose (mg/dL)
1 Week 2 Weeks 3 Weeks 4 Weeks 5 Weeks 6 Weeks 7 Weeks
Chow diet 123.0 ± 20.3 108.7 ± 11.1 c 103.3 ± 15.8 c 115.5 ± 16.4 c 110.7 ± 18.3 c 100.5 ± 11.6 c 105.5 ± 13.3 c
HFD 121.8 ± 5.1 185.8 ± 28.0 a 172.7 ± 26.5 a 190.2 ± 39.2 a 161.8 ± 10.7 a 167.8 ± 17.6 a 169.5 ± 22.4 a
HFD + GENS 50 * 133.5 ± 12.3 156.0 ± 13.7 a,b 140.2 ± 14.9 b 143.0 ± 12.5 b,c 143.3 ± 15.0 a,b 144.3 ± 13.5 a,b 131.3 ± 18.2 b,c
HFD + GENS 200 * 142.2 ± 39.4 142.7 ± 24.4 b 134.0 ± 14.1 b 149.0 ± 7.0 b 138.8 ± 12.9 a,b 127.7 ± 21.1 bc 139.7 ± 21.6 b
* (mg/kg/day), Data are mean ± SD (n = 6).
3.2. Effect of GENS on Adipogenic Factors and IPGTT in HFD-Fed Mice
We then analyzed the adipose tissues of HFD-fed mice to confirm how GENS regulated the
observed changes. To clarify whether GENS suppress the development of adipose tissue, we analyzed
crucial markers of adipogenesis, including C/EBPα and PPARγ [33], by western blotting. As shown
in Figure 2A, there was a 5.5-fold increase in the C/EBPα protein level in the adipose tissue of mice
fed HFD for 7 weeks compared to that of mice fed a chow diet. There was also a significant elevation
of the PPARγ protein expression in the adipose tissue of HFD-fed mice compared to a chow diet.
In contrast, GENS at 200 mg/kg/day almost completely suppressed the expression of C/EBPα and
PPARγ protein. This result is consistent with recent research, thereby suggesting that the consumption
of edible seaweed GENS may result in a lower weight gain through the inhibition of adipose tissue
development [19].
Hyperglycemia is characterized by an excessive amount of blood glucose and is often observed
in the obese [34,35]. Also, impaired glucose tolerance is a pre-diabetic state of hyperglycemia that
is associated with insulin resistance [36]. As shown Figure 2B, the 1.0 g/kg glucose control group
reached a glucose level of 142.5 ± 14.2 mg/dL at 30 min. On the other hand, the groups that received
50 or 200 mg/kg GENS had a significantly suppressed rise in blood glucose, with glucose levels
of 137.8 ± 25.7 mg/dL and 121.5 ± 24.8 mg/dL at 30 min, respectively. In comparison with the
1.0 g/kg glucose control group, the group that was administered 200 mg/kg GENS significantly
decreased their blood glucose levels, by approximately 14.7% at 30 min. At 60 min, the 1.0 g/kg
glucose level of the control group reached 100.5 ± 18.6 mg/dL. On the other hand, the groups that
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received 200 mg/kg GENS had a significantly suppressed the rise in blood glucose, with glucose levels
of 90.8 ± 18.0 mg/dL, when compared to the 1.0 g/kg glucose control group at 60 min.
Figure 2. Effect of GENS on key adipogenic factors in HFD-fed mice of white adipose tissue and glucose
tolerance. Five-week-old mice were maintained with or without GENS (50 and 200 mg/kg/day) under
HFD for 7 weeks. Each parameter was measured by western blot analysis with C/EBPα and PPARγ.
The protein expression level was normalized against GAPDH. Protein level was quantified using
Image J software (A). Five groups of male mice (5 weeks old) were fasted for 12 h (dark-period).
After 12-h fasting, mice were administered 1.0 g/kg glucose by intraperitoneal injection. The first
group received only Phosphate Buffered Saline (PBS), the second group received 1.0 g/kg glucose, the
third group received 1.0 g/kg glucose + 140 mg/kg metformin and the fourth and fifth group received
1.0 g/kg glucose + GENS (50 and 200 mg/kg). Blood glucose levels were measured at the indicated
times (0, 30, 60, and 90 min) (B). Data are mean ± SD (n = 6).
3.3. GENS Represses Hepatic Lipogenesis via the Activation of Thermogenesis-Associated Pathway in
HFD-Fed Mice
Because previous studies reported that HFD resulted in increases in hepatic lipogenesis and/or
non-alcoholic fatty liver [37,38], we also examined the effect of GENS on hepatic lipogenesis in the
hepatic tissues of mice. The levels of lipid droplets were evaluated by the combined use of Oil Red O
with classic hematoxylin and eosin (H&E) stains in formalin-fixed paraffin-embedded liver tissues.
As shown in Figure 3A, Oil Red O staining of liver sections confirmed the abundance of lipid in
HFD-fed mice compared to mice fed a chow diet, while GENS prevented hepatic lipogenesis in
HFD-fed mice. As shown in Figure 3B, the hepatic TG contents in HFD-fed mice were significantly
increased compared to chow diet-fed mice. On the other hand, the group that was administered 50 and
200 mg/kg GENS had significantly suppressed hepatic TG contents, by approximately 28.8% and
26.1%, respectively.
Several studies have demonstrated that SREBP-1 plays an important role in modulating the
transcription of genes involved in hepatic lipogenesis, including FAS, ACC, and stearoyl-CoA
desaturase1 (SCD1) [39,40]. As shown in Figure 3D, HFD-fed mice markedly enhanced the expression
of the SREBP-1 compared to mice fed a chow diet. In contrast, GENS reduced the expression of
SREBP-1 in a dose-dependent manner in HFD-fed mice. SREBP-1 regulated transcription of genes such
as hydoxymethylglutaryl-CoA (HMG-CoA) reductase and low-density lipoprotein receptor (LDLR)
encoding many other enzymes in the cholesterol biosynthetic pathway [41]. We further investigated
the effect of GENS on the SREBP-1 downstream target genes that contribute to the intracellular TG
synthesis. ACC, DGAT-1, and FAS are downstream target genes of SREBP-1 and play a crucial role
in TG synthesis and lipid accumulation [42]. As shown in Figure 3C, the expression of HMG-CoA
reductase and LDLR mRNA were notably increased in HFD-fed mice compared to mice fed a chow
diet. On the other hand, the GENS group markedly downregulated the expression of HMG-CoA
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reductase and LDLR mRNA compared to HFD-fed mice. As shown in Figure 3D, the expression levels
of the genes DGAT-1 and FAS in HFD-fed mice increased notably compared to mice fed a chow diet.
In contrast, the expression of the SREBP-1 downstream target genes ACC, DGAT-1, and FAS were
markedly downregulated in the GENS group compared to HFD-fed mice.
Figure 3. GENS represses hepatic lipogenesis and cholesterol factors in HFD-fed mice. Five-week-old
mice were maintained with or without GENS (50 and 200 mg/kg/day) under HFD for 7 weeks.
Each parameter was measured by western blot analysis with specific antibodies. The liver sections
stained with Oil red O (A); Hepatic TG content (B); Expression levels of HMG-CoA reductase and LDLR
genes were determined by quantitative RT-PCR in liver samples (C); p-AMPK, AMPK, SREBP-1, p-ACC,
ACC, DGAT-1, and FAS (D); PRDM16 (E). The protein expression level was normalized against AMPK,
ACC, and GAPDH. Protein level was quantified using Image J software. Data are mean ± SD (n = 6).
The phosphorylation of AMPK inhibits the expression of SREBP-1 to attenuate hepatic
lipogenesis [43]. To determine whether GENS decreased the expression of SREBP-1 through the
phosphorylation of AMPK, we examined the AMPK protein by western blot. We observed that HFD
slightly decreased the phosphorylation of AMPK compared to chow diet, while GENS stimulated the
HFD-induced reduction of AMPK phosphorylation. AMPK is a multiple nutrient sensor and a key
energy balance interactor of thermogenic transcription factors including PRDM16 [44,45]. Therefore,
our findings indicated that GENS could prevent hepatic lipogenesis via the activation of thermogenesis
and energy expenditure.
PRDM16 is a zinc finger protein that has been proposed to regulate brown adipocyte
differentiation, thermogenesis and energy expenditure in adipose tissue and skeletal muscles [36,37].
PRDM16 induces the cellular production of the PGC1α protein, which gives the mitochondria its
energy expenditure phenotype [38]. We thus proceeded to investigated if GENS was responsible for
the increase in PRDM16 expression. As shown in Figure 3E, HFD with GENS increased the expression
of PRDM16 in the mice, whereas HFD alone had no effect on the expression of PRDM16 compared to
chow diet. These results suggested that GENS is responsible for the increase in expression of PRDM16,
probably via the thermogenesis pathway in brown adipose tissue.
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3.4. GENS Stimulates the Expression of PRDM16 and UCP-1 Protein in Brown Adipose Tissue and Suppresses
Hyperglycemia in HFD-Fed Mice
To further assess the role of GENS in the development of brown adipose tissue, we investigated
thermogenesis-associated proteins in this tissue. As shown in Figure 4, HFD-fed mice had a lower
level of AMPK phosphorylation compared to mice fed a chow diet, while GENS prevented this
HFD-induced reduction.
Figure 4. Effect of GENS on energy expenditure protein expression in brown adipose tissue of HFD-fed
mice. Five-week-old mice were maintained with or without GENS (50 and 200 mg/kg/day) under
HFD for 7 weeks. Each parameter was measured by western blot analysis with p-AMPK, PRDM16,
and uncoupling protein-1 (UCP-1). The protein expression level was normalized against AMPK and
GAPDH. Protein level was quantified using Image J software. Data are mean ± SD (n = 6).
Although there was no difference in the expression of PRDM16 and UCP-1 between mice fed a
chow diet and those fed a HFD, we found GENS significantly enhanced the expression of PRDM16
and UCP-1 in brown adipose tissue compared to the corresponding controls. These results suggested
that GENS acts as a critical regulator of thermogenesis and the development of brown adipose tissue.
3.5. Effect of Combination of GENS and Orlistat on Body Weight, Organ Weight, Insulin, TG, and
HDL-Cholesterol in HFD-Fed Mice
Our data illustrated a potential mechanism for a thermogenic effect of GENS, suggesting that
combination therapy with GENS and orlistat may produce a strong synergistic effect on weight
gain prevention in vivo. Based on the above dose response in HFD-fed mice and on previous
literature, dosages of 50 mg/kg/day of GENS and 20 mg/kg/day of orlistat were chosen. Orlistat was
administered alone or in combination with GENS for 7 weeks in HFD-fed mice. As shown in Figure 5A,
orlistat significantly suppressed body weight change compared to HFD-fed mice, and a combination
of GENS and orlistat showed a synergistic effect on body weight change.
In particular, the calculation of total body weight gain revealed that orlistat reduced weight
gain by approximately 20.4% compared to HFD-fed mice (Figure 5B). Moreover, GENS and orlistat
exhibited better prevention of weight gain in terms of amounts of subcutaneous fat and abdominal
fat accumulation in the mice, as shown in Figure 5C,D. In addition, the combination inhibited weight
gain compared to HFD-fed mice given orlistat alone. We also observed that serum HDL-cholesterol
levels were 84 ± 14.6 mg/dL, 88.6 ± 11.9 mg/dL, and 109.6 ± 17.8 mg/dL in HFD-fed mice, HFD-fed
mice treated with orlistat, and HFD-fed treated with GENS + orlistat, respectively. In comparison with
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HFD-fed mice, mice receiving a combination of GENS and orlistat showed significantly increased
serum HDL-cholesterol levels, by approximately 30.5%. (Figure 5E). However, total food intake and
average water consumption were not significantly different among the group (Figure 5F and Table 6).
Figure 5. Synergistic effect of GENS and orlistat on weight change (A); body weight gain (B);
subcutaneous fat (C); abdominal fat (D); HDL-cholesterol concentration (E); total food intake (F);
serum levels of insulin (G); and serum levels of TG (H) in HFD-fed mice. Five-week-old mice were
maintained with or without GENS (50 and 200 mg/kg/day) under HFD for 7 weeks. Data are
mean ± SD (n = 6).
Table 6. Combination effect of GENS and orlistat on water consumption in HFD-fed mice.
Group
Water Consumption (mL)
1 Week 2 Weeks 3 Weeks 4 Weeks 5 Weeks 6 Weeks 7 Weeks
Chow diet 138.5 ± 13.4 119.5 ± 7.7 112.5 ± 10.6 a 111.0 ± 19.8 105.0 ± 26.8 a 128.5 ± 0.7 a 125.0 ± 2.8
HFD 130.0 ± 1.4 108.0 ± 0.0 93.00 ± 2.83 b 105.5 ± 2.1 81.0 ± 4.2 b 116.0 ± 7.0 b 121.5 ± 9.2
HFD + orlistat 20 * 112.5 ± 23.3 113.5 ± 16.2 97.0 ± 9.9 b 108.5 ± 7.6 92.0 ± 11.6 b 101.0 ± 0.0 c 115.0 ± 0.0
HFD + GENS 50 *
+ orlistat 20 *
121.0 ± 1.41 121.5 ± 0.7 95.0 ± 4.2 b 99.5 ± 2.1 99.5 ± 2.1 b 90.5 ± 3.5 c 118.0 ± 5.6
* (mg/kg/day), Data are mean ± SD (n = 6).
Notably, blood glucose analysis (Table 5) showed consistently that hyperglycemia was initiated at
2 weeks after beginning a HFD and persisted until 7 weeks (Table 7). These data indicated that GENS
and orlistat possibly stimulated insulin secretion in the bloodstream. Therefore, we have measured
the level of insulin among the group. As shown Figure 5G, the combination of GENS and orlistat
significantly suppressed the level of insulin by approximately 24.1% and 8.4% compared to HFD-fed
mice or HFD-fed mice with orlistat, suggesting that combination of GENS and orlistat ameliorated
impaired insulin homeostasis in HFD-fed mice.
Although there was an insignificant change in the blood glucose level at 20 mg/kg/day orlistat,
combined treatment with GENS and orlistat significantly inhibited the elevation of blood glucose
level at 6 and 7 weeks in HFD-fed mice. Furthermore, even though combined treatment with GENS
and orlistat did not have any synergistic effect on blood glucose level (Table 7), these mice showed a
significant decrease in plasma TG content compared to HFD-fed mice with or without orlistat alone
(Figure 5H).
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Table 7. Combination effect of supplementation with GENS and orlistat on fasting glucose level in
HFD-induced obese mice for 7 weeks.
Group
Blood Glucose (mg/dL)
1 Week 2 Weeks 3 Weeks 4 Weeks 5 Weeks 6 Weeks 7 Weeks
Chow diet 125.3 ± 23.9 115.8 ± 25.2 b 118.0 ± 20.0 b 120.0 ± 14.0 b 113.2 ± 7.6 b 108.2 ± 15.0 b 116.5 ± 11.7 b
HFD 123.3 ± 12.2 171.2 ± 30.7 a 145.3 ± 31.8 a 136.0 ± 21.5 b 132.0 ± 16.5 a,b 129.2 ± 18.7 a,b 148.2 ± 29.9 a
HFD + orlistat 20 * 122.0 ± 21.2 132.8 ± 31.6 a,b 135.0 ± 16.8 a,b 169.8 ± 24.5 a 146.7 ± 18.2 b 142.2 ± 23.2 a 143.5 ± 18.3 a
HFD + GENS 50 *
+ orlistat 20 *
116.7 ± 15.9 133.5 ± 34.0 a,b 156.0 ± 15.1 a,b 143.3 ± 24.3 a,b 124.0 ± 27.0 a,b 135.8 ± 33.5 a,b 126.8 ± 7.1 a,b
* (mg/kg/day), Data are mean ± SD (n = 6).
3.6. Effect of Combination of GENS and Orlistat on White Adipose Tissue and Hepatic Lipogenesis in
HFD-Fed Mice
To further elucidate the molecular mechanism of the synergistic effect of GENS and orlistat on
white adipose tissue and hepatic lipogenesis, we used western blot to evaluate the expression of
C/EBPα and PPARγ in white adipose tissue and SREBP-1, AMPK, and PRDM16 in hepatic tissue.
We noticed that high levels of C/EBPα and PPARγ were expressed in HFD-fed mice in the presence
or absence of orlistat, as shown in Figure 6A. In contrast, combined treatment of GENS and orlistat
reduced the expression of C/EBPα and PPARγ compared to the corresponding control.
Figure 6. Combination effect of GENS and orlistat on white adipose tissue and hepatic lipogenesis and
cholesterol synthesis-associated genes in HFD-fed mice. Five-week-old mice were maintained with or
without orlistat (20 mg/kg/day) and GENS (50 mg/kg/day) under HFD for 7 weeks. Each parameter
was measured by western blot analysis with C/EBPα and PPARγ (A); The liver sections stained with
Oil red O (B); Hepatic TG content (C); Expression levels of HMG-CoA reductase and LDLR genes were
determined by quantitative RT-PCR in liver samples (D); p-AMPK, AMPK, SREBP-1, p-ACC, ACC,
DGAT-1, FAS (E) and PRDM16 (F). The protein expression level was normalized against AMPK, ACC,
and GAPDH. Protein level was quantified using Image J software. Data are mean ± SD (n = 6).
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To examine whether the combination of GENS and orlistat synergistically inhibited hepatic
lipogenesis, we also performed Oil red O staining of formalin-fixed paraffin-embedded liver from
HFD-fed mice. As shown in Figure 6B, Oil red O staining revealed that the combination of GENS and
orlistat efficiently decreased hepatic lipogenesis.
In agreement with this observation, in mice fed with HFD, liver weights were 78.6% lower in
orlistat-treated mice and 70.9% lower in those receiving a combination of GENS and orlistat compared
to mice that were fed a HFD alone (Table 8). Moreover, in mice fed with HFD, liver TG contents
were 58.8% lower in those receiving a combination of GENS and orlistat compared to HFD-fed mice
(Figure 6C). The combination of GENS and orlistat dramatically decreased the expression of HMG-CoA
reductase and LDLR in HFD-fed mice (Figure 6D). In addition, western blot analysis revealed that
the combination of GENS and orlistat synergistically increased the phosphorylation of AMPK and
decreased the expression of SREBP-1, ACC, DGAT-1, and FAS in HFD-fed mice, as shown in Figure 6E.
Table 8. Effect of GENS and/or orlistat on organ weight in HFD-induced obese mice for 7 weeks.
Variables
Group Organ Weight (g)
Chow Diet HFD
GENS 0 * GENS 0 * Orlistat 20 * HFD + GENS 50 * + Orlistat 20 *
Liver 1.6 ± 0.0 b 2.0 ± 0.2 a 1.6 ± 0.1 b 1.4 ± 0.1 c
Subcutaneous fat 0.7 ± 0.3 a,b 1.1 ± 0.6 a 0.9 ± 0.3 a,b 0.5 ± 0.1 b
Abdominal fat 1.2 ± 0.6 b 2.0 ± 0.5 a 1.8 ± 0.5 a 1.0 ± 0.3 b
Heart 0.2 ± 0.0 0.3 ± 0.1 0.2 ± 0.0 0.3 ± 0.0
Lung 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0
Kidney 0.7 ± 0.1 0.7 ± 0.2 0.7 ± 0.0 0.7 ± 0.1
Spleen 0.2 ± 0.0 0.1 ± 0.0 0.2 ± 0.0 0.1 ± 0.0
* (mg/kg/day), Data are mean ± SD (n = 6).
We also found that orlistat alone did not change the expression of PRDM16, but rather
the combination of GENS and orlistat significantly induced the expression of PRDM16, thereby
indicating that orlistat can contribute to inhibiting lipid metabolism but does not affect thermogenesis
(Figure 6F). We sought to further investigate of the effect of combination of GENS and orlistat on
thermogenesis-associated proteins in brown adipose tissue by western blot. Consistent with the above
observations, we found that orlistat alone induced a statistically insignificant increase in the AMPK
phosphorylation, PRDM16, and UCP-1 expression, whereas the combination of GENS and orlistat
dramatically elevated AMPK phosphorylation and the expression of PRDM16 and UCP-1 (Figure 7).
These results suggested that orlistat plays the role of a negative regulator of lipogenesis, while GENS
synergistically acts as an enhancer of thermogenesis and subsequently inhibits the progression of
adipogenesis and changes in circulating TG content from hematogenous spread in HFD-fed mice in
the presence of orlistat.
To further analyze whether GENS and orlistat plays a role in systemic glucose sensitivity, we
performed IPGTT. As shown Figure 7B, the 1.0 g/kg glucose control group reached a glucose level of
138.7 ± 23.7 mg/dL at 30 min. On the other hand, the groups that received combination group
(20 mg/kg orlistat + 50 mg/kg GENS) had a significantly suppressed rise in blood glucose, with
glucose levels of 125.8 ± 8.9 mg/dL at 30 min. In comparison with the 1.0 g/kg glucose control
group, the group that was administered combination group (20 mg/kg orlistat + 50 mg/kg GENS)
significantly decreased their blood glucose levels by approximately 9.3% at 30 min. In the current
study, our result showed GENS improved glucose homeostasis in vivo. Moreover, the group that was
administered 200 mg/kg GENS and combination group (20 mg/kg orlistat + 50 mg/kg GENS) had a
significant decrease in blood glucose levels after glucose loading.
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Figure 7. Combination effect of GENS and orlistat on energy expenditure-associated protein expression
in brown adipose tissue of HFD-fed mice. Five-week-old mice were maintained with or without
orlistat (20 mg/kg/day) and GENS (50 mg/kg/day) under HFD for 7 weeks. Protein extracts from
brown adipose tissue were assayed for p-AMPK, PRDM16, and UCP-1 by western blot analysis with
specific antibodies. The protein expression level was normalized against GAPDH (A). Protein level
was quantified using Image J software. Five groups of male mice (5 weeks old) were fasted for 12 h
(dark-period). After 12-h fasting, mice were administered 1.0 g/kg glucose by intraperitoneal injection.
The first group received only PBS, the second group received 1.0 g/kg glucose, third groups received
1.0 g/kg glucose + 140 mg/kg metformin, the fourth group received 1.0 g/kg glucose + 20 mg/kg
orlistat and the fifth group received 1.0 g/kg glucose + 20 mg/kg orlistat + 50 mg/kg GENS. Blood
glucose levels were measured at the indicated times (0, 30, 60, and 90 min) (B). Data are mean ± SD
(n = 6).
4. Discussion
Here, we showed that GENS is sufficient to inhibit multiple characteristics of obesity, including
weight gain, adipose tissue mass, hepatic lipogenesis, and hyperglycemia, in the HFD-induced obese
mouse model. Notably, GENS altered energy metabolism by stimulating the expression of known
thermogenesis regulator molecules such as PRDM16 and UCP-1. Moreover, we demonstrated that
combined treatment with GENS and orlistat attenuated the plasma TG content and body weight gain
in HFD-fed mice. In obesity, excessive energy intake promotes an increase in the storage of lipids
in adipose tissue [39], thus resulting in an increase in adipose tissue mass through the formation
of new adipocytes and an increase in the size of adipocytes [40]. These events involve cellular
and molecular changes including morphological modifications of a number of critical adipogenic
transcription factors, such as C/EBPα and PPARγ [28]. HFD can activate the expression of C/EBPα
and PPARγ in tissues and cause hyperglycemia resulting from diet-induced early insulin resistance
through hematogenous spread [41]. The elevated C/EBPα and PPARγ expression and increased
hyperglycemia in obese mice was ameliorated by the intake of fruits, vegetables, and edible seaweed
and/or its derivatives. This suggests the natural dietary substances can attenuate characteristics
associated with obesity [12,46–48].
Our previous study, as well as recent studies, suggested that GENS may exert a protective effect
on adipogenesis in adipocytes in vitro [49] and in adipose tissue mass in vivo by regulating C/EBPα
and PPARγ proteins [19]. Consistent with previous results, our results showed that GENS decreased
the expression of C/EBPα and PPARγ in white adipose tissue in HFD-fed mice.
Diet-induced hepatic lipogenesis is associated with non-alcohol-induced fatty liver (NAFLD),
a disease state that is a crucial factor in insulin resistance and early-stage diabetes [50]. Prior studies
have suggested that GENS has the potential to ameliorate hepatic lipid accumulation and plasma TG
content in rats that have been fed a high fructose diet [51].
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However, these studies did not provide molecular mechanisms for how GENS regulates these
processes. In this study, we demonstrated that GENS suppressed hepatic lipogenesis through
modulation of the AMPK-SREBP-1 pathway in HFD-fed mice. In regulating energy metabolism,
AMPK stimulates the interaction between PGC1α and PRDM16 resulting in increased mitochondrial
biogenesis, thermogenesis, and energy expenditure [52]. Interestingly, we noticed that in HFD-fed
mice treated with GENS, PRDM16 in the liver was significantly increased, indicating that GENS may
elevate mitochondrial biogenesis or thermogenesis via activation of the thermogenic factor PRDM16
in these animals.
It has been previously demonstrated that HFD induces hepatic lipogenesis, leading to
hyperglycemia [53]. In this study, we revealed that hyperglycemia was induced in HFD-fed mice,
whereas GENS significantly prevented HFD-mediated hyperglycemia. Although we could not
address the detailed mechanism of the interaction between hepatic lipogenesis and hyperglycemia, we
speculate that mitochondrial function such as biogenesis and thermogenesis might be involved in the
link in these processes.
We hypothesized that if the anti-obesity effects of GENS were mainly due to the affect
thermogenesis, GENS might alter the expression of thermogenesis-associated protein in brown
adipose tissue. Thus, we analyzed the expression of thermogenic genes in brown adipose tissue,
and our results revealed that levels of the most important thermogenesis-associated proteins AMPK,
PRDM16, and UCP-1 were dramatically increased. Previous work has demonstrated that AMPK
increases the expression of Sirt1 and enhances mitochondrial biogenesis through the regulation of
PGC1α [54]. It is well known that PRDM16 plays a crucial role in controlling the expression of UCP-1
in brown adipocytes [55]. Therefore, we postulated that GENS may stimulate thermogenesis or energy
expenditure through the AMPK-PRDM16-UCP-1 pathway in HFD-fed mice.
Orlistat has been used to promote weight loss and plasma TG content normalization in NAFLD
and obesity patients [56,57]. It has also been reported as a specific intestinal lipase that breaks down
TG, thus resulting in a decrease in fat absorption [58]. As orlistat treatment can promote the inhibition
of dietary fat absorption and fatty acid synthesis, we utilized a different mechanism of activity than
GENS to assess whether the combination of low-dose GENS and orlistat affected obesity characteristics
in HFD-fed mice. We found that the combination was effective in weight-gain prevention in HFD-fed
mice. More importantly, the combined treatment with low-dose GENS and orlistat significantly
inhibited the expression of C/EBPα and PPARγ in white adipose tissue. It was reasonable to assume
that the beneficial effect of GENS and orlistat on adipose tissue mass in HFD-fed mice was through the
inhibition of adipogenesis since there was a significant difference in this variable between the HFD
group, the orlistat group, and the low-dose GENS + orlistat group. As the highest level of reduction in
hyperglycemia and plasma TG content was achieved with the combination of low-dose GENS and
orlistat in HFD-fed mice, this combination seems ideal to reduce obesity features. In addition, we
noticed that in these mice, the thermogenic genes AMPK, PRDM16, and UCP-1 were also synergistically
activated by the combination treatment. This might indicate that an active UCP-1 protein is a heat
generator that in mice contributes to loss of energy in the form of heat. The animal study was performed
at 20–24 ◦C, whereas thermoneutrality for mice is 28–30 ◦C. Therefore, the UCP-1 protein would be
expected to be active in the mice housed under the conditions used in the present study. As the GENS
mice had less adipose tissue, both subcutaneous and abdominal, they also have less insulating material.
This could mean that these mice had to generate more heat through UCP-1 activation. Obviously, this
would contribute to less adipose tissue mass as observed, but the mechanism could be independent of
any effect of GENS or orlistat. Under these circumstances, a reduced fat absorption would contribute
to less available energy, and hence accentuate the mobilization of fatty acids from white adipose tissue
for UCP-1 heat generation. Although the mechanisms of action of GENS and orlistat are distinct, we
have provided partial evidence that GENS and orlistat can act synergistically in HFD-fed mice.
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5. Conclusions
It is known that the incidence of overweight and obesity is responsible for increased abnormalities
in multiple signaling pathways, including adipogenesis, lipolysis, and energy expenditure-associated
pathways [59,60], and can cause hyperglycemia and NAFLD. In this study, we provided evidence to
suggest that in HFD-fed mice, thermogenesis is activated in response to GENS consumption, possibly
through the AMPK-PRDM16-UCP-1 pathway.
This results in the modulation of hepatic lipogenesis as reflected by altered AMPK-PRDM16-UCP-1
pathway and suppression of white adipose tissue mass expansion. Moreover, we postulated that
combination of GENS and orlistat is associated with more significant weight loss than the orlistat alone
in HFD-fed mice. In particular, our results demonstrated a synergistic effect between GENS and orlistat
on hyperglycemia and hepatic lipogenesis in HFD-fed mice. Therefore, we suggest that combination
therapy with GENS and orlistat may positively influence the outcomes related to obesity characteristics
in a diet-induced obese population.
Acknowledgments: This research was partially supported by Basic Science Research Program through the
National Research Foundation of Korea (NRF) funded by the Ministry of Education (2016R1D1A1A09917209).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Author Contributions: Jia Choi, Kui-Jin Kim, and Boo-Yong Lee conceived and designed the study; Jia Choi and
Eun-Jeong Koh performed the experiments; Jia Choi and Kui-Jin Kim analyzed the data; Jia Choi and Kui-Jin Kim
wrote the paper and edited the paper.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. World Health Organization. Obesity: Preventing and Managing the Global Epidemic; World Health Organization:
Geneva, Switzerland, 2000.
2. Farmer, S.R. Regulation of ppargamma activity during adipogenesis. Int. J. Obes. 2005, 29 (Suppl. 1), S13–S16.
[CrossRef] [PubMed]
3. Dandona, P.; Aljada, A.; Bandyopadhyay, A. Inflammation: The link between insulin resistance, obesity and
diabetes. Trends Immunol. 2004, 25, 4–7. [CrossRef] [PubMed]
4. Dobbs, R.; Sawers, C.; Thompson, F.; Manyika, J.; Woetzel, J.R.; Child, P.; McKenna, S.; Spatharou, A.
Overcoming Obesity: An Initial Economic Analysis; McKinsey Global Institute: Tamil Nadu, India, 2014.
5. Roberts, D.L.; Dive, C.; Renehan, A.G. Biological mechanisms linking obesity and cancer risk:
New perspectives. Annu. Rev. Med. 2010, 61, 301–316. [CrossRef] [PubMed]
6. Lau, D.C.; Douketis, J.D.; Morrison, K.M.; Hramiak, I.M.; Sharma, A.M.; Ur, E. Obesity Canada Clinical
Practice Guidelines Expert Panel. Can. Med. Assoc. J. 2007, 176, S1–S13. [CrossRef] [PubMed]
7. Pi-Sunyer, F.X.; Becker, D.M.; Bouchard, C.; Carleton, R.; Colditz, G.; Dietz, W.; Foreyt, J.; Garrison, R.;
Grundy, S.; Hansen, B. Clinical guidelines on the identification, evaluation, and treatment of overweight and
obesity in adults. Am. J. Clin. Nutr. 1998, 68, 899–917.
8. Heck, A.M.; Yanovski, J.A.; Calis, K.A. Orlistat, a new lipase inhibitor for the management of obesity.
Pharmacotherapy 2000, 20, 270–279. [CrossRef] [PubMed]
9. Rossner, S.; Sjostrom, L.; Noack, R.; Meinders, E.; Noseda, G. Weight loss, weight maintenance, and
improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes. Res. 2000, 8,
49–61. [CrossRef] [PubMed]
10. Heymsfield, S.B.; Segal, K.R.; Hauptman, J.; Lucas, C.P.; Boldrin, M.N.; Rissanen, A.; Wilding, J.P.; Sjöström, L.
Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults.
Arch. Intern. Med. 2000, 160, 1321–1326. [CrossRef] [PubMed]
47
Nutrients 2017, 9, 342
11. Kumanyika, S.K.; Obarzanek, E.; Stettler, N.; Bell, R.; Field, A.E.; Fortmann, S.P.; Franklin, B.A.;
Gillman, M.W.; Lewis, C.E.; Poston, W.C.; et al. Population-based prevention of obesity the need for
comprehensive promotion of healthful eating, physical activity, and energy balance: A scientific statement
from american heart association council on epidemiology and prevention, interdisciplinary committee for
prevention (formerly the expert panel on population and prevention science). Circulation 2008, 118, 428–464.
[PubMed]
12. Epstein, L.H.; Gordy, C.C.; Raynor, H.A.; Beddome, M.; Kilanowski, C.K.; Paluch, R. Increasing fruit and
vegetable intake and decreasing fat and sugar intake in families at risk for childhood obesity. Obes. Res. 2001,
9, 171–178. [CrossRef] [PubMed]
13. Szkudelska, K.; Szkudelski, T. Resveratrol, obesity and diabetes. Eur. J. Pharmacol. 2010, 635, 1–8. [CrossRef]
[PubMed]
14. Ejaz, A.; Wu, D.; Kwan, P.; Meydani, M. Curcumin inhibits adipogenesis in 3t3-l1 adipocytes and angiogenesis
and obesity in c57/bl mice. J. Nutr. 2009, 139, 919–925. [CrossRef] [PubMed]
15. Blankson, H.; Stakkestad, J.A.; Fagertun, H.; Thom, E.; Wadstein, J.; Gudmundsen, O. Conjugated linoleic
acid reduces body fat mass in overweight and obese humans. J. Nutr. 2000, 130, 2943–2948. [PubMed]
16. Ruzickova, J.; Rossmeisl, M.; Prazak, T.; Flachs, P.; Sponarova, J.; Vecka, M.; Tvrzicka, E.; Bryhn, M.;
Kopecky, J. Omega-3 pufa of marine origin limit diet-induced obesity in mice by reducing cellularity of
adipose tissue. Lipids 2004, 39, 1177–1185. [CrossRef] [PubMed]
17. Miyashita, K. The carotenoid fucoxanthin from brown seaweed affects obesity. Lipid Technol. 2009, 21,
186–190. [CrossRef]
18. Maeda, H.; Tsukui, T.; Sashima, T.; Miyashita, K. Seaweed carotenoid, fucoxanthin, as a multi-functional
nutrient. Asia Pac. J. Clin. Nutr. 2008, 17, 196–199. [PubMed]
19. Kang, M.-C.; Kang, N.; Kim, S.-Y.; Lima, I.S.; Ko, S.-C.; Kim, Y.-T.; Kim, Y.-B.; Jeung, H.-D.; Choi, K.-S.;
Jeon, Y.-J. Popular edible seaweed, gelidium amansii prevents against diet-induced obesity. Food Chem. Toxicol.
2016, 90, 181–187. [CrossRef] [PubMed]
20. Yang, T.-H.; Yao, H.-T.; Chiang, M.-T. Red algae (gelidium amansii) reduces adiposity via activation of
lipolysis in rats with diabetes induced by streptozotocin-nicotinamide. J. Food Drug Anal. 2015, 23, 758–765.
[CrossRef]
21. Seo, M.-J.; Lee, O.-H.; Choi, H.-S.; Lee, B.-Y. Extract from edible red seaweed (gelidium amansii) inhibits
lipid accumulation and ros production during differentiation in 3t3-l1 cells. Prev. Nutr. Food Sci. 2012, 17,
129–135. [CrossRef] [PubMed]
22. Choi, J.; Kim, K.-J.; Koh, E.-J.; Lee, B.-Y. Altered gelidium elegans extract-stimulated beige-like phenotype
attenuates adipogenesis in 3t3-l1 cells. J. Food Nutr. Res. 2016, 4, 448–453.
23. Kim, K.-J.; Choi, J.; Lee, B.-Y. Evaluation of the genotoxicity of a Gelidium elegans extract in vitro and in vivo.
J. Food Nutr. Res. 2016, 4, 653–657.
24. Wang, Z.; Oh, E.; Clapp, D.W.; Chernoff, J.; Thurmond, D.C. Inhibition or ablation of p21-activated kinase
(pak1) disrupts glucose homeostatic mechanisms in vivo. J. Biol. Chem. 2011, 286, 41359–41367. [CrossRef]
[PubMed]
25. Harlow, E.D.; Lane, D. Using Antibodies: A Laboratory Manual; Cold Spring Harbor Laboratory Press: Cold
Spring Harbor, NY, USA, 1999.
26. Morelli, A.; Filippi, S.; Comeglio, P.; Sarchielli, E.; Chavalmane, A.K.; Vignozzi, L.; Fibbi, B.; Silvestrini, E.;
Sandner, P.; Gacci, M.; et al. Acute vardenafil administration improves bladder oxygenation in spontaneously
hypertensive rats. J. Sex. Med. 2010, 7, 107–120. [CrossRef] [PubMed]
27. Dubuc, P.U. The development of obesity, hyperinsulinemia, and hyperglycemia in ob/ob mice. Metabolism
1976, 25, 1567–1574. [CrossRef]
28. Newcomer, J.W. Metabolic syndrome and mental illness. Am. J. Manag. Care 2007, 13, S170–S177. [PubMed]
29. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. In Diabet. Med.; 1999;
Volume 16, pp. 716–730.
30. Hillier, T.A.; Pedula, K.L.; Schmidt, M.M.; Mullen, J.A.; Charles, M.-A.; Pettitt, D.J. Childhood obesity and
metabolic imprinting the ongoing effects of maternal hyperglycemia. Diabetes Care 2007, 30, 2287–2292.
[CrossRef] [PubMed]
31. Watkins, M.L.; Rasmussen, S.A.; Honein, M.A.; Botto, L.D.; Moore, C.A. Maternal obesity and risk for birth
defects. Pediatrics 2003, 111, 1152–1158. [PubMed]
48
Nutrients 2017, 9, 342
32. Arai, T.; Yamashita, S.; Hirano, K.-I.; Sakai, N.; Kotani, K.; Fujioka, S.; Nozaki, S.; Keno, Y.; Yamane, M.;
Shinohara, E.; et al. Increased plasma cholesteryl ester transfer protein in obese subjects. A possible
mechanism for the reduction of serum hdl cholesterol levels in obesity. Arterioscler. Thromb. 1994, 14,
1129–1136. [CrossRef] [PubMed]
33. Hu, E.; Tontonoz, P.; Spiegelman, B.M. Transdifferentiation of myoblasts by the adipogenic transcription
factors ppar gamma and c/ebp alpha. Proc. Natl. Acad. Sci. USA 1995, 92, 9856–9860. [CrossRef] [PubMed]
34. Laakso, M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999, 48, 937–942.
[CrossRef] [PubMed]
35. Ikemoto, S.; Takahashi, M.; Tsunoda, N.; Maruyama, K.; Itakura, H.; Ezaki, O. High-fat diet-induced
hyperglycemia and obesity in mice: Differential effects of dietary oils. Metabolism 1996, 45, 1539–1546.
[CrossRef]
36. Nathan, D.M.; Davidson, M.B.; DeFronzo, R.A.; Heine, R.J.; Henry, R.R.; Pratley, R.; Zinman, B. Impaired
fasting glucose and impaired glucose tolerance. Diabetes Care 2007, 30, 753–759. [CrossRef] [PubMed]
37. Yang, L.; Zhang, Y.; Wang, L.; Fan, F.; Zhu, L.; Li, Z.; Ruan, X.; Huang, H.; Wang, Z.; Huang, Z.; et al.
Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22. J. Hepatol.
2010, 53, 339–347. [CrossRef] [PubMed]
38. Carmiel-Haggai, M.; Cederbaum, A.I.; Nieto, N. A high-fat diet leads to the progression of non-alcoholic
fatty liver disease in obese rats. FASEB J. 2005, 19, 136–138. [CrossRef] [PubMed]
39. Horton, J.D.; Goldstein, J.L.; Brown, M.S. Srebps: Activators of the complete program of cholesterol and fatty
acid synthesis in the liver. J. Clin. Investig. 2002, 109, 1125–1131. [CrossRef] [PubMed]
40. Yahagi, N.; Shimano, H.; Hasty, A.H.; Matsuzaka, T.; Ide, T.; Yoshikawa, T.; Amemiya-Kudo, M.; Tomita, S.;
Okazaki, H.; Tamura, Y.; et al. Absence of sterol regulatory element-binding protein-1 (srebp-1) ameliorates
fatty livers but not obesity or insulin resistance inlep ob/lep ob mice. J. Biol. Chem. 2002, 277, 19353–19357.
[CrossRef] [PubMed]
41. Brown, M.S.; Goldstein, J.L. The srebp pathway: Regulation of cholesterol metabolism by proteolysis of a
membrane-bound transcription factor. Cell 1997, 89, 331–340. [CrossRef]
42. Harris, C.A.; Haas, J.T.; Streeper, R.S.; Stone, S.J.; Kumari, M.; Yang, K.; Han, X.; Brownell, N.; Gross, R.W.;
Zechner, R.; et al. Dgat enzymes are required for triacylglycerol synthesis and lipid droplets in adipocytes.
J. Lipid Res. 2011, 52, 657–667. [CrossRef] [PubMed]
43. Li, Y.; Xu, S.; Mihaylova, M.M.; Zheng, B.; Hou, X.; Jiang, B.; Park, O.; Luo, Z.; Lefai, E.; Shyy, J.Y.-J.; et al.
Ampk phosphorylates and inhibits srebp activity to attenuate hepatic steatosis and atherosclerosis in
diet-induced insulin-resistant mice. Cell Metab. 2011, 13, 376–388. [CrossRef] [PubMed]
44. Hardie, D.G. Ampk—Sensing energy while talking to other signaling pathways. Cell Metab. 2014, 20, 939–952.
[CrossRef] [PubMed]
45. Kajimura, S.; Seale, P.; Tomaru, T.; Erdjument-Bromage, H.; Cooper, M.P.; Ruas, J.L.; Chin, S.; Tempst, P.;
Lazar, M.A.; Spiegelman, B.M. Regulation of the brown and white fat gene programs through a prdm16/ctbp
transcriptional complex. Genes Dev. 2008, 22, 1397–1409. [CrossRef] [PubMed]
46. Kang, J.H.; Tsuyoshi, G.; Han, I.S.; Kawada, T.; Kim, Y.M.; Yu, R. Dietary capsaicin reduces obesity-induced
insulin resistance and hepatic steatosis in obese mice fed a high-fat diet. Obesity 2010, 18, 780–787. [CrossRef]
[PubMed]
47. Maeda, H.; Hosokawa, M.; Sashima, T.; Murakami-Funayama, K.; Miyashita, K. Anti-obesity and
anti-diabetic effects of fucoxanthin on diet-induced obesity conditions in a murine model. Mol. Med. Rep.
2009, 2, 897–902. [CrossRef] [PubMed]
48. Jayaprakasam, B.; Olson, L.K.; Schutzki, R.E.; Tai, M.-H.; Nair, M.G. Amelioration of obesity and glucose
intolerance in high-fat-fed c57bl/6 mice by anthocyanins and ursolic acid in cornelian cherry (cornus mas).
J. Agric. Food Chem. 2006, 54, 243–248. [CrossRef] [PubMed]
49. Jeon, H.J.; Seo, M.J.; Choi, H.S.; Lee, O.H.; Lee, B.Y. Gelidium elegans, an edible red seaweed, and hesperidin
inhibit lipid accumulation and production of reactive oxygen species and reactive nitrogen species in 3t3-l1
and raw264.7 cells. Phytother. Res. 2014, 28, 1701–1709. [CrossRef] [PubMed]
50. Gregor, M.F.; Hotamisligil, G.S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 2011, 29, 415–445.
[CrossRef] [PubMed]
49
Nutrients 2017, 9, 342
51. Liu, H.-C.; Chang, C.-J.; Yang, T.-H.; Chiang, M.-T. Long-term feeding of red algae (Gelidium amansii)
ameliorates glucose and lipid metabolism in a high fructose diet-impaired glucose tolerance rat model.
J. Food Drug Anal. 2016. [CrossRef]
52. Zhang, H.; Zhang, S.; Jiang, C.; Li, Y.; Xu, G.; Xu, M.; Wang, X. Intermedin/adrenomedullin 2 polypeptide
promotes adipose tissue browning and reduces high-fat diet-induced obesity and insulin resistance in mice.
Int. J. Obes. 2016, 40, 852–860. [CrossRef] [PubMed]
53. Lin, J.; Yang, R.; Tarr, P.T.; Wu, P.-H.; Handschin, C.; Li, S.; Yang, W.; Pei, L.; Uldry, M.; Tontonoz, P.; et al.
Hyperlipidemic effects of dietary saturated fats mediated through pgc-1β coactivation of srebp. Cell 2005,
120, 261–273. [CrossRef] [PubMed]
54. Fernandez-Marcos, P.J.; Auwerx, J. Regulation of pgc-1alpha, a nodal regulator of mitochondrial biogenesis.
Am. J. Clin. Nutr. 2011, 93, 884S–890S. [CrossRef] [PubMed]
55. Seale, P.; Kajimura, S.; Yang, W.; Chin, S.; Rohas, L.M.; Uldry, M.; Tavernier, G.; Langin, D.; Spiegelman, B.M.
Transcriptional control of brown fat determination by prdm16. Cell Metab. 2007, 6, 38–54. [CrossRef]
[PubMed]
56. Zelber-Sagi, S.; Kessler, A.; Brazowsky, E.; Webb, M.; Lurie, Y.; Santo, M.; Leshno, M.; Blendis, L.; Halpern, Z.;
Oren, R. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic
fatty liver disease. Clin. Gastroenterol. Hepatol. 2006, 4, 639–644. [CrossRef] [PubMed]
57. Van Gaal, L.; Broom, J.; Enzi, G.; Toplak, H. Efficacy and tolerability of orlistat in the treatment of obesity:
A 6-month dose-ranging study. Eur. J. Clin. Pharmacol. 1998, 54, 125–132. [CrossRef] [PubMed]
58. Kiortsis, D.; Filippatos, T.; Elisaf, M. The effects of orlistat on metabolic parameters and other cardiovascular
risk factors. Diabetes Metab. 2005, 31, 15–22. [CrossRef]
59. Spiegelman, B.M.; Flier, J.S. Adipogenesis and obesity: Rounding out the big picture. Cell 1996, 87, 377–389.
[CrossRef]
60. Hamilton, M.T.; Hamilton, D.G.; Zderic, T.W. Role of low energy expenditure and sitting in obesity, metabolic
syndrome, type 2 diabetes, and cardiovascular disease. Diabetes 2007, 56, 2655–2667. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





Ischemia/Reperfusion-Induced Renal Injury in
a SIRT1-Dependent Manner
Wei-Fang Li 1, Kang Yang 1, Ping Zhu 2, Hong-Qian Zhao 1, Yin-Hong Song 1, Kuan-Can Liu 3,4,5,*
and Wei-Feng Huang 1,*
1 Medical College, China Three Gorges University, Yichang 443002, China; lwf199023@163.com (W.-F.L.);
yangkang0218@126.com (K.Y.); 15271506793@163.com (H.-Q.Z.); syh728@126.com (Y.-H.S.)
2 Department of Medicine, the First College of Clinical Medical Science, China Three Gorges University,
Yichang 443002, China; topgan2000@163.com
3 Institute for Laboratory Medicine, Fuzhou General Hospital, PLA, Fuzhou 350025, China
4 Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA
5 Dongfang Hospital, Xiamen University, Fuzhou 350025, China
* Correspondence: liukuancan@163.com (K.-C.L.); huangweifeng@ctgu.edu.cn (W.-F.H.);
Tel.: +86-591-2285-9490 (K.-C.L.); +86-717-639-7438 (W.-F.H.)
Received: 6 February 2017; Accepted: 17 April 2017; Published: 20 April 2017
Abstract: Renal ischemia/reperfusion (I/R) injury continues to be a complicated situation in clinical
practice. Genistein, the main isoflavone found in soy products, is known to possess a wide spectrum
of biochemical and pharmacological activities. However, the protective effect of genistein on renal I/R
injury has not been well investigated. In the current study, we explore whether genistein exhibits its
renal-protective effects through SIRT1 (Sirtuin 1) in I/R-induced mice model. We found the treatment
of genistein significantly reduced renal I/R-induced cell death, simultaneously stimulating renal
cell proliferation. Meanwhile, SIRT1 expression was up-regulated following the administration of
genistein in renal region. Furthermore, pharmacological inhibition or shRNA-mediated depletion of
SIRT1 significantly reversed the protective effect of genistein on renal dysfunction, cellular damage,
apoptosis, and proliferation following I/R injury, suggesting an indispensible role of the increased
SIRT1 expression and activity in this process. Meanwhile, the reduced p53 and p21 expression and
increased PCNA (Proliferating Cell Nuclear Antigen) expression were blocked after the depletion
of SIRT1 compared with the genistein treatment group in the renal I/R process. Hence, our results
provided further experimental basis for the potential use of genistein for the treatment of kidney
disease with deficiency of SIRT1 activity.
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1. Introduction
Renal I/R injury is a major cause of acute kidney injury (AKI), which is a clinical condition
of frequent occurrence and high mortality [1,2]. I/R injury can increasingly develop into AKI in
many clinical settings, such as kidney transplantation, renal artery angioplasty, sepsis, and partial
nephrectomy, or by the action of vasoconstrictor drugs and certain hypotensive states [3]. There are
many factors that likely contribute to I/R-induced renal injury. However, the exact molecular
mechanisms underlying renal I/R injury are not completely understood. Various pharmaceuticals
have been identified for the treatment of renal I/R injury in the laboratory, such as AICAR
(5-amino-4-imidazolecarboxamide riboside-1-b-D-ribofuranoside), yohimbine, and pioglitazone [4–6].
However, these are limited, and few renal protectants have been successfully translated into clinical
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applications. Therefore, it is critical and urgent to develop safe and effective drugs for treating
IR-induced renal injury.
SIRT1, an NAD+ (nicotinamide adenosine denucleotide)-dependent protein deacetylase,
exerts cytoprotective effects through multiple mechanisms, such as anti-apoptosis, anti-oxidative,
and anti-inflammation effects and the regulation of mitochondrial biogenesis and autophagy [7].
Many studies have shown that SIRT1 can regulate multiple physiological processes, including
gene transcription, glucose homeostasis, cellular stress response, and immune response through its
capability of deacetylating various factors. The target proteins of deacetylation by SIRT1 include
histones, transcriptional regulators (p53; forkhead box O transcription factors, FoxOs; Nuclear
factor κB, NF-κB; hypoxia-inducible factors 2α, hypoxia-inducible factors 2α, HIF 2α), enzymes
(acetyl-CoA synthase1, AceCS1), and other signaling molecules such as peroxisome proliferator
activated receptor γ co-activator 1α (PGC1-α), thus affecting crucial cellular pathways in physiological
and pathological processes [8]. The renal protected effects of SIRT1 have been demonstrated in various
kidney diseases [9]. For example, SIRT1 preserves podocyte function by tuning claudin-1, which
is a key regulator of albuminuria and glomerular function [10]. He et al. [11] have reported that
SIRT1 protects the kidney medulla from oxidative stress-induced cellular injury by regulating the
induction of COX2 (cytochrome c oxidase subunit II). In addition, in mesangial cells, SIRT1 can
prevent oxidative stress-induced apoptosis by the deacetylation of p53 [12]. SIRT1 inhibits TGF
β1 (transforming growth factor β1)-induced apoptosis in glomerular mesangial cells via Smad7
deacetylation [13]. Recent studies have suggested that SIRT1 protects against I/R-induced renal injury
by attenuating apoptosis and promoting regeneration [14]. The protection caused by SIRT1 is closely
involved in the inhibition of the p53 signaling pathway. Specific deletion of p53 in the proximal
tubule cells protects kidneys from I/R-induced renal functional and histologic deterioration [15,16].
Moreover, caloric restriction has been shown to provide protection against I/R-induced renal injury [17].
SIRT1 expression is strongly influenced by calorie restriction. While multiple genes respond to caloric
restriction, SIRT1 is at least thought to be involved in the health benefits attributed to long-term caloric
restriction [7].
Genistein (4′,5,7-trihydroxyisoflavone), the most extensively studied soy isoflavone thus far,
is a polyphenolic non-steroidal compound commonly used as a dietary supplement. Because genistein
possesses oestrogen-like biological activity, its biological effects have been explored in conditions
such as cancer, inflammation, and apoptosis [18]. Previously, we also found that genistein inhibited
cancer stem cell-like properties and reduced the chemoresistance of gastric cancer [19]. Genistein has
been reported to protect against I/R-induced cerebral injury in the rat [20], and it has a protective
role on I/R-induced small intestine injury [21]. Additionally, Canyilmaz, E. et al. demonstrated that
the administration of genistein protects mice against radiation-induced nephrotoxicity [22]. It is of
particular relevance that the physiological activity of genistein as a phytoestrogen is closely related to
SIRT1 activity [23]. Genistein has multiple beneficial properties, including low toxicity, it has potential
in clinical treatment. However, the role and potential mechanism of genistein in I/R-induced kidney
injury remains unknown.
In this study, we aimed to determine the role of genistein in I/R-induced kidney injury and then
dissect the exact mechanism responsible for the treatment of I/R-induced kidney injury. Thus, it will
be helpful for us to establish guidance for the treatment of I/R-induced kidney injury.
2. Materials and Methods
2.1. Experimental Animals, I/R, Genistein Treatment, and SIRT1 Inhibition
Seven- to nine-week-old BALB/c mice were supplied by the China Three Gorges University
Laboratory Animal Center, and they were housed in an air-conditioned room with 12-h light and dark
cycles. All of the experiments were carried out in accordance with NIH Guidelines for the Care and
Use of Laboratory Animals. The animals were kept in sterile cages (maximum of five per cage) and fed
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standard rodent chow and allowed free access to water ad libitum. All of the experimental protocols
were approved by our School of Medicine Animal Care and Use Committee. An animal’s ability to
drink water, feed, ambulate, and its general appearance were evaluated after operation. They were
monitored three times in 24 h after genistein treatment.
An established model of the renal I/R-induced injury was established previously [24]. Briefly,
an abdominal midline incision was made, and right nephrectomy was performed under anesthesia.
Mice were anaesthetized using 100 mg/kg ketamine and 0.75 mg/kg chlorpromazine intraperitoneally.
Left renal ischemia was induced by clamping renal pedicles for 45 min with microvascular clamps
and then subjected to reperfusion. Mice in the sham group underwent right nephrectomy and were
treated as indicated in the specific experiment. The mice were hydrated with warm saline during the
operation, and the body temperature was maintained constantly at 37 ◦C using a heating pad until
awake. The wounds were sutured after removal of the clips, and the animals were allowed to recover.
Genistein (Sigma Aldrich, St. Louis, MO, USA; dissolved in 0.9% sodium chloride containing
1% dimethyl sulphoxide) was given (intravenous injection, i.v.) 30 min before the induction of
ischaemia. For the pharmacological inhibition of SIRT1 activity, mice were treated (i.v.) with Sirtinol
(Sigma Aldrich, St. Louis, MO, USA; 1 mg/kg dissolved in 0.9% sodium chloride containing 1%
dimethyl sulfoxide) 60 min before the induction of ischemia. The others received the same volume
of vehicle. For the inhibition of SIRT1 by lentivirus, a 31-gauge needle was used to inject 100 μL of
ultracentrifugation-purified lentivirus (lentivirus, LV; LV-control or LV-shSIRT1, ≈3 × 107 TU) at the
lower pole of the left kidneys parallel to the long axis and was slowly removed 72 h later [25]; then,
induction of ischemia was performed.
For the dose-dependent analyses of genistein effects on I/R-induced renal injury, mice were
randomized into five groups (n = 6/group): (1) sham group; (2) I/R group; (3) G5 group; (4) G10 group;
and (5) G15 group. In the sham group, mice received the same volume of vehicle without I/R; in the
I/R group, mice received the same volume of vehicle with I/R; in the G5 group, mice were pre-treated
with 5 mg/kg genistein following I/R; in the G10 group, mice were pre-treated with 10 mg/kg
genistein following I/R; in the G15 group, mice were treated with 15 mg/kg genistein. The mice were
decapitated after 24 h of reperfusion, and blood samples were collected for the analysis of biochemical
measurements. The kidneys were excised and then washed with ice-cold saline for further analysis.
For the time-dependent analyses of the genistein effects on I/R renal-induced injury, mice were
randomized into three groups (n = 24/group): (1) sham group; (2) I/R group; and (3) G15 group.
In the sham group, mice received the same volume of vehicle without I/R; in the G15 group, mice
were pre-treated with 15 mg/kg genistein following I/R. Six mice in each group were decapitated
at 12, 24, 48, and 72 h of the reperfusion period, and blood samples were collected for the analysis
of biochemical measurements. The kidneys were excised and then washed with ice-cold saline for
further analysis.
For the inhibition of SIRT1 by Sirtinol, mice were randomized into four groups (n = 6/group):
(1) vehicle group; (2) Sirtinol group; (3) G15 group; and (4) Sirtinol + G15 group. Ischemia was induced
in all groups. In the vehicle group, mice received the same volume of vehicle; in the Sirtinol group,
mice were pre-treated with 1 mg/kg Sirtinol; in the G15 group, mice were pre-treated with 15 mg/kg
genistein; in the Sirtinol + G15 group, mice were treated with 15 mg/kg genistein and 1 mg/kg
Sirtinol. Sirtinol and genistein were administered as described above. The mice were decapitated after
24 h of reperfusion and blood samples were collected for the analysis of biochemical measurements.
The kidneys were excised and then washed with ice-cold saline for the further analysis.
For the inhibition of SIRT1 by lentivirus carrying shRNA targeting SIRT1, mice were randomized
into four groups (n = 6/group): (1) LV-control group; (2) LV-shSIRT1 group; (3) G15 group;
and (4) LV-shSIRT1 + G15 group. Ischemia was induced in all of the groups. In the LV-control group,
mice were injected with lentivirus carrying scrambled shRNA and were pre-treated with the same
volume of vehicle; in the LV-shSIRT1 group, mice were injected with lentivirus carrying SIRT1 shRNA;
in the G15 group, mice were injected with lentivirus carrying scrambled shRNA and were pre-treated
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with 15 mg/kg genistein; in the G15 + LV-shSIRT1 group, mice were injected with lentivirus carrying
SIRT1 shRNA and were pre-treated with 15 mg/kg genistein. Lentivirus injection and genistein
treatment were performed as described above. The mice were decapitated at 24 h of the reperfusion
period, and trunk blood samples were collected for the analysis of biochemical measurements.
The kidneys were excised and then were washed with ice-cold saline for further analysis.
2.2. Biochemical Determinations
Serum was obtained from blood samples to measure blood urea nitrogen (BUN) and serum
creatinine (Scr) using an automatic biochemistry analyzer (Hitachi 7060, Tokyo, Japan) after reperfusion.
2.3. Kidney Histology
For histological examination, the kidneys were fixed in 4% paraformaldehyde, embedded in
paraffin, sectioned at 4-μm thickness, and stained with hematoxylin and eosin (H&E). Tubular injury
was scored on a scale of 0–4 based on the percentage of tubules with necrosis, dilatation, cast formation
and cell lysis: 0, no damage; 1, 5%–25%; 2, 25%–50%; 3, 50%–75%; and 4, >75%. The morphological
changes from the cross-sectional area cortex and outer medulla were evaluated by a pathologist
according to the acute tubular necrosis (ATN) scoring system in a blinded manner [26].
2.4. Immunohistochemistry
For immunohistochemical (IHC) studies, 4-μm-thick sections were microwaved in 0.01 mol/L
sodium citrate (pH 6.0) three times for 5 min each. The primary antibodies used were anti-SIRT1
(1:100; Abcam, Cambridge, UK), anti-cleaved caspase-3 (Cell Signaling Technology, Danvers, MA,
USA) and anti-PCNA (1:200; Santa Cruz, Dallas, TX, USA), respectively. IHC was performed using the
UltrasensitiveTM SP (Mouse/Rabbit) IHC kit (Mai-xin Biotechnology Co., Fuzhou, China). Images
were acquired using a digital camera (Olympus, Tokyo, Japan) at 400× magnification, and the results
were analyzed by Image-Pro Plus 6.0 (Media Cybernetics, Rockville, MD, USA). The results were
defined as the number of positive cells/total number of cells.
2.5. TUNEL Assay
Apoptosis detection was performed using the terminal deoxynucleotidyl transferase-mediated
digoxigenindeoxyuridine nick-end labelling (TUNEL) assay (Roche Diagnostics, Mannheim, Germany)
according to the protocols of the manufacturer. Briefly, samples were incubated in equilibration
buffer for 5 min, followed by incubation in the labelling reaction reagent for 1 h at 37 ◦C, and DNA
fragments in apoptotic cells were recognized. The positive cellular counts of staining were assessed at
400× magnification using five randomly selected fields, and the apoptosis index was expressed as the
percentage of positive cells in high-power fields. Data were averaged.
2.6. Western Blotting
Proteins from kidney samples were isolated using lysis buffer followed by centrifugation.
Western blot analysis of the proteins in mouse kidneys was performed according to standard
protocols. Immunoblotting was performed using anti-SIRT1 antibody (1:5000; Abcam, Cambridge,
UK), anti-cleaved caspase-3 antibody (1:1000; Cell Signaling Technology, Danvers, MA, USA),
anti-pro-caspase-3 antibody (1:1000; Zen BioScience, Chengdu, China), anti-PCNA antibody (1:2000;
Santa Cruz, Dallas, TX, USA), anti-p53 antibody (1:1000; Santa Cruz, Dallas, TX, USA), anti-acetyl-p53
antibody (K381) (1:1000; Abcam, Cambridge, UK), and anti-p21 antibody (1:2000; Santa Cruz, Dallas,
TX, USA). The blots were detected using the Immobilon Western Chemiluminescent HRP Substrate kit
(Millipore, Danvers, MA, USA) followed by exposure to Kodak-X-Omat film (Shanghai, China).
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2.7. Statistical Analysis
All of the statistical analyses were performed using GraphPad Prism 5.0 software. The values are
expressed as the mean ± SEM (standard error of the mean). Pair-wise comparisons were performed
using Student’s t-test (two-tailed), and multiple-group comparisons were performed using one-way
ANOVA with Bonferroni’s post-hoc test. A p-value < 0.05 was considered significant.
3. Results
3.1. Genistein Protects the Kidney Against I/R Injury
Renal I/R injury increased the Scr (serum creatinine) and BUN (blood urea nitrogen) levels
to 1.8 ± 0.1 and 218.4 ± 9.7 mg/dL, respectively, from the levels in the sham group (0.3 ± 0.02
and 25.3 ± 1.7 mg/dL, respectively; Figure 1a, p < 0.05). The genistein-pretreated group showed
significant reduction in the elevated Scr and BUN levels in a dose-dependent manner. Genistein at
the dose of 15 mg/kg significantly decreased the Scr (0.5 ± 0.05 mg/dL, p < 0.05) levels and BUN




Figure 1. Effect of genistein on kidney injury following I/R injury. In the sham group, mice received the
same volume of vehicle without I/R; in the I/R group, mice received the same volume of vehicle with
I/R; in the G5 group, mice were pre-treated with 5 mg/kg genistein following I/R; in the G10 group,
mice were pre-treated with 10 mg/kg genistein following I/R; and in the G15 group, mice were treated
with 15 mg/kg genistein following I/R. The mice were decapitated after 24 h of reperfusion for further
analysis. The data were expressed as the mean ± SEM; n = 6; * p < 0.05 vs. Sham; # p < 0.05 vs. I/R.
(a) The Scr levels and BUN levels were examined 24 h after surgery; (b) A semi-quantitative assessment
of the lesion was performed by a pathologist in a blinded manner according to the ATN–scoring system.
Each tubular segment visible in the cortex and the outer medulla was evaluated; (c) Representative
images of the cortex and outer medulla in different groups stained with H&E. Original magnification,
400×. The black arrows indicate the areas of I/R-induced tissue damages.
To investigate the effect of genistein on I/R-induced renal tubular damage, kidney sections were
stained with H&E. Tubular dilatation, necrosis, brush border loss, and cast formation were evident in
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the I/R group. However, after pre-treatment with genistein, the damage was limited to mild swelling
of the tubular epithelial cells, and less histological damage was observed with the H&E stain (Figure 1c).
Pretreatment with genistein significantly reduced the tubular necrosis score in both the cortex and
medulla compared with the score in sections from mice with I/R injury (Figure 1b).
To further explore the protective effects of genistein on I/R-induced renal injury, mice were treated
with 15 mg/kg genistein or vehicle 30 min before the induction of ischemia, followed by 12, 24, 48,
and 72 h of reperfusion. Genistein treatment led to a significant decrease in the elevated Scr and BUN
levels in the I/R group of mice at 12, 24, 48, and 72 h post I/R injury (Figure A1). Genistein treatment
at 48 h post I/R injury had returned the Scr and BUN levels to those of the sham group. Examination
of the cortical and outer-medullary regions of the kidneys confirmed the results of the aforementioned
functional studies (Figure A2).
3.2. Genistein Increases SIRT1 Expression in Renal Cells after Renal I/R-Induced Injury
Previous studies have demonstrated that the regulation of SIRT1 by naturally occurring dietary
polyphenols is beneficial in the therapeutic intervention of various diseases [27]. To determine whether
SIRT1 is also involved in the protective effect of genistein, we analyzed the protein and mRNA
expression in renal tissues. No significant differences occurred in SIRT1 expression between the I/R
group and the sham group (Figures 2a and A3). Interestingly, pre-treatment with 10 and 15 mg/kg
genistein dramatically increased the expression of SIRT1 protein and mRNA (Figures 2a and A3,
p < 0.05). The mRNA and protein levels of SIRT1 in the 15 mg/kg genistein-treated group were
2.3- and 1.6-fold higher than those in the I/R group (p < 0.05), respectively. The upregulation of SIRT1
protein was further confirmed by the IHC assay (Figure 2b). The results showed that pre-treatment
with 15 mg/kg genistein significantly increased SIRT1 expression in the renal cortex and outer medulla
compared with that in the I/R group. These data indicate that SIRT1 may contribute to the protective
effects of genistein on tubular damage and the loss of renal function in I/R injury.
(a) (b) 
Figure 2. Effect of genistein on SIRT1 expression following I/R injury. Mice were treated as described
in Figure 1. The data were expressed as the mean ± SEM; n = 6; # p < 0.05 vs. I/R. (a) Western blots
analysis for SIRT1 expression in mouse kidney tissues. Densitometric analysis of the SIRT1 expression
by Image-Pro Plus 6.0. GAPDH was calibrated; (b) Representative images of SIRT1 expression in
the kidney, as determined by IHC. Original magnification, 400×. The black arrows indicate the
positive cells.
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3.3. Genistein Inhibits Apoptosis and Increases Proliferation after Renal I/R-Induced Injury
Several lines of experimental evidence have supported a crucial role for apoptosis in the
pathogenesis of I/R-induced injury [28]. Apoptotic cells were detected in the kidney of all groups using
terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling (TUNEL) staining. As shown
in Figure 3a, mice with I/R injury had more TUNEL-positive cells predominantly in the tubules of
the outer medulla than in the cortex region. Pre-treatment with genistein (5, 10, and 15 mg/kg)
resulted in a significant decrease in the number of apoptotic cells (30.1% ± 2.0%, 17.3% ± 1.6%,
and 8.7% ± 1.3%, respectively) compared with that in the I/R group (40.2% ± 2.3%) in the outer
medulla regions (Figure 3a, p < 0.05). Meanwhile, the level of cleaved caspase-3 in the kidney treated
with genistein (5, 10, and 15 mg/kg) was significantly lower than that in the I/R group (Figure 3b,
p < 0.05). This finding is consistent with the TUNEL assay.
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Figure 3. Effect of genistein on the cellular apoptosis and proliferation following I/R injury. Mice were
treated as described in Figure 1. The data were expressed as the mean ± SEM; n = 6; * p < 0.05 vs. Sham;
# p < 0.05 vs. I/R. (a) Representative photomicrograph of TUNEL-positive cells stained kidney tissues
from the I/R and G15 groups and the percentage of positive cells is illustrated; (b) Cleaved caspase-3
and pro-caspase-3 expression was analyzed by western blotting; (c) Representative photomicrograph
of PCNA-positive cells stained kidney tissues from the I/R and G15 groups and the percentage of
positive cells is illustrated. Original magnification, 400×. The black arrows indicate the positive cells.
Renal cell proliferation was assessed using proliferating cell nuclear antigen (PCNA).
Few PCNA-positive proliferating cells were detected in the kidneys of sham-operated mice.
The number of PCNA-positive cells was significantly increased in the renal cortex (11.1% ± 1.3%)
and outer medulla (12.6% ± 1.6%) following I/R (Figure 3c, p < 0.05). Pre-treatment with genistein
(5, 10, and 15 mg/kg) resulted in a significant increase of the number of PCNA-positive cells in the
kidney. The number of PCNA-positive cells for the 15 mg/kg genistein-treated group was significantly
higher (45.4% ± 2.0% and 41.3% ± 2.8% for cortex and outer medulla) than that in I/R mice (p < 0.05).
These results suggested that genistein inhibits apoptosis and promotes proliferation and then prevents
the mice from I/R-induced renal injury.
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3.4. The SIRT1 Inhibitor Abolishes the Protective Effects of Genistein on I/R-Induced Injury
To investigate whether SIRT1 is required for the renal-protective effects of genistein against
I/R-induced injury, Sirtinol, a SIRT1 inhibitor, was administered 60 min before the induction of
ischemia with or without genistein. Sirtinol preconditioning slightly aggravated I/R-induced renal
injury. The Scr, BUN, and injury score in Sirtinol-treated mice exhibited higher levels than those of
the vehicle mice, although no significant difference occurred between these two groups (Figure 4).
Notably, Sirtinol abrogated the protective effect of genistein. The reduction of Scr and BUN in
genistein-treated mice was inhibited by Sirtinol. Consistent with this result, the kidney of G15 + Sirtinol
mice displayed severe and extensive injury, with widespread loss of the brush border, tubular dilation,




Figure 4. Sirtinol abolishes the protective effect of genistein on renal function and histology in
I/R-induced injury. In the vehicle group, mice received the same volume of vehicle; in the Sirtinol
group, mice were pre-treated with 1 mg/kg Sirtinol; in the G15 group, mice were pre-treated with
15 mg/kg genistein; in the Sirtinol + G15 group, mice were treated with 15 mg/kg genistein and
1 mg/kg Sirtinol. Ischemia was induced in all of the groups. The mice were decapitated at 24 h of the
reperfusion period for further analysis. The data were expressed as the mean ± SEM; n = 6; * p < 0.05
vs. Sham; # p < 0.05 vs. I/R. The Scr (a, left) levels and BUN (a, right) levels were examined 24 h
after reperfusion. (b, left) Representative images of the cortex and outer medulla from the G15 and
G15 + Sirtinol groups stained with H&E. Original magnification, 400×. The black arrows indicate
the areas of I/R-induced tissue damages. (b, right) A semi-quantitative assessment of the lesion was
performed by a pathologist in a blinded manner according to the ATN–scoring system. Each tubular
segment visible in the cortex and outer medulla was evaluated.
Similarly, tubular cell apoptosis was also determined by the TUNEL assay and analysis of
cleaved caspase-3 expression. No significant difference occurred in the apoptosis and proliferation
of tubular cells between Sirtinol-treated mice and I/R mice (Figures 5 and A4). Pre-treatment with
Sirtinol abolished the protective effect of genistein on I/R-induced apoptosis (Figure 5a). In addition,
the promoted effect of genistein on renal proliferation was abrogated by Sirtinol following I/R
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(Figure 5b). Lower renal PCNA expression following I/R was also observed in Sirtinol-treated
mice using immunoblotting (Figure A5), suggesting that the protective effects of genistein depend on
SIRT1 activation in the kidney with I/R injury.
(a) 
(b) 
Figure 5. Mice were treated as described in Figure 4. The data were expressed as the mean ± SEM; n = 6;
* p < 0.05 vs. Vehicle; # p < 0.05 vs. G15. (a) Representative photomicrograph of TUNEL-positive from the
G15 and G15 + Sirtinol groups and the percentage of positive cells were illustrated; (b) Representative
photomicrograph of PCNA-positive from the G15 and G15 + Sirtinol groups and the percentage of
positive cells were illustrated. Original magnification, 400×. The black arrows indicate the positive cells.
3.5. SIRT1 Depletion Eliminates the Protective Effects of Genistein on I/R-Induced Injury
Because both SIRT1 and SIRT2 are inhibited by Sirtinol, the specific contribution of SIRT1 to
the protective effects of genistein on I/R-induced injury was determined using shRNA-mediated
knockdown with lentivirus. SIRT1 protein was significantly induced by genistein in kidneys injected
with lentivirus carrying the scrambled shRNA cassette; however, its expression was significantly lower
in I/R- and genistein-treated mice receiving lentivirus with the SIRT1 shRNA cassette (Figure A6).
Knockdown of SIRT1 was verified by IHC analysis (Figure A7). Consistent with the result using the
SIRT1 inhibitor Sirtinol, knockdown of SIRT1 with shRNA significantly reversed the effect of genistein
on renal dysfunction (Figure 6a), cellular damage (Figure 6b), apoptosis (Figure A8), and proliferation
(Figure A9) following I/R injury. Thus, the protective effects of genistein depend on SIRT1 expression
in the kidney with I/R injury.
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(a) 
(b) 
Figure 6. SIRT1 depletion abrogates the protective effect of genistein on renal function and histology in
I/R-induced injury. In the LV-control, mice were injected with lentivirus carrying scrambled shRNA
and pre-treated with the same volume of vehicle; in the LV-shSIRT1 group, mice were injected with
lentivirus carrying SIRT1 shRNA; in the G15 group, mice were injected with lentivirus carrying
scrambled shRNA and were pre-treated with 15 mg/kg genistein; in the LV-shSIRT1 + G15 group, mice
were injected with lentivirus carrying SIRT1 shRNA and were pre-treated with 15 mg/kg genistein.
Ischemia was induced in all of the groups. The mice were decapitated after 24 h of reperfusion for
further analysis. The data were expressed as the mean ± SEM; n = 6; * p < 0.05 vs. Sham; # p < 0.05
vs. I/R. The Scr (a, left) levels and BUN (a, right) levels were examined 24 h after reperfusion.
(b, left) Representative images of the cortex and outer medulla from G15 and G15 + LV-shSIRT1 groups
stained with H&E. Original magnification, 400×. The black arrows indicate the areas of I/R-induced
tissue damages. (b, right) Semi-quantitative assessment of the lesion was performed by a pathologist
in a blinded manner according to the ATN-scoring system. Each tubular segment visible in the cortex
and outer medulla was evaluated.
3.6. The Protective Effects of Genistein Is Associated with the SIRT1/p53 Axis
It has been reported that the expression of p53 is regulated by SIRT1, which then exerts its
anti-apoptotic and proliferative effect, thereby contributing to the pathogenesis of ischemic renal
injury [14]. Of interest is to investigate whether SIRT1/p53 axis contributes to the protective effects of
genistein on I/R-induced injury [15,16]. Our western blot analyses revealed that SIRT1/p53 signaling
was also involved in the protective effects of genistein: (1) genistein reduced the expression of p53 and;
(2) no significant difference occurred in p53 between LV-shSIRT1-treated mice and LV-control mice;
(3) by contrast, the reduction of p53 caused by genistein was significantly prevented by SIRT1 depletion;
(4) in addition, the level of the cell cycle-related p21, a target of p53, was significantly inhibited in the
kidneys of genistein-treated mice; (5) knock-down of SIRT1 with the shRNA cassette largely blocked
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the inhibitory effect of genistein on p21 expression; (6) there were inverse correlations between the
expression of p53 and p21 and PCNA in the kidneys of different groups following I/R (Figure 7a,b).
However, it did not significantly alter the acetylation status of p53 (Figure 7c). Taken together, all of





Figure 7. Effect of SIRT1 depletion on protein expression following I/R-induced renal injury. Mice
were treated as described in Figure 6. The data were expressed as the mean ± SEM; n = 6; * p < 0.05 vs.
LV-control; # p < 0.05 vs. G15. (a) Representative western blots for p53, Acetyl-p53, p21, and PCNA
expression in mouse kidney tissues; (b) Densitometric analysis of p53, p21, and PCNA expression by
Image-Pro Plus 6.0. GAPDH was calibrated; (c) Densitometric analysis of Acetyl-p53 expression by
Image-Pro Plus 6.0. Total p53 was calibrated.
4. Discussion
Renal ischemia-reperfusion is a common cause of acute kidney injury (AKI), which is a common
clinical complication characterized by an abrupt decrease in the glomerular filtration rate. Despite the
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improvement in therapeutic methods, including renal replacement therapy, the overall mortality of
AKI is estimated to be 50% [2]. There are several pathologic processes contributing to AKI, including
endothelial and epithelial cell death, intratubular obstruction, and changes in the local microvascular
blood flow, as well as immunological and inflammatory processes. Therefore, the mechanisms
underlying I/R damage to kidneys are most likely multifactorial and interdependent, involving
hypoxia, inflammatory responses, and free radical damage [1]. Effective treatments for I/R-induced
renal injury in clinics are still absent. It is crucial to screen effective drugs to treat I/R-induced renal
injury. It is well established that the inhibition of apoptotic signalling and cell death is an effective
measure to relieve I/R in a murine model. Pre-ischaemic activation of the A1 AR protects against
I/R injury in vivo through mechanisms that reduce necrosis and apoptosis [29], and other studies
have suggested that tubular cell regeneration and proliferation play an important role in the recovery
of AKI [14,28]. As a plant-derived isoflavone, genistein is a polyphenolic non-steroidal compound,
and its biological activity has been widely explored in cancer, inflammation, and apoptosis. Recently,
it has been reported that genistein plays a neuro-protective role in ischemic insults [30]. As a member
of the Sirtuin family, SIRT1 belongs to the typical class III histone deacetylases (HDAC). SIRT1 has
been involved in influencing a wide range of cellular processes including aging, transcriptional
reprogramming, apoptosis, inflammation, and stress resistance, as well as energy efficiency and
alertness during low-calorie situations [7,31]. Moreover, it can also control circadian clocks and
mitochondrial biogenesis, suggesting that SIRT1 is an important age-related protective factor against
I/R-induced kidney injury. Activation of SIRT1 attenuated I/R-induced renal injury; conversely,
the ablation of one allele of the SIRT1 gene significantly resulted in higher susceptibility to I/R-induced
kidney injury. Furthermore, the kidney-specific overexpression of SIRT1 could also protect against
cisplatin-induced AKI [32]. In this study, renal function and morphology were significantly recovered
24 h after renal I/R injury following pretreatment with genistein (5, 10, and 15 mg/kg). Meanwhile,
renal function and morphology were markedly recovered at 12, 24, 48, and 72 h after renal I/R
injury following pretreatment with 15 mg/kg genistein. These results strongly support that genistein
is an effective agent for the treatment of I/R-induced kidney injury. Consistent with our results,
anti-apoptosis activity caused by genistein is also the important mechanism for its neuro-protective
role in ischemic insults [30]. In addition, we also showed that the protective roles of genistein in
I/R-induced renal injury are associated with a higher cellular proliferation rate, which was evaluated
by the PCNA level. All of these studies indicated that genistein and SIRT1 both have multiple roles
in many physiological processes, suggesting that they may also contribute to the repair of renal
ischemia/reperfusion (I/R) injury.
Previously, many studies have revealed the close relationship between genistein and SIRT1,
and the expression of SIRT1 and its activity were stimulated by isoflavones such as resveratrol
and quercetin [27]. However, the effect of genistein on SIRT1 expression and activity is seemingly
controversial. On the one hand, genistein has been demonstrated to enhance SIRT1 expression and
activity in C2C12 myotubes [23] and breast cancer T47D cells but not in MCF-7cells [33]. Moreover,
genistein was found to increase AMPK (adenosine monophosphate activated protein kinase) activity
in liver cells, which could trigger SIRT1 activity [34]. On the other hand, genistein has also been
demonstrated to inhibit the expression of SIRT1 in prostate cancer cells [35]. A reasonable explanation
for these phenomena is that genistein might have dual effects on SIRT1 expression and activity,
and the effects depend on the different tissue contexts and dosage. Recently, one reporter provided
another explanation for the phenomena. The modulation of the intrinsic gene expression by genistein
could lead to a difference in radio-sensitivity in between cancerous and normal cells [36]. Interestingly,
our study clearly demonstrated that the expression of SIRT1 was significantly increased 24 h after
renal I/R injury following pretreatment with genistein (10 mg/kg and 15 mg/kg), and the inhibition
of SIRT1 activity or expression abolished the protective effects of genistein on I/R-induced renal
injury. Genistein treatment significantly reduced apoptosis and enhanced cellular proliferation rate,
further supporting the protective effect of SIRT1. However, the inhibition of SIRT1 activity or its
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expression reduced the proliferation rate mediated by genistein. Moreover, a significant reduction in
the p21 expression level occurred in genistein-treated mice. p21 is a cyclin-dependent kinase (CDK)
inhibitor, and it might bind to and inhibit the activity of cyclin-CDK2 or cyclin-CDK4 complexes,
thereby regulating cell cycle progression. Therefore, our study showed that genistein may exert its
renal protective effects on renal I/R injury through its stimulation of SIRT1 expression or activity.
SIRT1 expression or activity could be regulated directly or indirectly in vitro and in vivo. Hence,
it is necessary to explore the definite mechanism regarding how SIRT1 expression and activity are
regulated by genistein in renal cells.
As a tumor suppressor, p53 is involved in multiple essential cell functions, such as pausing the
cell cycle, promoting senescence and apoptosis, and regulating cell metabolism. The participation
of p53 has been reported in nephrotoxic injury and ischemic renal injury, and targeted deletion of
p53 in the proximal tubule prevents ischemic renal injury. p53 expression is negatively associated
with SIRT1 expression and activity after AKI [14]. Kidney-specific overexpression of SIRT1 protects
against AKI [30]. Furthermore, genistein decreases cisplatin-induced renal injury by preventing p53
induction [37]. Those data indicate that p53 expression is closely related to SIRT1 expression or activity
after AKI. To test the potential relationships between genistein, p53, and SIRT1, we examined the
level of p53, acetylated p53, p21, and PCNA (a proliferation marker) [13], respectively. Our study
demonstrated that p53 and p21 were significantly decreased 24 h after renal I/R injury, accompanied
by the induction of SIRT1 following pretreatment with genistein. The pivotal role of SIRT1 was
further supported by the finding that the inhibition of SIRT1 activity or expression significantly
blocks the repression of p53 expression, and p21 following the use of genistein. Moreover, there
was the inverse correlation between p53, p21, and PCNA expression. It has shown that enhanced
SIRT1 activity can reduce p53 expression by deacetylating p53 and promoting its ubiquitination
and proteasomal degradation [38]. Genistein caused a robust reduction in p53 abundance but
had no measurable effect on p53 acetylation associated with upregulated SIRT1 expression. It is
plausible that SIRT1 caused the deacetylation of p53, contributing to p53 degradation by genistein.
Remarkably, many factors contribute to the stability of p53 expression. These findings suggest the
existence of other SIRT1-dependent mechanisms that tune p53 expression by genistein. Together,
these data indicated that the SIRT1/p53 axis plays an important role in the protective effects of
genistein on I/R-induced renal injury. In addition to regulation of DNA synthesis, PCNA has
far-reaching impacts on a myriad of cellular functions by interaction with many protein and various
post-translational modifications [39]. The protective roles of genistein in I/R-induced renal injury
are associated with a higher PCNA level, implying the cellular proliferation involved at least in
part in the protective effects of genistein. Moreover, it has to make great efforts to explore the more
enigmatic PCNA-dependent function in this process, including senescence and apoptosis. In this study,
we found that genistein could protect against I/R-induced renal injury, and the reno-protective effects
of genistein were associated with reduced apoptosis and a higher renal proliferation rate. Surprisingly,
the upregulation of SIRT1 expression is closely correlated with improved function against kidney injury
in genistein-receiving mice. Pharmacological inhibition of SIRT1 abolished the reno-protective effects
of genistein, and knockdown of SIRT1 abrogated the beneficial effects of genistein on kidney injury
following I/R. Additionally, increased SIRT1 lead to reduced expression of p53, reduced apoptosis,
and a higher renal cellular proliferation rate and vice versa, suggesting genistein may promote cell
survival and enhance renal cellular proliferation via SIRT1/p53 axis to provide reno-protection in
I/R-induced renal injury (Figure 8). The major isoflavones in soybean are genistein and daidzein.
Daidzein can behave similarly to genistein and both of them have been shown to protect from metabolic
disease in a SIRT1-dependent manner [40]. Daidzein has been shown to induce the expression and
activity of SIRT1 in renal cells [40]. In the light of the protective effects of SIRT1 in kidney, daidzein
administration could ameliorate I/R-induced kidney injury by stimulating the expression and activity
of SIRT1. This needs to be testified in future study.
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Figure 8. Proposed scheme for the roles of SIRT1, p53, and other molecules in the protective effect of
genistein on I/R-induced renal injury. Genistein treatment significantly reduced renal I/R-induced
cell death, simultaneously stimulating renal cell proliferation. Paralleling the protective effect of
genistein against I/R-induced renal injury, SIRT1 expression was upregulated upon the administration
of genistein. Genistein reduced p53, p21, and cleaved caspase-3 expression and increased PCNA
expression. Pharmacological inhibition or shRNA-mediated depletion of SIRT1 significantly reversed
the effect of genistein on renal dysfunction, cellular damage, apoptosis, and proliferation following
I/R injury. The reduced p53, p21 expression, and increased PCNA expression were blunted after the
depletion of SIRT1 compared with the genistein treatment group in the renal I/R process.
5. Conclusions
In summary, we confirmed that genistein possesses protective effects on renal ischemia-reperfusion
injury and that the protective effect mainly depends on apoptosis inhibition and regeneration promotion
accompanied by the increased expression of SIRT1, whereas inhibition of SIRT1 activity or expression
blocked the protective effect. It is probable that genistein improves I/R-induced renal-injury in
a SIRT1-dependent manner, making it a potential reagent for treatment of kidney disease with deficiency
of SIRT1 activity. This need to be further verified using more in vivo and in vitro experiments.
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Appendix A
Appendix A.1. Lentivirus Preparation
Lentiviruses were generated by cotransfecting subcofluent HEK293T cells with the lentiviral
vectors (psh-control or psh-SIRT1) and packaging plasmids (pHR and pCMV-VSV-G) by
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calcium phosphate transfection. The targeted sequences for psh-SIRT1 and psh-control were
5′-AAGATGAAGTTGACCTCCTCA-3′ and 5′-TTCTCCGAACGTGTCACGT-3′, respectively. Viral
supernatants were collected 48 h after transfection, centrifuged at 3000× g for 15 min, and filtered
through 0.45-μm filters (Millipore, Danvers, MA, USA). The concentrations of lentivirus were
determined using ultracentrifugation approaches [41].
Appendix A.2. Quantitative Real-Time RT-PCR
Total RNA was extracted using TRIZOL Reagent (Invitrogen, Carlsbad, CA, USA) and was
reverse transcribed with ReverTra Ace (Toyobo, Dalian, China) to produce cDNA. Real-time PCR was
performed using SYBR (Synergy Brands) Green-based detection in StepOnePlus™ (ABI, Redlands,
CA, USA) according to the manufacturer’s instructions and using the following primer pairs: SIRT1
(NM_019812) (Forward: 5′-TGCTGGCCTAATAGACTTGCAA-3′, Reverse: 5′-CAGGAACTAGAGGAC
AAGACGTCA-3′); 18S rRNA (NR_003278) (Forward:5′-GGTCATAAGCTTGCGTTGATTAAG-3′,
Reverse: 5′-CTACGGAAACCTTGTTACGACTTT-3′).
Appendix B
Figure A1. Effect of genistein on renal function at different time points. In the sham group, mice
received the same volume of vehicle without I/R; in the I/R group, mice received the same volume
of vehicle with I/R; in the G15 group, mice were treated with 15 mg/kg genistein. The mice were
decapitated after 12, 24, 48, and 72 h of reperfusion for renal functional analysis. The data were
expressed as the mean ± SEM; n = 6; * p < 0.05 vs. Sham; # p < 0.05 vs. I/R. The Scr (A) levels and BUN
(B) levels were examined 12, 24, 48, and 72 h after reperfusion.
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Figure A2. Effect of genistein on renal histology in I/R-induced injury at different time points.
Mice were treated as described in supplemental Figure A1. The data were expressed as the mean ± SEM;
n = 6; * p < 0.05 vs. Sham; # p < 0.05 vs. I/R. (Top) Representative images of the cortex and outer
medulla at 12, 24, 48, and 72 h of the reperfusion period stained with H&E. Original magnification,
400×; (Bottom) Semi-quantitative assessment of the lesion was performed by a pathologist in a blinded
manner according to the ATN–scoring system. Each tubular segment visible in the cortex and outer
medulla was evaluated.
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Figure A3. Effect of genistein on SIRT1 mRNA expression following I/R injury. In the sham group,
mice received the same volume of vehicle without I/R; in the I/R group, mice received the same
volume of vehicle with I/R; in the G5 group, mice were pre-treated with 5 mg/kg genistein following
I/R; in the G10 group, mice were pre-treated with 10 mg/kg genistein following I/R; in the G15 group,
mice were treated with 15 mg/kg genistein. The mice were decapitated at 24 h of the reperfusion
period for further analysis. The data were expressed as the mean ± SEM; n = 6; * p < 0.05 vs. Sham;
# p < 0.05 vs. I/R. The SIRT1 mRNA levels for specific genes were normalized to 18S rRNA levels.
Figure A4. Sirtinol reverses the effect of genistein on apoptosis in I/R-induced acute renal injury.
Mice were treated as described in supplemental Figure 4. The data were expressed as the mean ± SEM;
n = 6; * p < 0.05 vs. Vehicle; # p < 0.05 vs. G15. (A) Representative photomicrograph of cleaved
caspase-3-stained kidney tissues from the G15 and G15 + Sirtinol groups. Original magnification, 400×;
(B) Cleaved caspase-3-positive cells were counted, and the percentage of positive cells is illustrated.
The black arrows indicate positive cells.
Figure A5. Sirtinol abrogates the effect of genistein on PCNA expression in I/R-induced acute renal
injury. Mice were treated as described in supplemental Figure 4. The data were expressed as the mean
± SEM; n = 6; * p < 0.05 vs. Vehicle; # p < 0.05 vs. G15. (A) Representative western blots for PCNA
expression in mice kidney tissues; (B) Densitometric analysis of the PCNA expression by Image-Pro
Plus 6.0. GAPDH was calibrated.
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Figure A6. Western blot analyses demonstrating the knock-down of SIRT1 in kidney tissues.
Seventy-two hours later after the injection of LV-control or LV-shSIRT1, genistein, or the same volume
of vehicle. For the LV-control group and G15 groups, mice were pre-treated with vehicle; for the
LV-shSIRT1 group, mice were pre-treated with vehicle; for the G15 and LV-shSIRT1 + G15 groups, mice
were pre-treated with 15 mg/kg genistein. Ischemia was induced in all of the groups. The mice were
decapitated after 24 h of reperfusion for the western blot analysis. The data were expressed as the
mean ± SEM; n = 6; * p < 0.05 vs. Sham; # p < 0.05 vs. I/R. (A) Representative western blots for SIRT1
expression in mouse kidney tissues; (B) Densitometric analysis of the SIRT1 expression by Image-Pro
Plus 6.0. GAPDH was calibrated.
Figure A7. IHC analyses demonstrating the knock-down of SIRT1 in kidney tissues. Mice were treated
as described in supplemental Figure 7. Representative photomicrograph of SIRT1-stained kidney
tissues from the G15 and G15 + LV-shSIRT1 groups. Original magnification, 400×. The black arrows
indicate positive cells.
69
Nutrients 2017, 9, 403
Figure A8. SIRT1 depletion reverses the effect of genistein on apoptosis in I/R-induced acute renal
injury. Mice were treated as described in supplemental Figure 7. The data were expressed as the
mean ± SEM; n = 6; * p < 0.05 vs. Sham; # p < 0.05 vs. I/R. (A) Representative photomicrograph of
TUNEL-stained kidney tissues from the G15 and G15 + Sirtinol groups. Original magnification, 400×;
(B) TUNEL-positive cells were counted and the percentage of positive cells is illustrated. The black
arrows indicate positive cells.
Figure A9. SIRT1 depletion reverses the increased effect of genistein on cellular proliferation in
I/R-induced acute renal injury. Mice were treated as described in supplemental Figure 7. The data
were expressed as the mean ± SEM; n = 6; * p < 0.05 vs. Sham; # p < 0.05 vs. I/R. (A) Representative
photomicrograph of PCNA-stained kidney tissues from the G15 and G15 + Sirtinol groups. Original
magnification, 400×; (B) PCNA-positive cells were counted, and the percentage of positive cells is
illustrated. The black arrows indicate positive cells.
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Abstract: Epidemiologic studies have suggested an inverse association between flavonoids and
cardiovascular disease (CVD). However, the results might have been influenced by the use of
dietary assessment methods, which are error prone. The aim of this paper was to systematically
review and analyse the literature for evidence of associations between polyphenol biomarkers
and CVD and mortality risk in observational studies. Eligible studies were identified through
PubMed, Web of Science, and reference lists. Multivariable adjusted associations were extracted.
Data were log-transformed and pooled using the random effects model. In total, eight studies were
included, investigating 16 different polyphenol biomarkers in association with CVD and mortality.
Blood and urine were used as biospecimens, and enterolactone, a lignan metabolite, was most
often investigated. Three meta-analyses were conducted investigating the association between
enterolactone, and all-cause and CVD mortality, and non-fatal myocardial infarction. A 30% and
45% reduced all-cause and CVD mortality risk were revealed at higher enterolactone concentrations.
Furthermore, inverse associations were observed between polyphenol biomarkers and all-cause
mortality, kaempferol, and acute coronary syndrome. There is evidence to suggest that enterolactone
is associated with a lower CVD mortality risk. This emphasises the importance of the role of the
microbiota in disease prevention. To strengthen the evidence, more studies are warranted.
Keywords: polyphenols; biomarkers; flavonoids; cardiovascular disease; mortality; observational;
meta-analysis; enterolactone
1. Introduction
Cardiovascular diseases (CVD) are the leading cause of death worldwide [1]. By tackling
modifiable lifestyle factors such as an unhealthy diet, most CVDs could in theory be prevented.
A healthy diet containing plant-based foods [1] is abundant in bioactive compounds, such as
polyphenols. Over 500 different heterogeneous molecular structures of polyphenols have been
identified in plant foods [2]. Based on their structure, four groups of polyphenols can be distinguished,
including flavonoids, phenolic acids, stilbenes, and lignans [3–5]. Of great interest to scientists is the
group of flavonoids as their compounds are widely distributed in plant foods [6]. This group can
be further classified into flavonols (main food sources: onions, curly kale, leeks, broccoli, apples,
blueberries), flavanols (tea, grapes, cocoa), flavanones (citrus fruits), flavones (parsley, celery),
anthocyanins (berries, black grapes), and isoflavones (soybeans) [3,7]. Also relatively abundant
in plant foods are phenolic acids (coffee, outer part of fruits); however, with respect to disease risk,
they have been investigated less often [5]. This is also the case for stilbenes, which are less dispersed in
Nutrients 2017, 9, 415; doi:10.3390/nu9040415 www.mdpi.com/journal/nutrients73
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plant foods (wine, peanuts) [8]. Lignans, like flavonoids, have been investigated often and are found
in linseed and cereals [5]. In the gut, lignans can be converted by microbiota to enterolactone (ENL)
and enterodiol (END) [5], and can be detected in human biofluids.
The extensive research on polyphenols in animal and human studies has shown that these
compounds possess a wide range of disease preventive properties including anti-inflammatory,
antioxidant, and estrogenic activities [6]. However, because of the heterogeneity of findings across
human studies, the role of polyphenols in CVD risk remains inconclusive. This might be due to
the method used to assess the polyphenol intake. Most studies estimate polyphenol exposure of a
participant’s diet from food composition tables such as the USDA database [9] and Phenol-Explorer [2].
However, these tables might be of limited use because only a very restricted number of foods have
been analysed for their polyphenol content using different analytical techniques [3]. Furthermore,
polyphenol values in foods fluctuate as a result of climate, soil, ripeness, processing, and storage [3].
To overcome these measurement errors and provide more accurate measures of polyphenol exposure,
the use of biomarkers has been suggested [10]. In large epidemiologic studies, mostly single samples
of serum, plasma, or urine are collected. Considering the relatively short half-life of most compounds,
habitual exposure is probably best reflected in 24-h urine. Zamora-Ros et al. [11] showed that the
total urinary polyphenol excretion from 24-h urine was correlated with dietary intake. Furthermore,
creatinine normalised spot urine proved to be a suitable biomarker when adjusted for factors modifying
creatinine excretion [11].
The aims of the current study were to: (1) systematically review the literature for evidence
of associations between polyphenol biomarkers and all-cause mortality, CVD mortality, and CVD
incidence in observational studies; and (2) conduct meta-analyses of individual biomarkers of
polyphenols and outcomes where possible. Isoflavone biomarkers and chronic disease and mortality
were covered elsewhere [12].
2. Methods
This review was conducted according to the PRISMA guidelines [13] (Supplementary Table S1).
A systematic search of the published literature was conducted in PubMed and Web of Science on
22 February 2017. The following search terms were used (both singular and plural): “biomarker”,
“plasma”, “serum”, ”urine”, “urinary”, “excretion”, “concentration”, “level”, with “polyphenol”,
“flavonoid”, “flavone”, “flavanone”, “flavonol”, “proanthocyanidin”, “anthocyanin”, “apigenin”,
“luteolin”, “hesperetin”, “hesperedin”, “naringenin”, “kaempferol”, “quercetin”, “tamarixetin”,
“matairesinol”, “epicatechin”, “epicatechin gallate”, “coumestrol”, “stilbene”, “resveratrol”,
“tannin”, “lignans”, “enterolactone”, “enterodiol”, “enterolignan”, “pinoresinol”, “lariciresinol”,
“secoisolariciresinol”, “matairesinol”, “phenolic acid”, “phytoestrogen”, with “cardiovascular
disease”, “coronary heart disease”, “heart disease”, “CVD”, “heart disease”, “coronary artery
disease”, “myocardial infarction”, “stroke”, “cerebrovascular disease”, “heart failure”, “mortality”,
“death”, “cardiovascular mortality”, with “observational”, “epidemiologic”, “cohort”, “longitudinal”,
“prospective”, “case-control”, “nested case-control”, not “animals” (using MeSH terms in PubMed).
2.1. In- and Exclusion Criteria
Two authors (JR and JB) independently screened the titles and abstracts of the publications.
A third acted as a moderator (UN), to remove any discrepancies. Articles were retained for review if
the following inclusion criteria were met: (1) investigation of multiple, adjusted associations between
polyphenol biomarker(s) and CVD risk or mortality; (2) use of an observational study design; (3) the
study involved humans; and (4) the study was published in a scientific journal (conference abstracts
and comments were excluded).
Articles were excluded if they met with at least one of the following criteria: (1) a dietary
intervention was conducted prior to biospecimen sampling; or (2) only a dietary assessment method
was used to assess polyphenol exposure. Finally, reference lists of all the included publications were
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screened to identify further articles meeting the inclusion criteria. No constraints were put on the
language of the articles.
2.2. Data Extraction
From each article, the following details were extracted: first author, year of publication, country
where the study was conducted, study design and cohort, characteristics of the participants (age, sex,
number of cases/controls or cohort), follow-up time, specimen type, polyphenol biomarker(s),
outcome(s), association measure, and confounding and matching variables.
2.3. Quality Assessment
The quality of the included studies was assessed using the Newcastle-Ottawa scale developed for
non-randomised studies [14]. The scale appraised three aspects including the selection of the study
groups, the comparability of the groups, and the ascertainment of either outcome or exposure from
cohort or nested case-control studies, respectively. The maximum number of ‘stars’ awarded to each
section was four, two, and three for selection, comparability, and outcome/exposure, respectively.
2.4. Statistical Analysis
Meta-analyses were conducted when at least two studies were available with a common exposure
and outcome. This resulted in a total of three meta-analyses investigating the association between ENL,
and all-cause and CVD mortality, and non-fatal myocardial infarction. For the meta-analyses, all effect
sizes (HR, OR, RR) and 95% confidence intervals (CI) were log-transformed to maintain symmetry
in the analysis. Standard errors were calculated from log CIs by subtracting the lower CI from the
upper CI and subsequently dividing by 3.92. The I2 statistic was calculated to test the percentage of
variation across studies due to heterogeneity [15]. Heterogeneity was assumed to be present because
of differences in the study design and population. Therefore, we used a random-effects model that
assumes a distribution of the true effect size by allowing both between- and within study variation [16].
Pooled estimates were visualized in forest plots. Potential publication bias was investigated by a
visual inspection of the funnel plot, whereby asymmetry illustrated publication bias, and was tested
quantitatively with the Egger’s test [17]. As CVD incidence and mortality differ between men and
women, where possible, subgroup analyses were performed. The package ‘meta’ [18] in R [19]
statistical software Version 3.3.2 was used to conduct the meta-analyses and ‘metabias’ was used to
assess publication bias. A p-value < 0.05 was considered statistically significant.
3. Results
3.1. Search Results
After removing duplicates, 719 studies remained (Figure 1). The titles and abstracts were
screened. Ten full-texts were read and in total eight observational studies [20–27] were identified that
investigated polyphenol biomarkers in association with mortality or CVD. In total, 16 polyphenolic
compounds were investigated (Table 1). Five studies investigated ENL [21–25], two END [22,23], and
one total polyphenols [26], resveratrol [27], lignans [23], flavonoids [20], flavonols [20], flavanones [20],
flavones [20], and phloretin [20]. Two studies solely investigated all-cause mortality [26,27], two
studied all-cause and CVD mortality [23,25], two studied CVD incidence and mortality [20,21], and
three CVD incidence [21,22,24]. The characteristics and results of the included studies are presented
in Tables 2 and 3, respectively. The following biospecimens were used: two studies used 24 h
urine [26,27], two used spot urine [20,23], three used serum [21,24,25], and one used plasma [22]. Six
different study populations from five different countries were studied including Denmark, Finland,
Italy, the Netherlands, and the USA. Four [23,25–27] studies had a prospective cohort study design,
three [20,22,24] were nested case-control studies, and one [21] had a case-cohort design. All publications
75
Nutrients 2017, 9, 415
were of moderate to good quality with scores for both cohort and nested case-control studies ranging
from five to eight stars (Supplementary Table S2).
Figure 1. Flowchart of the study selection.












Total polyphenols [26] 1 1




• Kaempferol 1 1
• Quercetin 1 1
• Tamarixetin 1 1




• Naringenin 1 1
• Hesperetin 1 1
Total flavone
[20]• Apigenin 1 1
Phloretin [20] 1 1
Resveratrol [27] 1 1
Lignans [23] 1 1 1
• Enterolactone [21–25] 5 2 3 3
• Enterodiol [22,23] 2 1 1 1
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Table 2. Characteristics of studies included in this systematic literature review investigating the
association between polyphenol biomarkers and cardiovascular disease and mortality.
Author (Year)
Country







(2013) Italy [26] ps InCHIANTI 24 h urine POLY 274 807 (58.7) ≥65 12
All-cause
mortality
Semba et al. (2014)
Italy [27] ps InCHIANTI 24 h urine RES 268 783 (41.4) ≥65 9
All-cause
mortality
Reger et al. (2016)
USA [23]
ps NHANES Spot urine ELIG, ENL,
END
108





ps KIHD Serum ENL
70






caco ATBC Serum ENL
340














393 786 (20.1) 50–64 8 (TP) Acute coronarysyndrome
Kuijsten et al. (2009)





Plasma ENL, END 236 519 (31.1) 20–59 4.5 Nonfatal MI
Vanharanta et al.
(1999) Finland [24] ncc KIHD Serum ENL 167 334 (0) 42–60 10
Acute coronary
events
1 Mean or median (med) follow-up time, total study period (TP) was calculated, when follow-up time was
not reported, by subtracting the year of last follow-up from the year of specimen collection. API, apigenin;
ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention study; caco, case-cohort; CHD, coronary heart disease;
CVD, cardiovascular disease; DCH, Diet Cancer and Health study; END, enterodiol; ENL, enterolactone; ELIG,
enterolignan; FLAVAN, flavanones; FLAVO, flavonol; HES, hesperetin; InCHIANTI, Invecchiare in Chianti; ISO,
isorhamnetin; KAE, kaempferol; KIHD, Kuopio Ischaemic Heart Disease Risk Factor Study MI, myocardial
infarction; n, number; NAR, naringenin; ncc, nested case-control study; NHANES, National Health and Nutrition
Examination Survey; POLY, polyphenols; ps, prospective study; QUE, quercetin; RES, resveratrol; TAM, tamarixetin;
TP, total period.
Table 3. Results of the studies included in this systematic literature review of studies investigating the




Association (95% CI) of
Extreme Quantiles
P-trend Confounders (C) and Matching (M) Variables
All-cause mortality
Zamora-Ros et al.
(2013) Italy [26] POLY
All-cause
mortality HR Q3/Q1 0.70 (0.49, 0.99) 0.05
C: age, sex, education, BMI, alcohol intake, smoking
status, renal function, PA, CVD, DM, cancer, COPD,
dementia, Parkinson’s disease, energy intake only
for TDPs
Semba et al. (2014)
Italy [27] RES
All-cause
mortality HR Q4/Q1 0.80 (0.54, 1.17) 0.43
C: age, sex, education, BMI, PA, total cholesterol,
HDL, MMSE score, mean arterial BP, and chronic
diseases: CHD, stroke, heart failure, cancer, DM,
peripheral artery disease, chronic kidney disease




0.65 (0.43, 0.96) 0.019 C: age, education, smoking status, BMI, total energy
intake, sodium intake, urinary creatinineENL 0.65 (0.44, 0.97) 0.014
END 0.98 (0.67, 1.43) 0.85
Vanharanta et al.
(2003) Finland [25] ENL
All-cause
mortality HR Q4/Q1 0.76 (0.52, 1.12) 0.09
C: age, year of examination, year of serum ENL
measurement, DM, hypertension, urinary excretion
of nicotine metabolites, BMI, alcohol, LDL, HDL,
dietary intake of fiber, folate, vitamins C and E,
saturated fatty acids






0.63 (0.37, 1.05) 0.32
C: period of analysis, BMI, waist circumference,
smoking, hypertension, DM, alcohol,
hypercholesterolemia, PA, level of school education
M: sex, age, smoking, time specimen collection
phloretin 0.87 (0.54, 1.39) 0.46
FLAVO 0.83 (0.50, 1.36) 0.46
ISO 0.72 (0.41, 1.25) 0.15
KAE 0.55 (0.32, 0.92) 0.12
QUE 0.94 (0.58, 1.51) 0.65
TAM 1.06 (0.65, 1.74) 0.78
FLAVAN 0.68 (0.41, 1.12) 0.26
HES 0.72 (0.43, 1.18) 0.34
NAR 0.63 (0.38, 1.02) 0.12
API 1.20 (0.73, 1.96) 0.73
77





Association (95% CI) of
Extreme Quantiles
P-trend Confounders (C) and Matching (M) Variables
Kuijsten et al. (2009)
the Netherlands [22]
ENL
Nonfatal MI OR Q4/Q1
1.49 (0.85, 2.61) 0.140
C: current smoking, BMI, systolic blood pressure,
total cholesterol, HDL cholesterol, ratio total/HDL
cholesterol, current smoking, SBP, ratio
total/HDL cholesterol
END 1.18 (0.67, 2.07) 0.860 M: age (5 years), sex, study center
Vanharanta et al.
(1999) Finland [24] ENL
Acute coronary
events
OR Q4/Q1 0.35 (0.14, 0.88) 0.01
C: serum apolipoprotein B, dietary iron intake, fam
hist of CHD, ischaemic findings on exercise test,
dietary calcium intake, urinary excretion of nicotine
metabolites, DM, SBP, maximum oxygen uptake
M: age, examination year, place of residence
Kilkkinen et al.
(2006) Finland [21] ENL
All CHD events
RR Q5/Q1
0.63 (0.33, 1.11) 0.07 C: age, BMI, total and HDL cholesterol, DBP, SBP,
alcohol intake, nr of smoking years and cigarettes
smoked per day, hist of CHD and DM, fasting time,
dietary factors
Nonfatal MI 0.67 (0.37, 1.23) 0.10
Coronary death 0.57 (0.26, 1.25) 0.18
Reger et al. (2016)
USA [23]
ELIG
CVD mortality HR Q3/Q1
0.48 (0.24, 0.97) 0.07 C: age, education, smoking status, BMI, total energy
intake, sodium intake, urinary creatinineENL 0.54 (0.27, 1.07) 0.10
END 0.71 (0.87, 1.78) 0.52
Vanharanta et al.
(2003) Finland [25] ENL
CHD mortality
HR Q4/Q1
0.44 (0.20, 0.96) 0.03
C: age, year of examination, year of serum ENL
measurement, DM, hypertension, urinary excretion
of nicotine metabolites, BMI, alcohol, LDL, HDL,
dietary intake of fiber, folate, vitamins C and E,
saturated fatty acids
CVD mortality 0.55 (0.29, 1.01) 0.04
API, apigenin; BMI, body mass index; CHD, coronary heart disease; COPD, chronic obstructive pulmonary
disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; DM, diabetes mellitus; ELIG, enterolignan;
END, enterodiol; ENL, enterolactone; fam hist, family history; FLAVA, flavanol; FLAVAN, flavanones; FLAVO,
flavonol; ISO, isorhamnetin; HDL, high-density lipoprotein; HES, hesperetin; hist, history; HR, hazard ratio; ISO,
isorhamnetin; KAE, kaempferol; LDL, low density lipoprotein; MMSE, mini-mental state examination; NAR,
naringenin; OR, odds ratio; PA, physical activity; POLY, polyphenols; Q, quantile; QUE, quercetin; RES, resveratrol;
RR, rate ratio; SBP, systolic blood pressure; TAM, tamarixetin; TDPs, total dietary polyphenols.
3.2. All-Cause Mortality
Four publications investigated all-cause mortality [23,25–27] (Table 3). The meta-analysis of two
studies [23,25] revealed a 30% lower all-cause mortality risk at higher ENL concentrations (Figure 2A).
Heterogeneity was not present and publication bias could not be indicated from the funnel plot.
Furthermore, decreased mortality risks of 30%, 35%, and 35% were observed at higher total urinary
polyphenol (TUP) [26], enterolignans [23], and ENL [23] concentrations, respectively. However,
no associations were observed for resveratrol [27] and END [23].
Figure 2. Forest of the association between enterolactone and (a) all-cause mortality; (b) CVD-mortality;
and (c) non-fatal MI.
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3.3. CVD Incidence and Mortality
In total, six studies investigated CVD incidence [20–22,24] or mortality [21,23,25]. Pooling data
for CVD mortality, a 45% reduced risk was revealed when the highest and the lowest quantile of
ENL concentration were compared (Figure 2B). Heterogeneity and publication bias were not present.
In a subgroup analysis of men, a similar result was found (RR (95% confidence interval (CI): 0.56
(0.34, 0.91)). When stratifying by sex, a 47% reduced non-fatal MI risk was observed (RR (95% CI):
0.53 (0.29, 0.98)). Inverse associations were also found between ENL and CHD mortality [25], and
kaempferol excretion and acute coronary syndrome (ACS) [20]; however, no associations were observed
for the other polyphenols in this study [20], and between END and CVD mortality in another study [23].
In the meta-analysis of three studies on ENL [21,22,24], no statistically significant association
was identified for non-fatal MI. Heterogeneity was high (I2 = 75%) and there was no indication for
publication bias according the Egger’s test. END was not statistically significantly associated with
nonfatal MI [22].
4. Discussion
To our knowledge, this is the first study to give a complete overview of the published
evidence of associations between polyphenol biomarkers and CVD risk and mortality in human
population-based studies. Only eight studies were found, allowing meta-analyses with only two or
three studies comparing ENL and mortality, CVD-mortality, or CHD incidence. The meta-analyses
of all-cause and CVD mortality revealed a 30% and 45% reduced risk at higher ENL levels,
respectively. No associations were observed in meta-analyses for incident MI and ENL concentrations.
Indeed, the microbiota-derived lignan metabolites ENL and END were most frequently investigated.
Single findings were observed between TUP and all-cause mortality, and kaempferol and ACS.
4.1. Comparison with other Studies on Dietary Polyphenols
In line with the inverse association that was revealed in the present meta-analysis of all- cause
mortality, is the 40% reduced risk observed for dietary lignans in Spanish community-dwelling
elderly [28] and the 31% reduced risk for matairesinol found in elderly Dutch men [29]. No association
was observed for total dietary lignans in this study [29]. In contrast to the reduced CVD mortality risk
in the current meta-analysis, a prospective study from the Netherlands did not find an association
with total dietary lignans; however, matairesinol again tended to be inversely associated [29].
No association was observed for total dietary polyphenols (TDP), as opposed to the statistically
significant inverse association for TUP [26] in the same study. However, in a larger sample of a
community-dwelling Spanish population, reduced risks of 37% and 52% were found for TDP and
stilbenes (a group that includes resveratrol), respectively [28]. The result for stilbenes was not reflected
in the resveratrol biomarker study [27] in the current review.
All in all, there seems to be some evidence from biomarker studies linking microbiota-derived
lignan biomarkers to mortality endpoints, but overall, only a few studies were available.
In agreement with the null-finding for non-fatal MI, are the results from the EPIC-Prospect
study [30]. The statistically significant reduced ACS risk of the kaempferol biomarker [20] is in line
with the results of a meta-analysis [31] and a prospective Italian study [32]. The null associations found
for flavonoid biomarkers and ACS [20] are consistent with a meta-analysis of total dietary flavonoids
and their subgroups [31], dietary flavonols and flavanones, in two prospective studies [33,34], and
flavones in three prospective studies [32–34]. In contrast, a statistically significant decreased CVD risk
trend was observed for dietary dihydrochalcone intake [34] (class of phloretin [20]).
Evidence from biomarker studies is scarce and more studies on all compounds are warranted.
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4.2. Validity of the Biomarker Measure
The main advantage of using biomarkers for an exposure assessment over dietary assessment
methods is that these account for inter-individual differences in absorption, distribution, and
metabolism [3]. Nevertheless, biomarker concentrations are influenced by several factors, of which
some are known and others are yet to be determined. Treatment with antibiotics is a known factor
that influences the formation of lignan metabolites [35]. The failure to account for antibiotic use is an
important limitation of the studies included in the meta-analyses [21–25]. The number of antibiotic
treatments and the time since the last treatment affect the microflora and were shown to result in
lower ENL concentrations, even 12–16 months after treatment [35]. Since all of the studies included
in the meta-analysis did not consider antibiotic use, their observed risks are likely to be attenuated.
The included studies used single samples of blood and urine, which were predominantly sampled
in a fasting state. This raises the question of which biomarker is better correlated with biological
relevance, especially considering the potential differences between individuals. The absorption, peak
plasma, metabolism, and excretion of polyphenols are likely to be determined by individual physiology.
Therefore, a single sample may not provide a reliable marker for the total bioavailable concentration
throughout time. Considering the relatively short half-lives of most polyphenolic compounds, 24 h
urine should contain all of the ingested compounds and/or their metabolites and conjungates.
4.3. Strengths and Limitations of the Present Review
The main strength of the present study is the inclusion of several meta-analyses of polyphenol
biomarkers. To our knowledge, these are the first meta-analyses of lignan biomarkers representing an
internal dose. Although we only conducted meta-analyses on two (for all-cause mortality) and three
(for CVD mortality and non-fatal MI) studies, a good overview of the level of consistency across the
studies is provided.
All of the studies included in the meta-analysis of CVD-mortality used Cox proportional hazard
models, either reporting HR or RR, which have the same meaning and are used interchangeably.
Because the highest and lowest exposure quantiles were compared, a dose-response relationship
could not be derived. Furthermore, the remaining three studies included in the systematic literature
were slightly heterogeneous with regard to the polyphenol biomarker measured. However, this
only emphasizes the complexity of the polyphenol exposure and the need to investigate the role
of the individual polyphenols in cardiovascular disease and mortality. Another strength is that the
quality of the included studies was judged to be moderate to good. Beside antibiotic use, another
potential confounder, creatintine excretion, was only considered in the study by Reger et al. [23].
The failure to account for urinary creatinine excretion could result in an over- or underestimation
of polyphenol concentrations, depending on the dilution of the urine. From the visual inspection of
the funnel plots and interpretation of the Egger’s test, publication bias was not present. However,
significant heterogeneity was observed in the meta-analysis of MI. This was further explored in the
sensitivity analysis. By excluding one study at a time, we observed that the study by Kuijsten et al.
(2009) introduced the heterogeneity, as after exclusion, we found an I2 of 25.6%. The heterogeneity
could have resulted from sex differences, as the inclusion of men did result in an inverse association.
Another explanation might be the difference in the biospecimens or the lower ENL concentrations
in this study [22], where the cut-off in the highest quartile was >17.5 nmol/L. In comparison, ENL
concentrations were much higher in the studies by Vanharanta et al. (1999) [24] and Kilkkinen et al.
(2006) [21], namely >30.1 and >28.24 nmol/L, respectively. This could be simply explained by
differences in dietary habits between the Netherlands and Finland, or because of the differences
in biomarkers used to measure ENL. Furthermore, in addition to the search in two large databases
and the articles’ reference lists, a search in gray literature could have resulted in the identification of
unpublished papers. Language bias was prevented by imposing no restrictions on language; in spite
of this, no non-English written publications were retrieved that met the inclusion criteria. Interestingly,
only one study [26] investigated polyphenol biomarkers and dietary polyphenols in the same study
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population. Therefore, the emerging question is whether these approaches would provide stronger
results when biomarkers are measured in conjunction with dietary intake. The current review, however,
suggests that the polyphenol biomarkers strongly reflect internal doses, which are not necessarily
strongly associated with long-term intake due to the many factors influencing bioavailability [3,36].
5. Conclusions
A number of studies have been published reporting on the associations between polyphenol
biomarkers, and all-cause, CVD mortality, and CVD risk. In the meta-analyses, inverse associations
were revealed between ENL and all-cause and CVD mortality. Furthermore, in the systematic review,
inverse associations were observed for TUP with all-cause mortality and ACS with kaempferol.
For future research, comparability across studies should be improved to enable a quantitative analysis.
Furthermore, it is recommended that groups investigate individual polyphenolic compounds and
even metabolites instead of total polyphenols from different groups and classes. It might be worth
considering collecting multiple biospecimen samples or 24 h urine samples that reflect circadian
polyphenol exposure, although this might not be desirable in large cohort studies as it places a burden
on the study participants.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/4/415/s1,
Table S1: PRISMA checklist, Table S2: Results of quality assessment of included studies using the
Newcastle-Ottawa scale for non-randomised studies.
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Abstract: Overweight and obesity have been steadily increasing in recent years and currently
represent a serious threat to public health. Few human studies have investigated the relationship
between polyphenol intake and body weight. Our aim was to assess the relationship between urinary
polyphenol levels and body weight. A cross-sectional study was performed with 573 participants
from the PREDIMED (Prevención con Dieta Mediterránea) trial (ISRCTN35739639). Total polyphenol
levels were measured by a reliable biomarker, total urinary polyphenol excretion (TPE), determined
by the Folin-Ciocalteu method in urine samples. Participants were categorized into five groups
according to their TPE at the fifth year. Multiple linear regression models were used to assess the
relationships between TPE and obesity parameters; body weight (BW), body mass index (BMI),
waist circumference (WC), and waist-to-height ratio (WHtR). After a five years follow up, significant
inverse correlations were observed between TPE at the 5th year and BW (β = −1.004; 95% CI: −1.634
to −0.375, p = 0.002), BMI (β = −0.320; 95% CI: −0.541 to −0.098, p = 0.005), WC (β = −0.742; 95% CI:
−1.326 to −0.158, p = 0.013), and WHtR (β = −0.408; 95% CI: −0.788 to −0.028, p = 0.036) after
adjustments for potential confounders. To conclude, a greater polyphenol intake may thus contribute
to reducing body weight in elderly people at high cardiovascular risk.
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1. Introduction
Overweight and obesity have been steadily increasing in recent years and currently represent a
serious threat to public health [1]. In 2014, more than 1.9 billion adults were overweight worldwide,
and of these over 600 million were obese [2]. With nearly three million adults dying each year as a
result of being overweight or obese, the impact of obesity on morbidity, mortality, and health care costs
is very high [3]. Lifestyle and dietary habits are key determinants in the prevalence of obesity [4–6].
Polyphenols, the most abundant antioxidants in nature, are widely distributed in plant-derived
foods such as vegetables, fruits, seeds, coffee, wine, and tea [7]. Only a few human studies have
reported a relationship between polyphenol intake and body weight, even though obesity is considered
a major independent risk factor for various chronic diseases [8,9]. Evidence for the effects of
polyphenols on obesity parameters in humans is inconsistent, possibly due to divergence among study
designs, characteristics of the participants, and metabolic pathways. Although some intervention
clinical trials with polyphenol-enriched food or polyphenol extracts do not show any effect on weight
or waist circumference [10–12], other studies have reported that polyphenols reduce body weight
and increase energy expenditure [13–16]. The oral bioavailability of polyphenols is particularly
important because, after being modified and metabolized by enzymes, their concentration in tissues
and biological fluids is quite low [9,12,15,17]. There is therefore a need for a biomarker to accurately
reflect polyphenol concentration after their absorption and metabolism.
Polyphenol plasma levels or total urinary polyphenol excretion, considered in recent years as a
reliable biomarker of total polyphenol intake, has been correlated with dietary polyphenol intake, and
has been applied to explore associations between polyphenol intake and several chronic disease risk
parameters [18–21]. Thus, the objective of the current study was to assess the associations between
total polyphenol intake, measured by total urinary polyphenol excretion (TPE), and obesity parameters
in an elderly population at high cardiovascular risk after five years of follow up.
2. Materials and Methods
The protocol for this trial and supporting Strengthening the Reporting of Observational studies in
Epidemiology (STROBE) checklist are available as supporting information.
2.1. Ethics Statement
All participants provided informed consent. The Institutional Review Board (IRB) of the Hospital
Clinic (Barcelona, Spain), accredited by the US Department of Health and Human Services (DHHS)
update for Federal wide Assurance for the Protection of Human Subjects for International (Non-US)
Institutions #00000738, approved the study protocol on 16 July 2002. The authors confirm that
all ongoing and related trials for this drug/intervention are carried out following the rules of the
Declaration of Helsinki of 1975 and registered (ISRCTN35739639).
2.2. Subjects
Participants were drawn from the PREDIMED Study (‘Prevención con Dieta Mediterránea’
(Prevention with the Mediterranean Diet), ISRCTN35739639). The information in the registry was
delayed after recruitment began, to be sure about the feasibility of the study protocol; we started
the trial as a ‘pilot study’ on October 2003, and, once we were sure that the intervention protocol
worked, we decided to submit the study protocol for registration (date of application: 2 September
2005). The protocol and recruitment method are reported in detail elsewhere [22].
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The present study looks at 573 participants that were recruited in two centers, the Clinic Hospital
of Barcelona and the University of Valencia, both in Spain, and all were followed-up after more than
five years. The period of recruitment was from 2003 to 2006, and the average follow up was 5.9 years.
2.3. Nutritional Measurements
The selected participants were asked to complete some questionnaires: a validated 137-item food
frequency questionnaire (FFQ) to assess dietary habits [23]; a 47-item general questionnaire aimed to
summarize information about lifestyle, health condition, education, history of illnesses, and medication
use; a 14 point questionnaire evaluating the degree of adherence to the Mediterranean diet [24];
and a validated Spanish version of the Minnesota Leisure-Time Physical Activity Questionnaire to
record physical activity [25]. Nutrient intake was adjusted by calories using the residual method [26].
All questionnaires were administered and repeated yearly during the follow up by trained staff in
face-to-face interviews.
2.4. Urine Samples
Spot urine samples from the participants were collected and coded at the clinic by a technician
and then immediately shipped to a central laboratory to be stored at −80 ◦C until analyzed.
2.5. TPE Measurements
The Folin-Ciocalteu method was applied to determine the content of TPE, using a clean-up
procedure with solid phase extraction (SPE) performed in 96-well plate cartridges (Oasis MAX),
which helped to remove urinary interferences. Finally, TPE was expressed as milligrams of
gallic acid equivalent (GAE)/g of creatinine. All details have been previously described by
Medina-Remón et al. [19].
2.6. Measurements
Weight and height were measured with calibrated scales and a wall-mounted stadiometer,
respectively. Body mass index (BMI) was calculated as weight in kilograms divided by the square
of height in meters. Waist circumference (WC) was measured midway between the lowest rib and
the iliac crest. Waist-to-height ratio (WHtR) was calculated as the waist in centimeters divided by
the height in meters. Blood pressure was determined in triplicate using a validated semi-automatic
sphygmomanometer (Omron HEM-705CP, Tokyo, Japan) by trained nurses. Measurements were taken
at three time points, separated by 2 min, while the participant was in a seated position after 5 min of
rest [27]. Obesity is defined as BMI more than 30 kg/m2.
2.7. Statistical Analysis
Results were expressed as mean ± SD for continuous variables or percentages for categorical
variables. Kolmogorov and Levene tests were applied to examine the normality distribution and
skewness. All participants, including total subjects, males, and females were divided into five
categories according to their TPE at the fifth year of follow up. Changes in nutrient intakes and
key food consumption according to the FFQs were assessed with yearly repeated-measures analysis
during the follow up period. A Bonferroni post-hoc test and paired t-test were used to compare each
variable within and between groups.
Multiple linear regression models were used to assess the relationship between anthropometric
parameters (Body weight (BW), BMI, WC, and WHtR) and quintiles of TPE at the fifth year, adjusted
for potential confounders, including sex, age, intervention groups, smoking status (never, current,
former), family history of coronary heart disease (CHD), physical activity, hypertension, diabetes,
dyslipidemia, marital status (single, married, widowed), education level (primary school, high school,
university), medication used (antihypertensive drugs, vitamins, insulin, oral hypoglycemic drugs,
86
Nutrients 2017, 9, 452
aspirin, or other antiplatelet drug supplements taken in the last month), recruitment centers, 14 unit
Mediterranean diet score, and energy intake at baseline. Multiple logistic regression analyses were
used to calculate the odds ratio (OR) for quintiles of TPE and obesity (BMI > 30 kg/m2). Models were
adjusted for potential confounders as in linear regression analyses.
All analyses were performed using SPSS software V21.0 (SPSS Inc., Chicago, IL, USA,). All models
were tested for the detection of outliers, multicollinearity, homoscedasticity, and normality and
independence of errors. All statistical tests were two-tailed, and the significance level was p < 0.05.
The detailed information of the participants is available as supporting information.
3. Results
A total of 650 subjects were randomly selected from two centers, the Hospital Clinic of Barcelona
and the University of Valencia. From them, 38 were excluded because they did not meet the inclusion
criteria during the intervention, and, after five years, 39 were excluded because their TPE concentrations
were considered outliers, which was defined as any data point more than 1.5 interquartile ranges below
the first quartile or above the third quartile; hence a total of 573 participants were finally included
(Figure 1).
Figure 1. Flowchart of study participants.
The baseline characteristics of participants grouped by quintiles of TPE at baseline are shown
in Table 1. There were a total of 277 men and 296 women with a mean age of 66.2 ± 6.1 years and
68.3 ± 5.4 years, respectively. Of those participants, 41.5% had diabetes, 80.5% had hypertension, 66.8%
had dyslipidemia, 16.9% were current smokers, and 37.5% had a family history of CHD. Compared
with participants with the lowest TPE, those with higher TPE were more likely to be women, older, less
likely to smoke, and also had lower body weight. Q4 shows the lowest prevalence of hypertension.
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The comparison of total urinary polyphenol excretion between baseline and the fifth year of
follow up by quintiles of TPE at the fifth year is shown in Figure 2. For the first two quintiles, TPE at
baseline was significantly higher than at the fifth year. By contrast, TPE at the top two categories was
higher than at baseline.
Figure 2. Total polyphenol excretion at baseline and at the fifth year of follow up by quintiles of TPE.
Table 2 summarizes information on key changes in food consumption during the intervention
according to quintiles of TPE. As shown, at the end of the intervention, the consumption of most of the
items belonging to a Mediterranean dietary pattern had increased significantly, including vegetables,
fruits, fish, extra virgin olive oil, olive oil, nuts, coffee, and milk. However, the intake of wine decreased
significantly, as well as intakes of cereals, meat, and pastries. Table 2 also shows changes in nutrient
intake and degrees of adherence to a Mediterranean diet. Significant increments were observed
in the consumption of total fat, fiber, polyunsaturated fatty acids (PUFA), monounsaturated fatty
acids (MUFA), folic acid, potassium (K), and magnesium (Mg), while total carbohydrates, protein,
cholesterol, sodium (Na), and saturated fatty acids (SFA) remained similar throughout.
89






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Nutrients 2017, 9, 452
The associations between TPE and obesity indexes were analyzed by linear regression models
(Table 3). For total participants, significant inverse associations were found between quintiles of TPE at
the fifth year and BW (β = −1.004; p = 0.002), BMI (β = −0.320; p = 0.005), WC (β = −0.742; p = 0.013),
and WHtR (β = −0.408; p = 0.036) after adjustment for potential confounders. For males, inverse
associations were found in BW (β = −0.959; p = 0.039) and BMI (β = −0.301; p = 0.034), while, for
females, only an inverse association was found in BMI (β = −0.332; p = 0.046) after a full adjustment.
Table 3. Multiple linear regression analyses with obesity indexes and quintiles of TPE at the fifth year
for male, female, and total participants.
β SE Beta Significance 95% CI
BW (kg) Male Model 1 −1.446 0.440 −0.195 0.001 −2.313 −0.580
Model 2 −1.259 0.440 −0.170 0.005 −2.126 −0.392
Model 3 −0.959 0.461 −0.131 0.039 −1.868 −0.050
Female Model 1 −1.103 0.415 −0.153 0.008 −1.920 −0.287
Model 2 −0.756 0.414 −0.105 0.069 −1.571 0.058
Model 3 −0.757 0.431 −0.107 0.080 −1.606 0.091
Total Model 1 −2.350 0.331 −0.285 <0.001 −3.000 −1.700
Model 2 −1.070 0.315 −0.130 0.001 −1.689 −0.451
Model 3 −1.004 0.320 −0.124 0.002 −1.634 −0.375
BMI (kg/m2) Male Model 1 −0.405 0.135 −0.179 0.003 −0.670 −0.139
Model 2 −0.370 0.136 −0.164 0.007 −0.639 −0.102
Model 3 −0.301 0.141 −0.135 0.034 −0.579 −0.023
Female Model 1 −0.344 0.156 −0.127 0.028 −0.652 −0.037
Model 2 −0.296 0.160 −0.110 0.064 −0.611 0.018
Model 3 −0.332 0.165 −0.123 0.046 −0.657 −0.007
Total Model 1 −0.295 0.104 −0.118 0.005 −0.499 −0.090
Model 2 −0.328 0.110 −0.131 0.003 −0.544 −0.111
Model 3 −0.320 0.113 −0.129 0.005 −0.541 −0.098
WC (cm) Male Model 1 −0.769 0.364 −0.127 0.036 −1.487 −0.052
Model 2 −0.786 0.369 −0.130 0.034 −1.513 −0.059
Model 3 −0.516 0.378 −0.087 0.173 −1.260 0.228
Female Model 1 −0.546 0.409 −0.078 0.183 −1.351 0.259
Model 2 −0.527 0.419 −0.075 0.209 −1.351 0.297
Model 3 −0.701 0.434 −0.101 0.108 −1.556 0.154
Total Model 1 −1.500 0.296 −0.208 <0.001 −2.082 −0.918
Model 2 −0.721 0.293 −0.100 0.014 −1.296 −0.147
Model 3 −0.742 0.297 −0.104 0.013 −1.326 −0.158
WHtR (cm/m) Male Model 1 −0.340 0.220 −0.093 0.124 −0.773 0.094
Model 2 −0.385 0.223 −0.105 0.085 −0.823 0.054
Model 3 −0.258 0.229 −0.072 0.261 −0.710 0.193
Female Model 1 −0.246 0.276 −0.052 0.374 −0.789 0.298
Model 2 −0.332 0.282 −0.070 0.240 −0.887 0.223
Model3 −0.501 0.294 −0.106 0.089 −1.079 0.078
Total Model 1 −0.298 0.178 −0.070 0.094 −0.648 0.051
Model 2 −0.367 0.189 −0.087 0.052 −0.739 0.004
Model 3 −0.408 0.194 −0.097 0.036 −0.788 −0.028
BW: body weight; BMI: body mass index; WC: waist circumference; WHtR: waist-to-height ratio. TPE: total
polyphenol excretion (mg GAE/g creatinine). β: Non-standardized coefficient (regression line coefficient); SE:
Standard error; Beta: Standardized coefficient; CI: Confidence interval; p: two-sided test of significance. Model 1,
unadjusted; Model 2 was adjusted for sex (only for total participants), age, and intervention groups; Model 3 adjusted
as in Model 2 plus smoking status (never, current, former), family history of CHD, physical activity, hypertension,
diabetes, dyslipidemia, marital status (single, married, divorced, widowed), education level (primary school, high
school, university), medication used (antihypertensive drugs, vitamins, insulin, oral hypoglycemic drugs, aspirin,
or other antiplatelet drug supplements taken in the last month), recruitment centers, 14 unit Mediterranean diet
score, and energy intake at baseline.
Table 4 shows the odds ratio (OR) and a 95% CI for obesity according to the quintile of TPE at
the fifth year. In fully adjusted models, for total participants in the category of highest TPE had a
lower prevalence of obesity (OR = 0.346, 95% CI = 0.176 to 0.178; p-trend = 0.039) than those in the
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lowest category. For males, compared with the reference group, the top quintile group (Q5) showed
significant reduction in the prevalence of obesity (OR = 0.340, 95% CI = 0.146 to 0.792 in Model 2).
Table 4. Multivariate adjusted odds ratios (95% confidence interval (CI)) for prevalent obesity (213 cases)
after a five years follow up.
Q1 Q2 95% CI Q3 95% CI Q4 95% CI Q5 95% CI p
Male Model 1 1 (ref.) 0.531 0.244 1.155 0.545 0.250 1.188 0.488 0.223 1.070 0.313 0.135 0.722 0.095
(90 case) Model 2 1 (ref.) 0.559 0.254 1.229 0.571 0.260 1.254 0.520 0.235 1.148 0.340 0.146 0.792 0.159
Model 3 1 (ref.) 0.586 0.243 1.416 0.588 0.238 1.452 0.511 0.204 1.283 0.387 0.146 1.029 0.418
Female Model 1 1 (ref.) 0.934 0.454 1.924 0.791 0.384 1.628 0.643 0.310 1.333 0.429 0.200 0.919 0.195
(123 case) Model 2 1 (ref.) 1.041 0.497 2.182 0.844 0.403 1.768 0.769 0.361 1.638 0.493 0.226 1.078 0.352
Model 3 1 (ref.) 1.257 0.538 2.934 0.748 0.317 1.764 0.595 0.244 1.450 0.461 0.181 1.170 0.223
Total Model 1 1 (ref.) 0.639 0.375 1.089 0.769 0.454 1.302 0.664 0.390 1.129 0.450 0.259 0.782 0.073
(213 case) Model 2 1 (ref.) 0.597 0.344 1.035 0.691 0.400 1.192 0.618 0.350 1.091 0.383 0.211 0.694 0.036
Model 3 1 (ref.) 0.604 0.332 1.100 0.720 0.399 1.300 0.560 0.298 1.054 0.346 0.176 0.678 0.039
Quintiles for males: Q1 < 70.61; Q2: 70.62–88.94; Q3: 88.95–108.61; Q4: 108.62–137.11; Q5 > 137.11; Quintiles
for females: Q1 < 91.67; Q2: 91.68–113.96; Q3: 113.97–138.28; Q4: 138.29–181.01; Q5 > 181.01; Quintiles for total:
Q1 < 79.02; Q2: 79.03–99.50; Q3: 99.51–124.53; Q4: 124.54–160.06; Q5 > 160.06. TPE is expressed as mg GAE/g
creatinine. Obesity was defined as BMI > 30 kg/m2. Model 1, unadjusted; Model 2 was adjusted for sex (only
for total participants), age, and intervention groups; Model 3 adjusted as in Model 2 plus smoking status (never,
current, former), family history of CHD, physical activity, hypertension, diabetes, dyslipidemia, marital status
(single, married, divorced, widowed), education level (primary school, high school, university), medication used
(antihypertensive drugs, vitamins, insulin, oral hypoglycemic drugs, aspirin or other antiplatelet drug supplements
taken in the last month) recruitment centers, 14 unit Mediterranean diet score, and energy intake at baseline.
Table 5 shows the incidence of obesity after five years of intervention, conducted in subjects
without obesity at baseline and adjusted for TPE and BW at baseline and other co-variables. The results
show significant reduction in the incidence of obesity (odds ratio (OR) = 0.095, 95% confidence interval
(CI) 0.018 to 0.498; p-trend, 0.018) at the end of the follow up after adjustments.
Table 5. Association between TPE after five years of follow up and the incidence of obesity
(39 new-onset case).
Q1 Q2 95% CI Q3 95% CI Q4 95% CI Q5 95% CI p
Model 1 1 (ref.) 0.912 (0.337 2.468) 0.676 (0.253 1.810) 0.351 (0.142 0.866) 0.406 (0.164 1.005) 0.054
Model 2 1 (ref.) 0.454 (0.185 1.115) 0.235 (0.072 0.767) 0.285 (0.093 0.868) 0.145 (0.037 0.558) 0.014
Model 3 1 (ref.) 0.382 (0.146 1.001) 0.193 (0.055 0.676) 0.272 (0.084 0.885) 0.119 (0.028 0.505) 0.014
Model 4 1 (ref.) 0.366 (0.126 1.062) 0.156 (0.040 0.612) 0.218 (0.054 0.881) 0.095 (0.018 0.498) 0.018
Model 1, unadjusted; Model 2 was adjusted for baseline TPE and baseline BW; Model 3 was adjusted as in
Model 2 plus sex, age, and intervention groups; Model 4 was adjusted as in Model 3 plus smoking status (never,
current, former), family history of CHD, physical activity, hypertension, diabetes, dyslipidemia, marital status
(single, married, divorced, widowed), education level (primary school, high school, university), medication used
(antihypertensive drugs, vitamins, insulin, oral hypoglycemic drugs, aspirin, or other antiplatelet drug supplements
taken in the last month) recruitment centers, 14 unit Mediterranean diet score, and energy intake at baseline.
Table 6 shows the associations between TPE at the fifth year and changes in anthropometric
parameters, analyzed by linear regression models. For total participants, inverse associations were
found between changes in BW (β = −0.363; p = 0.024) and BMI (β = −0.145; p = 0.023) and TPE in the
fifth year after adjustment. For males, there was not any inverse association, while for females, inverse
associations were found for changes in BW (β = −0.568; p = 0.008) and BMI (β = −0.221; p = 0.017)
after adjustment.
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Table 6. Multiple linear regression analyses with changes in anthropometric parameters and quintiles
of TPE at the fifth year.
β SE Beta p 95% CI
Changes in BW Male Model 1 −0.098 0.211 −0.028 0.642 −0.514 0.318
(kg) Model 2 −0.229 0.217 −0.066 0.294 −0.657 0.199
Model 3 −0.186 0.217 −0.053 0.393 −0.614 0.242
Model 4 −0.037 0.233 −0.011 0.872 −0.495 0.421
Female Model 1 −0.648 0.193 −0.193 0.001 −1.027 −0.269
Model 2 −0.664 0.196 −0.197 0.001 −1.049 −0.279
Model 3 −0.573 0.197 −0.17 0.004 −0.961 −0.185
Model 4 −0.568 0.213 −0.169 0.008 −0.987 −0.149
Total Model 1 −0.429 0.142 −0.125 0.003 −0.709 −0.149
Model 2 −0.539 0.15 −0.157 <0.001 −0.835 −0.244
Model 3 −0.436 0.153 −0.127 0.005 −0.737 −0.135
Model 4 −0.363 0.161 −0.108 0.024 −0.68 −0.047
Changes in BMI Male Model 1 −0.04 0.075 −0.033 0.589 −0.187 0.107
(kg/m2) Model 2 −0.087 0.077 −0.07 0.259 −0.238 0.064
Model 3 −0.072 0.077 −0.059 0.348 −0.224 0.079
Model 4 −0.019 0.082 −0.016 0.817 −0.18 0.142
Female Model 1 −0.256 0.083 −0.177 0.002 −0.419 −0.092
Model 2 −0.262 0.084 −0.181 0.002 −0.428 −0.096
Model 3 −0.223 0.085 −0.154 0.009 −0.391 −0.056
Model 4 −0.221 0.092 −0.153 0.017 −0.402 −0.04
Total Model 1 −0.176 0.056 −0.13 0.002 −0.286 −0.065
Model 2 −0.215 0.059 −0.159 <0.001 −0.331 −0.098
Model 3 −0.172 0.06 −0.128 0.005 −0.291 −0.054
Model 4 −0.145 0.064 −0.109 0.023 −0.27 −0.02
Changes in WC Male Model 1 −0.066 0.233 −0.017 0.776 −0.525 0.392
(cm) Model 2 −0.209 0.241 −0.054 0.386 −0.684 0.265
Model 3 −0.17 0.242 −0.044 0.484 −0.647 0.307
Model 4 −0.108 0.249 −0.029 0.666 −0.599 0.383
Female Model 1 −0.34 0.275 −0.072 0.217 −0.88 0.2
Model 2 −0.325 0.28 −0.069 0.247 −0.877 0.227
Model 3 −0.31 0.286 −0.066 0.279 −0.872 0.253
Model 4 −0.42 0.311 −0.089 0.178 −1.033 0.192
Total Model 1 −0.237 0.181 −0.055 0.190 −0.592 0.118
Model 2 −0.302 0.192 −0.070 0.118 −0.680 0.076
Model 3 −0.252 0.198 −0.059 0.203 −0.640 0.136
Model 4 −0.269 0.207 −0.063 0.195 −0.676 0.138
Changes in WHtR Male Model 1 −0.066 0.233 −0.017 0.776 −0.525 0.392
(cm/m) Model 2 −0.209 0.241 −0.054 0.386 −0.684 0.265
Model 3 −0.17 0.242 −0.044 0.484 −0.647 0.307
Model 4 −0.108 0.249 −0.029 0.666 −0.599 0.383
Female Model 1 −0.202 0.179 −0.066 0.262 −0.555 0.152
Model 2 −0.194 0.183 −0.063 0.29 −0.555 0.166
Model 3 −0.184 0.187 −0.06 0.325 −0.552 0.183
Model 4 −0.262 0.204 −0.085 0.199 −0.663 0.139
Total Model 1 −0.142 0.114 −0.052 0.216 −0.367 0.083
Model 2 −0.184 0.122 −0.068 0.131 −0.424 0.055
Model 3 −0.155 0.125 −0.057 0.215 −0.401 0.091
Model 4 −0.167 0.131 −0.062 0.203 −0.426 0.091
TPE: total polyphenol excretion; GAE: gallic acid equivalent; BW: body weight; BMI: body mass index. WC: waist
circumference; WHtR: waist-to-height ratio. Model 1, unadjusted; Model 2 was adjusted for baseline TPE and
baseline BW; Model 3 was adjusted as in Model 2 plus sex (only for total participants), age, and intervention groups;
Model 4 was adjusted as in Model 3 plus smoking status (never, current, former), family history of CHD, physical
activity, hypertension, diabetes, dyslipidemia, marital status (single, married, divorced, widowed), education
level (primary school, high school, university), medication used (antihypertensive drugs, vitamins, insulin, oral
hypoglycemic drugs, aspirin, or other antiplatelet drug supplements taken in the last month) recruitment centers,
14 unit Mediterranean diet score, and energy intake at baseline.
Changes in obesity parameters for male, female, and total participants between baseline and end
of follow up were observed (Table S1). For total participants, subjects in the highest TPE category
had the lowest BW (70.29 ± 10.25 kg) and BMI (28.40 ± 3.75 kg/m2) after the intervention. Inversely,
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those participants in the first quintile of TPE had significantly higher WC (101.41 ± 9.35 cm) and
WHtR (61.80 ± 5.15) compared with baseline values. For males, there was a significant inverse trend
among quintiles and BW and BMI both at baseline and the fifth year. Also a significant reduction
was observed comparing the top quintile with the bottom quintile both at baseline and the fifth year.
For females, there was a significant reduction of BW and BMI in the top quintile groups after five years
of intervention.
Table S2 shows the associations between changes in anthropometric parameters and changes in
TPE over five years with linear regression models. For total participants, inverse associations were
found between changes in BW (β = −0.355; p = 0.036), BMI (β = −0.139; p = 0.037) and TPE five
years after adjustment. For males, there was not any inverse association, while, for females, inverse
associations were found for changes in BW (β = −0.723; p = 0.003), BMI (β = −0.283; p = 0.006), and
WC (β = −0.701; p = 0.046) after adjustment.
4. Discussion
In this five years study conducted in elderly participants at high cardiovascular risk, a higher
total polyphenol intake, expressed as TPE, was inversely associated with weight parameters including
BW, BMI, WC, and WHtR, as well as with the prevalence of obesity after a five years follow up,
suggesting that polyphenols could be considered an independent contributor to the weight loss effects
of a Mediterranean diet.
Several PREDIMED sub-trials have reported a range of mechanisms for the weight loss effects of
a Mediterranean diet, including a high ingestion of dietary fiber, antioxidants, unsaturated fatty acids,
extra virgin olive oil, nuts, and moderate wine consumption [29–35]. The reduction we observed in
weight parameters might be partly attributed to the intake of the aforementioned food items; however,
in the fully adjusted models, we removed their effects by adjusting for adherence to the Mediterranean
diet (14 unit MedDiet questionnaire). Furthermore, even though the intake of these foods increased
after five years of follow up, none of them showed significant differences within quintile categories at
the end of the intervention; therefore, polyphenol intake could be considered an independent factor.
The present findings are consistent with previous reports on the inverse associations between
polyphenol intake and weight parameters. A 16 years longitudinal study from the Netherlands
associated a higher intake of total flavonols/flavones and catechins with a lower increase in BMI [36].
Other supporting evidence showed a significant decrease of 1.9 cm in WC and 1.2 kg in BW after
supplementation of catechin-rich green tea for 90 days, although at a much higher dose than habitual
intakes [37]. Two 12 week intervention studies also demonstrated the anti-obesity effects of green
tea intake, finding a considerable reduction in BW, BMI, WC, and total abdominal fat area [38,39].
Another clinical trial indicated that consumption of normal or high-polyphenolic orange juice reduced
body weight in obese or overweight adults, demonstrating an inverse association between polyphenol
intake and body weight [10]. On the contrary, the effect of daily decaffeinated green tea intake
on weight and body composition were tested among a group population in overweight breast
cancer survivors. Results showed a slight but not significant increasing in weight loss after the
intervention [40]. Compared with Asian populations, Caucasians show inconsistent results: a study
showed no effects on body weight with long-term green tea extract supplementation [11]; another
study with relapsing-remitting multiple sclerosis patients using one of the main green tea polyphenols,
(-)epigal-locatechin-3-gallate, after three months of consumption showed greater muscle metabolism
improvement in males than females [41]; supplementation with resveratrol exerted significant effects
on energy metabolism in obese subjects, while another two findings showed ineffectiveness in nonobese
women and obese men [42–44]. The results are inconsistent probably because of the different doses of
polyphenol intakes, sex-specific effects, sample sizes, or length of duration.
The Mediterranean diet could be considered rich in polyphenol content because it is characterized
by a high consumption of fruit and vegetables, virgin olive oil, legumes, and nuts and a moderate
consumption of wine [45]. Results from a meta-analysis of 16 randomized controlled trials with a
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Mediterranean diet showed an average reduction in participant weight of 1.75 kg and a reduction in
BMI of 0.57 kg/m2, as well as a greater reduction in BW of 3.88 kg under conditions of energy restriction,
suggesting that adherence to a Mediterranean diet helps to control weight [46]. The PREDIMED,
the European Prospective Investigation into Cancer and Nutrition (EPIC-Spain) cohort and the
Seguimiento Universidad de Navarra (SUN) cohort, also in Spain, have shown in the long-term
a significantly lower risk of overweightness/obesity associated with better Mediterranean diet
adherence [34,47,48]. We observed a 1.22 kg decrease in BW and 0.50 in BMI in the highest TPE quintile,
which partly agrees with previous studies reporting a similar reduction in body weight parameters.
Indexes of abdominal obesity, namely WC and WHtR, were significantly lower in the highest TPE
quintile. These parameters are more accurate discriminators of cardiovascular risk than BMI due to
the closer relationship between cardiovascular disease and abdominal obesity [49]. In agreement with
our findings, in a PREDIMED study, and several other studies, the Mediterranean diet was negatively
associated with WC and WHtR [50–52]. Additionally, two feeding trials with green tea polyphenol
extracts also showed beneficial effects on abdominal obesity parameters [39,53].
Our results indicate the weight loss effect of polyphenols is higher in females than males. There are
several possible reasons to explain the observed results: first, the prevalence of obesity is higher in
women than men, and weight loss tends to be lower in obese individuals [54]. In the current study, at
baseline, the prevalence of obesity was 32.9% for males and 44.9% for females, which is in line with
another elderly population in United States [55]. Second, a higher TPE increment was observed when
comparing females and males after five years, which may potentially explain the difference in weight
loss effectiveness. Third, self-characteristics concerning males and females may also contribute to
the difference. Women tend to have higher concentrations of leptin, an appetite regulation hormone
that helps to reduce energy intake [56]. Evidence shows a significant inverse association between
polyphenol intakes and plasma leptin levels, indicating higher polyphenol intake responses to better
weight loss effectiveness [10]. Furthermore, individual differences in the composition of the gut
microbiota may also contribute to differences in bioavailability and polyphenolic metabolites, further
influencing the weight loss effectiveness [57].
We also found less gain in WC in males, after five years of intervention. The observation could be
primarily explained by the greater percentage of muscle mass and mineral mass in males compared
with females. Waist circumference is affected by age, body weight, body composition, and fat
distribution [58]. Various types of polyphenol help to reduce visceral fat [9]. Additionally, since
waist circumference increases with age, it is worth noting that the average age is older in females in
our population, which could be considered another possible explanation.
Potential explanations of the observed inverse association between polyphenol intake and weight
loss likely involve several mechanisms due to the diversity of polyphenol chemical structures, complex
metabolic pathways, and oral bioavailability. Excess adipose mass and adipose tissue expansion
results from adipocyte hypertrophy and hyperplasia [59]. Common plausible mechanisms include
the suppression of fat absorption and anabolic pathways; inhibition of adipogenesis and lipogenesis;
stimulation of catabolic pathways with increment of lipolysis, apoptosis of mature adipocytes, and acid
β-oxidation; reduction of chronic inflammatory response relative to adiposity; and increment in energy
expenditure through up-regulating uncoupling protein (UCP1-3) [8,9]. However, knowledge of the
anti-obesity effects of polyphenols is limited and only a few specific compounds have been analyzed in
this context. For instance, it has been demonstrated that resveratrol, widely present in red grapes and
red wine, exerts an anti-obesity action by reducing adipogenesis and increasing apoptosis in mature
adipocytes and inhibiting fat accumulation processes and stimulating lipolytic and oxidative pathways
in vivo studies and clinical trials [43,60,61]. Contrary results have been observed with anthocyanins,
water-soluble plant pigments in blue, purple, and red fruits. On one hand, they seem to significantly
reduce body weight. This effect may be due to the suppression of lipid synthesis, the up-regulation of
adiponectin, which enhances insulin sensitivity, and the reduction in of serum triglycerides and leptin
levels [8,62]. However, two clinical trials showed non-significant reduction trends in body weight after
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supplementation with food rich in anthocyanins [63,64]. The anti-obesity effects of flavonoids, which
are a large group of polyphenols found in a wide range of Mediterranean diet foods [65,66], have been
mainly attributed to improvement in adipocyte functionality and fat oxidation [67]. Also playing a
key role in weight control is the down-regulation of a variety of pro-inflammatory adipocytokines,
particularly tumor necrosis factor alpha (TNF-α) [68]. A clinical trial indicates that the inhibition of
intestinal fat absorption may contribute to the weight loss after an ingestion of a green tea beverage
enriched with catechins [69]. In summary, even though the intake of some specific polyphenols has
been associated with body weight management, there is still not enough evidence for the effect of total
polyphenols or some classes of polyphenols, and further studies are needed to explore the mechanisms
involved as well as potential synergistic effects among them.
The association between weight loss and improvement in cardiovascular risk factors has been
widely discussed. Numerous studies indicate that polyphenol intake reduces cardiovascular risk
factors [70,71]. A previous study found a significant improvement in cardiovascular risk factors, with
a 5–10% of weight loss after one year [72]. We also found protective effects on cardiovascular risk
factors, including diastolic blood pressure, glucose concentration, and triglycerides concentration, with
the same population after five years of intervention [73]. A randomized study conducted in healthy
participants, feed with apple polyphenol, also supported that an improvement in cardiovascular risk
factor helps to regulate fat metabolism [74].
Some limitations of this study should be noted. First, given that the study was conducted among
elderly subjects at high cardiovascular risk, the results cannot be extrapolated to the general population.
Second, even though we adjusted for major potential confounders, we still cannot exclude residual
confounding from measurements. Third, even though WC and WHtR may reflect abdominal obesity
more accurately, they cannot differentiate between fat distribution in visceral adipose tissue and
subcutaneous abdominal adipose tissue; hence we cannot conclude if a reduction in abdominal obesity
parameters is beneficial to visceral or subcutaneous fat mass or both [75]. Another limitation is the
lack of specific measurements of polyphenol metabolism in vivo.
The present study also has several strengths. Its main strong point is the use of TPE, a biomarker
of polyphenol intake, which could provide more precise data than measuring total polyphenol intake
through self-reported information in FFQs or databases. Another strength is its prospective design.
Only a few studies have analyzed the association between total polyphenol intake and weight control,
and the current work is the first to associate anti-obesity effects with total polyphenol intake in
individuals at high cardiovascular risk [8,76]. In addition, the long-term duration of the intervention
provides more robust results compared with other short-term trials.
5. Conclusions
In summary, with five years of follow up, the present study shows that polyphenol levels
expressed as TPE in urine were inversely associated with BW, BMI, WC, and WHtR in an elderly
population at high cardiovascular risk. Therefore, we confirmed that a long-term polyphenol-rich diet
contributes to body weight loss, which can offer protection from several chronic diseases. For future
research, similar studies should be conducted in the general population, and specific mechanisms need
to be explored by further clinical trials.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/5/452/s1,
Table S1: Comparisons of obesity indexes, Table S2: Multiple linear regression analyses with changes in
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Abstract: Polyphenols are plant secondary metabolites containing antioxidant properties, which
help to protect chronic diseases from free radical damage. Dietary polyphenols are the subject of
enhancing scientific interest due to their possible beneficial effects on human health. In the last
two decades, there has been more interest in the potential health benefits of dietary polyphenols as
antioxidant. Black soybeans (Glycine max L. Merr) are merely a black variety of soybean containing
a variety of phytochemicals. These phytochemicals in black soybean (BSB) are potentially effective
in human health, including cancer, diabetes, cardiovascular diseases, cerebrovascular diseases, and
neurodegenerative diseases. Taking into account exploratory study, the present review aims to
provide up-to-date data on health benefit of BSB, which helps to explore their therapeutic values for
future clinical settings. All data of in vitro and in vivo studies of BSB and its impact on human health
were collected from a library database and electronic search (Science Direct, PubMed, and Google
Scholar). The different pharmacological information was gathered and orchestrated in a suitable spot
on the paper.
Keywords: polyphenols; black soybean; antioxidants; human diseases; health benefits
1. Polyphenols
Polyphenols are phytochemicals, found largely in fruits, vegetables, tea, coffee, chocolates,
legumes, cereals, and beverages. There are over 8000 polyphenols identified in nature and their
main functions are as antioxidant. They protect our body from free radical damage and defense against
UV radiation or aggression by pathogens. In the last two decades, there has been more interest in the
potential health benefits of dietary polyphenols as antioxidant. The average 100 grams fresh weight of
fruits (grapes, apple, pear, cherries, and berries) contain up to 300 mg of polyphenols. Typically, a cup
of tea or coffee or a glass of red wine contains more than 100 mg of polyphenols. In addition, cereals,
vegetables, dry legumes and chocolate also contribute to the polyphenolic intake and thereby protect
our body from chronic diseases [1]. Dietary polyphenols are the subject of enhancing scientific interest
due to their possible beneficial effects on human health. They are usually provided to the food as color,
flavor, bitter, and astringent, and maintain stability from oxidation. Several epidemiological studies
and associated meta-analyses strongly showed that the consumption of these polyphenols offered
better protection against chronic diseases such as cancers, cardiovascular diseases, cerebrovascular
diseases, diabetes, ageing and neurodegenerative diseases [2–5].
1.1. Types of Polyphenols
Polyphenols are divided into four different categories based on the presence of number of phenolic
groups and structural elements [6]. Food usually contains complex polyphenols, predominantly found
in the outer layers of the plants [1].
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1. Flavonoids: Have a potential effect on radical scavenging and inflammatory reactions. They
are predominantly found in fruits, vegetables, legumes, red wine, and green tea. They are
further divided into a number of subgroups namely, flavones, flavonols, flavanones, isoflavones,
anthocyanidins, chalcones, and catechins.
2. Stilbenes: Found in product of graphs, red wine, and peanuts. Resveratrol is the most well-known
compound among the group.
3. Lignans: Found in seeds like flax, linseed, legumes, cereals, grains, fruits, algae, and
certain vegetables.
4. Phenolic acids: Found in coffee, tea, cinnamon, blueberries, kiwis, plums, apples, and cherries
and have two subgroups, namely hydroxybenzoic acids, and hydroxycinnamic acids.
1.2. Role of Polyphenols in Plants and Humans
In the plant, polyphenols protect from UV radiation, pathogens, oxidative stress, and harsh
climatic conditions [1]. In the human body, polyphenols are antioxidants, and have diverse biological
properties such as anti-diabetic [7,8], anticancer [9,10], anti-inflammatory [11,12], cardioprotective [13],
osteoprotective [14,15], neuroprotective [16,17], antiasthmatic [18], antihypertensive [19],
antiageing [20], antiseptic [21], cerebrovascular protection [22], cholesterol lowering [23],
hepatoprotective [24], antifungal [25], antibacterial [26] and antiviral properties [27] (Figure 1).
Figure 1. Role of polyphenols in humans.
2. Black Soybeans
Soybeans contain various colors of seed coat including black, yellow, green, and brown. It is due to
the presence of anthocyanins, chlorophyll, and other pigments. Black soybeans (BSB) have been
widely consumed as food and as material for Oriental medicine for hundreds of years in Asia.
The black pigmentation is due to accumulation of anthocyanins in the epidermis palisade layer of the
seed coat [28]. Different anthocyanins in BSB have been identified, including cyanidin-3-glucoside,
delphinidin-3-glucoside, and pelargonidin-3-Glucoside [29]. BSB is an excellent dietary source for
disease prevention and health promotion.
In the last two decades, isoflavones and proteins are the primary health beneficial components in
BSB that have received attention [30–32]. Nevertheless, there are insufficient data to explain the health
benefits exclusive to BSB. They have potentially active phytochemicals such as isoflavones, sterols, phytic
acid, saponins, and phenolics, which are potentially effective for human health and prevention of various
chronic diseases [32]. Research showed that BSB has the greatest antioxidant properties compared to other
colored soybeans [33,34]. The characteristic antioxidant potential is due the presence of phenolics, which is
mainly distributed in the seed coat [35,36]. In the seed coat, around 20 phenolic compounds, predominantly
six anthocyanins, are greatly (13–50 times) distributed in several BSB varieties [32], which helps to reduce
the risk of chronic diseases such as metabolic disorders and cancers [37–40]. These varieties have the
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potential to be used in functional foods and food colorant development. The predominant quantity of
anthocyanins provides a black color to the seed coat and showed to have potent antioxidant properties,
which is mainly responsible for health-promoting effects of BSB. In addition to the anthocyanins, BSB
contain other phenolics such as tannins, isoflavones and phenolic acids [34,35].
Nutritional Importance of BSB
BSB has a high content of protein (32–43.6%). In addition to protein, BSB contains carbohydrates
(31.7–31.85%), lipids (15.5–24.7%), water (5.6–11.5%), minerals (calcium, phosphorous, magnesium,
potassium, sodium, selenium, etc.) and vitamins (Vitamin E, B complex, etc.) [41,42]. The BSB
lipid composition consists of 86% unsaturated fatty acids, especially linoleic (6.48–11.6%), linolenic
(0.72–2.16%) and oleic acids (3.15–8.82%), making it beneficial to human health [43]. Soybean is
characterized by the most digestible proteins, lysine and methionine. However, it is limited by sulfur
amino acids and tryptophan.
3. Anthocyanins Rich BSB
Anthocyanins are water-soluble natural pigments that belong to flavonoids, a larger subgroup
of polyphenols, and widely distributed in BSB and shown to provide numerous health benefits.
Major anthocyanins have been isolated and identified from the seed coat of BSB such as cyanidin
3-O-β-D-glucoside, delphinidin-3-O-β-D-glucoside, pelargonidin-3-O-glucoside, and petunidin
3-O-β-D-glucoside [29,44]. The minor anthocyanins such as catechincyanidin-3-O-glucoside,
delphinidin-3-O-galactoside, cyanidin-3-O-galactoside, and peonidin-3-O-glucoside have also
been isolated and identified based on the fragmentation patterns of high-performance liquid
chromatography–diode array detector–electrospray ionization/mass spectrometry analysis [45,46].
5,7,3′,4′-Tetrahydroxyflav-2-en-3-ol 3-O-β-D-glucoside have also been isolated from immature BSB [47].
The structure of anthocyanins-rich BSB is depicted in Figure 2.
Figure 2. Anthocynins isolated from back soybean [45–47].
4. Health Benefits of Anthocyanins Rich BSB
Anthocyanins rich BSB has potential health benefit as complementary medicine and utilized
in various formulation implied for antioxidant, anti-inflammatory, nephroprotective, antidiabetic,
anticancer, anti-infertility, anti-obesity, anti-arthritic, neuroprotective, antihyperlipidemic, anti-cataract
and wound healing properties. Detailed information on dose range, route of administration, the model
used, negative controls, and other pharmacological results based on the experimental research study
in vivo and in vitro, according to the appropriate title depicted, are presented in Table 1.
Some of the health benefits of anthocyanins rich BSB are listed below.
105




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Nutrients 2017, 9, 455
4.1. Enhance Bone Stability
BSB has high content of proteins and fibers. It has an enormous amount of minerals such as
calcium, phosphorous magnesium, iron, manganese, copper, and zinc, which contribute to maintain
and stabilize the bone and its strength [99,100]. The study showed that the consumption of BSB has a
definite protective effect on bone loss in postmenopausal osteoporosis study model and thereby BSB
inhibits bone turnover and prevent bone resorption. This study confirmed that the intake of BSB can
be used to prevent bone loss in estrogen deficiency animal studies [101]. In addition, the observational
and acute clinical trial studies also suggested that the isoflavone-genistein reduces bone loss and
enhances bone mineral density in osteopenic postmenopausal women [102].
4.2. Reduce Blood Pressure
Owing to the beneficial health effects on the human cardiovascular system, BSB has been a focus of
intensive research. BSB contains a low concentration of sodium, which helps to maintain blood pressure
at a normal range. A recent epidemiological study also showed that the anthocyanins rich BSB reduce
the risk of cardiovascular diseases and maintain the blood pressure in the affected individuals [38,103].
In addition, BSB has potent inhibitory activity on collagen-induced platelet aggregation and reduce
cardiovascular risk, and thereby improves blood circulation [104]. BSB has enormous quantities of
fiber, potassium, folic acid, pyridoxal phosphate, and phytonutrients (quercetin and saponins) and
lack of cholesterol, which supports to reduce cardiovascular complications. The fiber in BSB helps to
lower total cholesterol (TC), LDL-cholesterol (LDL-C) in the blood and liver that reduce the risk of
heart disease. It inhibits oxidative stress in postmenopausal women by increasing antioxidant activity
and improving lipid profiles [105].
4.3. Reduce Cardiovascular Complications
The consumption of BSB may reduce the risk of coronary heart diseases. Recent
researches have shown that BSB inhibit the effect of low density lipoprotein oxidation, inhibit
TNF-alpha-induced vascular cell adhesion molecule-1 (VCAM), intracellular adhesion molecule-1
(ICAM), and cyclooxygenase-2 levels [83]. Further, anthocyanins protected myocardial injury from
ischemia-reperfusion in rats [83]. Thus, anthocyanins from BSB seed coat benefit for pathological
conditions like coronary heart diseases [84].
4.4. In Managing Diabetes
BSB is known to be rich in anthocyanins, and they have been consumed since ancient times
for their beneficial effects on health. It has been reported that BSB seed coat may ameliorate obesity
and insulin resistance [79]. BSB has more fibers, which have a vital role to reduce the blood sugar.
Notably, one cup of BSB contributes around 15 g of fibers [106]. In addition, the BSB seed coat extract
contains polyphenol-rich food material consisting of 9.2% cyanidin 3-glucoside, 6.2% catechins, 39.8%
procyanidins, and others. These compounds remarkably prevent obesity and diabetes by enhancing
energy expenditure and suppressing inflammation [107,108].
4.5. Cancer Prevention
Several studies showed that anthocyanins rich BSB have been shown to inhibit cancer cell growth
by suppressing oxidative stress and inflammatory responses. Anthocyanin-rich BSB seed coat extract
possibly reduces the development of tumors in various organs such as intestines [51], breast [109],
prostate [65,110], stomach [80], ovary [111], endometrium [112], and liver [113]. In addition to the
anthocyanins, saponins also prevent cancer cells from proliferation and spreading throughout the
body [114]. BSB is high in folic acid, which plays a vital role in DNA synthesis and repair, thus BSB
prevents the formation of cancer cells from DNA mutations [115].
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4.6. Reduce Body Weight
BSB contain high quantity of fibers, which enhance satiety and decrease appetite, making an
individual feel full for longer time, and thereby reduce the overall calorie intake [116]. Many studies
have suggested that the consumption of anthocyanins rich BSB reduces the risk of adipogenic activity,
obesity [40,117], fatty acid content in subcutaneous [118] and overall mortality while promoting a
healthy complexion, visceral fat, increased energy, and overall reduce the body weight [49].
4.7. Antimicrobial Actions
Anthocyanins rich BSB may have antibacterial, anti-fungal, and anti-viral properties. The extract
from BSB produced significant growth reductions of food borne pathogens such as Escherichia coli,
Salmonella typhimurium and Campylobacter jejuni in broth-cultures as well as on chicken skin [119].
A previous study also showed an isolated monomeric protein (molecular mass of 25 kDa), containing
N-terminal sequence, which resembles a segment of chitin synthase. The protein, named glysojanin,
demonstrated a potent antifungal activity against Fusarium oxysporum and Mycosphaerella arachidicola
and antiviral potential against HIV-1, human adenovirus type 1 and coxsackievirus B1 [98,120].
5. Conclusions
Black soybeans have popularly been utilized as a food and medicinal material for a long time
with low price. Anthocyanins have antioxidant effect and can be useful for the treatment of diabetes,
cardiovascular disorders, cancers, etc. Although the exact mechanism by which anthocyanins prevent
the expression of adhesion molecules remains to be elucidated, they can be used as good materials to
modulate or prevent such chronic diseases. In any case, more support for such properties/dynamic
constituents has been acquired from cellular and molecular studies, while clinical studies are as yet
inadequate. Since animal research does not generally interpret human circumstances, additional
clinical studies are justified for comprehending the full interpretation of the effects of Anthocyanins in
BSB for human disease prevention. Subsequently, futures far-reaching clinical studies are required to
warrant the therapeutic convenience of anthocyanins in BSB. Furthermore, highlighting the synergistic
multi-component effects of BSB on biological functions would be a recommendation for further studies,
as well as studies of the mechanism of action and new biomarkers to prove the effectiveness of BSB
bioactive compounds in preventing and treating several symptoms and/or pathologies.
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Abstract: Isomaltulose, a naturally-occurring isomer of sucrose, is commonly used as an alternative
sweetener in foods and beverages. The goal of this study was to determine the effect of
isomaltulose together with green tea on postprandial plasma glucose and insulin concentration,
as well as antioxidant capacity in healthy subjects. In a randomized, single-blind, crossover study,
15 healthy subjects (eight women and seven men; ages 23.5 ± 0.7 years; with body mass index of
22.6 ± 0.4 kg/m2) consumed five beverages: (1) 50 g sucrose in 400 mL water; (2) 50 g isomaltulose
in 400 mL of water; (3) 400 mL of green tea; (4) 50 g sucrose in 400 mL of green tea; and (5) 50 g
isomaltulose in 400 mL of green tea. Incremental area under postprandial plasma glucose, insulin,
ferric reducing ability of plasma (FRAP) and malondialdehyde (MDA) concentration were determined
during 120 min of administration. Following the consumption of isomaltulose, the incremental
2-h area under the curve (AUC0–2 h) indicated a higher reduction of postprandial glucose (43.4%)
and insulin concentration (42.0%) than the consumption of sucrose. The addition of green tea to
isomaltulose produced a greater suppression of postprandial plasma glucose (20.9%) and insulin
concentration (37.7%). In accordance with antioxidant capacity, consumption of sucrose (40.0%)
and isomaltulose (28.7%) caused the reduction of green tea-induced postprandial increases in FRAP.
A reduction in postprandial MDA after drinking green tea was attenuated when consumed with
sucrose (34.7%) and isomaltulose (17.2%). In conclusion, green tea could enhance the reduction of
postprandial glucose and insulin concentration when consumed with isomaltulose. In comparison
with sucrose, isomaltulose demonstrated less alteration of plasma antioxidant capacity after being
consumed with green tea.
Keywords: isomaltulose; green tea; sucrose; glycemic response; antioxidant capacity
1. Introduction
There has been a marked increase in the consumption of sugar-sweetened beverages across the
globe [1,2]. Recent evidence has been able to substantiate the relationship between the consumption of
sugar-sweetened beverages and the risks of type 2 diabetes, obesity and cardiovascular diseases [3].
A number of randomized clinical trials have reported that the consumption of sweetened beverages
increased body weight and fat mass after 10 weeks [4]. There has been increasing concern regarding
the health effects of being overweight and obesity in adults, and this has, therefore, led to a rising
demand for low-energy food products. Low-glycemic sweeteners commonly offer an alternative
approach to using caloric sugars as substitutes for sucrose and high fructose corn syrup in foods and
beverages [5–7].
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Isomaltulose (6-O-D-glucopyranosyl-D-fructose), one type of low-glycemic sweetener, is a
naturally-occurring disaccharide found in honey, sugarcane and molasses [8]. Like sucrose, it is
digested by α-glucosidase in the small intestine and contributes the same caloric value of approximately
4 kcal/g [9,10]. However, the rates of isomaltulose digestion and absorption are much slower
than sucrose [11,12]. Furthermore, the consumption of isomaltulose was found to be safe without
gastrointestinal side effects [8]. Clinical studies provided more convincing evidence in support of
isomaltulose for controlling postprandial glucose profile in humans [12–14]. Therefore, isomaltulose
has been applied most recently in ready-to-drink products, such as sports drinks, instant drinks and
milk-based drinks [10,15].
Green tea (Camellia sinensis), one of the most popular beverages in the world, is a rich source
of polyphenols, specifically, epicatechin (EC), epicatechin gallate (ECG) and epigallocatechin gallate
(EGCG) [16]. Evidence from cohort studies showed an association between higher intake of tea-derived
polyphenols, such as flavan-3-ols [17,18] and, more specifically, catechins and theaflavins [19],
and lower risk of impaired glucose metabolism. However, no correlation was found for other
polyphenol groups [20]. Several studies have shown the beneficial effects of green tea, including
anti-hyperglycemic, anti-oxidative, anti-carcinogenic, anti-inflammatory and hypocholesterolemic
activity [21–23]. For example, catechin-rich green tea improves postprandial glucose concentration and
plasma antioxidant capacity in human subjects [24,25]. In a clinical trial, consumption of 1.5 g green tea
extracts in 500 mL water (total polyphenols with approximately 500 mg gallic acid equivalent) with 75 g
glucose decreased postprandial plasma glucose concentration in healthy subjects [26]. In a randomized
crossover design, consumption of 50 g of white bread with a green tea beverage (5 g green tea in 200 mL)
significantly decreased the postprandial plasma glucose level in healthy subjects [27]. Furthermore,
sucrose-loading (2.0 g/kg body weight) with green tea extract (0.5 g/kg body weight) significantly
decreased plasma glucose level in rats [28]. According to the literature, the plasma lowering effect
of green tea was evidently supported by clinical studies in human subjects who consumed green tea
with calorie sugars. However, there have not been any reports examining whether consumption of
isomaltulose and green tea alters plasma glucose concentration and antioxidant status. Therefore,
the aim of the current study was to investigate the effect of isomaltulose together with green tea on
postprandial plasma glucose and insulin concentration and antioxidant capacity in healthy subjects.
2. Materials and Methods
2.1. Preparation of Green Tea Beverages
Instant green tea leaf products were purchased from the local market. The content of the total
amount of polyphenolic compounds was determined using the Folin–Ciocalteu method, according
to the ISO 14502-1 method [29]. The phytochemical analysis of catechins was determined by using
high-performance liquid chromatograph (HPLC), according to the ISO 14502-2 method [30]. The
polyphenol content of the instant green tea was 12.30 g/100 g (dry weight basis). The phytochemical
components were 2.16 g (−)-epigallocatechin, 1.85 g (−)-epigallocatechin gallate, 0.7 g (−)-epicatechin,
0.57 g (−)-gallocatechin, 0.56 g (+)-catechin, 0.46 g (−)-epicatechin gallate, 0.16 g (−)-gallocatechin
gallate and 0.01 g (−)-catechin gallate in a 100-g dry weight basis. In the experiment, instant green tea
leaves in a bag (4 g) were infused with boiling water (400 mL, a serving portion) at 95 ◦C for 5 min.
Sugars (50 g sucrose or 50 g isomaltulose) were added into the green tea beverage (400 mL).
2.2. Subjects
The sample size was calculated according to Torronen et al., considering the postprandial of
glycemic response as the main variable [31]. A statistical power of 90% and an expected difference
of 95% in the baseline values were adopted to form a total sample of at least 14 individuals. A total
of eighteen subjects (aged 18–35 years old) were recruited from the local community through poster
advertisement and flyers. The subjects were screened in terms of anthropometry (BMI ranged
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18.5–22.9 kg/m2, % body fat <20% in men and <30% in women and waist circumference ≤90 cm in
men and ≤80 cm in women), blood pressure <140/90 mmHg and blood chemistry (fasting plasma
glucose level ≤100 mg/dL, total cholesterol <200 mg/dL, LDL-cholesterol <150 mg/dL, triglyceride
<150 mg/dL, blood creatinine level ranging from 0.7–1.4 mg/dL and alanine aminotransferase (ALT)
<40 IU/L). Participants were also excluded if they met the criteria for any evidence of physical illness,
smoking, heavy drinking, history of chronic diseases, allergy, gastrointestinal pathologies (e.g., short
bowel syndrome) and current use of drugs and food supplements. The study protocol was approved
by the Ethics Review Committee for Research Involving Human Research Subjects, Health Science
Group, Chulalongkorn University (No. 135/56). All subjects provided their written informed consent
to participate in this study.
2.3. Study Design
The study was designed as a randomized, single-blinded, five-visit crossover study with
a two-week washout period. At each experimental visit, after a 12-hour overnight fast, the subjects
consumed the following beverage: (1) 50 g sucrose in 400 mL of water; (2) 50 g isomaltulose in 400 mL
of water; (3) 400 mL of green tea; (4) 50 g sucrose in 400 mL of green tea; or (5) 50 g isomaltulose in
400 mL of green tea; within 5 min from the starting time. Blood samples were collected before and
after 15, 30, 45, 60, 90 and 120 min of administration. During the experimental period, the subjects
were instructed to avoid phenolic-rich foods (e.g., tea, coffee, fruit juices, berries, fruit, chocolate, etc.),
high-antioxidant diets, alcoholic beverages and excessive exercise within a week before each visit.
In addition, the subjects were asked to provide their food records and physical activity questionnaire
at every visit.
2.4. Blood Collection
Blood samples were collected into tubes containing anticoagulants from an intravenous catheter
inserted into a forearm vein. Blood samples were centrifuged at 3000 rpm for 15 min at 4 ◦C. Plasma
samples were kept in a microtube and stored at −20 ◦C until analysis. Plasma glucose and insulin
were analyzed using a glucose oxidase method (enzymatic colorimetric kits, GLUCOSE liquicolor,
Human GmbH, Wiesbaden, Wiesbaden, Germany) and insulin human ELISA kit (BQ kits, San Diego,
CA, USA), respectively.
2.5. The Ferric Reducing Ability of Plasma
The ferric reducing ability of plasma was performed according to a previous study with
slight modification [32]. In brief, the FRAP reagent was freshly prepared and warmed at 37 ◦C
by mixing the following solution: (1) 0.3 M sodium acetate buffer solution (pH 3.6); (2) 10 mM
2,4,6-tripyridyl-1-5-triazine (TPTZ) in 40 mM HCl solution; and (3) 20 mM FeCl3 solution at the ratio of
10:1:1 (v/v/v), respectively. Plasma (10 μL) was incubated with 90 μL of FRAP reagent in a microplate
for 30 min at room temperature in the dark. After that, the mixture measured the level of absorbance
at the wavelength 595 nm with a spectrophotometer. The FRAP values were calculated by using
a calibration standard curve of FeSO4 (0–2000 μM).
2.6. Lipid Peroxidation
Plasma malondialdehyde (MDA) was quantified using a method based on the formation of
thiobarbituric acid reactive substances (TBARS) and determined using fluorescence detection following
a previous method with slight modification [33]. The plasma sample (60 μL) was incubated with
30 μL of 10% sodium dodecyl sulfate and 1.2 mL of TBA reagent (530 mg thiobarbituric acid in a
mixed solution containing 50 mL of 20% acetic acid and 50 mL of 1 M NaOH). The mixtures were
incubated in a heat block at 97 ◦C for 1 h. Following incubation, the mixtures were immediately
removed from the heat block and placed in −20 ◦C for 10 min to stop the reaction. Next, the mixtures
were centrifuged at 13,000 rpm for 10 min at 4 ◦C, and then, the supernatant was loaded into the
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microplate. The absorbance was measured using a fluorescence reader (Perkin Elmer®, Turku, Finland)
at an excitation wavelength of 530 nm and an emission wavelength of 550 nm.
2.7. Statistical Analysis
For each test, the incremental data of plasma glucose, insulin, FRAP and MDA after consumption
were analyzed using a repeated measurement ANOVA, followed by Duncan’s test at a significance level
of p < 0.05. The incremental area under curves (iAUCs) were calculated according to the trapezoidal
method. A one-way analysis of variance (ANOVA) followed by Duncan’s test for multiple comparison
tests were performed to assess the differences between treatments (p < 0.05).
3. Results
3.1. Subjects
Twenty-two subjects were recruited for this study according to the flowchart (Figure 1).
Four subjects were excluded from the study following the basic inclusion and exclusion criteria
of the study. The eighteen remaining subjects were randomly assigned into five groups. Three subjects
withdrew after the first week due to reasons unrelated to the study. Fifteen subjects completed the
study, including eight women and seven men. The baselines characteristics of the fifteen subjects are
shown in Table 1. Furthermore, all subjects were instructed to maintain unchanged their lifestyles or
physical behavior during the experimental period.
Figure 1. Flowchart for a randomized, single-blinded, five-visit crossover study.
3.2. Glycemic Response
The incremental postprandial plasma glucose and insulin concentrations after the consumption
of beverages are shown in Figure 2. Consumption of isomaltulose was found to significantly lower
plasma glucose concentrations at 15, 30, 45 and 60 min and insulin concentrations at 15, 30 and 45 min
as compared to the consumption of sucrose. The results showed that consumption of sucrose together
with green tea significantly suppressed plasma glucose concentrations at 15, 30, 45, 60 and 90 min and
insulin concentration at 30 and 45 min. In addition, the ingestion of green tea-containing isomaltulose
caused a higher reduction of plasma glucose concentration (15 and 30 min) and insulin concentration
(30 and 45 min) than isomaltulose alone.
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Table 1. Baseline characteristics of fifteen subjects (8 women and 7 men).
Parameters Mean ± SEM
Age (years) 23.5 ± 0.7
Weight (kg) 21.0 ± 0.4
BMI (kg/m2) 22.6 ± 1.4
% Body fat
Women 22.6 ± 1.4
Men 13.6 ± 1.1
Waist circumference (cm)
Women 69.9 ± 2.4
Men 80.0 ± 2.2
Systolic blood pressure (mmHg) 115.3 ± 1.9
Diastolic blood pressure (mmHg) 71.9 ± 2.3
Fasting glucose (mg/dL) 81.5 ± 2.3
Total cholesterol (mg/dL) 186.5 ± 3.2
LDL-cholesterol (mg/dL) 119.0 ± 5.2
Triglyceride (mg/dL) 76.5 ± 6.3
Creatinine (mg/dL) 0.9 ± 0.1
Alanine aminotransferase or ALT (U/L) 10.7 ± 1.3
Postprandial iAUCs for glucose (43.3%) and insulin (42.0%) were largely reduced following
the ingestion of isomaltulose compared to sucrose, respectively (Figure 3). Consumption of green
tea-containing sucrose solution had lower iAUCs for glucose (43.4%) and insulin (32.1%) when
compared to the sucrose solution. In addition, green tea-containing isomaltulose significantly reduced
the iAUCs of glucose (20.9%) and insulin concentration (37.7%) when compared to isomaltulose.
Figure 2. Cont.
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Figure 2. The incremental postprandial plasma (A) glucose concentration and (B) insulin concentration
in healthy subjects after consumption of sucrose, isomaltulose, green tea, green tea plus sucrose and
green tea plus isomaltulose (n = 15). Data are expressed as means ± SEM. Values not sharing the same
superscript were significantly different between test groups in each time point (p < 0.05).
Figure 3. The incremental area under the curves (iAUCs) of plasma (A) glucose and (B) insulin
concentration in healthy subjects after consumption of sucrose, isomaltulose, green tea, green tea plus
sucrose and green tea plus isomaltulose (n = 15). Data are expressed as means ± SEM. Values not
sharing the same superscript were significantly different between test groups (p < 0.05).
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3.3. Antioxidant Capacities
The incremental postprandial plasma FRAP and MDA concentrations of treatments are shown
in Figure 4. Both sucrose and isomaltulose showed a slight decrease in postprandial plasma FRAP
level. Consumption of green tea increased the plasma FRAP level during the experimental period;
whereas the addition of sucrose to the solution caused a reduction in plasma FRAP level at 15, 30 and
90 min. In contrast, consumption of isomaltulose together with green tea maintained an increase in the
postprandial plasma FRAP level during the study. The findings also demonstrated that sucrose and
isomaltulose slightly reduced postprandial plasma MDA concentration during 2 h of consumption.
In comparison with sucrose and isomaltulose, consumption of green tea resulted in a higher reduction
of plasma MDA concentration. This effect declined with the combination of green tea with sucrose at
15 min and 30 min. In the meantime, replacing sucrose with isomaltulose slightly suppressed green
tea-induced reduction of plasma MDA concentration at 15 min and 30 min.
Figure 4. The incremental postprandial plasma (A) FRAP level and (B) malondialdehyde (MDA)
concentration in healthy subjects after consumption of sucrose, isomaltulose, green tea, green tea
plus sucrose and green tea plus isomaltulose (n = 15). Data are expressed as means ± SEM. Values
not sharing the same superscript were significantly different between test groups in each time point
(p < 0.05).
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The iAUCs of plasma FRAP and MDA concentrations are shown in Figure 5. Ingestion of green
tea demonstrated the highest iAUC of plasma FRAP among all treatments. However, the iAUCs of
plasma FRAP were significantly reduced with the consumption of green tea together with sucrose
(40.4%) and isomaltulose (28.6%), respectively. At the same time, sucrose and isomaltulose attenuated
green tea-induced reduction of iAUCs of plasma MDA by 34.7% and 17.2%, respectively.
Figure 5. The incremental area under the curves (iAUCs) of plasma (A) FRAP and (B) MDA
concentration in healthy subjects after consumption of sucrose, isomaltulose, green tea, green tea
plus sucrose and green tea plus isomaltulose (n = 15). Data are expressed as means ± SEM. Values not
sharing the same superscript were significantly different between test groups (p < 0.05).
4. Discussion
Previous studies have shown the antihyperglycemic activity of tea in healthy subjects [26,34].
Flavonoids, including catechin and its derivatives, exert effects on the reduction of postprandial
glucose concentration in postmenopausal women [25]. Our findings are consistent with previous
studies that the consumption of green tea together with sucrose reduces postprandial glucose
and insulin concentration. The possible mechanisms of flavonoid-enriched green tea for reducing
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postprandial glucose include the inhibition of α-glucosidase activity, intestinal sodium-glucose
co-transporter-1 (SGLT-1) and glucose transport-2 (GLUT-2) [35–37]. Furthermore, the flavins and
catechins preferentially inhibited maltase rather than sucrose [38]. A recent study also revealed that
epicatechin gallate competitively inhibited the glucose uptake through SGLT-1 [35]. In this connection,
the postprandial glucose-lowering effects of flavonoid-enriched green might be associated with the
inhibitory activity against the α-glucosidase and intestinal glucose transporter. Consistent with
previous studies, replacing sucrose with isomaltulose markedly reduced postprandial plasma glucose
and insulin concentrations in healthy and overweight subjects [13,39]. For example, consumption of
140 g cookies and 250 mL of liquid containing 50 g isomaltulose was found to be more effective
at reducing postprandial plasma glucose and insulin concentration than sucrose in overweight
subjects [39]. The suppression of hyperglycemia might be due to the slow digestion and absorption
rate of isomaltulose in the small intestine [11,12]. When the subjects received isomaltulose plus green
tea, a magnitude reduction of postprandial glucose and insulin concentration was achieved during
the experimental period as compared to isomaltulose. The significant effect was mainly observed
at 15 and 30 min. In addition to the isomerization of sucrose, isomaltulose can be slowly digested
by α-glucosidase (isomaltulase). Its digestive products (glucose and fructose) are absorbed into the
enterocytes by SGLT-1 and GLUT5, respectively. Finally, GLUT2 in enterocytes also aids in the transport
of glucose and fructose into the blood circulation. In light of this, the inhibition of α-glucosidase activity
could explain the interaction between tea catechins and isomaltulose in the gastrointestinal tract. It is
possible that tea catechins might suppress the digestion of isomaltulose by inhibiting isomaltulase
and/or slower absorption of the liberated glucose and fructose. Impaired digestion and/or absorption
results in the reduced peak of postprandial glucose and insulin concentration.
The consumption of antioxidant-containing foods has been implicated to play a possible role in the
prevention of chronic and age-related diseases [40]. Antioxidants reduce free radical-induced damage
to protein, lipid and DNA, thus leading to the prevention of oxidative injury [41]. An increase in plasma
FRAP level reflects the dietary intake of antioxidants and indicates the level of antioxidants in blood
circulation [32]. Malondialdehyde (MDA) is commonly used as a marker of lipid peroxidation. In blood
circulation, the accumulation of MDA contributes to modifying the structure of low-density lipoprotein
(LDL), one of the main initiators of atherogenesis [42]. In the present study, the consumption of green
tea increased plasma FRAP level concomitant with the reduction of plasma MDA concentration.
Similar findings have been reported in other human studies. In a crossover study with 10 healthy
subjects, green tea resulted in a 4% increase in FRAP after 40 min of consumption [43]. A greater
increase in plasma FRAP was observed between 30 and 60 min after healthy volunteers drank green
tea (2 g tea solids in 300 mL water) [44]. The decrease in plasma MDA concentration was seen
after the consumption of green tea [45,46]. This is in accordance with previous studies in that the
consumption of green tea resulted in a significant rise in plasma antioxidant activity associated with
an increase in the concentration of plasma catechins [40]. Several studies support that tea catechins
demonstrated antioxidant activity by scavenging free radicals and chelating redox-active transition
metal ions [21,23,47]. Previous studies provided the FRAP value of tea catechins, and the order was as
follows: ECG > EGCG ≈ GCG > GC ≈ EGC > C ≈ EC [48]. Furthermore, tea catechins prevented lipid
peroxidation both in in vitro and in vivo models [22,23,49]. The acute rise of plasma FRAP, together
with the reduction of the plasma MDA concentration, may be related in part to the presence of tea
catechins. When sucrose was added to green tea, an increase in plasma FRAP level and a reduction of
plasma MDA concentration were attenuated. In contrast to sucrose, isomaltulose did not impact the
alteration of plasma FRAP and MDA concentration. The mechanisms by which sucrose interferes with
plasma FRAP and MDA concentrations remain unclear. It is possible that sucrose remaining within the
intestinal lumen may serve to interfere with the absorption of catechin and its derivatives in association
with the reduction of the plasma FRAP level. A model of (−)-epicatechin gallate (ECG) absorption in
the enterocyte has been recently proposed. ECG is actively absorbed across the apical membrane by
monocarboxylate transporter-1 (MCT-1) [50]. Moreover, the uptake of ECG was sodium independent
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and pH gradient dependent. The interaction between sucrose and MCT-1 could occur in the gut; this
phenomenon may be of major importance in achieving a significant reduction of the tea catechins’
uptake into blood circulation. Additional experiments are required to determine the effect of sucrose
and isomaltulose regarding the absorption of tea catechins in intestinal cell models. Several studies
provide a correlation between the intake of the dietary total antioxidant capacity and the incidence of
chronic diseases and mortality. Cohort studies investigated the inverse associations between dietary
total antioxidant capacity (TAC) and stroke and myocardial infraction [51], reporting that a diet high in
TAC, as measured by the Trolox equivalent antioxidant capacity (TEAC) and FRAP, has been inversely
associated with pancreatic cancer risk [52]. Additionally, FRAP dietary equivalent intake was inversely
associated with mortality from cancer and cardiovascular diseases [53]. The sustained elevation of
total antioxidant status has been associated with the lower incidence of cardiovascular diseases (CVDs)
in populations who regularly consumed red wine [54]. Consumption of green tea together with
sucrose should be raised as a concern. Although drinking green tea together with sucrose suppressed
a rise in postprandial plasma glucose concentration, it also caused the lower antioxidant capacity
of plasma. This evidence may be a limitation regarding the inability to reach the sustained level
of total antioxidant capacity for chronic disease prevention. The beneficial effects of green tea can
sustain plasma antioxidant capacity concomitant with the suppression of postprandial glucose when
consumed with isomaltulose. A limitation of this study is the small number of subjects enrolled. As the
participants were healthy, there is a lack of an outcome associated with the alteration of antioxidant
status after the intake of green tea together with sucrose or isomaltulose.
5. Conclusions
The consumption of green tea enhances the reduction of postprandial glucose and insulin
concentration when the subjects consumed it with isomaltulose. Replacing sucrose with isomaltulose
in green tea improves the plasma antioxidant capacity, as measured by the level of FRAP and the
concentration of MDA. The evaluation of the long-term effects of green tea and isomaltulose deserves
further attention.
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Abstract: The neuroprotective role of phenolic acids from food has previously been reported by many
authors. In this review, the role of phenolic acids in ameliorating depression, ischemia/reperfusion
injury, neuroinflammation, apoptosis, glutamate-induced toxicity, epilepsy, imbalance after traumatic
brain injury, hyperinsulinemia-induced memory impairment, hearing and vision disturbances,
Parkinson’s disease, Huntington’s disease, anti-amyotrophic lateral sclerosis, Chagas disease and
other less distributed diseases is discussed. This review covers the in vitro, ex vivo and in vivo
studies concerning the prevention and treatment of neurological disorders (on the biochemical and
gene expression levels) by phenolic acids.
Keywords: cinnamic acids; benzoic acids; polyphenols; neuroprotection; neuroinflammation; central
nervous system; neuron; glial cell; neurological disorder
1. Introduction
Phenolic acids are one of the main classes of polyphenols. They are abundantly present in foods
such as berries [1], nuts [2], coffee and tea [3] and whole grains [4]. Importantly, a recent meta-analysis
showed that phenolic acid-rich foods decrease the risk of depression [5,6]. Figure 1 presents the
chemical structures of phenolic acids discussed in this work. Previously, authors focused mainly on
the antioxidant and antiradical activities of phenolic acids. However, in recent years, the interest in
protecting neurons and glial cells by phenolic acids has considerably increased, and a great number of
works elaborating the neuroprotective role of phenolic acids has been published. Changes in the central
nervous system, as well as in the peripheral parts of the nervous system, including sense organs, affect
the patient’s behavior and quality of life. Recently, we published a review paper on the anti-Alzheimer
and cognition-enhancing role of phenolic acids originating from food [7]. In the following (Table 1),
we present a review collating original papers concerning many other and previously omitted aspects
of the neuroprotective role of phenolic acids originating from food. The presented review serves as
assistance for quick access to the most prominent neuroprotective actions of phenolic acids.
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Figure 1. Chemical structures of phenolic acids discussed in this work.
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2. Neuroprotective Activities of Phenolic Acids
Table 1. Summary of the neuroprotective activities of phenolic acids.
Ferulic Acid Antidepressant-like Effect:
• reduction of the immobility in TST and FST; increased MAO levels in the hippocampus and frontal
cortex, serotonin and norepinephrine levels in the hypothalamus; inhibition of MAO-A activity in
the hippocampus and frontal cortex in mice (ferulic acid at 0.01, 0.1, 1 and 10 mg/kg/day, p.o.) [8]
or 20 and 40 mg/kg b.w., p.o.) [9];
• improvement of TST and FST scores without affecting locomotor activity; amelioration of SOD, CAT
in the blood and cerebral cortex, amelioration of GPx in the cerebral cortex; decrease of thiobarbituric
acid-reactive substances’ levels in the blood, hippocampus and cerebral cortex in mice [10];
• reversion of the TST and FST scores, significant alleviation of CUMS-induced depressive-like
behaviors in sucrose preference test and FST, significant upregulation of the BDNF, postsynaptic
density protein (PSD95) and synapsin I levels in the prefrontal cortex and hippocampus in male
Imprinting Control Region mice (ferulic acid intravenously injected, 100 mg/kg b.w.) [11].
Protection from Ischemia/Reperfusion Injury:
• promotion of EPO synthesis (increased EPO expression) in the hippocampus and the peripheral
blood of male Sprague–Dawley rats after the occlusion of the right middle cerebral artery and
reperfusion after 90 min [12];
• downregulation of the MEK/ERK/p90RSK signaling pathway in focal cerebral ischemic injury by
the prevention of middle cerebral artery occlusion-induced injury leading to decreased
phosphorylation of RAF proto-oncogene serine/threonine-protein kinase, MEK1/2 (dual specificity
kinase) and ERK1/2; attenuation of the injury-induced decrease in p90RSK and BAD
phosphorylation levels (ferulic acid at 100 mg/kg b.w.) [13];
• amelioration of neurological deficits and increased EPO expression in the hippocampus and the
peripheral blood of male Sprague–Dawley rats (induced by focal cerebral ischemia provoked by
occlusion of the right middle cerebral artery and reperfusion) [12];
• improvement of the neuroprotective activity of puerarin and astragaloside after the transient middle
cerebral artery occlusion by reducing neurological deficits, decreased infarct volume and decreased
expression levels of IL-1β and neuropeptide Y (single dose of ferulic acid, 43 mg/kg b.w., p.o.) [14].
Antinociceptive Effects:
• amelioration of the descending monoaminergic system coupled with spinal β2- and
5-hydroxytryptamine 1A receptors and the downstream of δ- and mu-opioid receptors in an animal
model involving CCI-induced neuropathic pain (amelioration of mechanical allodynia and thermal
hyperalgesia, elevation of spinal noradrenaline and serotonin 5-hydroxytryptamine receptors,
reduction of spinal MAO-A levels) (treatment with ferulic acid at 20, 40 and 80 mg/kg b.w., p.o.) [15].
PD:
• attenuation of CCI-induced neuropathic pain (in the left sciatic nerve) in rats due to increased
antioxidant and anti-inflammatory activity; decreased nociceptive thresholds, thermal hyperalgesia,
mechanical hyperalgesia, tactile allodynia; reduced biochemical markers: total protein, NO, lipid
peroxidase, IL-1β, and IL-6 (10, 20 or 30 mg/kg b.w., p.o.) [16]; dose-dependent amelioration of
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced loss of nigrostriatal dopaminergic neurons,
the decrease of the Bax/Bcl2 ratio, reduction of pro-apoptotic protein Bax levels and increased
expression of anti-apoptotic protein Bcl2 in PD C57BI/6 mice model (ferulic acid was given via
injections for 7 days, at a dose of 20, 40 and 80 mg/kg) [17];
• antioxidant and anti-inflammatory activities; rescue of dopamine neurons in substantia nigra pars
compacta area and nerve terminals in the striatum; restored SOD, CAT, glutamate levels; prevented
lipid oxidation; reduced the levels of ionized calcium-binding adapter molecule (Iba-1), GFAP
hyperactivity, pro-inflammatory cytokines; and reduced COX-2 and iNOS activities in the studies
using the rotenone-induced rat model of PD (chronic administration of ferulic acid for 4 weeks at
a dose of 50 mg/kg b.w.) [18].
Inflammation:
• inhibition of the LPS-induced microglial inflammation (without cytotoxicity) by partial targeting of
ERK signaling and attenuation of ERK; significant inhibition of the production of TNF-α, IL-6, IL-1β
and NO; and reduction of mRNA and protein levels of COX-2 and iNOS [19];
• dose-dependent prevention from LPS-induced upregulation of 3′5′-cyclic nucleotide
phosphodiesterase 4B, reversion of the LPS-induced downregulation of CREB and pCREB
(stimulation the cAMP/CREB signaling pathway) in PC12 cells [20].
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TBI:
• attenuation of oxidative stress caused by TBI; restriction of H2O2-induced DNA fragmentation;
downregulation of ROS caused by reduced mRNA gene expression; attenuation of inflammation
and apoptosis; upregulation of BDNF gene expression; downregulation of iNOS, endothelial NOS,
neuronal NOS, COX-2, IL-1β, TNF-α, SOD, as well as apoptosis-related genes (Fas-associated
protein with death domain, Casp-9 and BCL-2) in Neuro-2a cells in vitro [21].
Anti-allergic Effect:
• restoration of Th1/Th2 balance by modulation of dendritic cell function; reduction of
ovalbumin-specific immunoglobulin E and elevation of the immunoglobulin G2 antibody serum
levels; inhibition of the production of eotaxin, Th2 cytokines (IL-4, IL-5 and IL-13) and
proinflammatory cytokines; elevated production of Th1, interferon-γ in bronchoalveolar lavage fluid
and the culture supernatant of spleen cells; reduced expression of proinflammatory cytokines IL-1β,
IL-6 and TNF-α; increased expression of Notch ligand Delta-like 4 (DII4), MHX class II and CD40
protein; T-cell proliferation and Th1 cell polarization in dendritic cell cultures in an asthmatic mouse
model with ovalbumin-induced Th2-mediated allergic asthma (animals were orally fed with ferulic
acid at 25, 50 and 100 mg/kg b.w.) [22].
Anti-apoptotic Activity:
• inhibition of the p38 MAPK pathway and apoptosis by increasing the cell viability, preventing
membrane damage and increasing the SOD activity; reduced intracellular free Ca2+ ion levels, lipid
peroxidation, Casp-3 and COX-2 activation; reduced PGE2 production; increased scavenging of ROS
in hypoxia-stressed PC12 cells [23];
• protection against 2′-azobis(2-amidinopropane) dihydrochloride-induced oxidative stress leading to
the cell survival by elevating CAT and SOD activities, mitochondrial membrane potential, reduced
MDA levels, reduced LDH release from PC12 cells, and accumulation of intracellular Ca2+ levels in
PC12 cells [24].
Caffeic Acid Inflammation:
• antioxidant and anti-inflammatory activity, reduction (in a dose-dependent manner) of the cytokine
levels in serum and whole brain in the LPS-induced model of inflammation in mice (caffeic acid
administered orally at 30 mg/kg b.w.) [25].
PD:
• inhibition (in a dose-dependent manner) of α-synuclein fibrillation in the presence of
escitalopram [26].
Glutamate-induced Toxicity:
• in vitro neuroprotection activity of SH-SY5Y cells by caffeic acid derivatives from Arctium lappa
roots: 1,5-O-dicaffeoyl-3-O-(4-malic acid methyl ester)-quinic acid, 3,5-O-dicaffeoyl-quinic acid
methyl ester, 3,4-O-dicaffeoyl-quinic acid methyl ester, 4,5-O-dicaffeoyl-quinic acid methyl ester,
(2E)-1,4-dimethyl-2-[(4-hydroxyphenyl)methyl]-2-butenedioic acid, chlorogenic acid methyl ester,
caffeic acid methyl ester, 3,4,3′,4′-tetrahydroxy-δ-truxinate [27].
Anti-epileptic Activity:
• reduction of the levels of free radicals and DNA damage in the kindling CF-1 male mice model of
epilepsy induced by PTZ (caffeic acid at 1, 4 or 8 mg/kg b.w., i.p.) [28];
• reduction of the latency to sleep in the diazepam-induced sleeping time test, decreased
pilocarpine-induced genotoxic damage in acute seizure models in mice (caffeic acid at
4 or 8 mg/kg b.w., i.p.) [29].
Memory Impairment in Hyperinsulinemia:
• high-fat diet-induced hyperinsulinemic rats: amelioration of glucose uptake and cell viability,
improvement of memory impairment and brain glucose metabolism via significant reduction of
plasma glucose and insulin levels, amelioration of the cerebral insulin and leptin signaling pathways
(insulin receptor, phosphatidylinositol-3-kinase, protein kinase B, and insulin-degrading enzyme,
leptin receptor and phosphorylated Janus tyrosine kinase 2 Tyr813/Janus tyrosine kinase 2 in the





• protection of brain tissue against ionizing radiation-induced oxidative damage by amelioration of
the SOD activity in brains of male albino Sprague–Dawley rats (10 μmol ester/kg b.w./day, i.p.,
for 10 days after irradiation) [31];
• amelioration of the redox-balancing activity, positive modulation of the transcription-factor,
stimulation of Nrf2, inhibition of NF-κB activity, as well as signal transducer and activator of
transcription 3 (STAT3) [32];
• attenuation of the ifosfamide-induced central neurotoxicity in Wistar rats (after intraperitoneal
injection) by attenuating the increase in MDA and protein carbonyl content in brain tissue
(10 μmol ester/kg b.w., i.p.) [33,34].
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Anti-apoptotic Activity:
• protection of PC12 cells from the cellular death induced by neurotoxin methyl-4-phenylpyridinium
by increasing the neurite network (promotion of the formation, elongation and ramification;
inhibition of the shortage of neurites); increasing the expression of neuron-typical proteins
responsible for axonal growth (growth-associated protein 43) and synaptogenesis (synaptophysin
and synapsin I) [35];
• reduction of the incidents of volatile anesthetic sevoflurane-induced neurodegeneration
(neurotoxicity in neonatal rats) and apoptosis by activation of the phosphatidylinositide
3-kinase/protein kinase B signaling pathway, downregulation of the expression of Bax and BAD,
upregulation of Bcl-2 and Bcl-extra-large levels and modification of the expression of MAPK levels
(rat pups were administered with ester at 10, 20 or 40 mg/kg b.w. from postnatal Days 1–15) [36].
Inflammation:
• significant inhibition of the expressions of NOS, COX-2 and the production of NO; increased
expression of heme oxygenase-1 and EPO in microglia in in vitro tests [37].
Anticancer Activity:
• reduction of NO, intracellular Ca2+ levels, and CAT activity in C6 glioma cells when combined with
Dasatinib (Bcr-abl tyrosine kinase inhibitor), in comparison to Dasatinib applied alone [38].
Huntington Disease:
• reduction of striatal damage, immunoreactivity to glial GFAP and lymphocyte common antigen
(CD45) (markers of astrocyte and microglia activation); reduced behavioral deficits tested on the
rotarod in the chemical model of Huntington disease (male C57BL/6 mice); reduced mortality of
cultured striatal neurons of male C57BL/6 mice after the induction of the inflammation by 3NP [39].
Chlorogenic
Acid
Reversing of the Glutamate-induced Toxicity:
• inhibition of the glutamate-induced increase of intracellular Ca2+ concentrations, as well as
glutamate-induced death of primary cells isolated from mouse cortical neurons (cerebral cortex) [40].
Inflammation:
• attenuation of herpes simplex virus-1-induced inflammation in BV2 microglia, improving cell
viability and increasing (at the mRNA and protein levels) Toll-like receptor 2, Toll-like receptor 9 and
myeloid differentiation factor 88; significant inhibition of mRNA concentration, NF-κB p65
expression and TNF-α and IL-6 levels in microglia [41].
Antidepressant Effect:
• stimulation of axon and dendrite growth, promotion of serotonin release through enhancing
synapsin I expression (via 5-hydroxytryptamine receptors) in the cells of fetal raphe neurons
in vitro [42].
Antioxidant Activity:
• amelioration of the decrease of MDA and ROS levels in rat cortical slices after the H2O2-induced
oxidative stress [43].
Anti-epileptic:
• reduction of the pilocarpine-induced epilepsy (seizures) in mice by reducing the lipid peroxidation
and nitrite content, as well as the mRNA expressions of N-methyl-D-aspartate receptor,
metabotropic glutamate receptor 1 and metabotropic glutamate receptor 5 (chlorogenic acid
administered at 5 mg/kg b.w., p.o.) [44].
Anti-apoptotic:
• dose-dependent increase of cell viability, cell distribution ratio at the G2/M and S phases; promotion
of cell differentiation by preventing ethanol-induced apoptosis in rat PC12 cells by enhancing the
expression of growth-associated protein-43 (GAP-43); inhibition of the mitochondrial apoptotic
pathway by promoting mitochondria transmembrane potential, upregulation of the expression of




Reversing of the Glutamate-induced Toxicity:
• protection from nitroprusside-induced NO generation (chlorogenic and caffeic acids), significant
reduction of excitotoxicity (ferulic and caffeic acids), protection against H2O2-induced proteasome
inhibition and caspase-dependent intrinsic apoptosis, as well as endoplasmic reticulum stress
(caffeic acid) in primary cultures of rat cerebellar granule neurons [46].
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• induction/activation of the nuclear factor erythroid 2-related factor 2-antioxidant-responsive
element (Nrf2-ARE) signaling pathway and potentiation of the Nrf2/HO-1 signaling pathway
leading to the enhanced endogenous antioxidant defense (decreased superoxide production,
reduced expression of 4-hydroxynonenal and upregulation of SOD) in a rat model of noise-induced
superoxide production and overexpression of the lipid peroxidation marker 4-hydroxynonenal
(rosmarinic acid administered at 10 mg/kg b.w., i.p.) [47];
• protection against the iron-induced neurotoxicity in neuroblastoma SK-N-SH cells [48];
• prevention of the progression of oxidative stress caused by H2O2 in C6 glial cells by increasing the
cell viability and inhibiting the cellular lipid peroxidation, reduction of H2O2-induced expression of
inducible iNOS and COX-2 at the transcriptional level, downregulation of iNOS and COX-2 protein
expression in H2O2-induced C6 glial cells [49];
• antioxidant effect, inhibition of MAO-A and MAO-B and catechol-O-methyl transferase (COMT)
with no cytotoxicity on polymorphonuclear rat cells [50];
• enhancing the antioxidant status, decreasing the oxidative stress, efficiently ameliorating
inflammatory mechanisms by downregulation of NF-κB and pro-inflammatory cytokines after
spinal cord injury in Wistar rats (rosmarinic acid administered at 10 mg/kg b.w., i.p.) [51].
Anti-epileptic Activity:
• increasing the latency and decreasing the percentage of seizure incidents, reducing the levels of free
radicals and DNA damage in the kindling CF-1 male mice model of epilepsy induced by PTZ
(rosmarinic acid at 1, 2 or 4 mg/kg b.w., i.p.) [28];
• attenuation of seizures, mitigation of the oxidative stress, augmentation of the activity of defensive
systems, reduction of MDA and nitrite content and increase of CAT activity; prevention of the
hippocampal neuronal loss in CA1 and CA3 regions and mossy fiber sprouting in the kainite model
of temporal lobe epilepsy in rats (rosmarinic acid administered at 10 mg/kg b.w./d, i.p.) [52];
• acute anticonvulsant-like activity against seizures via increased latency to myoclonic jerks and
generalized seizure durations in the C57BL/6 female mouse model with PTZ-induced epilepsy
(rosmarinic acid at 3 or 30 mg/kg b.w., p.o., for 14 days) [53];
• improvement (in combination with diazepam) of the latency to first seizures, reduction of the latency
to sleep in the diazepam-induced sleeping time test in a model of PTZ-induced seizures in mice,
decreased pilocarpine-induced genotoxic damage in a mice acute seizure model (rosmarinic acid at
2 or 4 mg/kg b.w., i.p.) [29].
Huntington Disease
• improvement of the behavioral abnormalities and attenuation of the oxidative stress in 3NP-treated
rats (an animal model of Huntington disease) (rosmarinic acid at 12 mg/kg b.w., nasal delivery) [54].
Antidepressant Effect:
• downregulation of mitogen-activated protein kinase phosphatase-1, upregulation of BDNF and
modulation of dopamine and corticosterone synthesis in TST in a model of depression in mice
with bupropion as a positive control (rosmarinic acid administered for 7 days at 5 and
10 mg/kg b.w./day) [55].
Anti-tauopathy Activity:
• counteracting the stress-induced tauopathy by efficient suppression of the elevation of P-tau and
insoluble P-tau formation, reversion of the abnormal changes of chaperones and peptidyl-prolyl
cis/trans isomerase (Pin1) in middle-aged mice with induced chronic restraint stress [56].
Long-term Potentiation:
• enhancement of baseline field excitatory postsynaptic potentials (fEPSPs) following high-frequency
stimulation in CA1 synapses, increase of the expression of BDNF and ionotropic AMPA glutamate
receptor 2 (GluR-2) proteins and prevention of cell death in scopolamine-exposed organotypic
hippocampal slice cultures [57].
Anticancer Activity:
• dose-dependent suppression of cell proliferation and cytotoxic effect on glioblastoma cells without
antioxidant effect (at 171.3–290.5 μmol/L), but at higher doses, a prooxidant effect was observed,
leading to cell death through necrosis [58].
Inflammation:
• decrease of COX-2, PGE-2, IL-1β, matrix metallopeptidase 2 and NO levels in male Wistar rats that
underwent CCI (rosmarinic acid at 40 mg/kg b.w., i.p., after 7 and 14 days) [59].
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Protection from Ischemia/ Reperfusion Injury:
• decrease of MDA, increase of NRF1 levels and SOD activity, reduction of ischemic fiber degeneration
and Aβ protein expressions in rats’ sciatic nerve segments after abdominal aorta clamping
(p-coumaric acid at 100 mg phenolic acid/kg b.w.) [60];
• decrease of the oxidative damage, focal ischemia and neurological deficit scores in rat brains
subjected to cerebral ischemia (via intraluminal monofilament occlusion model) due to the
antioxidant and antiapoptotic activity (p-coumaric acid at 100 mg phenolic acid/kg b.w.) [61];
• decrease of MDA, hypoxia-inducible factor-1α levels and NF-κB immunopositive neuron number;
increase of NRF1, SOD activity and the number of normal neurons after ischemia-reperfusion injury
of the spinal cord (via infrarenal aorta cross-clamping model) in rats (p-coumaric acid at
100 mg/kg b.w.) [62].
Anticancer Activity:
• cytotoxic effect on neuroblastoma N2a cells by generation of ROS leading to dysfunction of
mitochondrial membrane, the release of cytochrome c, decreased intracellular reduced glutathione,
p53-mediated upregulated accumulation of Casp-8 messenger RNA, accumulation of
microtubule-associated 1A/1B light chain 3B protein (LC3-II) leading to apoptosis and
autophagy [63].
Sinapic Acid PD:
• partial amelioration of negative phenomena in the 6-OHDA-induced hemi-parkinsonian rat:
Improved turning behavior, prevented loss of dopaminergic neurons in substantia nigra pars
compacta, lowered iron reactivity and attenuated MDA and nitrite levels in midbrain homogenate




• reduction of COX-2 protein activity and PGE2 concentrations in frontal cortex and hippocampus;
reversal of selected abnormalities (exploratory behavior, central ambulation and total
ambulation-anxiety behavior, rearing, grooming, immobility period) studied in open field
exploratory behavior test in mid-aged rats after the exposure to CUMS (cinnamic aldehyde at 45 and
90 mg/kg b.w., p.o., for 21 days) [65].
Salicylic Acid Antioxidant Activity:
• sodium salicylate: amelioration of negative alterations in methamphetamine-induced mouse model,
including scavenging of ROS, reversing of the mitochondrial dysfunction and movement
abnormalities, and amelioration of the complex-I activity decrease leading to striatal dopamine
depletion (sodium salicylate at 50 and 100 mg/kg b.w.) [66];
• ex vivo neuroprotective and antioxidant effect in primary cortex neurons isolated from
Sprague–Dawley rat brains after the oxygen stress caused by paclitaxel and cisplatin [67].
Acetylsalicylic
Acid
Inflammation and Antioxidant Activity:
• counteracting the decrease of degenerative changes, decrease of inflammatory reactivity, and the
expression of estrogen receptors (atrophy) in hippocampus caused by
2,3,7,8-tetrachlorodibenzo-p-dioxin (acetylsalicylic acid at 50 mg/kg b.w., p.o., for 21 days) [68];
• reduction of the neuroinflammation markers and oxidative stress markers PGE2, 15-epilipoxin A4,
8-isoprostane and leukotriene B4 concentrations in HIV-1 transgenic rat model associated with
neurocognitive disorders (acetylsalicylic acid at 10 mg/kg/day in drinking water, for 42 days) [69].
Protection from Ischemia/ Reperfusion Injury:
• reduction of the early neurological deterioration in patients with acute ischemic stroke (in
combination with clopidogrel), in comparison to monotherapy (clopidogrel alone), in studies
involving 690 patients aged > 40 years with minor stroke or transient ischemic attack (aspirin at
100 mg/day in combination with clopidogrel at 75 mg/day, in comparison to monotherapy with
aspirin alone at 300 mg/day) [70];
• significant reduction of platelet aggregation and platelet-leukocyte aggregate numbers in patients
after acute ischemic stroke (1124 patients, among which 270 experienced neurological deterioration),
lower incidence of neurological deterioration in patients with pre-stroke concomitant treatment with
phenolic acid (acid at 200 mg/day, p.o.) [71].
Anti-amyotrophic Lateral Sclerosis (ALS) Effect:
• consumption was independently inversely associated with ALS risk, predominately in patients older
than 55 years, as observed in studies involving 729 patients with newly diagnosed ALS and
7390 sex-, age-, residence- and insurance premium-matched controls [72].
Normalization of Brain Function:
• moderate enhancement of rapamycin-mediated inhibition of dendritic cells’ allostimulatory capacity:
reduction of the number of mouse bone marrow-derived immature dendritic cells expressing CD40
protein and major histocompatibility complex class II (MHC II) molecules after the stimulation by
LPS [73].
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Inflammation:
• reduction of iron content in microglial cells by regulating the expression of iron transport proteins:
downregulation of transferring receptor 1, upregulation of ferroportin 1 and ferritin expressions in
microglial cells, partial reversion of LPS-induced disruption of cell iron balance under in vitro
inflammatory conditions by decrease of ferritin, IL-6, TNF-α, hepcidin mRNA contents previously
increased by LPS alone [74].
Chagas Disease:
• protection of the esophageal myenteric neurons from the atrophy caused by Trypanosoma cruzi
without alterations in the esophageal wall and the myenteric neurons in infected mice [75].
TBI:
• upregulation of proteins involved in the neuroprotection of cellular pathways in Sprague–Dawley
rats sustaining TBI, leading to the amelioration of previously provoked alterations in proteome and
glycoproteins (acid at 30 mg/kg, i.p.) [76].
Prevention of Hearing Loss:
• decrease of the progression of the age-related hearing loss, positive retinal microvascular changes,
amelioration of the mean pure tone average hearing threshold (decibels) in the better ear in studies
involving 1262 Australians aged over 70 years with normal cognitive functions after 3 years of




• attenuation of the loss of neurons in zebrafish and mice treated by 6-hydroxydopamine; increased
cell viability, Nrf2-related factor 2 protein expression, upregulation of the expression of antioxidant
enzymes such as heme oxygenase-1, SOD, CAT; decrease of MDA, NF-κB, and iNOS levels; decrease
of LDH release from cells in 6-OHDA-treated PC12 cells (protocatechuic acid in combination with
chrysin) [78];
• protection of brain mitochondrial functions (glycemic control, reduction of oxidative stress markers)
in the heart of streptozotocin-induced diabetic rats (protocatechuic acid at 50 and 100 mg/kg, p.o.,
for 12 weeks) [79].
Cell Proliferation:
• induction of proliferation of RSC96 Schwann cells by phosphorylation of the insulin-like growth
factor-I-mediated phosphatidylinositol 3 kinase/serine-threonine kinase (IGF-IR-PI3K-Akt)
pathway; activation of expression of cell nuclear antigen in a dose-dependent manner; positive
modulation of expressions of cell cycle proteins cyclin D1, E and A and a knockdown of PI3K by
small interfering RNA and inhibition of IGF-IR [80];
• prevention of the reduction of mitochondrial membrane potential along with the increased cell
viability, ameliorated mitochondrial complex I activity, reduction of the release of LDH and ROS
from cells in midbrain dopaminergic neurons injured by 1-methyl-4-phenylpyridinium in
Kun Ming mice [81].
Inflammation:
• inhibition of Toll-like receptor 4-mediated NF-κB and MAPKs signaling pathways and the inhibition
of the LPS-induced production of TNF-α, IL-6 IL-1β and PGE2 in LPS-induced BV2 (C57BL/6)
microglia [82].
PD:
• increase of tyrosine hydroxylase and dopamine receptor D2 and decrease of iNOS expression in
striatum and midbrain of C57BL mice after the induction of PD by
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (protocatechuic acid at a dose of 10 mg/kg in
combination with Madopar at 125 mg/kg, i.p., for 7 days) [83].
Inflammation:
• induction of the expressions of MAPK (ERK1/2, JNK and p38) followed by the activation of
downstream expressions of matrix-degrading proteolytic enzymes Pas, matrix metallopeptidase 2,
and matrix metallopeptidase 9 in RSC96 Schwann cells, which modified the cell migration and the
regeneration of damaged peripheral nerve [84].
Gallic Acid Antioxidant Activity:
• amelioration of the intracerebroventricular streptozotocin-induced oxidative damage by
normalization of thiobarbituric acid-reactive substances and total thiol contents, as well as GPx,
CAT and SOD activities in the rat striatum (gallic acid at 30 mg/kg, p.o., for 26 days) [85];
• amelioration of antioxidative enzymes in the development of depression (gallic acid at 0.8, 2 and
4 mg/kg b.w., p.o., for 10 days) [86].
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Traumatic Nerve Injury:
• dose-dependent improvement during the peripheral nerve degeneration (amelioration of the
motor coordination and sciatic nerve crush velocity) in rats with sciatic nerve crush (gallic acid at
200 mg/kg/2 mL, p.o.) [87].
Antidepressant Effect:
• amelioration of the anxiety and depression (tested in TST, elevated plus maze and novelty
suppressed feeding test), reduction of the cell densities in the CA1, CA2, CA3 and DG
hippocampal subdivisions after the administration of trimethyltin to Sprague–Dawley rats
(gallic acid at 150 mg/kg b.w., i.p., for 14 days) [88].
Cytotoxicity:
• reversion of the cyclophosphamide-induced neurotoxicity in Wistar rats by restoration of normal
levels of cerebellar and cerebral CAT, SOD, MDA, glutathione S-transferase, H2O2, GPx and nitrite
levels (gallic acid at 60 and 120 mg/kg b.w., p.o., for 10 days) [89].
Anticancer Activity:
• dose-dependent cytotoxicity in DBTRG-05MG human brain glioblastoma cells by the elevation of
intracellular Ca2+ levels in cells, increase of intracellular Ca2+ levels in combination with
thapsigargin, increase of ROS production and activation of mitochondrial apoptotic pathways [90].
Tannic Acid Antioxidant Activity:
• increase of the concentrations of NR2A and NR2B subunits of N-methyl-D-aspartate receptors,
elevation of the activities of antioxidant enzymes, decrease of lipid peroxidation in the brain
hippocampus in Wistar rats after 16-weeks exposure of animals to Al3+ and Pb2+ (tannic acid at
50 mg/kg b.w./day; a nasogastric probe was used) [91];
• counteracting against Pb2+-induced neurochemical perturbations in Wistar rats including the
reduction of oxygen radical species levels and enzymatic oxidants; amelioration of the activity of
non-enzymatic antioxidants, neurotoxicity biomarkers and histological changes (tannic acid at
50 mg/kg b.w., three times a week, for two weeks) [92].
Protection from Ischemia/reperfusion Injury:
• reduction of ROS and MDA levels, elevation of SOD and NRF1 levels in brain tissues in rats with
brain ischemia after middle cerebral artery occlusion induced by ethanol given intraperitoneally
(tannic acid at a dose of 10 mg/kg b.w. dissolved in 10% ethanol administered within half an hour
intraperitoneally) [93];
• reduction of infarct size, improved neurological function, suppressed neuronal loss, downregulation
of the GFAP expression, reduction of thiobarbituric acid reactive species and cytokine levels in
Wistar rats after the middle cerebral artery occlusion followed by reperfusion (tannic acid at




• reduction of depressive symptoms in a 4-week, double-blind, randomized, placebo-controlled study
involving 22 men and 25 women, due to the improvement of the peripheral dopaminergic activity
and increased (by 11.5%) homovanillic acid concentration in plasma of overweight or obese patients
with depressive symptoms (after the co-supplementation with 1.4 g cocoa extract/day
corresponding to 645 mg total polyphenols/day) [95];
• the lower number of suicide incidents in patients with schizophrenia and elevated homovanillic acid
levels in cerebrospinal fluid (28-year follow-up studies) [96].
Psychotic Disorders:
• normalization of the disturbed dopaminergic activity in patients with psychotic spectrum disorders,
especially schizophrenia, by partially taking over the functions in dopaminergic metabolism in the
central nervous system [97].
Syringic Acid Protection from Ischemia/reperfusion Injury:
• elevation of SOD activity, NRF-1 levels; reduced MDA, Casp-3 and Casp-9 levels leading to the
reduced oxidative stress and neuronal degeneration in Sprague–Dawley rat brain tissues after
cerebral ischemia caused by artery occlusion (syringic acid at 10 mg/kg b.w., i.p.) [98];
• reduction of the oxidative stress and neuronal degeneration by reduction of the number of apoptotic
neurons, beclin-1 protein and Casp-3-immunopositive neurons in spinal cords of Sprague–Dawley
rats with spinal cord ischemia (infrarenal aortic cross-clamping model) (syringic acid at
10 mg/kg b.w., i.p.) [99].
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Vision:
• prevention of retinal ganglion cells RGC-5 from H2O2-induced apoptosis through the activation of
phosphatidylinositol 3-kinase/protein kinase B signaling pathway, elevated expression of the Bcl-2
regulator proteins, decrease of the expression of Bax and cleaved Casp-3 protein [100].
Protection during Oxygen Deprivation/Reperfusion Injury:
• attenuation of the injury of primary hippocampal neuronal cells by the decrease of the following:
LDH leakage from cells, Bax and Casp-3 expressions, the levels of intracellular MDA, ROS, and Ca2+;
inhibition of oxygen deprivation/reperfusion-induced increase in phosphorylated JNK and p-p38
expression; increased cell viability, restoring the intracellular SOD, mitochondrial membrane
potential, and Bcl-2 expression [101].
Ellagic Acid Anticancer Activity:
• reduction of the number of human neuroblastoma SH-SY5Y cells by alterations of the mitochondrial
membrane potential, activation of Casp-3, Casp-9, fragmentation of DNA, and dose- and
time-dependent cell apoptosis by the mitochondrial pathway [102,103];
• decrease of cell proliferation, cell viability, decrease of the proportion at G0/G1 phase of the cell
cycle together with increased cell population at S phase; upregulation of Death receptor 4, Death
receptor 5, and MAP kinases (JNK, ERK1/2, and p38), as well as CCAAT-enhancer-binding
homologous protein (CHOP) and glucose-regulated protein 78 (GRP78) expressions leading to the
severe apoptosis in U251 human glioblastoma cells [104].
PD:
• restoration of the locomotion, reduction of the levels of neuroinflammatory biomarkers TNF-α and
IL-1β in the striatum and in hippocampus of a rat model of PD induced by 6-OHDA (right medial
forebrain bundle-lesioned rats) (ellagic acid at 50 mg/kg b.w./2 mL, by gavages) [105];
• amelioration of the rotenone-induced locomotor impairment in zebrafish (adult zebrafish exposed to
ellagic acid at 20 or 40 mg/kg b.w. in combination with curcumin at 20 or 40 mg/kg b.w., i.m.,
for 14 days) and Drosophila melanogaster (adult wild-Type flies exposed to ellagic acid at 0.05% and
0.1% in combination with curcumin at 0.05% and 0.1%, in feed for 7 days) (swimming behavior and
poorer climbing capability, respectively) [106].
Amnesia:
• reversion of the scopolamine-induced amnesia verified in the elevated plus maze and passive
avoidance paradigm tests, improvement of amnesia caused by diazepam in rats (ellagic acid at 30 or
100 mg/kg b.w., i.p.) [107].
Inflammation:
• downregulation of the p38 mitogen-activated protein kinase (p38 MAPK), amelioration of the
inflammatory pain including acetic acid-induced nociception, formalin-induced nociception,
and paclitaxel-induced neuropathic pain in the murine model (ellagic acid at 50 mg/kg b.w./2 mL
of saline, administered as a bolus into the subcutis for 5 days) [108].
Protection from the Ischemic Injury:
• reduction of the infarct size, weight, and volume of the brain; reduced apoptosis by reduced levels
of caspases, apoptotic pathway proteins, MAPK proteins, and inflammatory mediators
NF-κB (p65) and p-IK-Ba in hypoxic-ischemic brains of rat pups (ellagic acid at 10, 20 or
40 mg/kg b.w., p.o.) [109].
Protection during OxygenDeprivation/Reperfusion Injury:
• improvement of the rats’ nerve-related abilities, remedied infarct volumes and morphological
changes in the brain enhanced content of nestin protein in the brain semi-darkness zone in a
photothrombosis-induced model of brain injury in rats; elevation of β-catenin expression and
cyclin D1 gene expression in an oxygen-glucose deprivation and reperfusion model established in
in vitro primary cultured neural stem cells [110].
3. Penetration of Brain by Phenolic Acids
Previously, it has been estimated that the daily consumption of phenolic acids is noticeable
and totals ≈200 mg [111,112]. Moreover, the pharmacokinetic properties of phenolic acids are
excellent. Bourne and Rice-Evans (1998) showed that the peak concentration of ferulic acid in
plasma occurred 7–9 h after the consumption of tomatoes (360–640 g), with the recovery of the
phenolic acid reaching 11–25% of the amount consumed [113]. Recently, a cross-sectional analysis
of the consumption of polyphenols (involving 10 European countries and over half a million
participants) revealed that the total amount of these secondary plant metabolites was high (744 mg/day
in men and 584 mg/day in women in Greece to 1786 mg/day in men and 1626 mg/day in
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women in Denmark). Among polyphenols, phenolic acids represented the largest part (52.5–56.9%
in women and men, respectively) in the diets of all groups, with the exception of men in the
Mediterranean countries and “health-conscious” consumers in the United Kingdom (predominantly
vegetarians). However, in the Mediterranean countries and in the “health-conscious” group in
the U.K., phenolic acids were the second most distributed polyphenols (34–44%). Generally,
hydroxycinnamic acids (ranging from 27% in women from the “health-conscious” group in the
U.K. to 53% in men from non- Mediterranean countries) were the most important contributors
to total polyphenols in the diet. The most important dietary source of phenolic acids in all
studied European countries was coffee (58–75%), and the most distributed phenolic acids were
caffeoylquinic acids (mainly 5-caffeoylquinic, 4-caffeoylquinic and 3-caffeoylquinic acid), followed by
feruloylquinic, gallic, galloylquinic, 4-hydroxyphenylacetic, homovanillic, 3,4-dihydroxyphenylacetic
and dihydro-p-coumaric acids [114]. Other major research papers have confirmed the high dietary
intake of phenolic acids. Tresserra-Rimbau et al. (2013) calculated that the mean consumption
of phenolic acids in a group of 7200 participants was 304 ± 156 mg/day (a parallel-group, aged
55–80 years; a validated one-year food frequency questionnaire in a multicenter, randomized,
controlled five-year feeding trial). Phenolic acids were the main polyphenolics consumed (33% of all
polyphenols), and 5-caffeoylquinic acid was the most abundant individual polyphenolic compound.
Other phenolic acids broadly consumed were: 3-caffeoylquinic acid (49.75 ± 34.18 mg/day),
4-caffeoylquinic acid (42.60 ± 31.79 mg/day), ferulic acid (14.32 ± 14.35 mg/day), 5-feruloylquinic acid
7.24 ± 5.56 (mg/day), 4-feruloylquinic acid (6.17 ± 4.81 mg/day), syringic acid (4.82 ± 4.76 mg/day)
and verbascoside (4.61 ± 7.00 mg/day) [115]. Grosso et al. (2014), in a study involving 10,477 persons
aged 45–69 years (a validated 148-item food frequency questionnaire), estimated the daily intake of
phenolic acids at 800 mg (521 mg/day as aglycone equivalents, 46% of total intake of polyphenols).
The main phenolic acids were 5-caffeoylquinic and 4-caffeoylquinic acids (with average intake at
150 mg/day), followed by 3-caffeoylquinic acid (128.2 ± 111.6 mg/day), 5-O-galloylquinic acid
(60.8 ± 45.4 mg/day), ferulic acid (43.9 ± 33.7 mg/day), stigmastanol ferulate (37.5 ± 22.6 mg/day),
5-feruloylquinic acid (27.9 ± 14.3 mg/day), gallic acid 25.0 ± 11.2 mg/day) and 4-feruloylquinic acid
(20.4 ± 12 mg/day) [116].
The experimental data collated in Table 1 prove the positive role of phenolic acids in an indirect
manner. The amount of phenolic acids administered to experimental animals in feed is known, but the
authors did not study the content of phenolic acids in the brain. Therefore, the activity of phenolic
acids in brains (on the biochemical and gene expression levels, amelioration of the enzyme activity
changes) was discussed only by comparison with reference groups of animals fed with a standard diet.
Although it is assumed that the transfer of polyphenols through the blood-brain barrier is limited,
a considerable number of original papers confirm the presence of absorbed phenolic acid compounds in
the brain. Phenolic acids can be accumulated in the brain at pharmacologically-relevant, nanomolar or
micromolar concentrations, as described below. Gallic acid has been detected in trace amounts in brains
(mouse model of Alzheimer’s disease) after repeated administration of grape seed polyphenolic extract
for 10 days (intragastric gavage of 50, 100 and 150 mg/kg b.w.) [117]. Protocatechuic acid was detected
in brain micro-dialysates (at maximal concentration of 0.09 ± 0.07 μg/mL, ≈0.58 ± 0.45 nmol/mL)
15 min–4 h after the administration of Danshen extract (Salvia miltiorrhiza, intragastrically, 40 mg/kg
b.w.) to adult, male Sprague-Dawley rats [118]. 3-Hydroxybenzoic, benzoic and homovanillic acids
were detected (at 0.43–1.06 nmol/g, 2.53–15.63 nmol/g and 1.84–2.39 nmol/g, respectively) in extracts
of freeze-dried brain tissues of male Wistar rats orally fed with the grape seed proanthocyanidin
extract (125, 250, 375, 1000 mg extract/kg b.w.). The levels of phenolic acids were dependent on
the dose of the extract [119]. Benzoic acid was the main phenolic acid in brains of Sprague–Dawley
rats that consumed wild blueberry for four and eight weeks. Other minor phenolic acids were also
detected in brains, and the sum of all detected phenolic acids was 69.0 μg/g brain (which can be
estimated for nanomolar concentrations, taking into consideration the molecular masses of the various
phenolic acids) [120]. In another work, 3-hydroxybenzoic and 3-(3′-hydroxyphenyl) propionic acids
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were accumulated at μmol concentrations in perfused brain tissues of rats fed for 11 days with grape
seed polyphenol extract. Both phenolic acids were shown to accumulate in brains in a dose-dependent
manner. Treatment with 250 mg extract/kg b.w./day increased brain contents of 3-hydroxybenzoic
and 3-hydroxyphenylpropionic acid 3.2-fold and 7.7-fold, respectively (in comparison to controls).
Furthermore, hydroxybenzoic, 4-hydroxybenzoic, 3-hydroxyphenylacetic, 3,4-dihydroxyphenylacetic
and 3-hydroxyphenylpropionic acids were detected in brains, but no detectable changes in the content
of these phenolic acids were observed after the treatment with various doses of the extract [121].
Ferulic acid was detected in brains (2.6 μg/g of tissue, ≈13.39 nmol/mL) after the oral administration
to rats (521 μmol acid/kg b.w.), and the concentration of this acid in brains was decreased only by
50% 60 min after the consumption [122]. Other works confirm the penetration of brain by ferulic
acid [123], caffeic acid and caffeic acid phenethyl ester [124] and rosmarinic acid [125]. Ferulic,
caffeic, rosmarinic acids and caffeic acid phenethyl ester can also protect blood-brain barrier and brain
structures [126–129]. Chlorogenic acid was detected in the cerebrospinal fluid of rats that were fed
with chlorogenic acid-enriched Eucommia ulmoides bark extract (200 and 400 mg extract/kg b.w./day,
for seven days). The levels of phenolic acid were ≈0.42–0.56 ng/mL (≈0.0011–0.0015 nmol/mL)
(1 h and 1.5 h after consumption, respectively) [42]. Moreover, degradation of absorbed, more complex
polyphenols from foods yielding simple phenolic acids can be observed, thus increasing the levels
of bioavailable phenolic acids in the brain. For example, cyanidin 3-O-glucopyranoside is degraded
in vivo in SH-SY5Y bone marrow neuroblastoma cells, yielding protocatechuic acid [130]. Taking the
above results into consideration, it can be claimed that phenolic acids can effectively accumulate in
brain achieving the levels required for the pharmacological effect.
A very interesting aspect of the neuroprotective activity of phenolic acids in biological systems
is the activity rather at low and not at high concentrations, as was explicitly stated by some authors.
Caffeic acid dimethyl ether, when used at lower concentrations (15–50 μmol/L), was more efficient than
applied at a higher dose (at 50–100 μmol/L) for the elevation of the expression of heme oxygenase-1
in cultivated astrocytes, leading to the increased concentrations of reduced glutathione in cultured
cells [131]. Similarly, ferulic acid ethyl ester effectively induced heme oxygenase-1 protein expression
in cultivated astrocytes at low (5 μmol/L), but not at high concentrations (15 μmol/L), along with the
maximal expression of mRNA coding for heme oxygenase-1 [132].
4. Concluding Remarks
This review was designed as a compact, comprehensive, content-rich compendium of the latest
reports on the role of phenolic acids in improving neurological dysfunctions by direct positive influence
on neural and glial cells. Especially, the years 2014–2016 were very fruitful in terms of the very in-depth
knowledge about biochemical parameters, new specific markers and gene expression modifications
caused by phenolic acids, involved in the proper functioning of neural and glial cells.
In summary, it can be stated that due to a wide distribution in natural sources, a considerable
daily intake, relatively high stability in foods, as well as high intestinal absorption (in comparison
to more complex polyphenols) and efficient brain absorption, phenolic acids may be considered as
promising compounds for the future combination therapy of neurological disorders.
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BAD Bcl-2-associated death promoter
Bax Bcl-2-like protein 4
BCL B-cell lymphoma
BCL-2 B-cell lymphoma 2
Bcr-Abl fusion between break point cluster (Bcr) gene and the Abelson (Abl) tyrosine kinase gene






CCI Chronic constriction injury
CD40 Cluster of differentiation 40
COX-2 Cyclooxygenase-2
CREB cAMP response element-binding protein
CUMS Chronic unexpected mild stress
EPO Erythropoietin
ERK Extracellular signal-regulated kinase, protein-serine/threonine kinase
ERK1 Extracellular signal-regulated kinase 1, protein-serine/threonine kinase 1
ERK2 Extracellular signal-regulated kinase 2 protein-serine/threonine kinase 2
FST Forced swimming test








iNOS Inducible nitric oxide synthase





MEK Mitogen-activated protein kinase
MHX major histocompatibility complex II molecules
NF-κB Nuclear factor-κB
NO Nitric oxide
NRF1 Nuclear respiratory factor 1
Nrf2 Nuclear factor (erythroid-derived 2)-like 2
Nrf2/HO-1 Nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1
p38 MAP Kinase (MAPK), CSBP Cytokinin-Specific Binding Protein or RK
p90RSK MAPK-activated protein kinase-1 (MAPKAP-K1)






ROS Reactive oxygen species
SOD Superoxide dismutase
TBI Traumatic brain injury
Th1 T helper type 1 (Th1) cells
Th2 T helper type 2 (Th2) cells
TNF-α Tumor necrosis factor-α
TST Tail suspension test
145
Nutrients 2017, 9, 477
References
1. Mattila, P.; Hellström, J.; Törrönen, R. Phenolic acids in berries, fruits, and beverages. J. Agric. Food Chem.
2006, 54, 7193–7199. [CrossRef] [PubMed]
2. Grosso, G.; Estruch, R. Nut consumption and age-related disease. Maturitas 2016, 84, 11–16. [CrossRef]
[PubMed]
3. Crozier, A.; Jaganath, I.B.; Clifford, M.N. Dietary phenolics: Chemistry, bioavailability and effects on health.
Nat. Prod. Rep. 2009, 26, 1001–1043. [CrossRef] [PubMed]
4. Van Hung, P. Phenolic compounds of cereals and their antioxidant capacity. Crit. Rev. Food Sci. Nutr. 2016,
56, 25–35. [CrossRef] [PubMed]
5. Liu, X.; Yan, Y.; Li, F.; Zhang, D. Fruit and vegetable consumption and the risk of depression: A meta-analysis.
Nutrition 2016, 32, 296–302. [CrossRef] [PubMed]
6. Grosso, G.; Micek, A.; Castellano, S.; Pajak, A.; Galvano, F. Coffee, tea, caffeine and risk of depression:
A systematic review and close-response meta-analysis of observational studies. Mol. Nutr. Food Res. 2016, 60,
223–234. [CrossRef] [PubMed]
7. Szwajgier, D.; Baranowska-Wójcik, E.; Borowiec, K. Phenolic acids exert anticholinesterase and
cognition-improving effects. Curr. Alzheimer Res 2017, in press.
8. Li, G.; Ruan, L.; Chen, R.; Wang, R.; Xie, X.; Zhang, M.; Chen, L.; Yan, Q.; Reed, M.; Chen, J.; et al. Synergistic
antidepressant-like effect of ferulic acid in combination with piperine: Involvement of monoaminergic
system. Metab. Brain Dis. 2015, 30, 1505–1514. [CrossRef] [PubMed]
9. Chen, J.; Lin, D.; Zhang, C.; Li, G.; Zhang, N.; Ruan, L.; Yan, Q.; Li, J.; Yu, X.; Xie, X.; et al. Antidepressant-like
effects of ferulic acid: Involvement of serotonergic and norepinergic systems. Metab. Brain Dis. 2015, 30,
129–136. [CrossRef] [PubMed]
10. Lenzi, J.; Rodriguez, A.F.; Rós Ade, S.; de Castro, A.B.; de Lima, D.D.; Magro, D.D.; Zeni, A.L. Ferulic acid
chronic treatment exerts antidepressant-like effect: Role of antioxidant defense system. Metab. Brain Dis.
2015, 30, 1453–1463. [CrossRef] [PubMed]
11. Liu, Y.M.; Hu, C.Y.; Shen, J.D.; Wu, S.H.; Li, Y.C.; Yi, L.T. Elevation of synaptic protein is associated with the
antidepressant-like effects of ferulic acid in a chronic model of depression. Physiol. Behav. 2017, 169, 184–188.
[CrossRef] [PubMed]
12. Zhang, L.; Wang, H.; Wang, T.; Jiang, N.; Yu, P.; Chong, Y.; Fu, F. Ferulic acid ameliorates nerve injury
induced by cerebral ischemia in rats. Exp. Ther. Med. 2015, 9, 972–976. [CrossRef] [PubMed]
13. Koh, P.O. Ferulic acid attenuates the down-regulation of MEK/ERK/p90RSK signaling pathway in focal
cerebral ischemic injury. Neurosci. Lett. 2015, 588, 18–23. [CrossRef] [PubMed]
14. Ge, L.J.; Fan, S.Y.; Yang, J.H.; Wei, Y.; Zhu, Z.H.; Lou, Y.J.; Guo, Y.; Wan, H.T.; Xie, Y.Q. Pharmacokinetic and
pharmacodynamic analysis of ferulic acid-puerarin-astragaloside in combination with neuroprotective in
cerebral ischemia/reperfusion injury in rats. Asian Pac. J. Trop. Med. 2015, 8, 299–304. [CrossRef]
15. Xu, Y.; Lin, D.; Yu, X.; Xie, X.; Wang, L.; Lian, L.; Fei, N.; Chen, J.; Zhu, N.; Wang, G.; et al. The antinociceptive
effects of ferulic acid on neuropathic pain: Involvement of descending monoaminergic system and opioid
receptors. Oncotarget 2016, 7, 20455–20468. [CrossRef] [PubMed]
16. Aswar, M.; Patil, V. Ferulic acid ameliorates chronic constriction injury induced painful neuropathy in rats.
Inflammopharmacology 2016, 24, 181–188. [CrossRef] [PubMed]
17. Nagarajan, S.; Chellappan, D.R.; Chinnaswamy, P.; Thulasingam, S. Ferulic acid pretreatment mitigates
MPTP-induced motor impairment and histopathological alterations in C57BI/6 mice. Pharm. Biol. 2015, 53,
1591–1601. [CrossRef] [PubMed]
18. Ojha, S.; Javed, H.; Azimullah, S.; Khair, S.B.A.; Haque, M.E. Neuroprotective potential of ferulic acid in the
rotenone model of Parkinson’s disease. Drug Des. Devel. Ther. 2015, 9, 5499–5510. [PubMed]
19. Wu, J.L.; Shen, M.M.; Yang, S.X.; Wang, X.; Ma, Z.C. Inhibitory effect of ferulic acid on neuroinflammation in
LPS-activated microglia. Chin. Pharm. Bull. 2015, 31, 97–102.
20. Huang, H.; Hong, Q.; Tan, H.L.; Xiao, C.R.; Gao, Y. Ferulic acid prevents LPS-induced up-regulation of PDE4B
and stimulates the cAMP/CREB signaling pathway in PC12 cells. Acta Pharm. Sin. 2016, 37, 1543–1554.
[CrossRef] [PubMed]
146
Nutrients 2017, 9, 477
21. Dong, G.C.; Kuan, C.Y.; Subramaniam, S.; Zhao, J.Y.; Sivasubramaniam, S.; Chang, H.Y.; Lin, F.H. A potent
inhibition of oxidative stress induced gene expression in neural cells by sustained ferulic acid release from
chitosan based hydrogel. Mat. Sci. Eng. C 2015, 49, 691–699. [CrossRef] [PubMed]
22. Lee, C.C.; Wang, C.C.; Huang, H.M.; Lin, C.L.; Leu, S.J.; Lee, Y.L. Ferulic acid induces Th1 responses by
modulating the function of dendritic cells and ameliorates Th2-mediated allergic airway inflammation in
mice. Evid-Based Compl. Alt. Med. 2015. [CrossRef] [PubMed]
23. Lin, W.C.; Peng, Y.F.; Hou, C.W. Ferulic acid protects PC12 neurons against hypoxia by inhibiting the
p-MAPKs and COX-2 pathways. Iran. J. Basic Med. Sci. 2015, 18, 478–484. [PubMed]
24. Shen, Y.; Zhang, H.; Wang, L.; Qian, H.; Qi, H.; Miao, X.; Cheng, L.; Qi, X. Protective effect of ferulic acid
against 2,2′-azobis(2-amidinopropane) dihydrochloride-induced oxidative stress in PC12 cells. Cell. Mol. Biol.
2016, 62, 109–116. [PubMed]
25. Basu Mallik, S.; Mudgal, J.; Nampoothiri, M.; Hall, S.; Dukie, S.A.; Grant, G.; Rao, C.M.; Arora, D. Caffeic
acid attenuates lipopolysaccharide-induced sickness behavior and neuroinflammation in mice. Neurosci. Lett.
2016, 632, 218–223. [CrossRef] [PubMed]
26. Fazili, N.A.; Naeem, A. Anti-fibrillation potency of caffeic acid against an antidepressant induced
fibrillogenesis of human α-synuclein: Implications for Parkinson’s disease. Biochimie 2015, 108, 178–185.
[CrossRef] [PubMed]
27. Baj, J.P.; Hu, X.L.; Jiang, X.W.; Tian, X.; Zhao, Q.C. Caffeic acids from roots of Arctium lappa and their
neuroprotective activity. Chin. Trad. Herb. Drugs 2015, 46, 163–168.
28. Coelho, V.R.; Vieira, C.G.; de Souza, L.P.; Moysés, F.; Basso, C.; Picada, J.N.; Pereira, P. Antiepileptogenic,
antioxidant and genotoxic evaluation of rosmarinic acid and its metabolite caffeic acid in mice. Life Sci. 2015,
122, 65–71. [CrossRef] [PubMed]
29. Coelho, V.R.; Vieira, C.G.; de Souza, L.P.; da Silva, L.L.; Pflüger, P.; Regner, G.G.; Papke, D.K.; Picada, J.N.;
Pereira, P. Behavioral and genotoxic evaluation of rosmarinic and caffeic acid in acute seizure models induced
by pentylenetetrazole and pilocarpine in mice. Naunyn-Schmiedeberg's Arch. Pharmacol. 2016, 389, 1195–1203.
[CrossRef] [PubMed]
30. Chang, W.C.; Kuo, P.L.; Chen, C.W.; Wu, J.S.B.; Shen, S.C. Caffeic acid improves memory impairment
and brain glucose metabolism via ameliorating cerebral insulin and leptin signaling pathways in high-fat
diet–induced hyperinsulinemic rats. Food Res. Int. 2015, 77, 24–33. [CrossRef]
31. Alkis, H.E.; Kuzhan, A.; Dirier, A.; Tarakcioglu, M.; Demir, E.; Saricicek, E.; Demir, T.; Ahlatci, A.; Demirci, A.;
Cinar, K.; Taysi, S. Neuroprotective effects of propolis and caffeic acid phenethyl ester (CAPE) on the
radiation-injured brain tissue (Neuroprotective effects of propolis and CAPE). Int. J. Radiat. Res. 2015, 13,
297–303.
32. Khan, M.; Baarine, M.; Singh, I. Therapeutic potential of caffeic acid phenethyl ester in neurodegenerative
diseases. In Caffeic Acid: Biological Properties, Structure and Health Effects; Nova Science Publishers: New York,
NY, USA, 2015.
33. Ginis, Z.; Ozturk, G.; Albayrak, A.; Kurt, S.N.; Albayrak, M.; Fadillioglu, E. Protective effects of caffeic acid
phenethyl ester on ifosfamide-induced central neurotoxicity in rats. Toxicol. Ind. Health. 2016, 32, 337–343.
[CrossRef] [PubMed]
34. Akyol, S.; Erdemli, H.K.; Amautou, F.; Akyol, O. In vitro and in vivo neuroprotective effect of caffeic acid
phenethyl ester. J. Intercult. Ethnopharmacol. 2015, 4, 192–193. [CrossRef] [PubMed]
35. Santos, N.A.G.D.; Martins, N.M.; Silva, R.D.B.; Ferreira, R.S.; Sisti, F.M.; dos Santos, A.C. Caffeic acid
phenethyl ester (CAPE) protects PC12 cells from MPP+ toxicity by inducing the expression of neuron-typical
proteins. Neurotoxicology 2014, 45, 131–138. [CrossRef] [PubMed]
36. Wang, L.Y.; Tang, Z.J.; Han, Y.Z. Neuroprotective effects of caffeic acid phenethyl ester against
sevoflurane-induced neuronal degeneration in the hippocampus of neonatal rats involve MAPK and
PI3K/Akt signaling pathways. Mol. Med. Rep. 2016, 14, 3403–3412. [CrossRef] [PubMed]
37. Tsai, C.F.; Kuo, Y.H.; Yeh, W.L.; Wu, C.Y.; Lin, H.Y.; Lai, S.W.; Liu, Y.S.; Wu, L.H.; Lu, J.K.; Lu, D.Y. Regulatory
effects of caffeiccidphenethyl ester on neuroinflammation in microglial cells. Int. J. Mol. Sci. 2015, 16,
5572–5589. [CrossRef] [PubMed]
38. Balkhi, H.M.; Gul, T.; Haq, E. Anti-neoplastic and calcium modulatory action of caffeic acid phenethyl ester
and desatinib in C6 glial cells: A therapeutic perspective. CNS Neurol. Disord. Drug Targets 2016, 15, 54–63.
[CrossRef] [PubMed]
147
Nutrients 2017, 9, 477
39. Bak, J.; Kim, H.J.; Kim, S.Y.; Choi, Y.S. Neuroprotective effect of caffeic acid phenethyl ester in 3-nitropropionic
acid-induced striatal neurotoxicity. Korean J. Physiol. Pharmacol. 2016, 20, 279–286. [CrossRef] [PubMed]
40. Mikami, Y.; Yamazawa, T. Chlorogenic, a polyphenol in coffee, protects neurons against glutamate
neurotoxicity. Life Sci. 2015, 139, 69–74. [CrossRef] [PubMed]
41. Guo, Y.J.; Luo, T.; Wu, F.; Mei, Y.W.; Peng, J.; Liu, H.; Li, H.R.; Zhang, S.L.; Dong, J.H.; Fang, Y.; et al.
Involvement of TLR2 and TLR9 in the anti-inflammatory effects of chlorogenic acid in HSV-1-infected
microglia. Life Sci. 2015, 127, 12–18. [CrossRef] [PubMed]
42. Wu, J.M.; Chen, H.X.; Li, H.; Tang, Y.; Yang, L.; Cao, S.S.; Qin, D.L. Antidepressant potential of chlorogenic
acid-enriched extract from Eucommia ulmoides Oliver bark with neuron protection and promotion of
serotonin release through enhancing synapsin I expression. Molecules 2016, 21. [CrossRef] [PubMed]
43. Gul, Z.; Demircan, C.; Bagdas, D.; Buyukuysal, R.L. Protective effects of chlorogenic acid and its metabolites
on hydrogen peroxide-induced alterations in rat brain slices: a comparative study with resveratrol.
Neurochem. Res. 2016, 41, 2075–2085. [CrossRef] [PubMed]
44. Aseervatham, G.S.B.; Suryakala, U.; Doulethunisha; Sundaram, S.; Bose, P.C.; Sivasudha, T. Expression
pattern of NMDA receptors reveals antiepileptic potential of apigenin 8-Cglucoside and chlorogenic acid in
pilocarpine induced epileptic mice. Biomed. Pharmacother. 2016, 82, 54–64. [CrossRef] [PubMed]
45. Fang, S.Q.; Wang, J.X.; Wei, J.X.; Shu, Y.H.; Xiao, L.; Lu, X.M. Beneficial effects of chlorogenic acid on
alcohol-induced damage in PC12 cells. Biomed. Pharmacother. 2016, 79, 254–262. [CrossRef] [PubMed]
46. Taram, F.; Winter, A.N.; Linseman, D.A. Neuroprotection comparison of chlorogenic acid and its metabolites
against mechanistically distinct cell death-inducing agents in cultured cerebellar granule neurons. Brain Res.
2016, 1648, 69–80. [CrossRef] [PubMed]
47. Fetoni, A.R.; Paciello, F.; Rolesi, R.; Eramo, S.L.; Mancuso, C.; Troiani, D.; Paludetti, G. Rosmarinic acid
up-regulates the noise-activated Nrf2/HO-1 pathway and protects against noise-induced injury in rat
cochlea. Free Radic. Biol. Med. 2015, 85, 269–281. [CrossRef] [PubMed]
48. Qu, L.; Xu, H.M.; Jiang, H.; Hie, J.X. Protective effects of rosmarinic acid against iron-induced neurotoxicity
in SK-N-SH cells. Am. J. Hematol. 2015, 91, E95.
49. Lee, A.Y.; Wu, T.T.; Hwang, B.R.; Lee, J.; Lee, M.H.; Lee, S.; Cho, E.J. The neuro-protective effect of the
methanolic extract of Perillafrutescens var. japonica and rosmarinic acid against H2O2-induced oxidative
stress in C6 glial cells. Biomol. Ther. 2016, 24, 338–345. [CrossRef] [PubMed]
50. Andrade, J.M.D.; Passos, C.D.; Kieling Rubio, M.A.; Mendonça, J.N.; Lopes, N.P.; Henriques, A.T. Combining
in vitro and in silico approaches to evaluate the multifunctional profile of rosmarinic acid from Blechnum
brasiliense on targets related to neurodegeneration. Chem. Biol. Interact. 2016, 254, 135–145. [CrossRef]
[PubMed]
51. Shang, A.J.; Yang, Y.; Wang, H.Y.; Tao, B.Z.; Wang, J.; Wang, Z.F.; Zhou, D.B. Spinal cord injury effectively
ameliorated by neuroprotective effects of rosmarinic acid. Nutr. Neurosci. 2017, 20, 172–179. [CrossRef]
[PubMed]
52. Khamse, S.; Sadr, S.S.; Roghani, M.; Hasanzadeh, G.; Mohammadian, M. Rosmarinic acid exerts
a neuroprotective effect in the kainite rat model of temporat lobe epilepsy: Underlying mechanisms.
Pharm. Biol. 2015, 53, 1818–1825. [CrossRef] [PubMed]
53. Grigoletto, J.; de Oliveira, C.V.; Grauncke, A.C.; de Souza, T.L.; Souto, N.S.; de Freitas, M.L.; Furian, A.F.;
Santos, A.R.S.; Oliveira, M.S. Rosmarinic acid is anticonvulsant against seizures induced by pentylenetetrazol
and pilocarpine in mice. Epilepsy Behav. 2016, 62, 27–34. [CrossRef] [PubMed]
54. Bhatt, R.; Singh, D.; Prakash, A.; Mishra, N. Development, characterization and nasal delivery of rosmarinic
acid-loaded solid lipid nanoparticles for the effective management of Huntingtons disease. Drug Deliv. 2015,
22, 931–939. [CrossRef] [PubMed]
55. Kondo, S.; El Omri, A.; Han, J.; Isoda, H. Antidepressant-like effects of rosmarinic acid through
mitogen-activated protein kinase phosphatase-1 and brain-derived neurotrophic factor modulation.
J. Funct. Food. 2015, 14, 758–766. [CrossRef]
56. Shan, Y.; Wang, D.D.; Xu, Y.X.; Wang, C.; Cao, L.; Liu, Y.S.; Zhu, C.Q. Aging as a precipitating factor in
chronic restraint stress-induced tau aggregation pathology, and the protective effects of rosmarinic acid.
J. Alzheimers Dis. 2016, 49, 829–844. [CrossRef] [PubMed]
148
Nutrients 2017, 9, 477
57. Hwang, E.S.; Kim, H.B.; Choi, G.Y.; Lee, S.; Lee, S.O.; Kim, S.; Park, J.H. Acute rosmarinic acid treatment
enhances long-term potentiation, BDNF and GluR-2 protein expression, and cell survival rate against
scopolamine challenge in rat organotypic hippocampal slice cultures. Biochem. Biophs. Res. Commun. 2016,
475, 44–50. [CrossRef] [PubMed]
58. Ramanauskiene, K.; Raudonis, R.; Majiene, D. Rosmarinic acid and Melissa officinalis extracts differently
affect glioblastoma cells. Oxid. Med. Cell. Longev. 2016. [CrossRef] [PubMed]
59. Ghasemzadeh Rahbardar, M.; Amin, B.; Mehri, S.; Mirnajafi-Zadeh, S.J.; Hosseinzadeh, H. Anti-inflammatory
effects of ethanolic extract of Rosmarinus officinalis L. and rosmarinic acid in a rat model of neuropathic
pain. Biomed. Pharmacother. 2016, 86, 441–449. [CrossRef] [PubMed]
60. Güven, M.; Yuksel, Y.; Sehitoglu, M.H.; Tokmak, M.; Aras, A.B.; Akman, T.; Golge, U.H.; Goksel, F.;
Karavelioglu, E.; Cosar, M. The effect of coumaric acid on ischemia-reperfusion injury of sciatic nerve in rats.
Inflammation 2015, 38, 2124–2132. [CrossRef] [PubMed]
61. Güven, M.; Aras, A.B.; Akman, T.; Sen, H.M.; Ozkan, A.; Salis, O.; Sehitoglu, I.; Kalkan, Y.; Silan, C.; Deniz, M.;
et al. Neuroprotective effect of p-coumaric acid in rat model of embolic cerebral ischemia. Iran. J. Basic
Med. Sci. 2015, 18, 356–363. [PubMed]
62. Güven, M.; Sehitoglu, M.H.; Yuksel, Y.; Tomkak, M.; Aras, A.B.; Akman, T.; Golge, U.H.; Karavelioglu, E.;
Bal, E.; Cosar, M. The neuroprotective effect of p-coumaric acid on spinal cord ischemia/reperfusion injury
in rats. Inflammation 2015, 38, 1986–1995. [CrossRef] [PubMed]
63. Shailasree, S.; Venkataramana, M.; Niranjana, S.R. Cytotoxic effect of p-coumaric acid on neuroblastoma,
N2a cell via generation of reactive oxygen species leading to dysfunction of mitochondria inducing apoptosis
and autophagy. Mol. Neurobiol. 2015, 51, 119–130. [CrossRef] [PubMed]
64. Zare, K.; Eidi, A.; Roghani, M.; Haeri-Rohani, A. The neuroprotective potential of sinapic acid in the
6-hydroxydopamine-induced hem-parkinsonian rat. Metab. Brain Dis. 2015, 30, 205–213. [CrossRef]
[PubMed]
65. Yao, Y.; Huang, H.Y.; Yang, Y.X.; Guo, J.Y. Cinnamic aldehyde treatment alleviates chronic unexpected
stress-induced depressive-like behaviors via targeting cyclooxygenase-2 in mid-aged rats. J. Ethnopharmacol.
2015, 162, 97–103. [CrossRef] [PubMed]
66. Thrash-Williams, B.; Karuppagounder, S.S.; Bhattacharya, D.; Ahuja, M.; Suppiramaniam, V.; Dhanasekaran, M.
Methamphetamine-induced dopaminergic toxicity prevented owing to the neuroprotective effects of salicylic
acid. Life Sci. 2016, 1, 24–29. [CrossRef] [PubMed]
67. Cetin, D.; Hacimuftuoglu, A.; Tatar, A.; Turkez, H.; Togar, B. The in vitro protective effect of salicylic
acid against paclitaxel and cisplatin-induced neurotoxicity. Cytotechnology 2016, 68, 1361–1367. [CrossRef]
[PubMed]
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Abstract: Non-alcoholic fatty liver disease (NAFLD) confers an increased risk of cardiovascular
diseases. NAFDL is associated with atherogenic dyslipidemia, inflammation and renin-angiotensin
system (RAS) imbalance, which in turn lead to atherosclerotic lesions. In the present study, the impact
of a natural dietary supplement (NDS) containing Curcuma longa, silymarin, guggul, chlorogenic
acid and inulin on NAFLD and atherosclerosis was evaluated, and the mechanism of action was
examined. C57BL/6 mice were fed an HFD for 16 weeks; half of the mice were simultaneously
treated with a daily oral administration (os) of the NDS. NAFLD and atherogenic lesions in aorta
and carotid artery (histological analysis), hepatic expression of genes involved in the NAFLD (PCR
array), hepatic angiotensinogen (AGT) and AT1R mRNA expression (real-time PCR) and plasma
angiotensin (ANG)-II levels (ELISA) were evaluated. In the NDS group, steatosis, aortic lesions
or carotid artery thickening was not observed. PCR array showed upregulation of some genes
involved in lipid metabolism and anti-inflammatory activity (Cpt2, Ifng) and downregulation of
some genes involved in pro-inflammatory response and in free fatty acid up-take (Fabp5, Socs3).
Hepatic AGT, AT1R mRNA and ANG II plasma levels were significantly lower with respect to the
untreated-group. Furthermore, NDS inhibited the dyslipidemia observed in the untreated animals.
Altogether, these results suggest that NDS prevents NAFLD and atherogenesis by modulating the
expression of different genes involved in NAFLD and avoiding RAS imbalance.
Keywords: non-alcoholic fatty liver disease; atherogenic lesions; diet-induced obesity; natural dietary
supplement; renin-angiotensin system imbalance; Profiler PCR array
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most frequent hepatic disorder in developed
countries and may lead to steatohepatitis, cirrhosis and liver cancer. NAFLD is also considered
the hepatic component of metabolic syndrome (MetS) because it is associated with atherogenic
dyslipidemia, obesity and type 2 diabetes (T2DM) [1]. The precise mechanism of the onset and
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progression of NAFLD remains unclear although increased fatty acid syntheses, oxidative stress and
inflammation may play a fundamental role [2].
Emerging evidence suggests that angiotensin (ANG) II, a pro-oxidant cytokine, synthesized
mainly from the hepatic precursor angiotensinogen (AGT), may have a relevant importance in the
pathogenesis of NAFLD by generating reactive oxygen species and regulating the production of
pro-inflammatory mediators [3]. Patients with NAFLD present elevated ANG II levels [4,5], and
animals with liver steatosis show increased hepatic expression of AGT, AGT II and ANG II type 1
receptor (AT1R) [6,7]. The renin-angiotensin system (RAS) and its primary mediator ANG II have also
a direct influence on the progression of the atherosclerotic process via effects on endothelial function,
inflammation, fibrinolytic balance and plaque stability [8]. Increasing clinical evidence supports a
strong association between NAFLD and cardiovascular diseases (CVD), which represents the principal
cause of death in NAFLD patients, more so than liver-related complications [9,10]. Patients with
NAFLD have an altered flow-mediated vasodilatation and increased carotid-artery intimal medial
thickness, two reliable markers of subclinical atherosclerosis [11]. Therefore, the involvement of
AGT II in NAFLD pathogenesis and in atherosclerotic plaque formation may provide one of the
possible links between NAFLD and accelerated atherogenesis. Accordingly, the use of RAS blockers
seems to be potentially useful as a therapeutic approach against NAFLD [12] and atherosclerosis [13].
To date, there is no single approved pharmacologic therapy to treat metabolic dysfunctions occurring
in obesity, such as NAFLD and related atherosclerosis. The backbone of therapy currently includes
lifestyle management to induce weight loss and therapeutic treatment to reduce cardiovascular risk or
hyperglycemia [14]. Recently, natural herbs have been the focus of many researches both because of
their safety and efficacy and because their potential bio-active ingredients could help to prevent or
treat obesity and the related metabolic disorders [15]. The natural dietary supplement (NDS) used in
this study contains extracts from Cynara scolymus (chlorogenic acid), Silybum marianum (silymarin),
Taraxacum officinale (inulin), Curcuma Longa (curcuma) and Commiphora mukul (guggul), plant extracts
that exert protective actions mainly towards the liver. Recent evidence has shown that the treatment
with the NDS exerts beneficial effects in patients with MetS, reducing anthropometric parameters and
total cholesterol levels, but the mechanism of action is still unknown [16].
This study aims to investigate whether the treatment with this NDS is able to prevent the
development of NAFLD and related atherosclerotic lesions in aorta and carotid artery in a mouse
model of diet-induced obesity (DIO). In order to investigate the mechanism of action of the natural
supplement, its ability to modulate the expression of some RAS components (AGT and AT1R mRNA
in liver and circulating concentration of AGT II) or of genes involved in NAFLD was examined.
In addition, the impact of the NDS treatment in the plasma lipid profile was also analyzed.
2. Materials and Methods
2.1. Animals
The procedures were performed in accordance with the conventional guidelines for animal
experimentation (Italian D.L. (Legislative Decree) No. 116 of 27 January 1992 and subsequent
variations) and the recommendations of the European Economic Community (86/609/ECC).
Male C57BL/6J (B6) mice, purchased from Harlan Laboratories (San Pietro al Natisone Udine,
Italy) at 4 weeks of age, were housed in a room with controlled temperature and dark-light cycles,
with free access to water and food. After acclimatization (1 week), the animals were weighed and
divided into two groups, both fed a high-fat diet (HFD) (PF4051/D, Mucedola, Milan, Italy) composed
of 60% of energy as fat, 20% protein and 20% carbohydrates, for 16 weeks.
It has been shown that these animals, consequent to an HFD, develop obesity, hyperglycemia [17],
hepatic steatosis [18], atherosclerosis [19] and neurodegeneration [20].
One group served as a control of obesity-related dysfunctions (n = 6, untreated group), and the
other one (n = 6, treated group) received, simultaneously to the HFD, a daily administration of NDS
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(0.9 mg/mouse) for 16 weeks. The dose given to the DIO mice was extrapolated from the human
dosage (1.6 g/day) and calculated on the basis of the average body weight (40 mg).
The NDS used in this study is, in Italy, commercialized under the name Kèpar® and was provided
by Rikrea® S.r.l. (Modica-RG, Italy). The main constituents of the NDS are plant-derived polyphenolic
compounds that are well known for their antioxidant and anti-inflammatory properties. In particular,
NDS consists of extract from five plant sources, and each extract was obtained from a different part of
the plant (Table 1).
Table 1. Ingredients of the natural dietary supplement (NDS) formulation.
Herbal Components Part Used Quantity/100 g
Cynara scolymus, e.s. tit. 2.5%
chlorogenic acid Leaf
35 g (extract)
0.87 g (Chlor. acid)









e.s. tit. 95% curcumin Rhizome
10 g (powder)
9.5 g (curcumin)




e.s. tit.: Dry extract titrated; Chlor. acid: Chlorogenic acid.
The tablets of the NDS (Kèpar, Batch No. SL0010) were ground by pestle and 9 mg of powder
dissolved in 200 μL of water and used as stock solution. The daily dose was freshly made up, by
diluting 1:10 the stock solution (0.9 mg/mouse in 20 μL), and was administered by oral gavaging. The
administrated dose contained: 0.09 mg of Curcuma, 0.057 mg of silymarin, 0.0135 mg of guggul lipids,
0.008 of chlorogenic acid and 0.002 mg of inulin. During the 16 weeks of the treatment, changes in
body weight and food-intake, determined by measuring the difference between the pre-weighed chow
and the weight of chow at intervals of 24 h [21], were periodically monitored and compared between
the two groups of animals. After 16 weeks of treatment, mice were sacrificed, and blood, liver, aorta
and carotid artery were immediately collected for subsequent analysis.
2.2. Histological Analysis
Aorta, carotid arteries and liver specimens excised from each hepatic lobe were fixed in 4%
formalin for 24 h. After this treatment, the tissues were dehydrated in alcohol and embedded
in paraffin wax. Paraffin histological sections (5 μm thick) were stained with hematoxylin and
eosin and observed using an automated Leica DM5000 B microscope (Leica, Milan, Italy) connected
to a high-resolution camera, Leica DC300 F (Leica, Milan, Italy). According to the Non-alcoholic
Steatohepatitis Clinical Research Network (NASH CRN) scoring system, steatosis was determined by
analyzing the morphology and percentage of lipid vesicles in hepatocytes [22].
2.3. Atherogenic Index (AIS)
The atherogenic index serum (AIS), which is the measure of the atherosclerotic lesion extent based
on serum lipids [23], was determined in all groups. The atherogenic index serum is calculated using
the formula AIS = total cholesterol (TC)/HDL [24].
2.4. Biochemical Analysis
Lipid profile was measured in mice fasted for 6 h with free access to water. After this time, the
mice were euthanized, and the blood was drawn by cardiac puncture and immediately transferred into
chilled tubes containing a final concentration of 1 mg/mL EDTA. Then, the samples were centrifuged
at 825 g for 10 min, and the obtained plasma was stored at −80 ◦C until analysis. Plasma triglyceride,
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cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL) levels and AST- and
ALT-serum concentrations were measured using the ILAB 600 Analyzer (Instrumentation Laboratory,
Bedford, Massachusetts).
2.5. Quantitative Real-Time qPCR
Total RNA from livers of treated and untreated obese mice were extracted using the RNEasy
Mini Kit (Qiagen, Milan, Italy). Two nanograms of RNA were used to synthesize the first strand
cDNA using the RT First-Strand kit (Qiagen, Milan, Italy). Synthesized cDNAs were amplified using
RT2 SYBR Green/ROX qPCR Mastermix (Qiagen, Milan, Italy) and StepOne Real-Time instrument
(Applied Biosystem, Foster City, CA, USA).
Gene expression analysis was performed using sequence primers for mice AGT, AT1R and β-actin
(SigmaLife Sciences, Milan, Italy). The primers were as follows: AGT forward 5’-GTA CAG ACA
GCA CCC TAC TT-3’, reverse 5’-TTG TTG AAG AGG CAC TGC AC-3’; AT1R forward 5’-GAC CAA
CTC AAC CCA GAA AAGC-3’, reverse 5’-CCT TTG TCG AAC CAC CACTA-3’; β-actin forward
5’-CGG GAT CCC CGC CCT AGG CAC CAG GGT-3’, reverse 5’-GGA ATT CGG CTG GGG TGT TGA
AGG TCT CAAA-3’. Each PCR reaction was amplified in triplicate, and levels of expression were
calculated after normalization to β-actin. On the basis of the Ct value (threshold cycle; the number of
reaction cycles after which fluorescence exceeds the defined threshold) of the examined gene and of
the internal control gene, the relative expression level of RNA was calculated according to the 2−ΔΔCt
approximation method.
2.6. RT2 Profiler PCR Array
Synthesized cDNAs from NDS-treated and NSD-untreated livers were added to 96-well reaction
plates of the Mouse Fatty Liver PCR Array (PAMM-157Z, SABiosciences, Qiagen, Milan, Italy)
according to the manufacturer's instructions. The array profiles the expression of 84 key genes involved
in the mechanisms of non-alcoholic fatty liver disease (NAFLD) and hepatic insulin resistance. The
reaction was performed by using a StepOne Real-Time instrument (Applied Biosystem, Foster City,
CA, USA). Analysis was performed using the spreadsheet provided by Qiagen Company, Milan, Italy.
2.7. Measurement of Circulating Levels of Angiotensin II
Quantification of plasma AGT II was carried out by the ELISA kit for mice (Enzo Life Sciences, Inc.
Farmingdale NY, USA) according to the manufacturer’s instructions. The experimental detection limit
of the analysis was 3.9 pg/mL.
2.8. Statistical Analyses
Results are shown as means ± the standard error of the mean (S.E.M.). The letter n indicates the
number of animals. Statistical analyses were performed using Prism Version 6.0 Software (Graph Pad
Software, Inc., San Diego, CA, USA). The comparison between the groups was performed by ANOVA
followed by Bonferroni’s post-test. A p-value ≤ 0.05 was considered statistically significant.
3. Results
3.1. The Natural Dietary Supplement Prevents the Development of NAFLD
At the end of the treatment, the untreated mice had greater mass gain compared to the animals
treated with NDS (Figure 1A), although no difference in the food intake was observed (Figure 1B).
Furthermore, the liver weight (Figure 1C) and ratio liver weight/body weight (Figure 1D) was higher
than the treated group. In the untreated mice, steatosis affected the liver gross appearance.
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Figure 1. NDS reduces food intake, body and liver weight in HFD mice. Effects of the NDS treatment
(0.9 mg/mouse) on body weight (A), food intake (B), liver weight (C) and the ratio of liver weight/body
weight (D), in mice fed a high-fat diet (HFD). Data are the means ± S.E.M. (n = 6/group). * p ≤ 0.05.
In particular, the organ appeared enlarged with rounded edges. Moreover, it was pale-yellowish
color, friable with a greasy texture attributable to the fat accumulation in the hepatic parenchyma
(Figure 2A). Histologically, the liver exhibited micro- and macro-vesicular steatosis (Grade I: >5%–33%)
in the perivenular area (Zone 3) and transition area (Zone 2) (Figure 2C) with focal infiltration of
polymorphonuclear cells (Figure 2E). The hepatocytes showed a typical foamy aspect; numerous
small vacuoles coalesced and created cleared space displacing the nucleus to the periphery of the
cells (Figure 2E). On the contrary, in the NDS-treated mice, the liver gross anatomy was not affected
by fat accumulation (Figure 2B), and the histological analysis did not reveal the presence of steatosis
(Grade 0: <5%), but only the presence of small inclusions of lipids within hepatocytes (Figure 2D–F).
Moreover, in agreement with the liver maintaining the lobular architecture, plasma AST and ALT were
significantly lower in treated mice than in the untreated ones (Figure 2G).
In addition, NDS-treated mice showed decreased triglycerides, cholesterol and LDL and increased
HDL plasma levels in comparison with untreated animals (Figure 3).
3.2. The Natural Dietary Supplement Modulates the Expression of Genes Involved in NAFLD
To compare differences in the profile gene expression involved in NAFLD between the treated
and the untreated groups, we analyzed hepatic expression levels of 84 genes by PCR array analysis.
The position of the genes is signified in Table S1. In the hepatic tissue of treated mice, the expression
levels of 23 genes were affected (Table S1). Among these, nine were up- or down-regulated by more
than two-fold in comparison with the untreated animals (Figure 4A–C). In particular, NDS treatment
upregulates genes involved in lipid metabolism and anti-inflammatory mediators (Cpt2, Ifng), whereas
it downregulates genes involved in FFA up-take and in pro-inflammatory activity (Fabp5, Socs3).
158
Nutrients 2017, 9, 492
Figure 2. NDS prevents NAFLD development in diet-induced obesity (DIO) animals. Representative
images of gross anatomy and histological cross-sections of liver from NDS-treated and untreated
high-fat diet (HFD) mice. Liver morphologies of untreated HFD mice (A) and NDS-treated HFD mice
(B). Cross-sections from untreated HFD mice (C,E) show micro- and macro-vesicular steatosis (black
arrowhead) with polymorphonuclear cell infiltration (black arrow). Histological cross-sections from
NDS-treated HFD mice (D,F) show normal hepatocytes and maintaining of the lobular architecture.
Hematoxylin and eosin stain. Original magnification: (C,D) = ×200, (E,F) = ×400. (G) Plasma levels of
AST and ALT. Data are the mean values ± S.E.M. (n = 6/group). * p ≤ 0.05.
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Figure 3. NDS prevents altered the plasma lipid profile. Effects of NDS treatment (0.9 mg/mouse) on
plasma lipid concentrations. Data are the mean values ± S.E.M. (n = 6/group).* p ≤ 0.05.
Figure 4. NDS reduces the expression of genes involved in NAFLD pathogenesis. Livers of untreated
and treated high-fat diet (HFD) mice were used to perform the RNA for the PCR array analysis.
(A) Scatter plot of relative expression levels for each gene in mice samples (treated vs. untreated).
The figure depicts a log transformation plot of the relative expression level of each gene (2−ΔCt)
between untreated (x-axis) and treated mice (y-axis). The grey lines indicate a two-fold change in gene
expression threshold. Red rings indicate upregulated genes; green rings indicate downregulated genes.
(B) Histogram of some up- and down-regulated genes with a greater than two-fold expression change.
(C) Table of the names and functions of the quantitative real-time PCR of the chosen genes.
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3.3. The Natural Dietary Supplement Prevents Atherosclerosis Development
Untreated mice showed atherosclerotic lesions with features of the earliest stages of the disease.
In fact, the observed lesions did not develop beyond the fatty-streak presence. The lesions of aorta
were confined to the aortic root and were characterized predominantly by lipid-laden areas in the
tunica media, between smooth muscle cells and elastic lamina (Figure 5A,B). Carotid arteries showed
an increased thickening of the intima characterized by hyperplasia and the presence of myocytes
proliferating from the tunica media (Figure 5E,F). On the contrary, in NDS-treated mice, neither lesions
in aortic root (Figure 5C,D), nor carotid intimal hyperplasia and alterations in the tunica media or
adventitia (Figure 5G,H) were observed.
Figure 5. NDS prevents the development of atherosclerotic lesions. Representative images of
histological cross-sections of aortic arch and carotid artery in high-fat diet (HFD) mice. The black
arrow (A,B) denotes the prominent fatty streak between elastic laminae (arrowhead) in the aortic root
wall of untreated vs. treated (C,D) HFD mice. Carotid artery shows a hyperplasia of the intima (i) in
untreated HFD mice (E,F). On the contrary, no alterations of carotid artery are detected in treated HFD
mice (G,H). a = tunica adventitia. s = smooth muscle cells. Hematoxylin and eosin stain. Original
magnification: (A,C) = ×400; (B,D,F) and (H) = ×600; (E,G) = ×200.
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According to these data, the AIS was significantly higher in untreated HFD-fed mice in comparison
with the treated obese mice (Figure 6).
Figure 6. Atherogenic index serum (AIS) in HFD mice is reduced by NDS. Effects of NDS treatment
(0.9 mg/mouse) on AIS of high-fat diet (HFD)-fed mice. Data are the mean values ± S.E.M.
(n = 6/group). * p ≤ 0.05.
3.4. The Natural Dietary Supplement Reduces RAS Component Expression
To investigate whether variations in the levels of the RAS system are specifically involved in the
preventive effects of the natural supplement, we analyzed the hepatic mRNA levels of AGT and AT1R
by quantitative real-time PCR and circulating ANG II concentration by ELISA assay. In NDS-treated
mice, hepatic AGT and AT1R mRNA expression and plasma ANG II levels were significantly lower in
comparison with untreated mice (Figure 7A,B).
Figure 7. NDS reduces RAS component expression. (A) Expression levels of AGT and AT1R mRNAs
in liver of treated high-fat diet (HFD) mice and the untreated HFD group, by real-time RT-PCR
analysis. Data are the mean values ± S.E.M. (n = 3/group). * p ≤ 0.05. (B) Effects of NDS treatment
(0.9 mg/mouse) on circulating levels of angiotensin II in HFD mice, by ELISA. Data are the mean
values ± S.E.M. (n = 6/group). * p ≤ 0.05.
4. Discussion
The present study shows that the natural supplement, here utilized, is able to prevent the
development of NAFLD and atherogenic lesions in HFD obese mice. Such a preventive role is
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determined by its ability to reduce the expression of the RAS components (AGT, AT1R and AGT II)
and modulate positively the expression of genes involved in NAFLD. The NDS also improves the lipid
profile, a typical obesity-related dysfunction.
In recent years, there has been an increasing interest in the use of plant extracts as potential
therapeutic agents. A mixture of natural products is used in various therapeutic areas obtaining a
number of interesting outcomes due to their synergistic effects [25]. The natural dietary supplement
used in this work, known as Képar, is used in the Italian market to treat liver discomfort, caused by
gallstones, cirrhosis and toxic agents. It is composed of several plant extracts (Curcuma, silymarin,
guggul, chlorogenic acid and inulin) that exert, at least individually, beneficial effects on different
components of MetS. Curcumin improves insulin resistance and dyslipidemia [26]; silymarin exerts
anti-inflammatory effects in animal models of NAFLD [27]; guggul lipids have been successfully used
in obesity and hypercholesterolemia [28]; and chlorogenic acid, as well as inulin, may improve lipidic
and glycidic metabolism [29,30]. In the present study, we have demonstrated that the diet natural
supplement is able to prevent body weight gain, hepatic fat accumulation, atherosclerotic lesions
development and dysregulation of lipidic metabolism. In fact, NDS-treated HFD mice showed a body
weight significantly lower than the untreated HFD animals, without any differences in the food intake.
This suggests that NDS prevents body mass gain by an independent mechanism from central control
of the feeding behavior.
It is interesting to note that our study represents the first experimental evidence for a preventive
role of the natural supplement against obesity-associated steatosis development. In fact, the liver of
treated obese mice did not show hepatomegaly or other histomorphological alterations; on the contrary,
the untreated group liver showed the presence of moderate micro- and macro-vesicular steatosis in
Zone 3, a zonal distribution highly associated with the severity of steatosis [31]. The positive impact of
NDS treatment, besides liver morphology, was also observed on the hepatic function, as suggested by
the reduced ALT and AST plasma levels in treated-obese animals compared to the untreated group.
In addition, the results showed that plasma triglycerides and LDL were lower and HDL higher in
treated HFD animals in comparison to the untreated mice, demonstrating that NDS exerts beneficial
effects on lipid metabolism and, consequently, on cardiovascular functions [32].
In order to examine the mechanism by which NDS prevents NAFLD, we also analyzed and
compared the hepatic expression of genes involved in NAFLD pathogenesis in treated vs. untreated
animals. For the first time, it was demonstrated that NDS is able to modulate different signaling
pathways involved in de novo hepatic lipogenesis, lipid oxidation and inflammatory responses.
In fact, in NDS-treated liver, genes involved in fatty acid turnover (such as Fabp1 and Cpt2) and
anti-inflammatory activity (Ifng) were upregulated, while genes involved in FFA uptake (Fabp5),
lipogenesis (Scd1) and inflammation (Socs3) were downregulated. The increased level of Cpt-2 and
Fabp-1 provides an explanation of the reduced hepatic lipid depots observed in the NDS-treated
liver. Cpt-2 is involved in beta-oxidation and Fabp-1 in the rapid removal of fatty acid in the
oxidative organelles [33]. Downregulation of Fabp5 and Scd1 also contributes to preventing hepatic
lipid accumulation, as Fabp5 leads to the fatty acid uptake [34] and Scd1 converts saturated FA to
monounsaturated FA, the major substrates necessary for the synthesis of other lipids [35]. On the
other hand, Scd1 knockout mice result in being resistant to the development of obesity and hepatic
steatosis [36], and the fatty livers of ob/ob mice show increased Scd1 expression [37].
Microarray analysis also showed that the treatment with the natural supplement is able to
modulate the expression of factors involved in the inflammatory process. In particular, the liver of
treated HFD mice showed upregulation of Ifng, a protective mediator against the liver inflammatory
process [38], and a very strong downregulation of Socs3, usually overexpressed in inflamed steatotic
liver [39], providing a molecular basis for the protective role of the NDS in the HFD liver.
It is well known that NAFLD shares many risk factors with cardiovascular diseases, implying
a close relationship between NAFLD and adverse cardiovascular events, such as hypertension and
atherosclerosis [9]. Accordingly, we analyzed the impact of NDS treatment on the development of
163
Nutrients 2017, 9, 492
atherogenic lesions in our animal models. Our results showed that no atherosclerotic lesions were
present in the vessels of NDS-treated obese mice. On the contrary, early hallmarks of atherosclerosis
were highlighted in the untreated-HFD group. In fact, in agreement with Whitman’s report [40],
we observed “fatty streak-type” lesions in the aortic root, representative of foam cells, which are
lipid-laden macrophages. We also observed carotid artery intimal-medial wall thickening. Additionally,
AIS, a measure of the atherosclerotic lesion extent based on serum lipid concentration [23,24], was
significantly lower in NDS-treated animals compared with untreated mice, suggesting a preventive
action of the natural supplement on atherogenesis development. Therefore, the improvement of the
lipid profile could explain the absence of lesions in the NDS-treated animals. Different mechanisms
explain the increased risk of cardiovascular events in patients with NAFLD. In fact, besides the
proatherogenic lipid profile, the disease is associated with an increased production of pro-inflammatory
cytokines [41,42] and RAS imbalance. Patients with NAFLD present elevated circulating levels of ANG
II and over-activation of intrahepatic RAS [4,5]. Our results showed that in the liver of NDS-treated
obese mice, angiotensinogen and AT1R mRNA were significantly decreased, as well as the circulating
levels of ANG II, suggesting that the treatment with the natural supplement protects from NAFLD
and atherogenesis by preventing RAS imbalance.
5. Conclusions
In conclusion, the natural dietary supplement (Kèpar) is effective in protecting against the
development of NAFLD and atherosclerotic lesions in obesity conditions. The NDS prevents liver fat
accumulation, development of atherosclerotic lesions and improves hyperlipidemia. These beneficial
effects seem to be mediated by the ability of the natural supplement to modulate the expression of
different genes involved in NAFLD and to prevent the imbalance of RAS components.
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Abstract: Background- Cardiovascular diseases, including myocardial infarction, dyslipidaemia and
coronary artery pathology, are a major cause of illness and death in Western countries. Therefore,
identifying effective therapeutic approaches and their cellular signalling pathways is a challenging
goal for medicine. In this regard, several epidemiological studies demonstrate a relationship between
the intake of flavonoid-rich foods and the reduction of cardiovascular risk factors and mortality.
In particular, flavonoids present in citrus fruits, such as oranges, bergamots, lemons and grapefruit
(95% from flavanones), are emerging for their considerable nutraceutical value. Methods- In
this review an examination of literature was performed while considering both epidemiological,
clinical and pre-clinical evidence supporting the beneficial role of the flavanone class. We evaluated
studies in which citrus fruit juices or single flavanone administration and cardiovascular risk factors
were analysed; to identify these studies, an electronic search was conducted in PUBMED for papers
fulfilling these criteria and written in English. Results- In addition to epidemiological evidence
and clinical studies demonstrating that fruits in the Citrus genus significantly reduce the incidence
of cardiovascular disease risk, pre-clinical investigations highlight cellular and subcellular targets
that are responsible for these beneficial effects. There has been special attention on evaluating
intracellular pathways involved in direct cardiovascular and cardiometabolic effects mediated by
naringenin, hesperetin and eriodictyol or their glycosylated derivatives. Conclusions- Although some
mechanisms of action remain unclear and bioavailability problems remain to be solved, the current
evidence supports the use of a nutraceutical approach with citrus fruits to prevent and cure several
aspects of cardiovascular disease.
Keywords: citrus flavonoids; cardiovascular benefit; nutraceutical value
1. Introduction
Cardiovascular diseases are a main cause of illness and death in Western countries,
and cardiovascular drugs are the most commonly used medications. Therefore, cardiovascular
diseases remain a therapeutic and sanitary issue, affecting the largest number of patients in the
world. To alleviate the social and economic burden of cardiovascular diseases, recommendations have
been proposed for health and lifestyle interventions targeting multiple risk factors. Prevention of risk
factors is considered a primary approach for containing cardiovascular diseases [1].
The availability of nutraceuticals with a positive impact on cardiac function to reduce the incidence
and lethality of cardiovascular diseases is a challenging topic [2,3].
In this regard, flavonoids are important constituents endowed with beneficial properties that
humans can obtain through food, particularly through consuming fruit and vegetables. Some of these
are characteristic of specific foods (i.e., genistein and daidzein), whereas others are widespread
in several foods (i.e., quercetin and apigenin). Generally, flavonoids are distinct based on
Nutrients 2017, 9, 502; doi:10.3390/nu9050502 www.mdpi.com/journal/nutrients167
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structural characteristics in the following six sub-classes: flavonols, flavones, isoflavones, flavanones,
anthocyanins and flavanols (catechins and proanthocyanidins) [4].
In particular, the flavanone class is abundant in fruits and fruit juices of the Citrus genus;
approximately 95% of flavonoids are represented by this sub-class [5], and these foods are the main
source of flavanones. However, they are not unique because there are high levels in other foods,
such as in tomatoes [6].
Citrus flavanones are glycosylated in vegetables; of note, a disaccaridic moiety is linked to
the 7 position of aglycone and the aglycone type is characteristic of the fruit. Therefore, the same
aglycone can be combined with several glycosides to give different flavanones; for example, the most
representative flavanones in grapefruit are narirutin and naringin, those in orange fruit are hesperidin
and narirutin, and that in lemon is eriocitrin.
Of note, narirutin and naringin have the same aglycone, naringenin, and hesperidin is the
glycoside of hesperetin, while eriocitrin contains the aglycone eriodictyol (Figure 1) [7].
Figure 1. Chemical structures of citrus flavanones.
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These flavanones are not evenly distributed in the fruit; they are particularly present in the albedo
and in the membranes separating cloves rather than in the pulp. Peterson and his colleagues report
flavanone levels in the orange range between 35 and 147 mg/100 g, and naringin and narirutin in
grapefruit are present in a range between 44 and 106 mg/100 g [5].
Because the albedo and membranous parts are usually discarded to prepare fruit juices, the actual
level of flavanones is lower. Indeed, as reported by Tomas-Barbean and Clifford, the levels of hesperidin
and narirutin in orange juice are between 13 and 77 mg/100 mg. Ross et al. quantified naringenin in
grapefruit juice in the range of 17–76 mg/100 mL [8,9].
In Europe, orange or its fruit juice is the most commonly consumed citrus fruit; therefore, it is the
principal fruit source of citrus flavanones [10]. Moreover, O-glycoside flavanones are present in all
cultivars of orange, both red or pigmented and blond or non-pigmented; nevertheless, the number of
flavanones is higher in red cultivars in which a high level of anthocyanins is also present, representing
a peculiar feature [11].
2. Cardiovascular Benefits of Citrus Flavanones—Epidemiological, Clinical and
Pre-Clinical Evidence
Epidemiological evidence and clinical and pre-clinical studies suggest that flavanones present
in the Citrus genus positively influence cardio-metabolic parameters, preventing cardiovascular
disease [12–15].
In particular, a recent epidemiological study performed a Nurses’ Health Study on approximately
70,000 women, highlighting an inverse correlation between flavanone intake and cerebral ischaemia
risk, which is significant when considering women who consume high levels of flavanones
(>63 mg/day) versus low levels (<13.7 mg/day) [16].
Another prospective study was performed in Finland on approximately 10,000 men and women,
considering the correlation between the cardiovascular risk and flavonoid intake, revealing a 20%
reduction in cerebrovascular diseases in those who consumed the highest levels of flavanones
(4.7–26.8 mg aglycone/day) [17].
Similar results have been obtained in a Japanese cohort study conducted at JICHI Medical School.
In Japan, citrus fruits represent 30% of the annual consumption of fruit and, in enrolled individuals,
the incidence of cardiovascular diseases was evaluated during a period of approximately 11 years,
confirming the inverse correlation between these [18].
Moreover, Wang and colleagues published a systematic review and meta-analysis of prospective
cohort studies, which demonstrated that flavonoid consumption, especially of flavanones,
was associated with a decreased risk of cardiovascular disease (p = 0.002) [19]
Very recently, a meta-analysis of three randomized clinical trials, including 233 patients,
demonstrated a correlation between grapefruit intake and a reduction in blood pressure.
Although grapefruit intake does not significantly reduce body weight, it was responsible for a small,
but significant, reduction in the systolic blood pressure and waist circumference in overweight and
obese adults. The authors speculated that such beneficial effects can be related to naringin considering
its great abundance in grapefruit [20].
Cassidy et al. reported approximately three prospective studies (Nurses’s Health Studies) in
middle-aged and older US women and men in which the association between habitual intake of several
flavonoid sub-classes and risk of incident hypertension was examined. This analysis confirmed that
habitual flavonoid intake (principally from the consumption of flavanones present in grapefruits,
oranges and citrus juices) is correlated with a reduced incidence of hypertension [21].
Another recognized cardiovascular risk factor is metabolic syndrome, a condition characterized
by impaired glucose metabolism, dyslipidaemia, elevated blood pressure and abdominal obesity.
Grosso et al. published a cohort study in 2016 on another 10,000 Polish subjects, demonstrating an
interesting inverse association between polyphenols and metabolic syndrome, which is particularly
evident in individuals with the biggest intake of these [22].
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Therefore, evidence gathered thus far supports a preventive role of citrus fruits in addressing the
main risk factors of cardiovascular diseases, including overweight, hypertension and hyperglycaemia;
a deeper examination of specific cardio-vascular and cardio-metabolic parameters influenced by such
a flavonoid sub-class has been performed below.
A schematic table of the epidemiological and clinical evidence supporting the cardiovascular
benefits obtained with citrus flavanones is reported in Table 1.
Table 1. Epidemiological evidence, clinical trials or meta-analysis in which beneficial effects of citrus
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2.1. Effects on Cardiovascular Parameters
2.1.1. Reduction of Endothelial Dysfunction and Improvement of Vascular Function
The paradigm between hypertension and endothelial dysfunction has been widely demonstrated,
as well as that between the reduction of endothelial integrity and atherosclerotic processes. Indeed,
the vascular endothelium is a very active organ responsible for regulating vascular tone through the
effects of locally synthesized mediators, especially nitric oxide (NO), endothelial NO synthase (eNOS),
and superoxide, and its depletion is both a sign and cause of endothelial dysfunction resulting from
reduced activity of eNOS and amplified production of reactive oxygen species. Then, the integrity and
reactivity of endothelium must be ensured to prevent the progression of cardiovascular disease [35].
Clinical trials in the literature indicate a clear correlation between citrus flavanone intake,
vasodilatation and reduction of endothelial dysfunction. In particular, Reshef and colleagues described
a study on patients with mild hypertension (stage I) treated with sweetie fruit, which is a hybrid
between grapefruit and pomelo that contains a high level of flavonoids from the Citrus genus (25%
of naringin and 30% of narirutin). Two types of sweetie juices were obtained, one with a low
flavonoid level (166 mg/L naringin and 64 mg/L narirutin) and one with a high flavonoid level
(677 mg/L of naringin and 212 mg/L narirutin). After 5 weeks, a significant reduction in the diastolic
pressure value was observed in the high flavonoid group (p = 0.04) [23]. In agreement with this
study, a study on 4 weeks of treatment with 292 mg of hesperidin (corresponding to the levels present
in 500 mL of orange juice) showed a reduction in the diastolic pressure by 4 mmHg in moderately
overweight men (p = 0.02). Moreover, the intake of hesperidin supplement improved the post-prandial
reactivity of the microvascular endothelium (p < 0.05), demonstrating that hesperidin can positively
influence endothelial function. Based on these results, the authors encourage the consumption of citrus
foods [24].
A further confirmation of these observations was demonstrated in a clinical trial performed on
25 patients with metabolic syndrome. After 3 weeks of treatment with 500 mg daily of capsules
containing 98% of pure hesperidin, the expression of E-selectin, a biomarker of endothelial dysfunction,
was significantly reduced. This clinical effect was accompanied by an improvement in endogenous NO
production, inspiring the hypothesis that the vascular protection could be mediated by enhancement
of endothelial function [25,26].
Of note, a primary risk factor for cardiovascular diseases in aged women is the post-menopausal
condition, which is mainly due to dysfunction of the endothelium. Morand’s group reported a
clinical trial enrolling 52 women after menopause who were asked to consume a bottle (340 mL) of a
concentrated blond grapefruit juice (containing 105 mg of naringenin) or a iso-caloric and iso-energetic
drink daily. After 6 months of treatment, volunteers consuming grapefruit juice had a significant
change in their anthropometric parameters and vascular function, with improvement in arterial
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stiffness that was independent of blood pressure changes [36]. A positive impact of flavonoids
on hypertension has also been shown in a prospective cohort on French middle-aged women [28].
In agreement with several previously described studies, improvement in vascular function and slowing
of atherosclerosis progression have been reported in normotensive subjects (healthy volunteers and
patients with type 2 diabetes or coronary artery disease) [37,38] and in overweight men [39].
2.1.2. Lipid Level Reduction
Elevated levels of low-density lipoprotein cholesterol (LDL-C) and its deposition in the
macrophages of arterial walls contribute to the main cause of atherosclerosis progression, which is
a gateway for cardiovascular complications, including heart attacks, ischaemic stroke and coronary
diseases [40]. Several large randomized clinical trials with statin-based and non-statin based therapies
have demonstrated that a reduction in LDL-C levels reduced the cardiovascular risks [41].
Interestingly, naringenin promotes a decrease in LDL-C and triglycerides as well as inhibiting
glucose uptake. On the other hand, it increases high-density lipoprotein (HDL-C) and ameliorates
anti-oxidant defences, downregulating atherosclerosis-related genes [42].
Several pre-clinical studies have demonstrated the role of flavanones in atherosclerosis
progression. In particular, a 0.1% naringin or 0.05% naringenin supplement given to rabbits with high
cholesterol levels significantly decreased the expression levels of vascular cell adhesion molecule-1
(VCAM-1) and monocyte chemotactic protein-1 (MCP-1) after 8 weeks; at the same time, the hepatic
cholesterol acyltransferase (ACAT) activity, the basis for reducing atherosclerotic plaques, appeared
to decrease [43,44]. Similarly, another research group demonstrated that mice given high cholesterol
levels plus naringin (0.02%, corresponding to a half grapefruit) had a significant reduction (41%) of
atherosclerotic plaque compared to the high cholesterol level-alone group [45].
In terms of clinical evidence, the administration of capsules containing 400 mg/day of naringenin
for two months promoted a drop in the LDL-C, cholesterol and ApoB levels and an increase in HDL-C
levels in hypercholesterolemic, but not control, subjects, and there was an improvement in detoxifying
enzymes [29].
Moreover, patients with metabolic syndrome given a supplement of hesperidin (500 mg/day)
for 3 weeks had reduced cholesterol and ApoB levels [25]. In agreement, in a 2012 clinical study
performed in Spain on patients with a diagnosis of metabolic syndrome, the glycaemic profile was
unchanged after 4 and 6 months of citrus fruit juice treatment (300 mL daily), but the lipid profile
improved, as observed by decrease in the cholesterol, LDL-C, and C-reactive peptide (a well-known
inflammatory marker) levels (p < 0.05) [30].
Of the citrus fruits, bergamot fruit is worth noting because it is considered a promising
nutraceutical approach for controlling hypercholesterolaemia. Citrus bergamia administered to rats
with hyperlipidaemia (1 mL/rat/day) showed hepatic protection and a significant reduction in
the cholesterol, triglycerides and LDL-C levels (−29%, −46% and −52%, respectively) with an
approximately 28% increase in the HDL-C levels. These effects are the basis for anti-atherogenic
activity and are responsible for cardiovascular disease prevention [46]. Additionally, the authors
reported that bergamot can increase the excretion of sterols and bile acids. The mechanisms through
which bergamot has beneficial effects are not completely clear, though it cannot only be due to
citrus flavanones (naringenin, hesperetin and eriodictyol) [47]. Indeed, Di Donna et al. reported
the presence of 3-hydroxy-3-methyl-glutaryl flavanones with a behaviour similar to simvastatin in a
model of hypercholesterolaemic rats, speculating that these statin-like compounds could potentiate
the hypocholesterolaemic effects [48].
However, beyond these encouraging data, a more nebulous scenario appears based on
consideration for the citrus flavanone effects on hypercholesterolaemic patients. On the one hand,
a study enrolling 25 volunteers with high LDL-C and cholesterol levels demonstrated that 4 weeks
of feed with 600 mL/day of blond orange juice significantly reduced the plasma levels of oxidative
stress markers and apo A levels [31]. In agreement, a recent 6-month prospective study showed that
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bergamia extract (containing 150 mg of flavonoids with 16% neoericitrin, 47% neohesperidin and
37% naringin) reduced the plasma levels of lipids and improved the lipoproteic profile in moderate
hypercholesterolemic patients. Of note, such an ipolipidaemic effect was more evident in the group
with higher cholesterol levels [32].
On the other hand, a clinical study with 500 mg of naringin plus 800 mg of hesperidin did
not show a significant improvement in the lipid profile in moderate hypercholesterolaemia patients.
Of note, the citrus flavanone doses in the study correspond to the 95th percentile of daily consumption
in Western populations and were finalized to minimize the chance of not detecting a LDL-C lowering
effect. This outcome suggests that citrus flavonoids have no effect on LDL-C in people, at least not
when consumed in a capsule format [33]. Similar results have been reported in overweight patients
consuming 292 mg of hesperidin and 47.5 mg of narirutin for 4 weeks [24]. A possible explanation for
this discrepancy, according to some authors, could be caused by high inter-individual variability in the
pharmacokinetic parameters beyond by the type formulation. Although pre-clinical results are clearer
and encouraging, further clinical studies need to be performed.
3. Putative Mechanisms of Action Responsible for the Cardiovascular Benefits of Citrus Flavanones
3.1. Anti-Oxidant and Anti-Inflammatory Action
Oxidative stress and inflammation are pathologic processes that contribute to atherosclerotic
progression and the evolution of cardiovascular diseases. In healthy subjects, citrus flavanones do not
have significant anti-oxidant effects, suggesting that their anti-oxidant potency is negligible in normal
conditions. In hypercholesterolaemic subjects, Jung et al. demonstrated that naringin, administered for
8 weeks at a dose of 400 mg/day, significantly increased the SOD and catalase levels [29]. This result
suggests that flavanones of the Citrus genus could have an important impact on the improvement of
endogenous anti-oxidant defences in dyslipidaemia. Very recently, hesperidin has been demonstrated
to elevate anti-oxidant defences through increasing Nrf2 expression, suggesting an anti-ageing effect
of this flavonoid on senescent rat hearts [34]. Similar results emerged from an in vitro study on H9c2
cells in which naringenin significantly reduced the production of beta-galactosidase, a typical marker
of senescence, after doxorubicin treatment [49].
Several in vivo studies showed that flavanones can reduce chemokines as well as inflammatory
and adhesion molecules, whose expression is tightly regulated by the pro-inflammatory factor NF-kB.
This anti-inflammatory action accounts for anti-atherogenesis at the endothelium, smooth muscle cell
and monocyte/macrophage levels [50–52].
Five hundred milligrams of hesperidin can help reduce the plasma values of inflammatory factors
and genetic expression of proteins involved in cell proliferation, chemotaxis and platelet adhesion [23].
Moreover, a very recent in vitro study on human endothelial cells, showed that hesperetin and its
main metabolites inhibited TNF-α-induced cell migration [53]. On the other hand, 5 μM naringenin
decreased the production of a pro-inflammatory eicosanoid, PGE2, and reduced the expression of the
COX2 enzyme, while higher concentrations (30–100 μM) inhibited NFkB activation [54–56]. A further
central inflammatory target is represented by matrix metallopeptidases; MMP9 is particularly involved
in atherosclerotic lesions, and one study indicated that naringenin and naringin reduced MMP9
expression, reducing smooth muscle cell migration. Such an action could be at least partly related to
the suppression of NF-kB activation [57].
3.2. Vasodilator Activity
Vasoactive properties of the main flavonoids of the Citrus genus, naringenin and hesperetin, have
been widely described; particularly, Rizza et al. demonstrated that hesperetin induces vasodilatation
through endothelial production of nitric oxide (NO) and its derivative, glycosyl-hesperidin, which was
administered for 8 weeks to spontaneously hypertensive rats, was able to reduce pressure parameters
3% in addition to improving the endothelial response [25,58–60]. Moreover, on isolated coronary
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arteries of rodents, hesperetin caused vasodilatation by activating voltage-operated calcium channels
and potassium currents [61].
With respect to naringenin-mediated vasorelaxing effects, they are probably linked to opening
a calcium-activated potassium channel (BKCa) located on the sarcolemmatic membrane of smooth
muscle cells, as demonstrated by Saponara and colleagues [62,63].
Finally, a unique paper reported the vasorelaxing property of eriodictyol, a flavanone typical of
lemon; nevertheless, the authors reported a concentration-dependent reduction in the vascular tone
in the rat aortic rings without elucidating the mechanism of action. More recently, in vitro protective
effects on endothelial cells have also been demonstrated [64,65].
3.3. Anti-Ischaemic Activity
Myocardial infarction represents the main and often lethal manifestation of cardiovascular risk
such that agents able to prevent it are useful for containing the damage.
Several pre-clinical studies have demonstrated the cardioprotection conferred by citrus flavanones.
In ex vivo and in vivo myocardial ischaemia–reperfusion (I/R) models, naringenin could confer
cardioprotection, and this action seemed to be mediated through activation of BKCa channels expressed
on the inner mitochondrial membrane. This channel is structurally similar to that expressed on the
sarcolemma and is involved in vasodilatation that, at the mitochondrial level, plays a crucial role in I/R
events. Indeed, naringenin promoted reduced mitochondrial calcium uptake and mild mitochondrial
depolarization as well as restricting the probability of mitochondrial permeability transition pore
(MPTP) formation and apoptotic death of myocardiocytes [66–68].
On the other hand, hesperetin can have anti-apoptotic effects on cardiomyoblasts through the
mitochondrial JNK/Bax pathway [69].
3.4. Glucose Tolerance
A supplement for 4 or more weeks with flavanones reduces glycaemia and insulinaemia in
diabetic or insulin-resistant animals fed a high fat diet; moreover, glucose tolerance was improved.
The insulin-like property of naringenin has been demonstrated, and it has added to the in vitro
evidence that demonstrates the ability of naringin and hesperidin to reduce the PPAR-γ expression and
glucokinase activity, a key enzyme involved in the glucose use [70–72]. In this context, a poly-methoxy
flavone abundant in mandarin, tangeretin, should be mentioned. In diabetic rats, tangeretin markedly
reduced the plasmatic glucose levels, while it also increased the insulin secretion, enhancing complex
glucose metabolism [73].
4. Pharmacokinetic Profile of Citrus Flavanones
A significant problem with citrus flavonoids is their low bioavailability, restricting their efficacy
to the point of having to enrich the fruit juice with citrus flavanones or their analogues, which are
enzymatically more stable. Usually, the peak plasma concentration is reached 6 h after consumption
with a μM concentration and relative differences among several flavonoid types [74].
Their metabolism concerns conjugation at the intestinal and hepatic levels, leading to two types
of metabolites, glucuronide- and sulfate-conjugated. Principal excretion occurs through urine with a
peak between 6 and 12 hours after intake [75].
Another factor that could influence the bioavailability of citrus flavanones is their solubility
in fruit juice, and the preparation technique, homemade or industrial, is very important. Indeed,
an analytical evaluation revealed that the qualitative composition is not changed, but quantitative
analysis highlights significant differences [76]. However, the matrix factor is not the most critical.
The main factor responsible for the high inter-individual variability seems to be the colon bacteria
microflora [77], which is essential for flavonoid metabolism. Indeed, the consumption of fruit juice
guarantees intake of glycosylated flavanones, but they are pro-drugs that require bio-activation via the
hydrolysis of the glycoside portion to release the aglycone that is then responsible for pharmacological
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activity. Of note, an innovative view to improve the bioavailability of flavonoids and, more generally,
of polyphenols is represented by the evaluation of human intestinal microbiota. Indeed, it has been
demonstrated that the intestinal microbiota controls the bio-activation of flavonoids and regulates their
catabolism [78]. On the other hand, other authors have noted that polyphenolic components could
act as prebiotics and influence the growth of intestinal bacteria [79]. Further knowledge of the role of
microbiota in metabolic diseases, as well as in cardiovascular diseases, and of factors that modulate
microbiota will allow us to understand the true therapeutic benefits of various diet components and
suggest an appropriate diet that optimizes these beneficial effects [80].
5. Conclusions
In conclusion, the mechanisms responsible for the beneficial effects of citrus flavanones on the
cardiovascular system are multiple and remain somewhat unclear, although, in general, the available
clinical and pre-clinical studies suggest a positive correlation between their intake and a significant
reduction in the cardiovascular risk factors. However, such evidence is satisfactory to confer citrus
fruits with an interesting nutraceutical value in the context of the spread of cardiovascular disease in
Western countries and their heavy impact on the quality of life of patients.
Indeed, to date, cardiovascular drugs represent the most commonly used category in the world,
and, although there are large-scale pharmacological treatments, cardiovascular diseases are the
most widespread, consuming a high level of therapeutic resources and affecting health significantly.
Furthermore, their prevalence is expected to rise, particularly in Western countries, because of obesity
and the ageing population.
A nutraceutical approach, such as with citrus fruits, aimed at preventing and curing several
aspects of cardiovascular diseases could be very useful.
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Abstract: Cardiovascular diseases are the main cause of mortality and morbidity in the world.
Hypertension, ischemia/reperfusion, diabetes and anti-cancer drugs contribute to heart failure
through oxidative and nitrosative stresses which cause cardiomyocytes nuclear and mitochondrial
DNA damage, denaturation of intracellular proteins, lipid peroxidation and inflammation. Oxidative
or nitrosative stress-mediated injury lead to cardiomyocytes apoptosis or necrosis. The reactive
oxygen (ROS) and nitrogen species (RNS) concentration is dependent on their production and on the
expression and activity of anti-oxidant enzymes. Polyphenols are a large group of natural compounds
ubiquitously expressed in plants, and epidemiological studies have shown associations between a
diet rich in polyphenols and the prevention of various ROS-mediated human diseases. Polyphenols
reduce cardiomyocytes damage, necrosis, apoptosis, infarct size and improve cardiac function by
decreasing oxidative stress-induced production of ROS or RNS. These effects are achieved by the
ability of polyphenols to modulate the expression and activity of anti-oxidant enzymes and several
signaling pathways involved in cells survival. This report reviews current knowledge on the potential
anti-oxidative effects of polyphenols to control the cardiotoxicity induced by ROS and RNS stress.
Keywords: polyphenols; oxidative stress; cardiovascular disease; cardiomyocytes
1. Introduction
Cardiovascular diseases are the main cause of mortality and morbidity in the world [1].
Hypertension, ischemia, diabetes, anti-cancer drugs contribute to heart failure through oxidative
and nitrosative stresses which induce nuclear and mitochondrial DNA damage, denaturation of
intracellular proteins, lipid peroxidation and inflammation in cardiomyocytes [2,3]. Oxidative
or nitrosative stress-mediated injury lead to cardiomyocytes apoptosis or necrosis [2,3]. Reactive
oxygen (ROS) and nitrogen species (RNS) concentration is dependent on their production and on the
expression and activity of anti-oxidant enzymes [2]. ROS production is influenced by many factors,
such as dysfunction of oxidative enzymes (xanthine oxidase (XO), aldehyde oxidase, nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase and uncoupled nitric oxide synthase (NOS)),
dysregulation of mitochondria, microsomes and/or nuclei transport, neutrophil activation, arachidonic
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acid metabolism and auto-oxidation of catecholamines, flavins, quinones and proteins [4,5]. The main
ROS and RNS are superoxide, hydrogen peroxide, hydroxyl radical, nitric oxide (NO) and peroxynitrite.
The production of hydrogen peroxide regulates the expression of genes, in particular those activated
by nuclear factor-kappa B (NF-κB), and the overload of Ca2+ levels in cardiomyocytes subjected to
heart failure. The nitric oxide initiates lipid peroxidation and produces, by interacting with superoxide
anion, peroxynitrite which is implicated in atherosclerosis [4]. Peroxynitrites trigger lipid peroxidation,
protein oxidation, nitration and activation of matrix metalloproteinases (MMPs) [6]. However, NO can
also maintain inactive the oxidant enzymes (XO and NADPH oxidase) and balance the superoxide/NO
ratio [6]. In addition, iron and copper are the principal metal ions that induce the production of ROS
by Fenton or Haber-Weiss reactions. Iron and copper enhance the lipid peroxidation and production
of free radicals, including alkyl, alkoxy, peroxy and hydroxyl radicals. Conversely, selenium is an
important anti-oxidant ion which regulates the glutathione peroxidase (GSH-Px) [4].
The mitochondria are identified as a major source of ROS production in several organs with
high metabolic activity, for example in the heart [7]. Enzymes that produce ROS, both in membrane
(NADPH oxidase) and in matrix (tricarboxylic acid cycle, TCA) are present in the mitochondria. Under
normal conditions, ROS levels are low for the intra-mitochondrial presence of anti-oxidant systems.
The increase of ROS production simultaneously to the inhibition of anti-oxidant systems and/or of
ETC (electron transport chain) complex increase ROS levels [7]. Furthermore, sirtuins (SIRTs), localized
in the mitochondria, play an essential role in cardiovascular disease and influence energy metabolism,
DNA repair and oxidative stress. Sirtuins induce the deacetylation of forkhead box O (FoxO), NF-κB,
protein kinase B (Akt), p53, superoxide dismutase (SOD), and members of ETC complex I and influence
fatty acid oxidation, cardiac hypertrophy, ischemia/reperfusion (I/R) injury, apoptosis, oxidative stress
and autophagy in cardiomyocytes [8]. Angiotensin (Ang) II, platelet-derived growth factor (PDGF),
and tumor necrosis factor (TNF)-α induce the production of ROS in the cardiac muscle through the
NADPH oxidase and then cardiomyocytes apoptosis, cardiac hypertrophy, reduction of myofilament
sensitivity and cardiac contractility [9].
Several enzymatic and non-enzymatic mechanisms balance the production of ROS and transform
ROS into non-toxic molecules in myocardium, as in other organs [9]. An anti-oxidant enzyme is SOD,
which is present in three forms, copper-zinc SOD (CuZnSOD or SOD1), manganese SOD (MnSOD or
SOD2) and extracellular SOD (EC-SOD or SOD3) [8]. Other enzymes, including the catalase (CAT)
and GSH-Px reduce the production of ROS. SOD converts superoxide in hydrogen peroxide, which is
transformed into water and oxygen by CAT and GSH-Px. Thioredoxin and thioredoxin reductase form
an additional system that blocks ROS production through protein-disulfide oxidoreductase activity.
Intracellular non-enzymatic anti-oxidants are vitamins E and C, β-carotene, ubiquinone, lipoic acid,
urate and glutathione [6,10]. Anti-oxidant enzymes are activated during oxidative stress and after
activation of cytokines. However, these enzymes are down-regulated during the end stage of heart
failure [10].
Recently, many studies identified the potential anti-oxidant effects of polyphenols in cardiac
diseases. Polyphenols can reduce the cardiac damage due to ROS and RNS production [11] (Figure 1).
In this review, we report the last ten years researches on the potential effects of polyphenols in
modulating the cardiotoxicity induced by ROS or RNS.
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Figure 1. Generation of reactive oxygen species (ROS) and their cellular effects.
2. Polyphenols
2.1. Classification
Polyphenols are a large group of natural compounds found in foods and beverages of plant origin
(fruits, vegetables, cereals, herbs, spices, legumes, nuts, olives, chocolate, tea, coffee, and wine) [12,13].
Polyphenols are classified in flavonoids and non-flavonoids, according to the number of phenol
rings and structural elements bound to these rings. The most important classes of flavonoids found in
foods are flavonols, flavones, flavan-3-ols, anthocyanins, flavanones and isoflavones. The subclasses of
dihydroflavonols, flavan-3,4-diols, chalcones, dihydrochalcones, and aurones are minor components of
our diet. The most important classes of non-flavonoids are phenolic acids, stilbenes and lignans [14–16]
(Figure 2).
2.2. Polyphenols and Oxidative Stress and Epigenetic Regulation
Epidemiological studies have shown associations between a diet rich in polyphenols and the
prevention of human diseases [12,17–21]. Polyphenols are natural anti-oxidants present in the human
diet. This activity is related to their metal ions chelating and free radical scavenger properties.
Structural features of polyphenols allow them to act as direct free radical scavengers, such as the
catechol group on the B-ring, the presence of hydroxyl groups at the 3 and 5 position and the
2,3-double bond in conjugation with a 4-oxofunction of a carbonyl group in the C-ring [22]. However,
polyphenols can also behave as pro-oxidants at high doses or in the presence of metal ions, leading
to DNA degradation. However, there is no evidence of sistemic pro-oxidant effect of polyphenols in
humans [23].
It is of note that the direct anti-oxidant activity of polyphenols appears to be ineffective
in vivo, because of the low bioavailability and kinetic constraints, and it has been proposed that
the beneficial effects observed are due to an indirect anti-oxidant effect rather than to their direct
free radical scavenger properties. Indeed, it has been demonstrated that polyphenols possess an
indirect anti-oxidant capacity by modulating genes expression and by inducing the endogenous
anti-oxidant enzymatic defense system [24–26]. The indirect modality of oxidative stress protection
and the health benefits exerted by polyphenols are due to the hormetic mechanism of action.
Polyphenols activate adaptive cellular response pathways (hormetic pathways) that induce the
expression of genes encoding for anti-oxidant enzymes, phase-2 enzymes, protein chaperones and
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survival-promoting proteins. Example of these pathways are the Keap1/Nrf2/ARE, the Sirtuin-FoxO
and the NF-κB pathways [27,28]. In particular, it has been demonstrated that polyphenols activate
the Keap1/Nrf2/ARE pathway through an oxidative mechanism. In fact, polyphenols must be
metabolized into electrophilic compounds for inactivating the inhibitor Keap 1 and thus activating
Nrf2, a transcription factor regulating the expression of most Phase II and some Phase III genes [26].
By transcription-mediated signalling, polyphenols exert long-lasting effects as compared to other direct
anti-oxidant agents [27,29]. However, the hypothesis of activation of Phase II enzymes by polyphenols
has not been proven in human yet [28,30].
Figure 2. Chemical structure of polyphenols.
Several studies reported that epigenetic mechanisms are involved in the development and
progression of different diseases, including cardiovascular diseases [31]. Polyphenols can reduce
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the risk of cardiovascular disease by interacting with signaling cascades and epigenetic factors [32].
Several evidence reported that epigenetic mechanisms are involved in hormesis-like responses [33].
Epigenetic modifications depend on the cell type and the stage of the cardiovascular disease. For
example, the global DNA is hypermethylated in the early stage of atherosclerosis and hypomethylated
in the atherosclerotic lesions, while the peripheral blood leucocytes show global hypermethylation of
DNA. In addition, the methylation or acetylation of DNA regulatory regions up- or down-regulate
the expression of genes involved in cardiovascular diseases [34]. Polyphenols can reduce DNA
methylation, as well as histone modifications and can modify the expression of transcription factors
by epigenetic regulation [32,34–36]. Polyphenols silence chromatin by the inhibition of DNA
methyltransferases and the activation of class III histone deacetylases (commonly called sirtuins) in
vascular endothelium. These effects occur in atherosclerosis and other cardiovascular diseases [36,37].
MicroRNAs (miRNAs) are non-coding RNAs which modify the transcription with no interference
with DNA sequences [34]. miRNAs regulate gene transcription through the degradation or repression
of mRNA. Various miRNAs are also associated with cardiovascular diseases as biomarkers [34].
For example, increased levels of miRNA-1, miRNA-133b and miRNA-499 are observed in acute
myocardial infarction [38,39]. Elevated levels of miRNA-217 are associated with inhibited expression of
SIRT1 in atherosclerosis [40]. However, the levels of several miRNAs can also decrease in cardiovascular
diseases. In fact, miRNA-126 and miRNA-145 levels decrease in patients with coronary artery disease [41].
Polyphenols modulate the expression of several miRNAs [42]. For example, resveratrol regulates
the cardiac function through the expression of miRNA-20b, miRNA-149, miRNA-133, miRNA-21,
and miRNA-27 [32]. In addition, it has been reported that resveratrol exerts cardioprotective effects
through the up-regulation of miRNA-21 and SIRT1 expression in ischemic rats. miRNA-21 regulates
cardiac remodeling, cardiac cell growth and apoptosis [43].
In vitro studies underlying molecular mechanisms through which polyphenols affect oxidative
stress-induced cardiotoxicity are reported below.
3. In Vitro Effects of Polyphenols Against Oxidative Stress-Induced Cardiotoxicity
3.1. Flavonoids
3.1.1. Flavonols
Flavonols are the most common flavonoids present in plant-derived foods, wine and tea.
Quercetin, kaempferol and myricetin are the main flavonols [17].
Several studies investigated the effect of flavonols against H2O2-induced cardiotoxicity. Quercetin
or 3′-O-methyl quercetin treatment (30 μM) or rhamnetin, from berries of Rhamnus petiolaris, (1, 3,
5 μM) treatment of rat/H9c2 cardiomyocytes exposed to H2O2 decreased ROS production and
number of death cells by up-regulating the NQO-1, HO-1, TR (thioredoxin reductase 1), and total
glutathione S-transferase (GST) activities or by inhibiting MAPKs activation [44–46]. Conversely,
3′,4′-dihydroxyflavonol (DiOHF, 10 μM) protected rat cardiomyocytes against H2O2-induced oxidative
stress by increasing the phosphorylation of MAPKs and Akt and regulated the activation of the
reperfusion injury survival kinase (RISK) pathways [47].
Doxorubicin (DOX)/Adriamycin is an anthracycline antibiotic used in chemotherapy and it is
associated with cardiotoxicity. The treatment of H9c2 cardiomyocytes with quercetin (50, 100 μM),
isorhamnetin (6.25–25 μg/mL), kaempferol (20 μM) or dihydromyricetin (50 μM, a flavonoid
extracted from Ampelopsis grossedentata), decreased the DOX-induced apoptosis, ROS production,
lipid peroxidation and NADPH oxidase activity. Isorhamnetin also increased the production of
anti-oxidant enzymes and modulated MAPK activity [48–51].
Quercetin pretreatment (20 μM) of H9c2 cardiomyocytes significantly attenuated trauma-induced
apoptosis, TNF-α levels, ROS production and Ca2+ levels [52].
PKCε, a member of the PKC family of serine and threonine kinases, regulates several processes,
including mitogenesis, cell survival, metastasis and transcriptional regulation. The treatment of rat
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cardiomyocytes with quercetin (40 μM) or kaempferol (20 μM) before anoxia/reoxygenation (A/R)
mediated-injury increased PKCε, cells viability and the expression of SIRT1, decreased apoptosis
and ROS generation and restored the mitochondrial membrane potential [53,54]. The incubation of
sheep myocardial tissues with DiOHF (10−4–10−6 M) blocked ROS production after myocardial I/R
injury [55].
Taxifolin (5–50 μM), a derivative of dihydroquercetin, reduced hypertrophy, ROS generation and
protein synthesis induced by Ang II in neonatal rat cardiomyocytes [56].
The effects of quercetin and hydroxytyrosol, present in the leaves of olive (Olea europaea L.), have
been evaluated in H9c2 cardiomyocytes exposed to xanthine/XO-induced oxidative stress. Both
quercetin and hydroxytyrosol (0.1, 10 μg/mL) reduced the number of death cells, ROS generation
and the phosphorylation of the MAPK-activated protein kinase 2 (MAPKAPK-2) after exposure to
xanthine/XO [57].
3.1.2. Flavones
Flavones are found in plants as 7-O-glycosides. The most abundant flavones in foods are apigenin
(parsley, celery, onion, garlic, pepper, chamomile tea) and luteolin (Thai chili, onion leaves, celery).
Others flavones, less abundant in edible plants, are tangeretin, nobiletin, baicalein, wogonin and
chrysin [17].
The effect of apigenin and vitexin (a flavone glycoside of apigenin isolated from the leaf
of Crataegus pinnatifida Bunge) on A/R injury was recently assessed in H9c2 and neonatal rat
cardiomyocytes. Apigenin (40 μM) or vitexin (10, 30 and 100 μM) were able to increase cells viability
and to decrease ROS generation, cells apoptosis and necrosis [58,59].
Vitexin has also been shown to possess significant protective effects against myocardial I/R
injury in isolated rat hearts. Hearts were perfused with vitexin (50, 100, 200 μM) for 20 min before
ischemia. Treatment with vitexin inhibited I/R-induced reduction of coronary flow and decreased
I/R-induced histopathological alterations of myocardium, inflammatory cytokines and it inhibited
apoptosis [60]. Baicalein from the root of Scutellaria baicalensis was analyzed for its anti-oxidative effects
in chick cardiomyocyte models during hypoxia, simulated I/R, or mitochondrial complex III inhibition
with antimycin A. Baicalein (10–100 μM) was able to scavenge ROS and to decrease the number of
death cells in all different models [61]. Recently, it has been proven that baicalein protected H9c2
cardiomyocytes and also human embryonic stem cells-derived cardiomyocites (hESC-CMs) against
oxidative stress-induced cell injury. Baicalein (10, 30 μM) decreased ROS generation and the number
of death cells and activated Nrf2 pathway [62].
Conversely, Chang et al. reported that preconditioning with baicalein (10 μM) for a brief time
before I/R injury protected chick embryonic ventricular myocytes from apoptosis through mitochondrial
pro-oxidant mechanisms. Thus, the authors hypothesized that the oxidant-mediated protective effects
of baicalein was probably due to the modulation of mitochondrial pro-oxidant signaling as well [63].
Baicalein (1 μM) also reduced H/R-induced myocardium necrosis and apoptosis through μ- and
δ-opioid but not κ-opioid receptors pathways in chick embryonic cardiomyocites [64].
3.1.3. Flavan-3-Ols
The flavan-3-ol subclass includes several compounds with different chemical structures that
can be divided in monomers, (+)-catechin, (−)-epicatechin, (+)-gallocatechin, (−)-epigallocatechin,
(−)-epicatechin-3-O-gallate, (−)-epigallocatechin-3-O-gallate (EGCG), and polymers (proanthocyanidins).
They are found in fruits, berries, cereals, nuts, chocolate, red wine, and tea [17].
Several studies investigated the effects of flavan-3-ols in cardiomyocytes exposed to exogenous
and endogenous oxidant stress. Pretreatment of rat cardiomyocytes exposed to H2O2 with EGCG
(20, 50 μM or 50–100 mg/L) and theaflavin-3,3′ digallate (TF3, 20 μM) decreased ROS production,
cellular damage and apoptosis through the inhibition of telomere dependent apoptotic pathway [65–68].
EGCG (50 μM) was also able to protect H9c2 cardiomyocytes from H2O2-induced changes in the
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expression of β-catenin, N-cadherin and the gap junction protein Cx43 and to activate caveolin-1 by
modulating Akt/GSK-3β signaling [66].
Other studies investigated the cardioprotective role of flavan-3-ols in cardiomyocytes exposed to
DOX. EGCG (25, 38, 50, or 100 μM) and grape seed proanthocyanidin extract (GSPE, 50 μg/mL) protected
rat cardiomyocytes against DOX-induced oxidative stress by reducing apoptosis, ROS generation
and the distruption of mitochondrial membrane potential, and by increasing anti-oxidant enzymes
and by reversing DOX-induced intracellular Ca2+ depletion in the sarcoplasmic reticulum [69–71].
GSPE prevented cardiotoxicity induced by DOX, without interfering with DOX anti-neoplastic activity
in primary cultures of cardiomyocytes [71]. Two studies showed the role of flavan-3-ols against
toxicity induced by I/R injury. EGCG (10, 100 μM), and GSPE (50 μg/mL) protected rat and
chick cardiomyocytes from I/R-induced apoptosis and cellular damage [72,73]. Similarly, Hirai et al.
evaluated the cardioprotective effects of EGCG and the catechin epimer (GCG) in isolated guinea-pig
Langendorff hearts subjected to I/R. EGCG (3 × 10−5 M) or GCG (3 × 10−6 M) was introduced into the
perfusate 4 min before ischemia and during reperfusion. EGCG and GCG improved the recovery of left
ventricular end diastolic pressure (LVDP), increased the tissue levels of ATP and phosphocreatine and
inhibited apoptosis [74]. Wei and Meng analyzed the effect of EGCG against bisulfite/sulfite, an agent
that induces sulfur- and oxygen-based free radicals and affects voltage-gated sodium (Na+) channels
(VGSC), or lead in rat ventricular myocytes. EGCG (30 μg/mL) increased anti-oxidant enzymes and
decreased ROS levels and lipid peroxidation in ventricular myocytes of rats exposed to sulfite or
lead [75,76]. EGCG also protected Na+ channels against the oxidative damage induced by sulfite [75].
An in vitro study observed the effects of flavonoids isolated from Lindera erythrocarpa in H9c2
cardiomyocytes exposed to BSO (buthionine-(S,R)-sulfoximine), an inducer of oxidative stress and
cell death. It was found that (−)-epicatechin (3 μM), avicularin (3 μM) and quercitrin (3 μM) had the
ability to inhibit BSO-induced cardiomyocytes death [77].
3.1.4. Anthocyanins
Anthocyanins are a subclass of more than 550 compounds. The most abundant anthocyanins are
cyanidin, pelargonidin, delphinidin, peonidin, petunidin, and malvidin. They occur in two forms:
the aglycone form (anthocyanidin) and the heteroside form (anthocyanin). They are found mainly in
berries, cherries, red grapes, and currants [17].
Two studies evaluated the effects of malvidin, an anthocyanidine present in red wine,
and cyanidin-3-O-glucoside (Cy3G) in isolated rat hearts after I/R. Pretreatment with malvidin
(10−7 M) or Cy3G (20 μM) increased left ventricular (LV) pressure, reduced cells apoptosis and
necrosis [78,79].
Louis et al. investigated the in vitro effect of blueberry phenol fractions (BF) to prevent the
pathologic damage induced by norepinephrine (NE) in adult rat cardiomyocytes. NE induced cells
hypertrophy and death by activating calpains. Pretreatment with BF (6.55 μg/mL) reduced activation
of calpains and apoptosis and increased activity of anti-oxidant enzymes [80].
3.1.5. Flavanones
Flavanones are found mainly in citrus fruits and occur as aglycones, mono- and di-glycosides.
Naringenin and hesperetin are the most important aglycones; neohesperidin (hesperetin-7-O-
neohesperidoside) and naringin (naringenin-7-O-neohesperidoside) are neohesperidosides, and
hesperidin (hesperetin-7- O-rutinoside) and narirutin (naringenin-7-O-rutinoside) are rutinosides [17].
Naringenin (NGN) was proven to possess a cytoprotective effect against oxidative stress by
up-regulating the transcription of Nrf2 and its target genes (GCL and NQO-1). Indeed NGN (50 μM)
protected H9c2 cardiomyocytes from H2O2-mediated cells death, reduced lipid peroxidation and
increased the activity of anti-oxidant enzymes [81].
Several studies demonstrated that naringin was able to protect H9c2 cardiomyocytes against
high glucose (HG)-induced injury. Pretreatment with naringin (5 or 80 μM) increased cells
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viability and reduced the number of apoptotic cells, and dissipation of mitochondrial membrane
potential (MMP). Naringin protected H9c2 cardiomyocytes by inhibiting ROS production and
activation of MAPKs [82–84]. Naringin also confered protection against A/R-induced injury in H9c2
cardiomyocytes. Pretreatment with naringin (10, 20, 40 μg/mL) inhibited apoptosis and oxidative
stress. Naringin protected H9c2 cardiomyocytes through the activation of ERK1/2, PKCδ, Akt and
then the activation of Nrf2 signaling pathway [85].
Several studies analyzed the effect of naringenin-7-O-glucoside (NARG) extracted from Chinese
traditional medicine herb Dracocephalum Rupestre against DOX-induced oxidative stress and apoptosis.
NARG (5–40 μM) reduced DOX-induced apoptosis, necrosis, ROS generation and it up-regulated the
expression of endogenous anti-oxidant enzymes in H9c2 cardiomyocytes [86–88].
Yang et al. demonstrated that hesperetin (25 μM) exerted an anti-apoptotic effect in LPS-stimulated
H9c2 cardiomyocytes, through the mitochondria-dependent intrinsic apoptosis pathway [89].
3.1.6. Isoflavones
Isoflavones are classified as phyto-estrogens for their chemical structure. They are found in
soybeans, soy products, and leguminous plants. Isoflavones are present in plant food mainly as
aglycones (genistein, daidzein) and glycosides (genistin, daidzin, puerarin) [17].
Puerarin, a bioactive daidzein glucoside derived from Radix puerariniae, was studied for its effects
on Ang II-induced cardiac hypertrophy. In vitro pretreatment of neonatal murine cardiomyocytes with
puerarin (50, 100 μM) decreased NADPH oxidase activity, inhibited ROS production and the activation
of oxidative stress-related signaling pathways [90].
Calycosin, an O-methylated isoflavone derived from Astragali radix, has been evaluated for
its effects on oxidative stress-induced apoptosis in H9c2 cardiomyocytes. It has been found that
pretreatment with calycosin (5, 10, 20 μM) enhanced the expression and activation of ERα/β and Akt
phosphorylation and inhibited H2O2-induced cell injury and apoptosis [91].
3.1.7. Chalcones and Dihydrochalcones
Chalcones occur in tomatoes, licorice, shallots and bean sprouts, while dihydrochalcones are
present in apples [17].
Several studies reported the important role of chalcones against I/R injury. Isolated rat hearts,
pretreated with licochalcone D (1 μg/mL) or licochalcone B (0.5, 1 μg/mL) and then subjected to
I/R, showed decreased apoptosis, decreased expression of pro-inflammatory cytokines, reduced cells
necrosis and increased expression of anti-oxidant enzymes. The authors supposed that licochalcone
D exerted these effects through the activation of Akt and the block of NF-κB/p65 and p38 MAPK
pathways [92,93]. Isoliquiritigenin treatment (100 μM) of cardiomyocytes isolated from hearts with I/R,
activated the AMP-activated protein kinase (AMPK) and MAPKs signaling pathways while reduced
the mitochondrial potential and cardiac ROS levels [94]. It has been reported that safflor yellow A
(SYA), a chalcone extracted from Carthamus tinctorius, and hydroxysafflor yellow A (HSYA) protected
H9c2 and primary cultured neonatal rat cardiomyocytes exposed to A/R. The treatment with SYA
(40, 60, 80 nM) or HSYA (20 μM) before A/R injury increased the levels of anti-oxidant enzymes and
decreased cells necrosis and apoptosis through the up-regulation of HO-1 expression [95,96].
Another study investigated the in vitro effect of L6H9, a novel chalcone derivative, in the
pathogenesis of diabetic cardiomyopathy (DCM). The treatment with L6H9 (10 μM) before incubation
with glucose decreased the levels of pro-inflammatory cytokines, pro-apoptotic proteins and ROS
in H9c2 cardiomyocytes. In addition, L6H9 increased the expression of Nrf2 and Nrf2-downstream
anti-oxidant genes and inhibited fibrosis and hypertrophy [97].
Dludla et al. performed a study on the effects of a popular South African herbal tea, rooibos,
produced from the leaves and stems of Aspalathus linearis, on diabetic cardiomyopathy (DCM).
The authors evaluated the effects of an aqueous extract of fermented rooibos (FRE), containing
the chalcone aspalathin and the flavonoids isoorientin, orientin, quercetin-3-O-robinobioside, in
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cardiomyocytes isolated from STZ-induced diabetic rats. Pretreatment of cardiomyocytes with FRE
(1 and 10 μg/mL) protected cardiomyocytes against experimentally induced oxidative stress and
ischemia [98]. Another study demonstrated that aspalathin, found in Aspalathus linearis (rooibos),
protected H9c2 cardiomyocytes from chronic hyperglycemia-mediated apoptosis, by inhibiting the
loss of mitochondrial membrane potential and ROS production and by increasing anti-oxidant
enzymes [99].
3.2. Phenolic Acids
Phenolic acids are derivatives of benzoic acid and cinnamic acid and include the hydroxybenzoic
acids (protocatechuic acid, and gallic acid) and the hydroxycinnamic acids (caffeic acid, ferulic acid,
p-coumaric acid, and sinapic acid). The formers are found in few edible plants, while the laters are
found in fruits, coffee, and cereal grains [17]. Phenolic acids were able to protect cardiomyocytes against
H2O2-induced injury [100–104]. Gui-ling-gao (GLG, also known as turtle jelly) is a traditional food in
Southern China and Hong Kong. Li et al. revealed nine compounds in GLG using mass spectrometry:
caffeoylquinic acid, 5-O-caffeoylshikimic acid, astilbin, 3,4-dicaffeoylquinic acid, 4,5-dicaffeoylquinic
acid, neoisoastilbin, isoastilbin, engeletin and 3,5-dicafeoyylquinic acid. GLG (1.372 mM) had the
ability to scavenge free radicals and to abolish hemolysis, an index of oxidative damage. GLG increased
cell survival and reduced apoptosis in H9c2 cardiomyocytes exposed to H2O2 [100]. Castanea sativa
Mill. (CSM)-bark extract contains tannins and phenolic compounds, including ellagic acid, gallic
acid, and 4 ellagitannins (vescalin, castalin, vescalagin and castalagin). Pretreatment with CSM-bark
extract (50, 100 μg/mL) of neonatal rat cardiac myocytes for 24 h prior to H2O2 exposure protected
cells from oxidative stress-induced injury [101]. Phellinus linteus is a medicinal mushroom rich of a
phenolic compound, the hispidin. H9c2 cardiomyocytes treated with hispidin (30 μM) prior to H2O2
exposure, showed increased cell viability, reduced cells necrosis and ROS generation. In addition,
hispidin decreased H2O2-induced apoptosis through the activation of Akt/GSK3β and MAPKs [102].
Neonatal rat cardiac myocytes (RCMs) pretreated with methyl gallate (50 μM) for 30 min prior to
exposure to cobalt or H2O2, showed reduced apoptosis and ROS levels [103]. Ku et al. compared the
in vitro effect of caffeic acid (CA) and pyrrolidinyl caffeamide (PLCA), a derivative of CA. HL-1, a
mouse atrial cardiomyocyte cell line, was pretreated with CA and PLCA (3 μM) for 1 h before H2O2
administration. PLCA reduced the production of ROS and increased cells viability more than CA. In
addition, PLCA treatment preserved the expression of anti-oxidant enzymes in cardiomyocytes [104].
Song et al. demonstrated the cytoprotective effect of ferulic acid (1, 5, or 10 μg/mL) in hepatocytes
and cardiomyocytes against HG-induced injury and oxidative stress [105].
Atale et al. analyzed the effect of gallic acid-enriched methanolic Syzygium cumini pulp extract
(MPE) on cardiotoxicity induced by malathion, an organophosphate pesticide. MPE treatment (20 μg/mL)
restored the integrity of extra cellular matrix components and reduced the malathion-induced oxidative
stress in H9c2 cardiomyocytes [106].
The beneficial effects of caffeic, chlorogenic and rosmarinic acids against DOX-induced toxicity
were investigated in neonatal rat cardiomyocytes. Hydroxycinnamic acids (100, 200 μM) attenuated
DOX-induced cell damage and the iron-dependent DOX-induced lipid peroxidation of microsomal
and mitochondrial membranes [107].
Danshensu (3-(3,4-dihydroxyphenyl)-2-hydroxypropanoic acid) is the major water-soluble active
component of Danshen, the dried root of the traditional Chinese herb Salvia miltiorrhiza, and it has
been analyzed for its cardioprotective effects. Treatment with danshensu (10 μM) during reperfusion
protected H9c2 cardiomyocytes from I/R-induced apoptosis [108]. Similarly, isolated rat hearts,
perfused with danshensu (1, 10 μM) for 20 min and then subjected to I/R, showed reduced cells
necrosis and ROS production and increased activity of anti-oxidant enzymes. These effects were
achieved by the activation of Akt/ERK1/2/Nrf2 signaling pathways [109].
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3.3. Lignans
Lignans (ecoisolariciresinol, matairesinol, medioresinol, pinoresinol, and lariciresinol) are found
in high concentration in linseed and in minor concentration in algae, leguminous plants, cereals,
vegetables, and fruits [17].
Two studies investigated the transduction pathways involved in the cytoprotective effect of (−)
schisandrin B (Sch B), the most abundant dibenzocyclooctadiene lignan in S. chinensis (Turcz.) Baill, in
H9c2 cardiomyocytes. The treatment of H9c2 cardiomyocytes with (−)Sch B (15 or 20 μM) activated
the MAPKs, increased the nuclear expression of Nrf2 and reduced the H/R-induced apoptosis and
inflammation [110,111]. Chang et al. showed that the treatment with deoxyschizandrin (DSD, 1 μM)
and schisantherin A (STA, 1 μM) reduced apoptosis in cardiac cells subjected to I/R [112].
Cho et al. investigated the effect of syringaresinol in modulating HIF-1 (hypoxia inducible factor-1)
during H/R injury. Syringaresinol (25 μM) protected H9c2 cardiomyocytes against H/R induced-cells
damage, and reduced apoptosis. In addition, syringaresinol suppressed the expression of HIF-1 but
stimulated the nuclear expression and activation of FoxO3, which decreased the expression of ROS
and increased the expression of anti-oxidant enzymes [113].
Su et al. evaluated the in vitro effect of sesamin in DOX-induced citotoxicity in H9c2 cardiomyocytes.
Treatment with sesamin (40 μM) increased cells viability, reduced the release of free radicals and the
mitochondrial damage induced by DOX [114]. Zheng et al. demonstrated that sesamin treatment
reduced the Ang II-induced apoptotic rate and ROS production in H9c2 cardiomyocytes [115].
3.4. Stilbenes (Resveratrol)
The main dietary source of stilbenes is resveratrol (3,5,4′-trihidroxystilbene) from red wine,
grapes, berries, plums, peanuts, and pine nuts [17]. Many studies investigated the protective effects
of resveratrol against H2O2-induced damage in cardiomyocytes. Resveratrol treatment (10–50 μM)
protected H9c2 cardiomyocytes from H2O2-induced cell injury, apoptosis and autophagy and reduced
ROS generation through activation of SIRT1 and mitochondrial biogenesis signaling pathways [116–118].
Movahed et al. also demonstrated that pretreatment with resveratrol (30 μM) prevented necrosis
and the reduction of anti-oxidant enzymes activity in H2O2-exposed adult rat cardiomyocytes [119].
In addition, resveratrol treatment (50 μM) was effective in protecting rabbit ventricular myocytes
against the oxidative stress-induced arrhythmogenic activity and Ca2+ overload, through the reduction
of ROS production and inhibition of Ca2+/calmodulin-dependent protein kinases II (CaMKII) [120].
A study by Chen et al. demonstrated the protective effect of resveratrol against apoptosis induced by
hypoxia in H9c2 cardiomyocytes. Resveratrol (20 μM) increased SIRT1 expression, leading to inhibition
of forkhead box protein O1 (FoxO1) expression and activity [121].
Several studies showed the cardioprotective role of resveratrol in cardiomyocytes exposed to
I/R injury. Pretreatment with resveratrol (20 μM) protected neonatal rat ventricular cardiomyocytes
from I/R-induced oxidative injury, apoptosis, necrosis and mitochondrial dysfunction through the
induction of SIRT1 which modulated MAPKs signaling [122]. Resveratrol was effective in attenuating
the cardiotoxicity induced by chemotherapeutic drugs, such as DOX and arsenic trioxide, and by
anti-retroviral agents, such as azidothymidine (AZT). Danz et al. observed that resveratrol (10 μM)
inhibited DOX-induced ROS generation and necrosis through the activation of SIRT1 pathway in
neonatal rat ventricular myocytes [123]. Similarly, Gao and colleagues reported that pretreatment
with resveratrol (3μM) attenuated the mitochondrial ROS generation, apoptosis and necrosis induced
by AZT in human primary cardiomyocytes [124]. Zhao et al. investigated the protective effect of
resveratrol against arsenic trioxide (As2O3)-induced cardiotoxicity in H9c2 cardiomyocytes. They
demonstrated that pretreatment with resveratrol (10 μM) reduced cells apoptosis and necrosis,
increased cell viability and inhibited the generation of ROS and the intracellular Ca2+ mobilization
induced by As2O3 [125].
Resveratrol was also able to protect primary cultures of neonatal rat cardiomyocytes against
HG-induced apoptosis through the AMPK pathway. Resveratrol (50 μM) inhibited apoptosis and
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ROS production and increased the activity of anti-oxidant enzymes [126]. Das et al. demonstrated
that the treatment of human and murine cardiomyocytes with resveratrol (100 μM) reduced the
iron-induced oxidative stress by decreasing the levels of free radicals. The authors observed that the
inhibition of oxidative stress was dependent on the increase of SIRT1 and on the reduction of FoxO1
expression [127].
Several studies investigated the in vitro effects of resveratrol derivatives. The effect of polydatin,
a resveratrol glucoside, against phenylephrine induced-cardiac hypertrophy was investigated in
neonatal rat cardiomyocytes. Polydatin (50 μM) induced an anti-hypertrophic effect by decreasing
ROS production and by inhibiting the RhoA/ROCK signaling pathway, that play a role in mediating
the development of cardiac hypertrophy and heart failure [128]. Recently, Feng et al. investigated the
effect of an analog of resveratrol, bakuchiol (BAK), a monoterpene phenol isolated from the seeds of
Psoralea corylifolia (Leguminosae), against the I/R-induced oxidative damage. Pretreatment with BAK
(1 μM), administered 5 min before I/R, protected isolated rat hearts from I/R through the activation of




Curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is another polyphenol
compound and a member of the curcuminoid family. It is found in turmeric, a spice produced from
the rhizome of Curcuma longa [17].
Several studies investigated the protective effect of curcumin against the oxidative stress
in cardiomyocytes. Pretreatment of HL-1 cells with curcumin (5 μM) reduced Ang II-induced
cardiomyocytes hypertrophy, oxidative stress and apoptosis [130]. Kim et al. showed that the
curcumin (10 μM) pretreatment reduced the cardiotoxicity caused by TNF-α, peptidoglycan or H/R in rat
cardiomyocytes [131]. Curcumin also attenuated the I/R-induced toxicity through SIRT1 pathway [132].
Xu et al. analyzed the protective role of curcumin against A/R-induced mitochondrial injuries in rat hearts.
Curcumin (1 μM) restored the mitochondrial respiratory activity, inhibited the lipoperoxidation, protein
carbonylation and cells apoptosis [133]. Treatment of primary cultures of neonatal rat cardiomyocytes
with curcumin (10 μM) reduced the glucose-induced toxicity by decreasing the apoptotic rate and
ROS production. Curcumin reduced the toxicity through the NADPH-mediated oxidative stress and
PI3K/Akt pathway [134].
Several studies investigated the cardioprotective effects of curcumin derivatives. Nehra et al.
evaluated the effect of nanocurcumin after hypoxia. H9c2 cardiomyocytes treated with nanocurcumin
(50 μM), compared to cells treated with curcumin, showed reduced hypertrophy and apoptosis [135].
In addition, nanocurcumin (50 ng/mL) inhibited the hypertrophy, reduced necrosis and ROS
generation, restored the mitochondrial membrane potential and glucose transporters and increased
ATP levels in primary human ventricular cardiomyocytes (HVCM) [136]. The treatment of hearts with
AID (alpha-interacting domain of the L-type Ca2+ channel) peptide tethered nanoparticles containing
25 mg of curcumin (NP-C-AID) or resveratrol (NP-R-AID) reduced cells necrosis, ROS generation
and mitochondrial membrane potential in response to I/R injury. However, only NP-C-AID reduced
the oxidative stress by balancing the GSH/GSSG ratio, and the muscle damage [137]. The effects of
monocarbonyl analogues of curcumin (MACs) with high stability was evaluated in I/R-induced toxicity
and injuries. Among these MACs, the curcumin analogue 14p (10 μM) reduced the toxicity by blocking
the oxidative stress, apoptosis and by activating the Nrf2 pathway in H9c2 cardiomyocytes [138].
3.5.2. Olive Oil Polyphenols
Olive oil is a source of at least 30 phenolic compounds. The three phenolic compounds found in
highest concentration in olive oil are oleuropein, hydroxytyrosol and tyrosol [139].
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Bali et al. compared the effects of the ethanolic and methanolic extracts of olive leaves with the
effects of oleuropein, hydroxytyrosol, and quercetin, as a positive control, in H9c2 cardiomyocytes
exposed to 4-hydroxy-2-nonenal (HNE), which induced oxidative damage. H9c2 cardiomyocytes were
pretreated with each compound (0.1, 10 μg/mL) and then exposed to HNE. Both extracts of olive
leaves and the other compounds inhibited cells apoptosis, blocked ROS production, counteracted
mitochondrial dysfunction. The ethanolic extract, that contained large amounts of oleuropein,
hydroxytyrosol, verbascoside, luteolin, and quercetin, exerted a better protection against HNE-induced
cardiotoxicity than the methanolic extract or each phenolic compound [140].
3.5.3. Salvianolic Acid
Salvianolic acid B (SalB), derived from the Chinese herb Salvia miltiorrhiza, was investigated
against TNF-α-induced MMP-2 up-regulation and oxidative stress in human aortic smooth muscle
cells (HASMCs). Pretreatment with SalB (0.1, 1, 10 μM) inhibited the TNF-α-induced increase of ROS
production. In addition, the polyphenol suppressed the TNF-α-induced MMP-2 enzymatic activity [141].
SalB (5, 10 μM) was also able to protect human aortic endothelial cells (HAECs) from oxidized-low
density lipoprotein (ox-LDL) induced oxidative injury via inhibition of ROS production [142].
3.5.4. Silymarin and Silibinin
Silymarin (SM) is a standardized extract from the seeds of Silybum marianum L. Gaertneri,
and the main constituents are silibinin, and other flavonolignans (dehydrosilibinin, silychristin
and silydianin). Silymarin (0.50 mg/mL) showed ROS radical scavenging activities. Silymarin
(0.50 mg/mL) improved mitochondrial functions, reduced NO levels, protein carbonyl content and
lipid peroxidation and increased anti-oxidant and Kreb’s cycle enzymes in cardiac mitochondria
exposed to copper-ascorbate [143].
Silibinin (50–200 μM) reduced cellular damage after H2O2-exposure in H9c2 cardiomyocytes.
In addition, the treatment with silibinin (100–200 μM) inhibited MAPKs and Akt activation in
phenylephrine-induced hypertrophic H9c2 cardiomyocytes [144]. Gabrielova et al. demonstrated that
the treatment of rat neonatal cardiomyocytes with 2,3-dehydrosilybin (DHS) (10 μM) attenuated the
H/R-induced damage by decreasing the generation of ROS and protein carbonyls [145].
3.6. Combination of Polyphenols and Comparative Studies
Esmaeili and Sonboli demonstrated the anti-oxidant and free radical scavenging activities of
Salvia brachyantha extract, which contains phenolic and flavonoid compounds such as rosmarinic acid,
caffeic acid, luteolin, gallic acid, rutin and catechin. The pretreatment of H9c2 cardiomyocytes with
the Salvia brachyantha extract (50–100 μg/mL) reduced the production of ROS, increased anti-oxidant
enzymes and prevented cells apoptosis induced by xanthine/XO [146].
Chen et al. analyzed the cardioprotective role of the total flavonoids from Clinopodium chinense
(Benth.) O. Ktze (TFCC), against the adverse effects of DOX treatment in H9c2 cardiomyocytes. H9c2
cardiomyocytes treated with TFCC (25 μM) showed increased levels of anti-oxidant enzymes and
decreased cells necrosis and apoptosis and ROS production. Furthermore, TFCC blocked DOX-induced
over-expression of p53 and regulated the phosphorylation of MAPKs, Akt and PI3K [147].
Chang et al. evaluated and compared the oxidant scavenging capacity of five flavonoids
(wogonin, baicalin, baicalein, catechin and procyanidin B2) and their protective efficacy in a chick
cardiomyocytes model. Catechin and procyanidin B2 showed the best scavenging capacity for DPPH
(1,1-diphenyl-2-picryhydrazyl) and superoxide radicals. Only baicalein exhibited a significant hydroxyl
radical scavenging potency. The cardiomyocytes were treated with three different treatment protocols
during I/R. The cardiomiocytes were exposed to flavonoids (25 μM) before and during I/R (chronic
treatment) or during I/R or during reperfusion phase. The administration of all flavonoids, except for
wogonin, reduced apoptosis in chronic treatment. Baicalein, procyanidin B2, and catechin reduced
apoptosis when flavonoids were administered only during I/R. In addition, only baicalein and
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procyanidin B2 treatment during reperfusion phase reduced cells apoptosis. Flavonoids had different
radical scavenging capacities and protective effects against I/R injury depending on the timing of
treatment [148].
Akhlaghi et al. analyzed the effects of several flavonoids (all at 25 μM) in H9c2 cardiomyocytes
exposed to I/R injury. The pretreatment with catechin improved cells viability, while cyanidin showed
a mild protection. However, only the pretreatment of H9c2 cardiomyocytes with quercetin and EGCG
reduced the oxidative stress [149].
Mechanisms of action of in vitro effects of polyphenols to counteract the oxidative stress-induced
cardiotoxicity are summarized in Table 1.
4. Bioavailability of Polyphenols: Is the Effective Polyphenols Dose Feasible In Vivo?
Although in vitro studies reported that polyphenols exert strong anti-oxidant activity, their
beneficial effects in humans remains poor, because of their low bioavailability. Bioavailability is the
quantity of a compound that is absorbed and metabolized within the human body after dietary intake
and it is measured commonly with the maximum plasma concentration (Cmax) reached after the
intake. In fact, in order to produce in vivo effects, a compound must enter the circulation and reach
the tissues, in the native or metabolized form, in a sufficient dose to exert biological activity [17].
After dietary intake, polyphenols are metabolized and then the metabolites induce the physiological
effects observed in in vivo models [150,151]. The doses of polyphenols employed in vitro usually
range between μmol/L and mmol/L, but the concentrations of metabolites in the plasma are of only
nmol/L [150]. Endogenous factors affect the bioavailability of polyphenols, such as their metabolism
in the gastrointestinal tract and liver, their binding on the surfaces of blood cells and microbial flora in
the oral cavity and gut, and regulatory mechanisms that prevent the toxic effects of high polyphenols
levels on mitochondria or other organelles [152]. Furthermore, polyphenols are often used as aglycones
or conjugates to sugar and not as their active metabolites in in vitro studies [150].
Polyphenols can interact with several substances that influence their bioavailability. For example,
polyphenols can bind proteins and metal cations that modify their absorption [153]. Dietary factors can
affect the bioavailability of polyphenols, such as food matrix and food preparation techniques [154].
The rate and extent of intestinal absorption and the metabolites in the plasma mainly depend on
the chemical structure of polyphenols. Polyphenols show different bioavailability and it has been
estimated that the plasma concentration of polyphenols and total metabolites reached after an intake of
50 mg of aglycones ranged from 0 to 4 μM. In addition, the half-lives of polyphenols in human plasma
are in the range of few hours and depend on the food source [155]. However, in order to assess the real
in vivo potential of polyphenols it is essential to know not only their plasma concentration, but the
concentration of the active metabolites in the target tissues [155]. Thus, it would be necessary to employ
the active metabolites of polyphenols in in vitro studies [151]. Accordingly, although it is very difficult,
it would be important to analyze the concentration of polyphenols in a specific tissue [150]. A limited
number of studies detected the concentration of polyphenols in different tissues of mice and rats,
including endothelial cells and heart, after administration of the compounds. The tissue concentrations
are different depending on the type of tissue and the dose administered, but tipically range from 30 to
3000 ng aglycone equivalents/g tissue [13]. Unfortunately, it is much more difficult to evaluate the
tissue concentrations of polyphenols in humans and in fact the studies are very scarce [150]. Overall,
a better knowledge of this issue is needed.
Despite the limit of the in vitro studies, anti-oxidative effects of polyphenols have been reported
in in vivo experimental models.
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5. In Vivo Effects of Polyphenols Against Oxidative Stress-Induced Cardiotoxicity
5.1. Flavonoids
5.1.1. Flavonols
Several studies showed the in vivo cardioprotective effects of flavonols against DOX-induced
cardiotoxicity. The quercetin (100 or 15 mg/kg) pretreatment of mice and rats treated with DOX
improved cardiac function, blocked ROS generation and lipid peroxidation and increased anti-oxidant
enzymes [48,156]. Isorhamnetin (5 mg/kg, i.p.), kaempferol (10 mg/kg, i.p.) and dihydromyricetin
(125–500 mg/kg) administration reduced cardiomiocytes necrosis and apoptosis, ROS production and
lipid peroxidation and increased the production of anti-oxidant enzymes in in vivo models exposed to
DOX [49–51].
Flavonols effects were analyzed also in rats underewent I/R injury. Rats treated with kaempferol
(15 mM) recovered cardiac function, reduced infarct size and cardiomyocytes apoptosis [157].
Astragalin (kaempferol-3-O-glucoside) pretreatment (10 μM) showed cardioprotective effects in
rats via its anti-oxidative, anti-apoptotic, and anti-inflammatory activities [158]. The in vivo effects
of 3′,4′-dihydroxyflavonol (DiOHF) was investigated in sheep. The in vivo administration of DiOHF
(5 mg/kg) after I/R injury reduced ROS generation, neutrophil accumulation in coronary microvessels,
left ventricular diastolic pressure (LVDP) and infarct size, increased the left anterior descending
(LAD) coronary artery blood flow, the total plasma nitrate and nitrite and restored the myocardial
function [55]. The myocardial I/R injury was blocked by NP202, a novel pro-drug of DiOHF, through
the activation of MAPKs signaling in sheep [47].
A study by Bhandary et al. investigated the preventive effects of rutin, quercetin and various
isoflavones (biochanin A, daidzein, genistein) in an ex vivo model of I/R injury. They perfused rat
hearts with isoflavones (10 μM), quercetin (10 μM), and rutin (50 μM) before ischemia and during the
reperfusion time. Only rutin possessed the ability to attenuate cardiac I/R-associated hemodynamic
alterations [159]. In addition, rutin increased anti-oxidant molecules and reduced cells necrosis and
apoptosis and overall cardiac dysfunction in rats exposed to sodium fluoride-induced oxidative
stress [160].
The isoproterenol injection induced cardiotoxicity in rats. The co-treatment with vincristine
(25 mg/kg) and quercetin (10 mg/kg) attenuated the cardiotoxicity induced by isoproterenol [161].
Guo et al., employing a mouse model with transverse aortic constriction (TAC), demonstrated
that taxifolin, a dihydroquercetin derivative decreased ROS levels, attenuated the pressure overload,
blocked the cardiac remodeling, ventricular dysfunction and fibrosis [56].
5.1.2. Flavones
Several studies demonstrated the in vivo cardioprotective role of flavones against I/R. In murine
and rat models baicalein (30 mg/kg), apigenin (5 mg/kg) and vitexin (6, 3, 1.5 mg/kg) reduced I/R
injury-induced infarct size, apoptosis, pro-inflammatory cytokines and oxidative stress [162–164].
Employing diabetic rats subjected to myocardial I/R, it has been assessed the protective effects of
luteolin or breviscapine, a flavonoid extracted by Erigeron breviscapus. Luteolin (100 mg/kg/day
intragastrically) or breviscapine (60 mg/kg orally) reduced the ROS production [165,166]. Luteolin
also improved left ventricular function and cardiac tissue viability [165]. In addition, breviscapine
reduced the expression of ICAM-1 in rat myocardium, the inactivation of ATPase and associated ionic
disturbances [166].
The protective effect of apigenin in isolated rat heart suffered from A/R was also demonstrated. Rats
intraperitoneally injected with apigenin (4 mg/kg) showed reduced cells death and infarct size [58].
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5.1.3. Flavan-3-Ols
Several studies reported that the administration of green tea extract (GTE) (200 mg/kg or
400 mg/kg, prior to I/R injury) to rats reduced the myocardium damage, infarct size and apoptosis
and increased the anti-oxidant enzymes [167,168]. The anti-oxidant properties of flavan-3-ols were
also evaluated in DOX-exposed in vivo models. Oral pretreatment for 30 days with GTE (100, 200 and
400 mg/kg) or procyanidins (150 mg/kg daily) decreased the cardyomyocytes death and increased
anti-oxidant enzymes in rat models exposed to DOX [169,170].
Sheng et al. reported the protective effects of EGCG in cardiac hypertrophy induced by abdominal
aortic constriction in rats. They showed that EGCG (50 and 100 mg/kg) administered intragastrically
to rats for 6 weeks, decreased myocardium damage and ROS generation. The highest doses of EGCG
improved histological changes in the heart tissue, inhibited fibrosis and myocytes apoptosis [67]. Using
the same rat model, the authors evaluated the effect of EGCG and other traditional anti-hypertrophic
therapeutic agents on telomere dysfunction mediated apoptotic signal. They demonstrated that
treatment for 6 weeks with EGCG (50 and 100 mg/kg) or quercetin (100 mg/kg) reduced heart weight
indices and cardiac myocytes apoptosis in the hypertrophic myocardium [171].
Another investigation reported the effect of grape seed proanthocyanidins (GSP) against cadmium
(Cd), a toxic heavy metal that induced oxidative stress and cardiotoxicity. In this study, GSP pretreatment
(100 mg/kg) reduced Cd-induced disruption of cardiac myofibrils, cardiomyocytes necrosis and apoptosis,
production of pro-inflammatory cytokines and increased the levels of anti-oxidant enzymes in rats [172].
Wang et al. demonstrated that GSP (195 mg/kg, intragastric administration) treatment prevented
deoxycorticosterone (DOCA)-salt-induced cardiovascular remodeling and endothelial dysfunction in
mice, in part through the involvement of oxidative stress [173].
5.1.4. Anthocyanins
Liu et al. reported the effects of blueberry anthocyanins-enriched extracts (BAE) on cyclophosphamide
(CTX)-induced cardiac toxicity in rats. BAE (20 and 80 mg/kg daily by gavage) treatment attenuated the
CTX-induced cardiac injury through its anti-inflammatory and anti-oxidant proprieties. BAE decreased
mean arterial blood pressure and myocardial leukocyte infiltration, increased heart rate and improved
cardiac dysfunction, and reduced LV hypertrophy and fibrosis. Rats treated with BAE showed a
decrease expression of pro-inflammatory cytokines, an increase of anti-inflammatory cytokines and
anti-oxidant enzymes [174].
5.1.5. Flavanones
Two studies reported the cardioprotective role of the flavanone glycoside hesperidin on
I/R-induced arrhythmias in an in vivo rat model. Rats were administered with hesperidin (100 mg/kg,
p.o. for 15 days) and then subjected to I/R. The administration of hesperidin induced antiarrhythmic
effects, a reduction of inflammation, oxidative stress and cardiomyocytes apoptosis [175,176]. A similar
study was conducted with naringin. Naringin was administered per os (40, 80 mg/kg, daily) to rats
for 14 days and then I/R injury was induced by coronary artery occlusion. Naringin restored I/R
injury, as demonstrated by the normalization of cardiac injury markers, by the increased activity of
anti-oxidant enzymes, by the reduction of cells apoptosis, infarct size and inflammation [177].
The protective effect of hesperetin against DOX-induced oxidative stress and DNA damage was
analyzed in rat heart. Rat, treated with DOX and hesperetin (50 and 100 mg/kg b.w., p.o. by gavage for
5 consecutive days in a week), showed decreased ROS production and cells apoptosis [178]. Hesperetin
(30 mg/kg, p.o.) and hesperidin (200 mg/kg, p.o.) administration to murine and rat models inhibited
the cardiac remodeling and fibrosis, oxidative stress and apoptosis induced by pressure overload and
isoproterenol [179,180].
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In addition, Elavarasan et al. also demonstrated that the anti-oxidant activity of hesperidin
protected cardiac tissue of aged rats against age-related increase in oxidative stress. Hesperidin
(100 mg/kg/day, p.o. for 90 days) increased the activity of anti-oxidant enzymes [181].
The cardioprotective role of hesperidin and naringin on hyperglycemia-induced oxidative damage
in HFD/streptozotocin (STZ)-induced diabetic rats has been reported by Mahmoud et al. Diabetes
was induced and then rats were treated with hesperidin or naringin (50 mg/kg, p.o.) daily for 4 weeks.
Oral administration of hesperidin and naringin prevented diabetic complications and increased the
activities of anti-oxidant enzymes in experimental diabetic rats [182].
5.1.6. Isoflavones
In vivo effects of calycosin-7-O-β-D-glucoside (CG) on I/R injury were investigated by Ren et al.
Pretreatment of rats with CG (30 mg/kg i.v.) 30 min before the ligation of the left anterior descending
(LAD) coronary artery was able to improve cardiac function, to decrease infarct size and to enhance
the activity of SOD. CG alleviated I/R injury through the activation of the PI3K/Akt pathway and the
inhibition of apoptosis [183].
Gang et al. investigated the in vivo effect of puerarin in Ang II-induced cardiac hypertrophy.
Puerarin (100 and 200 mg/kg, gavage) reduced cardiac hypertrophy induced by Ang II in mice [90].
The effect of puerarin on severe burn-induced acute myocardial injury in rats was assessed by
Liu et al. Groups of adult Wistar rats were subjected to a 30% TBSA (total body surface area) full-thickness
dermal burn and resuscitated with an intraperitoneal injection of 4 mL/kg/TBSA of lactated Ringer’s
solution with or without puerarin (10 mg/kg). Results showed that puerarin protected cardiomyocytes
from severe burn-induced ultrastructural modifications and death [184].
5.1.7. Chalcones and Dihydrochalcones
Zhong et al. evaluated the in vivo effects of the chalcone derivative L6H9 against STZ-induced
diabetes in C57BL/6 mice. L6H9 (20 mg/kg by gavage) protected multiple organs in diabetic mice.
In particular, the heart of mice treated with L6H9 did not show structural abnormalities and fibrosis.
These mice showed lower levels of ROS, cytokines, and apoptosis [97].
Several studies investigated the in vivo effects of chalcones against I/R. Treatment with
licochalcone C (2.0 mM) increased LVDP, levels of anti-oxidant enzymes and decreased cardiomyocytes
mitochondrial injury, necrosis and apoptosis in rats [185]. Another study showed the effects of
intraperitoneal injection of Cl-chalcone (50 μg/kg) and F-chalcone (100 μg/kg) in albino rats with
I/R. Rat hearts treated with Cl-chalcone and F-chalcone showed limited infarct size and high levels of
anti-oxidant enzymes [186]. A study reported the protective effect of rooibos extract against myocardial
I/R injury. They showed that the aortic output recovery after reperfusion was improved in hearts
isolated from male Wistar rats supplemented with aqueous rooibos extract for 7 weeks when compared
to that supplemented with green tea (Camellia sinensis) extract [187].
5.2. Phenolic Acids
Ku et al. analyzed the response of pyrrolidinyl caffeamide (PLCA) against I/R-induced oxidative
stress in rats. PCLA administration (1 mg/kg i.p.) reduced the levels of troponin and lipid peroxidation,
improved cardiac functions and attenuated the myeloperoxidase (MPO) activity, a marker of neutrophil
accumulation [104].
Tang et al. investigated the effect of danshensu in spontaneously hypertensive rats (SHR).
Danshensu (10 mg/kg/day i.p.) decreased the HW/BW index, prevented the increase of blood pressure,
and reduced arrhythmias in rats exposed to I/R [188]. In addition, danshensu possessed a cardioprotective
effect against I/R injury when given to rats during reperfusion (30 and 60 mg/kg, for 3 h) [108].
The protective effects of the preparation Shenge, composed by 1:1 ratio of puerarin and danshensu,
has been evaluated on acute ischemic myocardial injury in rats. Rats were subjected to LAD coronary
artery occlusion and were injected intravenously with Shenge (30, 60, or 120 mg/kg b.w.) 15 min later.
200
Nutrients 2017, 9, 523
Shenge was able to improve electrocardiographic changes, the size of ischemic area and anti-oxidant
activities induced by the acute myocardial ischemia [189].
5.3. Lignans
Several studies analyzed the cardioprotective effects of Schisandrin (Sch) B against DOX-induced
oxidative stress. The administration of Sch B (25, 50 and 100 mg/kg) to mice and rats reduced
cardiomyocytes apoptosis and necrosis in left ventricle and the activity of MMPs induced by
DOX [190,191]. The pretreatment with Sch B (100 mg/kg) significantly increased the levels of GSH
redox cycling enzymes [190]. Su et al. also evaluated the in vivo effect of sesamin in DOX-induced
cardiotoxicity in rats. The treatment of rats with sesamin (20 mg/kg, orally, for 10 consecutive days)
reduced the DOX-induced toxicity through the normalization of the electrocardiography and the
decrease of histopathological changes [114]. Daily sesamin treatment (80 or 160 mg/kg, by gavage) in
SHR for 16 weeks improved LV hypertrophy and fibrosis. The treatment reduced the systolic blood
pressure, enhanced cardiac total anti-oxidant capabilities and TGF-β1 expression [192].
Chen et al., employing a mice model of myocardial infarction (MI) established by a permanent
ligation of the left anterior descending (LAD) coronary artery, reported that the MI mice treated with Sch
B (80 mg/kg) showed increased survival rate, improved heart function and decreased infarct size [111].
Chiu et al. demonstrated that Sch B also exerted a protective role against myocardial I/R injury
through the activation of ERK pathway in rats. Sch B (1.2 mmol/kg, intragastric) decreased LDH
leakage and increased GSH levels [110].
The effects of magnolol, extracted from Magnolia officinalis, deoxyschizandrin (DSD) and
schisantherin A (STA) was analyzed in rats subjected to I/R. Magnolol (10 mg/kg, i.p.), DSD
(40 μmol/kg, i.v.) and STA (40 μmol/kg, i.v.) reduced infarct size, arrhythmias and improved
I/R-induced myocardial dysfunctions [112,193].
5.4. Stilbenes (Resveratrol)
Resveratrol was able to prevent the development of oxidative stress in SHR. Treatment with
resveratrol (2.5 mg/kg b.w., daily, by oral gavage for 10 weeks) reduced ROS production [119].
Dolinsky et al. reported that resveratrol (2.5 mg/kg b.w., daily, by oral gavage for 2 weeks) reduced
the levels of cardiac HNE-protein adducts and the HNE adducts formation on liver kinase B1 (LKB1),
leading to a reduction of left ventricular hypertrophy [194].
Zhao et al. investigated the effect of resveratrol in a mouse model of arsenic trioxide (As2O3)-induced
cardiomyopathy in vivo. Pretreatment with resveratrol (3 mg/kg, i.v., on alternate days for three
days 1 h before As2O3 administration) attenuated As2O3-induced structural and electrocardiographic
abnormalities, increased increased anti-oxidant activity of mice treated with As2O3 [125].
Resveratrol exerted a beneficial effect in mice with diabetic cardiomyopathy induced by
strepozotocin (STZ). Mice fed with a diet enriched with resveratrol (60 and 300 mg/kg/day, for
16 weeks) showed an attenuation of oxidative injury, a decreased cardiomyocytes apoptosis and an
improved cardiac function. In addition, resveratrol increased the autophagic flux in diabetic mouse
hearts [195].
Das et al. reported that the oral administration of resveratrol reduced the myocardial injury
induced by iron. Mice treated with resveratrol decreased oxidative stress and myocardial fibrosis.
These responses were achieved by the increase in SIRT1 expression and the reduction in FoxO1
expression [127].
Resveratrol and polydatin, a resveratrol glucoside, attenuated DOX-induced cardiotoxicity in
rats. Resveratrol (10 or 15 mg/kg) reduced cardiac dysfunction, oxidative damage and apoptosis and
increased anti-oxidant enzymes [196,197]. In addition, a synergistic effect of polydatin and vitamin C
to reduce the cardiotoxicity of DOX was observed. The combined treatment (polydatin and vitamin C
both 200 μmol/kg) improved electrocardiography, reduced ROS production, increased anti-oxidant
activities, and improved the myocardial metabolism in rats [198].
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The treatment with resveratrol (20 mg/kg, s.c. or 5, 15, 45 mg/kg/day for 10 days, by gavage)
protected mice and rats against LPS and cisplatin-induced cardiotoxicity by restoring the intracellular
redox status [199,200]. The anti-hypertrophic effect of polydatin or isorhapontigenin, a resveratrol
analogue, was demonstrated in C57BL/6 mice subjected to transverse aortic constriction (TAC),
a model of pressure-overload-induced cardiac hypertrophy in vivo. Polydatin (50 mg/kg, daily by
gavage) reduced the TAC-induced cardiac hypertrophy [128].
5.5. Other Polyphenols
5.5.1. Curcumin
Several studies investigated the effect of curcumin in I/R. Curcumin exerts a cardioprotective
effect against I/R injury through the reduction of oxidative stress and mitochondrial dysfunction.
Curcumin pretreatment (200 mg/kg) reduced the loss of cardiac mechanical work, the lipid
peroxidation and the levels of inflammatory markers in rats [131,201]. In addition, curcumin reduced
the cardiotoxicity induced by I/R injury through the SIRT1 pathway. In fact, the in vivo pretreatment
of rats with curcumin increased the levels of SIRT1, anti-oxidant enzymes and reduced the cellular
damage and necrotic and apoptotic cells [132]. Li et al. showed that the administration of curcumin
analogue 14p (10 mg/kg) decreased the infarct size and myocardial apoptosis to the same extent
as the high dose curcumin (100 mg/kg) in a mouse model of myocardial I/R [138]. In another
study, the co-treatment of rats with curcumin (60 mg/kg) and isoprenaline reduced the percentage of
isoprenaline-induced apoptotic and necrotic cells and restored the levels of anti-oxidants. Curcumin
decreased the opening of mPTP induced by isoprenaline without modify mitochondria [202].
Diabetic cardiomyopathies are associated with high levels of membrane-bound protein kinase C
(PKC). Treatment of STZ-induced diabetic rats with curcumin (100 mg/kg/day for 8 weeks)
reduced cardiomyocyte hypertrophy, oxidative stress, myocardial fibrosis and left ventricular
dysfunctions [203].
Imbaby et al. analyzed the cardioprotective effects of curcumin and nebivolol against cardiotoxicity
induced by DOX therapy in rats. Oral administration of curcumin (200 mg/kg) attenuated DOX-induced
cardiotoxicity. The treatment increased survival rate and anti-oxidant enzymes, decreased lipid
peroxidation and histological alterations [204].
5.5.2. Olive Oil Polyphenols
In several studies, Andreadou et al. demonstrated the cardioprotective effect of oleuropein against
DOX. Oleuropein administration (100 or 200 mg/kg for 5 or 3 consecutive days) reduced cells damage
and necrosis in rats induced by DOX [205]. In addition, the same authors investigated the effect of
oleuropein in chronic DOX-induced cardiomyopathy in rats. The intraperitoneal administration of
oleuropein (1000 or 2000 mg/kg for 14 days) improved heart contractility, reduced apoptosis and
production of inflammatory cytokines, degenerative myocardial lesions and levels of nitro-oxidative
compounds [206].
5.5.3. Silymarin and Silibinin
Several studies analyzed the effect of silymarin against the cardiotoxicity induced by anti-cancer
drugs. Silymarin protected rats against DOX-induced injury. It has been observed that silymarin (50 or
100 mg/kg) reduced myocardial and renal damage and NO levels [207,208]. Silymarin treatment
(25, 50 or 100 mg/kg) reduced the serum levels of necrosis markers, enhanced anti-oxidant activities
and attenuated the damage of mitochondria in mice and rats exposed to cisplatin or acrolein [209,210].
The protective effect of silibinin against arsenic-induced oxidative stress has been analyzed in
rats. Silibinin administration (75 mg/kg) reduced the myocardial damage, the activity of heart
mitochondrial enzymes, levels of plasma and cardiac lipids, while it up-regulated the levels of
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anti-oxidant enzymes in hepatic tissues. Thus, silibinin attenuated the mitochondrial damage and
restored the heart function [211].
5.6. Combination of Polyphenols
Chen et al. evaluated the cardioprotection of flavonoids extracted from Clinopodium chinense
(Benth.) O. Ktze (TFCC) against DOX treatment in rats. TFCC (20, 40 and 80 mg/kg) treatment
induced the recovery of body and heart weights, balanced the levels of cardiac enzymes, inhibited
ROS production and apoptosis and up-regulated the level of anti-oxidant enzymes [147].
Table 2 summarizes molecular mechisms of in vivo effects of polyphenols against the oxidative
stress-induced cardiotoxicity.
Overall, Figure 3 shows the in vitro and in vivo effects of polyphenols in cardiovascular disease.
Figure 3. In vitro and in vivo effects of polyphenols in cardiovascular disease.
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6. Evidence from Human Studies
Although human studies are not the main focus of this review and have been reviewed
elsewhere [153,212,213], a short section of results from clinical trials is reported. This section might help
to understand whether in vitro and in vivo results obtained in experimental models can be mimicked
in humans. Many human studies have investigated the potential effects of polyphenols, such as
cocoa-, olive-, tea-, grape-contained polyphenols, in cardiovascular diseases [212]. Recently, it has been
reported that resveratrol intake (10 mg resveratrol capsule, per day for 3 months) reduced LDL, platelet
aggregation and improved endothelial function and vasodilation in 40 patients with coronary artery
disease [214]. In another study, resveratrol (400 mg, daily, for one month) reduced the expression of
ICAM-1, VCAM-1, IL-8 and mRNA of inflammatory and adhesion molecules in 44 healthy subjects.
The inflammatory markers are related with atherosclerosis and oxidative stress. Thus, resveratrol
intake could represents a preventive measure for the onset of atherosclerosis [215].
Zunino et al. investigated the effects of dietary grapes in a randomized, double-blind crossover
study in 24 obese human subjects. The obesity is associated with a major risk of cardiovascular
diseases. The authors reported that dietary grape powder supplementation (46 g, two times per
day for 3 weeks) reduced the plasma concentration of LDL and increased the production of IL-1β
and IL-6 in supernatants from lipopolysaccharide-activated peripheral blood mononuclear cells
(PBMCs) [216]. Zern et al. observed that the grape powder supplementation (36 g, per day for
4 weeks) showed an improvement in plasma lipids, inflammatory cytokines, and oxidative stress in
24 pre- and 20 post-menopausal women. This trial suggested that grape powder can influence the
expression of key risk factors for coronary heart disease in pre- and post-menopausal women [217].
Vaisman and Niv showed that red grape cell powder consumption (200 or 400 mg, per day for
12 weeks) improved the endothelial function, diastolic blood pressure and reduced oxidative stress
without adverse effects in 50 subjects with pre-hypertension and mild hypertension [218]. However,
several randomized placebo-controlled trials did not show differences between placebo and treated
groups [212]. For example, in a double-blind, randomized crossover trial, Mellen and colleagues
reported that the muscadine grape seed supplementation (1300 mg, per day for 4 weeks) did not
improve endothelial function, blood pressure or did not change the plasma markers of cardiovascular
risk in 50 subjects with increased cardiovascular risk [219].
Several studies reported the improvement of blood pressure after cocoa intake, in particular
dark chocolate, in hypertensive subjects and with endothelial dysfunction. It has been reported
that flavanol-enriched cocoa drink increased the levels of NO and NOS activity by improving the
endothelial dysfunction. But some trials did not show this effects both in short treatments and in
supplementation of one year with 27 g flavonoid-enriched chocolate [212].
Overall, the conclusions that may be drawn from clinical trials are much different from in vitro
and in vivo studies. Indeed, results from human trials employing polyphenols showed a controversial
response [212].
7. Limitations of the Polyphenols Studies
Overall, although in vitro studies were necessary to determine the polyphenols effective dose and
their mechanism of action, they have some limitations. One of the major drawback of in vitro studies
is the use of polyphenols in the aglycones form or in coniugation with sugar moieties and not the use
of the active metabolites. In addition, the effective doses were much higher than the concentrations
that can be reached in humans. Accordingly, the in vitro results must be carefully decoded.
The results obtained from in vivo studies also have some limitations. Indeed, the majority of the
information regarding the metabolism and distribution of polyphenols in target tissues is the results
of animal studies. However, the metabolism, the genome, the physiology and colonic microflora
of animals are much different from those of humans. Accordingly, these results are needed to be
carefully translated in humans. In addition, a variety of employed animal models does not mimic the
progression of the human disease.
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The controversial results obtained from human trials might reflect these drawbacks and further
be amplified by the human inter-individual variability in the colonic microflora composition that
might affect the absorption and the production of the polyphenol active metabolites. In addition,
the number of participants in many human studies might be too low and the observation time too
short for obtaining an unbeatable result.
Finally, a better knowledge of polyphenols interaction is required for understanding the
polyphenols beneficial effects observed in epidemiological studies.
8. Conclusions
Polyphenols possess many biological activities, including anti-oxidant, anti-inflammatory,
anti-microbial, anti-viral and anti-cancer properties. Several epidemiological studies have shown a
relation between a diet rich in polyphenols and the prevention of various human diseases.
Cardiovascular diseases are the mainly cause of mortality and morbidity in the world. Overall,
several in vitro and in vivo studies demonstrated the ability of polyphenols to counteract oxidative
stress-induced cardiomyocytes damage and death. Polyphenols exert long-lasting effects compared
to other direct anti-oxidant agents, because they induce a transcription-mediated signaling, thus
activating endogenous anti-oxidant enzymatic defense systems.
In light of the results from in vitro, in vivo and in some clinical trials, and of the activity of
polyphenols in the regulation of oxidative stress and inflammation, polyphenols could be useful
for the design of novel agents for the treatment of cardiovascular diseases [213]. However, it is
necessary a better understanding of the reason why not all individuals show cardiovascular benefits
after administration with dietary polyphenols. This knowledge is essential for the universal and
definite acceptance of the clinical usefulness of polyphenols in cardiovascular disease.
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145. Gabrielová, E.; Křen, V.; Jabůrek, M.; Modrianský, M. Silymarin component 2,3-dehydrosilybin attenuates
cardiomyocyte damage following hypoxia/reoxygenation by limiting oxidative stress. Physiol. Res. 2015, 64,
79–91. [PubMed]
146. Esmaeili, M.A.; Sonboli, A. Antioxidant, free radical scavenging activities of Salvia brachyantha and its
protective effect against oxidative cardiac cell injury. Food Chem. Toxicol. 2010, 48, 846–853. [CrossRef]
[PubMed]
147. Chen, R.C.; Xu, X.D.; Zhi Liu, X.; Sun, G.B.; Zhu, Y.D.; Dong, X.; Wang, J.; Zhang, H.J.; Zhang, Q.;
Sun, X.B. Total flavonoids from Clinopodium chinense (Benth.) O. Ktze protect against doxorubicin-induced
cardiotoxicity in vitro and in vivo. Evid. Based Complement. Altern. Med. 2015, 2015, 472565. [CrossRef]
148. Chang, W.T.; Shao, Z.H.; Yin, J.J.; Mehendale, S.; Wang, C.Z.; Qin, Y.; Li, J.; Chen, W.J.; Chien, C.T.;
Becker, L.B.; et al. Comparative effects of flavonoids on oxidant scavenging and ischemia-reperfusion
injury in cardiomyocytes. Eur. J. Pharmacol. 2007, 566, 58–66. [CrossRef] [PubMed]
149. Akhlaghi, M.; Bandy, B. Preconditioning and acute effects of flavonoids in protecting cardiomyocytes from
oxidative cell death. Oxid. Med. Cell. Longev. 2012, 2012, 782321. [CrossRef] [PubMed]
150. Visioli, F.; de La Lastra, C.A.; Andres-Lacueva, C.; Aviram, M.; Calhau, C.; Cassano, A.; D’Archivio, M.;
Faria, A.; Favé, G.; Fogliano, V.; et al. Polyphenols and human health: A prospectus. Crit. Rev. Food Sci. Nutr.
2011, 51, 524–546. [CrossRef] [PubMed]
151. Goszcz, K.; Deakin, S.J.; Duthie, G.G.; Stewart, D.; Leslie, S.J.; Megson, I.L. Antioxidants in cardiovascular
therapy: Panacea or false hope? Front. Cardiovasc. Med. 2015, 2, 29. [CrossRef] [PubMed]
152. Ginsburg, I.; Kohen, R.; Koren, E. Microbial and host cells acquire enhanced oxidant-scavenging abilities by
binding polyphenols. Arch. Biochem. Biophys. 2011, 506, 12–23. [CrossRef] [PubMed]
153. Khurana, S.; Venkataraman, K.; Hollingsworth, A.; Piche, M.; Tai, T.C. Polyphenols: Benefits to the
cardiovascular system in health and in aging. Nutrients 2013, 5, 3779–3827. [CrossRef] [PubMed]
154. Bohn, T. Dietary factors affecting polyphenol bioavailability. Nutr. Rev. 2014, 72, 429–452. [CrossRef]
[PubMed]
155. Manach, C.; Williamson, G.; Morand, C.; Scalbert, A.; Rémésy, C. Bioavailability and bioefficacy of
polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr. 2005, 81, 230S–242S.
[PubMed]
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Abstract: The aim of the current study was to elucidate the effect of seabuckthorn leaves (SL)
extract and flavonoid glycosides extract from seabuckthorn leaves (SLG) on diet-induced obesity
and related metabolic disturbances, and additionally, to identify whether flavonoid glycosides and
other components in SL can exert a possible interaction for the prevention of metabolic diseases by
comparing the effect of SL and SLG. C57BL/6J mice were fed a normal diet (ND, AIN-93G purified
diet), high-fat diet (HFD, 60 kcal% fat), HFD + 1.8% (w/w) SL (SL), and HFD + 0.04% (w/w) SLG (SLG)
for 12 weeks. In high fat-fed mice, SL and SLG decreased the adiposity by suppressing lipogenesis
in adipose tissue, while increasing the energy expenditure. SL and SLG also improved hepatic
steatosis by suppressing hepatic lipogenesis and lipid absorption, whilst also enhancing hepatic fatty
acid oxidation, which may be linked to the improvement in dyslipidemia. Moreover, SL and SLG
improved insulin sensitivity by suppressing the levels of plasma GIP that were modulated by secreted
resistin and pro-inflammatory cytokine, and hepatic glucogenic enzyme activities. SL, especially its
flavonoid glycosides (SLG), can protect against the deleterious effects of diet-induced obesity (DIO)
and its metabolic complications such as adiposity, dyslipidemia, inflammation, hepatic steatosis, and
insulin resistance.
Keywords: flavonoid glycosides; hepatic steatosis; inflammation; insulin resistance; obesity;
seabuckthorn
1. Introduction
The global prevalence of overweight and obesity has increased every decade in a number of
countries and has been described as a global pandemic [1,2]. In 2014, according to world health
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organization (WHO), more than 1.9 billion adults were overweight and over 600 million of them were
obese. Obesity is defined as excessive fat accumulation and is associated with various obesity-related
metabolic syndromes such as adiposity, dyslipidemia, insulin resistance, and non-alcoholic fatty
liver disease (NAFLD). Moreover, about 20–30% of severe obese patients have been diagnosed with
NAFLD, so it has become an emerging issue for healthcare management [3]. NAFLD is a modern
society health problem which ranges from the simple accumulation of triglycerides in the hepatocytes
with no inflammation (hepatic steatosis), to steatosis along with liver inflammation (non-alcoholic
steatohepatitis, NASH). Although the underlying mechanisms among adiposity, NAFLD, insulin
resistance, and inflammation are not fully understood, the dysregulation of lipid metabolism in liver
and adipose tissue is associated with adiposity and its complications [4].
Seabuckthorn (Hippophae rhamnoides L.) is a plant material and is in the family Elaeagnaceae.
Seabuckthron is native to Europe and Asia, and the majority of the seabuckthorn plant’s habitat is in
northern Europe, China, Mongolia, Russia, and Canada. It is a unique and valuable plant currently
cultivated in various parts of the world, and grows best in deep, well drained, sandy loam soil
with ample organic matter. All parts of the seabuckthorn plant are considered to be a rich source of
bioactive substances like isoflavones and flavonoids, which have various beneficial effects on health,
such as anti-atherogenic, anti-oxidant, anti-cancer, and anti-bacterial effects [5]. In particular, its leaf
extracts are reported to have marked anti-bacterial, anti-tumor, anti-inflammatory, and anti-oxidative
activities [6–8]. This leaf extract contains a high content of flavonoid glycosides, including isorhamnetin
3-glucoside and quercetin 3-glucoside, which are known to prevent adiposity and dyslipidemia [9,10].
With the benefits of having various habitat and bioactive effects, seabuckthorn plays a significant part
in the nutraceutical market. However, the potential anti-obesity effects of seabuckthorn leaves (SL)
extract still remain unclear, and no studies have determined the effect of flavonoid glycosides extract
from seabuckthorn leaves (SLG) on the lipid metabolism of adipose tissue and the liver in response to a
high fat diet (HFD). Thus, the present study was undertaken to evaluate the effect of SL ethanol extract
and flavonoid glycosides extract from SL (SLG) on adiposity, hepatic steatosis, insulin resistance, and
inflammation in diet-induced obese (DIO) mice, and to identify whether flavonoid glycosides and
other components in SL can exert a possible interaction for the prevention of metabolic diseases by
comparing the effect of SL and SLG.
2. Materials and Methods
2.1. Preparation of Seabuckthorn Leaves (SL) Extract and Flavonoid Glycosides Extract from SL (SLG)
The dried seabuckthorn (Hippophae rhamnoides L.) leaves (1.15 kg) were extracted twice with 80%
aqueous EtOH (10 L) under an ultrasonic cleaner (Power Sonic 420, Hwashintech, Incheon, Korea)
for 2 h, filtered, and evaporated under reduced pressure. The concentrated EtOH extract (430.12 g)
was obtained and isolated, and purified the flavonoids as follows. A portion (50 g) of the extract was
solubilized in 20% aqueous EtOH and successively loaded into a Diaion HP-20 (Mitsubishi Chem. Co.,
Tokyo, Japan) column (5.5 × 50 cm). The column was eluted successively with 20%, 30%, and 50%
aqueous EtOH, and each fraction was then evaporated to yield 20% EtOH fraction (Fr.) (32.3 g), 30%
EtOH fr. (6.9 g), and 50% EtOH Fr. (3.0 g), respectively. All fractions were monitored by a UV-vis
spectrophotometer and analytical HPLC to ascertain flavonoids. Among three fractions, the 30%
EtOH Fr. was chromatographed on a silica gel (70–230 mesh, Merck, Damstadt, Germany) column
(10.5 × 70 cm) with CHCl3-MeOH-H2O (65:35:7, v/v) as an eluent and obtained four fractions; Fr. 1
(0.35 g), Fr. 2 (0.92 g), Fr. 3 (0.85 g), and Fr. 4 (0.51 g). Fr. 2 and Fr. 3 were successively chromatographed
on a ODS-A (YMC Inc., MA, USA) column (4.5 × 60 cm) with 25% aqueous EtOH, and a Sephadex
LH-20 column (2.5 × 80 cm) with 80% aqueous EtOH, and yielded isorhamnetin 3-glucoside (4.7 mg)
from Fr. 2 and quercetin 3-glucoside (5.3 mg) from Fr. 3, respectively. Finally, the two flavonoids were
identified by NMR analysis (Table 1), and a comparison of the spectral data and the literature values
was conducted [11].
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Table 1. 1H- and 13C-NMR spectral data of two flavonoids isolated from seabuckthorn leaves (SL)
(600 MHz).
Position Isorhamnetin 3-Glucoside Quercetin 3-Glucoside
1H-NMR
6 6.43 (H, br s) 6.45 (H, d, J = 2.4 Hz)
8 6.72 (H, br s) 6.73 (H, d, J = 2.4 Hz)
2′ 7.92 (H, d, J = 1.3 Hz) 7.71 (H, d, J = 1.8 Hz)
3′ - -
5′ 6.88 (H, d, J = 8.4 Hz) 6.85 (H, d, J = 7.8 Hz)
6′ 7.60 (H, dd, J = 1.3 & 8.9 Hz) 7.60 (H, dd, J = 1.8 & 7.8 Hz)
Glu 1” 5.44 (H, d, J = 6.6 Hz) 5.20 (H, d, J = 7.2 Hz)
2”~6” 3.18 ~3.70 3.21 ~3.72
























Chemical shift in δ ppm, coupling constant (J) expressed in Hz in parenthesis and measured in the solvent
(MeOH-d4). Taking TMS as an internal standard.
2.2. Experimental Animals and Diets
Male C57BL/6J mice (four-week-old) were obtained from The Jackson Laboratory (Bar Harbor,
ME, USA). All mice were individually housed under a constant temperature (24 ◦C) and 12-h light/dark
cycle, fed a normal chow diet for a one-week acclimation period, and subsequently randomly divided
into four groups. The mice were fed a normal diet (ND, AIN-93G purified diet, n = 10), HFD (60%
of kilocalories from fat, n = 10), HFD with 1.8% (w/w) of SL (n = 10), and HFD with 0.04% (w/w) of
SLG (n = 10) for 12 weeks, respectively. A total of 1.8% (w/w) of SL contains 0.04% (w/w) of SLG.
The experimental diets were prepared every week and stored at 4 ◦C. At the end of the experimental
period, all mice were anesthetized with isoflurane (5 mg/kg body weight, Baxter, MN, USA) after 12 h
of fasting. Blood was taken from the inferior vena cava to determine the plasma lipid, adipokine, and
hormone concentrations. The liver and adipose tissue were removed, rinsed with physiological saline,
weighed, immediately frozen in liquid nitrogen, and stored at −70 ◦C until analysis. The animal study
protocols were approved by the Ethics Committee at Kyungpook National University (Approval No.
KNU 2015-0020).
The energy expenditure, morphology of the liver and fat tissues, glucose metabolism markers,
plasma lipid contents, hepatic and fecal lipid contents, glucose- and lipid-regulating enzyme activity,
and analysis of gene expression were performed as stated in the Supplementary Materials on the
materials and methods.
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2.3. Energy Expenditure
Energy expenditure was measured using an indirect calorimeter (Oxylet; Panlab, Cornella, Spain).
The mice were placed into individual metabolic chambers at 25 ◦C, with free access to food and water.
O2 and CO2 analyzers were calibrated with highly purified gas standards. The oxygen consumption
(Vo2) and carbon dioxide production (Vco2) were recorded at 3-min intervals using a computer-assisted
data acquisition program (Chart 5.2; AD Instrument, Sydney, Australia) over a 24-h period, and the
data were averaged for each mouse. Energy expenditure (EE) was calculated according to the following
formula: EE (kcal/day/kg of body weight0.75) = Vo2 × 1.44 × (3.815 + (1.232 × Vo2/Vco2)).
2.4. Morphology of the Liver and Fat Tissues
The liver and epididymal while adipose tissue (eWAT) were removed from each mouse. Samples
were subsequently fixed in 10% (v/v) paraformaldehyde/phosphate-buffered saline and embedded in
paraffin for staining with hematoxylin and eosin. Stained areas were visualized using a microscope set
at 200× magnification.
2.5. Plasma Biomarkers
Plasma lipid concentrations were determined with commercially available kits. Plasma
free fatty acid (FFA) levels were measured using the Wako enzymatic kit (Wako Chemicals,
Richmond, VA, USA), and triglyceride, total cholesterol, HDL-cholesterol, glutamic oxaloacetic
transaminase (GOT), and glutamic pyruvic transaminase (GPT) levels were determined using
Asan enzymatic kits (Asan, Seoul, Korea). Plasma apolipoprotein AI (apo AI; Eiken, Japan) and
apolipoprotein B (apo B; Eiken, Japan) levels were also measured using enzymatic kits. The values
of nonHDL-cholesterol, the ratio of HDL-cholesterol to total cholesterol (HTR), and the atherogenic
index (AI) were calculated as follow: nonHDL-cholesterol = ((total-cholesterol) − (HDL-cholesterol)
− (triglyceride/5)), HTR (%) = (HDL-cholesterol/total-cholesterol) × 100, AI = ((total-cholesterol) –
(HDL-cholesterol))/(HDL-cholesterol). Plasma insulin, incretin hormone gastric inhibitory polypeptide
(GIP), adipokines (resistin, leptin, and adiponectin), cytokines (tumor necrosis factor alpha (TNF-α),
interleukin 1β (IL-1β), IL-6, and plasminogen activator inhibitor-1 (PAI-1)) were determined with a
multiplex detection kit from Bio-Rad (Hercules, CA, USA). All samples were assayed in duplicate and
analyzed with a Luminex 200 Labmap system (Luminex, Austin, TX, USA). Data analyses were done
with the Bio-Plex Manager software version 4.1.1 (Bio-Rad, Richmond, CA, USA).
2.6. Fasting Blood Glucose, Intraperitoneal Glucose Tolerance Test, and Homeostatic Index of Insulin Resistance
The blood glucose concentration was measured by the glucose oxidase method using a glucose
analyzer (Glucocard, Arkray, Japan) in whole blood obtained from the tail vein after food withholding
for 12 h. The intraperitoneal glucose tolerance test (IPGTT) was performed at week 11. After 12 h
of fasting, the mice were injected intraperitoneally with glucose (0.5 g/kg of body weight). The
blood glucose level was determined from the tail vein at 0, 30, 60, and 120 min after the glucose
injection. The homeostatic index of insulin resistance (HOMA-IR) was calculated according to the
homeostasis assessment model as follows: HOMA-IR = (fasting glucose (mmol/L) × fasting insulin
(IU/mL))/22.51.
2.7. Hepatic and Fecal Lipid Contents
Hepatic and fecal lipids were extracted as previously described [12], and then dried lipid residues
were dissolved in 1 mL of ethanol for the triglyceride, cholesterol, and fatty acid (FA) assays. Triton
X-100 and a sodium cholate solution in distilled water were added to 200 μL of a dissolved lipid
solution for emulsification. Hepatic and fecal triglyceride, cholesterol, and FA contents were analyzed
with the same enzymatic kits that were used for the plasma analysis.
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2.8. Preparation of Hepatic Subcellular Fractions
Hepatic and adipocyte mitochondrial, cytosolic, and microsomal fractions were prepared as
previously described [13]. The mitochondrial fraction was used to measure glucose-6-phosphatase
(G6Pase) and β-oxidation, and the cytosolic fraction was used to measure glucose-6-phosphate
dehydrogenase (G6PD), malic enzyme (ME), fatty acid synthase (FAS), glucokinase, and
phosphoenolpyruvate carboxykinase (PEPCK) activities. The microsomal fraction was used to measure
phosphatidate phosphohydrolase (PAP) and acyl-CoA:cholesterolacyltransferase (ACAT) activities.
The protein concentrations were determined using the Bradford method.
2.9. Glucose- and Lipid-Regulating Enzyme Activity
Glucose-6-phosphate dehydrogenase (G6PD) [14], fatty acid synthase (FAS) [15], malic
enzyme (ME) [16], and phosphatidate phosphohydrolase (PAP) [17] activities were measured as
previously described. Glucose-6-phosphatase (G6Pase) activity was determined using the method of
Alegre et al. [18]. Phosphoenolpyruvate carboxykinase (PEPCK) activity was monitored in the direction
of oxaloacetate synthesis using a spectrophotometric assay developed by Bentle and Lardy [19]. Fatty
acid β-oxidation was measured spectrophotometrically by monitoring the reduction of NAD to NADH
in the presence of palmitoyl-CoA as described by Lazarow [15], with a slight modification.
2.10. Analysis of Gene Expression
The liver tissues were homogenized in the TRIzol reagent (Invitrogen, Grand Island, NY, USA),
and the total RNA was isolated according to the manufacturer’s instructions. The total RNA was
converted to cDNA using the QuantiTect Reverse Transcription kit (Qiagen Gmbh, Hilden, Germany).
mRNA expression was quantified by a quantitative real-time polymerase chain reaction (PCR) using the
QuantiTect SYBR Green PCR kit (Qiagen) and SDS7000 sequence detection system (Applied Biosystems,
CA, USA). Each cDNA sample was amplified using primers for the glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) gene labeled with SYBR green dye.
The amplification was performed as follows: 10 min at 90 ◦C, 15 s at 95 ◦C, and 60 s at 60 ◦C for a
total of 40 cycles. The cycle threshold (Ct) was defined as the cycle at which a statistically significant
increase in the SYBR green emission intensity occurred. The Ct data were normalized relative to those
for the housekeeping gene, GAPDH, which is stably expressed in mice. The relative gene expression
was calculated with the 2ΔΔCt method [20].
2.11. Primer
The primer were designed using a Primer 5.0 software (Primer-E Ltd., Plymouth, UK), SREBP1c
(Forward: 5′-GGA GCC ATG GAT TGC ACA TT-3′, Reverse: 5′-CCT GTC TCA CCC CCA GCA TA-3′),
CPT1α (Forward: 5′-ATC TGG ATG GCT ATG GTC AAG GTC-3′, Reverse: 5′-GTG CTG TCA TGC
GTT GGA AGT C-3′), ABCG5 (Forward: 5′-TCA ATG AGT TTT ACG GCC TGA A-3′, Reverse: 5′-GCA
CAT CGG GTG ATT TAG CA-3′), ABCG8 (Forward: 5′-GCA ATG CCC TCT ACA ACT CCT T-3′,
Reverse: 5′-GAG GAA CGA CAG CTT GGA GAT C-3′), IRS2 (Forward: 5′-CCC ATG TCC CGC CGT
GAA G-3′, Reverse: 5′-CTC CAG TGC CAA GGT CTG AAG G-3′), and GAPDH (Forward: 5′-ACA
ATG AAT ACG GCT ACA GCA ACA G-3′, Reverse: 5′-GGT GGT CCA GGG TTT CTT ACT CC-3′).
2.12. Statistical Analysis
The parameter values were expressed as the mean (standard error of the mean (SEM)). Significant
differences between the ND and HFD groups were determined by a student’s t-test and significant
differences among the HFD, SL, and SLG groups were determined by one-way ANOVA using the
SPSS program (SPSS Inc., Chicago, IL, USA). The results were considered statistically significant at
p < 0.05.
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3. Results and Discussion
3.1. SL and SLG Supplement Lowered Body Weight Gain and Improved Plasma Lipid Profiles in DIO Mice
HFD generally induces adiposity, hepatic steatosis, and insulin resistance through multiple
mechanisms. We also observed that HFD (60.3% energy from fat) feeding for 12 weeks promoted
the development of obesity, as indicated by significant increases in body weight (BW), BW gain, and
body fat mass, with increased energy intake (Figure 1A–E). The supplementation of SL and SLG
significantly decreased BW after six weeks and eight weeks of high-fat feeding, respectively, without
altering the energy intake (Figure 1A–D). Both SL and SLG also resulted in a significant decrease in
weights for all white adipose tissue (WAT) depots (epididymal, perirenal, mesenteric, subcutaneous,
and interscapular WAT), except for retroperitoneum WAT, which led to a decrease in the visceral WAT
and total WAT weights compared to the HFD group (Figure 1E). Thus, it is plausible that both SL
and SLG suppressed BW gain by regulating the expansion of fat mass. We also found that SL and
SLG supplementation improved dyslipidemia by decreasing the levels of plasma total-cholesterol,
nonHDL-cholesterol, triglyceride, FFA, ApoB, and AI, while increasing the Apo A-I/Apo B ratio
compared to the HFD group (Figure 1F). This finding is supported by a previous study [21], which
demonstrated the body fat and plasma lipid level lowering effects of powdered SL via the regulation
of lipid and antioxidant metabolism in DIO mice.
Figure 1. Effect of SL and SLG on body weight (A), body weight gain; (B), food intake; (C), food
efficiency ratio; (D), white adipose tissue weights; (E) and plasma lipids levels; (F) in C57BL/6J mice
fed HFD for 12 weeks. Data are shown as the mean ± SEM (n = 10). Significant differences between
HFD versus ND are indicated; * p < 0.001, ** p < 0.01, *** p < 0.001. abc Means not sharing a common
superscript are significantly different among the high-fat diet fed groups (HFD, SL, and SLG groups) at
p < 0.05. ND, normal diet group; HFD, high-fat diet group; SL, HFD + 1.8% (w/w) ethanol extract of
sea buckthorn leaves group; SLG, HFD + 0.04% (w/w) ethanol extract of flavonoid glycosides from sea
buckthorn leaves group; Food Efficiency Ratio, body weight gain/Energy intakes per day; HTR, ratio of
HDL-cholesterol to total cholesterol; AI, atherogenic index; FFA, free fatty acid; ApoA-I, apolipoprotein
A-I; ApoB, apolipoprotein B.
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3.2. SL and SLG Supplement Lowered Adiposity by Decreasing Lipogenesis in Adipose Tissue, While Increasing
Energy Expenditure in DIO Mice
Lee et al. [21] and Pichiah et al. [22] demonstrated that the supplementation of powdered SL
or SL ethanol extract effectively suppressed BW gain and the expansion of adipose tissue mass by
modulating the plasma leptin level and hepatic lipid metabolism. However, these previous studies
have not analyzed the markers associated with lipid metabolism in adipose tissue, despite the reduced
body fat mass induced by the SL supplement. Thus, we measured the activities of enzymes for
lipogenesis in epididymal fat and found that G6PD, ME, PAP, and ACAT enzyme activities were
suppressed by SL and SLG supplements compared to the HFD group, which is likely associated with
the reduced adiposity (Figure 2A,B). Notably, SL supplementation also markedly diminished the
activities of FAS compared to the HFD group. Interestingly, SL and SLG supplements led to an increase
in the reduced energy expenditure by HFD during both the light phase and dark phase (Figure 2C).
These observations indicate that SL and SLG have the potential to regulate adipocyte lipid metabolism
and energy expenditure, thereby ameliorating adiposity in DIO mice.
Figure 2. Effect of SL and SLG on adipocyte morphology (A) the activities of adipocyte lipogenic
enzymes; (B) and energy expenditure in C57BL/6J mice fed HFD for 12 weeks. Data are shown as
the mean ± SEM (n = 10). Significant differences between HFD versus ND are indicated; * p < 0.001,
*** p < 0.001. abc Means not sharing a common superscript are significantly different among the high-fat
diet fed groups (HFD, SL, and SLG groups) at p < 0.05. ND, normal diet group; HFD, high-fat diet
group; SL, HFD + 1.8% (w/w) ethanol extract of sea buckthorn leaves group; SLG, HFD + 0.04% (w/w)
ethanol extract of flavonoid glycosides from sea buckthorn leaves group; G6PD, glucose-6-phosphate
dehydrogenase; FAS, fatty acid synthase; ME, malic enzyme; PAP, phosphatidate phosphohydrolase;
ACAT, acyl-CoA:cholesterolacyltransferase.
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3.3. SL and SLG Supplement Lowered the Levels of Hepatic Lipids and Lipotoxicity Markers by Modulating
Hepatic Lipid Regulating Enzume Activities and Gene Expressions, and Increasing Fecal Lipids in DIO Mice
In general, a reduction of body fat mass and an improvement in dyslipidemia are highly correlated
with improved hepatic steatosis [4,23]. SL and SLG supplementation improved hepatic steatosis, as
well as adiposity, as evidenced by the reduced hepatic lipids accumulation and lipotoxicity markers
(plasma GOT and GPT) compared with the HFD group (Figure 3A–C). SL and SLG supplementation
markedly suppressed the hepatic lipogenic enzyme activities (FAS, ME, PAP, ACAT) and SREBP1c
gene expression, and elevated the hepatic β-oxidation enzyme activity and CPT1α gene expression
compared to the HFD group (Figure 3D,E), suggesting that SL and SLG may limit hepatic lipid
availability by inhibiting lipogenesis and increasing fatty acid oxidation, thereby reducing hepatic
lipotoxicity. Moreover, SLG supplementation significantly elevated fecal cholesterol, triglyceride,
and FA levels with the mRNA expression of hepatic ABCG5 and ABCG8 (Figure 3F,G). Similarly, SL
supplementation significantly increased fecal cholesterol and hepatic ABCG5 and ABCG8 mRNA
expressions (Figure 3F,G). These could contribute to the inhibition of the hepatic lipid load by
promoting biliary sterol excretion and decreasing the absorption of dietary fat.
Figure 3. Effect of SL and SLG on hepatic morphology (A) hepatic lipids contents; (B) hepatic
lipotoxicity markers; (C) hepatic lipid regulating enzyme activities; (D) and gene expressions; (E) fecal
lipids contents; (F) and hepatic gene expression related with biliary sterol excretion in C57BL/6J mice
fed HFD for 12 weeks. Data are shown as the mean ± SEM (n = 10). Significant differences between
HFD versus ND are indicated; * p < 0.001, ** p < 0.01, *** p < 0.001. ab Means not sharing a common
superscript are significantly different among the high-fat diet fed groups (HFD, SL, and SLG groups) at
p < 0.05. ND, normal diet group; HFD, high-fat diet group; SL, HFD + 1.8% (w/w) ethanol extract of
sea buckthorn leaves group; SLG, HFD + 0.04% (w/w) ethanol extract of flavonoid glycosides from sea
buckthorn leaves group; GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase.
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3.4. SL and SLG Improved Insulin Resistance and Glucose Tolerance by Modulating Activities of Hepatic
Glucose-Regulating Enzymes and Levels of Plasma Adipokines and Cytokines in DIO Mice
The striking improvement of hepatic steatosis coupled with the decreased adiposity in SL- and
SLG- treated mice was associated with a normalization of the plasma glucose and insulin levels, which
was a reflection of improved hepatic insulin sensitivity, as evidenced by the IPGTT and the reduced
HOMA-IR (Figure 4A–D). In addition, SL and SLG supplementations suppressed the gluconeogenesis,
as indicated by decreased hepatic G6Pase and PEPCK activities and the increased expression of hepatic
IRS2 mRNA (Figure 4E,F), which could be associated with the improved hepatic insulin sensitivity
observed in SL- and SLG-supplemented DIO mice, similar to previous studies [17,18].
The incretin hormone GIP is a peptide hormone produced by the intestinal K cell and it acts directly
on pancreatic islets to stimulate insulin secretion [24,25]. Fats strongly enhance GIP secretion [26], and
its concentrations in obesity or obese type 2 diabetes mellitus (T2DM) patients are elevated [27]. GIP, in
the presence of insulin, induces fatty acid uptake into adipose tissue and GIP receptor (GIPR)-deficient
mice on HFD showed not only improved obesity by increasing the energy expenditure, but also insulin
sensitivity, without differences in the energy intake compared to that of control mice [28]. Additionally,
recent studies demonstrated that the binding of GIP to GIPR in the 3T3-L1 cells and adipose tissue of
rats results in the increased secretion of resistin, and thus, GIP activates phosphoinositide 3-kinase
(PI3K) and Akt/PKB (protein kinase B) through secreted resistin, thereby suppressing AMP-activated
protein kinase (AMPK) in adipocytes, a key transcriptional factor in fatty acid oxidation [29,30].
Resistin is known as an adipose tissue-specific secretory factor, participating in the pathogenesis of
insulin resistance, adipogenesis, and inflammation in mice [31,32]. Leptin is also a peptide hormone
mainly expressed in adipose tissue, and can control the production and activation of pro-inflammatory
cytokines such as TNF-α, IL-6, and IL-12 with the consequent amplification of inflammation and
the development of liver fibrosis [33,34]. Previous human studies have shown that NAFLD patients
have increased circulating resistin and leptin that it is correlated with insulin resistance, obesity, and
the histological severity of the disease [34,35]. We also found that plasma GIP, resistin, and leptin
levels, as well as the leptin/adiponectin ratio, were increased in HFD-fed mice, but SL and SLG
reversed the HFD-induced increase in the plasma levels of GIP, resistin, and leptin, in addition to the
leptin/adiponectin ratio (Figure 4G,H). The leptin/adiponectin ratio has been proposed as a potential
surrogate biomarker for the diagnosis of metabolic diseases [36]. These observations suggest that
the decrease in plasma GIP, resistin, and leptin levels is partially linked with glucose homeostasis,
an increase in energy expenditure, and a decrease in the pro-inflammatory response, leading to the
prevention of obesity, consequent insulin resistance, and hepatic steatosis induced by HFD.
An increase in obesity-associated inflammation can also contribute to the development of insulin
resistance and hepatic steatosis [37]. It is well known that, in an obese state, the enlarged adipose
tissue leads to the dysregulated secretion of adipokines and cytokines. The pro-cytokines reach
metabolic tissues such as liver and muscle, and modify not only glucose and lipid metabolism, but
also inflammatory responses, thereby contributing to metabolic syndrome. High levels of circulating
TNF-α have been found in patients with obesity and NAFLD, and its levels are closely correlated
with liver disease severity [38,39]. Moreover, circulating levels of IL-1β were demonstrated to predict
T2DM when in conjunction with circulating IL-6 [40]. A previous study by Nov O [41] demonstrated
that by promoting adipose inflammation and limiting fat tissue expandability, IL-1β supports ectopic
fat accumulation in hepatocytes and adipose-tissue macrophages, contributing to impaired fat-liver
crosstalk in nutritional obesity. In addition, IL-6 and PAI-1 are also pro-inflammatory cytokines
synthesized by adipocyte, and its levels in plasma are increased in obesity and insulin resistance [42,43].
Interestingly, in the present study, SL and SLG significantly decreased plasma TNF-α, IL-1β, IL-6, and
PAI-1 levels, resulting in a reduced inflammatory response, which was associated with the noticeable
improvement in adiposity, insulin resistance, and hepatic steatosis by SL and SLG.
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Figure 4. Effect of SL and SLG on fasting blood glucose (A) IPGTT; (B), fasting insulin; (C) HOMA-IR;
(D) hepatic glucogenic enzymes; (E) hepatic IRS2 gene; (F) plasma GIP; (G) plasma adipokines; (H) and
plasma pro-inflammatory cytokines in C57BL/6J mice fed HFD for 12 weeks. Data are shown as
the mean ± SEM (n = 10). Significant differences between HFD versus ND are indicated; * p < 0.001,
** p < 0.01, *** p < 0.001. ab Means not sharing a common superscript are significantly different among the
high-fat diet fed groups (HFD, SL, and SLG groups) at p < 0.05. ND, normal diet group; HFD, high-fat
diet group; SL, HFD + 1.8% (w/w) ethanol extract of sea buckthorn leaves group; SLG, HFD + 0.04%
(w/w) ethanol extract of flavonoid glycosides from sea buckthorn leaves group; IPGTT, intraperitoneal
glucose tolerance test; HOMA-IR, homeostasis model assessment-estimated insulin resistance; PEPCK,
phosphoenolpyruvate carboxykinase; G6Pase, glucokinase, glucose-6-phosphatase; IRS2, insulin
receptor substrate 2; GIP, incretin hormone gastric inhibitory polypeptide; L:A Ratio, leptin:adiponectin
ratio; TNF-α, tumor necrosis factor α; IL, interleukin; PAI-1, plasminogen activator inhibitor-1.
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4. Conclusions
The data obtained from our animal study indicate that SL and SLG can suppress DIO and
modulate obesity-associated metabolic disorders such as insulin resistance and hepatic steatosis. SL
and SLG prevent adiposity and dyslipidemia by suppressing the lipogenesis and the absorption
of dietary fat, while increasing biliary sterol excretion and energy expenditure, which contributes
to the improvement of both hepatic steatosis and lipotoxicity. SL and SLG also prevent insulin
resistance by improving inflammation and decreasing gluconeogenesis. In this study, the anti-metabolic
effect of SL and SLG are similarly presented, and these results thus suggest that the effect of
seabuckthorn leaves may be caused by its flavonoid glycosides, including isorhamnetin-3-glucoside
and quercetin-3-glucosdie. Moreover, there was no synergic effect between flavonoid glycosides and
other components in seabuckthorn leaves. Figure 5 illustrates the possible mechanisms of the effects
of SL and/or SLG for antiobesity. Taken together, the present findings suggest that seabuckthorn
leaves, especially its flavonoid glycosides, ameliorates the deleterious effects of DIO and its metabolic
complications such as adiposity, dyslipidemia, inflammation, hepatic steatosis, and insulin resistance.
Figure 5. Proposed mechanism for SL and SLG regarding anti-obesity effects. SL and SLG altered the
hepatic lipid and glucose metabolizing factors and decreased lipid absorption by increasing fecal lipid
contents, thereby preventing hepatic steatosis via the reduction of the hepatic lipid load and eventually
improving insulin resistance. In addition, SL and SLG reduced adiposity by suppressing adipocyte
lipogenesis, while increasing the energy expenditure through decreasing the plasma GIP level, which
is associated with a decrease in plasma pro-inflammatory cytokine levels.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/6/569/s1.
Acknowledgments: This work was supported by the Kyungpook National University Bokhyeon Research
Fund, 2015.
Author Contributions: J.L., E.-Y.L., and M.-S.C. carried out all animal studies and wrote the manuscript; Y.J.K.,
A.D., J.-Y.C., S.-J.C., and U.J.J. collected the data and reviewed the manuscript; and M.-K.L and Y.B.P. supervised
the study.
Conflicts of Interest: The authors have declared no conflicts of interest.
233
Nutrients 2017, 9, 569
Abbreviations





CPT1α carnitine palmitoyltransferase 1α
DIO diet-induced obese
FAS fatty acid synthase
FFA free fatty acid
G6Pase glucokinase, glucose-6-phosphatase
G6PD glucose-6-phosphate dehydrogenase
GIP incretin hormone gastric inhibitory polypeptide
GIPR GIP receptor
HFD high-fat diet
HOMA-IR homeostasis model assessment-estimated insulin resistance
IL interleukin
IPGTT intraperitoneal glucose tolerance test
IRS2 insulin receptor substrate 2
ME malic enzyme
ND normal diet




SLG flavonoid glycosides from seabuckthorn leaves
SREBP1c sterol regulatory element-binding protein 1c
T2DM type 2 diabetes mellitus
TNF-α tumor necrosis factor α
WAT white adipose tissue
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Abstract: A particularly phenolic-rich fraction extracted from red wine from the São Francisco valley
(Northeastern Brazil) was chemically characterized and its hypotensive and antioxidant effects
on spontaneously hypertensive rats were studied both in vitro and in vivo. The liquid-liquid pH
dependent fractionation scheme afforded a fraction with high content of bioactive phenolics such as
flavonols, flavonol glycosides, phenolic acids and anthocyanins, whose identities were confirmed
by liquid chromatography coupled to mass spectrometry analysis. Pretreatment of spontaneously
hypertensive rats with this wine fraction at doses of 50 and 100 mg/kg by gavage for 15 days was
able to decrease mean arterial pressure and heart rate as well as decrease serum lipid peroxidation.
The fraction at concentrations of 0.01–1000 μg/mL induced concentration-dependent relaxation
of isolated rat superior mesenteric artery rings pre-contracted with phenylephrine and this effect
was not attenuated by endothelium removal. Our results demonstrate it is possible for phenolic
constituents of red wine that are orally bioavailable to exert in vivo hypotensive and antioxidant
effects on intact endothelial function.
Keywords: red wine; phenolics; hypertension; flavonoids
1. Introduction
Red wine is the result of grape fermentation processes, and is characterized by high levels of
polyphenols, including flavonoids, such as flavonols, flavones, proanthocyanidins, anthocyanins, and
catechins; and non-flavonoid compounds which include derivatives of hydroxycinnamic acid, benzoic
acid, hydrolysable acids and stilbenes, such as resveratrol [1,2].
Climactic factors such as temperature, humidity and solar radiation exert great influence on
the development, production and quality of grapes and therefore wine, as well as their phenolic
compound contents. Located in the Northeastern region of Brazil between the states of Pernambuco
and Bahia, at latitude 8 to 9◦ S and longitude 40◦ W, the São Francisco Valley (SFV) is a recently
developed wine-producing region in the country. This area has a tropical semi-arid climate with high
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temperatures, high brightness, abundant water for irrigation, sand-clay ground and annual rainfall of
300–800 mm [3]. These climactic characteristics allow producers to harvest twice a year and red wines
from the region are marked by high levels of bioactive phenolic compounds [4]. Previous studies by
our group with red wines from this region have demonstrated that these wines present considerably
higher levels of phenolic compounds than those reported in the literature for red wines in general [4].
The mechanisms involved in the pathophysiology of arterial hypertension are complex but
an increasing body of evidence mainly accumulated in the last decade by us and others suggests
the participation of reactive oxygen species (ROS) in the development and maintenance of high
blood pressure [5–7]. Oxidative stress is involved in the development of hypertension through
different mechanisms [8–12]. These mechanisms include for example the inactivation of nitric oxide by
superoxide, leading to endothelium dysfunction and vasoconstriction [13] and the effect of oxidative
stress on the oxidation of low density lipoproteins [14].
Several studies have demonstrated an association between the consumption of food and/or
beverages rich in phenolic compounds and a reduction on the risk of cardiovascular diseases [15–17].
A large number of existing epidemiological studies showed an inverse association between
consumption of a number of phenolic compounds and risk of hypertension. This evidence comes
not only from cross-sectional studies [18–20] but also from prospective ones [21,22]. The largest of
these prospective studies [21] involved 156,957 subjects with a follow-up period of 14 years and
revealed an 8% reduction in the risk of developing hypertension for those in the highest quintile of
anthocyanin intake when compared with those in the lowest quintile. A similar reduction of 10% in
the risk of developing hypertension for those in the highest quintile of flavonoid intake compared
with those in the lowest quintile was seen in a prospective cohort of 40,574 French women with a
follow-up period of 16 years [22]. Experimental evidence has implicated phenolic compounds in
several different mechanisms relevant in the pathogenesis of hypertension, including the lowering of
platelet aggregation [23], a decrease in the oxidation of low density lipoprotein [24], and an increase of
endothelium nitric oxide [25].
Previous results with the high levels of phenolics in SFV wines prompted us to prepare a fraction
from the Syrah red wine of SFV that concentrates biorelevant phenolic compounds (Fr 2 SySFV), to
chemically characterize this fraction and study the antioxidant and antihypertensive activity in a
variety of in vitro and in vivo assays using spontaneously hypertensive rats.
2. Materials and Methods
2.1. Standards and Reagents
Gallic acid, Folin–ciocalteu reagent, 1,1-diphenyl-2-picrylhydrazyl radical (DPPH), 2,20-azino-
bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 6-hydroxy-2,5,7,8-tetramethylchroman
-2-carboxylic acid (Trolox), potassium persulphate, quercetin, trans-resveratrol, ascorbic acid,
phenylephrine (Phe), and acetylcholine chloride, were purchased from Sigma–Aldrich (St. Louis, MO,
USA). Ethyl acetate and HPLC-grade acetonitrile was from Tedia (Tedia, Brazil). Water was purified
through a Milliq1 water purification system (Millipore, Billerica, MA, USA) and the other solvents
were all reagent-grade.
2.2. Wine Sample and Fractionation
The Fr 2 SySFV was obtained from a red wine produced in the São Francisco Valley region (Syrah
variety, Rendeiras winery, harvest 2013). The Syrah variety was chosen because it displayed the highest
phenolic content amongst different wines from SFV, Southern Brazil (Serra Gaucha) and Chile that were
screened (results not shown). Liquid–liquid extraction methods according to Ghiselli et al. (1998) [26]
were used to obtain several fractions containing different classes of polyphenolic compounds. Alcohol
removal was performed by vacuum distillation (50 ◦C). In brief, the de-alcoholized wine (100 mL) had
its pH adjusted to 2.0 and was first extracted with ethyl acetate (three times with 100 mL of EtOAc
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each). The aqueous phase was combined and concentrated under reduced pressure with ethanol
addition (at 50 ◦C) until dryness, producing Fr 1 SySFV. The organic phase was concentrated to dryness,
redissolved in water (100 mL), had its pH adjusted to 7.0 and was then further extracted with EtOAc
(three times with 100 mL of EtOAc each). The combined organic phase from this second extraction
was concentrated under reduced pressure (at 50 ◦C) until dryness to afford Fr 2 SySFV. The aqueous
residue from this extraction was adjusted to pH 2.0 and extracted again with EtOAc (three times with
100 mL of EtOAc each). The resulting organic phase from this third extraction was combined and
concentrated under reduced pressure (at 50 ◦C) to dryness, producing Fr 3 SySFV. The aqueous phase
from the third extraction was discarded.
2.3. Total Phenolic Content
The total phenolic content of the fractions was determined by Folin-Ciocalteu reagent according
to Waterhouse (2003) [27], with gallic acid as a standard, and expressed as milligrams of gallic acid
equivalents/100 milligrams of fraction (mg GAE/100 mg). Briefly, a solution at 1 mg/mL of each wine
fraction was transferred to a 5 mL volumetric flask together with 100 mL of the Folin-Ciocalteu reagent
and 3 mL of Milliq® water; it was then agitated for 30 s. The volume was completed with Milliq®
water and after 2 h the absorbance of the solution was measured at 760 nm in a ultraviolet/visible
(UV/Vis) spectrophotometer. Solutions of gallic acid (ranging from 0.5 to 50 mg/mL) were analyzed
in a similar manner to that described above and used to construct a calibration curve. Each sample
(wine fraction) was analyzed in triplicate and the total phenolic content was expressed as milligrams
of gallic acid equivalents/100 milligrams of fraction (mg GAE/100 mg).
2.4. Antioxidant Assays
The DPPH assay was used to measure the free radical-scavenging capacity of the wine fractions,
according to a previously reported method [28]. After preliminary screening, solutions were prepared
in methanol at final concentrations ranging from 3 to 30 μg/mL. Subsequently, 100 μL of the samples
were transferred to 96-well plates and then 100 μL of the DPPH solution (118.2 μg/mL in MeOH) was
added. The solutions were shaken and after 30 min of reaction at ambient temperature the absorbance
of the samples was measured on a UV/Vis spectrophotometer at 517 nm. Each sample was tested in
triplicate. The percentage radical-scavenging activity (%SA) was calculated using Equation (1) below:
%SA = ((Abscontrol − Abssample) × 100)/Abscontrol, (1)
where Abscontrol is the absorbance of a solution with DPPH and methanol alone, and Abssample is the
absorbance of the DPPH solution in the presence of the wine fractions or the standard used, i.e.,
ascorbic acid.
Trolox-equivalent antioxidant capacity (TEAC) and effective concentrations to sequester 50% of
free radicals (EC50 values) for the fractions against ABTS•+ radical cation were determined following
a previously published method [29], using 6-hydroxy 2,5,7,8-tetramethyl chroman 2-carboxylic acid
(Trolox), a vitamin E water-soluble analog, as standard. Initially, the ABTS•+ radical cation solution
was prepared by mixing 2.5 mL of a solution of ABTS (7.0 mM) with 44 μL of a solution of potassium
persulfate (140.0 mM), both in distilled water. The solution was kept protected from direct light at room
temperature for a period of 12–16 h before use. Then, the solution of the ABTS•+ radical was diluted
with ethanol (approximately 1:80 v/v) obtaining an absorbance (A) of 0.7 ± 0.05 at the wavelength of
734 nm, using an UV/Vis spectrophotometer. The solutions of the samples were prepared in EtOH
at concentrations of 0.5, 1.0 and 5.0 mg/mL. Through preliminary screening, appropriate quantities
of the sample solutions and the ABTS•+ solution were transferred to 2-mL Eppendorf tubes and the
volume was completed to 500 μL with EtOH. Sample concentrations ranged from 5 to 200 μg/mL.
Trolox was used as the standard substance at concentrations of 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 μg/mL.
The solutions were shaken and, after 6 min of reaction, the absorbance of the samples and the standard
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were measured on a UV/Vis spectrophotometer at a wavelength of 734 nm. Each concentration was
tested in triplicate. The percentage of sequestering activity (% SA) was calculated as described for
DPPH scavenging activity.
The results of the antioxidant assays were expressed as EC50 ± standard deviation (SD). EC50
values for the fractions were obtained by linear regression (using the software Graphpad Prism, v. 5.0,
Graphpad Software Inc., La Jolla, CA, USA) of the %SA values plotted against concentration and are
expressed as μg of fraction/mL solution
2.5. Quantification of Trans-Resveratrol and Quercetin by HPLC-UV Analysis
The content of trans resveratrol and quercetin was determined in Fr 2 SySFV, the fraction with
higher phenolic content and antioxidant activity. A reversed-phase chromatographic method to
determine trans-resveratrol and quercetin has been previously described and validated [4]. The HPLC
analyses were conducted on a Shimadzu liquid chromatograph system (Shimadzu Corp, Kyoto, Japan)
equipped with a LC-10 ATvp pump, variable wavelength detector SPD 10AVvp, controller module
SCL 10A vp, a LC-10AD vp pump, a vacuum degasser DGU-14A, and an autosampler. The analytes
were separated on a Phenomenex C18 column (250 mm × 4.6 mm, 5 μm), using a gradient system of
two eluents: acetonitrile and water containing 0.1% formic acid (35:65) at a flow rate of 1 mL/min. The
detection wavelength was 307 nm for trans-resveratrol and 370 for quercetin. The injection volume was
20 μL. The concentration of each component of interest was calculated based on a calibration curve
created from solutions of the trans-resveratrol standard at concentrations of 0.1, 0.3, 0.5, 1.0, 1.5 μg/mL
and quercetin at concentrations of 0.5, 0.7, 1.0, 1.5, 2.0 μg/mL.
2.6. Chemical Characterization by Liquid Chromatography Coupled to Mass Spectrometry (LC–MS) Analysis
We investigated the chemical composition of the fraction with higher total phenolic content and
highest antioxidant activity (Fr 2 SySFV). LC–MS analysis was performed on an ultra-performance
liquid chromatograph ACQUITY UPLC H-Class (Waters Corporation, Milford, MA, USA) coupled to
a quadrupole time-of-flight high-resolution mass spectrometer (Xevo G2-XS QTof, Waters, Manchester,
UK) with electrospray ionization (UPLC-ESI-QTOF-HRMS). The mass spectrometer was connected to
the ACQUITY UPLC system via an electrospray ionization (ESI) interface. Chromatographic separation
of compounds was performed on the ACQUITY UPLC with a conditioned autosampler at 4 ◦C, using
an Acquity BEH C18 column (50 mm × 2.1 mm i.d., 1.7-μm particle size) (Waters, Milford, MA, USA).
The column temperature was maintained at 40 ◦C. The mobile phase consisting of water with 0.1%
formic acid in water (solvent A) and acetonitrile (solvent B) was pumped at a flow rate of 0.4 mL min−1.
The gradient elution program was as follows: 0–5 min, 5%–10% B; 5–9 min, 10%–95% B. The injection
volume was 10 μL. MS analysis was performed in the negative ion mode. The scan range was from 50
to 1200 m/z for data acquisition. In addition, MSE experiments were carried out allowing both precursor
and product ion data to be acquired simultaneously in one injection. Source conditions were as follows:
capillary voltage, 2.0 kV; sample cone, source temperature, 100 ◦C; desolvation temperature 250 ◦C;
cone gas flow rate 20 L h−1; desolvation gas (N2) flow rate 600 L h−1. All analyses were performed
using the lockspray probe, which ensured accuracy and reproducibility. Leucine–enkephalin (5 ng
mL−1) was used as a standard or reference compound to calibrate the mass spectrometer during
analysis and introduced using the lockspray probe at 10 μL min−1 for accurate mass acquisition. All
the acquisition and analysis of data were controlled using Waters MassLynx v 4.1 software (Waters,
Milford, MA, USA). Simultaneous detection using a photodiode array detector (DAD) was performed
monitoring absorbance at wavelengths ranging from 210 to 500 nm.
2.7. Animals and Treatment
Thirty-two adult male spontaneously hypertensive rats rats (270–320 g) were housed in a
temperature-controlled room, set to a 12:12-h light–dark cycle with free access to standard rat chow
(Labina®, Purina, Paulinea, SP, Brazil) and water. When the animals aged 12 weeks, they were treated
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with a daily dose of Fr 2 SySFV (50 and 100 mg/kg, p.o. by gavage) or saline (0.9% NaCl) for fifteen
days. All procedures described in the present study are in agreement with the rules set forth by the
Institutional Animal Care and Use Committee of the Federal University of Paraiba (CEUA/UFPB
protocol n◦ 0601/13).
2.8. Blood Pressure and Heart Rate Recordings
One day before the experiments, rats were anesthetized with ketamine and xylazine (75 and
10 mg/kg, respectively, both by intraperitoneal injection (i.p.)) and fitted with femoral venous and
arterial catheters for drug injection and arterial pressure recordings, respectively. Blood pressure
measurements were performed 24 h after catheter implantation as previously described [30]. Changes
in blood pressure and heart rate were recorded in conscious rats using a pressure transducer
(MLT0380/D, ADInstruments, Sydney, Australia) connected to a computer (Mikro-tip Blood pressure
system, ADInstruments, Australia) running the LabChart software (ADInstruments, Australia).
2.9. Tiobarbituric Acid Reactive Species (TBARS) Assay
TBARS levels in samples were measured by a spectrophotometric assay that quantifies a
chromogen produced by the reaction of thiobarbituric acid with malondialdehyde (MDA), which is the
end product of lipid peroxidation, and reacts with TBA as a TBARS to produce a red colored complex
with peak absorbance at 532 nm as described previously [31]. Initially, 250 μL of serum was collected
from each group and stored at 37 ◦C for 1 h, after which 400 μL of 35% perchloric acid was added, and
the mixture was centrifuged at 14,000 rpm for 20 min at 4 ◦C. The supernatant was removed, mixed
with 400 μL of 0.6% thiobarbituric acid and incubated at 60 ◦C for 1 h. After cooling, the absorbance
at 532 nm was measured. A standard curve was generated using 1,1,3,3-tetramethoxypropane. The
results were expressed as nmol of MDA/mL of serum.
2.10. Vascular Reactivity Studies in Isolated Rat Superior Mesenteric Artery Rings
Rats were euthanized and the superior mesenteric artery was removed and cleaned from
connective tissue and fat. Rings (1–2 mm) were obtained and whenever appropriated, the endothelium
was removed by gently rubbing the intimal surface of the vessels and placed in physiological Tyrode’s
solution. The Tyrode’s solution composition was (in mmol/L): 158.3 NaCl; 4.0 KCl; 2.0 CaCl2;
1.05 MgCl2; 0.42 NaH2PO4; 10.0 NaHCO3; 5.6 glucose, kept at 37 ◦C and gassed with a carbogenic
mixture (95% O2 and 5% CO2) and maintained at pH 7.4. All preparations were stabilized under a
resting tension of 0.75 g for 1 h. The solution was replaced every 15 min to prevent the accumulation of
metabolites. Tension was recorded by a force transducer (PowerLab, ADInstruments, Australia). The
presence of functional endothelium was assessed by the ability of acetylcholine (10 mM) to induce 85%
relaxation of vessels pre-contracted with Phe (10 mM). Less than 10% of relaxation to acetylcholine
was taken as evidence that the vessel segments were functionally denuded of endothelium.
The rings were again contracted with Phe (10 μM) and after about 30 min, increasing and
cumulative concentrations of Fr 2 SySFV (0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100, 300, and 1000 μg/mL) were
added to obtain a contraction-response curve. The maximal relaxation was calculated using as reference
the maximum contracting response obtained to Phe (10 mM) when used at its highest concentration.
2.11. Statistical Analysis
Values were expressed as mean ± standard error of mean (SEM) unless otherwise stated. When
appropriate, the data were analyzed by Student’s t-test or two-way ANOVA followed by Tukey’s
post-test for multiple comparisons, using GraphPad Prism software (v. 5.0, GraphPad Software Inc.,
San Jose, CA, USA). Values of p < 0.05 were considered statistically significant.
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3. Results
3.1. Phenolic Content and Antioxidant Activity
The fractionation of red wine using liquid-liquid extraction afforded three fractions (Fr 1 SySFV,
Fr 2 SySFV and Fr 3 SySFV). The total phenolic content of these fractions as well as their antioxidant
activity expresssed as EC50 values are shown in Table 1. The total phenolic content of the fractions
ranged from 5.57 ± 0.01 to 58.45 ± 0.01 mg GAE/100 mg. The fraction with the highest phenolic
content was Fr 2 SySFV with 58.45 ± 0.01 mg GAE/100 mg. This fraction was obtained at neutral
pH and concentrates flavonoids, phenolic acids and flavonoid glycosides [26], compounds with
known antioxidant activity. It was thus expected that Fr 2 SySFV would display the highest radical
scavenging activity on antioxidant assays. The antioxidant activity against DPPH radical expressed
as EC50 values varied from 3.4 ± 0.03 to 56,27 ± 5.50 μg/mL. Fr 2 SySFV was the most active of the
three fractions tested (EC50 = 3.4 ± 0.03 μg/mL), while Fr 1 SySFV was the least active. Ascorbic
acid had an EC50 value of 4.38 ± 0.07 μg/mL, thus showing that Fr 2 SySFV had radical-scavenging
activities comparable to this standard. Similar results were found for the ABTS radical-scavenging assay
(Table 1), with Fr 2 SySFV again displaying the highest antioxidant activity (EC50 = 4.65 ± 0.04 μg/mL).
A strong correlation (r2 = 0.9999) was obtained between the EC50 values of the fractions on the two
radical-scavenging assays. Also, negative and strong correlations were obtained between total phenolic
content of the fractions and their EC50 values at DPPH or ABTS radical-scavenging assays (r2 =
−0.8447 and r2 = −0.8385, respectively). The content of trans-resveratrol and quercetin in Fr 2 SySFV
as determined by HPLC was 1.11 ± 0.009 and 8.56 ± 0.078 μg/mL, respectively.
Table 1. Total phenolic content of the wine fractions (expressed as gallic acid equivalents,
GAE/100 mg fraction) and their antioxidant radical scavenging activity (as EC50 values). DPPH:
1,1-diphenyl-2-picrylhydrazyl radical; ABTS: 2,20-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid.




Fr 1 SySFV 5.57 ± 0.01 56.27 ± 5.50 90.48 ± 1.34
Fr 2 SySFV 58.45 ± 0.01 3.4 ± 0.03 4.65 ± 0.04
Fr 3 SySFV 26.29 ± 0.03 13.25 ± 0.07 11.47 ± 0.55
Ascorbic acid - 4.38 ± 0.07 -
Trolox - - 3.77 ± 0.02
3.2. Chemical Characterization of Fr 2 SySFV by UPLC-ESI-QTOF-HRMS
The chemical characterization of Fr 2 Sy SFV confirmed that this fraction concentrated flavonols,
phenolic acids and flavonol glycosides. Figure 1 shows the total ion chromatogram with the marked
peaks of the main compounds identified. The identification was based on comparison of the predicted
versus theoretical exact mass of the compounds and also on the presence of characteristic fragment ions
(Table 2) on the mass spectrum. Twenty five compounds in total were thus identified and the chemical
classes included as major constituents flavonoids and its glycosides (myricetin, myricetin hexoside,
dihydroquercetin hexoside, quercetin hexoside, myricetin methyl ether hexoside, dihydrokaempferol
hexoside, myricetin dimethyl ether hexoside, dihydrokaempferol rhamnoside, quercetin, myricetin
methyl ether, quercetin methyl ether and luteolin), but also phenolic acids and derivatives (caffeic
acid, p-coumaric acid, syringic acid, dimethoxy-cinnamic acid, and methyl-methoxycinnamate),
catechins (catechin, epicatechin, epigallocatechin-coumaroyl, and epigallocatechin-cinnamoyl) and
anthocyanins (procyanidin dimer and procyanidin dimer monoglycoside). The presence of these
classes of compounds in Fr 2 SySFV confirms the efficacy of the wine’s liquid-liquid fractionation
scheme to concentrate the main bioactive phenolics in the neutral acetate fraction.
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Figure 1. Base peak total ion chromatogram of the wine fraction (Fr 2 SySFV) obtained by an MSE data
collection technique method using ultra performance liquid chromatography coupled with time of
flight mass spectrometry (UPLC-QTOF/MSE) in negative electrospray ionization mode (ESI-).
3.3. Treatment with Fr 2 SySFV Reduces Blood Pressure in Spontaneoulsy Hypertensive Rats (SHR) In Vivo
Figure 2 shows representative tracings illustrating changes in pulse arterial pressure (PAP),
mean arterial pressure (MAP) and heart rate (HR) in SHR groups pre-treated with Fr 2 SySFV and
saline-treated controls. Treatment of animals with Fr 2 SySFV for fifteen days at 50 mg/kg by gavage
(p.o) significantly reduced blood pressure when compared to the control group (146.1 ± 4.062 n = 7 vs.
159.0 ± 3.891 mmHg, n = 7, respectively) as well as when administered at 100 mg/kg (126.5 ± 5.322 n
= 8 vs. 150.0 ± 3.039 mmHg, n = 7, respectively). Only the 100 mg/kg dose was able to significantly
decrease the heart rate compared to the control group (314.6 ± 9.507, n = 8, 358.6 ± 15.00 bpm, n = 7,
respectively). These results are also shown in the group data in Figure 3.
 
Figure 2. Representative tracings illustrating the changes in pulse arterial pressure (PAP, mmHg), mean
arterial pressure (MAP, mmHg) and heart rate (HR, bpm) in spontaneously hypertensive rats (SHR)
pretreated with Fr 2 SySFV at 50 mg/kg (A) and 100 mg/kg (B) p.o. and in saline-treated controls.
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Figure 3. Effect of pre-treatment with Fr 2 SySFV on mean arterial pressure (MAP) of spontaneously
hypertensive rats (SHR) at doses of 50 mg/kg p.o. (A) and 100 mg/kg p.o. (B) and on heart rate
(HR) at 50 mg/kg p.o. (C) and 100 mg/kg p.o. (D) compared to saline-treated controls. * p < 0.05
and ** p < 0.005 when compared to SHR + saline group. Values are mean ± SEM., n = 7 for 50 mg/kg
groups and n = 8 for 100 mg/kg groups
3.4. Treatment with Fr 2 SySFV Reduces Oxidative Stress in Spontaneoulsy Hypertensive Rats
We investigated whether pretreatment of SHR rats with Fr 2 SySFV by gavage for fifteen days at
doses of 50 mg/kg and 100 mg/kg could affect the levels of serum lipid peroxidation as a measure
of oxidative stress. Serum malondialdehyde levels were compared in animals pre-treated with Fr 2
SySFV for 15 days p.o. and saline-treated controls (Figure 4). Pre-treatment with Fr 2 SySFV was able
to significantly decrease lipid peroxidation (0.9250 nmol/L ± 0.1750 n = 4 vs. 2.180 nmol/L ± 0.3891
n = 5) at the 100 mg/kg dose level but not at 50 mg/kg. This in vivo antioxidant effect confirms that
the phenolic compounds present in the wine fraction are bioavailable when administered by gavage
for 15 days and effectively contribute to plasma total antioxidant capacity.
Figure 4. Levels of serum malondialdehyde (MDA) in spontaneously hypertensive rats pre-treated
with Fr 2 SySFV for 15 days p.o. at doses of 50 mg/kg and 100 mg/kg and saline-treated controls.
* p < 0.05, when compared to SHR + saline group. Values are mean ± SEM., n = 5 for each group.
3.5. Fr 2 Sy SFV Induces Endothelium-Independent Vasorelaxation in Isolated Rat Superior Mesenteric Rings
Red wine flavonoids are known to exert direct vasorelaxant activity. Thus, in order to investigate
whether a direct decrease in peripheral resistance was contributing to the hypotensive effect of Fr 2
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Sy SFV observed in spontaneously hypertensive rats, we tested in vitro the effect of the fraction on
contractions induced by phenylephrine (PHE) on isolated rat superior mesenteric rings. In isolated
rat mesenteric artery rings with intact endothelium, Fr 2 SySFV (at 0.01–1000 μg/mL) induced a
concentration-dependent relaxation on the contractions induced by Phe (10 mM) (maximum relaxation
to contractions by Phe 10 mM = 103.5 ± 9.9%, n = 7) (Figure 5). After endothelium removal, the
vasorelaxant effect elicited by Fr 2 SySFV was not significantly attenuated (Emax = 105.6 ± 5.9% n = 6)
(Figure 5). These results demonstrate that a decrease in peripheral resistance is probably involved in
the hypotensive effects of Fr 2 SySFV observed in SHR and that the vasorelaxant effect of the fraction
is not mediated by endothelium.
 
Figure 5. Concentration–response curves showing the relaxant effect induced by Fr 2 SySFV
(0.01–1000 μg/mL) in rat mesenteric artery rings pre-contracted with phenylephrine (10 μM) in
presence ( ) and absence ( ) of functional endothelium. Results are expressed as mean ± SEM;
n = 7 for rings with intact endothelium and n = 8 for rings with denuded endothelium.
4. Discussion
Our results demonstrate that the fractionation of the red wine (Syrah variety) from the São
Francisco Valley (SFV), yielded a fraction with high total phenolic content. In this work as in a previous
study published by our group [4] the highest phenolic content as well as the highest antioxidant
activity was found in the neutral (pH 7) acetate fraction (Fr 2 SySFV). According to Menkovic et al.,
(2014) [32] that used the same fractionation scheme as ours to study a red wine produced in Serbia
from the Prokupac variety, the highest levels of phenolics were also observed in the EtOAc fraction
obtained at pH 7.0. However, the value of total phenolics found in the study by Menkovic et al. for
this fraction was almost half of what we found here for the Syrah red wine from the SFV, confirming
the particularly high phenolic content of the red wines from the region. The climate conditions of
the SFV and viticulture techniques including the use of controlled-stress irrigation, can contribute
to the phenolic profile of these wines as demonstrated previously [33,34]. Our data also confirmed
the correlation between the content of phenolic components and the radical scavenging activity of
wine and its fractions which has been described in numerous studies [35–38], despite some authors
reporting a lack of correlation between these variables and stressing the importance of the individual
phenolic compounds in determining antioxidant activity [39].
The levels of trans-resveratrol and quercetin in Fr 2 Sy SFV were similar to those found in
the literature for red wines [40–42], although higher levels of quercetin and trans-resveratrol have
been reported in wines from warm climates such as in the SFV [43,44]. The concentration of
trans-resveratrol is usually determined by the levels of biotic and abiotic stress in the grapes [45].
However, photoisomerization of trans-resveratrol into cis-resveratrol is known to occur with high
sunlight exposure or during fermentation and storage [46–48]. Indeed, levels of cis-resveratrol up
to five times those of trans-resveratrol were found in red wines from the SFV [4]. The fractionation
of the wine sample proved to be efficient in concentrating bioactive phenolics, since the presence of
expected chemical constituents in Fr 2 Sy SFV was confirmed by the experiments using UPLC/MS [26].
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Ghiselli et al. (1998) [26] also reported the presence of some procyanidins, catechin, epicatechin, and
quercetin-3-glucoside in the EtOAc extract at pH 7.0.
Evidence suggests that hypertensive animals have high levels of oxidative stress [6] and that
free radical production can directly or indirectly play a major role in cellular processes implicated in
cardiovascular diseases (CVD). Phenolic compounds have been largely considered dietary antioxidant
compounds although much controversy still exists about their bioavailability [49]. In the present study
the oral administration of Fr 2 Sy SFV in rats SHR for 15 days decreased arterial blood pressure at
all doses tested and decreased heart rate at the highest dose (100 mg/kg). In addition, the treatment
of animals with the fraction decreased oxidative stress as measured by serum malondialdehyde
levels. These results are in line with previous studies, indicating that the antioxidant activity of
phenolic compounds such as quercetin [31], vanillic acid [50], and rutin [51] are mainly responsible
for the effects of these compounds on blood pressure in different models of hypertension. Recently,
quercetin, one of the constituents of Fr 2 SySFV was shown to exert a reduction on blood pressure
and on serum malondialdehyde levels in spontaneously hypertensive rats [52]. The antihypertensive
effect of Fr 2 Sy SFV in reducing the mean arterial blood pressure is almost equipotent to that of
the lyophilized Cabernet Sauvignon red wine from SFV as reported by Ribeiro et al., 2016 [53].
These authors demonstrated that the oral treatment of animals with 100 mg/kg lyophilized wine
for 9 days reduced mean arterial blood pressure of chronically L-NAME-treated hypertensive Wistar
rats by 29 mmHg compared to a reduction of 24 mmHg in our study. One of the hallmarks of the
hypertensive pathophysiological process is endothelium dysfunction provoked by excessive reactive
oxygen species production and vascular inflammation [54]. Although numerous studies indicate
that red wine and polyphenols present in wine induce an endothelium-dependent vasorelaxant
effects [55–57], our results have shown that Fr 2 SySFV at concentrations of 0.01–1000 μg/mL induced
concentration-dependent relaxation of isolated rat superior mesenteric rings pre-contracted with
phenylephrine, an effect which was not attenuated by removal of ring endothelium. In a previous
study with a lyophilized red wine from SFV, Luciano et al. (2011) [25] demonstrated the vasorelaxant
activity of the wine was significantly attenuated by endothelium removal. It seems plausible to
hypothesize that in our work, the fractionation of red wine concentrated phenolic compounds with
endothelium-independent vasorelaxant activity. Indeed, it was previously shown that resveratrol is
able to induce endothelium-independent relaxation in human internal mammary artery [58]. Quercetin,
a flavonoid abundant in most red wines has also been shown to produce endothelium-independent
relaxation in arteries of resistance and conductance in rabbits [59].
Considering the 50 mg/kg dose in rats used in this study, Fr 2 SySFV corresponds to an intake of
approximately one 750-mL bottle of wine in humans (for a person with an average weight of 70 kg).
It is thus not very practical to consider this intake in terms of wine servings, although Fr 2 SySFV could
easily be formulated into a dietary supplement or alcohol-free drink. Although we may contemplate
vinification practices that could produce wines with chemical composition approaching that of Fr 2
SySFV, the wines would definitely have very different sensorial properties that could impact negatively
on their acceptance and commercial viability. Thus, a dietary supplement would definitely be the
most viable alternative to achieve an intake of phenolics in human diet that corresponds to the doses
administered in this study.
5. Conclusions
Taken together our results demonstrate that it is possible to concentrate bioactive and bioavailable
phenolics from red wine with important antioxidant and hypotensive activities that are not
dependent on intact endothelium function. These results warrant further studies on the effects
of individual phenolics on hypertension and on vascular reactivity. Of particular interest would be the
identification of the individual phenolics responsible for the endothelium-independent vasorelaxation
and hypotensive effects observed for the fraction.
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Abstract: Polyphenols, widely found in edible plants, influence the immune system. Nevertheless,
the immunomodulatory properties of hesperidin, the predominant flavanone in oranges, have not
been deeply studied. To establish the effect of hesperidin on in vivo immune response, two different
conditions of immune system stimulations in Lewis rats were applied. In the first experimental
design, rats were intraperitoneally immunized with ovalbumin (OVA) plus Bordetella pertussis toxin
and alum as the adjuvants, and orally given 100 or 200 mg/kg hesperidin. In the second experimental
design, rats were orally sensitized with OVA together with cholera toxin and fed a diet containing
0.5% hesperidin. In the first approach, hesperidin administration changed mesenteric lymph node
lymphocyte (MLNL) composition, increasing the TCRαβ+ cell percentage and decreasing that of B
lymphocytes. Furthermore, hesperidin enhanced the interferon (IFN)-γ production in stimulated
MLNL. In the second approach, hesperidin intake modified the lymphocyte composition in the
intestinal epithelium (TCRγδ+ cells) and the lamina propria (TCRγδ+, CD45RA+, natural killer,
natural killer T, TCRαβ+CD4+, and TCRαβ+CD8+ cells). Nevertheless, hesperidin did not modify
the level of serum anti-OVA antibodies in either study. In conclusion, hesperidin does possess
immunoregulatory properties in the intestinal immune response, but this effect is not able to influence
the synthesis of specific antibodies.
Keywords: antibody; flavanone; flavonoids; hesperidin; immune system; immunoregulatory; polyphenol
1. Introduction
Polyphenols are secondary metabolites of plants that are widely distributed in fruits (e.g.,
apple, grape, pear, cherry, berries), vegetables, nuts, flowers, cereals, legumes, chocolate, and
beverages (tea, coffee, and wine) [1]. Polyphenols, named thus for the presence of various phenolic
groups [2], are mainly classified according to their chemical structure into flavonoids (isoflavones,
neoflavonoids, chalcones, flavones, flavonols, flavonones, flavononols, flavanols, proanthocyanidins,
and anthocyanidins) or non-flavonoids (phenolic acids or phenolic amides) [3].
In the last 20 years, polyphenols have gained attention mainly due to their antioxidant
properties [3,4], and a large number of beneficial effects have been reported such as on degenerative
disease, cardiovascular disease, cancer, osteoporosis; and their influence on the immune system has
also been shown [2,5,6]. Focusing on polyphenol immunomodulatory properties, a number of in vitro,
in vivo, and clinical studies have confirmed the influence of various flavonoids on the innate and
acquired immune response by attenuating immune function, thus showing their beneficial role in
immune hypersensitivity [7]. Accordingly, flavonoid administration has been demonstrated to be
useful in the prevention of allergic asthma and rhinitis [8].
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Hesperidin (5,7,3-trihydroxy-4-methoxyflavanone-7-rhamnoglucoside) is a flavonoid belonging
to the flavanone class [9], its aglycone form being hesperetin [10]. Hesperidin is mainly found in
the fruits of the genus Citrus [1], particularly in the epicarp, mesocarp, endocarp, and juice of citrus
fruits [11] and it is the predominant flavanone found in oranges [12,13]. The majority of the flavonoids
found in citrus fruits are glycosides and just a little quantity of hesperitin is present [12].
To date, several pharmacological effects of hesperidin have been reported. It prevents
hypercholesterolaemia and fatty liver [14], osteoporosis [15], hypertension, and cerebral thrombosis,
among others [16]. In terms of its effects on the immune system, the role of hesperidin has
been described in reducing Th2 cytokines in mouse models of asthma [9,17] and in stimulated
macrophages [18]. Nevertheless, there are no in-depth studies concerning hesperidin’s effect on
immune tissues, including the intestinal lymphoid tissue, and on specific antibody synthesis. In this
line, the study of such effects on animal models is of interest because it allows the arrival of hesperidin
or its metabolites to the lymphoid tissues, and its analysis will contribute to a better understanding
of a flavanone-enriched diet on human health. For this reason, the aim of the current study was to
spotlight the effects of hesperidin on Th2 antibody production and on lymphoid tissues, focusing
on the gut-associated lymphoid tissue (GALT), which is the first line of defence encountered by the
hesperidin present in food. We have investigated this action under two different conditions triggering
Th2 immune responses and using three different hesperidin dosages.
2. Materials and Methods
2.1. Chemicals
Hesperidin was provided by Ferrer HealthTech (Murcia, Spain), with a purity of 95.5%
(High Performance Liquid Chromatography) containing 2% isonaringine, 1.5% didimine, and
other impurities.
Carboxymethylcellulose (CMC), cholera toxin (CT), fetal bovine serum (FBS), L-glutamine,
ovalbumin (OVA, grade V), penicillin-streptomycin, toxin from Bordetella pertussis (Bpt), and RPMI
1640 medium were provided by Sigma-Aldrich (Madrid, Spain). Imject™ alum adjuvant was
obtained from Thermo Fisher Scientific (Barcelona, Spain). Biotin-conjugated anti-rat immunoglobulin
(Ig)A, IgG1, IgG2a, IgG2b, and IgG2c monoclonal antibodies, anti-rat IgE monoclonal antibody, and
anti-rat fluorochrome-conjugated monoclonal antibodies (detailed later) were purchased from BD
Biosciences (Madrid, Spain), Biolegend (San Diego, CA, USA), or Novus Biologicals (Littleton, CO,
USA). Peroxidase conjugated and unconjugated goat anti-rat IgA antibody and IgA standard were
provided by Bethyl Laboratories (Montgomery, TX, USA). Peroxidase-conjugated anti-rat Ig was from
DakoCytomation (Glostrup, Denmark). 2-β-mercaptoethanol was from Merck (Darmstadt, Germany).
Ketamine was provided by Merial Laboratories S.A. (Barcelona, Spain) and xylazine by Bayer A.G.
(Leverkusen, Germany).
2.2. Animals and Experimental Designs
Three-week-old Lewis rats (Janvier Labs, Saint Berthevin CEDEX, France) were maintained at
the animal facility of the Faculty of Pharmacy and Food Science (University of Barcelona) housed
in cages (three rats per cage) and kept under controlled conditions of temperature and humidity in
a 12 h light-dark cycle. Animal procedures were approved by the Ethical Committee for Animal
Experimentation at the University of Barcelona (CEEA/UB ref. 5988) and conducted in compliance
with the Guide for the Care and Use of Laboratory Animals.
The effect of hesperidin on systemic and intestinal immune response was studied in two
experimental designs (Figure 1). The first design studied the influence of hesperidin in a systemic
immune response that was triggered by an intraperitoneal (i.p.) immunization, as previously
described [19]. Briefly, rats received an i.p. injection with 0.5 mg of OVA plus 50 ng of Bordetella
pertussis toxin (Bpt) in 0.5 mL of alum emulsion (1:3 alum:OVA+Bpt solution). Hesperidin was given
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by oral gavage three times per week at doses of 100 or 200 mg/kg of rat body weight (BW). Therefore,
the first experimental design included three groups: the reference immunized group (OVAip group),
the immunized group given 100 mg/kg hesperidin (H100 group), and the immunized group given 200
mg/kg hesperidin (H200 group). Hesperidin was prepared daily in 0.5% CMC as vehicle. The OVAip
group received the vehicle. In the second design, the effect of hesperidin on the intestinal immune
response was triggered in orally sensitized rats and was included in the rat food. For this, rats
were orally sensitized with OVA and CT, as previously described [20], and animals were fed either a
standard diet (AIN-93M, Harlan Teklad, Madison, WI, USA) (reference sensitized group: OVAoral
group), or a diet containing 0.5% hesperidin (H0.5 group). In both designs, the animals had free access
to water and food throughout the study. The consumption of water and food per cage was periodically
registered and referred to as water or food consumed per 100 g of BW of the rats included in the cage.
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Standard diet  or a diet containing 0.5% hesperidin
50 mg OVA + 30 g CT / rat (p.o.)
days 
b) Second experimental design
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Oral administration of hesperidin 100 mg/kg BW, hesperidin 200 mg/kg BW, or vehicle
0.5 mg OVA + alum + Bpt / rat (i.p.)
days
a) First experimental design
Figure 1. Experimental designs. (a) First experimental design: rats were immunized by intraperitoneal
(i.p.) route the first day of the study (day 0), and hesperidin was given by oral gavage three times per
week (indicated by arrows) for 4 weeks; (b) Second experimental design: rats were sensitized by oral
route (per os, p.o.) three times per week (indicated by arrows), and hesperidin was included in the rat
food throughout the 4 weeks. BW, body weight; OVA, ovalbumin; CT, cholera toxin.
2.3. Sample Collection and Processing
At the end of both studies, animals were anaesthetized by subcutaneous route with
ketamine-xylazine. Apart from faecal and blood samples, the mesenteric lymph nodes (MLN) and the
small intestine were collected. In the second design, the duodenal part of the intestine was discarded
and the rest was opened lengthwise in order to separate the Peyer’s patches (PP). From the ileum,
intraepithelial lymphocytes (IEL) and lamina propria lymphocytes (LPL) were isolated, as reported
previously [21]. From the resting tissue, gut lavage was obtained as previously described [21] and kept
at −20 ◦C for IgA quantification and at −80 ◦C for cytokine determination.
The lymphocytes from MLN (MLNL) and from PP (PPL) were also isolated, as detailed in
prior research [21,22]. Isolated lymphocyte counts and viability were determined by a Countess™
Automated Cell Counter (Invitrogen™, Thermo Fisher Scientific, Barcelona, Spain) in order to proceed
with the staining for the flow cytometric analysis or the culture of MLNL.
Blood samples were centrifuged and serum was kept at −20 ◦C for antibody determination.
From faeces, faecal homogenates supernatants were obtained and kept at −20 ◦C for intestinal IgA
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quantification. Briefly, faeces were dried, weighed, diluted with PBS pH 7.2 (20 mg/mL), homogenized
with a Polytron (Kinematica, Lucerne, Switzerland), and, finally, the supernatants obtained after
centrifugation were kept at −20 ◦C for intestinal IgA quantification.
2.4. Lymphocyte Phenotypic Analysis
MLNL, PPL, IEL, and LPL were stained with fluorescent-labelled antibodies, as previously
described [22]. The following fluorochrome-conjugated antibodies were used: FITC-TCRαβ,
FITC-CD8β, FITC-CD25, FITC-TLR4, FITC-CD103, PE-NKR-P1A, PE-TCRγδ, PE-TLR4, PerCP-CD8α,
APC-CD4, and APC-Cy8-CD45RA. Data were acquired by Gallios Cytometer (Beckman Coulter, Miami,
FL, USA) in the Scientific and Technological Centers of the University of Barcelona (CCiTUB) and the
analysis was performed with FlowJo v.10 software (Tree Star, Inc., Ashland, OR, USA). Results are
expressed as percentages of positive cells in the lymphocyte population selected according to their
forward and side scatter characteristics.
2.5. Specific Anti-OVA Antibodies and Intestinal IgA Quantification
The levels of the specific anti-OVA antibodies (total, IgG1, IgG2a, IgG2b, and IgG2c isotypes)
were determined by an indirect Enzyme-Linked ImmunoSorbent Assay (ELISA), as previously
described [22]. Specific anti-OVA IgE was measured with a modified ELISA, as formerly reported [19].
In all cases, a pool of sera from immunized rats was used as positive control and all data were calculated
in accordance with the arbitrary units (A.U.) assigned to this pool.
Total IgA concentration from serum, gut lavages, or faecal homogenates was determined with
a sandwich ELISA using a Rat IgA ELISA Quantification Set (E110-102) from Bethyl Laboratories
(Montgomery, TX, USA).
2.6. Cytokine Quantification
MLNL (6 × 106/mL) were cultured in RPMI 1640 medium supplemented with 10%
heat-inactivated FBS, 100 IU/mL penicillin-streptomycin, 2 mM L-glutamine, and 0.05 mM
2-β-mercaptoethanol and stimulated with 200 mg/mL of OVA in vitro. After 72 h, supernatants
were collected to assess cytokine production.
The cytokines secreted by MLNL and from gut lavage were evaluated by ProcartaPlex® Multiplex
Immunoassay (Affymetrix, eBioscience, San Diego, CA, USA) according to the manufacturer’s protocol.
The analysed cytokines were interleukin (IL)-10, IL-4, monocyte chemoattractant protein (MCP)-1,
tumour necrosis factor (TNF)-α, and interferon (IFN)-γ, their detection limits being 11.08, 1.03, 17.99,
3.91, and 4.64 pg/mL, respectively.
2.7. Statistical Analysis
Statistical analysis of the data was performed with the software package SPSS version 22.0 (IBM
Statistical Package for the Social Sciences, Chicago, IL, USA).
To assess the homogeneity of variance and the distribution of the results, Levene’s and
Shapiro-Wilk tests were performed, respectively. One-way ANOVA followed by Bonferroni’s post
hoc test were carried out in cases with homogenized and normally distributed variance from the
data. Kruskal-Wallis and Mann-Whitney U tests were performed in cases with non-homogenized
and/or non-normally distributed variance from the data. Significant differences were considered
when p ≤ 0.05.
3. Results
3.1. Effect of Hesperidin on Food and Water Intake and Body Weight
The administration of 100 or 200 mg/kg hesperidin by oral gavage altered neither food nor water
consumption in comparison to the reference group (OVAip group) (Table 1). Likewise, the inclusion of
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hesperidin in the food did not produce any change among groups in food or water intake (Table 2).
Moreover, the administration of hesperidin, both by oral gavage or in the food, did not affect BW
increase (data not shown).
Table 1. Food and water intake in the first experimental design. These values were established per day
and per cage and referred to 100 g of the total BW in the cage. Data are expressed as the range between
the two values obtained from two cages. OVAip, the reference immunized group; H100, the immunized
group given 100 mg/kg hesperidin; H200, the immunized group given 200 mg/kg hesperidin.
Food Intake (g/100 g BW/Day) Water Intake (mL/100 g BW/Day)
OVAip H100 H200 OVAip H100 H200
Day 4 13.06–13.97 12.80–13.07 13.59–13.92 11.73–11.74 11.52–15.78 11.95–12.11
Day 11 13.51–13.57 7.75–8.64 10.20–10.47 11.31–12.66 11.26–12.39 12.15–12.74
Day 18 11.60–12.03 11.94–12.02 11.82–12.24 10.39–11.03 11.07–13.83 11.42–12.11
Day 25 9.32–9.34 9.35–9.35 9.07–9.08 11.01–11.20 12.68–14.55 13.19–14.85
Day 28 9.58–10.16 9.38–10.03 9.73–9.85 11.77–12.87 13.95–15.61 14.05–15.05
Table 2. Food and water intake in the second experimental design. These values were established per
day and per cage and referred to 100 g of the total BW in the cage. Data are expressed as the range
between the two values obtained from two cages. OVAoral, animals were fed a standard diet; H0.5,
a diet containing 0.5% hesperidin.
Food Intake (g/100 g BW/Day) Water Intake (mL/100 g BW/Day)
OVAoral H0.5 OVAoral H0.5
Day 7 10.93–11.37 10.74–10.97 16.84–24.85 14.93–20.67
Day 14 11.65–11.70 11.28–11.52 11.39–14.45 11.05–16.23
Day 21 10.25–10.60 10.76–10.77 9.01–10.57 9.95–14.33
Day 28 8.33–8.55 7.90–8.57 9.57–10.52 8.24–12.44
3.2. Effect of 100–200 mg/kg Hesperidin on Mesenteric Lymph Node Lymphocyte Composition
and Functionality
The influence of hesperidin administration on the lymphocyte composition of mesenteric lymph
nodes was established (Figure 2). In comparison to the OVAip group, hesperidin, in both tested
doses, increased the proportion of TCRαβ+ cells (107% in both doses) in MLNL and, consequently,
decreased the proportion of B (CD45RA+) lymphocytes (81% and 77% for H100 and H200 doses,
respectively) (Figure 2a), thus increasing the ratio of TCRαβ+/B cells (Figure 2b). The changes were not
dose-dependent. No significant differences were seen in the two TCRαβ subsets, Th (TCRαβ+CD4+)
and Tc (TCRαβ+CD8+) cells, meaning that both subsets were increased by hesperidin administration
(Figure 2c–d). The expression of CD25 (a cell activation marker) was also determined in CD4+, CD8+,
and B cells. A decrease in the proportion of CD8+CD25+ cells was observed only in the rats receiving
the highest dose of hesperidin with respect to the OVAip group (Figure 2e).
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Figure 2. Proportion of mesenteric lymph node lymphocytes (MLNL) according to their phenotype in
the first experimental design. (a) TCRαβ+ and CD45RA+ lymphocytes; (b) TCRαβ+/CD45RA+ ratio;
(c) Th (TCRαβ+CD4+) and Tc (TCRαβ+CD8+) lymphocytes; (d) Th/Tc ratio; (e) CD25+ cells in CD4+,
CD8+, and CD45RA+ lymphocytes. Data are expressed as mean ± standard error (n = 6). Statistical
difference: * p < 0.05 (by Mann-Whitney U).
To establish the function of MLNL, the cytokine pattern secreted by these cells after in vitro
stimulation with OVA was determined (Figure 3a). Hesperidin administration, in both doses, induced
an increase in the release of IFN-γ (145% and 150% with respect to the OVAip group, for H100 and
H200 doses, respectively), a Th1-related cytokine. No differences in the secretion of IL-4, IL-10, TNF-α,
and MCP-1 were observed.
In addition, cytokines in gut lavage from the first experimental design were also determined,
reflecting their spontaneous secretion (Figure 3f–j). In this compartment, hesperidin did not modify
the production of the considered cytokines.
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Figure 3. Cytokine concentrations in the second experimental design. Cytokines from stimulated
MLNL (a–e) and gut lavage (f–j). Data are expressed as mean ± standard error (n = 6). Statistical
difference: * p < 0.05 (by Mann-Whitney U).
3.3. Effect of 100–200 mg/kg Hesperidin on Antibody Synthesis and Intestinal IgA
The untreated i.p. immunized group (OVAip) developed systemic anti-OVA antibodies (Figure 4a)
and no changes were seen after hesperidin administration. No serum IgE anti-OVA antibodies were
detected in any of the studied groups.
Additionally, intestinal IgA was determined in gut lavage and in faeces (Figure 4b,c) but no








































































Figure 4. Anti-OVA antibodies (Ab) and total immunoglobulin (Ig)A levels from the first experimental
design. (a) Serum anti-OVA Ab at the last day of the study; Total IgA from (b) gut lavage and (c) faecal
homogenates from the last day of the study. Data are expressed as mean ± standard error (n = 6).
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3.4. Effect of 0.5% Hesperidin on Intestinal Lymphocyte Composition
A second experimental design was then carried out focusing on the intestinal immune system,
including both inductive (MLN, PP) and effector (IEL, LPL) compartments and using an oral
sensitization process that challenged these specific sites. As the hesperidin intake in the first
experimental design did not affect the synthesis of anti-OVA antibodies, the second approach applied
hesperidin in a more continuous manner (included in the food) and using a higher dose. Therefore,
the effect of 0.5% hesperidin intake on lymphocyte composition in a rat oral sensitization model was
studied, analysing the phenotype of both inductive (MLNL and PPL) and effector sites (IEL and LPL)
of the GALT.
No differences were seen as a result of the intake of the 0.5% hesperidin diet on MLNL or PPL
(Table 3). In particular, in the mesenteric lymph nodes, the proportion of B (CD45RA+), T (TCRαβ+ and
TCRγδ+), and natural killer (NK) cells, as well as that of TCRαβ+CD4+, TCRαβ+CD8+, TCRαβ+NK,
CD4+CD25+, CD4+CD62L+, CD8+CD25+, and CD8+CD62L+ cells, was similar between the OVAoral
and the H0.5 groups. Likewise, in the Peyer’s patches, the proportion of B, T, and NK cells did not
differ between groups, and that of TCRαβ+CD4+, TCRαβ+CD8+, TCRαβ+NK, TLR4+ (including
CD45RA+TLR4+, CD4+TLR4+, CD8+TLR4+), CD45RA+CD25+, CD4+CD25+, and CD8+CD25+ cells
also remained unchanged. Interestingly, the 0.5% hesperidin diet modified the proportion of the
lymphocytes in the effector sites of the GALT (Table 3). In particular, hesperidin intake increased
the percentage of TCRγδ+ cells in IEL (140%) in comparison to the reference group (OVAoral group),
which was due to an increase in both TCRγδ+CD8αα+ and TCRγδ+CD8αβ+ subsets, although, in this
compartment, hesperidin did not significantly modify other important lymphocytes such as TCRαβ+
(and any of their CD4+, CD8+, and natural killer T –NKT- cell subsets) and NK cells. With regard to
LPL, the 0.5% hesperidin diet increased the proportion of B (CD45RA+) cells to 180% and decreased
that of TCRγδ+ and NK cells (35% and 29%, respectively) with respect to orally sensitized animals
(OVAoral group). In addition, although the total TCRαβ+ population was not significantly modified,
the percentage of TCRαβ+CD4+ cells increased (132%), whereas that of TCRαβ+CD8+ cells and
NKT cells decreased (52% and 42%, respectively) with respect to the OVAoral group. Likewise, the
hesperidin-enriched diet intake decreased the percentage of both CD4+ and CD8+ LPL expressing the
CD103+ (50% and 60%, respectively, from that found in the OVAoral group).
3.5. Effect of 0.5% Hesperidin on Antibody Synthesis and Total IgA
The oral sensitization procedure applied induced the development of serum anti-OVA antibodies.
However, as in the first experimental design, this immune response was not modified by hesperidin
(Table 4). In order to find out what happened in Th1/Th2-associated antibody isotypes, the
concentration of specific IgG1, IgG2a, IgG2b, IgG2c, and IgE antibodies was determined. The oral
sensitization caused the synthesis of antibodies belonging to IgG1, IgG2a, and IgG2b isotypes, as
previously reported [20,22]. The 0.5% hesperidin-enriched diet did not significantly modify the levels
of these anti-OVA antibodies (Table 4). Specifically, IgG2c and IgE were not detectable in any group.
In addition, intestinal and serum IgA was assessed after four weeks of the nutritional intervention.
In this approach, hesperidin intake produced an increase in intestinal IgA, whereas no changes were
found with respect to serum IgA (Table 4).
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Table 4. Serum and intestinal anti-OVA and total antibodies from the second experimental design
after 0.5% hesperidin diet. Data are expressed as mean ± standard error (n = 6). ND: not detectable.
Statistical difference: * p < 0.05 (by ANOVA).
Group
OVAoral H0.5
Serum total Ig anti-OVA [log(U.A./mL)] 3.45 ± 0.32 3.16 ± 0.34
Serum IgG1 anti-OVA [log(U.A./mL)] 1.52 ± 0.26 1.86 ± 0.29
Serum IgG2a anti-OVA [log(U.A./mL)] 1.40 ± 0.34 1.21 ± 0.50
Serum IgG2b anti-OVA [log(U.A./mL)] 1.48 ± 0.05 1.65 ± 0.23
Serum IgG2c anti-OVA ND ND
Serum IgE anti-OVA ND ND
Serum total IgA (μg/mL) 5.72 ± 0.15 5.36 ± 0.24
Intestinal total IgA (μg/g faeces) 34.60 ± 6.79 58.07 ± 7.61 *
4. Discussion
The current study shows the effect of hesperidin in two different approaches related to Th2
immune responses to ovalbumin: an i.p. immunization with the allergen Bpt and alum, and an oral
sensitization with the allergen plus cholera toxin. It was found that the administration of hesperidin in
i.p. immunized rats modified MLNL composition and functionality. Moreover, in orally sensitized
rats, this flavanone changed the proportions of IEL and LPL and increased intestinal IgA content.
However, hesperidin did not affect anti-OVA antibody production in any of the studied immune
system stimulations.
First of all, we wanted to establish the effect of the hesperidin administration in an i.p.
immunization model, triggering a systemic immune response. The hesperidin doses in this case
were in accordance with the quantity given to rats to protect against gentamicin nephrotoxicity [23].
The i.p. immunization was performed using the adjuvants alum (enhancer of Th2 response [24])
and Bpt (considered a potent agent to elicit IgE response [25]), as was previously reported in Brown
Norway rats [19]. However, this i.p. immunization in Lewis rats was not able to induce the production
of anti-OVA IgE, contrary to when using the Brown Norway strain, a high IgE responder [26].
In addition, although a specific antibody response was induced, hesperidin did not modify the
levels of such antibodies.
In order to establish the influence of hesperidin on the lymphocyte composition and function,
MLNL were analysed. We observed that both doses of hesperidin used here were able to increase
TCRαβ+ cell percentage and decrease that of B lymphocytes. This effect was opposite to results
observed after cocoa flavonoids intake [22]. The imbalance between the proportions of TCRαβ+ cells
and B cells could be due to an increase in the number of TCRαβ+ lymphocytes and/or a decrease in
the number of B lymphocytes. In agreement with these results, some flavonoids have demonstrated
their ability to reduce B cell viability [2,27]. In particular, catechin, a green tea flavanol, induces
apoptosis of human malignant B cells [28]. Therefore, the effect of hesperidin on reducing B cell
numbers may not be disregarded, although it is not reflected in antibody production. Consequently,
further studies are necessary to confirm the potential of hesperidin in expanding TCRαβ+ cells or
reducing B cell numbers.
Apart from the TCRαβ+ and B lymphocyte proportions, other TCRαβ+ subsets were determined.
No changes in the Th (TCRαβ+CD4+) and Tc (TCRαβ+CD8+) cells were observed as a result of
hesperidin administration, but a significant decrease in the proportion of CD8+CD25+ cells was found
after the administration of 200 mg/kg hesperidin. The surface CD25 molecule is expressed in activated
cells, and an increased number of blood T CD25+ cells in asthmatic patients has been reported [29].
Although we did not use a model of asthma, our results in terms of Tc CD25+ cell proportion would
correspond with the anti-asthmatic effects of hesperidin [9].
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On the other hand, stimulated MLNL induced the production of cytokines related to Th1 and Th2
responses. The administration of either 100 or 200 mg/kg hesperidin increased the amount of IFN-γ
released from stimulated MLNL, although no changes were found in Th2 cytokines. IFN-γ is a product
of Th1 cells that exerts inhibitory properties on Th2 differentiation [30], and its downregulation seems
crucial for the development of allergic diseases [31]. Therefore, the increase of this type of Th1 cytokine
suggests another hesperidin mechanism involved in the attenuation of allergic asthma. In addition,
it has been reported that the administration of 5 mg/mL of hesperidin in a mouse model of allergic
asthma inhibited the IL-4 production in splenocytes and the IL-5 concentration in the bronchoalveolar
fluid [9]. Overall, these data suggest that hesperidin displays an anti-allergic action by increasing Th1
cytokines or decreasing Th2 cytokines.
Despite the results found after inducing a systemic immune response, we aimed to focus on
the intestinal immune response, studying the effect of hesperidin on the GALT using a previously
established model of oral sensitization [20]. As the applied doses of hesperidin did not influence
antibody synthesis, we increased the dosage of flavanone, including it in the diet (0.5% hesperidin).
This dosage was chosen because it has been used in previous reports, such as in the inhibition of
bone loss in androgen-deficient male mice [15], in ovariectomized rats [32], and in senescent rats [33].
Considering the amount of food intake per rat, the diet with 0.5% hesperidin meant a consumption
of about 360 mg/100 g BW of hesperidin per week, which was higher than that provided in the first
experimental design (30 and 60 mg/100 g BW per week for 100 and 200 mg/kg hesperidin doses,
respectively).
In the second approach, in contrast to the first, the hesperidin-enriched diet did not modify the
composition of MLNL. Although in this second design we used a higher amount of flavanone than that
used in the first approach (6- or 12-fold times higher), the inclusion of hesperidin in the food (meaning
a slow intake) compared with the oral gavage (meaning a fast intake) and/or a different stimulation of
MLNL (by i.p. route or by intestinal route) may affect the cellular composition of this lymphoid tissue
differently. In addition, in this second approach, hesperidin did not affect the lymphocyte composition
of another inductive site of the GALT, the PP. Interestingly, however, the hesperidin intake changed
the proportion of cells found in the intraepithelial and the lamina propria compartments, the effector
sites of the GALT. In particular, the hesperidin diet increased the proportion of TCRγδ+ lymphocytes
in the intestinal epithelium, which is in line with previous results described after the intake of some
polyphenol-enriched foods such as unripe apple [34] and cocoa [21]. TCRγδ+ IEL have an important
role in maintaining the epithelial homeostasis, and several studies have related this cellular type
with mucosa-associated tolerance [21,34–37]. However, it has been recently suggested that TCRγδ+
IEL triggered by CT exhibit antigen-presenting cell activity in recipient mice fed an oral antigen and
contribute to breaking tolerance and inducing a Th2 response [38]. In particular, the oral administration
of CT in mice caused the migration of TCRγδ+ IEL to LPL, where they produce IL-10 and IL-17 [38]. Our
results regarding rats orally sensitized with OVA together with CT showed that hesperidin produced
an opposite effect in the proportion of TCRγδ+ cells both in IEL and LPL, suggesting a protective
action of hesperidin in the migration of these cells induced by CT. The hesperidin decrease in TCRγδ+
LPL is in line with the lower proportion of CD8+CD103+ cells in this compartment. The integrin
CD103 (also known as αE) binds to E-cadherin and mediates T cell adhesion to the intestine [39], and is
highly expressed at the mucosal sites [40], thus suggesting that CD8+CD103+ LPL would move to the
intraepithelial compartment (although CD8+CD103+ IEL proportion did not significantly increase).
In addition, after the intake of 0.5% hesperidin diet, LPL showed a relative higher proportion of B
cells, which could be related to the enhanced action of hesperidin in the antibody intestinal response,
thereby increasing intestinal IgA content, which is in line with other dietary polyphenols [41,42].
In addition, a rise of the Th/Tc proportion in the hesperidin-fed group was found, in agreement with
the results reported for LPL after a cocoa-enriched diet using the same rat oral sensitization model [21].
Despite all these lymphocyte composition changes, the specific antibody immune response was
not modified in the animals fed the hesperidin diet. In addition, when Th1- and Th2-related antibodies
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were studied (IgG2b, and IgG1 and IgG2a, respectively) [19], no particular effects were observed,
contrary to the impact of the intake of cocoa, a rich source of flavonoids, in the same oral sensitization
model [21,22]. A wide range of polyphenols has been demonstrated to play a role in decreasing
specific antibody production in allergy models [8] and it has also been reported that hesperidin
attenuated the OVA-specific IgE production in asthma models [9,17,43]. Nevertheless, in the current
study, no differences were detected in serum anti-OVA antibodies in either the first or the second
experimental designs.
5. Conclusions
In summary, the present results show that hesperidin administration in i.p. immunized rats
influences MLNL composition (increasing TCRαβ+ lymphocyte proportion and decreasing that of B
and CD8+CD25+ cells) and functionality (increasing IFN-γ synthesis). Moreover, a diet containing
0.5% hesperidin in orally sensitized rats increases intestinal IgA content and also modifies IEL and
LPL composition, suggesting the prevention of cell changes triggered by oral CT. However, this
hesperidin immunomodulation is not associated with the attenuation of specific antibodies induced
by both systemic and intestinal sensitization. Finally, it must be taken into account that this study
shows the properties of hesperidin alone; further studies must focus on establishing the effect of
hesperidin-enriched food and also the dosage of such foods to achieve these immune effects.
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Abstract: Claudin-2 is highly expressed in human lung adenocarcinoma tissues and may be a
novel target for cancer chemotherapy because knockdown of claudin-2 decreases cell proliferation.
We found that flavonoids including kaempferol, chrysin, and luteolin concentration-dependently
decrease claudin-2 expression in lung adenocarcinoma A549 cells. Claudin-2 expression is
up-regulated by mitogen-activated protein kinase kinase (MEK)/ extracellular signal-regulated kinase
(ERK)/c-Fos and phosphoinositide 3-kinase (PI3K)/Akt/nuclear factor-κB (NF-κB) pathways, but
these activities were not inhibited by kaempferol, chrysin, and luteolin. Promoter deletion assay using
luciferase reporter vector showed that kaempferol and luteolin inhibit the function of transcriptional
factor that binds to the region between −395 and −144 of claudin-2 promoter. The decrease in
promoter activity was suppressed by mutation in signal transducers and activators of transcription
(STAT)-binding site, which is located between −395 and −144. The phosphorylation level of STAT3
was not decreased, but the binding of STAT3 on the promoter region is suppressed by kaempferol
and luteolin in chromatin immunoprecipitation assay. The inhibition of cell proliferation caused by
kaempferol and luteolin was partially recovered by ectopic claudin-2 expression. Taken together,
kaempferol and luteolin decreased claudin-2 expression and proliferation in A549 cells mediated
by the inhibition of binding of STAT3 on the promoter region of claudin-2. The intake of foods and
nutrients rich in these flavonoids may prevent lung adenocarcinoma development.
Keywords: lung adenocarcinoma; claudin-2; kaempferol; chrysin; STAT3
1. Introduction
Epithelial cells form tight junctions (TJs) at the most apical pole of the lateral membrane between
neighboring cells. The TJs regulate the flux of ions and solutes through the paracellular pathway, cell
proliferation, polarization, and differentiation [1–3]. Most solid cancers are derived from epithelial
tissues and disruption of polarity accelerates cell proliferation and differentiation. Claudins are integral
membrane proteins of TJs and comprise a large family of 27 subtypes in a mammal [4,5]. Dysregulation
of claudins expression has been shown in various tumor tissues [6]. We have been reported that the
expression of claudin-2 is up-regulated in human lung adenocarcinoma tissues [7]. Similarly, the
elevation of claudin-2 expression is reported in liver [8], colon [9], and stomach cancer tissues [10].
The knockdown of claudin-2 decreases proliferation and migration in non-small-cell lung carcinoma
cells [7,11]. Therefore, claudin-2 may be one of the targets for anticancer function of foods and drugs.
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Anticancer activity is reported in polyphenols extracted from plants, fruits, vegetables, and bee
propolis [12,13]. Polyphenols include many classes of compounds ranging from flavonoids, phenolic
acids, and anthocyanins. Some flavonoids inhibit growth and invasion of cancer cells in various
in vitro and in vivo models. A population-based case-control study in Montreal, Canada, reported
that a low dietary intake of flavonoids increases the risk of lung cancer [14]. Antioxidant effect is
one of the key factors to reduce cancer risk [15]. Flavonoids have a basic structure consisting of
two aromatic rings linked by three carbon atoms that are confined in an oxygenated heterocycle
ring, and clarified as flavonols, flavones, flavanones, flavanols, anthocyanidins, and isoflavones [16].
The antioxidant activity is affected by the number and position of hydroxyl substituents [17]. Quercetin,
with 3′,4′ dihydroxy substituents in the B ring and conjugation between the A and B rings has strong
antioxidant activity, and shows apoptotic and anti-proliferative effects in human cancer cells derived
from lung [18], breast [19], gastrointestinal tract [20], and prostate [21]. We previously reported that
quercetin decreases claudin-2 expression in human lung adenocarcinoma A549 cells [22]. However,
other flavonoids that decrease claudin-2 expression have not been identified.
The expression of claudins is controlled by various transcriptional factors under physiological
and pathophysiological conditions. Signal transducers and activators of transcription (STAT) forms
a family with seven members in mammals (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and
STAT6) [23]. Among them, STAT3 and STAT5 are activated in a large number of human cancers
and play major roles in proliferation, apoptosis, and angiogenesis [24]. The activation of tyrosine
kinase signal promotes dimerization of STAT3 and its translocation into the nuclei. STAT3 binds to the
promoter regions of tumor-related genes [25]. A few reports indicate that STATs are involved in the
regulation of claudins expression. The activation of STAT1 and STAT3 decreases claudin-5 expression
in human brain microvascular endothelial cells [26] and claudin-2 expression in Madin-Darby canine
kidney (MDCK) II cells [27], respectively, but the binding site of STAT on the promoter region of
claudins is unknown.
In the present study, we searched for new substances that can decrease claudin-2 expression in
A549 cells and identified kaempferol, chrysin, and luteolin as the potential candidates. To clarify the
mechanism, we examined the effects of these flavonoids on intracellular signaling factors, promoter
activity of claudin-2, binding of transcriptional factor on promoter of claudin-2, and cell proliferation.
Our results indicate that kaempferol and luteolin may decrease claudin-2 expression through inhibiting
the interaction of STAT3 on promoter region of claudin-2 without affecting the phosphorylation of
STAT3, resulting in suppression of cell proliferation.
2. Experimental Section
2.1. Materials
Rabbit anti-claudin-1 and mouse anti-claudin-2 antibodies were obtained from Thermo Fisher
Scientific (Waltham, MA, USA). Goat anti-β-actin and rabbit anti-phosphorylated-c-Fos (p-c-Fos)
antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit anti-p-Akt, rabbit
anti-Akt, rabbit anti-ERK1/2, rabbit anti-c-Fos, rabbit anti-p-NF-κB p65 (Ser536), and rabbit anti-NF-κB
p65 antibodies were from Cell Signaling Technology (Beverly, MA, USA). Mouse anti-p-STAT3,
anti-STAT3, and anti-nucleoporin p62 antibodies were from BD Biosciences (San Jose, CA, USA).
Apigenin, genistein, and quercetin were from Wako Pure Chemical Industries (Osaka, Japan). Chrysin,
kaempferol, daidzein, and 7-hydroxyflavone were from Tokyo Kasei Kogyo (Tokyo, Japan). Hesperetin
was from LKT Laboratories (St. Paul, MN, USA). Luteolin and 4′-hydroxyflavone were from
INDOFINE Chemical Company (Hillsborough, NJ, USA). Flavonoids were dissolved in dimethyl
sulfoxide (DMSO). All other reagents were of the highest grade of purity available.
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2.2. Cell Culture and Transfection
The human lung adenocarcinoma A549 cell line was obtained from the RIKEN BRC through
the National Bio-Resource Project of the MEXT, Japan. The cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM, Sigma-Aldrich, St. Louis, MO, USA) supplemented with 5% fetal calf
serum (FCS, HyClone, Logan, UT, USA), 0.07 mg/mL penicillin-G potassium, and 0.14 mg/mL
streptomycin sulfate in a 5% CO2 atmosphere at 37 ◦C. The experiments were done in subconfluent
culture condition (about 70–80% confluent), because the expression of claudin-2 decreased in 100%
confluent condition [11]. The cells were treated with vehicle DMSO (control) and flavonoids (1–50 μM)
for 24 h in FCS-free DMEM. The vector containing human claudin-2 cDNA was prepared as described
previously [11]. The FLAG-tagged claudin-2 was sub-cloned into pTRE2-hyg vector and transfected
into A549 cells with Lipofectamine 2000 as recommended by the manufacturer. Stable transfectants
were selected with 500 ng/mL hygromycin B and maintained in the continuous presence of 50 ng/mL
hygromycin B.
2.3. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Immunoblotting
Cells were scraped into cold phosphate-buffered saline and precipitated by centrifugation.
They were lysed in a radioimmunoprecipitation assay lysis buffer containing 150 mM NaCl, 0.5 mM
ethylenediaminetetraacetic acid, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 50 mM Tris-HCl
(pH 8.0), a protease inhibitor cocktail (Sigma-Aldrich), and sonicated for 20 s. The aliquots were used
as whole cell extracts. After centrifugation at 6000× g for 5 min, the supernatants were collected and
used as cell lysates which including plasma membrane and cytoplasmic proteins. Nuclear fractions
were prepared using NE-PER nuclear and cytoplasmic fraction reagents as recommended by the
manufacturer (Thermo Fisher Scientific). Samples were applied to SDS-PAGE and blotted onto
a polyvinylidene difluoride membrane. The membrane was then incubated with each primary
antibody (1:1000 dilution) at 4 ◦C for 16 h, followed by a peroxidase-conjugated secondary antibody
(1:5000 dilution) at room temperature for 1 h. Finally, the blots were incubated in Pierce Western
Blotting Substrate (Thermo Fisher Scientific) and exposed to film, or incubated in ECL Prime Western
Blotting Detection System (GE healthcare, Chalfont St Giles, UK) and scanned with a C-DiGit Blot
Scanner (LI-COR Biotechnology, Lincoln, NE, USA). Blots were further stripped and reprobed with
anti-β-actin antibody. Band density was quantified with ImageJ software (National Institute of Health
software, NIH, Bethesda, MD, USA). The signals were normalized for the loading control β-actin
or nucleoporin p62. The expression levels were represented relative to the values in the absence
of flavonoids.
2.4. Measurement of O2− Scavenging Activity
Antioxidant activity of flavonoids and antioxidants was measured using the
hypoxanthine-xanthine oxidase system as the source of superoxide anion [28]. Reaction solution
contains 10 μM 2-methyl-6-p-methoxyphenyl ethynylimidazopyrazynone, 0.02 units/mL xanthine
oxidase, 0.12 mM hypoxanthine, and 20 mM KH2PO4 (pH 7.5). Test compounds were mixed in the
reaction buffer at the final concentration of 50 μM. A chemiluminescence intensity was measured with
a luminometer (AB-2270 Luminescencer Octa, ATTO, Tokyo, Japan). O2− scavenging activity was
calculated by the following formula: Scavenging activity (%) = (1 − CLS/CLC) × 100; where CLC,
chemiluminescence of control, CLA, chemiluminescence of sample.
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2.5. RNA Isolation and Polymerase Chain Reaction (PCR)
Total RNA was isolated from A549 cells using TRI reagent (Sigma-Aldrich). Reverse transcription
was carried out with ReverTra Ace qPCR RT Kit (Toyobo Life Science, Osaka, Japan). Semi-quantitative
PCR was carried out with DNA Engine Dyad Cycler (Bio-Rad, Richmond, CA, USA) using GoTaq
DNA polymerase (Promega, Madison, WI, USA). The PCR product was visualized with ethidium
bromide after electrophoretic separation on a 2% agarose gel. The size of PCR product was 86 bp
(claudin-2) and 100 bp (β-actin). Quantitative real-time PCR was performed with a Thermal Cycler
Dice Real-time System (TP700, Takara Bio, Shiga, Japan) or Eco Real-Time PCR system (AS One, Osaka,
Japan) using KOD SYBR qPCR Mix (Toyobo Life Science). The primers used to PCR are listed in
Table 1. The threshold cycle (Ct) for each PCR product was calculated with the instrument’s software,
and Ct values obtained for claudin-1 and -2 were normalized by subtracting the Ct values obtained for
β-actin. The resulting ΔCt values were then used to calculate the relative change in mRNA expression
as a ratio (R) according to the equation R = 2−(ΔCt(treatment)−ΔCt(control)).












2.6. Luciferase Reporter Assay
Using the reporter plasmids containing fragments of −1031/+37, −393/+37, −143/+37,
and −87/+37 of human claudin-2, luciferase reporter assay was carried out as described
previously [29]. The mutant of putative STAT-binding site (−252/−230) was generated using
the primer pairs (forward: 5′-GAATCTCGAGCAGCCACCTGTCTGGCTCCTGGC-3′ and reverse:
5′-AGGTGATGATGGCAGTGGTGGTTGTG-3′) and KOD-Plus-mutagenesis kit (Toyobo Life Science).
The luminescence of luciferase was measured with a luminometer.
2.7. Chromatin Immunoprecipitation (ChIP) Assay
Cells were treated with 1% formaldehyde to crosslink the protein to the DNA. ChIP assay
was carried out as described previously [29]. To co-immunoprecipitate the DNA, anti-STAT3
antibody or mouse IgG was used. The eluted DNA was amplified by quantitative PCR using
the primer pairs for claudin-2 promoter (forward: 5′-ACTTGAGTTAACACAGCCACCA-3′ and
reverse: 5′-ACTTTGAACGTGGAGCCAAAAT-3′). To confirm the same amounts of chromatins used
in immunoprecipitation between groups, input chromatin was also used.
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2.8. Cell Proliferation
Cells were seeded at 1 × 105 cells in 60-mm dishes. After 24, 48, and 72 h of culture, the cell
images were captured with a light microscope (CKX53, Olympus, Tokyo, Japan). Cell proliferation
was calculated by counting the number of cells using the CKX-CCSW software (Olympus).
2.9. Statistics
Results are presented as means ± S.E.M. Differences between groups were analyzed with a
one-way analysis of variance, and corrections for multiple comparison were made using Tukey’s
multiple comparison test. Comparisons between two groups were made using Student’s t-test. Statics
were performed using KaleidaGraph version 4.5.1 software (Synergy Software, Reading, PA, USA).
Significant differences were assumed at p < 0.05.
3. Results
3.1. Effects of Flavonoids on Claudin-2 Expression in A549 Cells
The protein level of claudin-2 in the cytoplasmic fraction was significantly decreased by quercetin,
apigenin, kaempferol, chrysin, luteolin, and daizein at the concentration of 50 μM in A549 cells
(Figure 1). The effects of kaempferol, chrysin, and luteolin were stronger than those of other flavonoids.
Genistein and hesperetin showed no effect on claudin-2 expression. Hesperetin, kaempferol, and
luteolin showed cytotoxicity at over 100 μM, but all flavonoids have little effect on cytotoxicity at the
concentration of lower than 50 μM (Supplementary Figure S1). These results indicate that the decrease
in claudin-2 expression is not due to cytotoxicity. The expression of other junctional proteins including
claudin-1, occludin, and E-cadherin was not changed by these flavonoids. In the present study, we
focused on the regulatory mechanism of which kaempferol, chrysin, and luteolin decrease claudin-2
expression because the effects of these flavonoids are the strongest.
3.2. Effects of Antioxidant Capacity on Claudin-2 Expression
The expression of claudin-2 was dose-dependently decreased by kaempferol, chrysin, and luteolin
(Figure 2). The effects were significant over the concentration of 1 or 10 μM. Certain flavonoids have
an antioxidant effect. Kaempferol, chrysin, and luteolin showed approximately 20% O2− scavenging
activity at 50 μM (Figure 3). 4′-Hydroxyflavonoe and 7-hydroxyflavone had little antioxidant activity,
which is similar to previous report [30]. In contrast, N-acetyl cysteine (NAC, 1 mM) and reduced
glutathione (GSH, 0.1 mM) had strong antioxidant activity. Although 4′-hydroxyflavonoe and
7-hydroxyflavone had little antioxidant activity, they decreased claudin-2 expression (Figure 4).
In addition, claudin-2 expression was not decreased by NAC and GSH. These results indicate that
antioxidant capacity may not be involved in the decrease in claudin-2 expression by flavonoids.
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Figure 1. Effects of flavonoids on expression of junctional proteins in A549 cells. Cells were
incubated in the absence and presence of 50 μM flavonoids including quercetin, apigenin, genistein,
hesperetin, kaempferol, chrysin, luteolin, and daidzein for 24 h. Cell lysates were immunoblotted with
anti-claudin-2, anti-claudin-1, anti-occludin, anti-E-cadherin, or anti-β-actin antibody. The expression
levels were represented relative to the values in control. n = 3–4. ** p < 0.01 significantly different from
control. NS, not significantly different.
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Figure 2. Dose-dependent effects of kaempferol, chrysin, and luteolin on claudin-2 expression. The cells
were incubated in the absence and presence of kaempferol (A), chrysin (B), or luteolin (C) for 24 h at
the concentration indicated. Cell lysates were immunoblotted with anti-claudin-2 or β-actin antibody.
The expression levels of claudin-2 were represented relative to the values in 0 μM. n = 3–4. ** p < 0.01
significantly different from 0 μM. NS, not significantly different.
 
Figure 3. Antioxidant effects of flavonoids and antioxidants. O2− scavenging activity was examined
using the hypoxanthine-xanthine oxidase system. Flavonoids (50 μM), N-acetyl cysteine (NAC, 1 mM),
and reduced glutathione (GSH, 0.1 mM) were mixed in the reaction buffer. n = 4.
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Figure 4. Effects of non-antioxidative flavones and antioxidants on claudin-2 expression.
(A,B) The cells were incubated in the absence and presence of 4′-hydroxyflavone or 7-hydroxyflavone
for 24 h at the concentration indicated. Cell lysates were immunoblotted with anti-claudin-1, claudin-2,
or β-actin antibody. The expression levels of claudin-1 and -2 were represented relative to the values
in 0 Mm; (C) Cells were incubated in the absence (control) and presence of NAC (1 mM) or GSH
(0.1 mM) for 24 h. Cell lysates were immunoblotted with anti-claudin-1, claudin-2, or β-actin antibody.
The expression levels of claudin-1 and -2 were represented relative to the values in control. n = 3.
** p < 0.01 significantly different from 0 μM or control. NS, not significantly different.
3.3. Effects of Flavonoids on mRNA Levels of Junctional Protein and Intracellular Signaling Pathway
Kaempferol, chrysin, and luteolin significantly decreased the mRNA level of claudin-2 without
changing that of claudin-1 (Figure 5). These results coincide with those of Western blotting. In contrast,
the mRNA level of occludin was increased by kaempferol and those of occludin and E-cadherin
were decreased by luteolin. We previously reported that the transcriptional activity of claudin-2 is
up-regulated by the MEK/ERK/c-Fos [29] and PI3K/Akt/NF-κB pathways [31]. Some flavonoids,
including kaempferol, chrysin, and luteolin, increased the phosphorylation levels of ERK1/2 and/or
c-Fos (Figure 6). On the contrary, these flavonoids had no effect on the phosphorylation of Akt and
NF-κB p65. These results indicate that the MEK/ERK/c-Fos and PI3K/Akt/NF-κB pathways may not
be involved in these flavonoids-induced decreases in claudin-2 expression.
 
Figure 5. Effects of flavonoids on mRNA levels of junctional protein. The cells were incubated in the
absence and presence of 50 μM flavonoids for 6 h. After isolation of total RNA, quantitative real-time
PCR was performed using specific primers for claudin-1, claudin-2, occludin, and E-cadherin. n = 4.
** p < 0.01 and * p < 0.05 significantly different from control. NS, not significantly different.
273
Nutrients 2017, 9, 597
 
Figure 6. Effects of flavonoids on the phosphorylation of intracellular signaling pathways. The cells
were incubated in the absence and presence of 50 μM flavonoids for 1 h. (A) Whole cell extracts were
immunoblotted with anti-p-ERK1/2, ERK1/2, p-c-Fos, or c-Fos antibody; (B) Whole cell extracts were
immunoblotted with anti-p-Akt, Akt, p-NF-κB p65, or NF-κB p65 antibody. The levels of p-ERK,
p-c-Fos, p-Akt, and p-NF-κB p65 were represented relative to the values in control. n = 3. ** p < 0.01
and * p < 0.05 significantly different from control. NS, not significantly different.
3.4. Effects of Flavonoids on the Promoter Activity of Claudin-2
To clarify a major transcriptional factor involved in the flavonoids-induced decreases in claudin-2
expression, we performed the promoter deletion assay of human claudin-2. Apigenin, kaempferol,
chrysin, and luteolin significantly decreased the promoter activity (Figure 7). These results coincide
with those of Western blotting. In contrast, quercetin, genistein, hesperetin, and daidzein did not
inhibit the promoter activity. Kaempferol, chrysin, and luteolin inhibited the activity of construct
of −395/+37, but the inhibitory effects of kaempferol and luteolin disappeared in the constructs of
−143/+37 and −87/+37. In contrast, the promoter activity of all deletion constructs was significantly
inhibited by chrysin. These results indicate that the kaempferol- and luteolin-sensitive transcriptional
factor may bind to the region between −395 and −144, and chrysin-sensitive one may bind to the
region between −86 and −1. TFSEARCH showed that the region between −395 and −144 of claudin-2
promoter contains a putative STAT-binding site. The promoter activity of mutant of STAT-biding site
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was not significantly inhibited by kaempferol and luteolin. These results indicate that STAT may be
involved in the decrease in claudin-2 expression by kaempferol and luteolin.
 
Figure 7. Effects of flavonoids on the promoter activity of human claudin-2. (A) Schematic drawing
of human claudin-2 luciferase reporter vector; (B) The cells were co-transfected with luciferase
−1031/pGL4.10 and pRL-TK vectors. After 24 h of transfection, the cells were incubated in the absence
and presence of 50 μM flavonoids for 24 h. The promoter activity of claudin-2 was represented relative
to the values in control; (C) The constructs of 5′-deletion series including −395, −143, and −87/pGL4
vector were co-transfected with the pRL-TK vector; (D) The construct of mutant of STAT-binding site
was co-transfected with the pRL-TK vector. The relative promoter activity was represented relative to
the values of control of −1031/pGL4 vector. n = 3–4. ** p < 0.01 significantly different from vehicle.
NS, not significantly different.
3.5. Inhibition of Association between STAT3 and Claudin-2 Promoter by Flavonoids
STAT3 is abundantly expressed in lung cancer cells and involved in the development of cancer [32].
The phosphorylation and nuclear localization of STAT3 were not inhibited by kaempferol, chrysin,
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and luteolin (Figure 8). In the ChIP assay, a primer pairs amplifying the STAT-binding site showed
positive PCR signals in the control cells using anti-STAT3 antibody (Figure 8B). In the kaempferol,
chrysin, and luteolin-treated cells, PCR signal was faint. The primer pairs amplifying STAT-binding
site showed PCR bands using input samples. These results indicate that these flavonoids inhibit
interaction between STAT3 and claudin-2 promoter. The interaction between transcriptional factor
and promoter region is often regulated by epigenetic modification, such as histone acetylation [33].
However, three flavonoids did not change acetylation levels of histone H3 (Figure 8C), indicating
that epigenetic mechanism may not be involved in the inhibition of association between STAT3 and
claudin-2 promoter.
  
Figure 8. Effects of flavonoids on the binding of STAT3 to promoter region of claudin-2. The cells
were incubated in the absence (control) and presence of 50 μM flavonoids for 1 h. (A) Whole cell
extracts and nuclear fractions were immunoblotted with anti-p-STAT3, anti-STAT3, or anti-nucleoporin
p62 antibody. The levels of p-STAT3 were represented relative to the values in control; (B) After
immunoprecipitation of genomic DNA by anti-STAT3 antibody, semi-quantitative PCR (left images)
and quantitative real-time PCR (right graphs) were performed using the primers amplifying the
putative STAT-binding site of claudin-2 promoter. Mouse IgG was used for negative control. Input
chromatin was used for normalization. The amount of PCR products is represented relative to the value
of control cells; (C) Nuclear fractions were immunoblotted with anti-acetyl histone H3 (K14 or K56) or
anti-histone H3 antibody. The levels of acetyl histone H3 were represented relative to the values in
control. n = 3. ** p < 0.01 significantly different from control. NS, not significantly different.
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3.6. Effects of Three Flavonoids and Ectopic Claudin-2 Expression on Cell Proliferation
Claudin-2 is partially involved in the regulation of proliferation in A549 cells [7,11]. Kaempferol,
chrysin, and luteolin decreased claudin-2 expression, so we examined the effects of these flavonoids on
cell proliferation. To avoid the effect of cytotoxicity, the cells were treated with these flavonoids at the
concentration of 10 μM (Supplementary Figure S1). Cell number was not changed by overexpression
of claudin-2 in the absence of flavonoids (Figure 9). Three flavonoids inhibited the increase in cell
number and decreased the expression of claudin-2, which were rescued by ectopic claudin-2 expression.
Therefore, these results indicate that kaempferol, chrysin, and luteolin may inhibit cell proliferation
mediated by the decrease in claudin-2 expression.
 
Figure 9. Rescue of cell proliferation by ectopic claudin-2 expression. Mock and claudin-2-overexpressing
cells were cultured in the absence (A) and presence of 10 μM kaempferol (B); chrysin (C); or luteolin (D).
Cell number was measured at 24, 48, and 72 h after inoculation; (E) Cell lysates were immunoblotted with
anti-claudin-2 or β-actin antibody. n = 3–4. ** p < 0.01 and * p < 0.05 significantly different from mock. NS,
not significantly different.
277
Nutrients 2017, 9, 597
4. Discussion
The effects of flavonoids on the barrier function and expression of claudins have been examined
in epithelial cells. Quercetin enhances intestinal barrier in Caco-2 cells through the elevation
of claudin-4 [34] and through the assembly of zonula occludens-2, occludin, and claudin-1 [35].
Genistein and daidzein protect lipopolysaccharide-induced disruption of barrier function in glandular
endometrial epithelial cells through the elevation of claudin-3, -4, and -8 [36]. In contrast, the
effects of flavonoids on the pathophysiological function and expression of claudins in cancer cells
have not been examined well. Here, we found that kaempferol, chrysin, and luteolin decrease
the mRNA and protein levels of claudin-2 in lung adenocarcinoma A549 cells. The expression of
claudin-2 is decreased by chemical inhibitors and dominant negative plasmids of MEK/ERK/c-Fos
and PI3K/Akt/NF-κB pathways in A549 cells [7,31]. These factors of intracellular signaling pathway
are activated in the lung cancer tissues [37,38]. However, kaempferol, chrysin, and luteolin did not
inhibit the phosphorylation of ERK1/2 and Akt, but they surprisingly increased these phosphorylation.
We suggest that kaempferol, chrysin, and luteolin decrease claudin-2 expression mediated by the
different mechanisms from MEK/ERK/c-Fos and PI3K/Akt/NF-κB pathways.
The regulatory mechanism of claudin-2 expression is different in each tissue. Claudin-2 expression
is down-regulated by the activation of MEK/ERK pathway in renal tubular Madin Darby canine kidney
type II (MDCK II) cells [39]. The effect of MEK/ERK pathway in MDCK II cells is opposite to that
in A549 cells [29]. At present, it is unknown why the MEK/ERK pathway has contrary effects on
claudin-2 expression in both cells. In intestinal Caco-2 cells, claudin-2 is up-regulated by caudal-related
homeobox 2 (cdx2) [40]. Cdx2 is an intestine-specific transcription factor highly expressed in the tissues
of dysplasia and cancer, but is not expressed in the lung. Therefore, cdx2 should not be involved in
the up-regulation of claudin-2 in lung cancer. To identify novel compounds that decrease claudin-2
expression, we had to search for them based on the novel mechanism of action.
It has been postulated that oxidative stress is closely associated with tumor formation, progression
and metastasis. Numerous naturally occurring anti-oxidant compounds possess anti-cancer
properties [12]. Oxidative stresses including hydrogen peroxide and nitric oxide decrease claudin-1
and -5 expression in colonic HT-29 cells [41], claudin-2 expression in MDCK II cells [42], and claudin-5
expression in ischemic brain [43], which are inhibited by antioxidants. Oxidative stress may be
one of the key factors controlling claudins expression. Kaempferol, chrysin, and luteolin showed
little antioxidative effect at the concentration used in the present study (Figure 3), whereas NAC
and GSH had strong antioxidant activity. Nevertheless, both NAC and GSH did not decrease
claudin-2 expression, whereas 4′-hydroxyflavonoe and 7-hydroxyflavone dose-dependently decreased.
These results suggest that anti-oxidative capacity is not necessary to decrease claudin-2 expression in
A549 cells, but the basic structure of flavones or flavonols is necessary.
Kaempferol, chrysin, and luteolin have been reported to inhibit properties of cancer mediated by
inhibition of phosphorylation of STAT3: Kaempferol induces differentiation in partially differentiated
colon cancer cells [44], chrysin suppresses hypoxia-induced metastasis of 4T1 mouse breast cancer
cells [45], and luteolin inhibits hypoxia-induced vascular endothelial factor expression [46]. In contrast,
our results indicated that these flavonoids do not inhibit the phosphorylation of STAT3, but they block
the interaction between STAT3 and the promoter region of claudin-2. The direct inhibition of the binding
of transcriptional factor and DNA are reported by some flavonoids. Apigenin, chrysin, and kaempferol
bind to peroxisome proliferator-activated receptor γ and suppress inducible cyclooxygenase (COX) and
nitric oxide synthase promoter activity in mouse macrophages [47]. Chrysin binds to nuclear factor for
IL-6 and suppresses COX-2 expression in lipopolysaccharide-activated Raw 264.7 cells [48]. The binding
site of flavonoids on STAT3 is unknown, but kaempferol, chrysin, and luteolin could interfere the
interaction between STAT3 and promoter region of claudin-2.
The pharmacological inhibitor and dominant-negative isoform of STAT3 have been reported
to induce cell cycle arrest in A549 cells [32]. So far, we reported that knockdown of claudin-2
inhibits cell cycle G1/S transition without affecting cytotoxicity [11]. In the present study, kaempferol,
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chrysin, and luteolin showed little cytotoxicity (Supplementary Figure S1) and decreased cell number.
The flavonoids-induced decrease in cell number was significantly rescued by ectopic claudin-2
expression. Therefore, we suggest that these flavonoids inhibit cell proliferation mediated by the
reduction of claudin-2 expression.
5. Conclusions
In the present study, we found that kaempferol, chrysin, and luteolin decrease claudin-2 expression
in A549 cells. Kaempferol and luteolin inhibited the promoter activity of human claudin-2, which was
rescued by deletion or mutation of STAT-binding site. The phosphorylation and nuclear localization
of STAT3 were not inhibited by kaempferol and luteolin, but the interaction between STAT3 and the
promoter region of claudin-2 was inhibited, indicating that kaempferol and luteolin may directly block
the interaction of STAT3 on DNA. Chrysin also inhibited the promoter activity of claudin-2, which was
not rescued by deletion of STAT-binding site. Other important transcriptional factors, which bind to
the region between −86 and −1 of claudin-2 promoter, should be involved in the inhibitory effect of
chrysin. Some foods that abundantly include these flavonoids may be useful to prevent development
of lung adenocarcinoma.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/6/597/s1,
Figure S1: Effects of flavonoids on cell viability.
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Abstract: Cardiovascular diseases (CVDs) are leading global health problems. Accumulating
epidemiological studies have indicated that consuming fruits was inversely related to the risk of CVDs.
Moreover, substantial experimental studies have supported the protective role of fruits against CVDs,
and several fruits (grape, blueberry, pomegranate, apple, hawthorn, and avocado) have been widely
studied and have shown potent cardiovascular protective action. Fruits can prevent CVDs or facilitate
the restoration of morphology and functions of heart and vessels after injury. The involved mechanisms
included protecting vascular endothelial function, regulating lipids metabolism, modulating blood
pressure, inhibiting platelets function, alleviating ischemia/reperfusion injury, suppressing thrombosis,
reducing oxidative stress, and attenuating inflammation. The present review summarizes recent
discoveries about the effects of fruits on CVDs and discusses potential mechanisms of actions based
on evidence from epidemiological, experimental, and clinical studies.
Keywords: fruit; cardiovascular disease; coronary heart disease; stroke; hypertension; mechanisms
of action
1. Introduction
Cardiovascular diseases (CVDs) are defined as disorders of the heart and vessels, and include
coronary heart disease (CHD) and stroke. According to the WHO report, CVDs are responsible for
17.5 million deaths in 2012 (7.4 and 6.7 million due to CHD and stroke, respectively), accounting for
31% of all global deaths a year, constituting the leading causes of death worldwide [1]. Thus, studies
on CVDs have drawn great attention around the world.
Diet represents the most important modifiable factor to prevent CVDs. There is evidence that
plant-based dietary patterns are associated with lower risk of CVDs [2]. Among the most important
key components, fruit has been suggested to play a major role in preventing CVDs [3]. Several
epidemiological studies demonstrated that fruit intake was inversely associated with the risk of
cardiovascular events [4–7]. It is estimated that a diet low in fruits is the third most important
risk factor of CVDs following high blood pressure (BP) and cigarette smoking, accounting for more
than 5 million deaths worldwide in 2010 [8]. In addition, much experimental evidence supports
the protective role of fruit against CVDs. Furthermore, several fruits, such as grape, blueberry,
pomegranate, apple, hawthorn, and avocado, have been widely studied and have shown strong
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cardiovascular protective effects. Additionally, the effectiveness of fruit intake in the primary
prevention of CVDs has been revealed by growing clinical data in patients with high metabolic
risk factors (hypertension, dyslipidemia, diabetes, and overweight/obesity). Currently, the common
method of controlling CVDs is the use of long-term pharmacotherapy. Nevertheless, drugs are
not effective on all patients and have side effects that may aggravate the patients’ symptoms and
signs. Some fruits (extract) possess similar or even more potent anti-hypertensive, lipid-lowering, and
hypoglycemic activities, which has inspired many researchers to explore new therapies for CVDs [9–12].
The cardioprotective mechanisms of fruits are not entirely clear, but their outstanding antioxidant
and free radical scavenging properties are considered principal [13]. In this context, people have paid
more attention to natural products rich in polyphenols, a group of compounds characterized by the
presence of an aromatic ring and phenolic hydroxyl groups [14–25]. Polyphenols are obtained through
daily diets because they cannot be synthesized or stored in the human body, and fruit is one of the
main dietary sources of polyphenols [26]. The richest sources of fruit polyphenols are dark berries,
such as grapes and blueberries [27]. Further, pomegranate, apple, hawthorn, and avocado are also
frequently consumed polyphenols-rich fruits. There is evidence that fruit rich in polyphenols helps to
control CVDs.
This review aims to summarize the effects of fruit on CVDs based on evidence from epidemiological,
experimental, and clinical studies, and special attention is paid to the mechanisms of action.
2. Epidemiological Studies
Epidemiological evidence supports that diets rich in fruit delay the onset, and attenuate the
severity, of CVDs (Table 1).
Evidence from the China Kadoorie Biobank Study showed that consuming fresh fruits daily
decreased systolic blood pressure (SBP) by 4.0 mmHg and blood glucose level by 0.5 mmol/L, which
was inversely associated with the risks of cardiovascular death (hazard ratios (HRs): 0.60, 95%
confidence intervals (CIs): 0.54–0.67) and major CVDs, i.e., CHD (HR: 0.66, 95% CI: 0.58–0.75), ischemic
stroke (HR: 0.75, 95% CI: 0.72–0.79), and hemorrhagic stroke (HR: 0.64, 95% CI: 0.56–0.74), as compared
with participants who never or rarely consumed fresh fruit [4]. In addition, two cohort studies of
women aged 35–69 [5] and over 70 years [6], respectively, showed that consuming fruits reduced the
risk of total CVD mortality. Additionally, a Japanese study suggested that frequent intake of citrus
fruit protected against CVDs; the HR for near-daily intake versus infrequent intake of citrus fruit was
0.57 (95% CI: 0.33–1.01) in men and 0.51 (95% CI: 0.29–0.88) in women [7].
A cohort study of women in Shanghai showed a protective role of higher dietary total fruit
and vegetable intake in CHD. Moreover, the study suggested that this association was primarily
driven by fruit. The corresponding HRs for fruit and vegetable intake were 0.62 (95% CI: 0.37–1.03)
and 0.94 (95% CI: 0.59–1.50), respectively [28]. In addition, a meta-analysis of 23 prospective cohort
studies of 937,665 participants and 18,047 CHD patients showed that fruit consumption was inversely
associated with a risk of CHD. Compared with those who consumed the lowest total fruits, the relative
risk (RR) of CHD was 0.86 (95% CI: 0.82–0.91) for those consuming the highest, and the dose-response
analysis indicated that the RR of CHD was 0.84 (95% CI: 0.75–0.93) per 300 g/day of total fruit
intake [29]. For individual fruit, apple intake reduced the risk of acute coronary syndrome (ACS) by
3%, and the dose-response analysis indicated that the HR of ACS was 0.97 (95% CI: 0.93–1.01) per
25 g/day of apple intake [30].
In terms of stroke, cohorts of Swedish women and men suggested that consuming
3.1 servings/day of total fruits alleviated total stroke risk by 13% compared with 0.4 servings/day
(95% CI: 0.78–0.97) [31]. Furthermore, the study also indicated that, among individual fruits,
consumption of apple/pear particularly decreased the risk of total stroke (HR: 0.89, 95% CI:
0.80–0.98) [31], which was consistent with the result of a study in Netherlands of 20,069 adults [32].
The study in Netherlands also reported that consuming >120 g/day raw fruit decreased the risk of
hemorrhagic stroke by 47% (95% CI: 0.28–1.01) compared with consuming ≤120 g/day raw fruits [33].
284
Nutrients 2017, 9, 598
In addition, the Nurses’ Health Study showed that high citrus fruit/juice intake was related to
a reduced risk of ischemic stroke (RR: 0.90, 95% CI: 0.77–1.05) [34]. Additionally, a cohort study with
20,024 participants recruited also proved that citrus fruits/juice intake was inversely associated with
risk of ischemic stroke (HR: 0.69, 95% CI: 0.53–0.91) [35].
Epidemiological studies have suggested that fruit consumption was related to a reduction in
cardiovascular risk factors. Hypertension is an independent risk factor of CHD and total stroke [36].
Three cohort studies all reported that higher fruit intake was correlated with the decreased risk of
hypertension [37–39]. A study of US women showed that total fruit and vegetables consumption
attenuated the risk of hypertension. In addition, after adjusting for lifestyle factors and other food
intake, total fruit (p = 0.0004) but not total vegetables (p = 0.56) remained significantly and inversely
correlated with risk of hypertension [37]. In addition, a study on residents from Ohasama, Japan,
revealed an association between fruit and vegetable intake and the risk of hypertension. In the
sex- and BMI-adjusted analysis, the highest quartile of fruit intake was associated with a significantly
lower risk of hypertension (HR: 0.40, 95% CI: 0.21–0.74), whereas no association was observed for
vegetable intake [38]. Moreover, a study consisting of three large longitudinal cohorts, Nurses’ Health
Study, Nurses’ Health Study II, and Health Professionals Follow-up Study, suggested that long-term
and increased consumption of whole fruits reduced the risk of hypertension [39]. Additionally,
a case–control study in Korea was also in line with this view [40]. Furthermore, cross-sectional
studies of patients with type 2 diabetes demonstrated that higher fruit intake was correlated with
a lower burden of CVDs by decreasing carotid intima-media thickness (IMT), the prevalence of carotid
plaque [41] and high-sensitive C-reactive protein (hs-CRP) levels [42], which have been well-established
predictors for cardiovascular incidents.
Epidemiological studies indicated that dietary intake of polyphenols was associated with a low
incidence of CVDs. The Nurses’ Health Study with 69,622 women involved showed that the RR for
the fifth quintile of flavanone intake versus the lowest quintile was 0.81 (95% CI: 0.66–0.99) [34]. In
addition, the relationship between flavonoids intake and CVDs in men was studied in the Health
Professionals Follow-Up Study. The results revealed that higher anthocyanin intake was related with
lower non-fatal myocardial infarction (MI) risk (HR: 0.87, 95% CI: 0.75–1.00), and higher flavanone
intake was associated with decreased ischemic stroke risk (HR: 0.78, 95% CI: 0.62–0.97). The study
also reported that over 90% dietary anthocyanins and flavanones came from fruits [43]. In addition,
the association between flavonoid intake and ischemic stroke was evaluated in a cohort study of
20,024 participants. The study suggested that flavanone intake was inversely associated with a risk
of ischemic stroke (HR: 0.72, 95% Cl: 0.55–0.95) [35]. Furthermore, the cardiovascular benefits of
flavonoid and stilbene were estimated in a cross-sectional study of 1393 Chinese adults. The study
showed that fruits including apple, plum, pear, and peach were the richest sources of flavonoids
and stilbenes. Higher anthocyanin intake was related with elevated serum HDL-C (p = 0.001), and
total flavonoid and flavonol intake was inversely associated with serum TG (p = 0.020, p = 0.035) and
TG/HDL-C ratios (p = 0.040, p = 0.045) in female subjects. However, significant relationships were not
found in male subjects [44].
However, a cohort of Italian women indicated no significant association between fruit intake and
the risk of CHD after adjusting for the consumption of vegetables [45]. In addition, a cohort of men
aged 50–59 years in France and Northern Ireland reported that there was no significant association
between fruit intake and ACS [46]. A large scale cohort of five ethnic groups, i.e., African American,
Native Hawaiian, Japanese American, Latino, and Caucasian showed that the consumption of fruits
did not protect against ischemic heart disease, and the results did not vary among ethnic groups [47,48].
Additionally, a cohort of Swedish women (aged 49–83 years) suggested that the highest quintile of fruit
intake did not significantly decrease the risk of heart failure compared with the lowest [49]. Results are
inconsistent maybe because data regarding fruit intake in these cohort studies were obtained on the
basis of dietary recall. The actual consumption of fruits can only be rudely assessed, partly because the
number of items and the information about portion size were limited.
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3. Experimental Studies
There has been accumulating evidence in vivo and in vitro supporting the cardiovascular
protective properties of fruits and investigating the underlying mechanisms (Table 2). Six fruits are
discussed in detail below because they have been widely studied and have shown potent cardiovascular
protective effects, while the fruits that were less investigated are discussed in the section entitled
“Other Fruits.”
3.1. Grape
Grapes are one of the most common and important fruits worldwide, and they are often consumed
raw or after being converted to juice, wine, or jam.
3.1.1. Protecting Endothelial Function
In CVDs, endothelial dysfunction is a systemic pathology of the endothelium, is caused by
an imbalance between vasodilator and vasoconstrictor substances produced by (or acting on) the
endothelium, and presents as impaired vascular endothelium-dependent relaxation and compliance,
which is the primary change in early hypertension [50]. Growing experimental and clinical data
highlight the importance of oxidative stress on endothelial dysfunction. Grape plays an essential role
in repairing endothelial impairment for its potent antioxidant and free radical scavenging capacities.
In a study, vascular benefits of whole grape powder were studied using the spontaneously hypertensive
rat (SHR). The results showed that grape treatment elicited a reduction in BP, improved arterial
relaxation, and increased vascular compliance [51]. Moreover, the relationship between endothelial
protective function of grape seed proanthocyanidin extracts (GSPEs) and oxidative stress was studied
in SHR and deoxycorticosterone acetate (DOCA)-salt hypertensive mice. The study indicated that
GSPEs reduced endothelin (ET)-1 production but increased nitric oxide (NO) production, which
exhibited improved endothelial function. Moreover, GSPEs ameliorated oxidative stress by improving
superoxide dismutase (SOD) and catalase (CAT) activities and reducing malondialdehyde (MDA)
formation [52,53]. Similarly, enzymatic extract of grape pomace (GP-EE) also induced endothelium-
and NO−-dependent vasodilatation of both rat aorta and small mesenteric artery (SMA) segments,
prevented contraction elicited by ET-1, and reduced superoxide anion radical (O2−) production [54].
Furthermore, another study showed that polyphenols in red grape skin and seeds increased endothelial
progenitor cells viability, adhesion and migration, and prevented endothelial dysfunction by reducing
reactive oxygen species (ROS) production [55]. In addition, red grape components increased the
expression of endothelial nitric oxide synthase (eNOS) [56]. In vitro, human umbilical vein endothelial
cells (HUVECs) were incubated with GSPEs to explore the signaling pathways of eNOS expression.
The result suggested that the increased eNOS expression was attributed to the activation of 5′-AMP
activated protein kinase (AMPK) and the increase in sirtuin-1 (SIRT-1) protein level, which was
critical for transcription factor Krüpple like factor-2 (KLF-2) induction [57]. In addition, another study
indicated that grape pomace extract (GPE) exerted antioxidant activity in endothelium (EA. hy926)
through the increase of glutathione (GSH) levels due to increased gamma-glutamylcysteine synthetase
(γ-GCS) levels and glutathione S-transferase (GST) activity [58]. Moreover, it was found that a low
dose (1 μg/mL) of grape seed extract (GSE) potentiated the inhibitory action of HUVECs on platelet
reactivity by about 10%, which accounted, at least partially, for the protective effects of grape products
against CVDs. However, a high concentration (up to 10 μg gallic acid equivalent/mL) of GSE impaired
endothelial cell proliferation in vitro [59].
3.1.2. Decreasing Blood Lipids
Hyperlipidemia can lead to lipoprotein deposition inside the vessel wall, and induce oxidative
stress and the formation of oxidized low-density lipoprotein (Ox-LDL), which plays a key role
in the pathogenesis of atherosclerosis. The GSE possesses potent lipid-lowering and antioxidant
288
Nutrients 2017, 9, 598
properties, which are beneficial to the prevention of atherosclerosis [60]. A study showed that plasma
triglycerides (TG) were attenuated by red grape consumption [61]. The hypolipidemic effect of
grape seed procyanidin extract at low doses was studied in hamsters, and results suggested that
25 mg/kg of the extract decreased body weight, protected against fat accumulation, lowered plasma
free fatty acid (FFA), and reduced lipid and TG accumulation in the mesenteric white adipose tissue
(MWAT). In addition, the extract exerted these effects in part through the activation of both β-oxidation
and the glycerolipid (GL)/FFA cycle, mainly in the retroperitoneal white adipose tissue (RWAT) [62].
High-density lipoproteins (HDL) are responsible for transporting 20–30% of the total plasma cholesterol
from tissues to the liver, as vehicles for reversing cholesterol transport, which help prevent or even
regress atherosclerosis [63]. A study indicated that grape polyphenols modulated the activity of
plasma HDL enzymes in old and obese rats. The result showed that grape polyphenols increased HDL
paraoxonase (PON) and lecithin-cholesterol acyltransferase (LCAT) activity, reduced cholesteryl ester
transfer protein (CETP) activity, and restored the function of HDL [64].
3.1.3. Decreasing Blood Pressure
The hypotensive effect of grape polyphenols has been detected in several studies [52,61].
Administration of GSPE markedly alleviated hypertension-induced arterial remodeling [51]. SHR
were used to assess the anti-hypertensive effect of grape seed procyanidin extract. The results showed
that the extract significantly decreased systolic and diastolic BP of SHR in a dose-dependent manner,
and at the dose of 375 mg/kg, the decrease of both BP reached the maximum value. Moreover, the
anti-hypertensive effect of the extract (375 mg/kg) in SHR was quite similar to that of Captopril
(50 mg/kg), which has been considered as a very effective anti-hypertensive drug in clinical practice [9].
Another study suggested chronic administration of GSPE significantly blocked the BP increase in ouabain
induced hypertensive rats model, and the improvement of the aortic NO production impaired by ouabain
was the possible mechanisms involved [57]. Furthermore, a study investigated the anti-hypertensive
effect and mechanism of red grape berry powder on rats with metabolic syndrome (MS). The study
indicated that grape berry powder lowered BP via its ability of inhibiting ET-1 secretion and increasing
eNOS levels of endothelium in a concentration-dependent manner [61].
3.1.4. Suppressing Platelets Function
Platelets play a pivotal role in physiological hemostasis. However, enhanced platelets
activation, adhesion, and aggregation aggravate the formation of arteriosclerotic plaques. A study
in vitro revealed the potential protective effects of GSE on hemostasis under the condition of
hyperhomocysteinemia by reducing the toxicity action of homocysteine (Hcy) and its most reactive
form homocysteine thiolactone (HTL) in blood. In human platelets incubated with Hcy (100 μM) or
HTL (1 μM), GSE decreased platelet adhesion to collagen and fibrinogen, the platelet aggregation, and
O2− production in platelets [65]. Additionally, a study in vitro indicated that 1 μg/mL GSE reduced
platelet reactivity by about 10% due to the direct effect of its polyphenol contents on HUVECs [59].
3.1.5. Alleviating Ischemia/Reperfusion Injury
A study investigated the cardio-protective effect of grape extracts rich in malvidin, an anthocyanin
isolated from red grape skins, on isolated and Langendorff perfused rat heart. The result showed that
malvidin elicited cardio-protective effect against ischemia/reperfusion (I/R) damages by activating
the phosphatidylinositol 3-kinase (PI3K)/NO/cyclic guanosine monophosphate (cGMP)/protein
kinase-G (PKG) pathway, increasing intracellular cGMP and the phosphorylation of eNOS, PI3K-AKT,
extracellular regulated kinase1/2 (ERK1/2), and glycogen synthase kinase-3 β (GSK-3 β) [56].
In addition, grape extracts moderated cardiac and cerebral ischemia damages against I/R, which
induced a drastic oxidative stress [56,66]. Moreover, a study investigated the relationship between
grape seed and skin extract (GSSE) and ischemic stroke, and results showed that the extract not
only reduced brain damage size and histology caused by I/R, but also inhibited oxidative stress,
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and improved transition metals associated enzyme activities [66]. Reperfusion arrhythmias (RA) are
the most important causes of sudden death following reperfusion [67]. Another study analyzed the
molecular mechanisms of protective effects of GSPE on RA. The study indicated that GSPE played an
essential role in decreasing free radical generation for it increased the activity of Na+/K+-ATPase due
to the upregulation of Na+/K+-ATPase α1 subunit [67].
3.1.6. Inhibiting Thrombosis
The dysfunction of vessel endothelial cells and platelets are major risk factors in the formation
of atherosclerotic plaque. For the antithrombotic effect of proanthocyanidins, a study revealed that
GSPE decreased the length and weight of thrombus, protected the integrity of endothelium, reduced
thrombogenesis-promoting factors P-selectin, von Willebrand factor (vWF), and cellular adhesion
molecules (CAMs), increased thrombogenesis-demoting factors CD34, vascular endothelial growth factor
receptor-2 (VEGFR-2), and ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin
type one motif, member 13), and downregulated inflammatory cytokines interleukine (IL)-6, IL-8, and
tumor necrosis factor-alpha (TNF-α). Thus, GSPE facilitated endothelial protection and inhibited platelet
aggregation, inflammatory responses, and thrombus formation [68].
Collectively, the consumption of grapes or products derived from grapes might reduce the incidence
of CVDs through correcting endothelial dysfunction, reducing blood lipids, anti-hypertension, inhibiting
oxidative stress, improving platelet function, alleviating I/R damages, protecting myocardial function,
anti-thrombosis, and resisting inflammation. These effects might be due to several phytochemicals, such
as resveratrol, anthocyanin, and proanthocyanidin.
3.2. Blueberry
Blueberry is a flavonoid-containing fruit and exerts cardiovascular benefits. The cardioprotective
effects of blueberry (Vaccinium ashei Reade) extract were investigated in hypercholesterolemic rats
for 14 days. The result showed that blueberry extract decreased aortic lesions, reduced serum
lipid profiles (total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and TG), and
increased activities of antioxidant enzymes (CAT, SOD, and glutathione peroxidase (GSH-Px)) [69].
The effects of supplementation with blueberry for 10 weeks on endothelial function and BP were
studied in rats fed a high-fat diet. The study showed that blueberry supplementation lowered SBP
by 14% and improved endothelial dysfunction and aorta relaxation in response to acetylcholine [70].
Furthermore, a study evaluated the potential protective effects of seven phenolic acids, identified
as metabolites of blueberry, on murine macrophage cell line RAW 264.7. The result indicated that
phenolic acids decreased foam cell formation induced by Ox-LDL, Ox-LDL binding to macrophages,
lipopolysaccharide (LPS)-induced mRNA expression, and protein levels of TNF-α and IL-6 via
inhibiting the phosphorylation of mitogen-activated protein kinase (MAPK), Jun N-terminal kinase
(JNK), p38, and ERK1/2, downregulated the mRNA expression and protein levels of scavenger
receptor CD36, and upregulated the mRNA expression and protein levels of ATP-binding cassette
transporter A1 (ABCA1), which facilitated cholesterol efflux and inhibited cholesterol accumulation in
macrophages [71].
In conclusion, blueberry possesses commendably cardioprotective ability including anti-atherogenic
properties, anti-inflammation, lowering BP, improving oxidative parameters, and vascular reactivity.
3.3. Pomegranate
The peel, seed, and juice of pomegranate are rich in antioxidants and have potent atheroprotective
effect and antihypertensive properties. The major bioactive constituent of pomegranate is punicalagin,
which is known to have cardiovascular protective ability for its antioxidant role as a scavenger and
ferrous chelator of hydrogen peroxide [72]. A study found that pomegranate extract (PE) reducing
aortic sinus and coronary artery atherosclerosis was associated with the reduced oxidative stress and
inflammation in the vessel wall of SR-BI/apoE double KO mice [73]. The high level of oxidative stress
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in the paraventricular nucleus of the hypothalamus is essential in the pathogenesis of hypertension.
A study investigated the antihypertensive properties of PE in a SHR model. The findings demonstrated
that PE alleviated hypertension by reducing oxidative stress, increasing the antioxidant defense system,
decreasing inflammation, and improving mitochondrial function in the paraventricular nucleus,
thereby activating AMPK-nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) pathway [74]. Similarly,
the activation of the AMPK pathway by PE was studied in the heart of a rodent obesity model.
The result showed that PE activated AMPK by quickly decreasing the cellular ATP/ADP ratio
specifically in cardiomyocytes, and the activation of the AMPK pathway accounted for the prevention
of mitochondrial loss by enhancing mitochondrial biogenesis and amelioration of oxidative stress via
increasing the activity of phase II enzymes in high-fat diet-induced cardiac metabolic disorders [72].
In addition, pomegranate seed extract improved motor and cognitive deficits due to permanent
cerebral hypoperfusion ischemia (CHI), which was most likely related at least in some part to its
antioxidant and free radical scavenging actions [75].
3.4. Apple
Apple is the second most consumed fruit in the world following banana. In recent years,
epidemiological studies have shown that eating apples is associated with the reduction of the
occurrence of CVDs [30,31]. Apple is a major source of fiber and contains antioxidants such as
vitamin C and good dietary polyphenols. Particularly, the reduced incidence of CVDs is related to
apple consumption, probably as a result of the cholesterol-lowering effect of polyphenols, the main
bioactive compounds of apple, which are concentrated in the fruit peel. The cholesterol-lowering effect
of apple was detected in male Wistar rats fed with a cholesterol-enriched diet (2%). The study showed
that Bravo de Esmolfe apple was able to decrease serum levels of TG, TC, LDL-C, and Ox-LDL by
27.2%, 21.0%, 20.4%, and 20.0%, respectively. It also indicated that the cholesterol-lowering ability
of apple was mainly due to phytocompounds, such as catechin, epicatechin, procyanidin B1, and
β-carotene [76]. The development of CVDs is related with the previous existence of MS. Another
study suggested that apple peel reduced the biochemical parameters (glycaemia, TC, high-density
lipoprotein cholesterol (HDL-C), LDL-C, TG, ureic nitrogen, insulin, and asymmetric dimethylarginine
(ADMA)) in CF-1 mice with MS, diminished the cholesterol accumulation area, and reverted the
progression of the atherogenesis in apoE−/− mice [77].
3.5. Hawthorn
Hawthorn (Crataegus pinnatifida Bge.) is a berry-like fruit from the species of Crataegus. It has been
used as food or a traditional medicine to improve digestion for thousands of years. Moreover, during
the last decades, hawthorn has received more attention because of its potential to treat CVDs, especially
hyperlipidemia and atherosclerosis [78]. A study investigated the hypolipidemic effect of hawthorn
fruit compounds (HFC, including hawthorn and kiwi fruit extract) in apoE−/− atherosclerotic mice
with high blood lipid levels. The study indicated that HFC reduced TG and LDL-C/TC ratio. Moreover,
the reduction of LDL-C was more evident in HFC than in Simvastatin (6 mg/kg/day), indicating HFC
could be considered for the treatment of hyperlipidemia and the prevention of atherosclerosis [10].
Similarly, hawthorn pectin pentaoligosaccharide (HPPS) suppressed weight gain, decreased serum TG
levels, increased lipid excretion in feces, upregulated the gene and protein expressions of peroxisome
proliferator-activated receptor α (PPAR-a), and enhanced the hepatic fatty acid oxidation-related
enzyme activities of acyl-CoA oxidase, carnitine palmitoyltransferase I, 3-ketoacyl-CoA thiolase,
and 2,4-dienoyl-CoA reductase by 53.8%, 74.2%, 47.1%, and 24.2%, respectively, in the liver of
hyperlipidemic mice [79]. The anti-atherosclerosis effect of hawthorn and the potential mechanisms
were investigated in apoE−/− mice. The result showed that hawthorn decreased atherosclerotic lesions,
serum TC and TG level, reduced the hepatic fatty acid synthase (FAS) and sterol regulatory element
binding protein-1c (SREBP-1c) mRNA levels by 42% and 23%, and increased total antioxidant capacity
(T-AOC), SOD and GSH-Px activities, and the mRNA expression levels of the antioxidant enzymes
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SOD1, SOD2, glutathione peroxidase-3 (Gpx3) in the livers of mice fed with hawthorn fruit diet [80].
Another study indicated that aqueous extract of hawthorn (Crataegus pinnatifida var. Major) inhibited
atherosclerosis progression in high-fat-diet-fed rats by improving lipid metabolism, decreasing
inflammatory cytokine responses, and protecting endothelium. The result showed that aqueous
extract of hawthorn inhibited artery lesion, decreased IMT, reduced TC, TG, LDL-C, and the levels
of CRP, IL-1β, IL-8, and IL-18, increased HDL-C, ET, 6-keto-prostaglandin F1α (6-keto-PGF1α), and
thromboxane B2 (TXB2). It also revealed that chlorogenic acid, procyanidin B2, (−)-epicatechin, rutin,
and isoquercitrin were the main components of the extract [81].
3.6. Avocado
Avocado is an essential tropical fruit containing lipophilic compounds, i.e., monounsaturated
fatty acids (MUFAs), polyphenols, carotenoids, vitamin E, phytosterols, and squalene, which have
been recognized for cholesterol-lowering ability [82]. However, the antioxidant capacities of these
lipophilic compounds have attracted far less attention compared with hydrophilic compounds in the
fruit. In fact, the lipophilic extract of the fruit had higher antioxidant capacity than its hydrophilic
extract [83]. A study indicated that avocado pulp, containing acetogenin compounds, inhibited
platelet aggregation with a potential preventive effect on thrombus formation [84]. Moreover, avocado
pulp contains variable oil contents and is widely used in many fields such as the pharmaceutical
industry [82]. Another study evaluated the effects of avocado oil administration on inflammatory and
lipid parameters in rats with metabolic changes induced by sucrose ingestion. The study demonstrated
that avocado oil reduced hs-CRP and TG, very low-density lipoprotein (VLDL), and LDL levels [85].
In addition, the protective effects of dietary consuming avocado oil on biochemical markers of liver
function in rats fed with sucrose were quite similar to olive oil [86]. Furthermore, a study has shown
that avocado seeds improved hypercholesterolemia, and facilitated the prevention and treatment of
hypertension, inflammatory conditions, and diabetes [87].
3.7. Other Fruits
Mango is rich in several bioactive components with antioxidant and anti-inflammatory properties,
such as carotenoids, vitamin C, and phenolic compounds. A study demonstrated that two doses (1%
and 10%) of freeze-dried mango pulp were effective in improving glucose tolerance and lipid profiles
and reducing adiposity in mice fed with a high-fat diet. Additionally, the study also reported that
the lower dose (1%) was more effective in modulating glucose than the higher dose (10%), and was
more powerful in lowering blood glucose concentration than the hypoglycemic drug, rosiglitazone
(50 mg/kg diet), in mice fed with a high-fat diet [11]. Moreover, the anti-hypertensive effects of
the standardized methanolic extract of papaya (Carica papaya) were evaluated in SHR. The result
showed that the angiotensin converting enzyme inhibitory effects of papaya (100 mg/kg) were similar
to those of enalapril (10 mg/kg). The flavonoids, especially quercetin, rutin, nicotiflorin, clitorin,
and manghaslin, were identified as bioactive components of the extract, which could be applied
to the treatment of hypertension [12]. In addition, several studies revealed that cherry, Guangzao
(Choerospondias axillaris), and acai (Euterpe oleracea Mart.) have significant cardioprotective effects and
have been shown to play a beneficial role in improving myocardial infarction induced by I/R via
anti-oxidative and anti-apoptotic activities [88–90]. In addition, bilberry, black raspberry, and sea
buckthorn berries improved serum lipid profiles and promoted a hypocholesterolemic effect, which
protected against hypercholesterolemia and prevented atherosclerosis [91–93]. Additionally, jujube
(Zizyphus jujuba) and blackberry (Rubus allegheniensis Port.) inhibited foam cell formation in human
monocyte-derived macrophages induced by acetylated LDL, which therefore were useful for the
prevention of atherosclerosis [94,95]. In addition, yellow passion fruit and boysenberry decreased BP
in SHR [96,97]. However, data on these individual fruits is still limited. Furthermore, the underlying
mechanisms of protecting cardiovascular system remain to be investigated.
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In conclusion, fruits such as grape, blueberry, pomegranate, apple, hawthorn, and avocado
showed protective effects on cardiovascular function. Grape products markedly alleviated
hypertension-induced cardiovascular remodeling and impaired endothelial function. Most fruits were
effective in reducing oxidative stress, regulating lipids metabolism, and modulating BP. Additionally,
some fruits attenuated platelet function, alleviated I/R injury, suppressed thrombosis, and inhibited
inflammation (Figure 1).
Figure 1. Effects and mechanisms of fruits on cardiovascular diseases (CVDs).
4. Clinical Trials
The anti-hypertensive effect of grape polyphenols in several randomized controlled trials (RCTs)
was evaluated by a meta-analysis, and results showed that daily grape polyphenols intake significantly
reduced SBP by 1.48 mmHg when compared with control subjects (p = 0.03). Contrarily, DBP was not
significantly decreased [108]. Grapes have potent hypolipidemic and anti-oxidative effects. Several
studies showed that grape reduced TC, LDL-C, and Ox-LDL and increased HDL-C in subjects
with various risk factors of CVDs [60,109,110]. Additionally, a study conducted on 60 healthy
volunteers indicated that supplying them with 700 mg polyphenol-rich grape extracts for 56 days
modulated the lipid profiles in terms of cardiovascular risk indicators, lowered TC and LDL-C, and
increased antioxidant capacity and vitamin E [111]. Moreover, a meta-analysis of 9 RCTs explored the
endothelium protective effect of grape polyphenols supplementation in adults. The study suggested
that consuming grape polyphenols improved endothelial function in healthy subjects, and the effect
was more obvious in subjects with high cardiovascular risk factors [112]. Besides grapes, other berries
such as strawberry, acai (Euterpe oleracea Mart.), Caucasian whortleberry (Vaccinium arctostaphylos L.),
sea buckthorn, and bilberry also have a potent lipid-lowering effect [113–121]. The benefits of berries on
the serum lipid metabolism might contribute to anthocyanin. The effects of berry-derived anthocyanin
supplements on the serum lipid profiles were studied in 120 dyslipidemic patients. The results
suggested that anthocyanin intake increased HDL-C and cellular cholesterol efflux to serum, and
decreased LDL-C, possibly due to the inhibition of CETP [122].
A clinical trial evaluated the cardiovascular protective effects of consumption of 75 g (about two
medium-sized apples) of dried apple for 1 year in 146 postmenopausal women. The study showed
that dried apple significantly lowered serum levels of TC and LDL-Cl by 9% and 16%, respectively,
at 3 months and further decreased by 13% and 24%, respectively, at 6 months, but stayed constant
thereafter. Furthermore, consumption of dried apple also reduced lipid hydroperoxide and CRP [123].
In addition, a study compared the cholesterol-lowering effect of 5 different apple species, Red Delicious,
Granny Smith, Fuji, Golden Delicious and Annurca apple, in mildly hypercholesterolaemic healthy
subjects. The study detected that Annurca apples led to the most significant outcome, reduced
TC and LDL-C levels by 8.3% and 14.5%, respectively, and an increased HDL-C level by 15.2%
(all p < 0.001) [124]. Moreover, another study compared the effects of whole fresh apple and processed
apple products (apple pomace, cloudy apple juice, or clear apple juice) on lipid profiles in healthy
volunteers. The result showed that whole apple, pomace, and cloudy juice lowered serum TC and
LDL-C; however, clear apple juice increased TC and LDL-C slightly, from which it could be concluded
that the fiber component was necessary for the lipid-lowering effect of apple in healthy humans [125].
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Additionally, the acute effects of apple on improving endothelial function were studied in some trials,
showing that apple improved endothelial function by affecting NO metabolites [126,127].
Kiwifruit is a good source of antioxidants due to its wealth in vitamins C and E, folate, carotenoids,
and phytochemicals and protects the body from endogenous oxidative damage [128]. A clinical trial
conducted on 85 hypercholesterolemic men showed that consuming two green kiwifruits daily in
conjunction with a healthy diet reduced inflammatory markers and lipid profiles in subjects with
modestly elevated CRP [129], but there were no significant differences in BP [130]. In addition, a study
of 43 subjects who had hyperlipidemia indicated that regular consumption of kiwifruit not only
modulated lipids profiles but also exerted beneficial effects on the antioxidant status via decreasing
LDL oxidation and oxidative stress [131]. Moreover, another study conducted on 118 subjects with
moderately elevated BP or stage 1 hypertension (SBP: 130–159 mmHg, DBP: 85–99 mmHg) showed
that mean 24 h ambulatory systolic/diastolic BP was lower in the group consuming three kiwifruits
versus the group consuming one apple daily [132]. The hypotensive effect of kiwifruit, to some extent,
was more notable in individuals with moderately elevated BP. Furthermore, the beneficial effects of
consuming three kiwifruits per day on BP and platelet aggregation were studied in male smokers.
The resulted showed that kiwifruits reduced the SBP and DBP by 10 mmHg (p = 0.019) and 9 mmHg
(p = 0.016), respectively, decreased platelet aggregation by 15% (p = 0.009), and lowered ACE activity
by 11% (p = 0.034) [133].
Avocados are a nutrient-dense source of MUFAs that can be used to replace saturated fatty acids
(SFA) in a diet to lower LDL-C. A meta-analysis of 10 RCTs assessing the impacts of avocados on TC,
LDL-C, HDL-C, and TG revealed that avocado decreased TC, LDL-C, and TG levels by 18.80 mg/dL,
16.50 mg/dL, and 27.20 mg/dL, respectively [134].
Finally, results from clinical trials are summarized in Table 3. Numerous clinical trials have
demonstrated that grape, apple, kiwifruit, and avocado were potential candidates for cardiovascular
protection due to their potent lipid-lowering efficiency. However, clinical studies on other fruits are
relatively few, and more research is needed to investigate the potential in combating CVDs.
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5. Conclusions
The CVDs are greatly related to unbalanced diets. Several fruits can modulate metabolic
risk factors such as hypertension, dyslipidemia, diabetes, and overweight/obesity, and inhibit
atherosclerosis, which is the key pathological process of CHD and stroke. Many epidemiological
studies investigating the relationship between fruit consumption and CVD risks yielded similar results
regarding the protective effects of fruits on CVDs. Moreover, the majority of experimental studies also
supported cardiovascular protecting properties of several fruits, such as grape, blueberry, pomegranate,
apple, hawthorn, and avocado. The mechanisms of action mainly included the modulation of
molecular events and signaling pathways associated with correcting endothelial dysfunction, reducing
disorders in lipids metabolism, anti-hypertension, suppressing platelets function, alleviating I/R injury,
inhibiting thrombosis, reducing oxidative stress, and inhibiting inflammation responses. In the future,
the protective effects of a greater number of fruits on CVDs should be evaluated, and the bioactive
components should be isolated and identified. Furthermore, the mechanisms of action should be
further studied.
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Abstract: Previous studies demonstrated effects of green tea on weight loss; however, green tea-induced
modulation of adipocyte function is not fully understood. Here, we investigated effects of
the major green tea phytochemical, epigallocatechin-3-gallate (EGCG) on triglyceride contents,
lipolysis, mitochondrial function, and autophagy, in adipocytes differentiated from C3H10T1/2
cells and immortalized pre-adipocytes in vitro. EGCG reduced the triglycerol content significantly
in adipocytes by 25%, comparable to the nutrient starvation state. EGCG did not affect protein
kinase A signaling or brown adipocyte marker expression in adipocytes; however, EGCG increased
autophagy, as measured by autophagy flux analysis and immunoblot analysis of LC3B, ATG7, and
Beclin1. EGCG treatment reduced mitochondrial membrane potential by 56.8% and intracellular
ATP levels by 49.1% compared to controls. Although mammalian target of rapamycin signaling
was not upregulated by EGCG treatment, EGCG treatment induced AMP-activated protein kinase
phosphorylation, indicating an energy-depleted state. In addition, EGCG increased the association
between RAB7 and lipid droplets, suggesting that lipophagy was activated. Finally, knockdown of
Rab7 attenuated the EGCG-dependent reduction in lipid contents. Collectively, these results indicated
that EGCG upregulated autophagic lipolysis in adipocytes, supporting the therapeutic potential of
EGCG as a caloric restriction mimetic to prevent obesity and obesity-related metabolic diseases.
Keywords: green tea; adipocytes; autophagy; epigallocatechin-3-gallate
1. Introduction
Green tea is consumed worldwide, and has been shown to have various health benefits [1],
including effects on weight loss and metabolic health improvement [2,3] The major bioactive
component in green tea is a polyphenolic catechin, epigallocatechin-3 gallate (EGCG) [1], to which the
weight loss effects of green tea have been attributed [2]. Although obesity is clearly associated with
metabolic syndrome [4], excessive fat mass per se does not appear to be the cause since lipodystrophic
patients, who lack adequate fat mass, are also highly insulin resistant [4,5]. Rather, disease occurs
when the functions of adipose tissues in metabolic homeostasis are impaired [4].
Adipocytes are a specialized cell type that can store energy in the form of neutral lipids, mainly
triglycerides (TGs) [4]. In addition to this anabolic function, breakdown of TGs occur in adipocytes,
contributing to mobilization of fatty acids from adipose tissues into circulation and other tissues [6].
Lipolysis can be defined as the hydrolysis of TGs into glycerol and fatty acids, and the three main
lipolytic enzymes involved in TG hydrolysis have been identified, namely adipose triglyceride
lipase (ATGL), hormone-sensitive lipase (HSL), and monoacylglycerol lipase (MGL) [7]. Lipolysis in
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adipocytes is controlled primarily by β-adrenergic stimulation [6], which mediates cAMP-dependent
protein kinase A (PKA) downstream signaling [7]. In particular, phosphorylation of HSL by PKA
increases the enzyme activity and translocation from the cytosol into lipid droplets [7]. Thus,
understanding of impact of EGCG on adipocyte lipolysis is important to decipher the molecular
mechanisms involved in the beneficial effects of green tea in metabolic health. However, the effects of
green tea on adipocyte lipid metabolism have not yet been investigated.
In addition to lipolysis by cytosolic lipases, as mentioned above, autophagy of lipid droplets has
been recognized as a complementary pathway for cellular lipid breakdown [8]. Autophagy is a process
through which cells consume themselves and is induced by nutrient starvation, calorie restriction, and
potential calorie restriction mimetics (CRMs) [9]. Recently, induction of autophagy by EGCG has been
investigated in several cell types, including hepatocytes and vascular cells [8]; however, the effects of
EGCG on autophagic lipolysis in adipocytes have not been examined.
To investigate the regulatory roles of EGCG in adipocyte lipid metabolism, we examined
the effect of EGCG on the metabolic functions of adipocytes differentiated from C3H10T1/2 [10],
3T3-L1, and immortalized pre-adipocytes. We then investigated the role of EGCG in lipid catabolism
pathways, including adrenergic activation of lipolysis, induction of brown adipocyte phenotypes, and
autophagy-related degradation of lipid droplets in adipocytes. To further investigate the mechanisms
by which EGCG reduces lipid contents in adipocytes, the mammalian target of rapamycin (mTOR) and
AMP-activated protein kinase (AMPK) signaling pathways were analyzed. Finally, the involvement of
autophagic lipolysis in the activation of lipid catabolism by EGCG was investigated by knockdown of
RAB7, a lipophagy-related gene in adipocytes.
2. Materials and Methods
2.1. Cell Cultures
C3H10T1/2 cells and 3T3-L1 preadipocytes were obtained from ATCC (Manassas, VA, USA)
and cultured, as previously described [11]. Briefly, cells were cultured to confluence in growth
medium (Dulbecco’s modified Eagle’s medium (DMEM: Sigma, St. Louis, MO, USA) supplemented
with 10% fetal bovine serum (FBS, Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and 1%
penicillin/streptomycin (Welgene, Gyeongsan-s, Gyongsangbuk-do, Korea) at 37 ◦C in a humidified
atmosphere with 5% CO2, and then exposed to adipogenic differentiation medium (DMEM containing
BMP4 (20 ng/mL, R&D systems, Minneapolis, MN, USA), 0.125 mM indomethacin (Cayman, Ann
Arbor, MI, USA), 2.5 mM isobutylmethylxanthine (IBMX, Cayman, Ann Arbor, MI, USA), 1 uM
dexamethasone (Cayman, Ann Arbor, MI, USA), 10 ug/mL insulin (Sigma, St. Louis, MO, USA)
and 1 nM triiodothyronine (T3, Cayman, Ann Arbor, MI, USA) for three days. For maintenance of
adipogenic differentiation, cells were exposed to DMEM containing 10% FBS, 10 μg/mL insulin (Sigma,
St. Louis, MO, USA) and 1 nM triiodothyronine (T3, Cayman, Ann Arbor, MI, USA) for three days.
To prepare immortalized preadipocytes with the potential to become brown adipocytes,
interscapular brown adipose tissues were isolated from C57BL/6 mice [12]. Primary preadipocytes
were collected in stromovascular factions by collagenase digestion and centrifugation, as previously
described [12]. For retrovirus production, viral constructs for SV40 large and small T antigens (plasmid
#13970, Addgene, Cambridge, MA, USA) were transfected into phoenix cells using Lipofectamin
2000. Immortalized preadipocytes are expanded in growth medium (DMEM with 10% FBS and 1%
penicillin/streptomycin) and differentiated in adipogenic differentiation medium for three days. Cells
were maintained in medium containing insulin for up to two weeks.
Fully differentiated adipocytes were exposed to DMEM supplemented with 10% FBS overnight
and then treated with indicated concentration of EGCG (purity >95%; Sigma, St. Louis, MO, USA)
or quercetin (purity >95%; Sigma, St. Louis, MO, USA). Earle’s balanced Salt Solution (EBSS,
Thermo Fisher, Waltham, MA, USA) was used for nutrient starvation. 8-bromoadenosine 3′5′-cyclic
monophosphate (8-Br-cAMP) was used for PKA activation.
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For inhibition of autophagy, chloroquine (an inhibitor of late phase (lysosomal degradation),
50 μM, Sigma, St. Louis, MO, USA) and 3-methyl adenine (3-MA, an inhibitor of early phase, 10 mM,
Sigma, St. Louis, MO, USA) were used. Adipocytes were pretreated with inhibitors for 30 min before
EGCG treatment.
For Rab7 knockdown, siRNA targeting Rab7 (cat. no. #EMU150241; Sigma, St. Louis, MO,
USA) was transfected into adipocytes differentiated from C3H10T1/2 cells, using Lipofectamin2000
(Thermo Fisher, Waltham, MA, USA). Intracellular TG content was determined using a commercially
available triglyceride colorimetric assay kit (Cayman Chemicals, Ann Arbor, MI, USA). ATP levels
were measured with an ATP Assay Kit (Roche, Indianapolis, IN, USA). For the assays, C3H10T1/2
cells were plated on 12-well plates at a cell density of 105 cells/mL and differentiated into adipocytes,
as described above. Cell lysates were prepared in each sample buffer from the assay kit. 10 μL
of cell lysate (4 × 104 cells/assay) was used for analysis of TG contents, and 25 μL of cell lysate
(105 cells/assay) was used for analysis of ATP levels. Data were normalized based on the protein
concentration of the corresponding cell lysate.
2.2. Gene Expression Analysis
RNA was extracted using the TRIzol® reagent (Invitrogen, Carlsbad, CA, USA), and 1 μg of
RNA was reverse transcribed using a cDNA synthesis kit (High-capacity cDNA Reverse Transcription
kit; Applied Biosystems, Foster City, CA, USA). One hundred nanograms of cDNA was subjected to
quantitative polymerase chain reaction (qPCR) in 20-μL reaction volumes (iQ SYBR Green Supermix;
Bio-Rad, Hercules, CA, USA) with 100 nM primers. qRT-PCR was performed using SYBR Green dye
and CFX Connect Real-time system (Bio-Rad, Hercules, CA, USA) for 45 cycles and fold change for all
samples was calculated by using the 2−ΔΔCt method. Peptidylprolyl Isomerase A (PPIA) was used
as a housekeeping gene for mRNA expression analysis. Primers used for qRT-PCR were described
previously [11].
2.3. Western Blotting
Protein were extracted in RIPA buffer (Thermo Fisher, Waltham, MA, USA) containing protease
(Sigma, St. Louis, MO, USA) and phosphatase Roche, Indianapolis, IN, USA) inhibitors, as previously
described [12]. Resolved proteins were transferred to polyvinylidene difluoride (PVDF) membranes,
and membranes were blocked for 1 h at room temperature in 5% bovine serum albumin or 5%
powdered skim milk in TBST. Then, the membranes were incubated with primary antibodies overnight
at 4 ◦C. Blots were then washed, incubated with a secondary anti-rabbit horseradish peroxidase
antibody (diluted 1:5000 in TBST; Cell Signaling Technology, Danvers, MA, USA) for 30 min at room
temperature, and visualized with SuperSignal West Dura Substrate (Pierce-Invitrogen, Waltham, MA,
USA). The following primary antibodies were used for Western blot analysis: anti-UCP1 (rabbit, Alpha
Diagnostic International, San Antonio, TX, USA), anti-cytochrome c oxidase subunit IV (COX IV;
rabbit, Cell Signaling, Danvers, MA, USA), phospho-HSL (Ser563, rabbit, Cell Signaling, Danvers,
MA, USA), HSL (rabbit, Cell Signaling, Danvers, MA, USA), LC3B (rabbit, Cell Signaling, Danvers,
MA, USA), anti-cAMP responsive element binding protein (CREB; rabbit, Cell Signaling, Danvers,
MA, USA), phospho-CREB (Ser133, rabbit, Cell Signaling, Danvers, MA, USA), AMPK (rabbit, Cell
signaling, Danvers, MA, USA), phospho-AMPK (Thr172, rabbit, Cell Signaling, Danvers, MA, USA),
mTOR (rabbit, Cell Signaling, Danvers, MA, USA), phospho-mTOR (Ser2481, rabbit, Cell Signaling,
Danvers, MA, USA), PLIN1 (rabbit, Santacruz, Dallas, TA, USA), RAB7 (rabbit, Cell Signaling, Danvers,
MA, USA), anti-RAB7 (rabbit, Cell Signaling), anti-ATG7 (rabbit, Cell Signaling, Danvers, MA, USA),
anti-BECLIN1 (rabbit, Cell Signaling, Danvers, MA, USA), and a/b tubulin (rabbit, Cell Signaling,
Danvers, MA, USA).
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2.4. Analysis of Autophagic Flux
For autophagic flux analysis, C3H10T1/2 cells were infected with pBABE-puro
mCherry-EGFP-LC3B [13] (Plasmid #22418, Addgene, Cambridge, MA, USA, a gift from Jayanta
Debnath) by using retrovirus infection as described previously. Autophagic flux was measured by
quantifying the pH-sensitive decrease in green fluorescent protein (GFP) intensity over red fluorescent
protein (RFP) intensity as an indication of autolysosome formation. For autophagic flux analysis
by flow cytometry, analytic cytometry was performed using BD FACSAria III (BD Biosciences,
San Jose, CA, USA). Raw data were processed using FlowJo software (Tree Star, Ashland, OR, USA).
Alternatively, long-term live-cell imaging was performed every 1 h with IncuCyte ZOOM Live Cell
Imaging equipment (Essen Bioscience, Ann Arbor, MI, USA), and the green and red fluorescence
intensities of the images were analyzed using ImageJ (imagej.nih.gov, accessed on 1/22/2016).
2.5. Analysis of Mitochondrial Function
To measure mitochondrial membrane potential, adipocytes cultured in 24-well plates
(105 cells/well) were incubated with 0.4 μM JC-1 (Sigma, St. Louis, MO, USA) for 30 min.
The fluorescence signal was determined by using Tecan microplate reader at 485 nm excitation
and 527 nm emission for green fluorescence, and 485 nm excitation and 590 nm emission for red
fluorescence. To measure oxygen consumption, adipocytes differentiated from C3H10T1/2 cells
(5 × 106 cells/assay) were collected in a hypotonic medium containing 120 mM KCl, 5 mM KH2PO4,
3 mM HEPES, 1 mM EGTA and 1 mM MgCl2 (pH 7.2) at 35 ◦C. Succinate (10 mM), digitonin (4 μg/mL),
adenosine diphosphate (ADP, 1 mM), oligomycinA (0.2 uM), carbonyl cyanide-4-(trifluoromethoxy)
phenylhydrazone (FCCP, 0.5 μM) and KCN (0.1 mM) were added sequentially. Oxygen concentrations
and oxygen consumption rates were measured by the Oxygraph plus system (Hansatech, Norfolk, UK)
with chart recording software. OCRs were normalized according to protein concentrations. Uncoupled
respiration was calculated by subtraction of the KCN-induced OCR from the oligomycin A-induced
OCR. ATP related respiration was calculated by subtraction of the oligomycin A-induced OCR from
the basal OCR.
2.6. Immunofluorescence Staining
For immunofluorescence staining, cells were cultured in four-chamber cell culture slides
(SPL), fixed with paraformaldehyde (4% in phosphate-buffered saline (PBS)) and subjected to
immunocytochemical analysis as previously described [14]. Briefly, fixed cells were incubated with
blocking buffer (5% normal goat serum in PBS) and permeabilization buffer (0.5% TritonX100 in PBS)
for 30 min at room temperature. The slides were incubated with a primary antibody in blocking
buffer overnight at 4 ◦C, washed, and then incubated with a secondary antibody in blocking buffer
for 1 h at room temperature. Antibodies used for immunofluorescence detection were anti-RAB7
antibody (rabbit, 1:100, Cell Signaling, Danvers, MA, USA), PLIN2 (mouse, 1:100, Santacruz, Dallas,
TA, USA), and LC3 (rabbit, 1:100, Cell signaling, Danvers, MA, USA). The secondary antibodies
used were goat anti-rabbit-Alexa Fluor 488 and goat anti-mouse-Alexa Fluor 594 (1:500, Invitrogen,
Carlsbad, CA, USA). For the negative control, primary antibodies were omitted. DAPI (Sigma) was
used for nuclear counterstaining. Intracellular neutral lipid was stained with BODIPY® 493/503
(4,4-Difluoro-1,3,5,7,8-Pentamethyl-4-Bora-3a,4a-Diaza-s-Indacene, Thermo Fisher, Waltham, MA,
USA) or HCS LipidTox Deep Red Neutral Lipid stain, for cellular imaging.
2.7. Statistical Analysis
Statistical analyses were performed using GraphPad Prism 5 software (GraphPad Software,
La Jolla, CA, USA). Data are presented as mean ± standard errors of the means (SEMs). Statistical
significance between two groups was determined by unpaired t-test, as appropriate. Comparisons
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among multiple groups was performed using a one-way or two-way analysis of variance (ANOVA),
with Bonferroni post hoc tests to determine p values.
3. Results
3.1. EGCG Reduced Lipid Content in Adipocytes
To test the effect of EGCG on lipid contents, differentiated adipocytes from C3H10T1/2 cells
were treated with EGCG under conditions that activate lipolysis (Figure 1). EGCG was used at
concentration of 10 μM according to previous works [13]. Then 8Br-cAMP was used as a positive
control that activates PKA and downstream events, including lipolysis. In addition, we included
nutrient starvation medium. As expected, nutrient starvation and 8Br-cAMP treatment reduced neutral
lipid contents significantly, as measured by BODIPY staining in live cells (Figure 1A) and reduced their
intracellular TG contents (Figure 1B). EGCG reduced the neutral lipid TG content significantly, and
this reduction was comparable with the levels in the nutrient starvation state (Figure 1A,B). The size
of the lipid droplets (LDs) was also reduced in adipocytes treated with EGCG (Figure 1C: mean
diameters of LDs: control (CTL) = 3.59 μm; EGCG = 2.72 μm; starvation = 2.62 μm; cAMP = 2.22 μm).
PKA signaling is a well-known pathway that activates lipolysis in adipocytes [7,14]; therefore, we
examined phosphorylation of the PKA downstream target proteins that are involved in upregulation
of lipolysis: hormone sensitive lipase (HSL) and cAMP response element-binding protein (CREB). HSL
is a primary lipolytic enzyme responsible for hydrolysis of diacylglycerol in adipocytes [7]. CREB is a
transcription factor that can be activated by phosphorylation of the Ser133 residue by PKA activation
and upregulates the expression of HSL as a downstream target [15]. We found that 8Br-cAMP increased
the phosphorylation levels of HSL and CREB significantly (by three-fold and four-fold, respectively)
compared with control conditions (Figure 1D,E). However, neither starvation nor EGCG treatment
increased the phosphorylation levels. Interestingly, expression of HSL was significantly higher in the
EGCG-treated groups than in the controls. The data suggested that EGCG reduced the lipid contents
effectively in adipocytes; however, this phenomenon is independent of PKA signaling.
3.2. Effects of EGCG on Browning of Adipocytes
Non-shivering thermogenesis via uncoupling protein 1 (UCP1) expression in brown adipocytes is
one of the mechanisms that activates catabolic metabolism to reduce the lipid content. Although it
has been suggested that in vivo thermogenesis can be stimulated by green tea extract treatment (by
upregulation of sympathetic tones) [16], the direct effects of EGCG on browning of white adipocytes
has not been investigated. Therefore, we evaluated the effects of EGCG on browning of adipocytes
differentiated from C3H10T1/2 cells (Figure 2A,B). In addition to EGCG, quercetin was tested because
its browning effect has been reported previously [17].
EGCG treatment upregulated the UCP1 protein level by 2 fold (Figure 2A). However, the transcript
levels of UCP1 were not significantly induced by EGCG treatment (Figure 2B). In addition, Ucp1 mRNA
levels were 300,000-fold lower than those in in vivo brown adipocytes (i.e., C3H10T1/2 Ucp1 (% of PPIA)
0.01 ± 0.005 vs. BAT Ucp1 (% of PPIA) = 3287 ± 1100, n = 6). Similarly, EGCG did not increase a brown
adipocyte marker (Dio2) and genes involved in mitochondrial metabolism (i.e., Ppargc1a, Acdam, Cox8b,
Ucp2) expression in adipocytes differentiated from C3H10T1/2 cells (Figure 2B). Analysis of oxygen
consumption rate demonstrated that EGCG treatment did not affect either ATP-linked respiration
or uncoupled respiration (Figure 2C,D). This suggested that upregulation of UCP1 expression or
mitochondrial respiration does not seem to be a major contributor to the loss of lipids.
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Figure 1. Effects of EGCG on lipid content and PKA signaling in adipocytes (A–C) BODIPY staining
(A), intracellular triglyceride levels (B), dimeters of lipid droplets (C) in adipocyte differentiated from
C3H10T1/2 cells treated with starvation medium, 8Br-cAMP (1 mM) and EGCG (10 μM) for 24 h (D,E)
Immunoblot analysis of p-HSL, HSL, p-CREB, and CREB in adipocyte differentiated from C3H10T1/2
cells treated with starvation medium, 8Br-cAMP (1 mM) and EGCG (10 μM) for 24 h. p values were
calculated using the two-tailed unpaired t-test (n = 3, means ± SE; * p < 0.05, ** p < 0.01, *** p < 0.001).
To test whether the minimal effect of UCP1 expression in adipocytes is related to cell type-specific
gene expression machinery, we tested the effect of EGCG on brown adipocyte cell lines and 3T3L1
cells. We established brown adipocyte cell lines by immortalization of preadipocytes isolated from
mouse interscapular BAT. As shown in Figure 3A, expression of UCP1 protein was confirmed in
adipocytes differentiated from immortalized brown preadipocytes (Figure 3A). Ucp1 mRNA expression
was approximately 1000 fold higher in the brown adipocytes, compared to the levels in 3T3L1 and
C3H10T1/2 (Figure 3B). The gene expression patterns in adipocytes differentiated from 3T3L1 were
similar to adipocytes from C3H10T1/2 cells resembling white adipocyte phenotypes (Figure 2B,C).
In addition, EGCG did not increase Ucp1 expression and other genes involved in mitochondrial
functions in brown adipocytes significantly (Figure 2D,E), which indicated that EGCG is not a
thermogenic signal for the activation of brown adipocyte metabolism.
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Figure 2. Effects of EGCG on brown adipocyte marker expression in adipocyte cultures. Immunoblot
analysis of UCP1 expression (A) and quantitative PCR analysis (B) of genes involved in mitochondrial
metabolism and brown adipocyte markers in adipocytes differentiated from C3H10T1/2 treated
with 8Br-cAMP (1 mM), EGCG (10 μM) and quercetin (10 μM) for 24 h (C,D) Analysis of oxygen
consumption of adipocytes differentiated from C3H10T1/2 cells treated with EGCG for 24 h; (C) An
example of analysis of oxygen consumption rate (OCR) with a series of treatments of indicated drugs;
(D) Comparisons of ATP-linked respiration and uncoupled respiration between cells treated with
EGCG and vehicle controls. p values were calculated using the two-tailed unpaired t-test (n = 3,
means ± SE; * p < 0.05, ** p < 0.01).
Figure 3. Cont.
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Figure 3. Establishment of BA cell lines and effects of EGCG on brown adipocyte marker expression in
adipocyte cultures. Immunoblot analysis of UCP1, perilipin1 (PLIN1), and COXIV expression (A) and
quantitative PCR analysis of UCP1 expression (B) in adipocytes differentiated from 3T3L1, C3H10T1/2,
and immortalized preadipocytes isolated from iBAT. Two-way ANOVA revealed significant main effects
of treatment (p = 0.0165) and cell types (p < 0.0001) in UCP1 expression and significant interaction
of treatment and cell types (p = 0.0060). Significant differences between control and treated group
were determined by post-hoc pairwise comparison with Bonferroni correction (mean ± SEM; n = 4
per condition, ***p < 0.001). (C) Quantitative PCR analysis of brown adipocyte gene expression in
adipocytes differentiated from 3T3L1 treated with 8Br-cAMP (1 mM), EGCG (10 μM) and quercetin
(10 μM) for 24 h. Immunoblot analysis of UCP1 expression (D) and quantitative PCR analysis (E) of
brown adipocyte gene expression in adipocytes differentiated from BA cell lines treated with 8Br-cAMP
(1 mM), EGCG (10 μM) and quercetin (10 μM) for 24 h. p values were calculated using the two-tailed
unpaired t-test (n = 3, means ± SE; * p < 0.05, ** p < 0.01, *** p < 0.001).
3.3. Effect of EGCG on Autophagy
EGCG reduced the lipid content in adipocytes without activation of HSL and PKA signaling;
thus, we hypothesized that EGCG activates an alternative pathway to consume lipids. Autophagy
has been reported as a novel regulator of lipolysis [8], acting as a lysosomal lipolytic pathway;
therefore, we examined autophagic responses after EGCG treatment. Differentiated adipocytes
from C3H10T1/2 cells were grown in nutrient starvation medium, and standard growth medium
containing EGCG or 8-Br-cAMP. To measure autophagic flux, conversion of LC3B-I into LC3B-II was
determined by Western blotting analysis. As shown in Figure 4A, an increased ratio of LC3B-II to
LC3B-I was observed in all three conditions, including EGCG and 8Br-cAMP treatment. Interestingly,
8Br-cAMP treatment (i.e., PKA activation) increased LC3B-II generation to levels similar to that
induced by starvation (Figure 4A). EGCG treatment increased other autophagy markers, Beclin1 and
ATG7 expression (Figure S1). Treatment with chloroquine, an inhibitor of lysosomal degradation,
increased accumulation of LC3bII in control and EGCG-treated groups, while 3-MA reduced LC3BII.
In agreement with the immunoblotting analysis, immunofluorescence staining of adipocytes treated
with EGCG showed punctuated patterns of LC3B staining (Figure 4B), which is a prominent feature of
autophagy. In addition, EGCG increased the association between RAB7 and lipid droplets, indicating
activation of lipophagy (Figure 4B). Next, autophagic flux was measured using LC3 tandemly tagged
with fluorescent proteins that detect lysosomal degradation [18] in C3H10T1/2 cells. This system
expresses a chimeric LC3 fused with eGFP and mCherry; thus, the pH-sensitive decrease in GFP
intensity over RFP intensity indicates autolysosome formation. As shown in Figure 4C, long-term live
cell imaging demonstrated that EGCG treatment induced a decrease in the green and red fluorescence
intensity ratio during the course of the treatment (Figure 5C,D). Furthermore, flow cytometry analysis
confirmed the decrease in green fluorescent intensity by EGCG treatment (Figure 3E). Collectively,
analyses of the autophagic response supported the induction of autophagy by EGCG.
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Figure 4. Effects of EGCG on autophagy responses in adipocytes. (A) Immunoblot analysis of LC3b
expression in adipocytes differentiated from C3H10T1/2 treated with starvation medium, 8Br-cAMP
(1 mM) and EGCG (10 μM) for 1 day. p values were calculated using the two-tailed unpaired t-test
(n = 3, means ± SE; * p < 0.05, ** p < 0.01); (B) Immunofluorescence staining of LC3b/PLIN2 or
RAB7/LipidTox in adipocytes differentiated from C3H10T1/2 treated with 8Br-cAMP (1 mM) and
EGCG (10 μM) for 24 h. Nuclei were counterstained with DAPI. Bars = 20 μm; (C) Representative
images from long-term live imaging of adipocytes expressing LC3B-GFP-RFP reporters treated with
EGCG; (D) Time course analysis of GFP/RFP ratio from (C); (E) Flow cytometric analysis of adipocytes
expressing LC3B-GPF-RFP reporters treated with ECGC.
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Figure 5. Effects of EGCG on activation of mTOR and AMPK in adipocytes. (A,B) Immunoblot analysis
of phosphorylation of mTOR and AMPK in adipocytes differentiated from C3H10T1/2 treated with
starvation medium, 8Br-cAMP (1 mM) and EGCG (10 μM) for 24 h. Mitochondrial membrane potential
(C), and intracellular ATP (D) in adipocytes differentiated from C3H10T1/2 treated with 8Br-cAMP (1
mM), FCCP (0.5 μM), EGCG (10 or 20 μM) or quercetin (10 or 20 μM) for 2 h. p values were calculated
using the two-tailed unpaired t-test (n = 3, means ± SE; * p < 0.05, ** p < 0.01, *** p < 0.001).
Autophagy can be activated by various extracellular and intracellular stimuli. Importantly,
starvation can lead to inhibition of the mammalian target of rapamycin (mTOR) pathway, which
is known as a nutrient sensing signaling pathway. To test whether EGCG mimics starvation by
inhibiting of mTOR signaling, we examined the phosphorylation levels of mTOR using Western
blotting. As shown in Figure 5A, starvation conditions and 8Br-cAMP treatment reduced mTOR
phosphorylation significantly; however, EGCG treatment did not affect p-mTOR or total mTOR levels.
AMP-activated protein kinase (AMPK) can directly phosphorylate UNC-51-Like kinase 1 (ULK1), a key
regulator of autophagy induction during energy starvation; thus, we examined p-AMPK levels [15].
Starvation, 8Br-cAMP, and EGCG treatment increased the phosphorylation of AMPK, indicating
depleted intracellular energy levels. Mitochondrial oxidative phosphorylation is the major pathway
of ATP generation; thus, we examined the mitochondrial membrane potential. The data indicated
that the membrane potential was reduced by EGCG treatment while it was increased by 8Br-cAMP
treatment (Figure 5C). Consistent with this signaling status, EGCG treatment reduced intracellular
ATP levels in adipocytes (Figure 5D).
Lipophagy has been described as a form of autophagy that is specialized for the degradation
of lipid droplets, and RAB7 was reported as a key molecule that enables the specific recognition
of LD proteins in the process of lipophagy [19]. Autophagy related genes, including Rab7, could
affect the differentiation of adipocytes [20]; therefore, we silenced Rab7 to transiently knockdown its
expression using a siRNA after full differentiation. siRNA transfection knocked down Rab7 expression
by 45% compared with negative controls using a scrambled sequence (Figure 6A). As indicated in
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Figure 6B, Rab7 knockdown attenuated the reduction in the lipid content induced by EGCG treatment
in adipocytes.
 
Figure 6. Effects of knockdown of RAB7 on EGCG induced reduction in lipid content in adipocytes.
(A) Immunoblot analysis of RAB7 in adipocytes differentiated from C3H10T1/2 treated with siRNA or
scrambled sequence controls. Two-way ANOVA revealed significant main effects of siRNA knockdown
(p < 0.0001) and EGCG treatment (p = 0.0122) in RAB7 expression and significant interaction of siRNA
knockdown and EGCG treatment (p = 0.0206). Significant differences between control and siRNA
were determined by post-hoc pairwise comparison with Bonferroni correction (mean ± SEM; n = 4
per condition, *** p < 0.001) (B) Representative images of adipocytes differentiated from C3H10T1/2
treated with vehicle or EGCG (10 μM) for 24 h. (n = 4, means ± SE; *** p < 0.001).
4. Discussion
Metabolic disease is a multifactorial disease and the numerous health benefits of green tea,
including its weight loss effects, have been proposed to have application in the prevention and/or
treatment of obesity-related metabolic disease [21]. Among the various bioactive constituents in
green tea, the polyphenolic catechin EGCG has been proposed to exert a weight loss effect [2,3,21];
however, the regulatory role of EGCG in adipocyte lipid metabolism remains unclear. In this study,
we examined the direct effects of EGCG on adipocyte metabolism using in vitro adipocyte cultures,
including its effects on lipolysis, thermogenic marker expression, mitochondrial metabolism, and
autophagy. We demonstrated that EGCG reduced lipid contents by activating autophagy, partly via a
reduction in intracellular ATP levels, mimicking the energy-depleted state.
The central finding in the current study was the demonstration of EGCG-induced autophagic
lipolysis in adipocytes. Although this is not the first study to report the effects of EGCG on adipocyte
function; previous works have focused on the inhibitory effects of EGCG on adipogenesis [22,23] but
not on adipocyte lipid catabolism. The involvement of lipophagy in the clearance of lipid droplets
has been investigated in several cell types, including hepatocytes and vascular cells [8]; however, the
involvement of EGCG in the direct activation of lipophagy in adipocytes has not been investigated.
The in vivo effects of EGCG on the autophagic lipolysis of adipose tissue were not addressed in this
study, and further studies are required. In support of the effects of EGCG on weight loss, in vivo effects
of green tea in mouse models have been shown to be related to the role of EGCG in the upregulation of
sympathetic nervous system activity, leading to increased energy consumption, thermogenesis, and fat
oxidation [21].
In this study, we found that lipophagy was an alternative pathway to reduce lipid contents without
downstream activation of PKA and that EGCG could activate this process. Our findings also suggested
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that lipophagy activation in adipocytes could be involved in mediating the weight loss effects of EGCG.
According to a previous pharmacokinetic analysis of green tea [24], the peak concentration of EGCG in
the blood reaches 326 ng/mL after a single dose (4.5 g) of green tea consumption. Considering the high
concentration of EGCG (10 μM) used in this study, further studies are required for the extrapolation of
in vitro data to the in vivo situation, such as dose-response curves with lower doses and analysis of the
tissue distribution of EGCG. Such studies will allow us to determine whether induction of autophagic
lipolysis by EGCG can be achieved by green tea consumption or pharmacologic treatment with EGCG.
Under fasting conditions, stimulation of catecholamine release into systemic circulation is
considered a major catabolic signal promoting the increase of lipid mobilization from adipocytes.
In this study, we examined the effects of nutrient starvation on adipocyte lipid metabolism separately
from catecholamine-stimulated β-adrenergic signaling. As expected, nutrient starvation increased
autophagy and lipophagy to reduce the lipid content, without catecholamine-stimulated lipolysis.
These data supported the view that the response of adipocytes to nutrient scarcity is integrated and
coordinated at the organismal level via intrinsic cell properties and hormonal signals. Interestingly,
the cAMP analog increased the levels of autophagy, and upregulation of mTOR signaling, and AMPK
activation stimulated the autophagic response. Although not investigated in this study, determining
the mechanism of PKA signaling in the induction of autophagy would be informative for subsequent
studies of adipocyte metabolism.
The mechanisms of autophagy induction have been investigated intensively in various research
areas related to chronic disease. In this study, we showed that reduction of ATP synthesis was the major
initiating stimulus for autophagy induction by EGCG. Consistent with our observations, previous
studies have reported that ATP synthase activity could be inhibited by resveratrol, several antioxidant
flavonoids, and polyphenolic catechins, including EGCG [25].
The development of CRM is a promising approach to prevent aging and obesity-related metabolic
diseases. In this regard, natural/pharmacological autophagy inducers have been investigated as CRMs
that share molecular mechanisms of health improvement with calorie restriction [9]. In this regard,
EGCG has been recognized as a CRM with acetyltransferase inhibitor activity [26]. Our findings
demonstrated that EGCG induced autophagic lipolysis to reduce the lipid contents in adipocytes by
inhibiting mitochondrial oxidative phosphorylation, and further supported the beneficial effects of
EGCG as a CRM. Our results suggested that the adipocyte-specific effects of CRMs deserve further
investigation as more favorable therapeutic targets for the reduction of adipocyte mass. Furthermore,
investigation of the mechanisms involved in the specific lysosomal degradation of lipid droplets
in adipocytes by other CRMs would lead to the identification of novel targets for drug discovery
and CRMs.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/7/680/s1,
Figure S1: Effects of EGCG on autophagy responses in adipocytes.
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Abstract: Breast cancer is the most common cancer among females worldwide. Several
epidemiological studies suggested the inverse correlation between the intake of vegetables and
fruits and the incidence of breast cancer. Substantial experimental studies indicated that many
dietary natural products could affect the development and progression of breast cancer, such as
soy, pomegranate, mangosteen, citrus fruits, apple, grape, mango, cruciferous vegetables, ginger,
garlic, black cumin, edible macro-fungi, and cereals. Their anti-breast cancer effects involve various
mechanisms of action, such as downregulating ER-α expression and activity, inhibiting proliferation,
migration, metastasis and angiogenesis of breast tumor cells, inducing apoptosis and cell cycle arrest,
and sensitizing breast tumor cells to radiotherapy and chemotherapy. This review summarizes the
potential role of dietary natural products and their major bioactive components in prevention and
treatment of breast cancer, and special attention was paid to the mechanisms of action.
Keywords: breast cancer; soy; fruit; vegetable; anticancer; mechanism of action
1. Introduction
Globally, breast cancer is the most commonly diagnosed cancer and the major cause of
cancer-related death among females [1]. In the United States alone, there are 255,180 new cases
of breast cancer and 41,070 deaths projected to occur in 2017 [2]. Breast cancer is generally categorized
into estrogen receptor (ER)-positive (such as MCF-7 and T47D cell lines) and ER-negative (such as
MDA-MB-231, MDA-MB-468, SKBR3 and MDA-MB-453 cell lines) breast cancer. By using more
biomarkers such as progesterone receptor (PR), and human epidermal growth factor receptor 2
(HER2), breast cancer is further divided into several molecular subtypes, such as luminal A, luminal B,
basal-like and HER2-positive ones [3,4]. Basal-like breast cancer is also considered as triple-negative
breast cancer (TNBC) in some cases, because TNBC is characterized as lacking the expression of
these three biomarkers [5]. These distinct subtypes of breast tumor would response differently to
treatment, which made breast cancer extremely intractable. Currently, surgical resection, adjuvant
chemotherapy, radiotherapy and hormone therapy represent the main treatment options for early-stage
breast cancer [6]. However, the development of drug resistance and major side effects has weakened
the efficacy of these therapies [7,8]. Besides, triple-negative breast cancer does not respond to
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hormone therapy [9]. This situation urges the research of finding more effective prevention and
treatment strategies with fewer side effects for breast cancer. Many exogenous and endogenous factors
could affect the onset and development of breast cancer. Exogenous factors include reproductive,
environmental and lifestyle factors, such as early menarche [10], nulliparity, oral contraceptive use [11],
parity and lactation (never having or short duration of breast feeding) [12,13], use of hormone
replacement therapy [14], alcohol consumption [15], diabetes [16,17], obesity [18], and night work
(circadian disruption) [19]. Genetic risk factors, such as mutations on breast cancer susceptibility gene
1 (BRCA1) and BRCA2, only account for approximately 5–10% of all breast cancer incidences [20].
Therefore, the prevention of breast cancer is highly crucial.
Diet and nutrition have been considered as an effective preventive strategy for cancer. A bunch of
dietary natural products have shown a potential role in prevention and treatment of cancers [21–26].
A recently published meta-analysis, which included 93 studies, pointed out that results on breast cancer
were among the few reaching a convincing evidence of a protective effect of healthy dietary pattern and
cancer risk, and the effect was especially prominent in postmenopausal, hormone receptor–negative
women [27]. Furthermore, various epidemiological studies suggested that consumption of soy
products, fruits, and vegetables (especially cruciferous vegetables) are associated with reduced risk
of breast cancer [28,29], and high consumption of some dietary natural products might reduce the
recurrence and increase the survival rate of breast cancer [30,31]. In addition, experimental studies
indicated that many dietary natural products and their bioactive components showed inhibitory
effects on breast cancer (Figure 1), through downregulating ER-α expression and activity, inhibiting
proliferation, metastasis and angiogenesis of breast tumor cells, inducing apoptosis and cell cycle
arrest, and sensitizing breast tumor cells to radiotherapy and chemotherapy [32–35]. Therefore, use of
naturally occurring dietary substances could be a practical approach to prevention and treatment of
breast cancer [36]. The objective of this review is to summarize the role of dietary natural products
and their bioactive compounds in the prevention and treatment of breast cancer, and discuss the
mechanisms of action.
 
Figure 1. Dietary natural products that showed inhibitory effects on breast cancer.
2. Soy
Soy products have been widely consumed in Asian regions for centuries. Many potential health
benefits have been linked with intake of soy products, such as lower incidences of coronary heart
diseases [37], type 2 diabetes [38] and breast cancer [39]. Soy products are rich in isoflavones, and
a meta-analysis of prospective studies indicated that intake of isoflavones was nearly significantly
associated with decreased risk of breast cancer [40]. Besides, another meta-analysis, which included five
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cohort studies, found that post-diagnosis intake of soy food was associated with reduced mortality (HR
for highest vs. lowest dose was 0.84, 95% CI = 0.71–0.99) and recurrence (HR = 0.74, 95% CI = 0.64–0.85)
of breast cancer, indicating that soy food intake might be linked with better survival [41]. Indeed,
numerous studies have supported the beneficial role of soy food intake for patients with breast
cancer, although some reverse results were also observed. Given the vast number of studies, relevant
peer-reviewed articles published in English within 5 years were included and discussed in this section.
2.1. Epidemiological Evidence
Most epidemiological studies have supported an inverse relationship between soy consumption
and risk of breast cancer, though most studies were conducted in Asian population due to the different
food preferences [39,42,43]. In recent years, epidemiological studies have widely investigated the effects
of soy foods on breast cancer defined by different status. The amount of soy isoflavone consumption,
estrogen receptor status of tumor, menopausal status of patients and timing of dietary exposure, could
influence the soy-breast cancer association [44]. A recent study found an inverse association between
adult soy intake and breast cancer risk (HR for fifth versus first quintile soy protein intake = 0.78; 95%
CI = 0.63–0.97) of the population based in Shanghai Women’s Health Study, with a predominance
observed in premenopausal women (HR = 0.46; 95% CI: 0.29–0.74). Further stratified analyses found
that soy intake during adulthood was significantly associated with decreased risk of ER−/PR− breast
cancer in premenopausal women (HR = 0.46; 95% CI = 0.22–0.97) and decreased risk of ER+/PR+
breast cancer in postmenopausal women (HR = 0.72; 95% CI = 0.53–0.96). The HER2 status did not
show a significant influence on the association [45]. Likewise, data extracted from the Takayama study
in Japan pointed out that the relative risk of postmenopausal breast cancer was lower in women with
larger consumption of soy (trend p = 0.023) and isoflavone (trend p = 0.046), although intake of soy
and isoflavone did not affect the relative risks of premenopausal breast cancer [46]. In addition, it was
found that high soy protein intake was associated with decreased breast cancer death (HR = 0.71, 95%
CI = 0.52–0.98). Further stratified analysis pointed out that high intake of soy isoflavone was associated
with a better prognosis of ER positive breast cancer (HR = 0.59, 95% CI = 0.40–0.93) [47]. Furthermore,
data from the Korean Hereditary Breast Cancer Study reported that intake of soy products showed
a lower risk of breast cancer in BRCA2 mutation carriers (HR: 0.39; 95% CI = 0.19–0.79 for the highest
quartile) than noncarriers [48]. Besides, a study investigated the association between soy intake and
tumor tissue miRNA and gene expression of TNBC patients, and found that long-term prediagnosis
soy intake might be associated with elevated expression of tumor suppressors (such as miR-29a-3p
and insulin-like growth factor 1 receptor (IGF1R)), and declined expression of oncogenes [49]. Ethnic
diversity could also affect the soy-breast cancer association, thus some studies included participants
from different ethnic groups or combined data from different cohort studies. A study combined 9514
breast cancer survivors from 2 US cohorts and 1 Chinese cohort. It was suggested that postdiagnosis soy
food consumption (≥10 mg isoflavones/day) was related to a significant decreased risk of recurrence
(HR = 0.75; 95% Cl = 0.61–0.92) and a nonsignificant lower risk of breast cancer specific mortality [30].
However, controversy still exists in this topic whether soy intake is associated with a reduced
breast cancer risk. A multiethnic cohort study recruited women of African Americans, Latinos, Japanese
Americans, Caucasians, and Native Hawaiians, and found that intake of prediagnosis soy was not
associated with all-cause or breast cancer specific mortality [50]. Furthermore, no statistically significant
relationship was observed between dietary isoflavone intake and overall risks of breast cancer across
racial/ethnic groups in the same cohort [51]. Besides, a study showed that total soy food intake was
not associated with an increased risk of cancer recurrence, but high intake of soy isoflavone increased
the risk of cancer recurrence in HER2-positive breast cancer patients [52]. Moreover, according
to a randomized phase II trial, a 6-month intervention of mixed soy isoflavones in high-risk or
healthy adult Western women induced no reduction of breast epithelial proliferation, suggesting the
poor efficacy of soy isoflavones for breast cancer prevention and an even possible adverse effect on
premenopausal women [53]. The inconsistence of these results might be attributed to multiple reasons,
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such as the difference between food frequency questionnaires (FFQ) designed to capture the amount
of soy intake [54].
2.2. Experimental Evidence
Despite the inconsistency in the abovementioned epidemiological studies, the fact that prevalence
of breast cancers in Asia is much lower than that in North American and European countries has
still raised an increasing interest in soy isoflavones as a potential therapeutic agent in breast cancer
chemoprevention [55]. In fact, numerous experimental studies have demonstrated the inhibitory
effects of soy products and soy isoflavones on breast cancer through various mechanisms of action.
In general, soy isoflavones (such as genistein and daidzein) exert their anti-breast cancer effects
through the ER-dependent signaling pathways, due to the structural resemblance with 17-β-estradiol
(Figure 2). For instance, genistein, one of the predominant soy isoflavones, could bind with both ERα
and ERβ [56,57]. The ERα/ERβ ratio is a prognostic marker for breast tumors, and plays a vital role
in the effect of soy isoflavones on breast cancer cells [58–60]. Genistein regulated the proliferation
and mitochondrial functionality of breast cancer cells in an ERα/ERβ ratio-dependent way, since
genistein treatment induced cell cycle arrest and improved mitochondrial functionality in T47D cells
(low ERα/ERβ ratio), without affecting MCF-7 (high ERα/ERβ ratio) and MDA-MB-231 (ER-negative)
cells [58]. Likewise, genistein regulated oxidative stress, uncoupling proteins, antioxidant enzymes
and sirtuin, which was also dependent on ERα/ERβ ratio of breast cancer cells [59]. Furthermore,
the synergetic effect of genistein with other anticancer drugs (cisplatin, paclitaxel or tamoxifen) was
also dependent on ERα/ERβ ratio, judging by that the anticancer effect of combination treatment
was more predominant in T47D cells than that in MCF-7 and MDA-MB-231 cells [60]. Additionally,
in mouse mammary tumor virus erbB2 female transgenic mice administrated with different doses of
17β-oestradiol, it was found that the breast cancer incidence of mice was reduced by soybean diet in
a high-oestrogen environment, but increased in a low-oestrogen environment [61].
 
(a) (b) (c) 
Figure 2. Structures of genistein (a); daidzein (b); 17-β-estradiol (c).
Soy isoflavones also showed inhibitory effects on the ER-negative MDA-MB-231 breast cancer
cells [62,63], indicating that apart from interacting with ER, soy isoflavones also exert anti-breast cancer
effect through various ER-independent mechanisms. For instance, soy products and soy isoflavones
could induce apoptosis in both ER+ and ER− breast cancer cells. A water-soluble extract of long-term
fermented doenjang (a fermented soybean product in Korea) induced cell cycle arrest, proliferation
inhibition, and consequential apoptosis in breast cancer cells [64]. In addition, growth inhibition
and apoptosis were induced by genistein in MCF-7-C3 and T47D cells, through downregulation
of the cancerous inhibitor of protein phosphatase 2A, an oncogene found overexpressed in breast
cancer [65]. Genistein also induced apoptosis in MCF-7 cells via the inactivation of the IGF-1R/p-Akt
signaling pathway and decreasing the Bcl-2/Bax mRNA and protein expression [66]. Besides,
6,7,4′-trihydroxyisoflavone, a metabolite of daidzein, induced apoptosis in MCF10CA1a cells, through
upregulation of DR4 expression and downregulation of XIAP, leading to the PARP cleavage.
This metabolite also induced cell cycle arrest at S- and G2/M phases by regulating cyclins and
cyclin-dependent kinases (CDKs) [67]. Besides, extract of a soybean biotransformed by fungus induced
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cell death on MCF-7 cells, which was associated with the activation of caspase-3 and upregulation of
proapoptotic molecule expression [68].
Soy isoflavones could also cause epigenetic alterations in breast cancer cells. Genistein inhibited
DNA methylation and increased expression of some tumor suppressor genes in breast cancer cells,
which might partly contribute to the anticancer effect of genistein [69]. In addition, quantitative
phosphoproteomics revealed that genistein inhibited the growth of TNBC cell through modulating the
DNA damage response and cell cycle in a more complex manner [70]. Furthermore, several prosurvival
signalings in breast cancer cells were blocked by soy isoflavones. Genistein dose-dependently inhibited
the growth of MDA-MB-231 cells by inhibiting activity of NF-κB via the Nocth-1 signaling pathway [71].
Genistein also decreased the breast cancer stem-like cell population both in vitro and in vivo, through
downregulation of the Hedgehog-Gli1 signaling pathway [72]. Equol is a bacterial metabolite of
daidzein. A study found that daidzein, R-(+)equol and S-(−)equol showed inhibition on the invasion
of MDA-MB-231 cells through the downregulation of MMP-2 expression [63].
The controversy also exists in the results of experimental studies. Several recent studies challenged
the inhibitory effect of soy isoflavones on breast cancer. For instance, a study found that isoflavone
extracts of 51 commercial soybean cultivars were estrogenic and stimulated the growth of ER+ MCF-7
cells by 1.14 to 4.59 folds [73]. In addition, a study found that genistein at physiological concentration
(5 μM) increased cellular levels of ROS and stimulated proliferation of breast cancer cell through the
induction of CYP1B1 gene expression [74]. Moreover, long-term genistein treatment at low doses
(≤500 ppm) promoted MCF-7 tumor growth and led to a more aggressive and advanced tumor
growth phenotype after stimulus withdrawal [75]. Besides, in an experimental model of breast cancer
with bone micro-tumors, soy isoflavones supplement (750 mg/kg) induced an increase of metastasis
to lungs [76]. Furthermore, daidzein promoted growth of breast cancer cells in vitro (1 μg/mL)
and stimulated estrogen-induced cell proliferation in rat uterus (0.066 mg/kg body weight (bw)),
which suggested a caution for the use of daidzein in hormone replacement therapy [77]. Likewise,
daidzein exposure promoted the expression of proto-oncogene BRF2 in ER+ breast cancer cells, through
enhancing the demethylation and/or mRNA stabilization [78]. In addition, overexpression of ABC
drug transporters is a contributor to multidrug resistance. Genistein treatment increased the expression
of ABCC1 and ABCG2 at the protein level in MCF-7 cells, leading to an enhancement in doxorubicin
and mitoxantrone efflux and resistance [79].
Collectively, most studies have supported a protective role of soy isoflavones against breast cancer,
though some adverse effects have also been reported. Nevertheless, it should be noted that since
the intrinsic cellular pathways often interfere or overlap, there was not a clear boundary between
ER-dependent and ER-independent mechanisms under the anti-breast cancer action of soy isoflavones.
Meanwhile, whether soy isoflavones promote or inhibit the growth of breast cancer seemed to be
dependent on their doses [80], thus the dosage and long-term safety of soy isoflavones need to be
further investigated before they are recommended as supplement for breast cancer patients.
3. Fruits
Fruits normally contain high content of polyphenols, which gives fruits great antioxidant activity
and may help reduce risk of cancer [81–85]. In a meta-analysis which included fifteen prospective
studies, high intake of fruits was associated with a weak reduction in risk of breast cancer (summary
RR for the highest versus the lowest intake was 0.92, 95% CI = 0.86–0.98, I2 = 9%) [86]. Besides, another
meta-analysis suggested a borderline inverse association between pre-diagnostic fruit intake and the
overall survival of breast cancer (summary HR for the highest versus the lowest intake was 0.83,
95% CI = 0.67–1.02, I2 = 0%) [87]. Some fruits, such as pomegranate, mangosteen and citrus fruits,
have shown inhibition on breast cancer cells.
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3.1. Pomegranate
Pomegranate (Punica granatum L.) has been utilized for medicinal purposes for centuries and is
described as “nature’s power fruit” [88]. Pomegranate fruit contained a high content of polyphenols,
among which ellagitannins predominate, and showed great antioxidant activity and anti-inflammatory
properties [89,90]. Pomegranate extract (PE) inhibited MCF-7 breast cancer cell growth by inducing
cell cycle arrest in G2/M phase and inducing apoptosis, and the effects might be associated with
downregulation of homologous recombination, which could sensitize cancer cells to double strand
breaks [91]. Another study revealed that PE exerted proapoptotic and antiproliferative effects on
DMBA-inflicted rat mammary tumorigenesis, possibly through concurrent disruption of ER and
Wnt/-catenin signaling pathways [92]. Furthermore, hydrophilic fraction of pomegranate seed oil
significantly decreased cell viability of MCF-7 and MDA-MB-231 breast cancer cell lines and induced
cell cycle arrest in G0/G1 phase [93]. Besides, pomegranate juice or combined with its components
(luteolin + ellagic acid + punicic acid) could block the metastatic processes of breast cancer cells,
as shown by inhibited cell growth, increased cell adhesion and decreased cell migration [94]. Another
study indicated that PE showed anticancer activities on breast cancer cells, which was partly due to
targeting microRNAs155 and 27a [95]. Additionally, pomegranate peel extract reduced cell proliferation
and induced apoptosis on MCF-7 cancer cells, by increasing expression of Bax and decreasing the
expression Bcl-2 [96]. Another study found that a pomegranate extract consisting of fermented juice
and seed oil could inhibit invasion and motility of human breast cancer by inhibiting RhoC and RhoA
protein expression. The bioactive components were identified as ellagitannins and phenolic acids in
the aqueous extract, and conjugated octadecatrienoic acids in the lipid extract of seed [97]. Besides,
pomegranate ellagitannin-derived compounds inhibited aromatase activity and proliferation of breast
cancer cell line, indicating a potential for the prevention of estrogen-responsive breast cancers [98].
Furthermore, the whole pomegranate seed oil and fermented pomegranate juice polyphenols both
inhibited the cancerous lesion formation induced by DMBA in a murine mammary gland organ culture,
suggesting a chemopreventive property and adjuvant therapeutic potential of pomegranate [99,100].
3.2. Mangosteen
Mangosteen (Garcinia mangostana L.) known as “queen of fruits” is a common tropical fruit. Crude
methanolic extract of mangosteen pericarp could inhibit proliferation and induce apoptosis on SKBR3
human breast cancer cell line [101]. In addition, phenolics from mangosteen fruit pericarp produced
great cytotoxicities against MCF-7 human breast cancer cells [102].
Mangosteen pericarp is a rich source of xanthones, such as α- and γ-mangostin, which have
a variety of bioactivities, such as antioxidant, anti-inflammatory, and anticancer activities [103]. In a
study, twelve xanthone constituents were isolated from the pericarp of mangosteen, among which
α-mangostin, γ-mangostin, garcinone D, and garcinone E, showed dose-dependent anti-aromatase
activity in SK-BR-3 breast cancer cells, with γ-mangostin being the most potent [104]. Furthermore,
a study showed that α-mangostin could induce apoptosis in T47D breast cancer cells through
modulating HER2/PI3K/Akt and MAPK signaling pathways [105]. In addition, α-mangostin
treatment on MDA-MB231 cell line carrying a p53 mutation induced mitochondria-mediated apoptosis
and cell cycle alterations (G1-phase arrest, upregulation of p21(cip1) expression and downregulation
of cyclins, cdc(s), CDKs and PCNA) [106]. Besides, α-mangostin isolated from mangosteen exerted
cytotoxicity on SKBR3 breast cancer cells and showed apoptotic bodies [107]. In addition, α-mangostin
effectively inhibited fatty acid synthase (FAS) expression and intracellular FAS activity, and induced
apoptosis in human breast cancer cells [108].
Furthermore, a study revealed that the presence of ERα is necessary for growth inhibition and
apoptosis induced by α-mangostin in human breast cancer cells, as evidenced by that MDA-MB-231
cells (ER-α negative) is less sensitive to α-mangostin than MCF-7 cells (ERα positive), and that
knockdown of ERα reduced the cell growth inhibition and caspase-7 activation induced by
α-mangostin [109]. Besides, lymph node metastasis partly contributes to the lethality of breast
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cancer. In a study, α-mangostin treatment (20 mg/kg/day) significantly increased survival rate
of mice carrying mammary tumors, and greatly suppressed tumor volume and the multiplicity of
lymph node metastases. In vitro studies showed that α-mangostin induced mitochondria-mediated
apoptosis and G1- and S-phase cell cycle arrest, and decreased levels of phospho-Akt-threonine
308 (Thr308) [110]. Besides, treatment of panaxanthone (approximately 80% α-mangostin and 20%
γ-mangostin) isolated from pericarp of mangosteen significantly suppressed mammary tumor volumes
in mice, and decreased the multiplicity of lung metastasis and lymph node metastasis. These
effects were associated with increases of apoptotic cell death, antiproliferation and antiangiogenesis.
The in vitro analysis also confirmed that α-mangostin induced apoptosis on BJMC3879 cells [111].
3.3. Citrus Fruits
Citrus fruits include a large class of fruits, such as orange, lemon, grapefruit, pomelo and
lime. Recently the anti-breast cancer activity of citrus fruits has attracted increasing attention.
A meta-analysis of observational studies pointed out an inverse association between citrus fruits
intake and the risk of breast cancer (OR, 0.90; 95% CI = 0.85–0.96; p < 0.001) [112].
Polysaccharides from Korean Citrus hallabong peels inhibited angiogenesis as shown by reducing
tube formation of human umbilical vein vascular endothelial cells, and suppressed cell migration
of MDA-MB-231 cells via downregulation of MMP-9 [113]. Besides, extracts from a citrus fruit
named Phalsak induced apoptosis in anoikis-resistant breast cancer stem cell line MCF-7-SC [114].
In addition, lemon citrus extract induced apoptosis in MCF-7 breast cancer cells via upregulating
the expression of bax and caspase-3 genes, and downregulating the expression of bcl-2 gene [115].
Furthermore, naringin, a flavonoid presenting abundantly in citrus fruits, inhibited cell proliferation,
and promote cell apoptosis and G1 cycle arrest in TNBC cell lines-based in vitro and in vivo models
through modulating β-catenin pathway [116]. Besides, hesperidin, a flavonoid derived from citrus
fruits, showed inhibitory effect on the proliferation of MCF-7-GFP-Tubulin cells [117].
3.4. Apple
Apple is widely consumed and an important part of the human diet. Flavonoids extracted from
the peel and flesh of Pink Lady apples could both inhibit MCF-7 breast cancer cell growth, with IC50 of
58.42 ± 1.39 mg/mL and 296.06 ± 3.71 mg/mL, respectively [118]. Besides, another study investigated
an apple cultivar called Pelingo, and found that the Pelingo apple juice contained high content of
polyphenol and exerted antiproliferative effect on MCF-7 and MDA-MB-231 cells. Pelingo juice also
inhibited 12-o-tetra-decanoyl-phorbol-13-acetate (TPA)-induced tumorigenesis of pre-neoplastic cells,
by inhibiting colony formation and TPA-induced ERK1/2 phosphorylation [119]. Additionally, apple
extract showed a significant antiproliferative effect on MCF-7 and MDA-MB-231 cells at concentrations
of 10–80 mg/mL (p < 0.05). Apple extract also significantly induced cell cycle arrest at G1 phase in
MCF-7 cells by decreasing cyclin D1 and Cdk4 proteins [120]. Another study showed that apple extract
and 2α-hydroxyursolic acid isolated from apple peel could both inhibit NF-κB activation induced
by TNF-α in MCF-7 cells through suppressing the proteasomal activities [121,122]. In addition,
2α-hydroxyursolic also showed antiproliferative and pro-apoptotic effects on MDA-MB-231 cells by
regulating the p38/MAPK signal transduction pathway [123]. Furthermore, pectic acid isolated from
apple could induce apoptosis and inhibit cell growth of 4T1 breast cancer cells in vitro, and prevent
tumor metastasis in BALB/c mice via overexpression of p53 [124]. Results of another study indicated
a synergistic inhibitory effect of the quercetin 3β-D-glucoside and apple extract combination on the
proliferation of MCF-7 cells [125].
3.5. Grape
Grape and its products such as wine are well recognized healthy food consumed in the world.
Dietary grape skin extract (0.5 and 1.0 mg/mL in drinking water) significantly inhibited the lung
metastasis of breast tumor in Balb/c mice implanted with 4T1 cells. In vitro study revealed that
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grape skin polyphenols inhibited migration of 4T1 cells, which might be associated with blocking
the PI3k/Akt and MAPK pathways [126]. Another study showed that grape seed extract suppressed
migration and invasion of the highly metastatic MDA-MB231 cells, possibly through inhibiting
β-catenin expression and localization, decreasing fascin and NF-κB expression and the activities
of urokinase-type plasminogen activator (uPA), MMP-2 and MMP-9 [127]. In addition, a red grape
wine polyphenol fraction showed selective cytotoxicity on MCF-7 cells, as evidenced by membrane
damage, disrupted mitochondrial function and G2/M cell cycle arrest [128]. Another study screened
Vitis amurensis grape for active compounds to inhibit vascular endothelial growth factor (VEGF)
production in tamoxifen-resistant MCF-7 cells, and amurensin G presented to be the most potent
one. The effect was through blocking Pin1-mediated VEGF gene transcription [129]. Furthermore,
muscadine grape skin extract could decrease cell invasion, migration and bone turnover in MCF-7 cells,
via inhibiting expression of Snail and phosphorylated signal transducers and activators of transcription
3 (STAT3) and abrogating Snail-mediated CatL activity [130].
3.6. Mango
Mango (Mangifera indica L.) is a commonly cultivated tropical fruit and rich in polyphenolic
compounds such as gallic acid and gallotannins. A study found that mango polyphenolics exhibited
cytotoxic effects on BT474 cells in vitro, and decreased tumor volume by 73% in mice bearing BT474
xenograft compared with control group. These effects were partially regulated through the PI3K/AKT
pathway and miR-126 [131]. Another study investigated three genetically diverse mango varieties,
and found that the peel extract of Nam Doc Mai mango contained the highest amounts of polyphenols,
inhibited cell viability of MCF-7 cells with an IC50 of 56 μg/mL, and significantly (p < 0.01) stimulated
cell death in MDA-MB-231 cells [132]. Furthermore, ethanolic extract of mango seed induced apoptosis
in MCF-7 and MDA-MB-231 cells, through increasing pro-apoptotic proteins (cytochrome c, Bax,
caspase-7, -8 and -9) and decreasing anti-apoptotic proteins (p53, Bcl-2, and glutathione). The
effects were also associated with the activation of oxidative stress in breast cancer cells [133,134].
Besides, gallotannins in mango are generally not absorbable, therefore they are rarely studied for
bioactivities. A study found that pyrogallol, the major microbial metabolite of gallotannins, and a
mango polyphenols fraction could both inhibit breast cancer ductal carcinoma in situ proliferation
in vitro, which was possibly through mediating the AKT/mTOR signaling pathway [135].
3.7. Other Fruits
Jujube (Ziziphus jujube) fruit has shown numerous medicinal and pharmacological effects, such
as antioxidant and anti-inflammatory activities [136]. A study found that Ziziphus jujube extracts
induced cell death by apoptosis in MCF-7 and SKBR3 breast cancer cells, without decreasing cell
viability of nonmalignant breast epithelial MCF-10A cells or normal human fibroblasts BJ1-hTERT [137].
In addition, betulinic acid was isolated from sour jujube fruit, and microencapsulated betulinic
acid could induce apoptosis in MCF-7 cells, through the mitochondria transduction pathway [138].
Furthermore, jujube aqueous extract treatment on MCF-7 cells exhibited antiproliferative and
pro-apoptotic effects, through upregulating expression of Bax and downregulating Bcl2 gene [139].
Some berry fruits except for grape mentioned above also showed inhibitory effects on breast
cancer cells. Methanolic extract of strawberry exerted cytotoxicity in T47D breast cancer cells
in vitro, and inhibited the proliferation of tumor cells in mice bearing breast adenocarcinoma
by activating apoptosis [140]. Besides, bilberry extract inhibited proliferation of MCF-7 cells in
a concentration-dependent manner (IC50 = 0.3–0.4 mg/mL), accompanied by induction of apoptotic
cell death [141]. Furthermore, Jamun is the ripe purple and edible berries of the plant Eugenia
jambolana Lam, and widely consumed in the United States. In a study, Jamun fruit extract showed
great antiproliferative and pro-apoptotic effect on MCF-7aro and MDA-MB-231 cells, but only mild
antiproliferative activity and no pro-apoptotic effect on the normal MCF-10A cells [142]. Additionally,
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cranberry extract could inhibit the proliferation of MCF-7 cells, which was partly attributed to the
induction of apoptosis and G1 phase arrest [143].
Polyphenolics from peach (Prunus persica) suppressed breast tumor growth and lung metastasis
in a dose range of 0.8–1.6 mg/day in mice (about 370.6 mg/day for a human adult of 60 kg),
which was regulated by inhibition of MMPs gene expression [144]. Another study investigated
the anticancer effect of plums (Prunus salicina), and found that immature plums exhibited higher
cytotoxic effects against MDA-MB-231 cells than mid-mature and mature plums, and contained
higher levels of total phenolics and condensed tannins. The immature plums also induced
apoptosis in MDA-MB-231 cells, associated with increased Bax levels, decreased Bcl-2 levels and
the cleavage of caspases and PARP [145]. Besides, flavanols from Japanese quince (Chaenomeles
Japonica) fruit exerted antiproliferative activity and inhibited invasiveness in MDA-MB-231 cells [146].
Additionally, a graviola fruit extract selectively inhibited the growth MDA-MB-468 breast cancer
cells (IC50 = 4.8 μg/mL), without affecting nontumorigenic MCF-10A breast epithelial cells in vitro.
Furthermore, 5-week dietary treatment of this extract (200 mg/kg) inhibited tumor growth by 32%
(p < 0.01) in mouse xenograft model, through the EGFR/ERK signaling pathway [147]. In addition,
litchi fruit pericarp extract inhibited cell growth (IC50 = 80 μg/mL) of human breast cancer cells dose-
and time-dependently in vitro, and 0.3 mg/mL oral administration of the extract for 10 weeks reduced
tumor mass volume by 40.70% in mice, through multiple mechanisms [148]. Besides, bromelain
isolated from the stems and immature fruits of pineapple induced cell death of GI-101A breast cancer
cells in vitro by promoting apoptosis [149].
Collectively, the intake of fruits is generally beneficial for the prevention and treatment of breast
cancer, and pomegranate, mangosteen, apple, citrus fruits, grape and mango have shown the most
promising effects. The anti-breast cancer action of these fruits might be attributed to the presence of
some bioactive component, such as ellagitannins in pomegranate and mangostin in mangosteen.
4. Vegetables
A meta-analysis of prospective studies indicated that high intake of fruits and vegetables
combined was associated with a weak reduction in risk of breast cancer, with the summary relative
risk (RR) for the highest versus the lowest intake of 0.89 (95% CI: 0.80–0.99, I2 = 0%). However,
no significant association was found between vegetable intake alone and risk of breast cancer [86].
In experimental studies, several vegetables, especially cruciferous vegetables, have shown inhibitory
effect on breast cancer cells.
4.1. Cruciferous Vegetables
Cruciferous vegetables, such as broccoli, cauliflower, watercress and Brussel sprouts, are grown
and consumed worldwide. According to a meta-analysis with 13 epidemiologic studies included,
intake of cruciferous vegetables was inversely associated with risk of breast cancer (RR = 0.85, 95%
CI = 0.77–0.94) [150]. Cruciferous vegetables have shown anti-breast cancer effect on experimental
models, which might be attributed to its high contents of glucosinolates. When the vegetables are
cut or chewed, the enzyme myrosinase is released, and glucosinolates would be degraded to form
isothiocyanates. Isothiocyanates include a variety of compounds such as benzyl isothiocyanate,
phenethyl isothiocyanate and sulforaphane, and have been long known to have chemopreventive
activities for various neoplasms including breast cancer [151,152]. Besides, the indole-3-carbinol
in cruciferous vegetables and its metabolite 3,3′-diindolylmethane also showed anti-breast cancer
action [153,154].
4.1.1. Isothiocyanates
Benzyl isothiocyanate (BITC)-induced inhibition on breast cancer cells is associated with apoptotic
cell death, and inhibition of mitochondrial fusion was found to be an early and critical event involved
in BITC-induced apoptosis [155]. Meanwhile, it was found that BITC-induced apoptosis in MCF-7 and
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MDA-MB-231 cells was not p53-dependent, but mediated by suppression of XIAP expression [156].
In addition, in breast cancer cells treated with BITC, the proapoptotic proteins Bax and Bak were
upregulated and the antiapoptotic proteins Bcl-2 and Bcl-xL were downregulated, indicating that
apoptosis was induced by BITC. Generation of ROS and cleavage of caspase-9, caspase-8, and caspase-3
were also involved in this process [157]. BITC could also inhibit the migration and metastasis of
human breast cancer cells. On the one hand, BITC markedly suppressed the invasion and migration
of MDA-MB-231 cells, which was involved with reduced uPA activity, and suppression of Akt
signaling [158]. On the other hand, epithelial-mesenchymal transition (EMT) process was triggered
during progression of cancer to invasive state [159]. BITC treatment inhibited TGF β-/TNF α-induced
migration via suppression on EMT process, as shown by the upregulated epithelial markers (E-cadherin
and occludin), and downregulated mesenchymal markers (vimentin, fibronectin, snail, and c-Met),
both in vitro and in vivo [160]. Besides, BITC exposure caused FoxO1-mediated autophagic death
in breast cancer cells and MDA-MB-231 xenografts [161]. BITC could also act against the oncogenic
effects of leptin on MDA-MB-231 and MCF-7 cells through suppressing activation of signal transducer
and activator of transcription 3 [162]. BITC inhibited the growth of MDA-MB-231 xenografts by
suppression on cell proliferation and neovascularization [163]. Additionally, BITC treatment inhibited
breast cancer stem cells in vitro and in vivo, possibly by targeting Ron receptor tyrosine kinase [164].
Phenethyl isothiocyanate (PEITC), another natural isothiocyanate, also showed growth inhibition
on breast cancer cells. Pharmacological concentrations of PEITC induced a PUMA-independent
apoptosis on BRI-JM04 breast cancer cells, which was mediated by Bim [165]. Besides, PEITC
suppressed adhesion, aggregation, migration and invasion of MCF-7 and MDA-MB-231 cells via
modulation of HIF-1α [166]. Moreover, PEITC administration significantly prolonged the tumor-free
survival and reduced the tumor incidence induced by N-methyl nitrosourea (NMU) in rats, since the
tumor incidences were 56.6%, 25.0% and 17.2% for control, 50 μmol/kg, and 150 μmol/kg group,
respectively. This chemopreventive activity might be attributed to its anti-angiogenic effects [167].
Besides, PEITC treatment (3 μM) to MCF-7 cells caused alterations in some genes in breast cancer, such
as p57 Kip2, p53, BRCA2, IL-2, and ATF-2, which were involved in tumor suppression and cellular
proliferation/apoptosis [168].
Sulforaphane (SFN), is also a potent inhibitor of mammary carcinogenesis through various
mechanisms of action. SFN could downregulate ERα expression in MCF-7 cells, partially by blocking
ERα mRNA transcription and increasing proteasome-mediated degradation [169]. SFN also induced
cell type-specific apoptosis in breast cancer cells, since SFN-activated apoptosis in different breast
cancer cell lines was initiated through different signaling pathways. To be specific, SFN activated
apoptosis in MDA-MB-231 cells through induction of Fas ligand which led to activation of caspase-8,
caspase-3 and poly (ADPribose) polymerase, while SFN induced apoptosis in the other breast cancer
cell lines by reduction of Bcl-2 expression, release of cytochrome c into the cytosol, activation
of caspase-3 and caspase-9, but not caspase-8, and poly (ADP-ribose) polymerase cleavage [170].
In addition, SFN suppressed the growth of KPL-1 human breast cancer cells both in vitro and in
athymic mice [171], and the anti-metastatic action of SFN might be through inhibiting MMP-9
expression via the NF-κB signaling pathway [172]. Moreover, it was found that SFN showed
antiproliferative effect on various TNBC cells through activating tumor suppressor Egr1 [173]. Besides,
SFN also downregulated telomerase in breast cancer cells by inducing epigenetic repression of hTERT
expression [174]. In addition, a study found that SFN showed anticancer efficacy in ER+ and COX-2
expressed breast cancer, which might be mediated by p38 MAP kinase and caspase-7 activations [175].
4.1.2. Indole-3-Carbinol
Indole-3-carbinol (I3C) is found at high concentrations in Brassica vegetables, and is a natural
anti-carcinogenic compound. Studies have indicated that I3C showed anti-breast cancer action, since it
could interact directly with the ERα and inhibit its activity, or through estrogen-independent actions,
such as blocking cell cycle progression and metastasis, and inducing apoptosis. I3C (50 or 100 μM)
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could suppress the cell adhesion, migration, and invasion in vitro as well as the in vivo lung metastasis
formation in MCF-7 and MDA-MB-468 cell lines, which was associated with upregulation of BRCA1
and E-cadherin/catenin complexes [176]. In addition, I3C pretreatment inhibited the migration through
suppressing the EMT process and downregulating FAK expression [177]. I3C-induced inhibition on
MMP-2 by blocking the ERK/Sp1-mediated gene transcription also contributed to its anti-invasive
action on breast cancer cells [178]. Furthermore, I3C could induce inhibition on breast cancer bone
metastasis by inhibiting CXCR4 and MMP-9 expression through downregulation of the NF-κB signaling
pathway [179]. I3C could also regulate the cell cycle progression of breast cancer cells. For instance, I3C
could inhibit CDK2 function in MCF-7 cells, by regulating cyclin E composition, the size distribution,
and subcellular localization of the CDK2 protein complex [180]. Moreover, I3C suppressed CDK6
expression in MCF-7 cells, via targeting Sp1 at a composite DNA site in the CDK6 promoter [181].
Moreover, I3C downregulated expression of telomerase gene through disruption of the combined
ERα- and Sp1-driven transcription of hTERT gene expression, leading to a cell cycle arrest in breast
cancer cell [182]. Besides, I3C could induce apoptotic cell death in MDA-MB-435 and MCF10CA1a
breast cancer cells, mainly through inducing overexpression and translocation of Bax to mitochondria,
resulting in mitochondrial depolarization and activation of caspases [183,184]. In addition, I3C exerted
antiproliferative action on estrogen-sensitive MCF-7 breast cancer cells, via suppressing the expression
of IGF1R and IRS1, which was dependent on downregulation of ERα [185]. Furthermore, I3C induced
stress fibers and focal adhesion formation through upregulation of Rho kinase activity, leading to
an inhibited motility of MDA-MB-231 cell [186]. Interferon gamma (IFNγ) played a key role in
prevention of the development of primary and transplanted tumors [187]. The anti-breast cancer effect
of I3C might also be through stimulating expression of interferon gamma receptor 1 (IFNγR1) and
augmenting the IFNγ response [188].
4.1.3. 3,3′-Diindolylmethane
3,3′-Diindolylmethane (DIM) is an in vivo acid-catalyzed condensation product of I3C and much
more stable than I3C. DIM is also a promising anticancer agent. Multiple targets and underlying
mechanisms of DIM-induced inhibition on breast cancer cells have been found. For instance, DIM
induced apoptosis in MCF-7 and MDA-MB-231 breast cancer cells (Figure 3), by decreasing total
transcript and protein levels of Bcl-2 and increasing Bax protein levels [189]. Apoptosis induced by
DIM in MCF10CA1a breast cancer cells was also modulated by inactivation of Akt and NF-κB [190].
Another study revealed the upstream mechanism of DIM-induced inhibition on Akt in MDA-MB-231
breast cancer cells, which was through blockade of hepatocyte growth factor/c-Met signaling [191].
Meanwhile, DIM inhibited breast cancer cell proliferation and induced cell cycle arrest in G2/M phase
in MCF-7 breast cancer cells, via enhancing miR-21-mediated Cdc25A degradation [192]. Meanwhile,
DIM treatment markedly increased the portion of cells in G1 phase through Sp1/Sp3-induced activation
of p21 expression [193]. The upstream events leading to DIM-induced p21 overexpression were further
studied, and results showed that DIM could act as a strong mitochondrial H+-ATP synthase inhibitor.
Hyperpolarization of mitochondrial inner membrane was induced by DIM treatment, which decreased
cellular ATP level and markedly promoted mitochondrial ROS production, and in turn induced
p21Cip1/Waf1 expression [194]. Besides, DIM lowered the invasive and metastatic potential of breast
cancer cells through downregulation of CXCR4 and CXCL12 [195]. In addition, survivin was found
to be another target of cell growth inhibition and apoptosis induced by DIM in MDA-MB-231 breast
cancer cells [196]. Like I3C, DIM could also stimulate the expression and secretion of IFNγ in MCF-7
cells through the activation of JNK and p38 pathways [197].
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Figure 3. Signaling pathways involved in DIM-induced apoptosis in breast cancer cells.
4.2. Other Vegetables
It is reported that the extract of red beetroot (Beta vulgaris L.) exhibited a dose-dependent cytotoxic
effect on MCF-7 cells in vitro [198]. Besides, a randomized study pointed out that daily intake of
8 ounces of fresh Balero or BetaSweet orange carrot juice increased plasma level of total carotenoid
by 1.65 and 1.38 μM respectively in overweight breast cancer survivors. This increase in total plasma
carotenoids was inversely associated with the level of 8-iso-PGFα, which was used as an oxidative
stress marker (OR: 0.13; 95% CI = 0.20–0.75). These results indicated that daily intake of fresh carrot
juice might benefit patients with breast cancer [199].
Collectively, cruciferous vegetables have shown a potential role in the prevention and treatment
of breast cancer, and the main bioactive components are isothiocyanates (including BITC, PEITC,
SFN), indole-3-carbinol and its metabolite 3,3′-diindolylmethane. The underlying mechanisms mainly
include down-regulating ERα and repressing ER signaling, inducing apoptosis and cell cycle arrest,
and inhibiting the metastasis of breast cancer cells.
5. Spices
Spices have been widely used in folk medicines and as food flavorings for a long time. In recent
years, several spices and their bioactive constituents, such as gingerols and shogaols in ginger,
organosulfur components in garlic, and thymoquinone in black cumin, have been suggested to
possess anti-breast cancer activity.
5.1. Ginger
Ginger (Zingiber officinale) is a commonly used spice around the world for dietary and medicinal
purpose since ancient period. Ginger has shown anti-breast cancer effect in recent researches.
For instance, methanolic extract of ginger exhibited inhibitory effect on the proliferation and colony
formation in MDA-MB-231 cells dose- and time-dependently [200]. Ginger extract also induced
apoptosis in MCF-7 and MDA-MB-231 cells, via up-regulation of Bax, and downregulation of Bcl-2
proteins, NF-κB, Bcl-X, Mcl-1, survivin, cyclin D1 and CDK-4. Besides, the expression of c-Myc
and hTERT, the two prominent molecular targets of cancer, was inhibited by ginger extract [201].
The anti-breast cancer property of ginger might be attributed to the bioactive constituents in ginger,
such as gingerols and shogaols.
Gingerols showed inhibition on the proliferation and metastasis of breast cancer cells [202,
203]. 10-Gingerol inhibited proliferation of MDA-MB-231 through inhibition on cyclin-dependent
kinases and cyclins, leading to a G1 phase arrest. Invasion of cancer cell was also inhibited by
10-gingerol through suppression of Akt and p38 (MAPK) activity [202]. Besides, 6-gingerol exerted
a concentration-dependent inhibition on migration and motility of MDA-MB-231 cells, accompanied
with a decreased of expression and activities of MMP-2 and -9 [203].
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Shogaols also inhibited metastasis of breast cancer cells through different mechanisms [204,205].
6-Shogaol reduced expression of MMP-9 via blockade of NF-κB activation, leading to an inhibited
invasion of MDA-MB-231 cells [204]. Besides, 6-shogaol inhibited invadopodium formation by
decreasing levels of c-Src kinase, cortactin, and MT1-MMP, which are key modulators of invadopodium
maturation, thereby inhibiting invasion of MDA-MB-231 cells [205]. Besides, 6-shogaol could inhibit
the growth and sustainability of spheroid generated from adherent breast cancer cells. This effect
was through γ-secretase-mediated downregulation of Notch signaling and induction of autophagic
cell death [206]. 6-Dehydrogingerdione is also an active constituent of dietary ginger, and induced
apoptosis and cell cycle arrest in G2/M phase in MCF-7 and MDA-MB-231 cells through mediation of
ROS/JNK pathways [207].
Furthermore, several clinical studies suggested a beneficial effect of ginger on patients with
breast cancer. In patients receiving oral supplement of ginger, nausea severity and the number of
vomiting episodes were significantly reduced than those of control group [208]. Besides, a single-blind,
controlled, randomized cross-over study revealed that breast cancer patients who received ginger
essential oil inhalation showed significantly lower nausea scores during acute phase, but no significant
difference in overall treatment effect. Besides, ginger aromatherapy improved the baseline for global
health status and appetite loss, while the vomiting was not improved [209].
5.2. Garlic
Garlic (Allium sativum) as a spice has been used worldwide. Meanwhile, it has been used in
folk medicine to treat a variety of ailments [210]. A recent case-control study suggested that high
consumption of certain Allium vegetables, especially garlic, is associated with a decreases risk of breast
cancer, with adjusted ORs of 0.41 (95% CI = 0.20–0.83) [211]. Experimental studies indicated that the
anti-breast cancer property of garlic might be attributed to organosulfur components, including diallyl
disulfide [212], diallyl trisulfide [213], S-allyl mercaptocysteine [214], and allicin [215].
Diallyl disulfide (DADS) is one of the major organosulfur compounds isolated from garlic oil,
and could induce apoptosis in MCF-7 breast cancer cells [216,217]. The pro-apoptotic effect might
be through inhibition of histone deacetylation [216] and inhibition of ERK and the activation of
the SAPK/JNK and p38 pathways [217]. Besides, DADS inhibited proliferation and metastasis of
human breast cancer [218,219]. The DADS treatment upregulated expression of miR-34a, which led to
inhibition on SRC expression and consequently triggered the blockade of the SRC/Ras/ERK pathway,
ultimately led to an inhibitory effect on the proliferation and metastasis of MDA-MB-231 cells [218].
The DADS treatment also inhibited growth and metastatic potential of TNBC cells through inactivation
of the β-catenin signaling pathway [219].
Diallyl trisulfide (DATS) also exhibited inhibitory effect on breast cancer by inducing apoptotic
cell death [220,221]. It induced apoptosis in both MCF-7 cells and tumor xenografts by overproduction
of ROS and subsequent activation of JNK and AP-1 [220]. The DATS also induced apoptosis in
MCF-7 cells through upregulating the expression level of FAS, cyclin B1, cyclin D1, Bax and p53,
and downregulating expression of Akt and Bcl-2 [221]. Furthermore, DATS inhibited migration and
invasion of TNBC cells, through inhibiting MMP2/9 by suppressing NF-κB and ERK/MAPK signaling
pathways [222]. Besides, a study indicated ERα might be a target of DATS in breast cancer cells, since
DATS inhibited the expression and activity of ERα in MCF-7 and T47D cells. Peptidyl-prolyl cis-trans
isomerase (Pin1) partially accounted for ERα protein suppression induced DATS treatment in MCF-7
cells [213]. Forkhead Box Q1 (FoxQ1) might be another novel target of DATS in breast cancer stem
cell [223]. Pharmacological concentrations of DATS (2.5 and 5 μM) induced a dose-dependent inhibition
on MCF-7 and SUM159 cells, which was associated with a decreased protein level of FoxQ1 [223].
S-allyl mercaptocysteine (SAMC), a water-soluble constituent derived from garlic, effectively
inhibited cell growth of MCF-7 and MDA-MB-231 cells, by inducing apoptosis and cell cycle arrest
in G0/G1 phase [214]. The mitochondrial apoptotic pathway was triggered by SAMC treatment, as
shown by upregulation of Bax, downregulation of Bcl-2 and Bcl-X-L, and activation of caspase-9 and
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caspase-3 [214]. Another major component of garlic, allicin, inhibited the invasion and metastasis
of MCF-7 cells induced by TNF-α, but not in MDA-MB-231 cells. The underlying mechanism was
through suppressing the VCAM-1 through inhibiting ERK1/2 and NF-κB signaling pathways and
increasing interaction between ERα and p65 [215].
5.3. Black Cumin
Black cumin (Nigella sativa) is a popular spice and has been used in folk medicine for over
1400 years. Recently, the anticancer effect of black cumin has attracted increasing attention. In a
study, a supercritical CO2 extract of black cumin exhibited pro-apoptotic and anti-metastatic effect on
MCF-7 cells in vitro [224]. Another study pointed out that the antiproliferative (IC50 = 62.8 μL/mL)
and pro-apoptotic effects of black cumin extract were through mediating both the p53 and caspase
pathways [225].
Thymoquinone (TQ) is the major bioactive component isolated from the seeds of Nigella sativa, and
has shown potent chemopreventive and chemotherapeutic activities [226]. Firstly, studies indicated
that TQ might be an Akt suppressor. Akt could be activated (phosphorylated) by PI3K, and promote
cell survival by inhibiting apoptosis through inactivating downstream targets, such as Bcl-2 family
member BAD and GSK-3β [227]. TQ induced cell cycle arrest and apoptosis in doxorubicin-resistant
MCF-7 cells [228], and in T-47D and MDA-MB-468 cells [229], all by inhibiting Akt phosphorylation.
TQ also inhibited tumor growth and induced apoptosis in mice bearing breast cancer xenograft, which
might be through inducing p38 phosphorylation via ROS generation [230]. Besides, studies indicated
that the antiproliferative effect of TQ on breast cancer might be through modulation of the PPAR-γ
activation pathway [231], and by mediating expression of COX-2 and production of prostaglandin E2
through PI3K/p38 kinase pathway [232].
5.4. Other Spices
Red chili peppers of the genus Capsicum are popular spice worldwide, and contained certain
amount of capsaicin (8-methyl-N-vanillyl-6-nonenamide), which has shown antiproliferative effect
on breast cancer cells [233–235]. Capsaicin treatment for 24 h induced apoptosis in MCF-7
cells dose-dependently in vitro through a caspase-independent pathway [233]. Besides, capsaicin
induced apoptosis in MCF-7 breast cancer cell, which was associated with inducing mitochondrial
dysfunction [234]. In another study, capsaicin inhibited growth and blocked migration of MCF-7,
MDA-MB231, T47D, SKBR-3 and BT-474 cell lines in vitro. In vivo, capsaicin decreased the volume of
breast tumors in mice by 50% without noticeable drug side effects, and suppressed the progression
of preneoplastic breast lesions by 80%. Mechanistically, these effects were through mediating the
EGFR/HER-2 pathway [235]. However, it should be noted that the role of capsaicin in cancer is
controversial. Some studies have indicated that capsaicin itself was mutagenic and promote tumor
formation, and might increase the cancer risk in humans [236–238].
Piperine is an alkaloid isolated from black pepper (Piper nigrum), and has been reported to have
anti-breast cancer activities. In a study, piperine exhibited growth, motility and metastasis inhibitory
effects on TNBC cells in vitro, and suppressed the growth of TNBC xenografts in immune-deficient
mice [239]. Another study found piperine induced cytotoxicity and apoptosis, and inhibited migration
of HER2-overexpressing breast cancer cells in vitro. Piperine significantly inhibited HER2 and FAS
expression, and downregulated EGF-induced MMP-9 expression via inactivation of AP-1 and NF-κB
through modulating ERK1/2, p38 MAPK and Akt signaling pathways [240]. Moreover, piperine
inhibited the growth of 4T1 cells (at doses of 35–280 pmol/L) time- and dose-dependently, and induced
apoptosis (at doses of 70–280 pmol/L) in a dose-dependent manner, accompanying activation of
caspase 3. Besides, injection of 5 mg/kg piperine dose-dependently inhibited the 4T1 tumor growth
and significantly suppressed the lung metastasis in vivo [241].
Saffron (Crocus sativus), a well-known spice, is widely used in the Mediterranean, Indian and
Chinese diet [242]. Saffron has showed anticancer effect in several studies, which was attributed
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to its bioactive compounds, such as crocin and crocetin [243,244]. According to an in vitro study,
incubating the highly invasive MDA-MB-231 cells with crocetin (1 and 10 μM) significantly inhibited
proliferation and invasion of cancer cells, and the effect was through downregulation of MMP
expression [243]. Besides, a study found that crocin and crocetin both inhibited the incidence
of N-methyl-N-nitrosourea (NMU)-induced breast tumors in rats. Moreover, crocetin was found
to be a more effective chemopreventive agent than crocin at both the initiation and promotion
stages [244]. Clove (Syzygium aromaticum) is commonly used as a spice and traditional Chinese
medicine [245]. Eugenol is the major contributor to the bioactivities of clove. A study indicated that
eugenol treatment inhibited the growth and proliferation of MCF-7 cells and induced apoptosis in vitro.
Besides, the level of intracellular glutathione was decreased and the level of lipid peroxidation was
elevated by eugenol treatment [246]. In another study, eugenol (2 μM) showed antiproliferative and
proapoptotic activity both in vitro and in xenografted human breast tumors, which was mediated
through targeting the E2F1/survivin pathway [247]. Besides, a supercritical fluid extract of rosemary
(Rosmarinus officinalis) exhibited inhibitory effect on breast cancer cells through mediation of ERα
and HER2 signaling pathways [248]. Wasabi (Wasabia japonica) is a popular spice in Japan. In a
study, 6-(methylsulfinyl)hexyl isothiocyanate derived from wasabi exhibited proapoptotic effect on
mice inoculated with MDA-MB-231 cells by inhibiting NF-κB and thus regulating the PI3K/AKT
pathway [249]. Besides, coriander, a common culinary spice, has been reported for its health promoting
effects. The coriander root extract exerted cytotoxicity on MCF-7 cells by affecting antioxidant enzymes,
inducing G2/M phase arrest and apoptotic cell death, which was associated with death receptor and
mitochondrial apoptotic pathways [250]. It should be noted that the turmeric and its main bioactive
component curcumin are not discussed in this section because their effects on breast cancer have been
extensively reviewed [251–254].
Collectively, ginger, garlic and black cumin have shown the most promising anti-breast cancer
effects among various spices. More attention has been paid to the effects of bioactive components
in spices, such as gingerols and shogaols in ginger, diallyl disulfide and diallyl trisulfide in garlic.
However, some adverse results have also been reported, such as the cancer-promoting effect of
capsaicin isolated from red chili peppers.
6. Edible Macro-Fungi
Several kinds of edible macro-fungi have shown inhibitory effect on breast cancer, such as
Antrodia camphorate, oyster mushroom (Pleutorus eous), and lingzhi mushroom (Ganoderma lucidum).
In a case-control study conducted among Korean women, a significant inverse association between
mushroom consumption and breast cancer incidence was found in postmenopausal women (OR = 0.17,
95% CI = 0.05–0.54, trend p = 0.0037 for average frequency; OR = 0.16, 95% CI = 0.04–0.54, trend
p = 0.0058 for daily intake). No significant association was found in premenopausal women [255].
Besides, according to a meta-analysis with 7 observational studies included, mushroom intake might
be inversely associated with risk of breast cancer (RR = 0.94, 95% CI = 0.91–0.97 for postmenopausal
women; RR = 0.96, 95% CI = 0.91–1.00 for premenopausal women) [256].
Antrodia camphorate is a medicinal mushroom widely used in Taiwan [257]. Methyl antcinate
A (MAA) is an ergostane-type triterpenoid isolated from the fruiting bodies of A. camphorate. MAA
suppressed the population of cancer stem-like cells in MCF-7 cell line through inhibiting Hsp27
expression and increasing expression of p53 and IκBα [257]. Besides, a polysaccharide (SP1) with
a molecular weight of 56 kDa was isolated from the fruiting body of mushroom Huaier (Trametes
robiniophila Murr.). SP1 induced apoptosis in MCF-7 cells through downregulation of metadherin,
which was overexpressed in most cancers [258]. Furthermore, an acidic polysaccharide, isolated from
Pleurotus abalonus fruiting body, showed antiproliferative and proapoptotic effect on MCF-7 cells
via ROS-mediated mitochondrial apoptotic pathway [259]. Treatment of this polysaccharide caused
reduction in mitochondrial membrane potential, activation of caspase-9/3, increase of Bax/Bcl-2
ratio, overproduction of intracellular ROS, and degradation of PARP [259]. In addition, spores and
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unpurified fruiting body of Ganoderma lucidum inhibited invasion of MDA-MB-231 cells via inhibiting
the expression of uPA and uPA receptor as well as the secretion of uPA [260]. The crude extract of
Ganoderma lucidum fruiting body also caused both apoptosis and necrosis in estrogen-independent
cell line, MDA-MB-435 [261]. Additionally, the aqueous extract of white button mushroom
(Agaricus bisporus) dose-dependently suppressed the aromatase activity in MCF-7aro cells, which
is an aromatase-transfected breast cancer cell line [262]. Besides, polysaccharides (50–250 μg/mL)
isolated from oyster mushroom (Pleutorus eous) suppressed angiogenesis by downregulating VEGF,
and induced apoptosis in MCF-7 cells through ROS-dependent JNK activation and mitochondrial
mediated mechanisms [263].
Collectively, the anti-breast cancer effects of edible macro-fungi are mainly attributed to the
polysaccharides with different molecular weights. Several mechanisms have been found to explain the
anti-breast cancer effects of edible macro-fungi, such as inhibiting proliferation, inducing apoptosis
and suppressing angiogenesis.
7. Cereals
Cereals are consumed worldwide, and rich in dietary fiber. A systematic review and meta-analysis
of the evidence from prospective studies indicated an inverse association between cereal fiber
intake and breast cancer risk (summary RR for the highest versus the lowest intake was 0.96,
95% CI = 0.90–1.02, I2 = 5%) [264].
Sorghum (Sorghum bicolor) is a primary cereal food in some parts of the world [265]. A study
showed that sorghum suppressed tumor growth, induced cell cycle arrest, and inhibited metastasis
via the Jak2/STAT pathway in nude mice bearing breast cancer xenografts [266]. Furthermore,
3-deoxyanthocyanin extracted from red sorghum bran exhibited cytotoxicity on MCF-7 cells with
a CTC50 value of 300 μg/mL, and induced apoptosis mediated by upregulating the p53 gene and
downregulating the Bcl-2 gene [267].
Barley (Hordeum vulgare L.) is widely consumed worldwide. A study showed that young barley
(the grass of the barley plant) exhibited significant antiproliferative and proapoptotic activities in
rat breast tumor model and in human breast cancer cells in vitro [268]. Wheat (Triticum aestivum) is
a common kind of cereal, and contains rich nutritional constituents, such as starches and proteins
(mainly in the endosperm), vitamins, minerals, phytochemicals and fibre (mainly in the wheat grain).
A study showed that germinated wheat flour inhibited the growth of MCF-7 and MDA-MB-231 cells
and induced apoptosis in vitro [269].
Collectively, sorghum, barley and wheat have shown the potential to inhibit the growth of breast
cacer cells, mainly through inducing apoptosis and cell cycle arrest, and inhibiting metastasis.
8. Synergistic Effects of Dietary Natural Products with Anticancer Therapies
At present, chemotherapy and radiotherapy are frequently used in cancer treatment, but they
are often accompanied with certain toxic adverse effects and drug resistance, which are common
causes of chemotherapy failure and disease recurrence. Some dietary products and their bioactive
components have shown synergistic effects with chemotherapy or radiotherapy, through enhancing
their therapeutic effect or reducing side effects. For instance, combination of genistein and doxorubicin
exerted a synergistic effect on MCF-7/Adr cells through stimulating the intracellular accumulation
of doxorubicin and suppressing HER2/neu expression [270]. Besides, combination of genistein and
centchroman (a selective estrogen receptor modulator) showed significantly higher cytotoxicity in
human breast cancer cell lines compared to each drug used alone, and the nontumorigenic human
mammary epithelial cell remained unaffected [271]. Moreover, equol enhanced the anticancer efficacy
of tamoxifen in MCF-7 cells through inducing caspase-mediated apoptosis [272]. Equol could also be
a potent radiosensitizer in both ER+ and ER− human breast cancer cells. It might be because equol
enhanced cell death following irradiation and increased the DNA damage induced by remaining
radiation, thereby reducing the surviving fraction of irradiated cells [273]. Furthermore, pomegranate
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extract enhanced tamoxifen-induced inhibition on cell viability of both sensitive and TAM-resistant
MCF-7 cells by inducing cell death [274]. Meanwhile, DIM acted synergistically with Paclitaxel to
inhibit growth of HER2/Neu human breast cancer cells via mediating the Her2/neu receptor and the
downstream target ERK1/2. The cotreatment of DIM and Paclitaxel also enhanced apoptosis through
the mitochondrial pathway (Bcl-2/PARP) [275]. Furthermore, DIM sensitized multidrug-resistant
human breast cancer cells to γ-irradiation, judging from that G2/M phase cell cycle arrest was
induced, intracellular ROS generation was increased and radiation-induced apoptosis was enhanced
by DIM treatment (20 and 30 μM, 2 h before irradiation) [276]. Besides, the inactivation Akt/NF-κB
signaling induced by DIM also contributed to sensitization of breast cancer cells to Taxotere-induced
apoptosis [277]. TQ could also enhance the efficacy of other antitumor agents. Combination treatment
of TQ and tamoxifen synergistically reduced cells viability and induced apoptosis in both ER+ MCF-7
and ER- MDA-MB-231 cell lines in vitro [278]. Besides, a TQ-Paclitaxel combination treatment inhibited
breast cancer growth in cell culture and in mice, through the interplay with apoptosis network [279].
Furthermore, piperine could enhance the efficacy of TRAIL-based therapies for TNBC cells, possibly
through the inhibition of survivin and activation of p65 phosphorylation [280]. Moreover, piperine
sensitized TNBC cells to the cytotoxicity induced by gamma radiation [239]. In addition, a supercritical
fluid extract of rosemary enhanced the therapeutic effect of 3 anti-breast cancer agents, tamoxifen,
trastuzumab, and Paclitaxel [248]. Rice bran is one of the byproducts of rice milling. A team found
that a modified arabinoxylan from rice bran increased the sensitivity of MCF-7 and HCC70 breast
cancer cells to daunorubicin through enhancing the accumulation of daunorubicin in cancer cells [281].
Later, they found that the modified arabinoxylan was also an effective chemosensitizer to Paclitaxel,
as evidenced by increased susceptibility of MCF-7 and 4T1 cells to Paclitaxel by over 100 folds.
Mechanistically, the synergistical effects were through enhancing apoptosis and DNA damage, and
inhibiting cell proliferation [282]. Furthermore, a study showed that wheat grass juice (squeezed
from the mature sprouts of wheat seeds) taken by breast cancer patients during FAC chemotherapy
(5-fluorouracil, doxorubicin, and cyclophosphamide combination) could reduce myelotoxicity and the
dose, without decreasing efficacy of the chemotherapy [283].
Finally, the epidemiological and experimental studies on dietary natural products for the
prevention and treatment of breast cancer are summarized in Tables 1 and 2, respectively. In addition,
some effects of dietary natural products against breast cancer and possible mechanisms are shown in
Figure 4.
Figure 4. Mechanisms involved in the anti-breast cancer action of dietary natural products.
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Table 1. Epidemiological studies on association between natural product intake and breast cancer.
Natural
Product
Study Type Subject Outcome Association Ref.
soy cohort study 70,578 Chinese women aged
40–70 years BC risk
overall: HR = 0.78, 95% CI = 0.63–0.97,
premenopausal women: HR = 0.46;
95% CI: 0.29–0.74),
[45]ER+/PR+ postmenopausal women:
HR = 0.72; 95% CI = 0.53–0.96
ER-/PR− premenopausal women:
HR = 0.46; 95% CI = 0.22–0.97
soy cohort study
15,607 Japanese women
aged 35 or above BC risk
postmenopausal women:
[46]
trend p = 0.023 for soy consumption;
trend p = 0.046 for isoflavone
consumption
soy prospective study 649 Chinese women with BC
BC death HR = 0.71, 95% CI = 0.52–0.98
[47]BC prognosis ER+ patients: HR = 0.59, 95% CI =0.40–0.93
soy cohort study
affected BC patients and




HR = 0.39; 95% CI = 0.19– 0.79 [48]
soy cohort study 9514 BC survivors risk of recurrence HR = 0.75; 95% Cl = 0.61–0.92 [30]
soy cohort study 3842 multiethnic women
all-cause mortality
no significant association [50]BC specific
mortality
soy cohort study 84,450 multiethnic womenwith BC BC risk no significant association [51]
soy cohort study 339 Korean women with BC risk of recurrence no significant association [52]
Citrus fruits meta-analysis 8393 participants: 3789 casesand 4,705 controls BC risk OR = 0.90; 95% CI = 0.85–0.96; p < 0.001 [112]
cruciferous
vegetables meta-analysis 18,673 BC cases BC risk RR = 0.85, 95% CI = 0.77–0.94 [150]
garlic case-controlstudy
285 Iranian women aged




362 women aged 30–65
years with BC BC risk
postmenopausal women:
[255]
for daily intake, OR=0.16, 95% CI =
0.04-0.54, p= 0.0058;
for average frequency, OR = 0.17, 95%
CI = 0.05–0.54, p = 0.0037
mushroom meta-analysis 6890 BC cases BC risk
premenopausal women:
[256]
RR = 0.96, 95% CI = 0.91–1.00;
postmenopausal women:
RR = 0.94, 95% CI = 0.91–0.97
BC, stands for breast cancer.
Table 2. The in vitro and in vivo effects of dietary natural products against breast cancer.
Natural Product Constituents Study Type Main Effect and Possible Mechanism Ref.
Soy
soy genistein in vitro
- inducing cell cycle arrest,
- improving mitochondrial functionality,
- regulating oxidative stress, uncoupling
proteins, antioxidant enzymes and sirtuin,
- enhancing effects of anticancer drugs
[58–60]
soy genistein in vivo reducing breast cancer incidence in ahigh-oestrogen environment [61]
fermented
doenjang NA in vitro
inducing cell cycle arrest, proliferation
inhibition, and apoptosis [64]
soy genistein in vitro
inducing apoptosis through:
- downregulation of the cancerous inhibitor of
protein phosphatase 2A
- the inactivation of the IGF-1R/p-Akt signaling
pathway
[65,66]
soy 6,7,4′-trihydroxyisoflavone in vitro inducing apoptosis and cell cycle arrest at S-and G2/M phases
[67]
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Table 2. Cont.
Natural Product Constituents Study Type Main Effect and Possible Mechanism Ref.
soybean NA in vitro
inducing cell death via activation of caspase-3
and upregulation of proapoptotic molecule
expression
[68]
soy genistein in vitro inhibiting DNA methylation and increasingexpression of tumor suppressor genes [69]
soy genistein in vitro
inhibiting cancer cell growth through
modulating the DNA damage response and
cell cycle
[70]
soy genistein in vitro
inhibiting cancer cell growth through
inhibiting activity of NF-κB via the Nocth-1
signaling pathway
[71]
soy genistein in vitro and in vivo decreasing breast cancer stem-like cellpopulation through Hedgehog pathway [72]
soy daidzein, equol in vitro inhibiting the invasion through thedown-regulation of MMP-2 expression [63]
Fruits
pomegranate NA in vitro inhibiting growth by inducing cell cycle arrestin G2/M and inducing apoptosis
[91]
pomegranate NA in vivo
preventing mammary tumorigenesis via
concurrent disruption of ER and Wnt/-catenin
signaling pathways
[92]
pomegranate luteolin, ellagic acid,punicic acid in vitro
inhibiting growth, increasing adhesion and
decreasing migration of breast cancer cells [94]
pomegranate NA in vitro and in vivo
showing cytotoxicities by targeting
microRNAs155 and 27a, reducing cell







inhibiting invasion and motility of cancer cells
by inhibiting RhoC and RhoA protein
expression
[97]
pomegranate ellagitannin-derivedcompounds in vitro
inhibiting aromatase activity and cell
proliferation [98]
pomegranate NA in vitro inhibiting the cancerous lesion formation [99,100]
mangosteen NA in vitro inhibiting proliferation and inducing apoptosis [101]





in vitro dose-dependent anti-aromatase activity [104]
mangosteen α-mangostin in vitro
inducing apoptosis through modulating
HER2/PI3K/Akt and MAPK signaling
pathways
[105]
mangosteen α-mangostin in vitro inducing mitochondria-mediated apoptosisand cell cycle alterations [106]
mangosteen α-mangostin in vitro showing cytotoxicities [107]
mangosteen α-mangostin in vitro inhibiting FAS expression and activity, andinducing apoptosis [108]
mangosteen α-mangostin in vitro inducing apoptosis and decreasing theexpression of ER alpha and pS2 [109]
mangosteen α-mangostin in vivo
increasing survival rates and suppressing
tumor volume and the multiplicity of lymph
node metastases [110]
in vitro inducing apoptosis and cell cycle arrest
mangosteen panaxanthone in vivo
suppressing tumor volumes and decreasing the
multiplicity of lung metastasis and lymph node
metastasis [111]
in vitro inducing apoptosis
Citrus fruit polysaccharides in vitro inhibiting angiogenesis and cell migration [113]
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Table 2. Cont.
Natural Product Constituents Study Type Main Effect and Possible Mechanism Ref.
Citrus fruit NA in vitro inducing apoptosis [114]
Citrus fruit NA in vitro
inducing apoptosis via upregulating the
expression of bax and caspase-3 genes and
downregulating the expression of bcl-2 gene
[115]
Citrus fruit naringin
in vitro inhibiting growth potential by targeting
β-catenin pathway [116]
in vivo
inhibiting cell proliferation and promoting cell
apoptosis and G1 cycle arrest through
modulating β-catenin pathway
Citrus fruit hesperidin in vitro anti-proliferative effect [117]
apple flavonoids in vitro inhibiting growth and inducing apoptosis [118]
apple polyphenol in vitro
inhibiting tumorigenesis of pre-neoplastic cells
by suppressing colony formation and ERK1/2
phosphorylation
[119]
apple NA in vitro inhibiting proliferation and inducing cell cyclearrest at G1 phase
[120]
apple 2α-hydroxyursolic acid in vitro inhibit NF-κB activation through suppressingthe proteasomal activities
[121,
122]
apple 2α-hydroxyursolic acid in vitro
antiproliferative and pro-apoptotic effect by
regulating the p38/MAPK signal transduction
pathway
[123]
apple pectic acid in vitro inducing apoptosis and inhibiting cell growth [124]
in vivo preventing tumor metastasis mice viaover-expression of P53
apple NA in vitro enhancing the anti-proliferative effect ofquercetin 3-beta-D-glucoside [125]
grape polyphenols in vivo inhibiting the lungs metastasis [126]
in vitro inhibiting migration by blocking the PI3k/Aktand MAPK pathways
grape NA in vitro suppressing migration and invasion [127]
grape polyphenols in vitro
inducing membrane damage, disrupting
mitochondrial function and inducing G2/M
cell cycle arrest
[128]
grape amurensin G in vitro inhibiting VEGF production [129]
grape anthocyanin in vitro
decreasing invasion, migration and bone
turnover, via inhibiting expression of Snail and
phosphorylated STAT3 and abrogating
Snail-mediated CatL activity
[130]
mango polyphenolics in vitro showing cytotoxic effects [131]
in vivo reducing the tumor volume by regulating thePI3K/AKT pathway and miR-126
mango polyphenols in vitro inhibiting cell viability [132]
mango NA in vitro inducing apoptosis via the activation ofoxidative stress
[133,
134]
mango pyrogallol in vitro inhibiting proliferation through mediating theAKT/mTOR signaling pathway [135]
jujube triterpenic acids in vitro inducing apoptotic cell death [137]
jujube betulinic acid in vitro inducing apoptosis through the mitochondriatransduction pathway [138]
jujube NA in vitro inhibiting proliferation and inducing apoptosis [139]
strawberry NA
in vitro showing cytotoxic effects
[140]
in vivo inhibiting the proliferation of tumor cells byactivating apoptosis
bilberry NA in vitro inhibiting proliferation and inducing apoptosis [141]
jamun fruit NA in vitro inhibiting proliferation and inducing apoptosis [142]
cranberry NA in vitro inducing apoptosis and G1 phase arrest [143]
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Table 2. Cont.
Natural Product Constituents Study Type Main Effect and Possible Mechanism Ref.
peach polyphenolics in vivo
suppressing tumor growth and lung metastasis
by inhibition of metalloproteinases gene
expression
[144]
plum phenolics andcondensed tannins in vitro inducing apoptosis [145]
quince fruit NA in vitro inhibiting proliferation and invasiveness [146]
graviola fruit NA
in vitro inhibiting the growth of cancer cells
[147]
in vivo inhibiting tumor growth by 32% (p < 0.01)through the EGFR/ERK signaling pathway
litchi fruit NA
in vitro inhibited cell growth
[148]in vivo reducing tumor mass volume






inducing apoptosis which was associated with:
- inhibition of mitochondrial fusion
- suppression of XIAP expression
- generation of ROS
[155–
157]
in vitro and in vivo
suppressing the invasion and migration
involving:
- suppression of uPA activity and of Akt
signaling
- suppression on EMT process
[158,
160]
in vitro and in vivo
- inducing FoxO1-mediated autophagic death,
- acting against the oncogenic effects of leptin,
- suppressing proliferation and
neovascularization,






isothiocyanate in vitro and in vivo
- inducing apoptosis,
- suppressing adhesion, aggregation, migration
and invasion,
- prolonging the tumor-free survival and
reducing the tumor incidence,




vegetables sulforaphane in vitro and in vivo
- downregulating ER-α expression,
- inducing apoptosis,
- inhibiting metastasis,
- activating tumor suppressor Egr1,
- downregulating telomerase,






in vitro and in vivo
suppressing metastasis through
- up-regulation of BRCA1 and
E-cadherin/catenin complexes
- suppressing EMT process and
downregulating FAK expression
- inhibition on MMP-2 expression
- inhibiting CXCR4 and MMP-9 expression by




in vitro and in vivo
- regulating the cell cycle progression
- downregulating expression of telomerase gene
- inducing apoptotic cell death
- suppressing the expression of IGF1R and IRS1
- inducing stress fibers and focal adhesion
formation







- inactivation of Akt and NF-κB activity




- inducing cell cycle arrest
- lowering the invasive and metastatic potential




red beetroot betanin in vitro showing a dose-dependent cytotoxic effect [198]
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Natural Product Constituents Study Type Main Effect and Possible Mechanism Ref.
Spices
ginger NA in vitro inhibiting the proliferation and colonyformation [200]
ginger NA in vitro inducing apoptosis and inhibiting expressionof c-Myc and hTERT [201]
ginger 10-gingerol in vitro inhibiting proliferation and metastasis,inducing cell cycle arrest [202]
ginger 6-gingerol in vitro inhibiting metastasis by suppressing MMP-2and -9. [203]
ginger 6-shogaol in vitro
inhibiting invasion by reducing MMP-9
expression via blockade of NF-κB activation [204]
inhibiting invasion by suppressing
invadopodium formation and MMP activity [205]
inhibiting growth and sustainability of
spheroid generated from adherent breast
cancer cells
[206]
ginger 6-dehydrogingerdione in vitro inducing apoptosis and cell cycle arrest inG2/M phase
[207]
garlic diallyl disulfide in vitro
inducing apoptosis though:
- inhibition of histone deacetylation
- inhibition of ERK and the activation of the
SAPK/JNK and p38 pathways
[216,
217]
in vitro and in vivo
inhibit proliferation and metastasis via:
- suppression of the SRC/Ras/ERK pathway




garlic diallyl trisulfide in vitro and in vivo
inducing apoptosis though:
- overproduction of ROS and subsequent
activation of JNK and AP-1
- upregulating FAS, Bax and p53, and




- inhibiting migration and invasion;
- inhibiting ER-α
- decreasing protein level of FoxQ1
[213,222,
223]
garlic S-allylmercaptocysteine in vitro
inducing mitochondrial apoptosis and cell
cycle arrest [214]
garlic allicin in vitro inhibiting invasion and metastasis [215]
black cumin extracts in vitro inducing apoptosis and inhibiting metastasis [224,225]
black cumin thymoquinone
in vitro and in vivo
inducing apoptosis through:
- inhibiting Akt phosphorylation




in vitro inhibiting proliferation by modulation of thePPAR-γ activation pathway [231]
in vitro regulating COX-2 and E2 [232]
red chili pepper capsaicin in vitro and in vivo - inducing apoptosis- inhibiting growth and migration
[233–
235]
black pepper piperine in vitro and in vivo
- inhibiting growth, motility and metastasis
- inducing apoptosis
- suppressing the lung metastasis
[239–
241]
saffron crocetin in vitro inhibiting proliferation and invasion, throughdecreasing MMP expression [243]
clove eugenol in vitro and in vivo
inhibiting growth and proliferation, inducing




rosemary extracts in vitro exerting antitumor activity through mediationof ER-α and HER2 signalings [248]
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wasabi 6-(methylsulfinyl)hexylisothiocyanate in vivo
inducing apoptosis by inhibiting NF-κB and
regulating the PI3K/AKT pathway [249]
coriander root extract in vitro affecting antioxidant enzymes, inducing G2/Mphase arrest and apoptosis [250]
Edible Macro-Fungi
Antrodia
camphorate methyl antcinate A in vitro
suppressing the population of cancer stem-like
cells [257]
Trametes
robiniophila Murr. polysaccharides in vitro
induced apoptosis through down-regulation of
metadherin [258]
Pleurotus abalonus polysaccharides in vitro
inhibiting antiproliferation and inducing






inhibiting invasion via inhibiting the
expression of uPA and uPA receptor [260]
causing both apoptosis and necrosis [261]
Agaricus bisporus extracts in vitro suppressing the aromatase activitydose-dependently [262]
Pleutorus eous polysaccharides in vitro inhibiting angiogenesis and inducing apoptosis [263]
Cereals
Sorghum extracts in vivo
suppressing tumor growth, inducing cell cycle
arrest, and inhibiting metastasis [266]
3-deoxyanthocyanin in vitro inducing apoptosis by upregulating the p53gene and downregulating the Bcl-2 gene [267]
barley extracts in vitro and in vivo exerting antiproliferative and pro-apoptoticactivities [268]
wheat germinated wheatflour in vitro inhibiting growth and inducing apoptosis [269]
9. Conclusions
The intake of some dietary natural products, such as soy, citrus fruits, cruciferous vegetables and
mushrooms, is suggested to be inversely correlated with the risk of breast cancer by epidemiological
studies. Furthermore, experimental studies also indicated that many dietary natural products
could be potential sources for prevention and treatment of breast cancer. The following natural
products and the corresponding bioactive components are noteworthy, including soy (genistein
and daidzein), pomegranate (ellagitannins), mangosteen (mangostin), citrus fruits (naringin), apple
(2α-hydroxyursolic), grape, mango, cruciferous vegetables (isothiocyanates), ginger (gingerols and
shogaols), garlic (organosulfur compounds), black cumin (thymoquinone), edible macro-fungi
(polysaccharides), and cereals. The anti-breast cancer effects of these natural products involve various
mechanisms of action, such as inhibiting proliferation, migration, metastasis and angiogenesis of
tumor cells, inducing apoptosis and cell cycle arrest, and sensitizing tumor cells to radiotherapy and
chemotherapy. In the future, more anti-breast cancer bioactive compounds should be isolated and
identified from dietary natural products, and more efforts should be made to assess the underlying
mechanisms, potential toxicity and adverse effects. Moreover, the clinical efficacy of dietary natural
products and their bioactive components on breast cancer patients needs to be further studied.
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breast cancer; TNF-α: tumor necrosis factor α; TQ: thymoquinone; TRAIL: TNF related apoptosis inducing
ligand; uPA: urokinase-type plasminogen activator; VCAM-1: vascular cell adhesion molecule 1; VEGF: vascular
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Abstract: Several randomized controlled trials (RCTs) and meta-analyses support the benefits
of flavanols on cardiometabolic health, but the factors affecting variability in the responses to
these compounds have not been properly assessed. The objectives of this meta-analysis were to
systematically collect the RCTs-based-evidence of the effects of flavanol-containing tea, cocoa and
apple products on selected biomarkers of cardiometabolic risk and to explore the influence of various
factors on the variability in the responses to the consumption of these products. A total of 120 RCTs
were selected. Despite a high heterogeneity, the intake of the flavanol-containing products was
associated using a random model with changes (reported as standardized difference in means (SDM))
in body mass index (−0.15, p < 0.001), waist circumference (−0.29, p < 0.001), total-cholesterol (−0.21,
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p < 0.001), LDL-cholesterol (−0.23, p < 0.001), and triacylglycerides (−0.11, p = 0.027), and with an
increase of HDL-cholesterol (0.15, p = 0.005). Through subgroup analyses, we showed the influence of
baseline-BMI, sex, source/form of administration, medication and country of investigation on some
of the outcome measures and suggest that flavanols may be more effective in specific subgroups such
as those with a BMI ≥ 25.0 kg/m2, non-medicated individuals or by specifically using tea products.
This meta-analysis provides the first robust evidence of the effects induced by the consumption
of flavanol-containing tea, cocoa and apple products on weight and lipid biomarkers and shows
the influence of various factors that can affect their bioefficacy in humans. Of note, some of these
effects are quantitatively comparable to those produced by drugs, life-style changes or other natural
products. Further, RCTs in well-characterized populations are required to fully comprehend the
factors affecting inter-individual responses to flavanol and thereby improve flavanols efficacy in the
prevention of cardiometabolic disorders.
Keywords: flavanols; tea; cocoa; apple; cardiometabolic disorders; meta-analysis; interindividual
variability; blood lipids; body mass index; waist circumference
1. Introduction
Metabolic disorders, principally, abdominal obesity, dyslipidemia (high levels of triacylglycerides
(TAGs) and low levels of high-density lipoprotein (HDL)), and insulin resistance have been associated
to an increased risk of Type-2 diabetes mellitus (DM) and cardiovascular diseases (CVDs). CVDs remain
the number one cause of death in developed countries and their prevalence is increasing rapidly
in developing nations and in adolescents [1]. It is now well established from population studies
that some aspects of CVDs risk can be modulated by various dietary interventions including an
increased consumption of plant foods [2], as part of a healthy balanced diet. In addition to other
protective compounds (i.e., fiber and vitamins), plant foods are an exclusive and abundant source
of phytochemicals, a large and diverse group of compounds which exhibit an array of biological
activities. The intake of these bioactive compounds are thought to contribute to the health benefits
associated with the consumption of such foods [3]. Polyphenols are some of the most abundant
phytochemicals in plant foods and increasing evidence from cohort studies indicate that the intake
of some of these compounds such as diverse flavonoids and/or, importantly, some of their derived
microbial metabolites (e.g., enterolactone) may help to reduce the development of CVDs and CVDs
mortality risk [4–7]. This evidence is supported by animal and clinical studies reporting beneficial
effects of the consumption of some polyphenol-rich foods or pure compounds on CVDs risk factors
such as blood cholesterol, blood pressure, endothelial function and arterial stiffness [8].
Polyphenols encompass several families of compounds, the most represented in plant foods
being phenolic acids and flavonoids [9]. A major group of flavonoids is constituted by flavanols that
are abundant in green tea, red wine, cocoa and various fruits such as apples [10]. A summary
of the major flavonoids present in tea (green and black), cocoa powder and apple is shown in
Table S1. The assessment of daily intakes of flavanols across Europe revealed a large variation
between countries (from 200 to 800 mg/day) depending on their dietary habits and the intake of
tea [11]. The flavanol group is composed primarily of the epicatechin and catechin monomers, and of
their oligomeric and polymeric forms, the procyanidins. Flavanol monomers and dimeric procyanidins
are bioavailable. They undergo extensive phase II conjugation and are found in the blood circulation
mostly as O-methylated, sulfated and glucuronidated conjugates (nM to μM range) [12,13]. In contrast,
the procyanidins polymers are not absorbed and do not contribute to the systemic pool of flavanols in
humans [14].
Human studies remain essential to understanding the effects of the plant bioactive compounds on
health and thus, an increasing number of randomized controlled trials (RCTs) with flavanol-containing
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products have been carried out over the past two decades. Meta-analyses constitute a useful tool to
integrate the accumulated RCTs and review the evidence in humans. Some of the main problems
affecting the results of meta-analyses are the usually limited number of studies included as well as
a range of factors that introduce heterogeneity in the findings. Identifying the factors underlying
variability, as well as developing new and innovative methodologies to account for such variability
constitute an overarching goal to ultimately optimize the beneficial health effects of plant food
bioactives. Among the potential factors involved in such heterogeneity are: (i) factors inherent
to the individuals: (epi) genetic factors, gut microbiota, baseline conditions (BMI, medication), sex,
health status, ethnicity, and age; and (ii) factors intrinsic to the type of study (design, duration, dose,
and type of product) [15].
The main goals of the present study were: (i) to systematically review and appraise, through
meta-analysis, the impact of flavanol-containing tea, cocoa and apple products, three main sources
of flavanols, on selected biomarkers of cardiometabolic risk, i.e., BMI, WC and blood lipid levels
(total-, LDL-, HDL-cholesterol and TAGs); and (ii) to further explore some of the factors that
may be implicated in the inter-individual variability in the response to the consumption of these
flavanol-containing products.
2. Materials and Methods
This systematic review and meta-analysis followed the PRISMA (Preferred Reporting Items
for Systematic Reviews and Meta-Analyses) statement guidelines [16], the Cochrane Handbook for
Systematic Reviews of Interventions [17], and the Centre for Reviews and Dissemination’s guidance for
undertaking reviews in health care [18]. The protocol for this review was registered in the International
Prospective Register of Systematic Reviews (PROSPERO, www.crd.york.ac.uk/prospero/index.asp)
with the registration number CRD42016033878.
2.1. Search Strategy
A comprehensive search on PubMed and Web of Science databases was conducted in July
2015. Search terms included a combination of keywords referring to: (1) bioactive (polyphenols,
flavonoids, flavanols, flavan-3-ol, (epi)catechin, (epi)gallocatechin gallate, theaflavins, thearubigin,
and procyanidin); (2) food source (apple, tea, and cocoa); (3) type of study and participants (trial,
experiment, study, intervention; human, subjects, men, women, patients, volunteers, and participants);
and (4) cardiometabolic outcomes (BMI, WC, total cholesterol, LDL cholesterol, HDL cholesterol, and
TAGs). No type of restriction was applied during the electronic searches.
2.2. Study Selection and Data Extraction
Two authors independently assessed all papers and in the case of disagreement, discussed findings
to reach a consensus, or in the absence of resolution, a third author was contacted. Studies included in
the meta-analysis were limited to human RCTs testing the effect of flavanol-containing tea, cocoa or
apple products, which had a control group receiving a placebo and measured one or more of the defined
outcomes (BMI, WC, total cholesterol, LDL cholesterol, HDL cholesterol, or TAGs). Manuscripts written
in any European language were included, whereas other manuscripts were excluded. Additionally,
the studies with the following characteristics were excluded: studies with flavanol-rich food sources
other than tea, cocoa or apples; and studies with multifactorial interventions (i.e., flavanols given as a
part of a multicomponent treatment; dietary or physical activity co-intervention). Data extraction was
performed in duplicate by two authors, independently, and cross-checked by a third author using a
standardized data extraction form. Extracted data included publication details (year of publication,
contact details, clinical trial and registration number); participant characteristics (geographical origin,
total number of participants included in the study and in the analysis, sex distribution, age, ethnicity,
health status, menopausal status, smoking habits, and use of medication); study setting and design
(cross-over or parallel design, duration of the intervention, number of arms and description, number
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of participants located in each arm and completing the study, composition of test and placebo, and
dose and mode of administration); and outcomes (type of sample, changes in the outcome, values
before and after intervention, and p-value).
2.3. Assessment of Quality and Data Analysis
The quality of the studies was assessed based on the Cochrane Collaboration measurement
with some modifications [19]. The specific items used for the assessments are detailed in a previous
meta-analysis following the same protocol [7].
Data for each outcome were analyzed using the Comprehensive Meta-Analysis Software,
version 3.0 (Biostat, Englewood, NJ, USA) [20]. The free scale index standardized difference in
means (SDM) was used to combine data from the highest number of collected valid studies, increasing
the pool of studies and the power to detect significant differences. SDM, standard error (SE) and
the corresponding 95% confidence intervals (CI) were calculated and pooled using random effects
models to determine test/placebo differences across studies. Statistical heterogeneity between studies
was assessed by using the Cochran Q test, the between-studies variance (T2) and I2 (an estimate
of the proportion of variance across studies caused by heterogeneity rather than by random errors)
where I2 values equal to 25%, 50% and 75% were considered as low, moderate and high heterogeneity,
respectively. Publication bias was assessed visually with funnel plots and statistically by applying
the Egger’s regression test. Further assessment of the possible associations between the overall
changes attributed to the supplementation with the flavanols and the duration of the intervention
was examined using random-effects meta-regression analysis. Using the random model, we have
additionally estimated the overall effect size as the difference in means (DM) and 95% CI.
Subgroup analyses were conducted to explore potential factors that may introduce heterogeneity
into the studies and influence the inter-individual variability in the response to supplementation
with the flavanol-containing products. We selected those factors that were more clearly described
throughout articles (Table 1). We included factors that might be attributed to some of the individuals’
characteristics, such as baseline BMI, sex, smoking habits and medication/health status. Age or
ethnicity could not be assessed due to unclear reporting. We also included stratification by the country
in which the study was carried out, the source and form of administration of the flavanols, as well
as the type of diet reported to be followed during the intervention. For each subgroup, the pooled
effects (SDM) and the significance of this value were estimated. Additionally, statistical comparisons
between subgroups were performed by applying a random-effects analysis and calculation of the
between-categories Q statistic, the p-value and the R2 index (proportion of between-studies variance
explained by each factor or covariate). Using some of the factors that partially explained some
of the between-studies variance for a particular variable, we applied a multiple meta-regression
analysis with a random-effects model to search for a potential combination of factors that best
explained the between-study variance for this variable. Statistical significance of the findings was
as follows: p-value < 0.05 was considered significant, while p-value ≥ 0.05 and < 0.1 was considered
marginally significant.
367
Nutrients 2017, 9, 746
Table 1. Potential factors influencing the heterogeneity in the responses to the supplementation with
flavanols-containing products investigated in this meta-analysis.
Factors


































Different disorders: overweight and/or obese,














(includes usual with some restrictions and NR)
a: BMI cut-off values as established by the WHO; b: Includes individuals specifically reported as healthy and
not medicated (in some cases medication was not reported, NR); c: Includes individuals not medicated that were
overweight and/or obese, or specifically indicated to be borderline, mild condition or at risk of a disease; d: Includes
individuals with one or more than one of the following disorders: dyslipidemia, glucose disorders or type-2 diabetes,
blood pressure disorders (hypertension), medicated obesity, metabolic syndrome (most cases were also medicated
but in some cases medication was NR); e: Individuals reported to have only one of the specified disorders.
3. Results
3.1. Description of the Included Studies
A total of 1409 articles were initially identified through the search on the electronic databases.
After removal of duplicates and screening, 188 trials were selected for data extraction. After detailed
analysis of the full text, 71 articles were excluded, due to lack of relevant outcomes, aspects of study
design or publication language. The final number of articles selected for meta-analysis was selected
from a total of 117 articles published between 1997 and July 2015 (included) [21–137]. The detailed
study selection flow diagram is shown in Figure 1.
Figure 1. Flow diagram showing the study selection process.
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3.2. Quality and Characteristics of the Selected Studies
Most of the studies (70%) were classified as studies with a moderate to low risk of bias (quality
score ≥5.0 and <8.0 or ≥8.0 and ≤10.0, respectively) while 30% of the studies obtained a low quality
score (<5.0) and were considered as a high risk of bias.
The studies were carried out in countries distributed over five continents: Asia (Japan, Korea,
China, Taiwan, Thailand, Saudi Arabia, and Iran), North America (USA and Canada) and Latin
America (Brazil and Mexico), Europe (Denmark, Finland, The Netherlands, Germany, Poland, UK,
Switzerland, Italy, Spain, Portugal, and Greece), Africa (Mauritania, South Africa, and Republic
of Mauritius), and Australia. Thus, they were considered representative of a global population.
The participants in these studies also represent a mixed population of men and women ranging
from young adults to elderly participants, and with a higher prevalence of individuals with a
BMI ≥ 25.0 kg/m2 (overweight and/or obese volunteers). The quality and depth of reporting of
the factors potentially contributing toward inter-individual variability of the effect of flavanols varied
among studies. The smoking habits were not reported in most studies but for those studies that did,
the participants were typically non-smokers or a mixed sample population. Only two studies [34,57]
were carried out specifically with smokers. The total sample population included healthy individuals,
overweight and/or obese individuals as well as individuals with an incipient or with a reported
chronic risk factor or metabolic disease, comprising principally hypertension, hyperlipidemias, type-2
diabetes, metabolic syndrome, atherosclerosis, coronary artery disease and heart failure. Among these,
some participants were taking medication, others were not medicated or medication use was not
reported. Studies were selected if the source of flavanols was tea, cocoa, or apple provided as liquid
(tea drinks, cocoa beverages, and apple juice) or solid (powder or extracts in capsules, snacks, tablets,
and foods) forms. Interventions ranged typically 1–6 months, during which participants followed
either a controlled diet or their habitual diets.
3.3. Overall Impact of the Supplementation with Flavanol-Containing Tea, Cocoa or Apple Products on Blood
Lipids, BMI and WC
The number of RCTs varied in function of the outcome measure studied, from 46 to 120 trials,
recruiting a total high number of participants ranging from 2875 to 5931 individuals. Forest
plots detailing weighted SDM, SE, 95% confidence intervals and relative weight for the impact of
supplementation with flavanol-containing tea, cocoa or apple products on BMI, WC, and blood lipid
levels are shown in Figures S1–S6. Visual inspection of the Funnel plots (Figures S7–S12) evidenced
symmetrical shapes and absence of publication bias in the case of WC, total cholesterol, LDL, HDL
and TAGs. Some asymmetry was however detected for BMI. These results were further confirmed
by Egger’s regression. A summary of the random overall effects for each lipid and obesity-related
variable, heterogeneity and bias analyses is presented in Table 2.
Table 2. Overall changes (SDM), heterogeneity and publication bias analyses for the impact of
flavanol-containing products on BMI, WC and blood lipids levels.





BMI 74 4156 2127 2029 −0.153 −0.227, −0.078 −4.009 <0.001 0.027 99.6 73 (0.021) 26.7 1.04 0.024
WC 46 2875 1478 1397 −0.293 −0.438, −0.147 −3.932 <0.001 0.168 156.7 45 (<0.001) 71.3 −1.47 0.101
TC 112 5812 2982 2830 −0.214 −0.328, −0.099 −3.651 <0.001 0.273 479.1 111 (<0.001) 76.8 −0.76 0.226
LDL-C 105 5726 2928 2798 −0.235 −0.345, −0.125 −4.171 <0.001 0.229 408.0 104 (<0.001) 74.5 −0.46 0.459
HDL-C 112 5928 3023 2905 0.152 0.047, 0.256 2.836 0.005 0.214 408.0 111 (<0.001) 72.8 0.72 0.208
TAGs 120 5931 3023 2908 −0.114 −0.215, −0.013 −2.213 0.027 0.209 407.7 119 (<0.001) 70.8 −0.33 0.570
BMI: Body Mass Index; WC: Waist Circumference; TC: Total Cholesterol; LDL-C: Low density Lipoprotein
Cholesterol; HDL-C: High Density Lipoprotein Cholesterol; TAGs: Triglycerides; n: total number of studies
included in the analysis; NT: number of total participants; NS: number of participants in the supplemented group;
NC: number of participants in the control group; SDM: standardized difference in means; 95% CI: lower and upper
confidence limits for the average SDM: df : degrees of freedom; Z: statistic for testing the significance of the average
SDM; Tau2: between-studies variance; Q: heterogeneity statistic; I2: heterogeneity index.
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Despite a high heterogeneity across the studies (I2 = 70–77% for most variables except for BMI
which was more moderate, I2 = 26.7%), the overall pooled analysis (shown as SDM) significantly
confirmed a reduction of BMI (−0.153, p-value < 0.001), WC (−0.293, p-value < 0.001), blood total
cholesterol (−0.214, p-value < 0.001), LDL (−0.235, p-value < 0.001), and TAGs (−0.114, p-value = 0.027).
HDL levels were also significantly increased (0.152, p-value = 0.005). Sensitivity analyses were carried
out using the leave-one-out approach where the meta-analysis was performed with each study removed
in turn. The pooled estimates consistently showed a similar effect and significance emphasizing the
robustness of these results and that the effect was not driven by any particular study (data not shown).
Further support of these results was found by a significant relationship between the duration of the
supplementation with the flavanol products and the reduction of WC; total-, LDL- and HDL-cholesterol;
and TAGs using random-effects meta-regression analysis. Regression coefficients and p-values for
each variable can be seen in Table S2.
3.4. Analysis of the Potential Factors Influencing Inter-Individual Responses to Flavanols Consumption
3.4.1. Stratification by the Individuals’ Baseline BMI, Sex, Smoking, and Country
Following stratification by the baseline BMI (Table 3), the effects of the flavanol-containing products
on BMI, WC, total- and LDL-cholesterol remained significant only in those studies carried out in
overweight/obese volunteers (BMI ≥ 25.0 kg/m2). HDL-cholesterol levels were also increased in this
subgroup (p = 0.063) whereas the reducing effects on TAGs levels were not significant in any of the two
subgroups. Statistical comparison between ≥25.0 vs. <25.0 kg/m2 subgroups did not reach significance
for any of the variables investigated. Of note, 61% of the total between-study variance in BMI could be
explained by the respective baseline BMI values (total between Q = 2.53, p-value = 0.112, R2 index = 0.61).
Regarding stratification by sex, the reduction of WC was significant in both men and women after
intervention with flavanol-containing products. However, total- and LDL-cholesterol were significantly
reduced only in female whereas BMI was significantly lowered only in male. The effects on HDL and
TAG levels were no longer significant after stratification by sex (Table 3). Between groups comparison
indicated a difference between sexes (total between Q = 2.833, p-value = 0.092) and a considerable
contribution of the sex to the between-study variance for BMI (R2 index = 1.0).
The reduction of BMI, WC, and total- and LDL-cholesterol in response to the flavanol-containing
products was significant in studies carried out in non-smoker volunteers. It was not possible, however,
to establish a comparison with habitual smokers due to the very low number of studies carried out
with this type of volunteers (n = 2 studies).
Comparison between studies carried out in East Asian countries (assuming Asian ethnicity)
against those carried out elsewhere evidenced similar results for BMI, WC, total and LDL cholesterol
in both subgroups although the results were slightly less significant in the East Asian subgroup.
A small proportion (7%) of the BMI between-groups variance was explained by the study location (East
Asian vs. others) (total between Q = 0.963, p-value = 0.327, R2 index = 0.07). In addition, we found
a significant difference in TAG levels in response to flavanol-containing products between the East
Asian subgroup and the others with a more pronounced effect in the East Asian studies (total between
Q = 7.419, p-value = 0.024, R2 index < 0.01). When grouping in North America and European countries,
we detected a significant reduction of BMI and WC in the Europe group but not in the American one,
whereas the LDL-cholesterol reduction resulted significant in the American group only. Statistical
comparison between North America and Europe groups showed a difference in the BMI response
(total between Q = 3.143, p-value = 0.076) and a 28% of the between-group variance explained by this
factor (R2 index = 0.28). Within Europe, the studies carried out in countries of the Mediterranean
area resulted in significant reductions of BMI, WC, total- and LDL-cholesterol and in an increase of
HDL (p = 0.078). In the non-Mediterranean countries, we only detected a significant reduction of
total-cholesterol. Comparison between the two subgroups indicated a significant difference in the WC
reduction (Total between Q = 5.228, p-value = 0.022, R2 index < 0.01).
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3.4.2. Stratification by the Individuals’ Medication and Health/Disease Status
The influence of medication on the response to the consumption of the flavanol-containing
products was also explored (Table 4). The subgroup including participants without any reported
medication showed significant reductions of BMI, WC, total- and LDL-cholesterol as well as a reduction
of TAGs (p = 0.063). In contrast, in the subgroup of studies including participants under medication
the effects did not reach statistical significance. Further comparison between the two subgroups
(Yes vs. No medication) revealed no significant differences between them (total between Q = 2.59,
p-value = 0.107) but 34% of the between-groups variance for the BMI response was explained by this
factor (R2 index = 0.34).
Regarding health/disease status, participants were stratified as healthy, at risk or with a reported
disease. Both in healthy subjects and in participants with a disease, the total- and LDL-cholesterol
levels were significantly reduced. Studies conducted with volunteers categorized as at a risk exhibited
the most significant reduction of BMI and WC in response to the flavanols. Stratification of the
studies by the type of disorder showed a significant reduction of BMI and WC in overweight and/or
obese individuals, a significant increase of HDL-cholesterol levels in patients with a dyslipidemia
and a significant reduction of LDL-cholesterol in patients with diabetes or hypertension (Table 4).
Comparison between each of the subgroups against the healthy subgroup was not significant for any
of the variables investigated.
3.4.3. Stratification by the Source/Administration Form of the Flavanols and the Diet during
the Intervention
Among the sources of flavanols investigated, our meta-analysis confirmed that supplementation
with tea derived products significantly impacts on all the investigated variables except for TAGs
(Table 5). Studies carried out with cocoa as the source of flavanols exhibited a significant effect on
total-, LDL-cholesterol and TAGs levels whereas intervention with the apple-derived products appears
to only modulate total- and LDL-cholesterol levels. Statistical comparison between the sources of
flavanols highlighted a significant difference in the effect on BMI between tea and cocoa products
(p-value = 0.012) with a 29% of the between-groups variance explained by this factor (R2 index = 0.29).
The apple group resulted also significantly more efficient than the cocoa or tea groups in the reduction
of total-cholesterol. In addition, the apple products showed a greater effect on LDL-cholesterol than
the tea derived products.
Regarding the supplementation form, the results showed that the administration of tea as solid
extracts caused a significant and efficient modulation of all the variables investigated except for HDL
and TAGs, whereas the tea beverages were significant at reducing only BMI and LDL-cholesterol
(Table 5). Statistical comparison between liquid and solid tea-flavanols administration pointed out
at a difference between the two subgroups at reducing LDL cholesterol (p-value = 0.096) with 11%
of the between-group variance explained by this factor (R2 index = 0.11). A very limited number of
studies have reported so far the effects of tea purified epigallocatechin gallate (EGCG), one of the
main flavanols present in tea. Overall, these studies only support a significant reduction of BMI by
this compound. Of note, and as opposed to tea products, the purified EGCG appears to reduce the
levels of HDL (results not significant) and increase those of TAGs (p = 0.077) (Table 5). Comparison
between the EGCG subgroup and the tea drink or the tea extract subgroups indicated that the form
of administration (as a purified compound or as a mixture) partially contributed to explaining the
between groups variances for HDL (total between Q = 5.211, p-value = 0.022, R2 index = 0.10, EGCG
vs. tea drink; total between Q = 3.835, p-value = 0.050, R2 index = 0.12, EGCG vs. tea extract) and for
TAGs (total between Q = 3.282, p-value = 0.070, R2 index = 0.06, EGCG vs. tea drink; total between
Q = 3.765, p-value = 0.052, R2 index = 0.09, EGCG vs. tea extract).
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Table 5. Analysis of the influence of the original source of flavanols and of the diet (during the
intervention) on the effects (SDM) of the supplementation on BMI, WC, and blood lipids levels.

















BMI 0.001 a −0.11 −0.224 −0.223 −0.212 −0.290 −0.162 −0.149
p-value (NS) (NS) (0.000) −0.007 (0.002) (0.022) (0.030) (0.001)
(n, N) (21, 1014) (5, 319) (46, 2704) (20, 1167) (26, 1537) (7, 384) (23, 1032) (49, 2990)
WC −0.106 −0.206 −0.354 −0.22 −0.506 −0.465 −0.500 −0.164
p-value (NS) (NS) (0.000) (NS) (0.000) (NS) (0.000) (0.084)
(n, N) (8, 430) (2, 155) (34, 2228) (16, 1074) (17, 1110) (2, 171) (18, 903) (27, 1868)
TC −0.177 −1.352 −0.143 −0.083 −0.208 −0.051 −0.215 −0.213
p-value −0.018 −0.041 (0.036) (NS) (0.008) (NS) (0.032) (0.003)
(n, N) (38, 1625) (7, 402) (65, 3666) (36, 2051) (26, 1615) (7, 437) (39, 1682) (73, 4130)
LDL-C −0.252 −0.587 −0.191 −0.119 −0.270 −0.216 −0.184 −0.260
p-value −0.013 −0.007 (0.008) −0.045 (0.000) (NS) (0.062) (0.000)
(n, N) (35, 1577) (8, 386) (61, 3723) (35, 2235) (26, 1488) (7, 206) (38, 1540) (67, 4186)
HDL-C 0.16 0.197 0.150 0.17 0.13 −0.291 0.245 0.104
p-value (NS) (NS) (0.031) −0.071 (NS) (NS) (0.008) (NS)
(n, N) (37, 1603) (7, 386) (66, 3820) (38, 2292) (27, 1484) (7, 437) (40, 1759) (72, 4169)
TAGs −0.183 −0.173 −0.050 −0.047 −0.053 0.314 −0.139 −0.105
p-value −0.047 (NS) (NS) (NS) (NS) −0.077 (NS) (NS)
(n, N) (39, 1691) (10, 455) (69, 3700) (38, 2121) (30, 1544) (7, 437) (46, 1939) (73, 3922)
a Standardized difference in means (SDM); BMI: Body Mass Index; WC: Waist Circumference; TC: Total
Cholesterol; LDL-C: Low density Lipoprotein Cholesterol; HDL-C: High Density Lipoprotein Cholesterol; TAGs:
Triacylglycerides; p-value < 0.05 was considered significant ; p-value < 0.1 and ≥ 0.05 was considered marginally
significant ; NS: No significant change/effect; (n): Number of studies included; (N): Total number of participants;
EGCG: Epigallocatechin gallate.
Regarding the type of diet (controlled vs. usual) during supplementation with the
flavanol-containing products, the reducing effects on BMI, WC, total- and LDL-cholesterol remained
significant or marginally significant in both subgroups. The levels of TAGs were also reduced although
not significantly. We detected, however, a significant increase in the HDL-cholesterol levels only in the
subgroup that followed a controlled diet (Table 5). Further, statistical comparison of the two subgroups
highlighted a significant difference on the reduction of WC between them (total between Q = 4.761,
p-value = 0.029) and a 7% explanation of the between-groups variance by this factor (R2 index = 0.07).
3.4.4. Multiple Meta-Regression Analysis of BMI Modulators of the Response to Flavanol-Containing
Products Consumption
Multiple meta-regression analysis was performed (Table 6) to derive the independent effect of
some of the covariates previously found to partially explain some of the between-groups variance
for BMI, i.e., baseline BMI (64%), country where the study was carried out (East-Asian vs. all other
countries) (7%), medication use (34%) and source of flavanols (tea vs. cocoa products) (29%).
Although sex also appeared to contribute greatly to the BMI between-groups variance (R2 = 1),
it was not included in the multiple regression due to the limited number of studies clearly reporting
sex and used in the analysis. The full model reached statistical significance, with a large proportion
of variance (94%) accounted for and a considerable number of studies included (n = 40 studies).
Both medication and source of flavanols were significantly correlated with the reducing effect
on BMI, once controlled the influence of the other predictor. In particular, higher effects of the
flavanols-products on BMI were found in the absence of the medication and with the consumption of
tea products.
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Table 6. Main results of the multiple random-effects meta-regression model for the contribution of the
covariates, medication and source of flavanols, on BMI response (Standardized difference in means).
Covariate Coefficient SE 95% Lower 95% Upper Z p-Value
Intercept −0.0679 0.0899 −0.2440 0.1082 −0.76 0.4500
Medication (No vs. Yes) 0.2481 0.0995 0.0530 0.4431 2.49 0.0127
Source of flavanols (Cocoa vs. Tea) −0.3278 0.1022 −0.5282 −0.1274 −3.21 0.0013





Number of studies included 40 (54% of the total studies used in the meta-analysis)
SE: standard error for each regression coefficient; Z: statistic for testing the statistical significance of each predictor;
P: probability level; QR: statistic for testing the statistical significance of the full meta-regression model; df : degrees
of freedom; R2: proportion of total between-studies variance explained by the model analog.
4. Discussion
The consumption of flavanols may contribute to improve cardiometabolic health via the
moderation of a range of associated risk factors. Recent meta-analyses (Table S3) [138–151] suggest that
the consumption of flavanol-containing tea and tea products could reduce total- and LDL-cholesterol as
well as body mass index (BMI) and waist circumference (WC), while chocolate and cocoa flavanols also
appear to regulate blood lipid levels. Nonetheless, the results of these analyses are inconsistent, partly
due to the large heterogeneity of the clinical trials included. In addition, some of the anthropometric
indicators of obesity such as BMI and WC have not yet been systematically investigated. We herein
present the largest meta-analysis investigating the impact of flavanol-containing tea, cocoa and apple
products, three major dietary sources of these bioactive compounds [152] on several biomarkers of lipid
metabolism and anthropometric variables, such as BMI and WC. Our analysis confirms that the intake
of these products is significantly associated with: (1) reduced BMI and WC; and (2) a more favorable
lipid profile with a decrease in total- and LDL-cholesterol, and TAG plasma levels, and an increase in
HDL-cholesterol levels. In addition, our analyses show that the changes in these biomarkers following
consumption of the flavanol-containing products can be influenced by a number of factors and thus,
the benefits of these products can significantly vary between specific population subgroups. It is of
utmost interest to clarify the impact of these factors in order to discern which population subgroups
could most benefit of the intake of these bioactive compounds.
4.1. Baseline BMI
There is evidence that baseline BMI may be a potential factor with an impact on the
individuals’ response to supplementation with different natural products. For instance, treatment
with natural probiotics has been shown to significantly increase HDL only in patients with a
baseline BMI ≥ 29 kg/m2 [153] or significantly reduce BMI only in participants with a baseline
BMI ≥ 25 kg/m2 [154]. Regarding flavanol-containing products, a previous meta-analysis of the
effects of black tea on blood cholesterol failed to detect differences in the modulation of cholesterol
levels between individuals with normal weight or overweight and obese phenotype, but the results
of this meta-analysis were estimated using a very small number of trials per subgroup (4 and 5,
respectively) [141]. Our stratification approach by baseline BMI provides some evidence that the
changes following consumption of flavanol-containing products on BMI, WC and cholesterol levels
are more pronounced in individuals with a baseline BMI ≥ 25 kg/m2 and supports the fact that
supplementation with these products may have a better impact on these risk factors in overweight
and/or obese people. Nevertheless, it is not yet clear whether there is a general better efficacy of natural
treatments in overweight and/or obese people, or if the effects may vary depending on the biomarkers
or the products investigated. More trials in individuals with a normal BMI < 25.0 kg/m2 are still
needed to further compare and demonstrate significant differences in the benefits of flavanol-containing
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products in relation to body weight, since most are conducted in populations of greater cardiometabolic
risk, who are often obese in nature.
4.2. Sex
Understanding the differing responses by sex is becoming increasingly important. Previous work
has shown that the reducing effects of green tea on total and LDL-cholesterol were significantly greater
in men than in women, giving preliminary evidence of that supplementation with flavanol-containing
green tea could have a different effect depending on the sex of the individuals [142]. Our results also
support differences between women and men in their capacity to regulate the levels of total and LDL
cholesterol in response to the consumption of flavanol-containing products with women exhibiting a
more efficient reduction than men. A recent meta-analysis looking at the effects of flavonols (another
flavonoids class) on lipids levels, failed to detect a difference between men and women, possibly due to
the very low number of trials and participants in the two subgroups [7]. Comparing the regulation of
cardiometabolic risk factors between women and men is complex because of the hormonal protection in
premenopausal women [155]. We were not able to stratify our analyses based on the age or menopausal
status of the women, as these factors were not sufficiently well characterized in the trials selected for
the meta-analyses. Nevertheless, our results point out to a different response to flavanols consumption
between sexes and reinforce the need to further investigate this factor in future trials specifically
designed for this purpose.
4.3. Country Where the Study Was Carried Out
Ethno-cultural differences are associated with the risk of development of cardiometabolic
disorders [156] and thus, it is important to explore and clarify whether different ethnic groups
differ in their responses to consumption of plant bioactives as effective treatment against these
diseases. Unfortunately, most of the clinical trials included in the present meta-analysis have not clearly
identified the ethnicity of the participants. In the absence of this information, we have explored the
potential influence of the country where the studies were carried out. A common comparison is that
between studies undertaken in Asian countries vs. non-Asian ones. It has been reported that Asians
showed a more marked decrease in the levels of TAGs in response to 
-3 fatty acids supplementation
as compared to subjects within a USA/European group but, no significant differences were found for
total cholesterol or BMI [157]. Flavonols have also been shown to significantly reduce TAGs, total and
LDL-cholesterol in studies conducted in Asian countries as compared to those in the EU/European
subgroup [7]. Regarding flavanol-containing products, previous meta-analyses have suggested that tea
and tea extracts reduce BMI and WC both in Asian and non-Asian trials [140] and that, cocoa products
significantly reduce LDL-cholesterol in European countries as compared to USA [149]. Nevertheless,
these analyses were all underpowered. Our stratification analysis by country included, in general,
a big number of studies per subgroup and showed no apparent differences in the responses to the
consumption of tea, cocoa and apple products between East Asian countries and all other countries
except for TAGs which were significantly reduced only in the Asian subgroup. We also found some
different responses between North American (USA/Canada) and European subgroups, as well as
between European Mediterranean and non-Mediterranean ones. This may be partially related to
features such as the ethnicity of the participants but also to other factors associated with the life-style of
the country. More studies are needed in order to understand the influence of this factor in the response
to interventions with plant natural compounds.
4.4. Health and Medication Status
Previous meta-analyses had suggested that the consumption of green tea [146,147], black tea [139],
and cocoa products [149] had moderating effects on lipid levels both in healthy subjects and in patients
with hyperlipidemia or at a higher cross-over or cross-over or s risk. Other bioactive compounds such
as flavonols also had a more pronounced effect in the disease subgroup than in the healthy subgroup
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as significantly evidenced for LDL-cholesterol [7]. Our results show and corroborate a significant
reduction of total- and LDL-cholesterol by the flavanol-containing tea, cocoa and apple products both
in healthy participants and in individuals with a disease. On the other hand, BMI and WC were
reduced and HDL increased in the three subgroups of healthy, “at risk” and individuals with a disease
but the results reached statistical significance in the “at risk” group only. As a whole, these results
support a metabolic benefit of the consumption of plant bioactive compounds, and in particular of
flavanols, regardless of the health status of the individuals.
An important consideration regarding the use of plant bioactive compounds as modulators of
cardiometabolic risk biomarkers is their potential use as treatment on their own or as coadjuvants in
combination with pharmacological drugs [158]. Our results show that the use of flavanol-containing
products in the absence of medication was significantly associated with the reduction of BMI, WC,
total and LDL cholesterol, as well as TAGs giving some evidence of their efficacy as therapeutics.
The number of clinical trials in which the flavanols were supplemented in combination with other
drugs was in general smaller than studies carried out in the absence of medication (see Table 4) thus
the pooled results did not reach significance. Nonetheless, these data point to a modulatory effect of
the flavanol-containing products in medicated individuals. Whether the combined therapy is more
efficient and safe than individual treatment with drugs or with natural plant bioactives warrants
further investigation.
4.5. Source and Form of Administration of the Flavanols
Our results confirm that the flavanol-containing tea products are effective regulators of blood
cholesterol (total, LDL and HDL) as well as of BMI and WC. The cocoa or apple products were effective
at reducing total- and LDL-cholesterol and the cocoa products were also able to significantly decrease
the levels of TAGs. These results might suggest that the metabolic regulatory efficacy of these three
flavanol-containing products could be ranked as tea > cocoa > apple but caution should be taken with
this interpretation due to the differences in the number of studies carried out with each source of
flavanols as well as the differences in the doses and the composition of the products. Further studies
are needed to corroborate this comparison. Our analysis also suggests that the administration of tea as
a solid extract might be more efficient than tea beverages at reducing WC and total cholesterol. Earlier
meta-analyses had suggested that the type of administration of green or black tea either in solid form
(extracts and, capsules) or as a drink did not differ at reducing total- and LDL-cholesterol [139,146,147].
Unlike those previous analyses, where the number of studies per subgroup was very small, our
stratification between tea drinks and tea extracts included a considerable number of studies per
subgroup (>15) and gives preliminary evidence of a potentially higher efficacy of the tea when
administered as a solid powder. We may hypothesize that this could be partially related to the presence
of higher doses of the bioactive flavanols in such extracts.
4.6. Magnitude of the Changes
An interesting issue worth discussing here is the magnitude of the changes attributed to
the intake of the flavanol-containing products and to the extent these changes can contribute
to the regulation of the analyzed biomarkers in comparison with other approaches, i.e., drugs,
lifestyle changes, or other natural compounds. Based on the Cohen guidelines [159], the effects
of the flavanol-containing products (expressed as SDM) are, in general, small (≤0.2) or medium
(between 0.2 and 0.5) although changes in some specific risk markers in some specific subgroups can
be considered high (≥0.8). We used the same random effects model to generate the overall size effects
by computing the difference in means (Table S4) and compare these values to some of the reported
effects of pharmacological, behavioral or dietary interventions on BMI, WC and lipid levels. Some of
the most potent reducing effects on BMI can be achieved with restricted energy diet (−2.7 kg/m2) [160],
pharmacological interventions (−1.3 kg/m2) [161] or behavioral (diet, exercise) interventions (−0.9 to
−1.2 kg/m2) [162,163]. These reductions constitute between 5% and 10% of the WHO established
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limit values for overweight (BMI = 25.0–29.9 kg/m2) and obesity (BMI ≥ 30.0 kg/m2). Alternatively,
intervention with probiotics [154] or nutraceuticals (e.g., lipoic acid) [164] shows a more modest
but also significant reduction of BMI (approximately −0.5 kg/m2, ~2% change of the WHO values).
On average, the size effect of the flavanol-containing products on BMI was smaller (−0.15 kg/m2,
Table S3) but, notably, this effect may be enhanced in specific subpopulations (up to −0.91 kg/m2 in
studies conducted in European Mediterranean countries), more similar to other behavioral or dietary
interventions. WC can also be significantly and efficiently reduced by brisk walking (−2.83 cm, ~3% of
the established 102/88 cm risk values) [162] and, more modestly (−0.53 cm, ~0.5% of the established
risk values) by intervention with supplements such as 
-3 polyunsaturated fatty acids [165]. Along
these lines, intervention with the flavanol-containing products significantly reduces WC by 1.7 cm and
can reach reducing values of −4.58 cm in studies conducted in European Mediterranean countries.
Regarding the cholesterol lowering effects, statins remain, at present, the first-choice agents.
The pooled effects of various statins on total- and LDL-cholesterol were −0.89 mmol/L (~17% of
the desirable 5.17 mmol/L limit level) and −0.92 mmol/L (~27% of the near optimal 3.36 mmol/L
level), respectively [166]. Intervention with natural products such as red yeast rice or spirulina
can be as effective as the statins, whereas other plant dietary bioactive compounds such as soluble
fiber, sterols/stanols, probiotics and flavonols also significantly reduce total- and LDL-cholesterol by
0.5–0.1 mmol/L [7,167]. In this context, the flavanol-containing products show a similar efficiency at
lowering total cholesterol (−0.13 mmol/L) and LDL cholesterol (−0.17 mmol/L). Again, in specific
subgroups (e.g., supplementation with flavanol-containing apple products) the reduction of total
cholesterol was much more efficient (−0.44 mmol/L). These results are very relevant considering that
the reduction of LDL-cholesterol by 1 mmol/L has been associated with a 23% reduction of CVDs
risk [168] and reinforce the interest in understanding the influence of different factors on the regulatory
efficiency of plant bioactive compounds, in general, and of flavanols in particular.
4.7. Additional Recent Evidences
Since the completion of this meta-analysis, additional RCTs investigating the effects of tea or
cocoa products containing flavanols on lipid and anthropometric variables have been added to the
existing literature [111,169–183]. The heterogeneity of these trials remains high with population
samples including mixed sexes and ages, obese, overweight, healthy, hyperlipidemic and/or diabetic
subjects, etc. The products were administered in different forms, mostly as green tea extracts/capsules
or cocoa drinks and at different doses and intervention periods. Some of these studies further
support the reduction of total- and LDL-cholesterol by green tea or cocoa flavanols or the increase
of HDL by dark chocolate or cocoa [111,169–171]. Others show no significant effects on these
variables [175]. Noteworthy, some of these trials included stratification analyses by baseline conditions,
medication, disease, age, sex, or even genotype and further point to specific responses in some
subgroups [169,172,174,176,179]. Likewise, the intake of a cocoa product caused a greater increased
of HDL in normocholesterolemic patients than in dyslipidemic patients [176], green tea capsules
caused a significant reduction of total-cholesterol in women with a cholesterol baseline value above
5.17 mmol/L [169] or of LDL-cholesterol in patients not receiving anti-hyperlipidemic drugs [179].
Of note, the interactions between two factors: baseline BMI and catechol-O-methyltransferase (COMT)
genotype, was also recently investigated although the COMT genotype did not modify the effect of
green tea extract on any of the variables investigated including BMI [172]. In our study, we were able
to identify several factors that may contribute to explaining the heterogeneity on the BMI changes in
response to the flavanol-containing products. By multiple meta-regression analysis, we also found that
supplementation with these products may be most effective at reducing BMI when specifically using
tea products in non-medicated patients. These results highlight the importance of understanding not
only the factors affecting the variability in the responses but also the interactions between these factors.
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5. Conclusions
To the best of our knowledge, the meta-analysis conducted here is the largest one to date that
compiles the evidence on the effects on various metabolic risk factors after supplementation with
three sources of flavanols, tea, cocoa, and apple products. Our results show consistent and significant
modulatory effects on BMI, WC and lipid levels. The size of these effects is modest but similar
to that prompted by other natural products. We have also presented evidence of the influence of
several factors on these beneficial effects that suggest that flavanols might be very effective in specific
subpopulations such as overweight people or non-medicated individuals or when the source of these
bioactive compounds is tea. Moreover, a combination of these factors may best explain interindividual
variability in the response to the flavanols-containing products.
Although the total number of studies included in the meta-analysis was quite large, the number
of studies (and of participants) remained small in some of the subgroup analyses. In addition, many of
the studies reported limited or unclear information about the potential factors that may influence the
treatment. These limitations affect the capability of the meta-analysis to unequivocally detect moderator
variables and limit the significance of our findings. More randomized comparison studies with larger
number of well-phenotyped volunteers and providing detailed descriptions of the participants and
study characteristics are still needed. This research is crucial for a better understanding of the factors
most relevantly involved in the variability of the responses to the consumption of these compounds
and to achieve maximum efficacy so that flavanols may become an effective non-pharmacological
alternative to battle hyperlipidemia, overweight/obesity and associated cardiometabolic disorders
in humans.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/7/746/s1.
Figure S1: Forest plot of the meta-analysis evaluating the effects of supplementation with flavanols-containing
tea, cocoa or apple products on human body mass index (BMI). A total of 74 studies (displayed in alphabetical
order) were analysed. Pooled results are shown at the bottom using a random-effects model. SDM: Standardized
difference in means, SE: standard error, 95% CI: lower and upper confidence limits for the average SDM, RW:
relative weight; Figure S2: Forest plot of the meta-analysis evaluating the effects of supplementation with
flavanols-containing tea, cocoa or apple products on human waist circumference (WC). A total of 46 studies
(displayed in alphabetical order) were analysed. Pooled results are shown at the bottom using a random-effects
model. SDM: standardized difference in means, SE: standard error, 95% CI: lower and upper confidence limits
for the average SDM, RW: relative weight; Figure S3: Forest plot of the meta-analysis evaluating the effects of
a prolonged supplementation with flavanols-containing tea, cocoa or apple products on human blood levels
of total cholesterol. A total of 112 studies (displayed in alphabetical order) were analysed. Pooled results are
shown at the bottom using a random-effects model. SDM: standardized difference in means, SE: standard error,
95% CI: lower and upper confidence limits for the average SDM, RW: relative weight; Figure S4: Forest plot of
the meta-analysis evaluating the effects of a prolonged supplementation with flavanols-containing tea, cocoa
or apple products on human blood levels of LDL cholesterol. A total of 105 studies (displayed in alphabetical
order) were analysed. Pooled results are shown at the bottom using a random-effects model. SDM: standardized
difference in means, SE: standard error, 95% CI: lower and upper confidence limits for the average SDM, RW:
relative weight; Figure S5: Forest plot of the meta-analysis evaluating the effects of a prolonged supplementation
with flavanols-containing tea, cocoa or apple products on human blood levels of HDL cholesterol. A total of
112 studies (displayed in alphabetical order) were analysed. Pooled results are shown at the bottom using a
random-effects model. SDM: standardized difference in means, SE: standard error, 95% CI: lower and upper
confidence limits for the average SDM, RW: relative weight; Figure S6: Forest plot of the meta-analysis evaluating
the effects of a prolonged supplementation with flavanols-containing tea, cocoa or apple products on human
blood levels of triglycerides (TAGs). A total of 120 studies (displayed in alphabetical order) were analysed. Pooled
results are shown at the bottom using a random-effects model. SDM: standardized difference in means, SE:
standard error, 95% CI: lower and upper confidence limits for the average SDM, RW: relative weight; Figure S7:
Funnel plot and Eager statistics (intercept and 2-tailed p-value) of the meta-analysis evaluating the effects of a
prolonged supplementation with flavanols-containing tea, cocoa or apple products on human BMI; Figure S8:
Funnel plot and Eager statistics (intercept and 2-tailed p-value) of the meta-analysis evaluating the effects of a
prolonged supplementation with flavanols-containing tea, cocoa or apple products on human WC; Figure S9:
Funnel plot and Eager statistics (intercept and 2-tailed p-value) of the meta-analysis evaluating the effects of a
prolonged supplementation with flavanols-containing tea, cocoa or apple products on human blood levels of
total cholesterol; Figure S10: Funnel plot and Eager statistics (intercept and 2-tailed p-value) of the meta-analysis
evaluating the effects of a prolonged supplementation with flavanols-containing tea, cocoa or apple products
on human blood levels of LDL cholesterol; Figure S11: Funnel plot and Eager statistics (intercept and 2-tailed
p-value) of the meta-analysis evaluating the effects of a prolonged supplementation with flavanols-containing tea,
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cocoa or apple products on human blood levels of HDL cholesterol; Figure S12: Funnel plot and Eager statistics
(intercept and 2-tailed p-value) of the meta-analysis evaluating the effects of a prolonged supplementation with
flavanols-containing tea, cocoa or apple products on human blood levels of triglycerides (TAGs); Table S1: Mean
content (mg/100 fresh weight, FW) in flavonoids of green and black tea infusions, cocoa powder and whole apple
illustrative of the composition of the three main sources of flavanols examined in this study: tea, cocoa and apple
(data are based on the Phenol-Explorer database); Table S2: Results of the meta-regression of the changes in BMI,
WC and blood lipids levels vs. duration of the supplementation with the flavanol-containing tea, cocoa or apple
products; Table S3: Summary of most recent meta-analysis looking at the effects of flavanol-containing tea or
cocoa products on anthropometric measurements and blood lipids associated with the development of metabolic
disorders; Table S4: Overall effect size estimations (DM) for the impact of flavanols containing products on BMI,
WC and blood lipids levels.
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Abstract: Phytochemical-rich diets are protective against chronic diseases and mediate their protective
effect by regulation of oxidative stress (OS). However, it is proposed that under some circumstances,
phytochemicals can promote production of reactive oxygen species (ROS) in vitro, which might
drive OS-mediated signalling. Here, we investigated the effects of administering single doses
of extracts of red cabbage and grape skin to pigs. Blood samples taken at baseline and 30 min
intervals for 4 hours following intake were analyzed by measures of antioxidant status in plasma,
including Trolox equivalent antioxidant capacity (TEAC) and glutathione peroxidase (GPx) activity.
In addition, dose-dependent production of hydrogen peroxide (H2O2) by the same extracts was
measured in untreated commercial pig plasma in vitro. Plasma from treated pigs showed extract
dose-dependent increases in non-enzymatic (plasma TEAC) and enzymatic (GPx) antioxidant
capacities. Similarly, extract dose-dependent increases in H2O2 were observed in commercial pig
plasma in vitro. The antioxidant responses to extracts by treated pigs were highly correlated with
their respective yields of H2O2 production in vitro. These results support that dietary phytochemicals
regulate OS via direct and indirect antioxidant mechanisms. The latter may be attributed to the ability
to produce H2O2 and to thereby stimulate cellular antioxidant defence systems.
Keywords: hydrogen peroxide; reactive oxygen species; plant extracts; red cabbage; grape;
glutathione peroxide; total antioxidant capacity; porcine; piglet; Landrace
1. Introduction
A phytochemical-rich diet is strongly associated with reducing the risk of chronic diseases
including cancer [1], cardiovascular [2], and neurodegenerative diseases [3]. The health benefits
of dietary phytochemicals have been attributed to their ability to mitigate oxidative stress and
inflammation (OSI), which is associated with normal metabolism [4,5] but is also involved in the
onset of chronic diseases [6]. Production of reactive oxygen species (ROS) occurs under normal
conditions in cells, the main source from by-products of the electron transport chains [7]. Uncontrolled
ROS can lead to OSI and unregulated OSI can result in molecular and cellular damage which in turn
leads to an increased risk of chronic diseases [8]. However, OSI is an important defence mechanism of
the body against infections and injuries [9]. Therefore, transient peaks or optimal steady state levels of
ROS in the body are likely involved in maintaining good health and reducing the risk of disease [10].
It was believed that dietary phytochemicals exert protection via direct scavenging of ROS,
as observed in many in vitro studies [11–13]. However, this concept has been challenged as the
concentrations of phytochemicals in human plasma in vivo after consumption of phytochemicals are
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much lower (in the nM to low μM range) compared to concentrations used in the in vitro studies
(in the low μM to mM range) [14,15]. There are clearly discrepancies between the studies of these
mechanisms in the whole organism.
The health benefits of dietary phytochemicals are thought to be attributed to their ability to
generate electrophilic or chemical stress signals, which trigger the cellular defence system to protect
against molecular damage and subsequent chronic diseases [16–19]. The cellular antioxidant defence
is made up of a non-enzymatic, inducible enzymatic defence and the DNA repair systems [20].
The non-enzymatic defence includes antioxidant molecules such as vitamin C, vitamin E, uric
acid, glutathione, and thioredoxin that directly scavenge ROS and metal-chelating proteins such as
transferrin, coeruloplasmin, and metallothionein that prevent ROS formation via controlling the level
of pro-oxidative free metal ions [20]. The enzymatic antioxidant defence includes several pathways that
remove ROS through enzymatic reactions. For example, superoxide dismutase converts superoxide
anions into hydrogen peroxide (H2O2), which is subsequently transformed by catalase into oxygen and
water or by glutathione peroxidase (GPx) into water [20]. The reduction of H2O2 by GPx consumes the
reduced form of glutathione and generates the oxidised form, which can be recycled by glutathione
reductase to restore the glutathione pool [20].
Dietary phytochemicals have been associated with increasing the levels of both non-enzymatic
and enzymatic antioxidant defence in animal [21–26] and human dietary intervention studies [27–30].
Consumption of phytochemical-rich diets increased the expression of genes associated with DNA
repair, immune, and inflammatory responses in humans [10,31–33]. The varied roles that dietary
phytochemicals may play in the whole organism are complex, perhaps overlapping and have not been
fully elucidated. The ability of dietary phytochemicals to generate stress signals can be related to
their ability to produce ROS, in particular H2O2 [34]. Phytochemicals have been reported to produce
H2O2 in cell culture media, which was potentially responsible for their cytotoxic effects in cell culture
studies [35–38]. However, no research has been done on the ability of phytochemicals to produce
H2O2 in plasma. Understanding this pro-oxidant action will provide information about how the
phytochemicals can stimulate ROS-induced cellular antioxidant defence to provide protective effects
against OSI.
Absorption of phytochemicals into circulation and uptake by target cells are essential for
phytochemicals to exert biological effects [39]. As phytochemicals are recognised by the human
body as xenobiotics, their presence in the human body is transient [40] and influenced by their
physicochemical properties. Recently, we have developed the phytochemical absorption prediction
(PCAP) model, allowing direct calculation of the time required for phytochemicals to reach their
maximal plasma concentrations (Tmax) after oral consumption, based on their molecular mass and
lipophilicity descriptor log P [41]. Further, a liquid chromatography mass spectrometry (LC-MS)
method has been developed to characterise Tmax ranges of phytochemical mixtures based on molecular
mass and log P [42]. Here, we extend this modelling to dietary intervention in pigs, an animal model
with physiological and anatomical similarities to the digestive tract of humans [43].
Phytochemicals across a broad range of chemical classes have been shown to impart positive
health benefits [3,40]. Grape products and Brassica vegetables are among the most widely studied
for their antioxidant capacity and protection against chronic diseases [44,45]. Grape skin contains
predominately polyphenols including anthocyanidins, phenolic acids, and stilbenes [44], whilst red
cabbage (a member of the Brassica vegetables) contains a wider variety of phytochemicals including
polyphenols (anthocyanidins, phenolic acids), glucosinolates, and vitamins [46].
The aim of this study was to use a pig model to establish the absorption kinetics of phytochemical
extracts from red cabbage and grape skin and to examine their effects on two measures of antioxidant
status (plasma total antioxidant capacity and plasma GPx activity). Direct induction of the pro-oxidant
effects of the plant extracts in pig plasma was measured by H2O2 production in pig plasma when
exposed to the plant extracts in vitro. This study provides both in vitro and ex vivo evidence to support
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that one of the likely modes of action by phytochemicals is to induce H2O2 in plasma and to thereby
initiate protective action by enzymatic and non-enzymatic cellular defences.
2. Materials and Methods
2.1. Materials
All chemicals including gallic acid, Folin-Ciocalteu reagent, sodium carbonate (Na2CO3),
hydrogen peroxide (H2O2), sulfuric acid (H2SO4), xylenol orange, Iron(II) sulphate (FeSO4),
butylated hydroxytoluene (BHT), tris(hydroxymethyl)aminomethane (Tris), glycine, citrate, urea,
hydrochloric acid (HCl), Trolox, bathocuproinedisulfonic acid sodium salt (BCS), copper(II) chloride
(CuCl2), methanol, formic acid, acetonitrile, L-histidine, (S)-dihydroorotate, shikimate, 4-pyridoxate,
3-hydroxybenzyl alcohol, 2,5-dihydroxybenzoate, 3-hydroxybenzaldehyde, trans-cinnamate,
estradiol-17α, deoxycholate, retinoate, oleic acid, and heptadecanoate were of analytical grade and
from Sigma-Aldrich (St. Louis, MO, USA). 96 well plates were from Greiner UV-Star (Greiner Bio-One,
Frickenhausen, Germany).
Tris-glycine-urea buffer pH 7 contained 0.086 M Tris, 0.09 M glycine, 4 mM citrate, and 8 M urea,
adjusted to pH 7 using 2 M HCl. Ferrous ion oxidation-xylenol orange (FOX) reagent contained 25 mM
H2SO4 containing 0.1 mM xylenol orange, 0.25 mM FeSO4, and 4 mM BHT in 90% methanol.
2.2. Preparation of Plant Extracts
Grape skin extract was obtained from Tarac Technologies (Nuriootpa, South Australia, Australia).
The extract was freeze-dried (Virtis Genesis 35EL, SP Scientific, Warmister, PA, USA) and stored with a
small head space with desiccant at −18 ◦C.
Red cabbage extract was produced by the following process. Fresh red cabbage was purchased
from a local retailer (Coles supermarket, Werribee, Victoria, Australia). Edible parts of the red cabbage
were washed and blended in a food processor with water (1:2 ratio, w/v) before boiling by microwave
heating at 800 W for 10 min. After cooling to ambient temperature, the mixture was ultrasonicated
at 300 W for 11 min (Hielscher, Germany) before bag filtration (1 μm pore size, Sefar Filtration Inc.,
Depew, NY, USA). The filtrate was freeze-dried (Virtis Genesis 35EL, SP Scientific, Warmister, PA, USA)
and stored with desiccant and low head space at −18 ◦C.
2.3. Total Phenolic Content of Plant Extracts
Total phenolic content of the plant extracts was quantified using the Folin-Ciocalteu assay [47].
In brief, 20 μL samples (blank, standard, or 2 mg/mL plant extract in 20% methanol) was added to
1 mL of 0.2 N Folin-Ciocalteu reagent and 180 μL of Milli-Q water and mixed for 15 s, and allowed to
stand for 3 min before 800 μL of 7.5% Na2CO3 was added to the mixture. The mixture was shaken for
15 s followed by incubation at 37 ◦C for 1 h in the dark. The absorbance at 765 nm was measured using
a Varioskan Flash microplate reader (Thermo Fisher Scientific, Waltham, MA, USA). The total phenolic
content of plant extracts was reported as gallic acid equivalent (GAE) using a 7-point calibration curve
of gallic acid standard with concentrations of 0–500 μg/mL in 20% methanol after blank subtraction.
Total phenolic content of the plant extracts was 26.6 ± 1.5 mg GAE/g for red cabbage extract and
327.1 ± 13.9 mg GAE/g for grape skin extract. Analysis was performed in duplicate.
2.4. Prediction of Human Absorption Kinetics of Plant Extracts
Predicted human absorption kinetics, the ”functional fingerprints” of plant extracts, were
determined using untargeted liquid chromatography mass spectrometry (LC-MS) profiling method [42]
in combination with the PCAP model [41]. Untargeted LC-MS profiling analysis was performed using
an Agilent 6520 quadrupole time-of-flight (QTOF) MS system (Agilent, Santa Clara, CA, USA) with a
dual sprayer electrospray ionisation (ESI) source attached to the Agilent 1200 series high performance
liquid chromatography (HPLC) system (Santa Clara, CA, USA) comprised of a vacuum degasser and
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binary pump with a thermostated auto-sampler and column oven. The MS was operated in positive or
negative mode using the following conditions (positive/negative, respectively): nebulizer pressure
30/45 psi, gas flow-rate 10 L/min, gas temperature 300 ◦C, capillary voltage 4000/−3500 V, fragmentor
150, and skimmer 65 V. The instrument was operated in the extended dynamic range mode with data
collected in the mass to change ratio (m/z) range of 70–1700. Chromatography was carried out using
an Agilent Zorbax Eclipse XDB-C18, 2.1 × 100 mm, 1.8 μm column maintained at 40 ◦C (±1 ◦C) at
a flow rate of 400 μL/min with a 20-min run time. A gradient LC method was used with mobile
phases comprised of (A) 0.1% formic acid in deionized water and (B) 0.1% formic acid in acetonitrile.
Gradient: A 5-min linear gradient from 5% to 30% mobile phase B, followed by 5-min gradient to 100%
mobile phase B and then a 5-min hold, followed by a 5-min re-equilibration at 5% mobile phase B.
Molecular feature extraction (MFE) was conducted using Agilent MassHunter Qualitative analysis
(version B.07.00, Agilent) and MassHunter Profinder (version B.06.00, Agilent). Binning and alignment
tolerances were set to: retention time: ±0.1% + 0.15 min; mass window: ±20 ppm + 2 mDa. Allowed
ion species: H+, Na+, K+, NH4+, and neutral losses: H2O, H3PO4, CO2, C6H12O6. MFE was restricted
to the 1000 largest features and 1–2 charge states. After elimination of the molecular features which
were common in the two plant extracts (i.e., primary metabolites), the remaining molecular features
represented the phytochemicals (i.e., secondary metabolites) of the plant extracts.
The lipophilicity descriptor log P was determined using a calibration curve of retention time
and log P of twelve standards including L-histidine, (S)-dihydroorotate, shikimate, 4-pyridoxate,
3-hydroxybenzyl alcohol, 2,5-dihydroxybenzoate, 3-hydroxybenzaldehyde, trans-cinnamate,
estradiol-17α, deoxycholate, retinoate, oleic acid, and heptadecanoate. Log P values of standards were
calculated using the Molinspiration Chemoinformatics calculator.
The combination of log P and molecular mass were used to calculate predicted time of maximal
plasma absorption (Tmax) in humans using the PCAP model [41]. The functional fingerprints of plant
extracts were generated by plotting predicted human Tmax and peak area (relative ion count) of the
phytochemicals detected by LC-MS [42].
2.5. Dietary Intervention Using an Animal Model
2.5.1. Animals and Background Diet
The study used six female pigs (Large White × Landrace, 2.5 months old, weight ~30 kg). The pigs
weighed 23.2–25.4 kg (mean 24.4 kg, standard error (SE) 3 kg) at the start of the study and 42.8–45.4 kg
(mean 44.5 kg, SE 0.3 kg) on study completion five week later. The pigs were housed in individual
pens for the duration of the study (12 h light/dark cycle, temperature 18–24 ◦C). The animals were
fed a commercial background diet (Ridley AgriProducts, Melbourne, VIC, Australia) at an energy
intake of 0.5 MJ digestible energy/kg body weight (BW)/day representing about 80% of usual energy
intake and consumed water ad libitum. The composition of the feed includes 18% protein, 40.37%
starch, 2.73% sugar, 4.9% fat, 19.35% fibre, 4.95% ash, 0.9% calcium, and 0.65% phosphorus. The study
was approved by the Animal Ethics Committee of the Faculty of Veterinary and Agricultural Sciences,
The University of Melbourne, Australia (approval number 1513762.1).
2.5.2. Cephalic Vein Catheterisation Procedure
The cephalic veins of the animals were catheterised under general anaesthesia allowing 7-day
post-surgery recovery. Pigs were injected intramuscularly with ketamine hydrochloride (10 mg/kg BW;
Ketalar, Pfizer, NY, USA) mixed with xylazine (1 mg/kg BW; Rompun, Bayer, Leverkusen, Germany)
to induce sedation and anesthesia. Pigs were then intubated and maintained on 1–4% isoflurane
inhalation anaesthesia (Rhone Merieux, Footscray West, VIC, Australia). A silastic catheter was
inserted into the external cephalic vein and advanced to the anterior vena cava via the cephalic vein;
exteriorisation of the catheter in the interscapular space and storage of the catheter in a cloth pouch
glued to the back of the animals was performed as described previously [48]. After catheterisation, the
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neck incision and exit site were irrigated with benzyl penicillin (BenPen, CSL, Parkville, VIC, Australia)
and the animals were given 2 mL of 150 mg/mL of antibiotic amoxicillin (Moxylan, Jurox, Rutherford,
NSW, Australia) and 2 mL of 100 mg/mL analgesic/anti-inflammatory ketoprofen (Troy Labs Pty. Ltd.,
Smithfield, NSW, Australia). After surgery, the animals were monitored for feeding behaviour, general
disposition, and rectal temperature. Any animals with elevated temperatures (>39 ◦C) were given
2 mL of 150 mg/mL amoxicillin. Catheters were flushed daily with physiological saline containing
100 units/mL (U/mL) heparin.
2.5.3. Experimental Design and Procedure
The study was performed in a crossover 4 × 2 factorial design with the factors being two plant
extracts at four doses (including placebo control) in triplicate. The wash-out period between treatments
was for a minimum of two days. To account for differences in the total phenolic contents of the plant
extracts, doses of red cabbage and grape skin extracts were standardised for their total phenolic content
as gallic acid equivalents (GAE). On each experiment day, the pigs received a single dose of one of two
treatments: red cabbage or grape skin extracts at one of four doses: 0, 2.22, 4.44, and 11.11 mg GAE/kg
BW. Considering that the grape skin extract had a higher total phenolic content compared to the red
cabbage extract, the doses were selected based on previous studies of grape skin extract administered
safely to mice [49–51]. The maximal dose of 11.11 mg GAE/kg BW corresponding to 30 mg grape skin
extract/kg BW was selected for our pig study, as this dose is equivalent to the proven safe dose of
200 mg grape skin extract/kg BW in mice [52].
At 8 am on each experiment day, pigs were weighed after an overnight fast. After a baseline
(0 h) blood sample, pigs were gavaged with a single dose of plant extract solids reconstituted in
water to 50 mL and blood samples collected every 0.5 h for 4 h. The catheter was washed before
collecting each blood sample by withdrawing 10 mL of fresh blood. A 10-mL blood sample was then
collected using a syringe and immediately placed into a heparinised collection tube (BD Vacutainer®,
BD Australia, North Ryde, NSW, Australia) and immediately placed on ice. Lastly, the cannulas were
refilled with 100 U/mL heparin in saline and secured in the interscapular pouch. Plasma was obtained
by withdrawing supernatants of blood centrifuged at 2000× g for 10 min at 4 ◦C, and aliquots were
frozen at −20 ◦C until analysis. During 4 h of blood sampling period, no foods were given to pigs.
After the last blood sampling, pigs were fed the background diet.
2.5.4. Plasma Total Antioxidant Capacity Assay
Plasma total antioxidant capacity ex vivo and in vitro was measured using the cupric reducing
antioxidant capacity (CUPRAC) assay [53] and reported as Trolox equivalent antioxidant capacity
(TEAC). Plasma TEAC ex vivo was performed on plasma samples collected from the pigs after oral
intake of the plant extracts. Plasma TEAC in vitro was performed on reconstituted commercial pig
plasma (3.8% trisodium citrate as anticoagulant, Sigma-Aldrich, St. Louis, MO, USA). Freeze-dried
commercial pig plasma was reconstituted in Milli Q water to the indicated volume by the manufacture,
and aliquots were frozen until analysis. On the day of plasma TEAC in vitro analysis, commercial pig
plasma aliquots were thawed and spiked with either gallic acid standard, red cabbage, or grape skin
extracts to final concentrations of 0.05, 0.1, 0.2, 0.4, and 0.5 mg GAE/mL. Plasma samples (collected
from the pigs or spiked commercial plasma) were diluted 1:5 with Tris-glycine-urea buffer pH 7 before
the CUPRAC assay.
The CUPRAC assay is based on the capacity of a sample to reduce a Cu(II) complex to a Cu(I)
complex, which can be measured at 485 nm wavelength. Equal volumes (50 μL) of 7.5 mM BCS,
10 mM CuCl2 and Tris-glycine-urea buffer were added to each well of a 96-well plate, followed by
addition of 100 μL of samples (blank, standard, or diluted plasma). The plate was incubated at
22 ◦C for 1 h and absorbance at 485 nm was measured. Results were reported as TEAC based on a
6-point calibration curve using Trolox as the standard (0–100 μM) after blank subtraction. Analysis
was performed in duplicate. Yields of increased plasma TEAC in vitro (nmol/μmol GAE) by the
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spiked phytochemicals were reported as the slope of linear regression of plasma TEAC as a function of
phytochemical concentrations.
2.5.5. Plasma Glutathione Peroxidase Activity
Plasma GPx activity ex vivo was performed on plasma samples collected from the pigs after
oral intake of the plant extracts using a commercial kit (Trevigen, Gaithersburg, MD, USA). Briefly,
plasma samples (20 μL) were added to a reaction mixture containing premixed glutathione, reduced
form of nicotiamide adenine dinucleotide phosphate (NADPH), glutathione reductase, and cumene
hydroperoxide. Absorbance at 340 nm were monitored at 1 min intervals for 15 min, at 25 ◦C. The GPx
activity was calculated from the rate of change in absorbance using GPx standard as a positive control.
Results were reported as units/mL, where 1 unit of GPx activity was defined as the amount of enzyme
that caused the oxidation of 1 nmol of NADPH to NADP+ per minute at 25 ◦C. Analysis was performed
in triplicate.
2.6. Hydrogen Peroxide Production of Plant Extracts in Pig Plasma In Vitro
The dose response production of H2O2 by phytochemicals in reconstituted commercial pig
plasma (Sigma-Aldrich, St. Louis, MO, USA) was measured using the FOX assay [54]. Reconstituted
commercial pig plasma was spiked with either gallic acid standard, red cabbage, or grape skin extracts
to final concentrations of 0.05, 0.1, 0.2, 0.4, and 0.5 mg GAE/mL and was incubated at 37 ◦C for 1 h
before the FOX assay of H2O2. The concentrations were selected to be in the equivalent range of the
doses used in the animal study with pigs having 70 mL circulating blood/kg BW and plasma making
up 55% of blood volume [55].
After incubation, the plasma sample was diluted 1:5 with Tris-glycine-urea buffer pH 7 and
assays were conducted as follows. 90 μL of samples (blank, standard, or diluted plasma) were mixed
with 10 μL of methanol and 900 μL of FOX reagent. The mixture was vortexed for 5 s followed by
incubation at 22 ◦C for 30 min. After incubation, the mixture was centrifuged at 15,000 rpm for 10 min
at 22 ◦C and absorbance of the supernatant was measured at 560 nm. Concentrations of plasma
H2O2 were calculated based on a 6-point calibration curve using H2O2 as the standard (0–90 μM)
after blank subtraction. Analysis was performed in duplicate. Yields of H2O2 production in vitro
(nmol/μmol GAE) by the spiked phytochemicals were reported as the slope of the linear regression of
H2O2 concentration as a function of phytochemical concentrations.
2.7. Data Analysis
All curve-fitting was performed using SigmaPlot for Windows Version 12.5 (Systat Software Inc.,
Chicago, IL, USA). The general linear model (GLM), analysis of covariance (ANCOVA), and Tukey’s
test 95% confidence grouping analyses were performed in Minitab 16 statistical software (Minitab Inc.,
State College, PA, USA). Pearson’s correlation analysis was performed in Minitab 16 statistical software
(Minitab Inc.).
3. Results
3.1. Predicted Human Absorption as Functional Fingerprints of Plant Extracts
Predicted absorption as ‘functional fingerprints’ of red cabbage and grape skin extracts were
analysed by our LC-MS method with the application of the PCAP model. These functional fingerprints
show the predicted ranges of time required for phytochemicals in the extracts to reach their maximal
plasma concentrations in human (Tmax) after oral consumption. Accordingly, red cabbage was
predicted to have a long Tmax range of 0.4–11 h (Figure 1a) whilst grape skin was predicted to
have shorter Tmax ranges of 0.4–3.7 h and 8.2–8.3 h (Figure 1b). The functional fingerprints of the plant
extracts informed blood sampling time between 0–4 h at 0.5 h intervals in the current animal study.
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Figure 1. “Functional fingerprints” of plant extracts predicting absorption in humans based on the
PCAP model [41] and the LC-MS method [42]. Functional fingerprints of (a) red cabbage; and (b) grape
skin extracts. Tmax, the time required for phytochemicals to reach their maximal plasma concentration.
3.2. Time Course Effects of Oral Consumption of Plant Extracts on Plasma Antioxidant Status Ex Vivo of Pigs
The animals consumed four doses of either red cabbage or grape skin extracts (0–11.11 mg
GAE/kg BW) and plasma samples were taken every 0.5 h for 4 h. After oral consumption of red
cabbage extract, in comparison to baseline at time 0, a significant increase in plasma TEAC was
observed at 0.5 h in pigs consuming the maximal dose of 11.11 mg GAE/kg BW (Figure 2a) and a
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Figure 2. Effects of oral consumption of red cabbage extract on the plasma antioxidant status of
pigs. Pigs consumed red cabbage extract at four doses in mg gallic acid equivalent/kg body weight:
0 (black circle), 2.22 (white circle), 4.44 (black triangle), and 11.11 (white triangle). Plasma antioxidant
status was measured as: (a) plasma Trolox equivalent antioxidant capacity (TEAC); and (b) plasma
glutathione peroxidase (GPx) activiy. Data points labelled “*” are significantly different from baseline
at time 0 (p ≤ 0.05, Tukey’s test). Results represent the mean and error bars represent standard error of
the mean (N = 3).
After consumption of grape skin extract, in comparison to baseline at time 0, a significant increase
in plasma TEAC was observed after 1 h in pigs consuming 2.22 mg GAE/kg BW (Figure 3a) and
significant increases of plasma GPx activity were observed at 2.5, 3.5, and 4 h in in pigs consuming
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4.44 mg GAE/kg BW (Figure 3b). In contrast, a significant reduction in plasma GPx activity was
observed at 1 h in pigs consuming 4.44 mg GAE/kg BW (Figure 3b).
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Figure 3. Effects of oral consumption of grape skin extract on the plasma antioxidant status of pigs. Pigs
consumed grape skin extract at four doses in mg gallic acid equivalent/kg body weight: 0 (black circle),
2.22 (white circle), 4.44 (black triangle), and 11.11 (white triangle). Plasma antioxidant status was
measured as: (a) plasma Trolox equivalent antioxidant capacity (TEAC); and (b) plasma glutathione
peroxidase (GPx) activiy. Data points labelled “*” are significantly different from baseline at time 0
(p ≤ 0.05, Tukey’s test). Results represent the mean and error bars represent standard error of the mean
(N = 3).
3.3. Effects of Plant Extracts on Plasma Total Antioxidant Capacity and Plasma Hydrogen Peroxide
Concentration In Vitro
The dose response effects of the plant extracts on plasma TEAC and plasma H2O2 concentration
in vitro were analysed after spiking plasma with either gallic acid standard, red cabbage, or grape
skin extracts to final concentrations of 0.05, 0.1, 0.2, 0.4, and 0.5 mg GAE/mL. Proportional increase
in plasma TEAC was observed with increased concentrations of all three phytochemical sources and
followed linear regression relationships (Table 1). Yields of increased plasma TEAC in vitro by the
phytochemicals were 1606.3 ± 98.1, 633.2 ± 74.7, and 1077.8 ± 120.4 nmol/μmol GAE for gallic acid
standard, red cabbage, and grape skin extracts, respectively (Table 1).
Table 1. Effects of plant extracts on plasma Trolox equivalent antioxidant capacity (TEAC) and plasma
levels of hydrogen peroxide (H2O2) in vitro.
Phytochemical Sources
Plasma TEAC Plasma H2O2
Yield (nmol/μmol GAE) * Linear Fit R2 Yield (nmol/μmol GAE) * Linear Fit R2
Gallic acid standard 1606.3 ± 98.1 0.99 68.7 ± 4.5 0.97
Red cabbage extract 633.2 ± 74.7 0.96 22.4 ± 1.1 0.99
Grape skin extract 1077.8 ± 120.4 0.96 44.2 ± 2.1 0.99
* Gallic acid standard and plant extracts were directly spiked into commercial pig plasma at concentrations of
0.05–0.5 mg gallic acid equivalent (GAE)/mL. Increased plasma TEAC and plasma H2O2 levels followed linear
regressions with slopes representing yields of increase. Comparing three phytochemical sources, significant
differences in yields of plasma TEAC and plasma H2O2 were observed (p ≤ 0.05, analysis of covariance (ANCOVA)).
Significantly high correlation between plasma TEAC and plasma H2O2 was observed (r = 1, p ≤ 0.05, Pearson’s
correlation analysis). Results represent the mean ± standard error of the mean (N = 2).
Similar to plasma TEAC in vitro, proportional increase in plasma H2O2 concentrations was
observed with increased concentrations of all three phytochemical sources and followed linear
regression relationships (Table 1). Yields of H2O2 production in vitro by the phytochemicals in plasma
were 68.7 ± 4.5, 22.4 ± 1.1, and 44.2 ± 2.1 nmol/μmol GAE for gallic acid standard, red cabbage, and
grape skin extracts, respectively (Table 1).
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Comparing the three phytochemical sources, significant differences in yields of plasma TEAC
and plasma H2O2 were observed (p ≤ 0.05, ANCOVA). Further, significantly high correlation between
yields of plasma TEAC and plasma H2O2 were observed (r = 1, p ≤ 0.05, Pearson’s correlation analysis),
with gallic acid having the strongest effect (highest yields) followed by grape skin and red cabbage
extracts (Table 1).
3.4. Effects of Phytochemical Dose and Their H2O2 Production Capacity In Vitro on Plasma Antioxidant Status
of Pigs Ex Vivo
Means across all pig plasma sampling points (0.5 h interval for 4 h, Figures 2 and 3) were combined
to investigate the overall dose effects of the plant extracts on pig plasma antioxidant status (Figure 4).
For both plant extracts, plasma TEAC ex vivo significantly increased at all three doses 2.22, 4.44, and
11.11 mg GAE/kg BW compared to dose 0 (Figure 4a). There was no significant difference in plasma
TEAC among the three doses of red cabbage extract whilst plasma TEAC at grape skin extract dose of
4.44 and 11.11 mg GAE/kg BW was significantly reduced compared to the 2.22 mg GAE/kg BW dose
(Figure 4a). The phytochemical dose (mg GAE/kg BW) of the two plant extracts was standardised
to their in vitro H2O2 production yields (nmol/μmol GAE, Table 1) to estimate the H2O2 production
(nmol/kg BW) by the plant extract dose used in the animal study. The in vitro H2O2 production yields
of the two plant extracts had similar effects on the mean plasma TEAC of pigs compared to their




Dose (mg GAE/kg body weight)





















* * * ,#
H2O2 production (nmol/kg body weight)
























Dose (mg GAE/kg body weight)




























H2O2 production (nmol/kg body weight)




























Figure 4. Total plasma antioxidant capacity and glutathione peroxidase activity of pig plasma as a
function of phytochemical dose and H2O2 production efficacy. Means across all pig plasma sampling
time points (0.5 h interval for 4 h) of plasma TEAC versus (a) phytochemical doses and (b) H2O2
production efficacy. Means across all pig plasma sampling time points of plasma GPx activity versus
(c) phytochemical doses and (d) H2O2 production efficacy. The H2O2 production (nmol/kg body
weight) was calculated based on the yield of H2O2 production (nmol/μmol GAE) of the plant extracts
in vitro (Table 1). Data points labelled “*” are significantly different from dose 0 (p ≤ 0.05, Tukey’s
test). Data points labelled “#” are significantly different from the previous dose (p ≤ 0.05, Tukey’s test).
Results represent the mean and error bars represent standard error of the mean (N = 27).
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Similarly, for both plant extracts, significant increases in pig plasma GPx activity were observed
at all three doses (Figure 4c). There was no significant difference in GPx activity among the three doses
of grape skin extract whilst GPx activity at a red cabbage extract dose of 4.44 mg GAE/kg BW was
significantly increased compared to the 2.22 mg GAE/kg BW (Figure 4c). After standardisation of
the phytochemical dose to their in vitro H2O2 production yields (Table 1), the plasma GPx activity in
response to the two plant extracts was remarkably similar (Figure 4d).
4. Discussion
This study examines the consumption of dietary phytochemicals by pigs and shows that
non-enzymatic and enzymatic antioxidant defences were increased. Absorption kinetics of red cabbage
and grape skin extracts were characterised in pigs after oral consumption using plasma TEAC as a
measure of the non-enzymatic antioxidant response [56] and plasma GPx (an antioxidant enzyme)
activity [57]. The blood sampling time of the study (0.5 h interval for 4 hours) was chosen to capture
the range of time expected for the phytochemicals to achieve their maximal plasma concentrations
(Tmax), predicted from their functional fingerprints (0.4–4 h). Consistent with the predicted functional
fingerprints, a significant increase in plasma TEAC was observed at 0.5 h after consumption of red
cabbage (11.11 mg GAE/kg BW) and at 1 h after consumption of grape skin (2.22 mg GAE/kg BW).
Peaks of plasma TEAC have been observed to coincide with peaks of plasma phytochemicals in
humans after consumption of tea [58] and chocolate [59]. Therefore, the identification of increased
plasma TEAC within this selected time frame after plant extract ingestion validates the utility of the
phytochemical absorption prediction (PCAP) model [41] and its application to the production of the
functional fingerprints.
These results highlight the ability of the PCAP model to guide experimental design to ensure that
the functional impact of the phytochemicals is captured during the sampling regime. For example,
a previous study investigating the pharmacokinetics of three phytochemicals carvacrol, thymol, and
eugenol in pigs reported the time of maximal absorption (Tmax) at 1.39, 1.35, and 0.83 h, respectively [60].
Using our PCAP model [41], the Tmax of these phytochemicals for humans was predicted to be 1.76,
1.67, and 1.58 h, respectively. Comparing to the reported Tmax in pigs [60], the predicted Tmax of these
phytochemicals in humans was very similar and followed the same sequence with Tmax of carvacrol
> thymol > eugenol. This similarity of observed Tmax compared to predicted Tmax suggests that the
PCAP model can be useful for predicting absorption of phytochemicals in pigs as well as in humans.
In the present study, the plant extract doses were standardised for their respective total phenolic
contents as GAE analysed by the Folin-Ciocateu assay. Whilst ascorbic acid is known to interfere with
this assay [61], based on analyses conducted by others [61–67], the contributions of ascorbic acid to
the GAE results are estimated to be 0.3% and 4% for grape skin and red cabbage extracts, respectively.
These minimal contributions of ascorbic acid to the GAE results reflected the naturally low ascorbic
acid content of grape skin [62], and the effects of microwave cooking [66] and ultrasonication [67]
which reduced the ascorbic acid content of red cabbage during plant processing. Accordingly, the GAE
results presented herein are considered accurate indicators of the total phenolic content of the two
plant extracts.
In comparison to plasma TEAC, a delayed increase in plasma GPx activity was observed at 1.5 h
after consumption of red cabbage (2.22 mg GAE/kg BW) and at 2.5, 3.5, and 4 h after consumption of
grape skin (4.44 mg GAE/kg BW). The observed time delay of plasma GPx activity after plasma TEAC
is consistent with a previous study [68]. This delay may be explained by the induction of GPx activity
occurring in response to the presence of phytochemicals in the plasma, as indicated by increased
plasma TEAC [58,59]. Accordingly, increased plasma TEAC and increased plasma GPx activity after
consumption of the plant extracts indicate that phytochemicals provide health benefits via both direct
antioxidant activity and indirectly via the induction of enzymatic antioxidant defence mechanisms.
The dose response effects of red cabbage and grape skin extracts increased plasma TEAC in vitro
after direct addition of the extracts to the pig plasma in the present study. As the phytochemical
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doses increased, there was a proportional increase in plasma TEAC in vitro (633.2–1606.3 nmol/μmol
GAE), supporting the direct antioxidant activity of phytochemicals in vitro as observed in many
studies [69–71]. In comparison to the in vitro experiments, same doses of red cabbage and grape skin
extracts consumed by the pigs did not result in a proportional increase in plasma TEAC and plasma
GPx activity ex vivo. When plant extracts were orally administered to pigs, increased plasma TEAC
was observed at all doses compared to 0 but an increase in dose did not result in significant further
increase of TEAC above the lowest dose. Further, an increase in dose of grape skin extract resulted in
decreased plasma TEAC at doses of 4.44 and 11.11 mg GAE/kg BW compared to the dose at 2.22 mg/kg
BW. The differences in plasma TEAC responses to the plant extracts may be attributed to their distinct
phytochemical compositions [44,46]. Similarly, plasma GPx activity significantly increased for all doses
compared to dose 0 but further increase of doses did not show a clear response relationship.
The observed differences between in vitro and ex vivo have also been observed in other
studies [69,70]. Direct addition of tea [69] or apple phytochemicals [70] to human plasma in vitro
increased plasma TEAC. However, consumption of the same or higher concentrations of tea [69]
and apple phytochemicals [70] by humans did not reproduce the same effects as observed in vitro.
The differences between in vitro and ex vivo results can be explained by the low bioavailability of
phytochemicals in vivo as they are handled by the body as xenobiotics [40]. Further, these differences
may be attributed to the increased complexity of the in vivo system wherein both direct and indirect
antioxidant mechanisms may arise, as indicated by increased plasma GPx activity ex vivo.
Hypothetical pro-oxidant effects of phytochemicals in vitro via measurement of H2O2 levels
in plasma were studied after direct addition of plant extracts. Similar to the results measuring
plasma TEAC in vitro, incubation of red cabbage and grape skin extracts in pig plasma resulted
in a proportional increase in plasma H2O2 levels (22.4–68.7 nmol/μmol GAE). Pro-oxidant effects
of phytochemicals in vitro have been observed in the presence of oxygen and metal ions such as
copper and iron [35–37,72–75]. Concentrations of iron and copper ions in human plasma are 2.13 and
0.81 μg/g, respectively [76], and iron levels of 0.1 μg/g [35] and copper levels of 3 μg/g [73] have been
reported to initiate H2O2 production in vitro. The formation of H2O2 by phytochemicals in plasma
observed here may be attributed to the electron transfer process between phytochemicals, oxygen, and
metal ions present in plasma [73].
The ability of phytochemicals to produce H2O2 has been proposed to be responsible for the
cytotoxic effects of phytochemicals in cell culture studies [35–37]. H2O2 has been widely used as
an oxidative stress inducer in many studies investigating the protective effects of phytochemicals in
response to oxidative stress [77–79]. However, the ability of phytochemicals to produce H2O2 may
explain their indirect antioxidant protection mechanism. High concentrations of H2O2 (≥100 μM)
are harmful for cells but low concentrations of H2O2 (≤50 μM) can be beneficial to initiate the
antioxidant cellular defence [80,81]. Low concentrations of H2O2 have been observed to stimulate
wound healing in keratinocytes [82] and in mice [83]. Similarly, the health benefits of regular exercise
have been proposed to be associated with their production of low levels of ROS (such as H2O2) that
induce adaptive responses to protect against molecular damage and, subsequently, aging [84,85].
Supporting this mechanism, H2O2 has been reported to activate the nuclear factor-erythroid-2-related
factor 2 (Nrf2) de novo [86] which is a transcription factor involved in inducing the antioxidant
response by regulating coordinated induction of stress response genes encoding antioxidant enzymes
such as superoxide dismutase, catalase, and GPx [87]. Activation of Nrf2 has been proposed as a
therapeutic potential for protection against chronic diseases [87,88]. Many phytochemicals are known
as Nrf2 activators including curcumin (in turmeric) [89], epigallocatechin gallate (in green tea) [90],
lycopene (in tomato) [91], resveratrol (in grape) [92], and sulforaphane (in broccoli) [93]. Accordingly,
H2O2-mediated induction of Nrf2 in response to phytochemical supply may explain the correlation
between H2O2 production and increased plasma GPx activity observed in our study.
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5. Conclusions
The findings of the current study provide new insights in mechanisms by which dietary
phytochemicals impact health, apart from direct ROS-scavenging pathways. An additional role
is proposed whereby protection against oxidative tissue damage results from the promotion of cellular
oxidative stress defence by dietary phytochemicals. This research demonstrates for the first time
that H2O2 production analysis represents a useful predictive indicator of the in vivo efficacy of
dietary phytochemicals.
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Abstract: Backgrounds: There is growing evidence from both observational and intervention studies
that Whole Grain (WG) cereals exert beneficial effects on human health, especially on the metabolic
profile. The aim of this study was to perform a meta-analysis of randomised controlled trials (RCT) to
assess the acute and medium/long-term effect of WG foods on glycaemic control and insulin sensitivity
in healthy individuals. Methods: A search for all the published RCT on the effect of WG food intake
on glycaemic and insulin response was performed up to December 2016. Effect size consisted of
mean difference (MD) and 95% CI between the outcomes of intervention and the control groups
using the generic inverse-variance random effects model. Results: The meta-analysis of the 14 studies
testing the acute effects of WG foods showed significant reductions of the post-prandial values of the
glucose iAUC (0–120 min) by −29.71 mmol min/L (95% CI: −43.57, −15.85 mmol min/L), the insulin
iAUC (0–120 min) by −2.01 nmol min/L (95% CI: −2.88, −1.14 nmol min/L), and the maximal
glucose and insulin response. In 16 medium- and long-term RCTs, effects of WG foods on fasting
glucose and insulin and homeostatic model assessment-insulin resistance values were not significant.
Conclusions: The consumption of WG foods is able to improve acutely the postprandial glucose and
insulin homeostasis compared to similar refined foods in healthy subjects. Further research is needed
to better understand the long-term effects and the biological mechanisms.
Keywords: whole grain; glycemia; insulin; healthy subjects; meta-analysis; RTC
1. Introduction
Over the past decades, the burden of non-communicable chronic diseases, such as cardiovascular
diseases (CVD), metabolic syndrome, diabetes and cancer, is rapidly increasing worldwide [1].
Non-communicable chronic diseases are generally preventable by managing modifiable risks factors,
including dietary habits. Diet may play a key role in the promotion and maintenance of good health,
but modern lifestyle is leading to a shifting away from traditional dietary patterns in favour of eating
habits characterized by increased portion sizes, away-from-home foods, and unhealthy snacking.
This process, known also as “Westernization” of the diet, is characterized by major consumption of
refined sugars and fats, animal products and refined cereals, as well as decreased consumption of fruit,
vegetable, and whole-grain (WG) cereals.
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WG cereals contain all three parts of a natural grain kernel, including endosperm, germ, and bran
and they are a rich source of dietary fibre, resistant starch, antioxidants, vitamins and minerals, such
as folic acid, magnesium, and selenium [2]. The refinement process is performed by removing the bran
and some of the germ, resulting in a loss of micronutrients and dietary fibre in favour of a softer texture
and extended freshness. Thus, the endosperm alone, mainly composed of starchy carbohydrates,
proteins, and small amounts of vitamins and minerals, is used to produce refined white flours.
There is growing evidence from both observational and intervention studies that WG cereals exert
beneficial effects on human health [3]. WG food consumption has been associated with a modification
of risk factors related to non-communicable chronic diseases, including post-prandial insulinaemic
response, blood lipid profile, and intestinal microbiota [4–6]. A series of previous meta-analyses
have shown a decreased risk of CVD [7], type-2 diabetes [8], metabolic syndrome [9], and cancer [10]
associated with higher intake of WG foods. The mechanisms underlying the health benefits of WG
foods may be explained, at least in part, by the high content of fibre that positively affects gut health
(increasing transit time and faecal bulking). Moreover, other mechanisms, such as anti-inflammatory,
antioxidant, hormonal (i.e., in hormone activation and synthesis of zinc, selenium, and nicotinic
acid), anti-carcinogenic (i.e., content in phenolic compounds), and metabolic effects (i.e., vitamins and
minerals), have to be considered [11].
A previous meta-analysis of 14 cohorts showed that WG food consumption was associated with
lower fasting glucose and insulin concentrations independently from demographics and lifestyle
factors, in non-diabetic European descents [12]. Although several clinical trials have been carried out
to show the effects of WG consumption in healthy individuals, results are still conflicting. The aim
of this study was to perform a meta-analysis of randomised controlled trials (RCT) to assess the
acute and medium/long-term effect of WG foods on glycaemic control and insulin sensitivity in
healthy individuals.
2. Methods
2.1. Search Strategy and Selection of the Studies
A search for all the published RCT on the effect of WG intake on glycaemic and insulin response
was performed independently by three authors (J.G., C.V. and M.V.). Studies were identified from
PubMed, Science Direct Online and The Cochrane Library up to December 2016. The search strategy
included following key words: (“whole grain” or” whole meal” or “whole wheat” or “whole
kernel”) and (“blood glucose” or “HbAlc” or “glycated haemoglobin” or “fasting plasma glucose” or
“glycolated haemoglobin” or “FBG” or “insulin” or “HOMA-IR”). The search was restricted to studies
published in English. The reference list of the included studies was checked to identify relevant study
not previously included. Inclusion criteria were: (i) studies conducted on healthy human subjects;
(ii) parallel or crossover design; (iii) comparison of WG foods with foods with lower levels or no WG
content; and (iv) presented means, standard deviations (SDs), or standards errors (SEs) at baseline
and/or endpoint for the outcomes investigated. Exclusion criteria were the following: (i) studies with
different design; (ii) studies evaluated only individual components of the grain; (iii) studies in which
it was not possible to evaluate the WG foods effect because part of combined meals; and (iv) studies
with fewer than 10 subjects in the intervention group.
2.2. Data Extraction and Study Quality
Data were independently extracted by three reviewers using a standard form. The information
extracted included: first author and year of publication, country, study design, participant
characteristics, number of subjects in comparison groups, type of WG foods, length of intervention,
matching characteristics, and main results of the outcomes investigated. Primary outcomes
consisted of changes from baseline in fasting glucose and insulin concentrations and in glucose
and insulin incremental area under the curve (iAUC) values. Secondary outcomes included mean
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changes in HbA1c concentrations, peak and incremental glucose and insulin and homeostatic model
assessment-insulin resistance (HOMA-IR) values. Changes from baseline were chosen as primary
outcome as in many studies they were the only data presented, although this might not be the best
approach (Bland and Altman).
The quality of each study was assessed following the principles of the Newcastle-Ottawa Quality
Assessment Scale [13], consisting of 3 domains of quality as follows: selection (4 points), comparability
(2 points), and outcome (3 points) for a total score of 9 points (9 representing the highest quality).
Studies scoring 0–3 points, 3–6 points, and 7–9 points were identified as low, moderate, and high
quality, respectively.
2.3. Statistical Analysis
In order to perform the comparison, all the values were converted to mmol/L for glucose
concentrations and pmol/L for insulin concentrations. IAUC were converted to min x mmol/L for
glucose iAUC values and min x nmol/L for insulin iAUC. When insulin was reported in μIU/mL
(microunits of insulin per millilitre), a conversion factor of 6.945 was applied to convert to pmol/L
(picomoles of insulin per litre) [14]. Change from baseline to endpoint was used for the analysis
of fasting glucose, fasting insulin and HOMA-IR. When SD was not reported, it was derived from
available data (95% confidence interval (CI), p-values, t or F statistics, and SE) using the method
suggested by the Handbook for Systematic Review of Interventions [15]. When needed, the SD for
changes from baseline was imputed using a pooled correlation coefficient according to a published
procedure [15]. When it was not possible, a correlation coefficient of 0.5 was applied for imputing
missing SDs, as it is a conservative value between 0 and 1. End-of-treatment values were used for
glucose and insulin iAUC while data on HbA1 were insufficient to perform a meta-analysis. Results of
trials containing multiple intervention or control arms were reported separately. Effect size consisted
of mean difference (MD) and 95% CI between the outcomes of intervention and the control groups
using the generic inverse-variance random effects model. A two-sided p-value 0.05 was considered
statistically significant. Heterogeneity between trial results was tested using the I2 statistic [16] and a
value over 50% indicated a significant level of heterogeneity. Stability of results and possible source of
heterogeneity between the studies was explored through sensitivity analyses by excluding results of
one study at the time. In the analysis where SDs changes form baseline were imputed, a sensitivity
analysis using also a 0.25 and a 0.75 correlation coefficients were performed to confirm the results.
Moreover, subgroup analyses were used to evaluate the influence of some factors, including study
design, geographical area, length of the study, and weight status. Publication bias was examined by
visual inspection of the funnel plots. The analyses were carried out using Review Manager version 5.2
(RevMan 5.2, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark).
3. Results
3.1. Study Selection and Main Characteristics
The flow chart of the search strategy is showed in Figure 1. From the initial 875 studies,
a total of 51 articles were considered for the full-text examination. After the exclusion of 10 studies,
41 articles met the inclusion criteria for the qualitative analysis, while 30 were included in the
quantitative meta-analysis.
Table 1 shows the characteristics of the 41 RCTs, which included 1033 healthy subjects (587 males and
682 females). Trials were conducted across 10 countries, including Sweden (eight trials) [17–24], Finland (five
trial) [25–29], Canada (five trials) [30–34], UK (five trials) [4,35–38], Australia (three trial) [39–41], Denmark
(three trials) [42–44], Italy (three trials) [5,45,46], USA (three trials) [47–49], Germany (one trial) [50], Japan
(one trial) [51], Kuwait (one trial) [52], Singapore (one trial) [53], Spain (one trial) [54] and Switzerland
(one trial) [55]. Five studies [35,37,42,45,47] had a parallel design and 36 [4,5,17–34,36,38–41,43,44,46,48–55]
had a cross-over design. Twenty-five studies [17–22,24–34,40,41,43,44,46,49,52–54] evaluated the effects of
410
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the consumption of a single WG meal in an acute study, while 16 studies [4,5,23,32,35–42,45,47,48,50,51,55]
evaluated the effects of a medium/long-term consumption in a RCT study with an intervention
period ranging from two weeks to 16 weeks (median six weeks). The totality of the study
included scored high quality. Even though studies were conducted on healthy individuals,
22 enrolled normal weight individuals [17–22,24–26,31,34,40,41,43,44,46,49,51–55], 11 overweight
individuals [5,23,27–30,32,36–38,47], and seven obese individuals [33,35,39,42,45,48,50].
Records identified through 
database searching 
























Additional records identified 
through other sources 
(n = 19) 
Records after duplicates removed 
(n = 875) 
Records screened 
(n = 875) 
Records excluded by 
screening titles or 
abstracts 
(n = 842) 
Full-text articles assessed 
for eligibility 
(n = 50) 
Full-text articles excluded, 
with reasons 
(n = 10) 
 2 no data available 
 8 no whole grain 
Studies included in 
qualitative synthesis 
(n = 40) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 29) 
Figure 1. PRISMA flowchart indicating the results of the search strategy.
In the studies evaluating the acute effects of the consumption of a single WG meal, a wide variety
of different meals were compared with control meals including mainly white wheat bread (Table 1).
As regards medium/long-term RCT in 12 studies [5,23,35–41,48,50,51,55], participants consumed
a diet in which food with refined cereals were substituted with WG foods, while in four studies
the intervention groups were invited to consume WG sourdough bread [32], WG biscuits [45], WG
breakfast cereals [4] or WG oats [47] during the normal diet.
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3.2. Acute Studies
3.2.1. Glucose iAUC
Fourteen studies reported data on glucose iAUC, two of which relative to the time period
0–90 min [24,52], 10 to the time period 0–120 min (145 subjects) [18–21,31,34,40,46,53,54], four to the
time period 0–180 min (61 subjects) [25,27,43,49], and two to the time period 0–240 [28,41]. Four studies
were not reported because there was no information on the AUC calculation or because of different
type of AUC was used [17,29,33,44]. Six studies [24,28,34,41,44] did not present relevant data for
the meta-analysis.
Plasma glucose concentrations after the WG meal for the time periods 0–120 min were lower
compared with the control meal (MD = −29.71 mmol min/L, 95% CI: −43.57, −15.85 mmol min/L;
Figure 2). Significant heterogeneity was found between studies (I2 = 80%; p <0.001).
Figure 2. Forest plot of the meta-analysis carried out to investigate the effect of whole grain
consumption on glucose iAUC. iAUC: incremental area under the curve; WWBc, whole-wheat cookies;
WWBCr, whole-wheat crackers RK, rye kernels; WK, wholegrain wheat kernels; WGRB, whole grain
rye bread; WGRB-lac, whole grain rye bread with lactic acid; WGRP, whole grain rye porridge; WLRB,
wholemeal rye bread; WLRC, wholemeal rye crispbread; WKRB, whole kernel rye bread; WRB, Whole
rye bread.
The visual inspection of the funnel plot showed asymmetry due to the study of Alminger et al. [18]
(Supplementary Materials, Figure S1). Heterogeneity was reduced to 40% (p = 0.06) when three
studies were excluded [18,20,54], with no change in the results (MD = −36.46 mmol min/L, 95% CI:
−46.80, −26.12 mmol min/L), despite no substantial differences between these three studies and the
416
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others have been observed. These results did not achieve statistical significance in the 0–180 min
analysis (MD = −15.40 mmol min/L, 95% CI: −31.52, 0.73 mmol min/L; Figure 2) with no evidence of
heterogeneity (I2 = 0%, p = 0.76).
Among the excluded studies, glucose response after consumption of the WG meal did not
significantly differ from the refined grain meal across all the studies (Table 1).
3.2.2. Insulin iAUC
Insulin iAUC 0–120 min was evaluated in 5 studies [17,18,21,40,54] (58 subjects), while 8
studies [25,27,29,30,33,43,46,49] evaluated the iAUC 0–180 min (83 subjects). Two studies reported
data on insulin iAUC relative to the time period 0–240 min [28,41] and were excluded from the analysis.
Three studies were excluded because there was no information on the AUC calculation or because of
different type of AUC was used [17,29,33].
The WG products induced significantly lower 0–120 min incremental areas than foods with lower
amount or no WG foods (MD = −2.01 nmol min/L, 95% CI: −2.88, −1.14 nmol min/L; Figure 3), with no
evidence of heterogeneity (I2 = 0%; p = 0.49). In the studies evaluating the iAUC 0–180 min, a significant
insulin iAUC reduction with no evidence of heterogeneity was found (MD = −3.64 nmol min/L, 95% CI:
−5.00, −2.28 nmol min/L; I2 = 1%, p = 0.44; Figure 3). Four [17,28,29,41] out of the five excluded trials
showed a significantly smaller iAUC for the WG consumption in comparison with the WWB, while
one study [33] found no difference between the WG and refined grain meals.
Figure 3. Forest plot of the meta-analysis carried out to investigate the effect of whole grain
consumption on insulin iAUC. iAUC: incremental area under the curve; WGRB, whole grain rye
bread; WGRB-lac, whole grain rye bread with lactic acid; WGRP, whole grain rye porridge; WKRB,
whole kernel rye bread; WLRB, wholemeal rye bread; WLRC, wholemeal rye crispbread; WRB, Whole
rye bread; WWBc, whole-wheat cookies; WWBCr, whole-wheat crackers.
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3.2.3. Maximal Glucose and Insulin Response
Four studies [25–27,53] for a total of 71 subjects and 11 different test meals considered maximal
glucose and insulin response incremental as outcome. The meta-analysis showed a significantly lower
maximal glucose response (MD = −0.25 mmol/L, 95% CI: −0.43, −0.06 mmol/L) with low evidence
of heterogeneity (I2 = 40%; p = 0.08) for the experimental compared with control groups (Figure 4).
Concerning the study of Zafar et al. [52], blood glucose concentrations were significantly lower after
WG products compared to refined food, however it was excluded from the analysis due to the lack of
data. As regards maximal insulin responses, all test meals products induced a lower maximal insulin
response with a MD of −73.78 pmol/L (95% CI: −108.56, −38.99 pmol/L) and moderate evidence of
heterogeneity (I2 = 49%; p = 0.05; Figure 4).
Figure 4. Forest plot of the meta-analysis carried out to investigate the effect of whole grain
consumption on maximal glucose and insulin response. WLRC, wholemeal rye crispbread; WLRB,
wholemeal rye bread; WKRB, whole kernel rye bread; WGP, whole grain pasta; WKRB, whole kernel
rye bread; WRB, Whole rye bread.
3.3. Medium- and Long-Term Studies
3.3.1. Fasting Glucose
In total, 10 crossover studies [4,5,23,32,36,39,48,50,51,55] and five parallel studies [35,37,42,45,47]
accounting for 773 subjects (325 males and 448 females) reported fasting glucose outcomes for medium-
and long-term WG meals intake. Two studies [4,39] were excluded because baseline fasting glucose
values were not reported. When the results from all of the studies were grouped in a meta-analysis,
there was no summary effect on fasting glucose in the WG group compared to the control group
(MD = −0.04 mmol/L, 95% CI: −0.13, 0.04 mmol/L) with no significant evidence of heterogeneity
(I2 = 33%; p = 0.11; Figure 5). The visual inspection of the funnel plot showed asymmetry due to the
study of Li et al. (Supplementary Material, Figure S2) [51]. Sensitivity analyses showed that, after
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excluding results of Vitaglione et al. [45], where subjects were selected specifically with unhealthy
dietary and lifestyle behaviours, and Rave et al. [50], where participants were obese subjects with
elevated fasting blood glucose, summary effect size resulted in a low significant reduction of fasting
glucose in favour of the intervention group with no evidence of heterogeneity (MD = −0.08 mmol/L,
95% CI: −0.16, −0.01 mmol/L; I2 = 0%, p = 0.72).
Figure 5. Forest plot of the meta-analysis carried out to investigate the effect of whole grain
consumption on fasting glucose and insulin. WG, whole grain; HFW, high-fibre wheat; HFR,
high-fibre rye.
3.3.2. Fasting Insulin
Plasma insulin was evaluated in 13 studies [4,5,23,32,35,37–39,42,45,47,48,50] with a total of
730 subjects (355 males and 375 females) and the meta-analysis was not significantly different in the
WG group compared to the controls (MD= −2.26 pmol/L, 95% CI: −6.58, 2.06 pmol/L; I2 = 17%,
p = 0.27; Figure 5). Two studies [4,5] were excluded for the lack of baseline values.
3.3.3. HOMA-IR
Data on HOMA-IR were reported in seven studies [5,32,37,42,47,48,50] accounting for 377 healthy
subjects (152 males and 225 females). The study of Giacco et al. [5] was excluded because of the lack of
baseline values. The results of the meta-analysis showed no evidence of an effect on HOMA-IR for
the medium- and long-term WG consumption compared to the control group (MD = −0.18, 95% CI:
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−0.48, 0.13) with no significant evidence of heterogeneity (I2 = 35%; p = 0.16; Figure 6). Sensitivity
analyses showed that the exclusion of two studies [42,50] changed the summary effect size from
non-significant to significant (MD = −0.39, 95% CI: −0.69, −0.08; I2 = 0%, p = 0.52). A possible reason
for heterogeneity relied on the fact that the intervention, in both studies, was conducted in the context
of a strict hypocaloric diet.
Figure 6. Forest plot of the meta-analysis carried out to investigate the effect of whole grain
consumption on HOMA-IR. WG, whole grain.
3.3.4. Subgroup Analyses
Table 2 shows the results of categorical subgroup analyses for the effect of medium- and long-term
consumption of wholegrain meals on fasting glucose and insulin. The subgroup analyses of fasting
glucose concentrations indicated that the overall outcome of fasting glucose did not differ between
subgroups. Instead, a significant reduction in fasting insulin concentrations were observed for studies
not conducted in the European region (MD = −10.71 pmol/L, 95% CI: −18.19, −3.24 pmol/L).
No significant heterogeneity was observed across the studies (I2 = 0%). The sensitivity analysis
of the duration subgroups resulted in a significant lower fasting insulin (MD = −8.17 pmol/L, 95% CI:
−15.24, −1.10 pmol/L; I2 = 19%, p = 0.28) after the removing of the study of Rave et al. [50], which
was conducted on obese subjects with elevated fasting blood glucose.










I2 (%) p I2 (%) p
Study design
Parallel 8 −0.03 (−0.17, 0.11) 58 0.03 7 −0.14 (−4.40, 4.12) 0 0.61
Crossover 8 −0.04 (−0.15, 0.07) 0 0.49 6 −4.76 (−12.37, 2.86) 38 0.14
Geographical area
Europe 11 −0.02 (−0.12, 0.08) 44 0.06 8 0.78 (−3.09, 4.66) 0 0.80
Other 4 −0.17 (−0.36, 0.02) 0 0.84 5 −10.71 (−18.19, −3.24) 0 0.59
BMI category
Normal/overweight 9 −0.12 (−0.22, −0.02) 0 0.83 5 −3.15 (−12.14, 5.84) 2 0.40
Obese 5 0.04 (−0.11, 0.19) 58 0.04 8 −1.17 (−6.21, 3.86) 23 0.25
Duration
≤6 weeks 10 −0.05 (−0.16, 0.05) 0 0.54 8 −5.93 (−13.31, 1.44) 13 0.38
>6 weeks 5 −0.01 (−0.16, 0.13) 64 0.02 6 0.56 (−3.78, 5.89) 0 0.89
4. Discussion
The present study showed significant advantages in iAUC peak and incremental, both for
post-prandial glucose and insulin in favour of the WG compared to control meals in acute studies.
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In some studies, benefits on glycaemic excursions [20,56], feeling of fullness, lower feeling of hunger
and lower desire to eat [22] were found after the consumption of a WG meal. Overall, these results
contribute to explain, from a mechanistic point of view, the association between WG food consumption
and lower risk of type-2 diabetes [57], metabolic syndrome [58], and CVD [59] in epidemiological
studies. Diets rich in refined carbohydrates induce a rapid increase in blood glucose concentrations
with a high demand for insulin from the pancreatic β-cells [60], which in turn may increase the risk of
insulin resistance [61]. In contrast, WG cereals are able to acutely lower blood glucose levels, which
may improve insulin sensitivity and beta-cell function.
In relation to the postprandial blood glucose response, the difference between WG and refined
grain meals was more relevant and statistically significant when the two hours’ response was evaluated.
This is in line with other studies on the impact of different carbohydrates foods on postprandial blood
glucose [62–64]. In fact, meal carbohydrates influence directly the early postprandial blood glucose
response, whereas the late blood glucose levels are linked mainly to the hormonal (mainly insulin and
glucagon) and metabolic (free fatty acids) response.
Results from medium and long-term trials showed no statistically significant difference in
HOMA-IR, fasting plasma glucose and insulin levels after WG compared to refined grain meals.
This is not in line with evidence reported in some cross-sectional studies [62,64]. However, after
a sensitivity analysis with exclusion of studies including obese individuals with unhealthy dietary
habits at baseline, both fasting plasma glucose and HOMA-IR showed a significant difference between
WG and the control meal. This suggests that the evidence available from intervention trials on the
long-term effects of WG is still inadequate to drawn definitive conclusions and the analysis on a more
homogenous group of individuals might lead to more consistent results.
The possible mechanisms for the beneficial effects of WG foods include the slow rate of digestion
and the fermentation of fibre and resistant starch by microbiota in the large intestine with the
production of short-chain fatty acids (SCFA). SCFA in the liver increase glucose oxidation, decrease
fatty acid release, and increase insulin clearance, thus improving glucose homeostasis and insulin
sensitivity [65]. Moreover, the pancreatic beta cells are extremely sensible to oxidative damage [66]
and could be protected by some antioxidants present in WG cereals, such as polyphenols (ferulic
acid, lignans, and anthocyanins) and alkylresorcinols, demonstrated to be direct radical scavengers
in animal models [67]. Nevertheless, the ability of WG cereals to improve glycaemic control may be
related to the synergistic action of multiple compounds more than a single component [68].
The results of this meta-analysis should be considered in light of some limitations. First, the lack
of a clear universal definition of the concept of WG food as well as the different properties of the source
of dietary WG could lead to some bias. Separate investigations across the various whole grain foods
produced from different crops may be useful to reduce heterogeneity and to obtain a more robust
scientific evidence of the impact of WG from specific sources on glycaemic responses. Second, the
sample sizes of some RCTs were relatively small and some of the variables analysed were not primary
outcomes of the studies. Third, the imputation of SD could lead to a bias of the results. However, the
sensitivity analyses imputing different values of correlation confirmed that the general results were
robust. Fourth, several studies were not included due to the lack of available information necessary
for the quantitative analysis; as some of these studies reported not significant results, the possibility
of selection bias should be considered. Finally, only few studies reported HbA1c and no conclusions
about the effect of WG foods on blood glucose levels over a period of time can be made.
In conclusion, the results of the present meta-analysis suggest that consumption of WG foods may
improve acutely the postprandial glucose and insulin homeostasis compared to similar refined foods
in healthy subjects. These effects, in addition to a better appetite regulation, need to be confirmed by
future long-term studies designed ad hoc to test whether WG foods may contribute to reduce the risk
of type 2 diabetes and other chronic diseases. Moreover, the results of the acute studies included in
this meta-analysis relied mostly on studies evaluating the effects of oat, rye and barley; these cereals
provide a relatively lower contribution to the overall cereal intake worldwide [69] than wheat. In fact,
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WG wheat products have a larger diffusion at the population level, at least in Western countries.
Therefore, further research is needed to better understand the long-term effects and the biological
mechanisms that underline the health benefits of WG food consumption.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/7/769/s1.
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